<SEC-DOCUMENT>0001628280-23-018472.txt : 20230516
<SEC-HEADER>0001628280-23-018472.hdr.sgml : 20230516
<ACCEPTANCE-DATETIME>20230516171250
ACCESSION NUMBER:		0001628280-23-018472
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20230401
FILED AS OF DATE:		20230516
DATE AS OF CHANGE:		20230516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioventus Inc.
		CENTRAL INDEX KEY:			0001665988
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				810980861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37844
		FILM NUMBER:		23928632

	BUSINESS ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		(919) 474-6700

	MAIL ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bvs-20230401.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:082d4e54-0693-403f-8feb-755a4f49db3a,g:bca9874b-627b-4a4e-9dc7-9b090a7fd814,d:9241aba1c0c547f8878bef4099b579e9--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:bvs="http://www.bioventus.com/20230401" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bvs-20230401</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl8yLTEtMS0xLTE5NDkyOQ_1f65354c-a697-4039-a719-c98001b24b6e">false</ix:nonNumeric><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl81LTEtMS0xLTE5NDkyOQ_ebe66632-90b4-417b-8e31-592cdc5a088d">0001665988</ix:nonNumeric><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl84LTEtMS0xLTE5NDkyOQ_77546604-b736-4b7f-893f-1babe6b17c79">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl8xNi0xLTEtMS0xOTQ5Mjk_0af18a71-71af-4c45-9399-2c6f9321c9d9">2023</ix:nonNumeric><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl8xNy0xLTEtMS0xOTQ5Mjk_783558cb-1acc-4aca-bfe7-98c378db45d9">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bvs-20230401.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i52374b540ac247b597e34da4fa742209_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb6a37547344ac9aad38b881bb074fc_I20230512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i97dc12b8bc0f49cea30123f6d5847691_I20230512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if08a873c6cd84f99985971869a2e69d5_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98f850194f2743b69d130043cb5b83f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9ff7993c944b92a4bd359489e2eaa2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie046b8a033654588aa416481153be819_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5136a92c314002a0d0deb5ff33d794_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a77552c277241be958f7a79b2d31cfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42904e813fb462d9dc6296126b6c027_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a95c8964854c0ea4aa51dff316c9de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac87cf08602645f0945125525d86864a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc3dce8230ba45119afeb7423bdc2a1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35eb85bfb0344959b05e48db02d1b900_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c947a790104295ae50f5e97a83a1ab_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22d0b8a085484d5a96145656d90e23f7_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if617eff8c0b4423a8de0547fb060a911_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ffafbcd14f4f3491e4973003291b92_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id808e9e13e51453cba22d69e6a1554cb_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ab2fcc47d94402b6ff38f1493add69_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38144d2db4094669a2e5d9b194b1693f_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d0b867fa5943ee856db6daa307d849_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75851ee9fae0477786892678243e9687_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ad4457b2c747a98ed6638c8f80b5d0_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc622914d7b4479b2f4c07410226853_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc88da3e7a54c03802bbbf690e497ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d734f3503d4c13a2b1d964e624c27c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213ccc4548494407ab148000e45c5ee6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe3f930f8964d73927338dd023b5b3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9135fb165b2b49eb9e44a33009bf3cba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i951147d4bd5642aabe42d38fc7311981_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23499e24e764f54b220fbe6a3325161_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5615fc08d24ff491b3bbb101a069f3_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa0f2fc11fb4924a6e04334ad932d5a_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2accf9b821314f3bad4a25bd77746a1c_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6503af7f6a41e696df5e32d186a5ab_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c005cdfc09f429a8813448058fdbe09_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d6267e834a1443ea11cee027905e439_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie45a988315ec4dc5bee4e8ba6723c8a4_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ddf2d069db4849bee3aa72aa59d848_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34aedf09bd844e088614ef324e5b1a3e_I20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c0fbba09b6496a91ab1685ca96483a_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>bvs:employee</xbrli:measure></xbrli:unit><xbrli:context id="i96799592dc2f46ce951da575359089fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b737d439dfc4c049b11e5aa48820383_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8306c6c2e0b4d1497206736d20693f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178bff9b64ed42ff81776518c4189b1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66988f17121f479d987ec3f6a81fa043_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:EquityRebalancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i673ea96088114535bb4f91785d7e72e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:EquityRebalancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42fe425b80941f48b28aca4ecd33ade_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:ErrorCorrectionInCalculationOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a4b0b14d204b00844c680753360a35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:ErrorCorrectionInCalculationOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9117991cb301409cb832cbb9dd88871a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:EquityRebalancingForIssuanceOfStockThroughEquityPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109b3bd8eade44d394a7ae03c62fed13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:DeferredTaxImpactFor2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i688306a9d855467ca189676c7d19b6cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ebfe75a99584627ab0c086aca856452_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bvs:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib35b3d444a98478a89240114e08c3916_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da15f6d37344cae8110d560e17ae77c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15da563fbc3546a19bdbbb85a92d1730_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764545bc9ad949eea69c3be558616715_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62641fead14343468e0f3d886ba7a6ca_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70245e2f7da94059ae58287036f79af6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98809c525a964717bfbdd03b0ff34ad8_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib032dbd53db04880ad76314b46e1e9e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5c981648904e9b80b64c023d15fa42_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4af42355014f9cba9ef136263bb498_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b54bc099ff64cdf83d289598ea44468_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ccfda1a2d4406197267d9884f36892_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0829461c73da4cc59c0a31bf4e8fdc00_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fad609af52e483890feb9ddbe45ddcc_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bvs:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i00ae122881df443da212c3e259b30aac_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e7f859e2de4e2e9bea8834f864b660_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa935ec3263472594eb58a3df3c2f65_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c00fe1120844212b2fb0039b542d999_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2d5c54e1f649d99de1b04258d57249_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4a9d2699d26472ebf9e64d62424696d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2781c3a6a04fffb4599cdde6001d9a_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd6603021274a84ba8c4328e971097b_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf3b97bb69794fb5a74d6264e30703c9_D20220712-20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bvs:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d2594349e442f5aa4558186daaac0f_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>bvs:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i975eb89011db4560ba2bcc2086c60016_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJuly12023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49db16cff51046329cf250fb5ac89e34_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableBySeptember12023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f444d9528924284aadcb1788007ff06_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJanuary12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe7aa5cbcd4e4539a13ab3abf8e8c9f7_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJanuary12026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f4d905bbb34b16a050cfc582ff2ea9_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJanuary12027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd90e131a7bf4a278b55541190ffe001_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f12085d4424a5b9d5157232a465367_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:TrailingTwelveMonthSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5248f80680c045179f84e361ed1ba3cc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1247f024a75548eba0514a747599cee5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac987576c674d6cbf92d74ed2df1b8b_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f97030445ee47889c1b38177e4a3a23_D20230213-20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJuly12023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-13</xbrli:startDate><xbrli:endDate>2023-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80bae10979d2454580adedb3b2a6c481_D20230227-20230227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb5d183410449b1908570eb5651c0ca_D20230227-20230227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:ElronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f75d22eb20045e4a96e961e0a09ca92_D20230227-20230227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a06c7e9385495f98dce248522deff1_D20230227-20230227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad8c492357214f09a0573977291f320f_D20220712-20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2752ec5905e4a858220620c6f6f6ab1_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff82fadf30aa4ced9c49563731d130d5_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dafe4682a984e7cb23b5b32626f258b_D20220703-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-03</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f99c0f111c40f4b35d75accc7a326e_I20220711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387d0ba33ecf49d4ae4397e0b83f1636_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9202c7ec716435aaa3082106434860a_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bvs:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61effdba045e47f7bcb546d32bcd31c3_D20220712-20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe5797c14874b5fa84ef6a0757f4034_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id56740f57a5e43aca22cc898a646c454_D20220712-20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-12</xbrli:startDate><xbrli:endDate>2022-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bdab0f0d4d463fa6398c22775dd54e_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if35ea5d41b5b485f883e49f6ae8fdc25_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa1cdc09860462383a3492205a224d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad26eeedf4bb4bbda6790671a5bdff05_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c79358e91348e084baee11c93bc142_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d9f38043fa4c028d7126e56c12e67d_I20191206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a847747334d4e8ba6cc594e9dcdc9df_I20191206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047d1c54f41c47e5b83b854cf55d776f_D20220711-20220711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76987f19a9c44ee4a8433bbef3cdc2e3_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe65f363fbb4e1787d372f14d6ed933_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c898ba97cad4ab6b65934419909f8e3_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if392e17bdeab412496b7af16131a7aba_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityJuly2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie47412cb505a4ad484457826df28f027_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b6613394184391936737b585ea4d43_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefdfaf8115ec421eb8f0d09f38e11095_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5252c9ad17db48d1988ebc871c1bdd70_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa95b5adcef4db8a8cea991408aafb7_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42967b0b3404880892fef4d2d36f92f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df20ba54290443e83e1927334a06e3b_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031d0465b2ad444390d6fdd9eb9e80b5_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivative"><xbrli:measure>bvs:derivative</xbrli:measure></xbrli:unit><xbrli:context id="idd2c5ab49e734e9bb3b79cadbd93c30d_D20221028-20221028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-28</xbrli:startDate><xbrli:endDate>2022-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8a6fd92ded42a9ae62df80dfacd5bc_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bff1a06928a49e684d3ba0fc962346e_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfb6349253c4e3280459ada7054fafc_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9956bf782d64ea1bd2b96df630c6d75_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3cb0bc9269646a2a591dda918400054_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ef7632e5b4407e87abff23d73b268c_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad35dc89c0f44e299cceeb0f722b12ee_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961477208dd54a26b2ccf6e64c912305_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2705284e689b4650bdc0ab6b3be0e86e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6df20213a847689d562669ec8c0eb2_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848696f930194e1d8e9f0ab3b2518dab_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabedf0c4173d4d219e5a4a7c97ef7c6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief782f56b0bd4c4ba52ecbb991a64e23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7804b256d26143329ce8b1c8bfdeb7ee_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a1162e408641aeb42666f59ea6e3c1_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b95fd7a3234324ac4b5f9ada511b59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb4f2d80cc44287b347cfd75169b5a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323f1175cc564a45a27343e1faec2e7a_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87246041109544cf8fb41b557c4513b7_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd7797604384c719b067b4dc6cf3c42_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41945a367312405a869c8711b228f155_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2479f6ea4f13427d9a5c83ccd6ec9614_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9b7a1c5154425c8c24265aade7743e_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id47714ccd1064cd1b7ff9cd499c1fc55_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094ee1c434914509890caa47833deaa5_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e007318d4e4feaa4ef8dfd98ef3932_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c0aac0923c4bc7a1174492aa74af25_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb624597b214504b42d1ecb52e98a8c_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4fed2036ec84bff9a6d9d643492a512_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia114f5984aa5487d94a7e5a2f9dd47c1_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c391ae2f04e49239fb30fb662e626cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a367805653149a6bd4c69f62610cedd_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90132788802142b1b654aab8435a8fb6_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i977440bad8ac48adba402f0ac93702bf_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455ecc502ecd43c8a0240143ce3f7613_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bvs:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd867d34482345439425ee5ab5255266_I20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b2195c740e24fa3b47460484cabe3cd_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e141c8e8054b31a54f133d51dc223c_I20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4f6b39d2a74a85bb0d2edd723d8a7b_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>bvs:segment</xbrli:measure></xbrli:unit><xbrli:context id="i77db743857a644e9a0320ade7e6a5d2a_I20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8504a2e91ba84dfd8a6e426662ca386d_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id407ba4965db4b79a8fd6e8dc15e23b0_I20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ca1d77ddbc4f598510ff5ccb96d1ee_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>bvs:vote</xbrli:measure></xbrli:unit><xbrli:context id="i4f28a6c8e2a44fe9b2c8149437d14601_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b082e001c941259cd51349877d6268_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00441e04d2f34f5aa2bc5b4cd5b53c4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3508c22776a24e489023f7a0f04b1e3e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad3381ddd884b6e8d796b931cdf5c98_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f9f122c646249b6ba80f94f1d27ce49_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideca15b277be4a5a80bfeb0ef5169075_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb4089d2b0824f41a82aadcb2951f8f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc806e7a00b4d2aa28a38d41193abfe_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i621e34ed2397424fbf3217653350ee1d_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bda7af6c3f04de89092466d5c2c03b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaac88ea486b416ea279e01dd9088634_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab3e51b5150437a9922627be2e141bb_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd02248ff5a4c349ca283983f6fb643_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826a2b73e7024f2bbb971c7170189c53_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cb3b3b1ef8485b8260800eb571e90a_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec54bc3bcce4e0cba062fc969afa5c3_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e76064517ae4b5e9d9e3a322bd12ee1_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab463c35574b4f8ca9e4c2daa0b62cf5_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie37855daa1184dc78d7515b03e113ea3_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7889eb67185b4a7fb1f2a59966756eb0_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c1ba06aa134309858a469840e28937_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i544e8c2721cb486fa712dc07d475a475_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cafecddd27a4b469315f336ef3ed50d_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5b22816b48c442798421ebd10c98786_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eab176afd194ef687ade1014da11d08_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd943395fc7408b9c20e3013b149ed9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief777ae06245484290df025fea9e0d3d_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d6024603534c5ea5af4d437fd6040e_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c209e0543284533a6ae897763a26743_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471155b226eb40c690334fd2874e4f56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9c750d3df948a0bfe95f8639979859_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73d4aa340243422abe25f197db4c3b59_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc2830275f954d0484c2c3f9c65710b4_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa741b924a3549099b1b5111321fbba2_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4cade8aa8d459cab8ee8fe3bbf1bdd_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7304128a25744503b8891660f963b710_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6cde82adad47b0938be5a986d174e9_I20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a9b09aeea047d997e35f25ccf68400_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0195281e11e649b9b130d85d5763b801_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269ccd94849d4d2ba444fb9e4e51782b_I20210819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e70fc04918244f2994b165f1a124430_D20210819-20210819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-19</xbrli:startDate><xbrli:endDate>2021-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id46b7f3929c94e30aa38e125d5c1fb3a_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270d95a5216e45eca0d7972f80ac3edb_D20221223-20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095df0e9d3b640bdad1576e09c931392_D20221228-20221228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a13de58ac44d4ca44be08ddc84b03b_D20221228-20221228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:BionessIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:HAProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-10</xbrli:startDate><xbrli:endDate>2021-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76920cf66e21420bb4f0e4336311f5de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:HAProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c32e79d61845d9a2b670c38ccad90a_D20190823-20190823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-23</xbrli:startDate><xbrli:endDate>2019-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b5a733f4024b57989f06cbdb94c545_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc6602c201f442ea229c5c1441c0506_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-09</xbrli:startDate><xbrli:endDate>2016-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c5e680b22440109145605beffbd285_D20201222-20201222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2020-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85686a2c0fc64b148872e20370023dd3_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c67e34f91494006b4a5bd61a96084e8_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a1353106cf447ca65be040ed56b6d0_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6030c2e18bb140f29cddb91bd8f88824_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if757a0e5be5f42b2b08f3b701abff4af_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671287cbd69c46ef9a385740e8dbd49c_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7e30af75d7460f92fef399bf827f6b_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5376f01c85d24e8cb1ee7b9a3e0894e7_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9051c125b094e389ac08453ae46745f_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1101072b1f7f4d799ac5ea6ab0705a18_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc532b467295442c823324184b9ebe64_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260d2a092ee24cd08e4a8a8282a56d28_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib522fb2bab9949e69f42dd7e1b248159_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f3a6d840244f7f92937f02e11c783d_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915d046eaaee44c7881495d91a8a7d49_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id797d5aea258432e9c7d0ca865cdaee7_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc30004a37a84a44919da8653b8b5a85_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic681d0153e8d44509633594dee0fc4c2_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f9608964984704ad0bc120b4fb197e_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10818604d3f84a4b9f8471323205d604_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i221faa30c740451eb553a94e1f7b7017_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a1c8e6882a4bff9613fb79fbc5344d_D20230406-20230406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-06</xbrli:startDate><xbrli:endDate>2023-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852f13a0b8994a0b9c4197a33edb508f_I20230510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bbfa06653064902b83b28df8ecfa4bc_D20230510-20230510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-10</xbrli:startDate><xbrli:endDate>2023-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9241aba1c0c547f8878bef4099b579e9_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDI5_1dcfb747-1997-4f62-88db-84a86e44c996">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NjEzZmM4MjcyYWY3NGY4NWExOGQwYzU2Nzk3NWQ4MzIvdGFibGVyYW5nZTo2MTNmYzgyNzJhZjc0Zjg1YTE4ZDBjNTY3OTc1ZDgzMl8wLTAtMS0xLTE5NDkyOQ_db7be0c1-5f52-4156-9e62-b96dd55ccdbf">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18xNjc_e2e37d07-13d8-4f5e-9870-fe54c4c86506">April&#160;1, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6M2UxODI0NzM5MmM5NDhhNzhkYzYxYzA1ZWE4ZjFhZjkvdGFibGVyYW5nZTozZTE4MjQ3MzkyYzk0OGE3OGRjNjFjMDVlYThmMWFmOV8wLTAtMS0xLTE5NDkyOQ_b3fb16d0-94f5-405d-938b-f12053be90e7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from ____________ to ____________</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMz_367f6484-9c77-4284-9c04-bdc6878e3708">001-37844</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMw_75d63c1a-3333-4b17-b02c-8ab39206720a">BIOVENTUS INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18wLTAtMS0xLTE5NDkyOQ_be7012ad-cff3-426a-9dbd-5233c47efcbf">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18wLTItMS0xLTE5NDkyOQ_ed5faaee-cfda-444c-b316-1381caef3741">81-0980861</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18zLTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOjYyNzViYTE2MGFkZjQ1MjI4MTg3N2ZjYjAxYWYzMmRmXzQ_1c74a39b-a7a5-48e6-b58c-58709c19020a">4721 Emperor Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18zLTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOjYyNzViYTE2MGFkZjQ1MjI4MTg3N2ZjYjAxYWYzMmRmXzg_de7a295a-07f1-4b1d-b6c7-5a35ac66838d">Suite 100</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y180LTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOmE3NWI1ODYzMzM5YTQxNmFiMWEwZGE5ZDkxZGQ4YzgzXzQ_c7e12db7-8050-4895-af9f-109b734ba442">Durham</ix:nonNumeric>, <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y180LTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOmE3NWI1ODYzMzM5YTQxNmFiMWEwZGE5ZDkxZGQ4YzgzXzg_9cc1d233-b372-4b75-94c4-a2e8b9155c54">North Carolina</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y180LTItMS0xLTE5NDkyOQ_53865b20-a675-4056-a84d-3e13bf6da12c">27703</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDM0_b093a719-4e77-4853-a33e-6266d3781939">919</ix:nonNumeric>) <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMx_d37d6fea-70f1-4093-8dbd-3b6f2788fa59">474-6700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6ZDkxY2RmYjgwZGVlNDc3ZjgzNjk5NGUxODBiMmUzNDkvdGFibGVyYW5nZTpkOTFjZGZiODBkZWU0NzdmODM2OTk0ZTE4MGIyZTM0OV8xLTAtMS0xLTE5NDkyOQ_fe465e07-05b2-41ae-a048-b443fd28e7ab">Class A Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6ZDkxY2RmYjgwZGVlNDc3ZjgzNjk5NGUxODBiMmUzNDkvdGFibGVyYW5nZTpkOTFjZGZiODBkZWU0NzdmODM2OTk0ZTE4MGIyZTM0OV8xLTEtMS0xLTE5NDkyOQ_acbc4e00-fb55-47bb-8bef-1eb16e59bf9e">BVS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6ZDkxY2RmYjgwZGVlNDc3ZjgzNjk5NGUxODBiMmUzNDkvdGFibGVyYW5nZTpkOTFjZGZiODBkZWU0NzdmODM2OTk0ZTE4MGIyZTM0OV8xLTItMS0xLTE5NDkyOQ_fd21cadd-7b82-49c5-96fa-0fa30063ef58">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDM1_2fef7d53-7981-412d-a123-75d2f2e9f362">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMy_8d42b3d3-2bba-4951-a714-fa6ab8020718">Yes</ix:nonNumeric>&#160;&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6MmE3OTBmMGQ2NTc2NGEzYWE0NDcxNjQ3NzdiOTViOGQvdGFibGVyYW5nZToyYTc5MGYwZDY1NzY0YTNhYTQ0NzE2NDc3N2I5NWI4ZF8wLTMtMS0xLTIyNjU2Ng_9741b8bd-c9d5-4074-8f92-eda4e01ab358">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6MmE3OTBmMGQ2NTc2NGEzYWE0NDcxNjQ3NzdiOTViOGQvdGFibGVyYW5nZToyYTc5MGYwZDY1NzY0YTNhYTQ0NzE2NDc3N2I5NWI4ZF8xLTQtMS0xLTE5NDkyOQ_04870ba7-d902-43e7-b4bd-f5df5d4661a8">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6MmE3OTBmMGQ2NTc2NGEzYWE0NDcxNjQ3NzdiOTViOGQvdGFibGVyYW5nZToyYTc5MGYwZDY1NzY0YTNhYTQ0NzE2NDc3N2I5NWI4ZF8yLTQtMS0xLTE5NDkyOQ_ffc6d98e-720b-464e-9775-48bc0a2cfe7d">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDM2_3c8f9df9-65fb-43fe-8144-8ae397605f16">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM180OTQ3ODAyMzI3MDMw_f0040b2e-a21c-47b4-96b8-ab7d8401649c">&#9746;</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May 12, 2023, there were <ix:nonFraction unitRef="shares" contextRef="iaeb6a37547344ac9aad38b881bb074fc_I20230512" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18xOTMy_8587f332-f51f-44e3-b889-a6501ed551f2">62,486,725</ix:nonFraction> shares of Class A common stock outstanding and <ix:nonFraction unitRef="shares" contextRef="i97dc12b8bc0f49cea30123f6d5847691_I20230512" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18xOTgy_24891739-7ae7-414d-a2c5-80de1b79e3aa">15,786,737</ix:nonFraction> shares of Class B common stock outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:5.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOVENTUS INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:5.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_13">PART I. FINANCIAL INFORMATIO</a>N</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_19">Consolidated Condensed Statements of Operations and</a> <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_19">Comprehensive </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_19">Loss</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_19"> for the </a>three months ended April&#160;1, 2023 and April&#160;2, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_19">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_25">Consolidated Condensed Balance Sheets as of </a>April&#160;1, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_25"> and </a>December&#160;31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_25">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_28">Consolidated Condensed Statements of Changes in Stockholders&#8217;</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_28"> </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_28">Equity for the</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_19"> </a>three months ended April&#160;1, 2023 and April&#160;2, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_28">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_31">Consolidated Condensed Statements of Cash Flows for the</a> three months ended April&#160;1, 2023 and April&#160;2, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_31">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_34">Notes to the Unaudited Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_34">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_88">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_88">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_109">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_112">38</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_115">PART II. OTHER INFORMATION</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_118">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_118">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_121">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_124">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_127">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_127">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_130">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_130">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_133">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_133">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_136">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_136">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_139">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right;text-indent:5.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9241aba1c0c547f8878bef4099b579e9_139">45</a></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div id="i9241aba1c0c547f8878bef4099b579e9_10"></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to "Bioventus," "we," "us," "our," "the Company," and similar references refer to Bioventus Inc. and its consolidated subsidiaries, including Bioventus LLC (&#8220;BV LLC&#8221;).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and Section 27A of the Securities Act of 1933, as amended (Securities Act), concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements regarding our business strategy, including, without limitation, expectations relating to our acquisitions of Misonix and Bioness, expected expansion of our pipeline and research and development investment, new therapy launches, expected costs related to, and potential future options for, MOTYS, recent dispositions of non-core assets, our operations and expected financial performance and condition, and impacts of the COVID-19 pandemic and inflation. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#8217;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Important factors that may cause actual results to differ materially from current expectations include, among other things: the risk that previously identified material weaknesses or new material weaknesses could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner; we might not be able to continue to fund our operations for at least the next twelve months as a going concern; we might not meet certain of our debt covenants under our Credit Agreement and might be required to repay our indebtedness; risks associated with the disposition of our Wound Business and expected impacts on our business; restrictions on operations and other costs associated with our indebtedness; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; we maintain cash at financial institutions, often in balance that exceed federally insured limits; we are subject to securities class action litigation and may be subject to similar or other litigation in the future, which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes; our ability to maintain our competitive position depends on our ability to attract, retain and motivate our senior management team and highly qualified personnel; we are highly dependent on a limited number of products; our long-term growth depends on our ability to develop, acquire and commercialize new products, line extensions or expanded indications; we may be unable to successfully commercialize newly developed or acquired products or therapies in the United States; demand for our existing portfolio of products and any new products, line extensions or expanded indications depends on the continued and future acceptance of our products by physicians, patients, third-party payers and others in the medical community; the proposed down classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration (FDA) could increase future competition for bone growth stimulators and otherwise adversely affect the Company&#8217;s sales of Exogen; failure to achieve and maintain adequate levels of coverage and/or reimbursement for our products or future products, the procedures using our products, such as our hyaluronic acid (HA) viscosupplements, or future products we may seek to commercialize; pricing pressure and other competitive factors; governments outside the United States might not provide coverage or reimbursement of our products; we compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do; the reclassification of our HA products from medical devices to drugs in the United States by the FDA could negatively impact our ability to market these products and may require that we conduct costly additional clinical studies to support current or future indications for use of those products; our failure to properly manage our anticipated growth and strengthen our brands; risks related to product liability claims; fluctuations in demand for our products; issues relating to the supply of our products, potential supply chain disruptions and the increased cost of parts and components used to manufacture our products due to inflation; our reliance on a limited number of third-party manufacturers to manufacture certain of our products; if our facilities are damaged or become </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inoperable, we will be unable to continue to research, develop and manufacture our products; failure to maintain contractual relationships; security breaches, unauthorized disclosure of information, denial of service attacks or the perception that confidential information in our possession is not secure; failure of key information technology and communications systems, process or sites; risks related to international sales and operations; risks related to our debt and future capital needs; failure to comply with extensive governmental regulation relevant to us and our products; we may be subject to enforcement action if we engage in improper claims submission practices and resulting audits or denials of our claims by government agencies could reduce our net sales or profits; the FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing our products; if clinical studies of our future product candidates do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere, we will be unable to expand the indications for or commercialize these products; legislative or regulatory reforms; our business may continue to experience adverse impacts as a result of the COVID-19 pandemic; risks related to intellectual property matters; and other important factors described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part I. Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our subsequent Quarterly Reports on Form 10-Q, and as may be further updated from time to time in our other filings with the SEC. You are urged to consider these factors carefully in evaluating these forward-looking statements. These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_19"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bioventus Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations and Comprehensive Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended April&#160;1, 2023 and April&#160;2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMi01LTEtMS0xOTQ5Mjk_6f78b36e-9fe6-4adf-8462-d173ff5ce7f9">119,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMi03LTEtMS0xOTQ5Mjk_56d3c6e2-66e6-46ae-a53a-327c1fc4b14e">117,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (including depreciation and amortization of</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;$<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjo0YjQyODdjM2Y3YWM0MzBhODcyZGRiZDAyOWJmZDI4OF82NA_4959689f-4a5e-471c-b15c-8c4a0f02cb59">14,339</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjo0YjQyODdjM2Y3YWM0MzBhODcyZGRiZDAyOWJmZDI4OF82OA_a3d4891b-4e27-4c46-b894-e6b59463b8e1">9,218</ix:nonFraction>, respectively)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy01LTEtMS0xOTQ5Mjk_4ebf14b6-43d0-4189-9477-99b3e2cdc663">45,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy03LTEtMS0xOTQ5Mjk_8598e660-aa20-4dc1-b9bb-cbbde3786a26">41,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNC01LTEtMS0xOTQ5Mjk_73578f0e-7371-48a6-9693-31bb31f7337a">73,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNC03LTEtMS0xOTQ5Mjk_91900987-5934-4a63-ac98-f53f51fae2fe">75,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNS01LTEtMS0xOTQ5Mjk_69798614-c9c0-44d2-9f19-67afa124564f">80,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNS03LTEtMS0xOTQ5Mjk_04240f13-ca59-4f2f-8eb0-1b100213de8d">86,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNi01LTEtMS0xOTQ5Mjk_e44ea684-5789-44f0-b7e5-de551b730db3">3,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNi03LTEtMS0xOTQ5Mjk_e87fc751-fc5f-4aee-8d7a-4dc8a7ec11f9">6,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNy01LTEtMS0xOTQ5Mjk_6b361373-ed6b-43ae-a000-b9dc70550b53">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNy03LTEtMS0xOTQ5Mjk_984d0adf-0810-43fe-86f1-a3fab4acadb7">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOC01LTEtMS0xOTQ5Mjk_a6069c35-32c6-4122-ad93-c94ebe6782fe">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOC03LTEtMS0xOTQ5Mjk_8b855133-61dc-4b3d-a14b-ed2fca5b7b23">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOS01LTEtMS0xOTQ5Mjk_b85bab56-222d-4a4c-a86b-3973f6ea6b6e">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOS03LTEtMS0xOTQ5Mjk_cb317be1-91e4-4de4-a7ab-32be0334d059">3,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTAtNS0xLTEtMTk0OTI5_806bba9c-3d8a-4e02-a8e1-d5b9695444ef">78,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTAtNy0xLTEtMTk0OTI5_822cf4d9-da5a-47fb-ac02-bb0600813d4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTItNS0xLTEtMTk0OTI5_e50af166-cb5f-46a4-b1d4-267a50cce74a">92,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTItNy0xLTEtMTk0OTI5_8c93989b-4409-4717-97b4-99c610ecd6df">21,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTMtNS0xLTEtMTk0OTI5_b9f7b372-1e8e-43c5-97d6-184187f5da60">9,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTMtNy0xLTEtMTk0OTI5_23b38b28-e018-42b8-9967-689264e1933c">1,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTQtNS0xLTEtMTk0OTI5_c1167361-def5-4648-bd33-9c03bfa08e29">1,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTQtNy0xLTEtMTk0OTI5_761dba21-981f-4be1-ad09-9a18ae9389fb">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTUtNS0xLTEtMTk0OTI5_cb188ee0-685e-43b3-80f8-a5878e81d056">8,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTUtNy0xLTEtMTk0OTI5_80d003d9-cce0-47fe-a73f-87a930e01472">1,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTYtNS0xLTEtMTk0OTI5_d3a90ef9-dfc4-4d2c-9d0b-ee13fe0a1f4d">100,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTYtNy0xLTEtMTk0OTI5_7c833e57-4701-43cc-bf93-b4eb0a208420">19,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTctNS0xLTEtMTk0OTI5_15f3b1ea-cd82-4125-a5e8-037f3bbf491e">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTctNy0xLTEtMTk0OTI5_2799c544-b93c-444e-a6b4-406bff307624">5,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTgtNS0xLTEtMTk0OTI5_929fb60e-c54a-443f-ab74-4c296278ea1c">100,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTgtNy0xLTEtMTk0OTI5_008990f6-ae09-4731-a377-b2e9f8e79859">14,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNS0xLTEtMjA1Mjc0_af781833-2b37-451a-ac76-29e7a666aa65">74,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNy0xLTEtMjA1Mjc0_5cf943f4-c3bb-46f9-9771-8679b2eb67dd">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNS0xLTEtMjA5MDQ3_592145ee-eeaf-4e78-b49c-ce35b3866124">174,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNy0xLTEtMjA5MDQ3_9fd9c572-0e75-4d69-9d38-2934f3f35ee6">14,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to noncontrolling interest - continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNS0xLTEtMTk0OTI5_bd4cb1ac-2b26-44f1-aaea-644af287b0e0">20,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNy0xLTEtMTk0OTI5_7faa21e0-efaf-490c-8f3d-87dcf687b84b">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to noncontrolling interest - discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjEtNS0xLTEtMjE0MDIy_ab3cb1ad-cbb3-4f0d-877e-8821caff0db3">14,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjEtNy0xLTEtMjE0MDIy_28a4f071-46b8-453b-817e-4741252193ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNS0xLTEtMTk0OTI5_d88dca1a-cc0e-424c-8014-91361b41d509">139,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNy0xLTEtMTk0OTI5_199f45e6-ca60-4bb0-9245-d88c8e9cf055">11,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjItNS0xLTEtMTk0OTI5_8ebdc0a9-2895-4e40-a475-9cd2e63cc073">100,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjItNy0xLTEtMTk0OTI5_9a668a94-79ed-47dc-a07e-22fcd5fb8620">14,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjQtNS0xLTEtMTk0OTI5_9505799e-b459-4eb5-b4e5-c4e59aa6f5d1">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjQtNy0xLTEtMTk0OTI5_dea767e0-271f-42a4-83fc-f077f608d5cf">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjUtNS0xLTEtMTk0OTI5_b5c501ea-8d83-4e88-9cbe-5da35260d1e4">99,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjUtNy0xLTEtMTk0OTI5_4430e4bd-d432-457c-b8a7-b5803163444b">15,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest - continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjYtNS0xLTEtMTk0OTI5_625a5283-1d86-43ee-a54b-aaa91aa427ba">20,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjYtNy0xLTEtMTk0OTI5_b8e25166-1cb4-47fa-bce4-511d020fc522">3,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest - discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNS0xLTEtMjE0MDg3_3ea709e3-18e7-49f4-a057-2a6509505392">14,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNy0xLTEtMjE0MDg3_7a80705a-d7f0-4414-866a-a8fcbca89e3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Bioventus Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjctNS0xLTEtMTk0OTI5_241f9c73-87ba-4e55-aafc-3385cf53bb4d">64,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjctNy0xLTEtMTk0OTI5_31957620-e0e6-427d-893c-bdf1198ba53a">11,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share of Class A common stock from continuing operations, basic and diluted:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="INF" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNS0xLTEtMTk0OTI5_b03ca516-a186-4d40-849c-eb9ace7928a3"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="INF" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNS0xLTEtMTk0OTI5_bfb43913-de54-4f88-b4f5-ce965cb8a414">1.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="INF" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNy0xLTEtMTk0OTI5_6bf7111d-b123-46c9-b2aa-d40ff044536d"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="INF" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNy0xLTEtMTk0OTI5_86e755d4-e6d8-46c4-988e-26c6a5191f82">0.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share of Class A common stock from discontinued operations, basic and diluted:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="INF" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjE1ODU1_6912ab97-5cb9-4f1b-9bfa-c86e7c4bb957"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="INF" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjE1ODU1_bf19b76c-fbb6-4429-830b-fd60fd4bf1ee">0.96</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="INF" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjE1ODU1_33d39feb-c3c9-4a12-adea-e68d77910a22"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="INF" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjE1ODU1_a9e84df8-b77a-4536-9d7d-fccf19836603">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share of Class A common stock, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjA5MDUz_272cc204-4587-4c3c-a262-11cc17e13591"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjA5MDUz_6fe78d61-0066-4983-97d9-ab96a48a7db9">2.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjA5MDU5_23282a4a-c2e8-449e-83b0-9e8f6e0d5e38"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjA5MDU5_b737bd29-b5fe-421c-b928-038b3a0e0f93">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of Class A common stock<br/>&#160;&#160;&#160;&#160;outstanding, basic and diluted:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNS0xLTEtMTk0OTI5_c4eaa163-8f6a-4e02-b5e8-1cb8bb7acab3"><ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNS0xLTEtMTk0OTI5_f7c58b2f-8d1d-42b4-9980-6b3abd15c221">62,124,752</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNy0xLTEtMTk0OTI5_669abd42-75ee-4bbc-9606-eff35b4b53cf"><ix:nonFraction unitRef="shares" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNy0xLTEtMTk0OTI5_c6c358ab-6275-4192-a14b-b78b567f820e">60,484,969</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bioventus Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets as of April&#160;1, 2023 and December&#160;31, 2022 (Unaudited)</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMy0xLTEtMS0xOTQ5Mjk_d4d4adea-6c93-4abb-83a1-e6554b614bd8">47,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMy0zLTEtMS0xOTQ5Mjk_ae47e722-e6ef-4904-80c0-2c814788d157">30,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNS0xLTEtMS0xOTQ5Mjk_ff18c16c-cf0c-46bc-a817-390472ebb8ec">118,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNS0zLTEtMS0xOTQ5Mjk_776fb93c-38e1-4586-96e7-7d7dab246c96">136,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNi0xLTEtMS0xOTQ5Mjk_55d8a95b-97c8-43c8-af65-cc6bd17bc6a3">87,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNi0zLTEtMS0xOTQ5Mjk_1975ba56-dd80-4bd2-b470-fd40345f80c0">84,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNy0xLTEtMS0xOTQ5Mjk_0be00cc2-4db2-4441-88e7-858b3ccc6834">17,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNy0zLTEtMS0xOTQ5Mjk_25d918e6-8990-4953-ac75-7fc1c9d327d1">18,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0xLTEtMS0yMTQyNDQ_da23a49e-233b-4d19-b6ba-c700d84f558e">37,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0zLTEtMS0yMTQyNDQ_262d4916-db9c-4bf8-be40-ed1ef1851d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets attributable to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0xLTEtMS0yMTQyMDM_e62ea808-a942-4fc5-a240-1aace90164ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0zLTEtMS0yMTQyMDM_6fb2c322-3172-4f93-ba21-973e2e663f01">2,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0xLTEtMS0xOTQ5Mjk_de2b5a50-a3b4-44fc-b1b1-41ba575907a4">308,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0zLTEtMS0xOTQ5Mjk_2170d361-f551-4411-b4bf-f243037bc5d2">272,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTEtMS0xLTEtMTk0OTI5_b236cfcf-2668-4d8e-98f5-31386d2a01fa">36,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTEtMy0xLTEtMTk0OTI5_c8d06013-03e9-4c85-bbf4-862bb480be26">27,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTItMS0xLTEtMTk0OTI5_b85af913-7946-4b73-b29f-2a22e84e31a2">7,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTItMy0xLTEtMTk0OTI5_4164b726-5ffc-43c2-9fc2-b1c4e9ae4d16">7,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTMtMS0xLTEtMTk0OTI5_4f64f907-bbb1-4153-a3ee-3b0018bc6de0">516,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTMtMy0xLTEtMTk0OTI5_ee9d4da8-485c-4247-bd98-7780057aca36">639,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTQtMS0xLTEtMTk0OTI5_a02711dc-2568-4e09-8117-a2cf95529023">16,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTQtMy0xLTEtMTk0OTI5_dbe1c2a7-d9cc-47b3-8e65-4904d7ffc071">16,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTYtMS0xLTEtMTk0OTI5_d7f3b0ca-99ba-43c7-97f2-236a3f798aaa">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTYtMy0xLTEtMTk0OTI5_c064a074-a6b3-4854-b5bc-4fe7dfc2ef35">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term assets attributable to discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTgtMS0xLTEtMjE0MjEz_0c953616-047c-40f7-8aaf-eab9925d65c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTgtMy0xLTEtMjE0MjEz_693a7856-c5dc-4605-a2a8-5aad6a990ebc">405,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTctMS0xLTEtMTk0OTI5_60040d30-ef7f-4baf-8b48-f86f66b0ae50">887,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTctMy0xLTEtMTk0OTI5_7e13ec81-bc21-428d-b093-f1b04cf8ada8">1,372,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjEtMS0xLTEtMTk0OTI5_bad16082-672b-4954-8fe5-91c21a1c27bf">32,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjEtMy0xLTEtMTk0OTI5_cec3ed7d-346b-426f-96a6-798c60ff8146">36,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjItMS0xLTEtMTk0OTI5_03797d1a-b5f2-4f22-8d78-0206edccd60f">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjItMy0xLTEtMTk0OTI5_3dd529be-ba08-4780-bc4f-3ce6a7805820">111,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjQtMS0xLTEtMTk0OTI5_c5e7927c-1d9e-49b0-a956-c161fa2c2355">41,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjQtMy0xLTEtMTk0OTI5_3ac88680-369d-4498-a53c-6711ee6427fd">33,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjYtMS0xLTEtMTk0OTI5_8ef7b633-f684-4609-bcd1-6b5607d8229b">4,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjYtMy0xLTEtMTk0OTI5_5f0b9445-4352-488e-b240-2892fdb0a45f">3,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="bvs:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMS0xLTEtMjE0MjU4_07e119b1-e333-4bab-b141-ad7969f0dde8">1,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="bvs:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMy0xLTEtMjE0MjU4_7a2a923d-34b8-46d5-a6d5-609784e561b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities attributable to discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMS0xLTEtMjE0MjIx_e110c76b-248b-4170-8764-975cdb9b56dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMy0xLTEtMjE0MjIx_9d91fb50-7011-4920-805a-bfe28bb5a1af">119,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjctMS0xLTEtMTk0OTI5_091c6520-ab1c-45a1-ac07-df1dc76dd0f9">196,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjctMy0xLTEtMTk0OTI5_786fcc40-f3ef-496b-af70-9bfb354378a0">304,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMS0xLTEtMTk0OTI5_942f1686-c813-4c5a-aebf-0d6731f4f10c">404,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMy0xLTEtMTk0OTI5_15540c26-a8de-49db-aa59-2b339a169147">385,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzAtMS0xLTEtMTk0OTI5_bdd35038-4c09-4f09-9ac1-02e818ed2a55">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzAtMy0xLTEtMTk0OTI5_4a22d40c-bf5c-47df-8cd0-96ba077ed961">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzItMS0xLTEtMTk0OTI5_aa8efe7d-0ab6-4df2-af5b-77873a7b49d6">17,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzItMy0xLTEtMTk0OTI5_f7829a9d-b011-43d3-91b4-0982b8126ec1">17,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzMtMS0xLTEtMTk0OTI5_3fee3a16-5422-4dd1-8f03-b9e78ada6406">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzMtMy0xLTEtMTk0OTI5_574f56e6-3045-4649-8650-7142dfda5b7a">22,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term liabilities attributable to discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzctMS0xLTEtMjE0MjMx_39dfcc4e-2ecf-4172-bc63-0b46ac69a604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzctMy0xLTEtMjE0MjMx_59b29e9d-749b-4a80-9613-0662506b62d6">228,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzQtMS0xLTEtMTk0OTI5_74525c9a-5421-4811-96db-a448a17d3289">647,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzQtMy0xLTEtMTk0OTI5_0ee6b307-e506-4d9a-8fea-649dee00a3c9">960,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzYtMS0xLTEtMTk0OTI5_9ea9ab36-eef5-4ec7-af8a-110be2a0b789"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzYtMy0xLTEtMTk0OTI5_23f6d2fd-7108-49fb-b3e6-83d9c01ea79a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMjE_1832993b-0964-49c3-bd78-5f499fefdd6d"><ix:nonFraction unitRef="usdPerShare" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMjE_787230e3-3f95-4f0d-b1b9-6631939ca16a">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMzU_449aea91-4b38-44a2-a6a4-659fda2433ef"><ix:nonFraction unitRef="shares" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMzU_82c349aa-a8b1-48a7-9ade-6f98d104c7a6">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfNTc_06775ce2-e69a-43f2-a479-2781aaf90010"><ix:nonFraction unitRef="shares" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfNTc_5f32de10-4caf-45d2-86e3-03391499b332">0</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class A common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMjY_21f251a9-91c6-4dc4-a8e5-11bca5ee6616"><ix:nonFraction unitRef="usdPerShare" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMjY_9a7ce701-0344-4d83-87bd-c4978aeb83c0">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfNDA_c931e119-8891-4938-a484-5593899b5f25"><ix:nonFraction unitRef="shares" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfNDA_cd375da6-7365-47ef-8367-df76d9eb4cef">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of April&#160;1, 2023 and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfOTc_0d3b61c7-1e5c-4abd-8766-a81479032cdb"><ix:nonFraction unitRef="shares" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfOTc_6c60294c-60e8-42d8-a4b7-0c65239968da">62,507,917</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMTA0_2a496aa7-d817-4b98-8a84-cb849a860edb"><ix:nonFraction unitRef="shares" contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMTA0_cbf0440d-74d3-4108-98f5-c287b1998ecd">62,063,014</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of April&#160;1, 2023 and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMS0xLTEtMTk0OTI5_5d32e2aa-eda4-4281-973c-8d7b0fe72dcf">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMy0xLTEtMTk0OTI5_704b3b58-58e4-48c9-bd19-c69c2c66e2fc">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class B common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfMjY_ac56d0f9-ff85-41b4-9ae2-c6e86931389f"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfMjY_c1e8247e-cbc0-4b10-a639-fab82fdada5b">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNDA_0fbc4fb1-8e4d-42a0-880a-6a979827b7ba"><ix:nonFraction unitRef="shares" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNDA_622eb6ec-029a-43bd-84f2-cff4f2545b19">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="shares" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_2fce4d3a-0c39-4d53-8413-26a37b41f9c7"><ix:nonFraction unitRef="shares" contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_3b5542e8-8290-461b-b7af-c054687adba1"><ix:nonFraction unitRef="shares" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_56e9f9dc-2d1c-42a5-968c-8801514b4c57"><ix:nonFraction unitRef="shares" contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_828ce548-1e4d-4650-9934-307a86ea8192">15,786,737</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of April&#160;1, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMS0xLTEtMTk0OTI5_20374194-6515-4037-836a-ecdb523b8ae8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMy0xLTEtMTk0OTI5_465134a7-712d-49e6-ae56-1a06a0fda0d9">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDItMS0xLTEtMTk0OTI5_0563a5a6-aac2-442c-8308-f2c0a338973b">492,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDItMy0xLTEtMTk0OTI5_8068cf2e-eaf1-418d-afcd-b90dbb3ac252">490,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDMtMS0xLTEtMTk0OTI5_07c9dff9-9491-446d-a984-e0bb398b5651">304,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDMtMy0xLTEtMTk0OTI5_348cdff5-a9d7-41ac-a1f2-1c6c39e3c403">165,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDQtMS0xLTEtMTk0OTI5_9f5860d8-16f2-4d66-94f1-7656fa1bf88a">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDQtMy0xLTEtMTk0OTI5_8b89febb-3c98-4f87-8ee3-195010357d7d">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity attributable to Bioventus Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDUtMS0xLTEtMTk0OTI5_284f8f23-4d46-4df0-8d29-b685f887f9a2">188,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDUtMy0xLTEtMTk0OTI5_428e74c1-d032-40e9-b67c-12a488f0e262">325,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDYtMS0xLTEtMTk0OTI5_5f294efa-3d38-4567-9541-eeae45592702">51,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDYtMy0xLTEtMTk0OTI5_47b08bbc-0254-4bc4-bbe7-3bc9a754d4d7">86,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDctMS0xLTEtMTk0OTI5_80e5b187-5aa5-42bc-8d1e-ed33c38852cf">240,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDctMy0xLTEtMTk0OTI5_4b8e2517-de03-450c-baa4-32e61d36c171">412,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDgtMS0xLTEtMTk0OTI5_d50dc02c-d71e-43ee-a0f0-064254eb241d">887,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDgtMy0xLTEtMTk0OTI5_09326ae2-7ceb-4e23-b399-617ac3951070">1,372,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bioventus Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Changes in Stockholders&#8217; Equity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended April&#160;1, 2023 and April&#160;2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share amounts)</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended April 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-<br/>controlling <br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total Stockholders'<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a77552c277241be958f7a79b2d31cfe_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xLTEtMS0xOTQ5Mjk_ddcbc87c-02e5-4b2c-a506-b4f1cc004a20">62,063,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a77552c277241be958f7a79b2d31cfe_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0yLTEtMS0xOTQ5Mjk_a4501166-456b-4f33-8e70-1d00f4dabcbb">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia42904e813fb462d9dc6296126b6c027_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy00LTEtMS0xOTQ5Mjk_209d37a7-2c38-4125-85cc-b5d21254e368">15,786,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42904e813fb462d9dc6296126b6c027_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy01LTEtMS0xOTQ5Mjk_003ea853-0662-49e9-8c49-db4a8963e2fe">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a95c8964854c0ea4aa51dff316c9de_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy03LTEtMS0xOTQ5Mjk_0542432a-0e20-4c24-81f4-1a4795d2a578">490,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac87cf08602645f0945125525d86864a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy05LTEtMS0xOTQ5Mjk_cec40da3-6324-42a2-8b8a-1bfdbde866cc">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3dce8230ba45119afeb7423bdc2a1c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xMS0xLTEtMTk0OTI5_cd0a29ba-c162-4798-810f-8669a85bf087">165,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35eb85bfb0344959b05e48db02d1b900_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xMy0xLTEtMTk0OTI5_3912dd0a-3963-4861-ae9f-3639d37f27e9">86,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xNS0xLTEtMTk0OTI5_cf484776-3719-4aaa-960a-86d12e887ebb">412,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Issuance of Class A common stock for equity plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4c947a790104295ae50f5e97a83a1ab_D20230101-20230401" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0xLTEtMS0xOTQ5Mjk_fe61e6d8-8d4a-4e63-8416-759a1d057b3f">444,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c947a790104295ae50f5e97a83a1ab_D20230101-20230401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0yLTEtMS0xOTQ5Mjk_f76296c3-6c4a-4366-8307-7390e22c6689">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d0b8a085484d5a96145656d90e23f7_D20230101-20230401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC03LTEtMS0xOTQ5Mjk_30170b72-2d1c-4a08-b6be-7a96697e06d3">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0xMy0xLTEtMTk0OTI5_df04f010-28f3-4b7a-8875-5f590c2a8366">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0xNS0xLTEtMTk0OTI5_0d69b5cb-3a21-483f-bab0-d0381f00c064">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if617eff8c0b4423a8de0547fb060a911_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNS0xMS0xLTEtMTk0OTI5_5e68431e-4a3e-42d8-9be7-2964446038b3">139,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNS0xMy0xLTEtMTk0OTI5_1cbbf7bc-54bc-4cd0-beb2-ce837705ceef">35,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNS0xNS0xLTEtMTk0OTI5_991bcf0f-07c1-406b-a9ba-5ea727026bf0">174,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Equity based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d0b8a085484d5a96145656d90e23f7_D20230101-20230401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNi03LTEtMS0xOTQ5Mjk_db659739-d8b3-446e-af68-9ad7c3ab79eb">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNi0xMy0xLTEtMTk0OTI5_60ca3e26-e1b8-43cd-bce9-1054ec45cbe7">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNi0xNS0xLTEtMTk0OTI5_0e9f7bbe-5f5e-4623-ac23-3c6a420deaba">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ffafbcd14f4f3491e4973003291b92_D20230101-20230401" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfOS05LTEtMS0xOTQ5Mjk_d5013ebf-38b1-48d4-9355-94fbe0e38414">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfOS0xMy0xLTEtMTk0OTI5_b9d2d218-c63d-4430-9d29-879c9a888a49">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfOS0xNS0xLTEtMTk0OTI5_3bcfd8f9-5888-4b96-ba1d-9221a8da9aff">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance at April 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id808e9e13e51453cba22d69e6a1554cb_I20230401" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMS0xLTEtMTk0OTI5_92295b8f-a1fe-4394-908f-aaa423d61772">62,507,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id808e9e13e51453cba22d69e6a1554cb_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMi0xLTEtMTk0OTI5_523f721b-3bab-43c5-b6cf-7d84f62950b6">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87ab2fcc47d94402b6ff38f1493add69_I20230401" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtNC0xLTEtMTk0OTI5_29af4abe-1f08-4f0c-9868-1ae1b113afc3">15,786,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ab2fcc47d94402b6ff38f1493add69_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtNS0xLTEtMTk0OTI5_6eb616cb-d66c-4ebd-93bd-95242c061c9f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38144d2db4094669a2e5d9b194b1693f_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtNy0xLTEtMTk0OTI5_81795cba-5e04-4f0c-8c97-826f5d6fcc32">492,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d0b867fa5943ee856db6daa307d849_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtOS0xLTEtMTk0OTI5_39ffbc35-6e2f-44b1-ba2e-daede38f41a3">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75851ee9fae0477786892678243e9687_I20230401" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMTEtMS0xLTE5NDkyOQ_f703c215-7819-4b17-91c8-610929ed8b0d">304,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ad4457b2c747a98ed6638c8f80b5d0_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMTMtMS0xLTE5NDkyOQ_5a50573d-d8b4-4856-a2ac-f1dec9900d33">51,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMTUtMS0xLTE5NDkyOQ_ad139635-ecc2-4d77-84e6-5cbad192be3a">240,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended April 2, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-<br/>controlling <br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total Stockholders'<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cc622914d7b4479b2f4c07410226853_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xLTEtMS0yMDU0OTc_a291a187-3a46-497d-9994-1e9538f776e6">59,548,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc622914d7b4479b2f4c07410226853_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0yLTEtMS0yMDU0OTc_7973541e-5a8c-4127-ad7d-5ed1285d326e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfc88da3e7a54c03802bbbf690e497ca_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy00LTEtMS0yMDU0OTc_60047545-6793-41ea-b277-b73b7e9a5633">15,786,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc88da3e7a54c03802bbbf690e497ca_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy01LTEtMS0yMDU0OTc_b25a6269-c20f-43f0-9b02-d318158ca1da">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d734f3503d4c13a2b1d964e624c27c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy03LTEtMS0yMDU0OTc_59ee2ee3-c332-4afb-9a4b-86601287bb28">473,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213ccc4548494407ab148000e45c5ee6_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy05LTEtMS0yMDU0OTc_6be76368-70b4-45d2-b40f-49ffcf91b497">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe3f930f8964d73927338dd023b5b3d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xMS0xLTEtMjA1NDk3_827e6fe8-fcf5-4ea0-9381-d81b8a679998">6,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9135fb165b2b49eb9e44a33009bf3cba_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xMy0xLTEtMjA1NDk3_886a7251-e32a-4bc9-a12d-c3d252c76ed1">140,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xNS0xLTEtMjA1NzQ1_6154db04-2022-4c1d-85eb-08d4288a2f6a">607,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Issuance of Class A common stock for equity plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i951147d4bd5642aabe42d38fc7311981_D20220101-20220402" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0xLTEtMS0yMDU0OTc_ace9b7a1-ac1c-4b2c-b4c1-0bfb2464a503">1,808,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951147d4bd5642aabe42d38fc7311981_D20220101-20220402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0yLTEtMS0yMDU0OTc_c42f7a8b-baac-4a56-a322-518be474e084">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC03LTEtMS0yMDU0OTc_ec4b5a9a-ce82-47bb-933d-abac5d5b999a">4,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0xMy0xLTEtMjA1NDk3_18edd23f-ea1c-49c9-bb2b-c8124677a684">2,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0xNS0xLTEtMjA1NzQ1_63349cf3-54ef-4bbd-b508-defa395c2821">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Deferred taxes on equity rebalancing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402" decimals="-3" name="bvs:DeferredTaxesOnEquityRebalancing" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS03LTEtMS0yMjkxNjg_646b93fc-0aab-4079-9834-04626cca2be0">1,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="bvs:DeferredTaxesOnEquityRebalancing" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xNS0xLTEtMjI5Mjk5_f5d3b171-4a49-4484-9984-7c04f56ea5a1">1,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5615fc08d24ff491b3bbb101a069f3_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xMS0xLTEtMjA1NDk3_e24a5148-ca3b-46a5-afe3-1c908f57a097">11,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xMy0xLTEtMjA1NDk3_56ed39a1-9589-4bf0-add5-647ce1026507">3,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xNS0xLTEtMjA1NzQ1_42c9259f-345a-487d-a357-13f22d0b1727">14,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Equity based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNi03LTEtMS0yMDU0OTc_a8053492-9e27-47ee-93f5-3c94ed7dcfe9">3,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNi0xMy0xLTEtMjA1NDk3_ebc5a205-0d0d-43d6-90ac-5b8f399d538a">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNi0xNS0xLTEtMjA1NzQ1_48b5d702-8855-4744-9655-ba5511528a4c">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tax withholdings on equity compensation awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOC03LTEtMS0yMDU0OTc_28ea32f4-5004-4bd8-8620-ea6e995e3f8f">3,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNy0xNS0xLTEtMjA1NzUw_7f780756-9687-4697-8e0e-51c9a11d16e8">3,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7aa0f2fc11fb4924a6e04334ad932d5a_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS05LTEtMS0yMDU0OTc_38272f74-e6af-4afd-bf02-d1d50258f8ff">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xMy0xLTEtMjA1NDk3_cb8e0683-223f-416f-8dab-d9e85356eda0">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOC0xNS0xLTEtMjA1NzUw_744b862d-4730-44ae-9401-e2279aeae1a6">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance at April 2, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2accf9b821314f3bad4a25bd77746a1c_I20220402" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xLTEtMS0yMDU3NTA_5fe63325-0c9c-4271-9e11-4880b89d7642">61,357,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2accf9b821314f3bad4a25bd77746a1c_I20220402" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0yLTEtMS0yMDU3NTA_9a11df44-1552-4e33-83f7-74afac937226">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice6503af7f6a41e696df5e32d186a5ab_I20220402" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS00LTEtMS0yMDU3NTA_1e9b582e-fa93-42ad-b66b-0451f1528c12">15,786,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6503af7f6a41e696df5e32d186a5ab_I20220402" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS01LTEtMS0yMDU3NTA_af139b9c-6a02-4531-ad32-9facb9ac7ce2">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c005cdfc09f429a8813448058fdbe09_I20220402" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS03LTEtMS0yMDU3NTA_2b41c6f5-16ca-43b2-8496-ad3dd2d043c5">476,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d6267e834a1443ea11cee027905e439_I20220402" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS05LTEtMS0yMDU3NTA_2d1a711a-61a5-422e-9dce-89a3f0a991a4">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie45a988315ec4dc5bee4e8ba6723c8a4_I20220402" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xMS0xLTEtMjA1NzUw_e1050470-58cd-4d42-9a18-dffa299b585a">17,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ddf2d069db4849bee3aa72aa59d848_I20220402" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xMy0xLTEtMjA1NzUw_6aa05080-4e93-478d-98a2-083c9df8de4f">135,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34aedf09bd844e088614ef324e5b1a3e_I20220402" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xNS0xLTEtMjA1NzUw_9302bec7-5b2f-4e00-bccb-bcaaded2becb">593,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bioventus Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended April&#160;1, 2023 and April&#160;2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands) (Unaudited)</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMy0xLTEtMS0xOTQ5Mjk_c22a7d0c-2ff6-4b20-b027-0ff3ce036135">174,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMy0zLTEtMS0xOTQ5Mjk_20991158-845d-4ec1-9afc-d07eeb6d9d24">14,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNC0xLTEtMS0yMjExNTI_fec0b1bd-e472-4b4d-bf11-79c6cad501b2">74,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNC0zLTEtMS0yMjExNTI_ecbe3be4-b6bb-4c60-ab9f-afca68eb951a">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0xLTEtMS0yMjIyMjU_da2ebc14-9758-4c4d-8d67-9d805961ac41">100,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0zLTEtMS0yMjIyMjU_a2216c96-7aaa-4253-beb9-591a03bcf7a0">14,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0xLTEtMS0xOTQ5Mjk_a6c4cbae-f004-4d9b-8aca-dc980fffce9d">16,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0zLTEtMS0xOTQ5Mjk_97ac337a-91c0-4128-aaa3-4f5622b05422">12,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNi0xLTEtMS0xOTQ5Mjk_4757e3a4-e66a-4133-b35f-b146785bdf15">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNi0zLTEtMS0xOTQ5Mjk_5a36dbb8-3ea0-4e7f-844d-211365d99fc3">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNy0xLTEtMS0xOTQ5Mjk_3d0fcda4-1203-4dee-87a6-4014d7177fba">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNy0zLTEtMS0xOTQ5Mjk_56fb20b1-d271-43fb-b0b7-5e0d421c5398">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfOS0xLTEtMS0xOTQ5Mjk_e409a443-6ec2-4120-a261-ee89fe24dd31">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfOS0zLTEtMS0xOTQ5Mjk_f78e9ada-7242-44a3-9530-3c18f703aa8c">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of interest rate swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTAtMS0xLTEtMTk0OTI5_2f76a6d4-0ada-4849-a8b4-1470fb652a70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTAtMy0xLTEtMTk0OTI5_776ed11f-181d-4ef6-8e67-2f4665c53996">3,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTEtMS0xLTEtMTk0OTI5_2a0de218-939b-4217-a060-eab90ae8bef6">2,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTEtMy0xLTEtMTk0OTI5_7de61231-35c7-4990-8e69-bef0fb74a660">17,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTMtMS0xLTEtMTk0OTI5_a52416a0-630f-4cb2-8290-7c803b1944a8">78,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTMtMy0xLTEtMTk0OTI5_670fd253-75f5-47a1-b7ed-36f6b083c786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency fluctuations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTYtMS0xLTEtMTk0OTI5_628a8bab-0bc6-43e2-910f-8c853496fb15">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTYtMy0xLTEtMTk0OTI5_19568fd8-352b-4a55-869d-a4a7ce1e2827">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTctMS0xLTEtMTk0OTI5_5c6e1149-74c0-4583-9c9d-e5d30eeb34e1">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTctMy0xLTEtMTk0OTI5_83fac994-47a7-4033-b101-43af1d749329">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTktMS0xLTEtMTk0OTI5_1034b071-8e92-4288-9913-66ee54945e7c">13,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTktMy0xLTEtMTk0OTI5_c24c6cb5-7d76-45de-94d6-07f4ae452ddc">4,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjAtMS0xLTEtMTk0OTI5_c053bf15-b253-48ef-a123-3d8d34a70756">5,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjAtMy0xLTEtMTk0OTI5_c426e92a-94d2-4ed9-8951-5e7c960987ca">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMS0xLTEtMTk0OTI5_e04c071a-c475-48d9-95ce-cdb95740aaa0">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMy0xLTEtMTk0OTI5_d311d62d-b21a-4dbf-bd55-1a8927800108">7,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current and noncurrent assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMS0xLTEtMTk0OTI5_253ab342-df66-4a30-aa31-cae6c2e90eef">2,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMy0xLTEtMTk0OTI5_90f96cca-f98f-4102-b07a-7687b3c4c5fc">1,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from operating activities - continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjMtMS0xLTEtMTk0OTI5_78556f9c-eb7e-4020-8961-8e33687de3a8">4,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjMtMy0xLTEtMTk0OTI5_77dc10a8-9f65-41f9-b6eb-d200b5f6d223">21,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from operating activities - discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMS0xLTEtMjA1Njk5_eb5ae84c-5083-4bbe-bca7-49a3930ea04a">2,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMy0xLTEtMjA1Njk5_fadb9ef2-7b65-4ad7-b558-7dc0e81286ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMS0xLTEtMjA5MDY1_8bbafd3f-ddca-41d2-9905-8de372152c2a">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMy0xLTEtMjA5MDcy_ec68eb82-d7b9-4544-ab73-6c5c004bebd8">21,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjYtMS0xLTEtMTk0OTI5_52f10118-e1e9-4e85-99a2-911b54056e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjYtMy0xLTEtMTk0OTI5_cc44d4c1-64b1-4a78-83ab-6d3fd1992feb">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjctMS0xLTEtMTk0OTI5_9dfbeb82-fdaf-4cb7-bb41-6cd2ca260024">3,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjctMy0xLTEtMTk0OTI5_c650ece2-56de-411c-a90a-46fd17b162d4">2,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and acquisition of distribution rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjgtMS0xLTEtMTk0OTI5_aa66a23b-dc5e-4311-9c71-c100e576de89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="bvs:ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjgtMy0xLTEtMTk0OTI5_6bcf8a5e-d569-4ec7-8333-cada97f9aff0">1,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from investing activities - continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMS0xLTEtMTk0OTI5_21dca16d-8176-408a-b440-06e5a0ca1b7d">3,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMy0xLTEtMTk0OTI5_5b5ca455-ef22-4f04-97c2-ea6769d94cb4">4,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from investing activities - discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjktMS0xLTEtMjA1NzIx_38e08659-bcf3-49fe-826b-89ea6c7be2c8">11,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjktMy0xLTEtMjA1NzIx_e66d62dd-edfd-4297-81d9-2e8f10c89dd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMS0xLTEtMjA5MDc0_07ab95cf-8559-4fb6-b37c-f8271f2cc30c">15,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMy0xLTEtMjA5MDgx_72af5757-aade-48f3-9bd9-9387c855dfe9">4,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of Class A and B common stock </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzMtMS0xLTEtMTk0OTI5_8546e83f-d973-4315-b2e3-20314d715dff">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzMtMy0xLTEtMTk0OTI5_6e1cf93a-347f-42f1-9d8e-06db578423a5">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax withholdings on equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzQtMS0xLTEtMTk0OTI5_1e16af37-b7e9-4e37-a07e-e4a4c20dfedc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzQtMy0xLTEtMTk0OTI5_36b09565-0876-4d14-a0b2-04b589333ea6">3,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowing on revolver</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzUtMS0xLTEtMTk0OTI5_b69a4615-79ee-4474-b42f-e4d8980f20df">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzUtMy0xLTEtMTk0OTI5_f8894f84-c473-4be7-82d1-9d5b267ba9d4">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment on revolver</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzYtMS0xLTEtMTk0OTI5_fc0e75a4-a8e2-4ca8-b52e-1706c3846663">20,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzYtMy0xLTEtMTk0OTI5_f11d7125-7041-490e-ac58-fb71e90a032b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt refinancing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:PaymentOfDebtRefinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzctMS0xLTEtMTk0OTI5_f35e89f8-fbf2-40d4-9ae5-cc7e0c7afbfe">1,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="bvs:PaymentOfDebtRefinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzctMy0xLTEtMTk0OTI5_3f67be15-77dc-43e1-96fd-79179245ba7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzgtMS0xLTEtMTk0OTI5_36fea623-35e6-49b2-9e18-861d83f51e73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzgtMy0xLTEtMTk0OTI5_98c046b2-0856-4206-a212-86dfbec58367">4,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDAtMS0xLTEtMTk0OTI5_c906803a-a284-48a8-b4bd-aadacde06ed0">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDAtMy0xLTEtMTk0OTI5_ab450336-ea94-4358-ba3e-2a8c9469ef4e">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDEtMS0xLTEtMTk0OTI5_6f321e70-51b5-4287-9328-3e6742f25167">27,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDEtMy0xLTEtMTk0OTI5_28c82b39-f9b4-4f54-a348-0adbd53b87cb">9,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDItMS0xLTEtMTk0OTI5_138d5eb3-f16e-438e-842d-e0aa9daa4247">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDItMy0xLTEtMTk0OTI5_e9caeb79-4dee-4925-8dc0-7beadfca773e">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDMtMS0xLTEtMTk0OTI5_7cc7f738-b501-4469-b479-229b94b30dfc">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDMtMy0xLTEtMTk0OTI5_30eb61ff-3c95-43fa-ba74-18bdbc4e0105">16,559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDQtMS0xLTEtMTk0OTI5_f40b4eab-ed6f-4e59-bdc3-50351698cbb1">31,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDQtMy0xLTEtMTk0OTI5_56c4cd3f-347e-4136-907d-ebf0ed8381a2">99,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at the end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDUtMS0xLTEtMTk0OTI5_8821a0b5-b105-47d5-b5eb-8cc6be10896f">47,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34aedf09bd844e088614ef324e5b1a3e_I20220402" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDUtMy0xLTEtMTk0OTI5_973c508f-e842-49e6-ab37-e2c68d1262a4">82,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable for purchase of property, plant and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDgtMS0xLTEtMTk0OTI5_5992052b-c01b-4bb7-a333-11b52192149c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDgtMy0xLTEtMTk0OTI5_64e3c82b-6a3c-4fdd-a017-1195b9d4b83b">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bioventus Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to the unaudited consolidated condensed financial statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except unit and share amounts)</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_37"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfODMxNg_cd3cc40e-e4f5-4010-8577-a26a4cbf1af6" continuedAt="i360e3540f76d4ce0b3131c2cd3959905" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i360e3540f76d4ce0b3131c2cd3959905" continuedAt="i6baa4ea7cad5429e8770f7372cb832ad"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioventus Inc. (together with its subsidiaries, the &#8220;Company&#8221;) was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (&#8220;BV LLC&#8221;). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;), which was conducted through what is commonly referred to as an umbrella partnership C Corporation (&#8220;UP-C&#8221;) structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC held by its continuing LLC owner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately <ix:nonFraction unitRef="employee" contextRef="ia9c0fbba09b6496a91ab1685ca96483a_I20230401" decimals="-1" name="dei:EntityNumberOfEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfOTA1_48cf55e4-50b0-4b70-9664-66d0898a84b6">1,040</ix:nonFraction> employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim periods</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2023 end on April 1, July 1 and September 30. Comparable periods for 2022 ended on April 2, July 2 and October 1. The fourth and first quarters may vary in length depending on the calendar year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) considered necessary for a fair statement of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The consolidated balance sheet at December&#160;31, 2022 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Correction of immaterial misstatements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended April 1, 2023 and as part of the balance sheet review process, the Company identified misstatements in its calculation of the carrying amount of noncontrolling interest as it applies to the Company&#8217;s complex UP-C tax and ownership structure as prescribed in the amended and restated limited liability company agreement of BV LLC. Specifically, the Company failed to adjust the carrying amount of its noncontrolling interest to reflect changes in ownership interests relating to BV LLC. As a result, the previously issued consolidated financial statements reflect an understatement of noncontrolling interest and an overstatement of additional paid-in capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of further research conducted, the Company discovered an additional error related to historical deferred income tax balances. The Company concluded that it had inappropriately calculated deferred income taxes by using an incorrect book basis in its investment of BV LLC during the Company&#8217;s IPO, which resulted in an overstatement of deferred tax liabilities, an understatement of noncontrolling interest and an understatement of additional paid-in capital.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i6baa4ea7cad5429e8770f7372cb832ad" continuedAt="i4d604a8e73104f02b20ecec1d25ae23d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The statements affected by these errors include the consolidated balance sheets and consolidated statements of stockholders&#8217; and members&#8217; equity issued in the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2022 and December 31, 2021. There was no impact to any other financial statements for the periods presented. The Company concluded that these misstatements were not material, individually or in the aggregate, as evaluated under the Securities and Exchange Commission Staff Bulletin No. 99, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Materiality;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> No. 108, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Considering the Effects of Prior Year Misstatements in Current Year Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; and Financial Accounting Standards Board ASC 250-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting Changes and Error Corrections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. However, because of the significance of these items, and to facilitate comparison among periods, the Company has decided to revise its previously issued consolidated financial statements on a prospective basis. The Company will correct its prior period presentation for this error in its future 2023 quarterly financial statements included in its Forms 10-Q and 2023 Annual Report on Form 10-K for the period ended December 31, 2023. The adjustments did not have an impact on revenues, total assets or cash flows.</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfNDk0NzgwMjM2OTQzMg_440f231b-a455-4dca-b9d2-9776d8fd7a5d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are selected line items from our aforementioned impacted financial statements illustrating the effect of the error corrections thereon:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets &#8212; December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (b)(d)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96799592dc2f46ce951da575359089fe_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMS0xLTEtMS0yMjc2NTM_85d03cf8-68c7-4a91-bb2c-9304f5bb9471">74,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMS0zLTEtMS0yMjc2NTM_a8c9fdeb-591e-4e2e-a804-30469cf8f5fa">71,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMS01LTEtMS0yMjc2ODg_57ec7ad4-d242-4ca6-b680-8ab534b39635">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96799592dc2f46ce951da575359089fe_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0xLTEtMS0yMjk0MjM_a32495a7-8ab9-4751-800c-bf9945eb844a">1,032,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231" decimals="-3" sign="-" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0zLTEtMS0yMjk0MjM_7c92afb3-9fe7-428f-a34f-ce9b9956a818">71,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi01LTEtMS0yMjk0MjM_7f31e268-4635-4ffa-9912-61a4c95e50ac">960,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital (a)(b)(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96799592dc2f46ce951da575359089fe_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0xLTEtMS0yMjc2NTM_5e770ec2-bc2c-4f69-b3c7-3bf639053bef">481,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0zLTEtMS0yMjc2NTM_9d187e9d-9bf6-4504-abdc-c5b939533ad0">8,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi01LTEtMS0yMjc2ODg_b3e4853a-1291-4001-abd4-e65ce0344244">490,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest (a)(c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96799592dc2f46ce951da575359089fe_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMy0xLTEtMS0yMjc2NTM_284559f5-7928-4231-bbe6-9d92eeb86a46">23,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMy0zLTEtMS0yMjc2NTM_6382ddb4-fcea-433c-bab2-3fb2c7619a54">63,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMy01LTEtMS0yMjc2ODg_0f99c1f4-7171-4514-b0e9-41dcd5fa0cf1">86,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96799592dc2f46ce951da575359089fe_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfNS0xLTEtMS0yMjk0MzY_fcd3c759-8702-496b-af8d-54f730dbd315">340,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfNS0zLTEtMS0yMjk0MzY_78c412b7-5c14-4b71-a36c-8b99fc78ac99">71,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfNS01LTEtMS0yMjk1MTg_7551063a-ea95-497d-bafc-d3f7d10bfd90">412,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets &#8212; December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (b)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMS0xLTEtMS0yMjc2NjE_7248716a-a289-4b88-93ac-0420d9492a78">133,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMS0zLTEtMS0yMjc2NjE_abee2060-8818-40dc-ba55-e64140e7ccb0">73,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMS01LTEtMS0yMjc2OTI_271fd6dc-3b7e-4b9b-a5df-e45640ae9a70">59,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0xLTEtMS0yMjk0NTA_9668c6ff-da6a-4c25-8514-514370e555bf">692,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231" decimals="-3" sign="-" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0zLTEtMS0yMjk0NTA_09f1d06f-7ce5-4ae7-8c17-3949a2a79830">73,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi01LTEtMS0yMjk1MjE_385c2c1f-943e-499f-a6d3-48f51e7a15d1">618,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital (a)(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0xLTEtMS0yMjc2NjE_f922582e-8808-40ff-bf5a-0cbfe212e413">465,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0zLTEtMS0yMjc2NjE_fb427fa4-f034-42e6-849e-1bfae1a6172c">8,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi01LTEtMS0yMjc2OTI_f849bd43-98b9-4cac-b01e-2e721b19b7c8">473,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMy0xLTEtMS0yMjc2NjE_0b7f73c4-b304-4a76-ab7f-8d15cf1dbdf3">74,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMy0zLTEtMS0yMjc2NjE_cd1b0399-86d4-49ff-9f33-e88643f5f938">65,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMy01LTEtMS0yMjc2OTI_a9915564-8c50-4e4d-bc05-08840b4d0301">140,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfNS0xLTEtMS0yMjk0NTk_cee11484-aa95-484b-a36e-ffc457799125">533,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfNS0zLTEtMS0yMjk0NTk_ee8eca04-3908-425e-86f3-63091061d550">73,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfNS01LTEtMS0yMjk1MjE_06c28f3b-a20b-40aa-a712-dae73e872193">607,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated statements of changes in stockholders&#8217; and members equity as of December 31, 2022 and December 31, 2021 have been corrected to reflect the above adjustments. The Company revised the amounts originally reported for the years ended December 31, 2022 and December 31, 2021 for the following items:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Recorded a $<ix:nonFraction unitRef="usd" contextRef="i66988f17121f479d987ec3f6a81fa043_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_10a7bac9-e3c3-4dc8-858a-8d80f955e246"><ix:nonFraction unitRef="usd" contextRef="i66988f17121f479d987ec3f6a81fa043_I20211231" decimals="-3" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_17f39e94-e0d2-4612-88bb-74f020835565"><ix:nonFraction unitRef="usd" contextRef="i673ea96088114535bb4f91785d7e72e6_I20221231" decimals="-3" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_585b19f9-1f38-49e4-bc4f-1475d8996729"><ix:nonFraction unitRef="usd" contextRef="i673ea96088114535bb4f91785d7e72e6_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_e6ad43af-c616-4b60-83fc-c6d5aacd782c">65,821</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> decrease to additional paid-in capital and a corresponding increase to noncontrolling interest. This action effectively rebalanced equity appropriately between the Company and its noncontrolling interests according to their respective BV LLC ownership interests.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Recorded a $<ix:nonFraction unitRef="usd" contextRef="ib42fe425b80941f48b28aca4ecd33ade_I20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MTU2OA_b7d0fce3-35ac-495f-87c0-455771f7403b"><ix:nonFraction unitRef="usd" contextRef="ib7a4b0b14d204b00844c680753360a35_I20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MTU2OA_c3e0c611-0f42-4f47-bf83-1ef0163ef428">73,867</ix:nonFraction></ix:nonFraction> decrease to deferred income tax balances and an increase to additional paid in capital to reflect the correction of an error that occurred during the calculation of deferred taxes at the Company&#8217;s IPO.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Reflects the entry as discussed in (a) above and additional rebalancing activity of $<ix:nonFraction unitRef="usd" contextRef="i9117991cb301409cb832cbb9dd88871a_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MjU0NQ_17ad9802-693e-4728-9d0c-4ff6bf4b26ee"><ix:nonFraction unitRef="usd" contextRef="i9117991cb301409cb832cbb9dd88871a_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MjU0NQ_418dda73-6dcb-4e8b-a8ff-245176f04125">2,588</ix:nonFraction></ix:nonFraction> relating to the issuance of Class A common stock for equity plans during the year ended December 31, 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects the entry as discussed in (b) and an additional $<ix:nonFraction unitRef="usd" contextRef="i109b3bd8eade44d394a7ae03c62fed13_I20221231" decimals="-3" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5NzY5OA_20101671-f1e7-48e9-b3b2-4c125873dad2"><ix:nonFraction unitRef="usd" contextRef="i109b3bd8eade44d394a7ae03c62fed13_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5NzY5OA_4c5ccd6e-e78a-4c6c-969d-15b2da77eb9d">1,977</ix:nonFraction></ix:nonFraction> increase to deferred income tax balances and a reduction to additional paid in capital to reflect the deferred tax impact during the year ended December 31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfODMxNw_4d571af7-e801-4269-b131-7f145ebc5312" continuedAt="i7392de77c4b8480ca30946720cee4ce5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared under the going concern basis of accounting, which presumes that the Company&#8217;s liquidation is not imminent; however, based on the Company&#8217;s current financial position and liquidity sources, including current cash balances, and forecasted future cash flows, the Company is at risk of violating certain of its financial covenants under the Credit and Guaranty Agreement, dated December 6, 2019 (as amended on October 29, 2021, July 11, 2022 and March 31, 2023).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If mitigating steps are not taken or are not successful, the Company is at substantial risk of failing its covenants in 2024. A breach of a financial covenant under the Credit and Guaranty Agreement could accelerate repayment of our obligations under the agreement. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion concerning the Company&#8217;s long-term debt obligations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i4d604a8e73104f02b20ecec1d25ae23d"><ix:continuation id="i7392de77c4b8480ca30946720cee4ce5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing plans to mitigate these conditions and events, such as considering various additional cost cutting measures, and exploring additional divestiture opportunities such as the recently announced plan to divest certain assets within its Wound Business; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. Therefore, these plans do not alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of efforts to improve its financial condition, on February 27, 2023, the Company reached an agreement to return the assets and liabilities of CartiHeal (2009) Ltd. (&#8220;CartiHeal&#8221;), a wholly-owned subsidiary of the Company, to its former securityholders. The deconsolidation of CartiHeal relieved deferred consideration liabilities and milestone obligations related to the acquisition of CartiHeal. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding the acquisition and subsequent deconsolidation of CartiHeal. In addition, the Company announced a restructuring plan in December 2022 to align the Company&#8217;s organizational and management cost structure to improve profitability and cash flow. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div></ix:continuation><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfODMxOA_6ac81bc4-1093-4097-845b-c79b7d145ad0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an accelerated public company filer. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when emerging growth companies are required to adopt.</span></div></ix:nonNumeric></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_40"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3Ng_4f5fc942-15be-4f61-9b6f-8da3373d3deb" continuedAt="ic67d82ac8d854faa94c052df0890a456" escape="true">Balance sheet information</ix:nonNumeric></span></div><ix:continuation id="ic67d82ac8d854faa94c052df0890a456" continuedAt="i471175c9062a4b7bb75b4bcbdf05b457"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract.</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM4MA_c29ad0f9-4ee8-408e-9efc-427fe646406e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net of allowances, consisted of the following as of:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMS0xLTEtMS0xOTQ5Mjk_cf5caad8-369a-402d-98a3-911ef6da7e32">125,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMS0zLTEtMS0xOTQ5Mjk_e5607546-b163-412f-9a6f-43f1fddaa7e8">143,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMi0xLTEtMS0xOTQ5Mjk_15b49ff7-3caa-4952-b179-4d3577ca9b73">7,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMi0zLTEtMS0xOTQ5Mjk_17b70b49-c1f8-46d6-bf4d-db3b03eb2bda">7,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMy0xLTEtMS0xOTQ5Mjk_df84b14b-51d5-4dcb-84d8-b5196eb260ab">118,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMy0zLTEtMS0xOTQ5Mjk_880c5935-7e10-4dad-adba-4ebb4b7162c7">136,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Other receivables of $<ix:nonFraction unitRef="usd" contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231" decimals="-3" name="us-gaap:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzA5Mg_06ff59a8-a3c5-463f-b825-30ff443a3ac7">350</ix:nonFraction> attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzEyMw_8b9fe9d4-6136-4848-8816-eb55a2b14af7">5,012</ix:nonFraction> was reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding assets held for sale and the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfODc5NjA5MzA1MDQxNw_01181ec7-9169-44e9-a804-a84f084da0e1">898</ix:nonFraction> was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding assets held for sale.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of the Company&#8217;s receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately <ix:nonFraction unitRef="number" contextRef="i7ebfe75a99584627ab0c086aca856452_D20230101-20230401" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTgyMg_8877fbae-d543-4a78-bd1b-fc0bd3400565">11.8</ix:nonFraction>% of the accounts receivable balance as of April&#160;1, 2023. Historically, the Company&#8217;s reserves have been adequate to cover credit losses.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i471175c9062a4b7bb75b4bcbdf05b457" continuedAt="iec9b00ea65294aceba60c485e57d5c2b"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3OQ_18fe389e-c129-4df0-a3bb-0721aa8d68a7" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in credit losses were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMi01LTEtMS0xOTQ5Mjk_66758c8b-4a87-431e-b6e5-6fac754e70c8">7,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMi03LTEtMS0xOTQ5Mjk_e2dc5820-84df-4b1c-9dd1-5c9da18af5d3">3,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMy01LTEtMS0xOTQ5Mjk_5ec26220-3957-4b4e-8c9f-738a69abdb7c">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMy03LTEtMS0xOTQ5Mjk_371aad8a-57ff-48ed-aa53-4a818681d34b">1,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNC01LTEtMS0xOTQ5Mjk_58a9d274-f31d-46cf-948d-2d35f42dbc9b">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNC03LTEtMS0xOTQ5Mjk_74f8ee07-2815-4ce0-8d69-a0f86d48ac8c">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNS01LTEtMS0xOTQ5Mjk_31603083-1e7f-4cf0-9171-50e8950c73e6">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNS03LTEtMS0xOTQ5Mjk_f356f6a8-5be3-4142-b261-ed8d9f4b80d6">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to held for sale</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi01LTEtMS0yMjA4MzE_7b370d97-e449-467f-a8a7-8016d5bb73f2">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="bvs:AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi03LTEtMS0yMjA4MzE_55d1e47e-544e-4c7f-801c-00a43a6ba94b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi01LTEtMS0xOTQ5Mjk_48c93884-23ff-4ba0-a2b7-0d31c1b99e05">7,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34aedf09bd844e088614ef324e5b1a3e_I20220402" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi03LTEtMS0xOTQ5Mjk_c5d77038-f720-4f17-8607-613b83336e16">4,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3NQ_8f6cddd6-250e-42ec-a964-e4d64db7ef2f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following as of:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMS0xLTEtMS0xOTQ5Mjk_de186ad7-53fe-4744-b04c-4457fa3078d5">24,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMS0zLTEtMS0xOTQ5Mjk_3526546a-91b4-497b-a4fc-e050c90c1619">19,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMi0xLTEtMS0xOTQ5Mjk_df76bae2-9114-444e-b4c1-848203cedb1d">65,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMi0zLTEtMS0xOTQ5Mjk_dea3d011-a50a-425c-9e1b-20f2a8adea65">67,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMy0xLTEtMS0xOTQ5Mjk_fb80fce8-f014-4f64-818e-b82d69ca32b2">90,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMy0zLTEtMS0xOTQ5Mjk_069edabe-78aa-4b9c-969c-09735b65c185">86,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess and obsolete reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNC0xLTEtMS0xOTQ5Mjk_a2c8ead4-fee1-403f-a44f-159cf1c4da17">2,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNC0zLTEtMS0xOTQ5Mjk_cdfe41e9-00f5-4013-a7c2-7de78e0fd732">1,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNS0xLTEtMS0xOTQ5Mjk_230d91b6-308f-4db0-a388-f96029e7b032">87,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNS0zLTEtMS0xOTQ5Mjk_dd84416d-5dc3-46b5-80b7-1e1022753652">84,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Raw material inventory of $<ix:nonFraction unitRef="usd" contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NDEyNw_690eb1c3-b684-4dc1-983d-061190c7ada8">642</ix:nonFraction> attributable to CartiHeal has been reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Finished goods inventory of $<ix:nonFraction unitRef="usd" contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3NzIyNA_d662a991-a58d-42b4-885a-0b8bf6b91522">1,481</ix:nonFraction> was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid and other current assets</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3Nw_e9412efa-20bb-41df-b5fe-f49d12288441" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following as of:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMS0xLTEtMS0xOTQ5Mjk_f8e7dae5-b9ef-45b7-89d6-d0fae88d45d0">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMS0zLTEtMS0xOTQ5Mjk_754a84e4-8dc4-45a8-ad1b-4252e1ff3ca8">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMi0xLTEtMS0xOTQ5Mjk_85c0f72c-2da0-4b27-a1ed-4cf9ee97b07d">12,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMi0zLTEtMS0xOTQ5Mjk_253fd5c9-6113-4b23-bb52-f5670c89757f">14,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMy0xLTEtMS0xOTQ5Mjk_b3f79bae-ffd7-4247-ac74-17ea9704acaf">17,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMy0zLTEtMS0xOTQ5Mjk_bbff2765-2607-465f-8d81-05466849fbd8">18,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Prepaid and other current assets of $<ix:nonFraction unitRef="usd" contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ2OTM0MQ_c53e27ea-d2da-4b23-9a84-1bd47e855ab5">134</ix:nonFraction> attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 balance sheet. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="iec9b00ea65294aceba60c485e57d5c2b" continuedAt="i8fb5f5f602724938a8558b9b300af4ef"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets, net</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDk0NzgwMjM1MzEzMQ_75274965-7ff0-4d93-b8ec-adc6d0b39258" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following as of:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35b3d444a98478a89240114e08c3916_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMS0xLTEtMS0yMTgxNzY_4ffb9247-047f-4b48-9ae8-ececc0c29aca">676,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da15f6d37344cae8110d560e17ae77c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMS0zLTEtMS0yMTgxNzY_4c6b7795-4795-4521-979c-eeff1cdb4796">790,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da563fbc3546a19bdbbb85a92d1730_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMi0xLTEtMS0yMTgxNzY_39247d63-743d-4b15-98ee-bda1b76ead19">61,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764545bc9ad949eea69c3be558616715_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMi0zLTEtMS0yMTgxNzY_ac7c9242-cd49-4c35-9989-f8b87babf8ad">61,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62641fead14343468e0f3d886ba7a6ca_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMy0xLTEtMS0yMTgxNzY_fb8d28c7-c0b6-4d6e-951d-2338c741a067">57,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70245e2f7da94059ae58287036f79af6_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMy0zLTEtMS0yMTgxNzY_0e5fc975-c98c-4b7b-9ca0-e41de95a58c1">67,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98809c525a964717bfbdd03b0ff34ad8_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNC0xLTEtMS0yMTgxNzY_0b89c3fe-47bf-437a-a8e2-29d429aabea0">5,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib032dbd53db04880ad76314b46e1e9e6_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNC0zLTEtMS0yMTgxNzY_5d8676bd-2250-46cc-80f1-71ee79ebca66">5,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5c981648904e9b80b64c023d15fa42_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNS0xLTEtMS0yMTgxNzY_54a570cd-7fbe-4455-b239-559d1490972a">13,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4af42355014f9cba9ef136263bb498_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNS0zLTEtMS0yMTgxNzY_525ae0e4-ff53-4373-ae1d-f4b5d0ccd1b9">13,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNi0xLTEtMS0yMTkxNDM_348eb240-7777-408b-9cad-8be282eed8ad">815,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNi0zLTEtMS0yMTkxNDM_abf124c0-3691-468d-bf98-ddb6f4a38352">938,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib35b3d444a98478a89240114e08c3916_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOC0xLTEtMS0yMTgxNzY_a1a54f62-ccb6-4553-86ac-a98ec30dd04e">188,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da15f6d37344cae8110d560e17ae77c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOC0zLTEtMS0yMTgxNzY_408ad1b4-930c-45a1-a18a-9a69d9aa17f6">187,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15da563fbc3546a19bdbbb85a92d1730_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOS0xLTEtMS0yMTgxNzY_3c4eba73-8e9c-47ab-a827-ab2d490d1580">45,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i764545bc9ad949eea69c3be558616715_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOS0zLTEtMS0yMTgxNzY_5a5d54e0-e78e-4635-b567-e74e46583352">44,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62641fead14343468e0f3d886ba7a6ca_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTAtMS0xLTEtMjE4MTc2_0955bf45-1024-496e-bc17-b8c19d121c1e">57,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70245e2f7da94059ae58287036f79af6_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTAtMy0xLTEtMjE4MTc2_16d1889c-ce5b-4d23-bb7b-f44fbdf4a020">58,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa5c981648904e9b80b64c023d15fa42_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTEtMS0xLTEtMjE4MTc2_53698820-1ab0-4193-a4c1-d7254b2af55a">6,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a4af42355014f9cba9ef136263bb498_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTEtMy0xLTEtMjE4MTc2_f7791ee7-68f6-4bec-9c75-db493d13dcca">6,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTItMS0xLTEtMjE5MTQz_90cc6ebc-88dc-4d1a-8df1-2dccab221780">298,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTItMy0xLTEtMjE5MTQz_f2b354a9-0a58-4037-99f8-2d3f4383902e">297,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net before currency translation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="bvs:FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTMtMS0xLTEtMjE5MTQz_1d319fa2-fffb-474b-8060-9c4cfbc9b13d">517,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="bvs:FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTMtMy0xLTEtMjE5MTQz_aec5228f-dbd7-4ef8-a994-d8c516d9a3ca">641,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" sign="-" name="bvs:FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTQtMS0xLTEtMjE4MTc2_3034171e-57f8-4616-9d2d-3883773b3fb9">1,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" sign="-" name="bvs:FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTQtMy0xLTEtMjE4MTc2_91f15f8c-f68e-4f37-ab7c-d813c90306b6">1,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTUtMS0xLTEtMjE5MTQz_56ff39e2-09b0-4c8c-867a-c55eda861fc8">516,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTUtMy0xLTEtMjE5MTQz_9141611b-4c5e-44ba-8703-68121a44b4e6">639,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Intellectual property and accumulated depreciation attributable to CartiHeal totaling $<ix:nonFraction unitRef="usd" contextRef="i6b54bc099ff64cdf83d289598ea44468_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3MzQ5OQ_fff3eede-f78d-438d-a88f-38d070a10a3d">410,200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6b54bc099ff64cdf83d289598ea44468_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3MzUwNw_59ae2330-0f94-4a10-9c9a-2cdcc3b7fc4a">11,327</ix:nonFraction>, respectively, were reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Net intellectual property and customer relationships of $<ix:nonFraction unitRef="usd" contextRef="i49ccfda1a2d4406197267d9884f36892_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfODc5NjA5MzA1MzM0OQ_8cbc9f62-029e-4638-a9f3-23f54dcc3e40">23,458</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0829461c73da4cc59c0a31bf4e8fdc00_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfODc5NjA5MzA1MzQwNQ_00a26cca-e66a-4776-a2b8-058d2b789ccd">8,377</ix:nonFraction>, respectively, were reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding assets held for sale.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Company recorded an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i1fad609af52e483890feb9ddbe45ddcc_D20230101-20230401" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3MzEwMA_d89309b7-75fb-4489-a186-fc96621b19b5">78,615</ix:nonFraction> in the U.S. reporting segment of net intellectual property attributable to a business held for sale. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding businesses held for sale.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for intangibles subsequent to reclassifications and impairment for the remainder of 2023 and for the years ended December 31, 2024 through 2027 is expected to be $<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzA2NQ_c04ef67d-37ce-4ca3-acb4-48655647f862">22,041</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAxMA_52970d6e-cb35-4e37-8a7c-90e54aad126e">26,347</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAxNQ_1f47c4a1-574d-4cae-a350-f39a04708fe2">22,874</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAyMA_f8e230ac-8dd2-4ef6-8981-76fe97650c5f">20,030</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAyNA_6785fb9a-9dfd-41f5-b3e3-e63f11a6752b">19,652</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company assesses goodwill impairment by applying a quantitative impairment analysis comparing the carrying value of the Company&#8217;s reporting units to their respective fair values. A goodwill impairment exists if the carrying value of the reporting unit exceeds its fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reporting_unit" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMjYwMg_28d68b32-76f8-4276-8f42-739da70200a9">two</ix:nonFraction> reporting units and assesses impairment based upon qualitative factors and if necessary, quantitative factors. A reporting unit's fair value is determined using the income approach and discounted cash flow models by utilizing Level 3 inputs and assumptions such as future cash flows, discount rates, long-term growth rates, market value and income tax considerations. Specifically, the value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company then reconciles the values of all reporting units to the market capitalization of the Company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i8fb5f5f602724938a8558b9b300af4ef"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill resides within the International segment, of which $<ix:nonFraction unitRef="usd" contextRef="i00ae122881df443da212c3e259b30aac_I20230401" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1MDAyNQ_19a744c8-c69a-4454-82a2-dbeb7d2765bc">6,297</ix:nonFraction> related to CartiHeal and was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. The amount was recorded in discontinued operations, net of tax on the consolidated condensed statements of operations for the three months ended April 1, 2023 as a result of CartiHeal&#8217;s deconsolidation. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details concerning the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022, due to a significant decline in the Company&#8217;s Class A common stock price, circumstances became evident that a possible goodwill impairment existed as of the third quarter 2022 balance sheet date. The Company concluded that the carrying value of the U.S. reporting unit exceeded its fair value and recorded a non-cash goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia6e7f859e2de4e2e9bea8834f864b660_D20230101-20230401" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3NDM5MA_b043f424-3e2b-4489-80fa-7993a3f44568">189,197</ix:nonFraction> during the year ended December 31, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3NDQ0Ng_3d6c6496-6ca1-49d7-b0e2-415304411ee5">no</ix:nonFraction> accumulated impairment losses prior to the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued liabilities</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3OA_8c66f3c3-38f1-403a-b4a2-20a0d532eca9" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following as of:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="bvs:GrossToNetDeductionsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMS0xLTEtMS0xOTQ5Mjk_dce1f7c2-e32e-4260-a06d-fb6ab72603a0">66,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="bvs:GrossToNetDeductionsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMS0zLTEtMS0xOTQ5Mjk_98033d1b-a035-4bb5-89b3-5d8e18e10154">71,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus and commission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMi0xLTEtMS0xOTQ5Mjk_bbef86ad-5b66-4600-8a60-5dcee14cd3af">9,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMi0zLTEtMS0xOTQ5Mjk_1de87d01-c528-4c30-929f-8d3f6386d976">9,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="bvs:AccruedSalariesAndEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMy0xLTEtMS0xOTQ5Mjk_14aefbd7-3f42-4850-8aeb-31430d8b099c">6,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="bvs:AccruedSalariesAndEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMy0zLTEtMS0xOTQ5Mjk_38d8d5d9-df0b-4f7c-868b-c9f4156f34af">11,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0xLTEtMS0yMjU4NDg_9ddb00b3-96c7-40de-abde-dbdee65975fa">6,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0zLTEtMS0yMjU4NDg_6a6b6f60-ddc2-4fd9-8140-0ea5fc9a11d5">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0xLTEtMS0xOTQ5Mjk_96357458-c79d-4fd9-b209-91153b57b1c2">4,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0zLTEtMS0xOTQ5Mjk_4c514d31-0321-4467-a8c9-a06e49db1247">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNS0xLTEtMS0xOTQ5Mjk_8942487b-67a2-4785-a3f2-445dad439227">22,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNS0zLTEtMS0xOTQ5Mjk_744f88e8-19cd-4aaf-9f16-014b795707bb">16,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNi0xLTEtMS0xOTQ5Mjk_79dd636b-1219-4417-a3b8-c1b769c1b999">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNi0zLTEtMS0xOTQ5Mjk_1d5f94c2-7269-48ec-b681-256926300f98">111,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Bonus and commissions of $<ix:nonFraction unitRef="usd" contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401" decimals="-3" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3ODkyOA_d3eb9a20-d22a-4d32-9677-1baf08e7a969">588</ix:nonFraction> were reclassified into liabilities held for sale within the April&#160;1, 2023 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other liabilities attributable to CartiHeal of $<ix:nonFraction unitRef="usd" contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3OTQ2MQ_a49a3f9f-cb4f-4828-9209-2a91ae8e9a57">384</ix:nonFraction> were reclassified into current liabilities attributable to discontinued operations within December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div></ix:nonNumeric></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_43"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="bvs:AcquisitionsAndInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyNzc_a65084a3-5895-4572-8306-b67f14814702" continuedAt="i50d02123049d43b9ad49df333856b89d" escape="true">Acquisitions and divestitures</ix:nonNumeric></span></div><ix:continuation id="i50d02123049d43b9ad49df333856b89d" continuedAt="i0a046f6d4f1a4316bdc55952e0a6a83a"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Wound Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its businesses and products in order to calibrate its strategic focus, enhance liquidity, prioritize investments and allocate capital to its core business units. As a result of this assessment, the Company has committed to a plan to divest certain assets within its Wound Business, specifically those attributable to TheraSkin and Theragenesis (the &#8220;Wound Business&#8221; or  the &#8220;Disposal Group&#8221;). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified the identifiable net assets of the Disposal Group as held for sale. Assets and liabilities determined to be part of the Disposal Group have been recorded as single amounts within the Company&#8217;s consolidated financial statements. Assets held for sale are reported at the lower of the carrying amount or fair value less costs to sell, which is expected to occur within one year. The Company has ceased the depreciation and amortization attributable to assets classified as held for sale. Assets and liabilities held for sale are reviewed each reporting period to determine whether existing carrying values are fully recoverable in comparison to estimated fair values less costs to sell.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Wound Business for impairment during the first quarter of 2023. The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i3fa935ec3263472594eb58a3df3c2f65_D20230101-20230401" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ4MDc4Mg_7245cf5a-0c1c-4c39-bbf0-895f4e159af4">78,615</ix:nonFraction> ($<ix:nonFraction unitRef="usd" contextRef="i3fa935ec3263472594eb58a3df3c2f65_D20230101-20230401" decimals="-3" name="bvs:AssetImpairmentChargesAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ4MDkzNQ_5b22d88b-aec1-484d-8f54-b70d06ce7128">63,337</ix:nonFraction> after tax) impairment as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values less any costs to sell. The fair value of intangibles of the Wound Business was determined based on the consideration offered for the Wound Business.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i0a046f6d4f1a4316bdc55952e0a6a83a" continuedAt="i2f7ce455d8bd4b04942b52c662cccbbd"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDk0NzgwMjM1MjE5Nw_1586423b-4e40-4da2-92e4-dcfdac7b3bc6" continuedAt="i04a0c5bba73244809e486113cdd3d807" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the major classes of assets and liabilities of the Wound Business that were classified as held for sale were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of assets classified as held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMi0wLTEtMS0yMTc1MDkvdGV4dHJlZ2lvbjpiNzRjOTYzMGNmMDQ0YzA4OTBiNzYyYTg5NzVlY2Q2OV8xNjQ5MjY3NDQxNzA5_86d0c0ed-df43-43b9-b2ad-e3996f6b0711">898</ix:nonFraction></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMi0xLTEtMS0yMTc1MDI_5cc95a4b-a495-42b7-a5f7-dedf1113f3ac">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMy0xLTEtMS0yMTc1MDI_f7ed63e8-042e-4243-bc4c-53cc6819b730">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfNC0xLTEtMS0yMTc1MDI_0c76bec5-ed44-430e-8a23-743cfd8866e1">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfNS0xLTEtMS0yMTc1MDI_ba0b3257-650e-427f-a9f9-94337712b5a5">31,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfNi0xLTEtMS0yMTc0OTg_33310649-7d3f-4b95-a023-c360372175a7">37,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of liabilities classified as held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfOS0xLTEtMS0yMTc1MDM_c5c0780d-2cc0-462d-bf50-dba9a2c1cbde">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMTAtMS0xLTEtMjE3NTAz_01b5d852-ade5-4f13-817a-3728d6028ebe">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMTEtMS0xLTEtMjE3NTAw_af36eb34-4e58-472b-85e6-de76061038ba">1,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CartiHeal (2009) Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2022, the Company completed the acquisition of <ix:nonFraction unitRef="number" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTE3_96d6b7e2-4965-414e-8330-908edae653bf">100</ix:nonFraction>% of the remaining shares in CartiHeal, a privately held company headquartered in Israel and the developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. The Company previously held an equity interest in CartiHeal&#8217;s fully diluted shares with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i2e2d5c54e1f649d99de1b04258d57249_I20220712" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDc1_c2033e53-bc62-4e6a-8252-d3da61696ee5">15,768</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic4a9d2699d26472ebf9e64d62424696d_I20221231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDgy_a6249e02-3437-4347-97bf-2d71827885a3">16,771</ix:nonFraction> as of July 12, 2022 and December&#160;31, 2022, respectively. Net equity losses associated with CartiHeal for the three months ended April&#160;2, 2022 totaled $<ix:nonFraction unitRef="usd" contextRef="i6a2781c3a6a04fffb4599cdde6001d9a_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNjM3_0fb9ac46-7a15-464f-a74c-d44e86f917e5">401</ix:nonFraction>, which was included in discontinued operations, net on the consolidated condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired CartiHeal (the &#8220;CartiHeal Acquisition&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfODQ3_918b3479-4e9a-444f-bdce-4df90222ba8c">315,000</ix:nonFraction> and an additional $<ix:nonFraction unitRef="usd" contextRef="ibcd6603021274a84ba8c4328e971097b_I20220712" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfODY4_36102905-ff92-4d3d-8e12-b79b84d38e33">135,000</ix:nonFraction>, payable after closing upon the achievement of a certain sales milestone (&#8220;Sales Milestone&#8221;, or &#8220;CartiHeal Contingent Consideration&#8221;). The Company paid $<ix:nonFraction unitRef="usd" contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTAyOA_d88aee28-1950-4250-a29e-167a2697f5d9">100,000</ix:nonFraction> of the aggregate purchase price upon closing consisting of a $<ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTA5Mg_806778aa-a6cc-4635-b75c-5676324eaadc">50,000</ix:nonFraction> deposit held in trust and $<ix:nonFraction unitRef="usd" contextRef="iaf3b97bb69794fb5a74d6264e30703c9_D20220712-20220712" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTEyMQ_cebfc6a4-7406-45a3-bc19-ec5140780e65">50,000</ix:nonFraction> from a financing arrangement (Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding financing arrangements). The Company also paid approximately $<ix:nonFraction unitRef="usd" contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTI4OA_fa4c8f59-0c74-46e6-ba2d-e59b5744dde2">8,622</ix:nonFraction> of CartiHeal&#8217;s transaction-related fees and expenses and deferred $<ix:nonFraction unitRef="usd" contextRef="i18d2594349e442f5aa4558186daaac0f_I20220712" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTM1Nw_819e195a-36ba-4421-870b-5b9734e2bdda">215,000</ix:nonFraction> (&#8220;Deferred Amount&#8221;) of the aggregate purchase price otherwise due at closing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Deferred Amount was to be paid in <ix:nonFraction unitRef="tranche" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="INF" name="bvs:BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTQ3Mg_79ab5f3c-fe9f-4315-9c61-b22bac5ce9d4">five</ix:nonFraction> tranches commencing in 2023 and ending no later than 2027 as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="i975eb89011db4560ba2bcc2086c60016_I20220712" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTU0NQ_372b7c1b-24ce-4186-82bd-5b097c051cf6">50,000</ix:nonFraction> due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents the results of the pivotal clinical trial (&#8220;First Paper Milestone&#8221;) or July 1, 2023; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="i49db16cff51046329cf250fb5ac89e34_I20220712" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTc0Nw_5c3c684e-deb5-4bed-a6d8-c60bc4ccaab0">50,000</ix:nonFraction> due upon the earliest to occur &#8212; the implantation of Agili-C devices in 100 patients in the United States or September 1, 2023;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="i5f444d9528924284aadcb1788007ff06_I20220712" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTg3OA_b1dbea08-0cbc-427d-8689-4429ba31e4f4">25,000</ix:nonFraction> due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents any new or additional clinical data subsequent to the First Paper Milestone with respect to Agili-C (&#8220;Second Paper Milestone&#8221;) or January 1, 2025;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="ibe7aa5cbcd4e4539a13ab3abf8e8c9f7_I20220712" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjE0MQ_5989d551-322b-41b2-bdf3-5d33b8bc365e">25,000</ix:nonFraction> due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents any new or additional clinical data subsequent to the First and Second Paper Milestone with respect to Agili-C or January 1, 2026; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="i99f4d905bbb34b16a050cfc582ff2ea9_I20220712" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjM5NA_7d02ef34-6738-4721-8256-b1af60e8101f">65,000</ix:nonFraction> due upon the earliest to occur &#8212; obtaining a U.S. Category 1 Current Procedural Terminology (&#8220;CPT&#8221;) code from Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for Agili-C or January 1, 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the CartiHeal Amendment (as defined below), the Company owed interest on each tranche of the Deferred Amount at a rate of <ix:nonFraction unitRef="number" contextRef="icd90e131a7bf4a278b55541190ffe001_I20220630" decimals="3" name="bvs:BusinessCombinationContingentConsiderationLiabilityInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjcyNA_f7ac38f3-ebd1-4adf-9315-f8fdd4bb7477">8.0</ix:nonFraction>% annually, until such tranche is paid. The Sales Milestone was payable upon the achievement of $<ix:nonFraction unitRef="usd" contextRef="i22f12085d4424a5b9d5157232a465367_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjgyNQ_af36d542-b4b7-4989-b4c8-3a1ce087c37f">75,000</ix:nonFraction> in trailing twelve month sales pursuant to the CartiHeal Amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had entered into an Option and Equity Purchase Agreement with CartiHeal (&#8220;Option Agreement&#8221;) in January 2020 and a subsequent amendment in June 2022 (&#8220;CartiHeal Amendment&#8221;). The Option Agreement provided the Company with an exclusive option to acquire <ix:nonFraction unitRef="number" contextRef="i5248f80680c045179f84e361ed1ba3cc_I20220630" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMzE1NA_e0384fab-4650-4d07-a91e-7fb196e2b2e3">100</ix:nonFraction>% of CartiHeal&#8217;s shares (&#8220;Call Option&#8221;), and provided CartiHeal with a put option that would require the Company to purchase <ix:nonFraction unitRef="number" contextRef="i1247f024a75548eba0514a747599cee5_I20220630" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMzI3OA_3e7331a7-6ff2-495e-b630-ce7fd43eff01">100</ix:nonFraction>% of CartiHeal&#8217;s shares under certain conditions. In August 2021, CartiHeal achieved pivotal clinical trial success, as defined in the Option Agreement, for the Agili-C implant. In order to preserve the Company&#8217;s Call Option, in accordance with the Option Agreement and upon approval of the Company&#8217;s Board of Directors (&#8220;BOD&#8221;), the Company deposited $<ix:nonFraction unitRef="usd" contextRef="i6ac987576c674d6cbf92d74ed2df1b8b_I20210831" decimals="-3" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMzYyOA_58ee2cf1-b2a5-4ed5-b01e-2928ad6643ad">50,000</ix:nonFraction> into escrow in August 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i2f7ce455d8bd4b04942b52c662cccbbd" continuedAt="i39288bcbc7c343c29c8bdb8bb118acf0"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The First Paper Milestone under the Option Agreement occurred on February 13, 2023, which obligated the Company to make the first $<ix:nonFraction unitRef="usd" contextRef="i2f97030445ee47889c1b38177e4a3a23_D20230213-20230213" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2NzI4OQ_fe04328f-e66f-4fc2-9ca1-d85db8207528">50,000</ix:nonFraction> payment, plus applicable interest, under the Option Agreement. On February 27, 2023, the Company entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Elron Ventures Ltd. (&#8220;Elron&#8221; and together with the Company, the &#8220;Parties&#8221;) as representative of CartiHeal&#8217;s selling securityholders under the Option Agreement collectively, the &#8220;Former Securityholders&#8221;). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings relating to non-payment of any obligations arising under the Option Agreement during a period of 30 calendar days (the &#8220;Interim Period&#8221;) in exchange for (i) a one-time non-refundable amount of $<ix:nonFraction unitRef="usd" contextRef="i80bae10979d2454580adedb3b2a6c481_D20230227-20230227" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2Nzc1Mg_ea3f9e85-ccb5-42b9-be91-b5f4088aacd1">10,000</ix:nonFraction> and (ii) a one-time non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="iebb5d183410449b1908570eb5651c0ca_D20230227-20230227" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2Nzc1OQ_38e30f53-b41f-43d4-aec5-81dba78c68b5">150</ix:nonFraction> to Elron to be used in accordance with the expense fund provisions of the Option Agreement. The Interim Period expired on March 29, 2023 and the Company did not exercise its right to extend the Interim Period. In addition, the Parties mutually released any further claims under the Option Agreement and related transaction documents, including without limitation a release by the Former Securityholders of any rights to enforce the provisions of the Option Agreement or make further monetary claims against the Company and/or its respective affiliates and representatives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company transferred <ix:nonFraction unitRef="number" contextRef="i3f75d22eb20045e4a96e961e0a09ca92_D20230227-20230227" decimals="INF" name="bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2NzY4MA_147e4a87-ad0e-4628-8111-3b1defa1a31b">100</ix:nonFraction>% of its shares in CartiHeal to a trustee (the &#8220;Trustee&#8221;) for the benefit of the Former Securityholders pursuant to the Settlement Agreement. The Company had no ownership interest and no voting rights during the Interim Period. Accordingly, the Company concluded that upon execution of the Settlement Agreement, the Company ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Company&#8217;s international reporting segment. The Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss upon disposal was $<ix:nonFraction unitRef="usd" contextRef="ib6a06c7e9385495f98dce248522deff1_D20230227-20230227" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2Nzc3MA_ea587dca-1159-4058-9578-9a61d2871c6c">60,639</ix:nonFraction> and was recorded within discontinued operations, net within the consolidated condensed statements of operations and comprehensive loss. The loss on disposal is comprised of the book value of CartiHeal&#8217;s net assets at the time of disposal, goodwill attributable to CartiHeal and the previously discussed non-refundable payments made to Elron. The Company allowed the Interim Period to expire on March 29, 2023 as the Company was not able to find a financing solution to fund the payment obligations under the Option and Equity Purchase Agreement on terms the Company believed to be favorable to it and its shareholders.</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyNzg_ddcdacc0-9f5e-4e4b-ae62-374e28be0197" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of consideration for the CartiHeal Acquisition was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMC0xLTEtMS0xOTQ5Mjk_96019e31-9290-4e1a-b567-033cb1b73bc9">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712" decimals="-3" name="bvs:BusinessCombinationConsiderationTransferredTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMS0xLTEtMS0xOTQ5Mjk_5a6ade91-206a-4bb6-af8e-c9c76904d3c7">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal of cash at closing</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712" decimals="-3" name="bvs:BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMi0xLTEtMS0xOTQ5Mjk_8ecab0ba-2d8f-4fc1-924f-07327e949d6b">108,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2752ec5905e4a858220620c6f6f6ab1_I20220712" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMy0xLTEtMS0xOTQ5Mjk_6a22fffe-2515-4998-8f11-e3998973606d">183,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales Milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff82fadf30aa4ced9c49563731d130d5_I20220712" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfNC0xLTEtMS0xOTQ5Mjk_8b545ef9-7334-423c-a2e2-2a8778ae5218">61,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfNS0xLTEtMS0xOTQ5Mjk_a83d5e29-b8a7-4f5d-8300-593cdcef55c1">39,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfNi0xLTEtMS0xOTQ5Mjk_d93feb64-9399-44f3-97ad-67c79bae7612">393,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Remeasurement of the Company&#8217;s equity method investment in CartiHeal, net of equity losses as a result of the purchase. The remeasurement included a gain of $<ix:nonFraction unitRef="usd" contextRef="i4dafe4682a984e7cb23b5b32626f258b_D20220703-20221001" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2ODQ4NA_4dae2b0a-0239-4859-96d0-ef8afb5cba07">23,709</ix:nonFraction> calculated as the difference between the fair value and the carrying value of the Company&#8217;s investment in CartiHeal at the acquisition date and was recognized in other income during the third quarter of 2022 on the consolidated condensed statements of operations and comprehensive loss. The fair value was based upon: (i) the consideration transferred to members owning <ix:nonFraction unitRef="number" contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712" decimals="4" name="bvs:BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDM2OQ_9b11cabf-ba4a-4492-843b-78f6373ad56d">89.97</ix:nonFraction>% of CartiHeal&#8217;s fully diluted shares; (ii) calculating the value of CartiHeal&#8217;s fully diluted shares based upon the transferred consideration; and (iii) applying the calculated value to the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="id9f99c0f111c40f4b35d75accc7a326e_I20220711" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDU3MQ_a126934f-684d-4ed2-bec2-6c35f913304c">10.03</ix:nonFraction>% ownership in CartiHeal&#8217;s fully diluted shares at the acquisition date.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i39288bcbc7c343c29c8bdb8bb118acf0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the CartiHeal Acquisition using the acquisition method of accounting whereby the total purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyODQ_75b4e3bd-0af0-41c4-a3b1-ee9442b38325" continuedAt="iffaa0c54cacc4cd88714063fef8fda76" escape="true">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="iffaa0c54cacc4cd88714063fef8fda76"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMC0xLTEtMS0xOTQ5Mjk_b8c57df0-0379-4d00-8fa5-e2540db4863c">393,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMi0xLTEtMS0xOTQ5Mjk_01d68fe1-1f5a-41f9-a1ba-3e60b1ecfa42">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMy0xLTEtMS0xOTQ5Mjk_fb7221ed-2ecb-4b59-9560-082ededab4bf">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNC0xLTEtMS0xOTQ5Mjk_d1416fcf-9b65-417f-a84c-c81b3b5dbc2d">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNS0xLTEtMS0xOTQ5Mjk_7b947b4a-836a-4431-ad2a-f56571968631">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNi0xLTEtMS0xOTQ5Mjk_5a9b7b88-26e1-462e-b9e5-5f8acb12c4f6">410,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNy0xLTEtMS0xOTQ5Mjk_5e9f166a-0649-4ba2-9cf1-ef1a613463b9">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfOC0xLTEtMS0xOTQ5Mjk_19136628-00d9-4478-9093-ad6b120d2079">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfOS0xLTEtMS0xOTQ5Mjk_197d3c34-7861-48ec-97e1-4546a9a0986a">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTAtMS0xLTEtMTk0OTI5_8548faae-0d56-438b-bdba-3bacdcd8b130">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTEtMS0xLTEtMTk0OTI5_e858cc0e-343e-484c-854a-f95510b882a0">79,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTItMS0xLTEtMTk0OTI5_83f7ffc1-b0a9-4994-a5f1-fc02c6c47d9d">2,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTMtMS0xLTEtMTk0OTI5_1416bbdd-6e4c-4c8d-a7a6-7ccec9c6bdce">333,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resulting goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTQtMS0xLTEtMTk0OTI5_93200637-60e0-4c03-bdf6-b730ce3ffc1d">60,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly 100% of the goodwill represents estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized and is attributable to expected revenue growth in new markets. The goodwill was not deductible for tax purposes and $<ix:nonFraction unitRef="usd" contextRef="i387d0ba33ecf49d4ae4397e0b83f1636_I20230401" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNTY5OA_f50d352b-1e41-45cd-af91-db8569cd6d2e">55,295</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if9202c7ec716435aaa3082106434860a_I20230401" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNTcwNQ_98cadecb-becf-4e52-a260-aefbec8422aa">4,999</ix:nonFraction> was allocated to the U.S. and International reporting units, respectively.</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyODM_aad23bce-90d0-4d2b-9bad-3e766e63848c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CartiHeal&#8217;s intangibles consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual Property - US Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61effdba045e47f7bcb546d32bcd31c3_D20220712-20220712" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMS0xLTEtMS0xOTQ5Mjk_941249de-6705-4b2a-9def-eef2df3579c1">20</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe5797c14874b5fa84ef6a0757f4034_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMS0zLTEtMS0xOTQ5Mjk_a0e5adbd-4e7a-4f11-9b63-afe075fdec40">351,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual Property - International Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id56740f57a5e43aca22cc898a646c454_D20220712-20220712" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMi0xLTEtMS0xOTQ5Mjk_e81d01dd-cccf-4cb3-b22c-0a41b908b512">8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bdab0f0d4d463fa6398c22775dd54e_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMi0zLTEtMS0xOTQ5Mjk_9c2ce2ed-92f2-4b4d-80cb-ff2b4edaf3c0">58,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMy0zLTEtMS0xOTQ5Mjk_deee3e39-eec5-4a0c-a5cd-a356d8226fbf">410,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired CartiHeal intangibles was determined using an income approach, a valuation technique that estimates the fair value of an asset based on market participant expectations of the cash flows that an asset would generate over its remaining useful life. The determination of the useful lives was based upon consideration of market participant assumptions and transaction specific factors.</span></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_49"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMzE0OQ_569280bc-dba1-478c-bff4-535c12d41115" continuedAt="i57d75f9ed42643d7bd2daa1249427928" escape="true">Financial instruments</ix:nonNumeric></span></div><ix:continuation id="i57d75f9ed42643d7bd2daa1249427928" continuedAt="ice931f8d8c30412f9c4317b7438a248c"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMzE1MA_4a8cdd7e-6d6e-4e25-abbb-7f0213406fb4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended Term Loan due October 2026 (<ix:nonFraction unitRef="number" contextRef="if35ea5d41b5b485f883e49f6ae8fdc25_I20230401" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMS0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjoyNGUxMmZjZWQyNjk0NjM0Yjg3NGU0NzExNTMyNTQ1ZV80MA_20f49a38-a5ff-412a-a569-04984cee06ad">9.19</ix:nonFraction>% at April&#160;1, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35ea5d41b5b485f883e49f6ae8fdc25_I20230401" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMS0xLTEtMS0xOTQ5Mjk_d3a5aea8-0596-4695-9ce6-b2f87dbe5d2c">420,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa1cdc09860462383a3492205a224d2_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMS0zLTEtMS0xOTQ5Mjk_801edd19-d216-41c9-95d8-88f25003e887">420,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver due October 2025 (<ix:nonFraction unitRef="number" contextRef="iad26eeedf4bb4bbda6790671a5bdff05_I20230401" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMy0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpjY2YzN2EzYzc2OGM0M2UzODdjZDVlNGQ0MDY4OWZkY18zMg_2557ba11-4182-4e26-bea3-c7ddcbc3aea3">9.28</ix:nonFraction>% at April&#160;1, 2023)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad26eeedf4bb4bbda6790671a5bdff05_I20230401" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMy0xLTEtMS0xOTQ5Mjk_bd0a369b-9fb6-4145-92be-8f39060957a7">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c79358e91348e084baee11c93bc142_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMy0zLTEtMS0xOTQ5Mjk_f85ba94d-42cf-4c69-8cdf-af2d9a8b7395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNS0xLTEtMS0xOTQ5Mjk_2075f7bc-716d-43ad-98cd-257ea68df8cf">41,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNS0zLTEtMS0xOTQ5Mjk_7446df9d-aa94-4d32-8d59-168e43acc52d">33,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNi0xLTEtMS0xOTQ5Mjk_3c8242de-a983-4778-bb8b-c3df3e849a35">1,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNi0zLTEtMS0xOTQ5Mjk_4c476855-a29f-4e5e-80bb-ad834e88f81f">1,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNy0xLTEtMS0xOTQ5Mjk_f1adc969-ce72-4fc6-a0e4-aa707d2a9479">2,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNy0zLTEtMS0xOTQ5Mjk_ffafa1cb-91dc-4f99-80cf-a6e1e1406f8d">1,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfOC0xLTEtMS0xOTQ5Mjk_e278190e-2f07-4926-be26-4c27bd55564a">404,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfOC0zLTEtMS0xOTQ5Mjk_3ac38454-6b69-4e61-a979-3a44c77e0b6a">385,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the &#8220;2019 Credit Agreement&#8221;) that was comprised of a $<ix:nonFraction unitRef="usd" contextRef="id9d9f38043fa4c028d7126e56c12e67d_I20191206" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ0NjA3Nw_d6920178-296f-4d8d-b8d8-3ab47e1261d4">200,000</ix:nonFraction> term loan (&#8220;Original Term Loan&#8221;) and a $<ix:nonFraction unitRef="usd" contextRef="i0a847747334d4e8ba6cc594e9dcdc9df_I20191206" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ0NjA4Nw_a4fab3c6-f2b4-43a8-a13c-23e8e844f337">50,000</ix:nonFraction> revolving facility (the &#8220;Revolver&#8221;). The Company amended the 2019 Credit Agreement on October 29, 2021 in connection with the Misonix Acquisition in which the Company prepaid $<ix:nonFraction unitRef="usd" contextRef="i047d1c54f41c47e5b83b854cf55d776f_D20220711-20220711" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYwMA_7875e3e3-b258-42ca-a353-822aed13949c">80,000</ix:nonFraction> on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $<ix:nonFraction unitRef="usd" contextRef="i76987f19a9c44ee4a8433bbef3cdc2e3_I20211029" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjU5MA_ef209a97-6cb0-4d9e-acf0-dc6f1881016a">360,750</ix:nonFraction> term loan (&#8220;Term Loan&#8221;) and the Revolver.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="ice931f8d8c30412f9c4317b7438a248c"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, the Company further amended the 2019 Credit Agreement, as amended on October 29, 2021 (the &#8220;First Amended 2019 Credit Agreement&#8221;), in conjunction with the CartiHeal Acquisition. Pursuant to the First Amended 2019 Credit Agreement, an $<ix:nonFraction unitRef="usd" contextRef="i047d1c54f41c47e5b83b854cf55d776f_D20220711-20220711" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYwNA_0fa0ba87-a00a-4a69-bc0b-431ea25632ec">80,000</ix:nonFraction> term loan facility (the &#8220;July 2022 Term Loan&#8221; and, together with the Term Loan, the &#8220;Term Loan Facilities&#8221;) was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was not in compliance with certain financial covenants as of December 31, 2022. As a result, on March 31, 2023 (the &#8220;Closing Date&#8221;), the Company entered into another amendment to the 2019 Credit Agreement (collectively, with the October 2021 and July 2022 amendments, the &#8220;Amended 2019 Credit Agreement&#8221;) to, among other things, modify certain financial covenants, waive the noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLC&#8217;s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending June 30, 2024, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $<ix:nonFraction unitRef="usd" contextRef="ibfe65f363fbb4e1787d372f14d6ed933_I20230331" decimals="-3" name="bvs:DebtInstrumentCovenantLiquidityMinimum" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA1Mw_f096b5bc-57f3-4f1d-8157-d16f5fcd4fa4">10,000</ix:nonFraction> as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2019 Credit Agreement had deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i4c898ba97cad4ab6b65934419909f8e3_I20230401" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDc4Mg_62740e22-2855-48e0-852c-530049041051">3,661</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="if392e17bdeab412496b7af16131a7aba_D20230101-20230401" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDkyNg_1b7d722e-bdc3-4aa9-83c2-3be44b2d34e2">1,617</ix:nonFraction> were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $<ix:nonFraction unitRef="usd" contextRef="i4c898ba97cad4ab6b65934419909f8e3_I20230401" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDkzMw_021f2782-23c6-4b43-99d0-7f2bc2884891">2,044</ix:nonFraction> were capitalized on the consolidated condensed balance sheets. There was <ix:nonFraction unitRef="usd" contextRef="ie47412cb505a4ad484457826df28f027_D20230101-20230401" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjIxOQ_43ec7c23-5f15-4c7d-bb71-6e56ac55c848">no</ix:nonFraction> loss on debt refinancing and modification as a result of the March 2023 amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;1, 2023, $<ix:nonFraction unitRef="usd" contextRef="ic5b6613394184391936737b585ea4d43_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA2NA_43eef2ef-320b-446a-9945-c00878f03b2a">416,585</ix:nonFraction> was outstanding on the Term Loan Facilities, net of original issue discount of $<ix:nonFraction unitRef="usd" contextRef="ic5b6613394184391936737b585ea4d43_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA3NA_11ec51ca-ebb9-483b-98cc-be699d25a58b">2,876</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="ic5b6613394184391936737b585ea4d43_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA4NA_97d60a46-613e-4bec-ad1c-d72fbfde370c">1,251</ix:nonFraction>. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="iefdfaf8115ec421eb8f0d09f38e11095_D20230101-20230401" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ4NDc2Mw_a34788f3-ac12-4c59-8018-ebc07ff34bbe">223</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5252c9ad17db48d1988ebc871c1bdd70_D20220101-20220402" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ4NDc1Ng_71fe65ef-cf82-412e-aaf5-adc0f2a9eac5">203</ix:nonFraction> for deferred cost amortization in interest expense for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="idaa95b5adcef4db8a8cea991408aafb7_I20230401" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYyNg_37aadce1-7bc4-48d0-bdd7-3ded59f7d963">29,000</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="ie42967b0b3404880892fef4d2d36f92f_I20221231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYyMA_f78abcc9-e4f2-4d4e-a867-0ff025f0aac5">no</ix:nonFraction> outstanding borrowings on its Revolver as of April&#160;1, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Term Loan Facilities was $<ix:nonFraction unitRef="usd" contextRef="i8df20ba54290443e83e1927334a06e3b_I20230401" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDYyMg_b0ddd72e-588d-4342-a88a-9d6d90bec8b2">414,402</ix:nonFraction> as of April&#160;1, 2023. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instruments within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically entered into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company had <ix:nonFraction unitRef="derivative" contextRef="i031d0465b2ad444390d6fdd9eb9e80b5_I20230401" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMjM2NQ_b79a9fad-8dad-447a-a0cb-062e193d7ece">one</ix:nonFraction> non-designated interest rate swap agreement that was terminated on October 28, 2022. The Company received $<ix:nonFraction unitRef="usd" contextRef="idd2c5ab49e734e9bb3b79cadbd93c30d_D20221028-20221028" decimals="-3" name="us-gaap:DerivativeCashReceivedOnHedge" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ0NjM0NQ_109902c6-d166-42b4-ba9f-9ef46624b0b5">7,738</ix:nonFraction> upon the swap&#8217;s termination. The swap was carried at fair value on the balance sheet with changes in fair value recorded as interest income or expense within the consolidated condensed statements of operations and comprehensive loss. Net interest income of $<ix:nonFraction unitRef="usd" contextRef="idd8a6fd92ded42a9ae62df80dfacd5bc_D20220101-20220402" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMjcxMA_a020cd7a-4cef-4248-9d3f-6d2ef0ce5924">3,924</ix:nonFraction> was recorded related to the change in fair value of the interest rate swap for the three months ended April&#160;2, 2022.</span></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_52"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfNDMyNg_88a776f9-4289-461a-80b5-26e3d5850fb3" continuedAt="i8b5f056f12a74e9197fe79bd9d019cd6" escape="true">Fair value measurements</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b5f056f12a74e9197fe79bd9d019cd6" continuedAt="i5fbde0b96b5b4cf188fb67e5b3bda5ec">The process for determining fair value has not changed from that described in the Annual Report on Form 10-K for the year ended December 31, 2022.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i5fbde0b96b5b4cf188fb67e5b3bda5ec"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 inputs. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfNDMyNw_3b94c5ab-a48f-4353-8eaa-380971961209" continuedAt="idf261ff1eb1e4ee4a4c04c4f3dec55a4" escape="true">The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:</ix:nonNumeric></span></div><ix:continuation id="idf261ff1eb1e4ee4a4c04c4f3dec55a4"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount - Current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bff1a06928a49e684d3ba0fc962346e_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS0xLTEtMS0xOTQ5Mjk_8316b098-cc35-44ad-961e-49c1f14b296c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfb6349253c4e3280459ada7054fafc_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS01LTEtMS0xOTQ5Mjk_a150ba4a-4b0f-4ea1-958f-80487e32e81e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9956bf782d64ea1bd2b96df630c6d75_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS03LTEtMS0xOTQ5Mjk_a014bf3c-f816-4c91-8ec8-3cbca5f6417b">117,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3cb0bc9269646a2a591dda918400054_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS0xMS0xLTEtMTk0OTI5_7193333c-5af9-40f0-8249-768d3ab0b10f">117,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount - Long Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bff1a06928a49e684d3ba0fc962346e_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi0xLTEtMS0xOTQ5Mjk_563cebf1-0d4b-4fa9-b49e-8fcb5742d7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfb6349253c4e3280459ada7054fafc_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi01LTEtMS0xOTQ5Mjk_8de50d41-39d9-4c75-a877-8df8d5b620c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9956bf782d64ea1bd2b96df630c6d75_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi03LTEtMS0xOTQ5Mjk_49d48353-a33b-42d8-a28d-4db8a46c0229">79,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3cb0bc9269646a2a591dda918400054_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi0xMS0xLTEtMTk0OTI5_2d7ae156-8a0f-428b-8424-e1ccc9e92ac3">79,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CartiHeal contingent consideration- Sales Milestone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ef7632e5b4407e87abff23d73b268c_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy0xLTEtMS0xOTQ5Mjk_c1d02257-0b57-47dd-9bcf-fb42380d5cd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad35dc89c0f44e299cceeb0f722b12ee_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy01LTEtMS0xOTQ5Mjk_0e558235-5e58-47ab-af4e-5d96da45aed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961477208dd54a26b2ccf6e64c912305_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy03LTEtMS0xOTQ5Mjk_3ab366e6-5035-480b-a5ca-a53ce6d309e3">67,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2705284e689b4650bdc0ab6b3be0e86e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy0xMS0xLTEtMTk0OTI5_e30f596a-6197-4d4f-be7b-f97b5389e17d">67,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioness contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6df20213a847689d562669ec8c0eb2_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC0xLTEtMS0xOTQ5Mjk_f6575ea2-0516-4fe0-b5f7-2c31e5922f85">17,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848696f930194e1d8e9f0ab3b2518dab_I20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC01LTEtMS0xOTQ5Mjk_461cb467-e110-42e3-b814-6f5afee84237">17,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabedf0c4173d4d219e5a4a7c97ef7c6d_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC03LTEtMS0xOTQ5Mjk_45a5b3fc-6620-4c8c-9c12-5ff7057bbb45">17,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief782f56b0bd4c4ba52ecbb991a64e23_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC0xMS0xLTEtMTk0OTI5_23ab0951-4557-44cc-be61-06c899fe4b99">17,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7804b256d26143329ce8b1c8bfdeb7ee_I20230401" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS0xLTEtMS0xOTQ5Mjk_2878387d-75be-4251-9c5a-093b29129782">17,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a1162e408641aeb42666f59ea6e3c1_I20230401" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS01LTEtMS0xOTQ5Mjk_954aa1e1-a947-4348-9920-425f6ce71bfc">17,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b95fd7a3234324ac4b5f9ada511b59_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS03LTEtMS0xOTQ5Mjk_daeb060c-f502-4daf-bb96-4b78a1eaadee">281,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb4f2d80cc44287b347cfd75169b5a5_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS0xMS0xLTEtMTk0OTI5_9e629854-6ce2-4366-9c8c-c96b7c37d535">281,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Deferred Amount and contingent consideration attributable to CartiHeal have been reclassified to discontinued operations within the December 31, 2022 balance sheet. CartiHeal was fully deconsolidated during the first quarter of 2023. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Amount</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Deferred Amount that resulted from the CartiHeal Acquisition was calculated based on the total amount payable on each due date for the five payment tranches including applicable interest. As previously discussed, the Company reached a settlement Agreement with the Former Securityholders. Pursuant to the Settlement Agreement, the Company was relieved of the obligations under the Deferred Amount. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs. As previously discussed, the Company reached a settlement agreement with the Former Securityholders and was relieved of the CartiHeal Contingent Consideration obligations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures and Note 14. Discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unobservable inputs</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfNDMyOA_b5db0740-c7b9-4294-96eb-17aa443fa0bb" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioness contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i323f1175cc564a45a27343e1faec2e7a_I20230401" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjQ0MGFhNzI2NDEyNTQ4Njc5YjcxODM1OGY4Njk3ZmQ1L3RhYmxlcmFuZ2U6NDQwYWE3MjY0MTI1NDg2NzliNzE4MzU4Zjg2OTdmZDVfNS01LTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpjODcwODA5NzM2NzY0ZGVkYjk3YTk3ZWU3NzYyOWI3Nl80_beec15d8-f081-4040-8a39-775c73c3aa04">6.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i87246041109544cf8fb41b557c4513b7_I20230401" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjQ0MGFhNzI2NDEyNTQ4Njc5YjcxODM1OGY4Njk3ZmQ1L3RhYmxlcmFuZ2U6NDQwYWE3MjY0MTI1NDg2NzliNzE4MzU4Zjg2OTdmZDVfNS01LTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpjODcwODA5NzM2NzY0ZGVkYjk3YTk3ZWU3NzYyOWI3Nl85_52399048-adfc-4a66-8b54-35f04a37bbd6">6.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2025</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness totaled $<ix:nonFraction unitRef="usd" contextRef="i7dd7797604384c719b067b4dc6cf3c42_D20230101-20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMjgwNw_fd057231-014d-4dad-9700-04774ee8b75a">287</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i41945a367312405a869c8711b228f155_D20220101-20220402" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMTY0OTI2NzQ1MDg4OQ_a974684d-7af2-4073-9543-5c249237bc09">269</ix:nonFraction> for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss. Changes in contingent consideration related to the CartiHeal Acquisition totaled $<ix:nonFraction unitRef="usd" contextRef="i2479f6ea4f13427d9a5c83ccd6ec9614_D20230101-20230401" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMTY0OTI2NzQ1MTExMQ_e7179251-e30f-4494-83e3-887bbf5c20ce">1,710</ix:nonFraction> for the three months ended April&#160;1, 2023 and is reported within discontinued operations, net within the consolidated condensed statements of operations and comprehensive loss. Pursuant to the Settlement Agreement, the Company was relieved of CartiHeal related obligations. The Company deconsolidated the remaining $<ix:nonFraction unitRef="usd" contextRef="i2479f6ea4f13427d9a5c83ccd6ec9614_D20230101-20230401" decimals="-3" name="bvs:ContingentConsiderationLiabilityWrittenOffForDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMTY0OTI2NzQ1MTMxMQ_7cb619dc-7a0c-4bca-a6e3-f6aea6a447e7">68,961</ix:nonFraction> contingent consideration liability as a result. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding the deconsolidation of CartiHeal.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0NQ_f7022b3a-61a5-47df-86a6-ded375f6c467" continuedAt="i8c70694896244b5ca164840130cab667" escape="true">Equity-based compensation</ix:nonNumeric></span></div><ix:continuation id="i8c70694896244b5ca164840130cab667" continuedAt="i464474684c544f9598240ab4c4696537"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates an equity-based compensation plan (the &#8220;2021 Plan&#8221;), which allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;), other stock-based awards, and cash awards (collectively, &#8220;Awards&#8221;). As of April&#160;1, 2023, <ix:nonFraction unitRef="shares" contextRef="iaf9b7a1c5154425c8c24265aade7743e_I20230401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTE5NQ_c6be1e4b-c1ee-4f16-ae09-6522118b86f0">11,278,656</ix:nonFraction> shares of Class A common stock were authorized to be awarded and <ix:nonFraction unitRef="shares" contextRef="iaf9b7a1c5154425c8c24265aade7743e_I20230401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTI2Mw_1923be53-cf3a-4af3-a7db-c07d363b3130">2,762,266</ix:nonFraction> shares were available for Awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense for Awards granted under the 2021 Plan for the three months ended April&#160;1, 2023 and April&#160;2, 2022, totaled $<ix:nonFraction unitRef="usd" contextRef="id47714ccd1064cd1b7ff9cd499c1fc55_D20230101-20230401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTQzMg_fc25ed25-7a42-464f-b766-dc156c30153d">1,718</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i094ee1c434914509890caa47833deaa5_D20220101-20220402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTQzOQ_77f68325-4d0c-46ba-bcc1-ab47042606d1">4,731</ix:nonFraction>, respectively. The expense is primarily included in selling, general and administrative expense with a nominal amount in research and development expense on the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were $<ix:nonFraction unitRef="usd" contextRef="id47714ccd1064cd1b7ff9cd499c1fc55_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTcxNg_1ef1115c-bded-4002-8e3f-4efe3c41079a">430</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i094ee1c434914509890caa47833deaa5_D20220101-20220402" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTY0OTI2NzQ0NzE1MQ_4b25d3fd-04cb-488b-8621-23eb59545e0b">1,225</ix:nonFraction> income tax benefit related to this expense for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;1, 2023, the Company granted time-based RSUs which vest at various dates through January&#160;3, 2027. RSU compensation expense is recognized over the vesting period, which is typically between <ix:nonNumeric contextRef="i13e007318d4e4feaa4ef8dfd98ef3932_D20230101-20230401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjA5OA_7945e421-9e6b-4ef6-b057-9135123dba74">1</ix:nonNumeric> and <ix:nonNumeric contextRef="i61c0aac0923c4bc7a1174492aa74af25_D20230101-20230401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjEwNQ_9c5d2898-fe2a-4dc2-ab93-f66fc725f7b0">4</ix:nonNumeric> years. Unamortized compensation expense related to the RSUs totaled $<ix:nonFraction unitRef="usd" contextRef="idcb624597b214504b42d1ecb52e98a8c_I20230401" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjE3MA_f9118b6e-e218-44d3-b3a1-8c407769c180">2,265</ix:nonFraction> at April&#160;1, 2023, and is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjI2MQ_d5dffc3b-1c14-4e4e-aa75-fdaed9d26773">2.50</ix:nonNumeric> years. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0Ng_ba676761-3cb0-400b-9dd5-f7bf89038d75" continuedAt="i1e4e7018edca4d6784e66c1f44bee081" escape="true">A summary of the RSU award activity for the three months ended April&#160;1, 2023 is as follows (number of units in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i1e4e7018edca4d6784e66c1f44bee081"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant-date fair value per unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4fed2036ec84bff9a6d9d643492a512_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMS0xLTEtMS0xOTQ5Mjk_2e7d56e4-e033-4c8b-87d6-c17e6e99c6ac">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4fed2036ec84bff9a6d9d643492a512_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMS0zLTEtMS0xOTQ5Mjk_619c1710-6fc1-4f74-b3f1-32736af5a371">11.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMi0xLTEtMS0xOTQ5Mjk_c39d88db-af31-4f69-a6ee-58ba736838e0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMi0zLTEtMS0xOTQ5Mjk_969be3a7-4268-4cac-9b85-ca984428f81e">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMy0xLTEtMS0xOTQ5Mjk_8e8a1c43-8633-4f42-8a62-63824ba54188">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMy0zLTEtMS0xOTQ5Mjk_ab35691a-e5e9-4f55-bf4a-5bf762d31d27">12.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNC0xLTEtMS0xOTQ5Mjk_2f481c96-168f-4407-a2f3-b632ed13ce48">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNC0zLTEtMS0xOTQ5Mjk_a1ab470b-3719-4940-b4cf-0504eddd5fef">12.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at April 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcb624597b214504b42d1ecb52e98a8c_I20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNS0xLTEtMS0xOTQ5Mjk_bc09b8b2-272c-4064-aceb-201546d4a2c4">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idcb624597b214504b42d1ecb52e98a8c_I20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNS0zLTEtMS0xOTQ5Mjk_6633fdd8-6ce3-42d7-b0e1-10aa1f8f68c4">11.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;1, 2023, the Company granted time-based stock options which vest over <ix:nonNumeric contextRef="ia114f5984aa5487d94a7e5a2f9dd47c1_D20230101-20230401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjQ2Mg_e36e0955-cb9d-42b4-96a6-3e883aac4db6">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjQ2OA_68e4aaaa-640f-4861-be05-3c7639d151a6">4</ix:nonNumeric> years following the date of grant and expire within <ix:nonNumeric contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjUxNw_aaad5bd7-dbfd-43ef-9110-c7f1af16a183">10</ix:nonNumeric> years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically <ix:nonNumeric contextRef="ia114f5984aa5487d94a7e5a2f9dd47c1_D20230101-20230401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjcwMQ_e36e0955-cb9d-42b4-96a6-3e883aac4db6">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjcwNw_68e4aaaa-640f-4861-be05-3c7639d151a6">4</ix:nonNumeric> years, net of actual forfeitures. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0Nw_53942260-ab2f-4b96-abfa-bac0c0403789" continuedAt="i4ed01779a8ef4ca08e3262cf6d5433b9" escape="true">A summary of the Company&#8217;s assumptions used in determining the fair value of the stock options granted during the three months ended April&#160;1, 2023 is shown in the following table.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i4ed01779a8ef4ca08e3262cf6d5433b9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMC0xLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjoyOWIwOWEyNGI0MjA0NWFiYmEzZjEwNzdlNzgyMTU5Yl85_e307afe2-9dff-421e-b23c-7dda90eabc64">3.9</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMS0xLTEtMS0xOTQ5Mjk_b0cd2cca-06bc-4327-8048-ffdaf9e120fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMi0xLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjo4YTJmNmZkMDA2ZTg0MDk4OTgwY2QwZThhZTQ2Y2M0N185_70a1fbef-695f-4b66-8930-414f9efb9b38">35.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of stock options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMy0xLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpmMjkyZDA3OTU3MmI0NmJmOGVjZjQ1ZGM4NmZiMzM2N180_f6798dc5-cd7c-4dd9-8c5a-1c8f71f0a9d6">6.25</ix:nonNumeric></span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended April&#160;1, 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjk3Ng_0dc55b54-facd-4a2a-b235-46b2c7d5dd9d">1.10</ix:nonFraction> per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company&#8217;s peers&#8217; common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $<ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMzM5OQ_9db80acc-d7a7-4c64-802e-cb7911dfcc31">9,614</ix:nonFraction> at April&#160;1, 2023, and is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMzQ5MA_82d22d43-6d76-4a1f-a398-6f2aa729adf9">3.78</ix:nonNumeric> years. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i464474684c544f9598240ab4c4696537"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0OA_c74c32b4-15a2-4b03-a553-b36989a4c026" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows for the three months ended April&#160;1, 2023 (number of options in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMS0xLTEtMS0xOTQ5Mjk_5432f590-18dc-404c-be8f-cad7ed0d6c29">8,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMS0zLTEtMS0xOTQ5Mjk_6243866d-44fb-4d81-a257-07a74fd8c850">11.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMi0xLTEtMS0xOTQ5Mjk_46b6c646-d780-4ddf-bc46-1eea971440bf">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMi0zLTEtMS0xOTQ5Mjk_3a0dd0c7-6aef-48f6-9718-f592fc9b468e">2.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNC0xLTEtMS0xOTQ5Mjk_f66225eb-4928-4535-880e-98855e504457">636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNC0zLTEtMS0xOTQ5Mjk_b6a9d516-33be-404f-ac37-890c588ea145">12.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS0xLTEtMS0xOTQ5Mjk_cd57779e-2cad-47eb-b369-cb723286055d">8,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS0zLTEtMS0xOTQ5Mjk_fed3a0dc-6adb-4734-bea9-14ac67d17b7e">11.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS01LTEtMS0xOTQ5Mjk_d2700611-6fb0-4f92-ab81-ad7f225548c2">7.44</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS03LTEtMS0xOTQ5Mjk_240cf713-2bc1-4a3e-bd25-3730d7d96245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and vested at April 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi0xLTEtMS0xOTQ5Mjk_888115e4-abb7-4bd5-bbcd-5bd2f703480b">5,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi0zLTEtMS0xOTQ5Mjk_36e051f6-c7f9-4a45-a754-18f8427e3416">10.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi01LTEtMS0xOTQ5Mjk_d027dd3d-f1f3-461a-ab34-8346345ef5e1">6.74</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi03LTEtMS0xOTQ5Mjk_b52f2467-1584-4b45-b09a-2d2d3dbffcd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#8217;s Class A common stock for options that had exercise prices lower than $<ix:nonFraction unitRef="usdPerShare" contextRef="i7c391ae2f04e49239fb30fb662e626cb_I20230331" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMzgyMg_b7bf2eb3-56e9-4eae-952a-2f40606bfa42">1.07</ix:nonFraction> per share, the closing price of the Company&#8217;s Class A common stock on March&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates a non-qualified Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which provides for the issuance of shares of the Company&#8217;s Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of April&#160;1, 2023, the aggregate number of shares reserved for issuance under the ESPP was <ix:nonFraction unitRef="shares" contextRef="i7a367805653149a6bd4c69f62610cedd_I20230401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDMzMw_358e53ae-dc73-4b09-8aca-34479a84bfd6">1,181,830</ix:nonFraction>. A total of <ix:nonFraction unitRef="shares" contextRef="i90132788802142b1b654aab8435a8fb6_D20230101-20230401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDM1NQ_d32f57be-e3b4-4a04-80c7-5f07df73bc8c">222,076</ix:nonFraction> shares were issued and $<ix:nonFraction unitRef="usd" contextRef="i90132788802142b1b654aab8435a8fb6_D20230101-20230401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDM4OA_faabf218-3903-4e88-bd1d-8dc098e6f507">128</ix:nonFraction> of expense was recognized during the three months ended April&#160;1, 2023. A total of <ix:nonFraction unitRef="shares" contextRef="i977440bad8ac48adba402f0ac93702bf_D20220101-20220402" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDQ2Nw_fbd81999-75c4-4d45-b62c-6eca315f9e4c">48,993</ix:nonFraction> shares were issued and $<ix:nonFraction unitRef="usd" contextRef="i977440bad8ac48adba402f0ac93702bf_D20220101-20220402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDUwMA_aa27d502-5f27-4564-ad20-9765a75bcb61">158</ix:nonFraction> of expense was recognized during the three months ended April&#160;2, 2022.</span></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzM1MQ_747acf5b-6963-46ea-a5e6-1063838cf575" continuedAt="ic483cf9cd07c496083cff842ab228381" escape="true">Stockholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="ic483cf9cd07c496083cff842ab228381" continuedAt="i566e5a73ac194dffa29f07d68948b32f"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company closed an IPO of <ix:nonFraction unitRef="shares" contextRef="i455ecc502ecd43c8a0240143ce3f7613_D20210216-20210216" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NzIwMQ_990b29a5-4c03-475a-b28d-0bb7e537a8b8">9,200,000</ix:nonFraction> shares of Class A common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd867d34482345439425ee5ab5255266_I20210216" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NzIyMw_753af6c1-f554-460e-85f1-abb34023068a">13.00</ix:nonFraction> per share, which includes <ix:nonFraction unitRef="shares" contextRef="i9b2195c740e24fa3b47460484cabe3cd_D20210216-20210216" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NzIxNA_693e04de-10c1-4476-823e-9385a86220cc">1,200,000</ix:nonFraction> shares issued pursuant to the underwriters' over-allotment option. In connection with the IPO, the Company completed the following transactions (&#8220;Transactions&#8221;).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amended and restated the limited liability company agreement of BV LLC (&#8220;BV LLC Agreement&#8221;), to, among other things, (i) provide for a new single class of common membership interests in BV LLC (&#8220;LLC Interests&#8221;); (ii) exchange all of the existing membership interests in BV LLC (&#8220;Original BV LLC Owners&#8221;) for new LLC Interests; and (iii) appoint Bioventus Inc. as the sole managing member of BV LLC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amended and restated the Bioventus Inc. certificate of incorporation to, among other things, (i) provide for an increase in the authorized shares of Class A common stock; (ii) provide for Class B common stock with voting rights but no economic interest, which shares were issued to the Original BV LLC Owners on a <ix:nonFraction unitRef="number" contextRef="i24e141c8e8054b31a54f133d51dc223c_I20210216" decimals="INF" name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0Njc4NA_a36d7ccc-54bb-46b6-8832-856edf562c42">one</ix:nonFraction>-for-one basis with the number of LLC Interests they owned; and (iii) provide for undesignated preferred stock.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquired, by merger, <ix:nonFraction unitRef="segment" contextRef="ifa4f6b39d2a74a85bb0d2edd723d8a7b_D20210216-20210216" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0Njc5Mg_7598f89d-1168-45f2-86ab-a56dfc2c9a93">ten</ix:nonFraction> entities that were Original BV LLC Owners (&#8220;Former LLC Owners&#8221;), for which the Company issued <ix:nonFraction unitRef="shares" contextRef="ifa4f6b39d2a74a85bb0d2edd723d8a7b_D20210216-20210216" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjIwMw_c2e47b77-a55c-47cd-a228-bd3ec63c2499">31,838,589</ix:nonFraction> shares of Class A common stock as merger consideration (&#8220;IPO Mergers&#8221;). The only assets held by the Former LLC Owners were <ix:nonFraction unitRef="shares" contextRef="i77db743857a644e9a0320ade7e6a5d2a_I20210216" decimals="INF" name="bvs:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjMyOA_f4cbc1fa-b83a-4fa0-a6d8-ece9c051aaa7">31,838,589</ix:nonFraction> LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the IPO Mergers, the <ix:nonFraction unitRef="shares" contextRef="i8504a2e91ba84dfd8a6e426662ca386d_D20210216-20210216" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjQ1MA_e6074dfd-4e48-4970-9c0f-cbf8dbacbd50">31,838,589</ix:nonFraction> shares of Class B common stock were canceled, and the Company recognized the <ix:nonFraction unitRef="shares" contextRef="i77db743857a644e9a0320ade7e6a5d2a_I20210216" decimals="INF" name="bvs:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjUzMQ_f4cbc1fa-b83a-4fa0-a6d8-ece9c051aaa7">31,838,589</ix:nonFraction> LLC Interests at carrying value, as the IPO Mergers are considered to be a recapitalization transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment and restatement of certificate of incorporation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company amended and restated its certificate of incorporation to, among other things, provide for: (i) the authorization of <ix:nonFraction unitRef="shares" contextRef="id407ba4965db4b79a8fd6e8dc15e23b0_I20210216" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjM3_8bba0eae-1d4c-48a8-8872-9d8eb6c4df8c">250,000,000</ix:nonFraction> shares of Class A common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="id407ba4965db4b79a8fd6e8dc15e23b0_I20210216" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjkx_13858c42-c27d-4f15-b189-6c9f9b29733a">0.001</ix:nonFraction> per share; (ii) the authorization of <ix:nonFraction unitRef="shares" contextRef="i24e141c8e8054b31a54f133d51dc223c_I20210216" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzMx_53a5e4b7-bc91-4e28-a488-7c420bf1a9d5">50,000,000</ix:nonFraction> shares of Class B common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i24e141c8e8054b31a54f133d51dc223c_I20210216" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzg1_87eb60e1-6fb2-49bb-b616-763a6691fdba">0.001</ix:nonFraction> per share; (iii) the authorization of <ix:nonFraction unitRef="shares" contextRef="ibd867d34482345439425ee5ab5255266_I20210216" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfNDI2_68e219b6-9bc1-42a4-8eb5-f29c838d8915">10,000,000</ix:nonFraction> shares of undesignated preferred stock that may be issued from time to time by the BOD in one or more series; and (iv) the establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered <ix:nonNumeric contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" name="bvs:BoardOfDirectorLengthOfTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzM1Mg_4a4dda13-be7e-45b1-8257-343d5b2d4c5d">three-year</ix:nonNumeric> terms.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i566e5a73ac194dffa29f07d68948b32f"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A and Class B common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="id9ca1d77ddbc4f598510ff5ccb96d1ee_D20230101-20230401" decimals="INF" name="bvs:CommonStockNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfNzM3_2e0b85c9-8e09-4b7f-9ea7-6f3e8bf2fc90">one</ix:nonFraction> vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the <ix:nonFraction unitRef="number" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTE3NA_00ebfb48-36e7-4c29-844c-e25957eee3ee">one</ix:nonFraction>-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by the Smith &amp; Nephew, Inc. (the &#8220;Continuing LLC Owner&#8221;). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a <ix:nonFraction unitRef="number" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="INF" name="bvs:CancellationRatioRequiredStockToLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTQ2Mw_cd6fd32e-f938-465c-b7fb-df91c1190574">one</ix:nonFraction>-for-one basis upon the redemption or exchange of any outstanding LLC Interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must, at all times, maintain a <ix:nonFraction unitRef="number" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTU4OQ_1a59b0dc-81d7-4729-a5c9-1cd5e7201dde">one</ix:nonFraction>-to-one ratio between the number of outstanding shares of Class A common stock and the number of LLC Interests owned by the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BV LLC recapitalization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BV LLC Agreement provides that holders of LLC Interests may, from time to time, require the Company to redeem all or a portion of their LLC Interests for newly-issued shares of Class A common stock on a <ix:nonFraction unitRef="number" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="INF" name="bvs:SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjMyMg_fbbc0a01-31b9-4468-af9f-ec5e0f85e471">one</ix:nonFraction>-for-one basis. The Company may elect to settle any such redemption in shares of Class A common stock or in cash.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment also requires that the Company, at all times, maintain (i) a <ix:nonFraction unitRef="number" contextRef="ie046b8a033654588aa416481153be819_I20230401" decimals="INF" name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjUxMw_6d9b6924-e477-4047-8859-426f92d908f2">one</ix:nonFraction>-to-one ratio between the number of outstanding shares of Class A common stock and the number of LLC Interests owned by the Company and (ii) a <ix:nonFraction unitRef="number" contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401" decimals="INF" name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjY1OA_1c9eb68d-9c1a-4c75-8d57-cb8d08757140">one</ix:nonFraction>-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with any redemption, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the three months ended April 1, 2023 or during the year ended December&#160;31, 2022. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzM1Mw_9f6340c3-5ae3-41d9-ac76-814afb829de7" continuedAt="i8990ebccb0ba49158a64336bb489bfbd" escape="true">The following table summarizes the ownership interest in BV LLC as of April&#160;1, 2023 and December&#160;31, 2022 (number of units in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="i8990ebccb0ba49158a64336bb489bfbd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LLC Interests</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ownership %</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LLC Interests</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ownership %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of LLC Interests owned</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioventus Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f28a6c8e2a44fe9b2c8149437d14601_I20230401" decimals="-3" name="us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy0xLTEtMS0xOTQ5Mjk_ec20c26f-8565-472f-af44-b79ef5ad5b29">62,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81b082e001c941259cd51349877d6268_D20230101-20230401" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy0zLTEtMS0xOTQ5Mjk_e28945ea-fad7-4c93-be67-83767944e8eb">79.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00441e04d2f34f5aa2bc5b4cd5b53c4a_I20221231" decimals="-3" name="us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy01LTEtMS0xOTQ5Mjk_d205b40d-9a5e-42c9-83b6-db1e504cf71d">62,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3508c22776a24e489023f7a0f04b1e3e_D20220101-20221231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy03LTEtMS0xOTQ5Mjk_29cc78a6-1625-41f7-aeae-90ea8eb045ff">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing LLC Owner</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad3381ddd884b6e8d796b931cdf5c98_I20230401" decimals="-3" name="us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC0xLTEtMS0xOTQ5Mjk_36f719c8-a97a-4259-b435-e282f6aa573b">15,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f9f122c646249b6ba80f94f1d27ce49_D20230101-20230401" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC0zLTEtMS0xOTQ5Mjk_59b92ae9-99ef-48b1-968b-12487c5b60e4">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideca15b277be4a5a80bfeb0ef5169075_I20221231" decimals="-3" name="us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC01LTEtMS0xOTQ5Mjk_08c75029-76b4-4ef1-9300-53f21ca70608">15,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb4089d2b0824f41a82aadcb2951f8f4_D20220101-20221231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC03LTEtMS0xOTQ5Mjk_6b4e6bf2-04d3-4263-a413-d7463e95a33f">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc806e7a00b4d2aa28a38d41193abfe_I20230401" decimals="-3" name="us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS0xLTEtMS0xOTQ5Mjk_32a54703-8971-4784-b596-b667cff2afd3">78,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i621e34ed2397424fbf3217653350ee1d_D20230101-20230401" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS0zLTEtMS0xOTQ5Mjk_784facc4-387d-45b1-873f-0a74c4598677">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bda7af6c3f04de89092466d5c2c03b2_I20221231" decimals="-3" name="us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS01LTEtMS0xOTQ5Mjk_6bbc67ba-8966-4ea2-904d-c52cd0ba6aaa">77,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifaac88ea486b416ea279e01dd9088634_D20220101-20221231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS03LTEtMS0xOTQ5Mjk_6e295749-9d92-420c-9682-66aec26a4520">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RleHRyZWdpb246NGZjY2I0ZDg3NWMzNDg1MDhjZjkwMmIyNmU0YThlZWJfODYx_1e20e611-8fdf-4aa9-a259-6743d78a8b07" continuedAt="icb61e6669a9f41cca95ca08f58a061b6" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:continuation id="icb61e6669a9f41cca95ca08f58a061b6"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RleHRyZWdpb246NGZjY2I0ZDg3NWMzNDg1MDhjZjkwMmIyNmU0YThlZWJfODYy_34548fa4-9787-4bf2-b073-c0d4d9feb3dc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income from continuing operations, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNC01LTEtMS0xOTQ5Mjk_5c1f37cb-f2d8-458d-bc80-2336b651e6d7">100,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNC03LTEtMS0xOTQ5Mjk_c93e5039-e1cf-47b4-89b9-4829172570c0">14,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests &#8212; continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNS01LTEtMS0xOTQ5Mjk_ac405912-24a6-4f49-a9fc-673761973c20">20,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNS03LTEtMS0xOTQ5Mjk_cc4a3a4b-b543-4f42-8e21-4f34ffcdbb2c">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212;<br/>&#160;&#160;&#160;&#160;continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNi01LTEtMS0xOTQ5Mjk_4f7265d4-25ae-4ada-8ca7-6509fb706177">79,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNi03LTEtMS0xOTQ5Mjk_94b34fc7-9e1c-4b49-b05f-49e8e426b697">10,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNy01LTEtMS0yMDU4NDc_554d0be0-8a67-4fc9-896c-6f5e5c805329">74,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNy03LTEtMS0yMDU4NDc_54beabfa-eba6-4151-a112-aab9f696f291">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests &#8212; discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOC01LTEtMS0yMDU4NDc_4c652b70-4a68-44d5-9aac-434b7c77c8dc">14,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOC03LTEtMS0yMDU4NDc_d00a63f4-4b50-4a41-a8a2-5fd384ee6f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212;<br/>&#160;&#160;&#160;&#160;discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTAtNS0xLTEtMjA4Mzk3_8d53dbda-daa2-4e04-85ec-bd6c84f66bbb">59,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTAtNy0xLTEtMjA4NDE3_16f144cc-4167-404f-bffd-220c70fe6da1">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of Class A common stock outstanding - basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS01LTEtMS0xOTQ5Mjk_71e12476-c79d-4087-8d6d-7dcbc00b0dc5"><ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS01LTEtMS0xOTQ5Mjk_adc8dc81-f911-47e1-94c3-c10c1d23b0b5">62,124,752</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS03LTEtMS0xOTQ5Mjk_77fdd71a-f32d-41af-a36b-e1ad0bcb5600"><ix:nonFraction unitRef="shares" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS03LTEtMS0xOTQ5Mjk_f88a63c9-ebe5-4a31-828c-ca66a9afeb58">60,484,969</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock from continuing operations, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNS0xLTEtMTk0OTI5_1050414d-088e-4810-ae5b-0786d6a86618"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNS0xLTEtMTk0OTI5_56b5a6a4-6f97-460d-b068-df762fed5273">1.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNy0xLTEtMTk0OTI5_16fbcf89-4770-4690-8b57-ed30c7a16a3b"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNy0xLTEtMTk0OTI5_ac927454-802c-4344-83b1-f3f378c609a0">0.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock from discontinued operations, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNS0xLTEtMjA1OTEx_12371584-2406-4711-a734-ec6de401e62b"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNS0xLTEtMjA1OTEx_e77a9596-c911-4efc-a22c-6b12c60843b5">0.96</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNy0xLTEtMjA1OTEx_39be4774-2959-4be1-a3e6-eab27b9c071e"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNy0xLTEtMjA1OTEx_76b3e5a2-6781-482a-882e-6daea7649b26">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNS0xLTEtMjA4NDE5_8859b6f7-5e9d-4c46-99a7-30f8f87d5725"><ix:nonFraction unitRef="usdPerShare" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNS0xLTEtMjA4NDE5_d26df951-4a80-4872-be61-2fbe520f63ba">2.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNy0xLTEtMjA4NDI0_3a34c45a-3a12-4601-b7e8-4ba42a0f94f6"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNy0xLTEtMjA4NDI0_3f2591c7-30a1-4599-b661-b2e4d44b27e0">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented.</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RleHRyZWdpb246NGZjY2I0ZDg3NWMzNDg1MDhjZjkwMmIyNmU0YThlZWJfODYw_b6c9088b-141a-4bb6-accc-9a8627622336" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following number of weighted-average potentially dilutive shares as of April&#160;1, 2023 and April&#160;2, 2022 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LLC Interests held by Continuing LLC Owner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ab3e51b5150437a9922627be2e141bb_D20230101-20230401" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMi01LTEtMS0xOTQ5Mjk_e6e54bba-26af-4e0e-b7a7-5ffe2c80e71a">15,786,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bd02248ff5a4c349ca283983f6fb643_D20220101-20220402" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMi03LTEtMS0xOTQ5Mjk_14302b47-65a7-42dd-a121-7b92da884ac9">15,786,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i826a2b73e7024f2bbb971c7170189c53_D20230101-20230401" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMy01LTEtMS0xOTQ5Mjk_4984d1b6-7250-4927-b4b0-0b29c10bea87">8,517,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11cb3b3b1ef8485b8260800eb571e90a_D20220101-20220402" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMy03LTEtMS0xOTQ5Mjk_087fc10b-ba5f-4ec4-b7eb-9fac7f10e2ad">8,757,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ec54bc3bcce4e0cba062fc969afa5c3_D20230101-20230401" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNC01LTEtMS0xOTQ5Mjk_7bcc7d16-b10d-4408-8984-f46f8b1d97f0">1,070,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e76064517ae4b5e9d9e3a322bd12ee1_D20220101-20220402" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNC03LTEtMS0xOTQ5Mjk_0fe54166-33ce-41f5-bb6a-a2558565184b">462,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNi01LTEtMS0xOTQ5Mjk_979d25f2-437c-4dbd-bcf0-54aa9c9de903">25,373,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNi03LTEtMS0xOTQ5Mjk_6470052f-4d20-45c7-8a01-1e3cf508060e">25,006,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.</span></div></ix:nonNumeric></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_67"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTAzNw_836ac42a-66a0-4522-bead-953c858c80e7" continuedAt="i49233f0e5bc44cafb4734ce5ca4855bd" escape="true">Restructuring costs</ix:nonNumeric></span></div><ix:continuation id="i49233f0e5bc44cafb4734ce5ca4855bd" continuedAt="i00d9d96f3b5842c5b920213d43768081"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs are not allocated to the Company&#8217;s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company announced a restructuring plan in December 2022 (the &#8220;2022 Restructuring Plan&#8221;) that is intended to align the Company&#8217;s organizational and management cost structure to improve profitability and cash flow. The Company expects to incur $<ix:nonFraction unitRef="usd" contextRef="iab463c35574b4f8ca9e4c2daa0b62cf5_I20230401" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDMzOA_319bbef8-ef62-4697-b7c3-358969cfc1ea">4,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="ie37855daa1184dc78d7515b03e113ea3_I20230401" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDM0Nw_67ad2bc3-f1f8-4d42-a49b-bdc1b513a3b9">5,000</ix:nonFraction> of pre-tax costs under the 2022 Restructuring Plan primarily consisting of employee severance and additional expenses for third-party and other related costs. Pre-tax charges recognized during the three months ended April&#160;1, 2023 and the year ended December&#160;31, 2022 totaled $<ix:nonFraction unitRef="usd" contextRef="i7889eb67185b4a7fb1f2a59966756eb0_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDUxMg_3b780c82-6a89-4f3b-b1e6-9d40e39e3c1f">262</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie6c1ba06aa134309858a469840e28937_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDUyMA_a7f7c3fd-568e-4de8-a459-3f7d22176924">4,581</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i00d9d96f3b5842c5b920213d43768081"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted restructuring plans for businesses acquired to reduce headcount, reorganize management structure and consolidate certain facilities during the second half of 2021 (the &#8220;2021 Acquisition Restructuring Plan&#8221;) and during the first quarter of 2022 (the &#8220;2022 Acquisition Restructuring Plan&#8221;). The Company planned total pre-tax charges for the 2021 Acquisition Restructuring Plan and 2022 Acquisition Restructuring Plan are $<ix:nonFraction unitRef="usd" contextRef="i544e8c2721cb486fa712dc07d475a475_I20230401" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDg2OA_63519f08-858e-4e32-a406-0617f6202050">3,500</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6cafecddd27a4b469315f336ef3ed50d_I20230401" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0Njc2Mg_133f1b60-8590-4ebf-bbd3-fd31420df198">2,300</ix:nonFraction>, respectively. There was nominal activity related to the 2021 Acquisition Restructuring Plan during the three months ended April&#160;1, 2023 and $<ix:nonFraction unitRef="usd" contextRef="if5b22816b48c442798421ebd10c98786_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzU3Mg_9c5dc467-4269-4e7d-af3c-410cd88bb781">377</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i8eab176afd194ef687ade1014da11d08_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzIwMg_eaa3f6f9-0782-4127-a01a-4bdefe4e4b28">719</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1bd943395fc7408b9c20e3013b149ed9_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzIxMA_988d386d-c62f-4f8c-826d-8dbfa0fa8446">2,487</ix:nonFraction> recognized during the three months ended April&#160;2, 2022, and the years ended December 31, 2022 and 2021, respectively. The 2021 Acquisition Restructuring Plan is essentially completed. Costs incurred attributable to the 2022 Acquisition Restructuring Plan totaled $<ix:nonFraction unitRef="usd" contextRef="ief777ae06245484290df025fea9e0d3d_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDk1NQ_291abcef-3b5a-4d57-bbe8-4da5fe503933">84</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i96d6024603534c5ea5af4d437fd6040e_D20220101-20220402" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzYwOQ_5e3222ff-e74b-4376-aa60-716bf7298dd8">200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2c209e0543284533a6ae897763a26743_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzQ0OA_44a5065b-f450-47c7-8ba5-fc99d7ac7020">1,479</ix:nonFraction> during the three months ended April&#160;1, 2023 and April&#160;2, 2022, and the year ended December 31, 2022, respectively.</span></div><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTAzOA_4e021099-14d3-4df7-9fa3-e5084af105af" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restructuring charges and payments for plans related to businesses recently acquired comprised of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">severance and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">temporary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">labor costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">charges </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471155b226eb40c690334fd2874e4f56_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMS0xLTEtMS0xOTQ5Mjk_a386d694-2def-473a-ac79-b8fb76c90818">3,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9c750d3df948a0bfe95f8639979859_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMS0zLTEtMS0xOTQ5Mjk_2f359a54-09c7-43f4-ae31-59aa3c74af82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMS01LTEtMS0xOTQ5Mjk_11ad120c-ac91-45b0-979f-d36350ffd0a6">3,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d4aa340243422abe25f197db4c3b59_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMi0xLTEtMS0xOTQ5Mjk_71460a50-8c03-4c43-b702-0f86500cf304">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2830275f954d0484c2c3f9c65710b4_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMi0zLTEtMS0xOTQ5Mjk_22022868-b176-4cbc-9be4-7768da7ca7d2">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMi01LTEtMS0xOTQ5Mjk_b25dc8d9-48ee-4510-af8e-ef4f38f46767">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73d4aa340243422abe25f197db4c3b59_D20230101-20230401" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMy0xLTEtMS0xOTQ5Mjk_17fb1742-42db-4ab0-8f2a-78edb5ad1765">1,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc2830275f954d0484c2c3f9c65710b4_D20230101-20230401" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMy0zLTEtMS0xOTQ5Mjk_39987a64-6cb3-48f6-b8d6-b42bb930ddbc">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMy01LTEtMS0xOTQ5Mjk_82119ea3-4edd-4d66-87cf-bd861eb5d0cb">1,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at April 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa741b924a3549099b1b5111321fbba2_I20230401" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfNC0xLTEtMS0xOTQ5Mjk_d7b3b0ac-84a4-46a2-9cad-0f0f7df941ac">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4cade8aa8d459cab8ee8fe3bbf1bdd_I20230401" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfNC0zLTEtMS0xOTQ5Mjk_e60f5fa7-9d8f-4ce0-985e-feb0c150fc83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfNC01LTEtMS0xOTQ5Mjk_a82422e5-812d-4d5b-a9bb-c026f32298c8">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_70"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMzQzMQ_96078492-21f0-41dc-aba8-611dadb5a49f" continuedAt="i21392a76cb2d498cbdb86cc9e9ca15cf" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="i21392a76cb2d498cbdb86cc9e9ca15cf"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company's annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended April&#160;1, 2023 and April&#160;2, 2022, the Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMTU0NQ_1faee7d2-f5ea-4be5-947e-fb3d7e061e75">0.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMTU0OQ_b693afe4-b7bf-49e4-80ee-c60943c6919c">26.3</ix:nonFraction>%, respectively. The decrease for the three months ended April&#160;1, 2023 was primarily due to changes in our forecasted effective rate and a net increase in reserve for uncertain tax positions. The change in the forecasted effective rate for the three months ended April&#160;1, 2023 compared to three months ended April 2, 2022 was primarily due to an increase in the valuation allowance applied to our net deferred tax assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company entered into a tax receivable agreement (&#8220;TRA&#8221;) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of <ix:nonFraction unitRef="number" contextRef="ibd867d34482345439425ee5ab5255266_I20210216" decimals="2" name="bvs:TaxReceivableAgreementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMjY1Mg_3e35dcdc-aa23-4bb1-9494-a61e3eb9ce1a">85</ix:nonFraction>% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. As of April&#160;1, 2023, the Continuing LLC Owner had not exchanged LLC Interests for shares of Class A common stock and therefore the Company had not recorded any liabilities under the TRA.</span></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_73"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ2MTQ_0b86d73a-e52b-482c-aeb8-7e9bde10ef04" continuedAt="ie71cad8970fb4d739332c043d5fea475" escape="true">Commitments and contingencies</ix:nonNumeric></span></div><ix:continuation id="ie71cad8970fb4d739332c043d5fea475" continuedAt="i981707d1e3364398b1dd17732f4b9795"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from <ix:nonNumeric contextRef="i7304128a25744503b8891660f963b710_I20230401" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMjc3_b66bfb0d-16c4-4634-8cd6-1e49a203849f">1</ix:nonNumeric> month to <ix:nonNumeric contextRef="ieb6cde82adad47b0938be5a986d174e9_I20230401" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMjgz_560d2b06-0ad8-4fa8-a3e9-790381f544b8">10</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i981707d1e3364398b1dd17732f4b9795" continuedAt="i81ec8a780d51407b851251672d839c54"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ2MTU_0e9aef88-77aa-4ac0-b11b-34b928f416c6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMi01LTEtMS0xOTQ5Mjk_c0d096a7-877c-4b3d-b602-21aae44a2b71">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMi03LTEtMS0xOTQ5Mjk_01a3dbff-2f5a-419e-b73f-ed012051603a">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMy01LTEtMS0xOTQ5Mjk_3d450174-a0ee-4c6d-a6ec-40f04d48b6ba">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMy03LTEtMS0xOTQ5Mjk_c1932e72-f667-4177-9844-be2e3553fa76">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of finance lease assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNS01LTEtMS0xOTQ5Mjk_f773334e-33b4-4956-949c-e32ffb288af2">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNS03LTEtMS0xOTQ5Mjk_2cba2b46-2094-4047-868e-12c238187a06">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNi01LTEtMS0xOTQ5Mjk_c7327dd1-7150-4b8e-b663-f1a966e5952e">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNi03LTEtMS0xOTQ5Mjk_7f56f196-180b-40a5-b461-2e05fd85609a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNy01LTEtMS0xOTQ5Mjk_c2ab5fb5-4ee9-470e-8df6-2a8e0896ab57">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNy03LTEtMS0xOTQ5Mjk_557964d1-fbd7-499f-82e0-adb879473ca8">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Includes variable lease cost and sublease income, which are immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to operating leases were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMi0xLTEtMS0xOTQ5Mjk_0655c80d-6f27-4ae1-bac1-2deb7b581c88">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMi0zLTEtMS0xOTQ5Mjk_30cc6fe2-2ef6-4d42-8053-ba6c6dc32371">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from financing leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMy0xLTEtMS0xOTQ5Mjk_abb2d710-c8b4-4964-9cec-f3c73938c0e2">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMy0zLTEtMS0xOTQ5Mjk_9e3b0b0c-aa46-4b37-acf1-38f31e0618cf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNC0xLTEtMS0xOTQ5Mjk_a6908e4f-a29e-45fa-b18f-6408ccb71326">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNC0zLTEtMS0xOTQ5Mjk_52d6203e-950f-4268-8dfd-4e0679284f7e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNy0xLTEtMS0xOTQ5Mjk_5b962972-080f-4aa2-a610-37655d88b3c4">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNy0zLTEtMS0xOTQ5Mjk_d4abccae-5d96-4c98-98ef-ef35bd640d58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfOC0xLTEtMS0xOTQ5Mjk_7ff4ab7b-252a-4691-befa-2e72d835c821">9,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfOC0zLTEtMS0xOTQ5Mjk_bd28ca92-c4da-411f-b64f-4a9554711536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="bvs:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ2MTM_5fb05a03-1d55-4f18-ace5-8b2f68c73390" continuedAt="ibd9b5c720a2045c9933780dd68e20f1f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet and other information related to operating leases were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMS0xLTEtMS0xOTQ5Mjk_931502d0-74c1-4322-8b22-970c872b689a">16,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMS0zLTEtMS0xOTQ5Mjk_22a5d79e-4bd7-421f-b1df-52e95e986ce3">16,690</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities- current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMy0xLTEtMS0xOTQ5Mjk_db7b10a4-6c8c-43fe-a8b5-54c8b88789c8">3,854</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMy0zLTEtMS0xOTQ5Mjk_ea045424-2453-4e2d-b59b-747a2404c43d">3,552</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities- noncurrent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNC0xLTEtMS0xOTQ5Mjk_4a3fca90-5b63-4994-8bf2-51d563254ad4">13,455</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNC0zLTEtMS0xOTQ5Mjk_6041d043-dd41-4768-863d-cf4abb2db739">14,355</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNS0xLTEtMS0xOTQ5Mjk_0779a34f-76bf-4841-84dc-0eeff5b4cf14">17,309</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNS0zLTEtMS0xOTQ5Mjk_92e33127-a367-4c73-b6b8-62962807cf5d">17,907</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524">Property, plant and equipment - net (finance leases)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0xLTEtMS0xOTQ5Mjk_699c3417-58f6-40d8-804b-06d03a63e380">9,034</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0zLTEtMS0xOTQ5Mjk_3bc39c0d-26e2-45b8-8b0a-ced5498dafe3">128</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities - current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTAtMS0xLTEtMTk0OTI5_f51d8707-74aa-49d4-99b3-275fd2ce8db1">419</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTAtMy0xLTEtMTk0OTI5_f52803e0-702f-454f-8455-ee575113138b">55</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTEtMS0xLTEtMTk0OTI5_9a10eb5a-086e-47f4-9bb7-87ee284c7e86">6,602</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTEtMy0xLTEtMTk0OTI5_b7c4912c-2635-4726-989e-cf7846add64f">76</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTItMS0xLTEtMTk0OTI5_bb173895-20da-4cb1-9852-2b8c193477f1">7,021</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTItMy0xLTEtMTk0OTI5_a1890181-895d-4ae6-b799-3db2f31d2a43">131</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years) for leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTUtMS0xLTEtMTk0OTI5_98db71bb-aca9-4f51-bd4d-5fc0e76523a2">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTUtMy0xLTEtMTk0OTI5_5e498186-c6bb-4d31-861b-469066a5a35f">4.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTYtMS0xLTEtMTk0OTI5_59fb114d-fa1c-4a3e-93ad-37e0c1aa945d">10.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTYtMy0xLTEtMTk0OTI5_4883e639-c92f-4c34-a2fb-4d989b87b4ae">2.4</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate for leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTgtMS0xLTEtMTk0OTI5_6c8eacff-41a4-4ee9-9942-5614fd6f1e8e">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTgtMy0xLTEtMTk0OTI5_4589d190-4fde-4fea-934d-8694cae6fdde">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401" decimals="2" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTktMS0xLTEtMTk0OTI5_a6c718aa-f6f3-4d2f-ab3e-39f0882b2eea">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTktMy0xLTEtMTk0OTI5_c247e01c-47d6-4ee3-a7c0-c5b068fbddb4">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Operating lease assets totaling $<ix:nonFraction unitRef="usd" contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1ODY2OA_e3721815-da24-43ab-93ea-2b5c1992d624">618</ix:nonFraction> attributable to CartiHeal was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i81ec8a780d51407b851251672d839c54" continuedAt="i06283180cf704e09b131abba7b11068f"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><ix:continuation id="ibd9b5c720a2045c9933780dd68e20f1f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Operating lease liabilities-current totaling $<ix:nonFraction unitRef="usd" contextRef="i75a9b09aeea047d997e35f25ccf68400_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1OTE2NA_9533f58c-f1d7-4da7-844d-2858f4ef866e">176</ix:nonFraction> and operating lease liabilities-noncurrent of $<ix:nonFraction unitRef="usd" contextRef="i75a9b09aeea047d997e35f25ccf68400_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1OTQzNQ_83e42eed-0b40-4495-9611-2a18268fded7">442</ix:nonFraction> were reclassified into current liabilities attributable to discontinued operations and long-term liabilities attributable to discontinued operations, respectively, within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental and legal contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Company&#8217;s complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bioventus shareholder litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina, Ciarciello v. Bioventus, Inc., No. 1:23&#8211; CV &#8211; 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserts violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees&#8217; Retirement System as lead plaintiff. The lead plaintiff&#8217;s amended consolidated complaint is due to be filed with the Court on June 12, 2023. Defendants&#8217; motion to dismiss the amended consolidated complaint is due on July 17, 2023. The Company believes the claims alleged lack merit and intends to defend itself vigorously. The outcome of the litigation is not presently determinable, and any loss is neither probable nor reasonably estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bioness patent litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, the Company, through its subsidiary Bioness, filed a lawsuit in the United States District Court for the Eastern District of Virginia against Aretech, LLC (&#8220;Aretech&#8221;) alleging infringement by Aretech of various patents related the Bioness&#8217; Vector Gait and Safety Support System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On August 8, 2022, Aretech filed an answer to the lawsuit denying infringement and asserting various affirmative defenses and counterclaims to the Bioness complaint. Bioness filed a motion to dismiss the defendant&#8217;s counterclaims on September 28, 2022. In response to Bioness&#8217; motion to dismiss the counterclaims, on October 19, 2022, Aretech filed an amended answer and counterclaims. On November 16, 2022, Bioness filed a partial motion to dismiss certain of the amended counterclaims. On January 23, 2023, the court granted-in-part Bioness&#8217; motion dismissing Aretech&#8217;s antitrust and inventorship-related counterclaims, but allowed certain of Aretech&#8217;s counterclaims to proceed. On March 23, 2023, the parties entered into a settlement and license agreement that resolved all claims in the litigation. The agreement also provides cross licenses to the parties for certain of their respective patents relevant to the claims asserted in the litigation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i06283180cf704e09b131abba7b11068f" continuedAt="i2d04384ad96d41f3959039433382d3bf"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Misonix stockholder</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Stein v. Misonix, Inc., et al., Case No. 2:21-cv-05127 (E.D.N.Y.) (the &#8220;Stein Complaint&#8221;). The Stein Complaint named Misonix and members of its board of directors as defendants. The Stein Complaint was dismissed on April 6, 2022. On September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.) (the &#8220;Ciccotelli Complaint&#8221;) against Misonix, members of its board of directors, the Company, and its subsidiaries, Merger Sub I and Merger Sub II, as defendants. Plaintiff voluntarily dismissed the Ciccotelli Complaint on November 10, 2021. On October 12, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Rubin v. Misonix, Inc. et al., Case No. 1:21-cv-05672 (S.D.N.Y.) (the &#8220;Rubin Complaint&#8221;) and on October 15, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Taylor v. Misonix, Inc. et al., Case No. 1:21-cv-08513 (S.D.N.Y.) (the &#8220;Taylor Complaint&#8221;). The Rubin Complaint and the Taylor Complaint name Misonix and members of its board of directors as defendants. Plaintiffs voluntarily dismissed the Rubin and Taylor Complaints on January 21, 2022 and February 18, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaints asserted claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021 or the Definitive Proxy Statement filed with the SEC on September 24, 2021, regarding Misonix and/or Bioventus&#8217; projections and J.P. Morgan&#8217;s financial analysis. The complaints had sought, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger; (ii) rescission in the event that the merger is consummated; and (iii) an award of costs, including attorneys&#8217; and experts&#8217; fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Misonix former distributor</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2017, Misonix&#8217;s former distributor in China, Cicel (Beijing) Science &amp; Technology Co., Ltd., filed a lawsuit against Misonix and certain of its officers and directors in the United States District Court for the Eastern District of New York. The complaint alleged that Misonix improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted Misonix&#8217;s motion to dismiss each of the tort claims asserted against Misonix, and also granted the individual defendants&#8217; motion to dismiss all claims asserted against them. On January 23, 2020, the court granted Cicel&#8217;s motion to amend its complaint, to include claims for alleged defamation and theft of trade secrets in addition to the breach of contract claim. Discovery in the matter ended on August 5, 2021. On January 20, 2022, the court granted Misonix&#8217;s summary judgment motion on Cicel&#8217;s breach of contract and defamation claims. Cicel&#8217;s motion for reconsideration of the court&#8217;s summary judgment ruling in Misonix&#8217;s favor was dismissed by the Court on April 29, 2022. On July 18, 2022, Cicel voluntarily dismissed the remaining claim for trade secret theft and later filed an appeal to the United States Court of Appeals for the Second Circuit. The Company believes that it has various legal and factual defenses to these claims and intends to vigorously defend the appeal of the lower court&#8217;s summary judgment rulings in its favor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bioness shareholder</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to closing the Bioness Acquisition, Bioness had been named as a defendant in a lawsuit, for which the Company is indemnified under the indemnification provisions contained in the Bioness Merger Agreement. The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting the acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover attorney fees and other expenses totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i0195281e11e649b9b130d85d5763b801_D20210201-20210228" decimals="-3" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1NTA3MA_8172215a-c91c-4e08-bf90-09a229e1248c">3,000</ix:nonFraction> incurred by the director and shareholder in connection with the matter.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i2d04384ad96d41f3959039433382d3bf" continuedAt="i0acf37dbeef3457ebdff5095562dd0dd"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, the court issued a ruling granting, in part, plaintiff&#8217;s motion for summary judgment, awarding plaintiff attorney&#8217;s fees and related expenses incurred in connection with performance of the plaintiff&#8217;s directorial duties, and denying fees and expenses incurred in a non-director capacity. In its ruling, the court&#8217;s order also directed the parties to agree upon a process that will govern the payment of and challenges to plaintiff&#8217;s payment requests and required Bioness to pay <ix:nonFraction unitRef="number" contextRef="i269ccd94849d4d2ba444fb9e4e51782b_I20210819" decimals="INF" name="bvs:LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDEyMg_89782c57-a78c-48c4-bd75-f4ba90e91405">50</ix:nonFraction>% of the demanded amount into escrow if more than <ix:nonFraction unitRef="number" contextRef="i269ccd94849d4d2ba444fb9e4e51782b_I20210819" decimals="INF" name="bvs:LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDEyOA_fa47342f-5865-43e1-93ae-f582c79adbdd">50</ix:nonFraction>% of the total invoiced amount was in dispute. Pursuant to the court&#8217;s order, Bioness paid approximately $<ix:nonFraction unitRef="usd" contextRef="i2e70fc04918244f2994b165f1a124430_D20210819-20210819" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDEzOA_69b4745f-cc91-4153-898e-6219799b68fc">1,300</ix:nonFraction> into escrow. On November 1, 2022, at a hearing before Delaware State Court of Chancery, the court ruled in favor of the former Bioness director awarding attorney&#8217;s fees in connection with the underlying pre-merger litigation and the advancement action in the amounts claimed, less approximately $<ix:nonFraction unitRef="usd" contextRef="id46b7f3929c94e30aa38e125d5c1fb3a_D20221101-20221101" decimals="-3" name="bvs:LitigationSettlementExpenseOfClaimant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE0NA_7d8fadac-41a3-4c89-a138-c0b66600d61d">50</ix:nonFraction>. On December 23, 2022, Bioness and the plaintiff entered into a settlement agreement resolving the matter for the aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="i270d95a5216e45eca0d7972f80ac3edb_D20221223-20221223" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE2Mg_e102b6ff-4c58-452b-8b81-6a11e6b2f041">2,500</ix:nonFraction> payable to the plaintiff. The settlement was satisfied by releasing the $<ix:nonFraction unitRef="usd" contextRef="i270d95a5216e45eca0d7972f80ac3edb_D20221223-20221223" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE3MQ_d9bef4e2-d842-4efe-a166-076258879d5d">1,300</ix:nonFraction> previously paid by Bioness and held in escrow and by an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i095df0e9d3b640bdad1576e09c931392_D20221228-20221228" decimals="-3" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE1Mw_9b322c0f-bf1a-4d6f-9f9b-8508aeca821d">1,200</ix:nonFraction>. Pursuant to the indemnification obligations under the Bioness Merger Agreement, this subsequent payment was made on behalf of Bioness on December 28. 2022, by the selling majority shareholder under that agreement. The Company subsequently recovered the $<ix:nonFraction unitRef="usd" contextRef="if8a13de58ac44d4ca44be08ddc84b03b_D20221228-20221228" decimals="-3" name="bvs:LitigationSettlementAmountRecoveredFromEscrow" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE4MA_79ba340d-94a5-4334-aa41-e2823557d571">1,300</ix:nonFraction> paid into escrow from the selling Bioness shareholders pursuant an indemnification request under the Bioness Merger Agreement. An order dismissing the case was entered by the court on January 27, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2022, the above referenced minority shareholder of Bioness filed another action in the Delaware State Court of Chancery in connection with the Company&#8217;s acquisition of Bioness. This action names the former Bioness directors, the Alfred E. Mann Trust (Trust), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Company&#8217;s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bioness&#8217; and other the defendant&#8217;s motions was held before the Court of Chancery on January 19, 2023. The Company believes that there are various legal and factual defenses to the claims plaintiff made against us and intend to defend ourselves vigorously. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110" decimals="-3" name="bvs:CollaborativeArrangementRightsAndObligationsUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTA3MzY_48d41a82-1380-4c3b-81a7-9b2be052632c">853</ix:nonFraction>. An additional payment of $<ix:nonFraction unitRef="usd" contextRef="i76920cf66e21420bb4f0e4336311f5de_D20220101-20221231" decimals="-3" name="bvs:CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTA3NjU_81aea977-6739-4358-a19a-be0a445d1b0d">853</ix:nonFraction> was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $<ix:nonFraction unitRef="usd" contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110" decimals="-3" name="bvs:CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTA5Mjg_f6f8246c-6622-4289-861c-8fac18619cf5">1,707</ix:nonFraction> will be paid to the seller within five days. The Company is required to pay royalties through 2026 of <ix:nonFraction unitRef="number" contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110" decimals="3" name="bvs:CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEwMzM_e424bfa3-901d-40b8-9b50-1790691985a7">5.0</ix:nonFraction>% on the first $<ix:nonFraction unitRef="usd" contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110" decimals="-3" name="bvs:CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEwNDk_e122375a-7248-45a3-b724-cf5a98a53b81">569</ix:nonFraction> in sales and <ix:nonFraction unitRef="number" contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110" decimals="3" name="bvs:CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEwNjU_5f61d367-aa2c-4607-967d-ed5b2328a9c8">2.5</ix:nonFraction>% thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a <ix:nonFraction unitRef="number" contextRef="if6c32e79d61845d9a2b670c38ccad90a_D20190823-20190823" decimals="INF" name="bvs:CollaborativeArrangementRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEyMTc_2749f3fe-cd79-4c12-b9e0-0a6159f02b05">3</ix:nonFraction>% royalty on certain commercial sales, or a nominal minimum amount per quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed, but during the second quarter of 2022, the Company elected to discontinue the development of MOTYS, the initial product candidate under development. On October 21, 2022, the Company provided notice to MTF of termination of the Development Agreement and the related cGTP Commercial Supply Agreement with MTF for MOTYS, effective December 20, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#8217;s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended April&#160;1, 2023 and April&#160;2, 2022 totaled $<ix:nonFraction unitRef="usd" contextRef="ia7b5a733f4024b57989f06cbdb94c545_D20230101-20230401" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI1MDM_d5b72a07-1818-45ee-9941-f34a42109100">2,321</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3cc6602c201f442ea229c5c1441c0506_D20220101-20220402" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI1MTA_f3277917-8c8d-462f-b0a2-aee437997aae">3,332</ix:nonFraction>, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a supply agreement entered on February 9, 2016 for the Company&#8217;s three injection OA product, the Company is subject to annual minimum purchase requirements for <ix:nonNumeric contextRef="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209" name="bvs:SupplyCommitmentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI4MTI_e7fac437-df49-4c86-98dc-77204cd9afc2">10</ix:nonNumeric> years. After the initial <ix:nonNumeric contextRef="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209" name="bvs:SupplyCommitmentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI4MzQ_e7fac437-df49-4c86-98dc-77204cd9afc2">10</ix:nonNumeric> years, the agreement will automatically renew for an additional <ix:nonNumeric contextRef="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209" name="bvs:SupplyCommitmentRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI4OTU_12d54ec6-122c-4033-8b44-7dc2d1437dd5">5</ix:nonNumeric> years unless terminated by the Company or the seller in accordance with the agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a supply agreement for the Company&#8217;s five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for <ix:nonNumeric contextRef="if1c5e680b22440109145605beffbd285_D20201222-20201222" name="bvs:SupplyCommitmentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTMxNzI_fd66c5e3-32e3-486b-a3de-b72775eaf137">8</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="i0acf37dbeef3457ebdff5095562dd0dd"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company causes letters of credit (&#8220;LOCs&#8221;) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of April&#160;1, 2023 and December&#160;31, 2022, the Company had one LOC outstanding for a nominal amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#8220;claims made&#8221; basis for expenses in excess of $<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:StopLossInsuranceThresholdPerMemberPerYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ1OTE_7ae92c31-95a1-49c4-821c-f5a306fc6d5f">200</ix:nonFraction> per member per year.</span></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_79"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RleHRyZWdpb246NTY1MWNjNDA0NzFjNDhiZGE0ZTM5M2U0NWIzZjc4OGFfNDMx_26708eaa-700d-4888-a250-f9d98bde074d" continuedAt="ib2cc7a6bba2a458489d341ee828dec13" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="ib2cc7a6bba2a458489d341ee828dec13"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policies for recognizing sales have not changed from those described in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RleHRyZWdpb246NTY1MWNjNDA0NzFjNDhiZGE0ZTM5M2U0NWIzZjc4OGFfNDMy_4cd1855a-0bc0-410b-83c9-706ac2053741" continuedAt="i55df55861fa24feaa4133888af3da5d8" escape="true">The following table presents the Company&#8217;s net sales disaggregated by major products (Vertical) within each segment as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i55df55861fa24feaa4133888af3da5d8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85686a2c0fc64b148872e20370023dd3_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMy01LTEtMS0xOTQ5Mjk_7ee96e39-1a7b-44fb-98c8-dfc0adc3c3f5">40,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c67e34f91494006b4a5bd61a96084e8_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMy03LTEtMS0xOTQ5Mjk_c92d7bda-af01-4110-8cb0-5d79c50945ae">47,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a1353106cf447ca65be040ed56b6d0_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNC01LTEtMS0xOTQ5Mjk_d153af86-1e4e-4a35-9e7c-49ce10fcc0ca">32,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6030c2e18bb140f29cddb91bd8f88824_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNC03LTEtMS0xOTQ5Mjk_7b156323-c76e-4116-9dc0-a33d8c7adfd7">28,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if757a0e5be5f42b2b08f3b701abff4af_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNS01LTEtMS0xOTQ5Mjk_4dce002e-3dad-440a-9e4d-ff72e68a549f">30,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671287cbd69c46ef9a385740e8dbd49c_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNS03LTEtMS0xOTQ5Mjk_5b515961-49ea-4ff2-a082-4ad7c7796376">27,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7e30af75d7460f92fef399bf827f6b_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNi01LTEtMS0xOTQ5Mjk_168c65d9-3f75-4c88-8daf-5e1233131768">103,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5376f01c85d24e8cb1ee7b9a3e0894e7_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNi03LTEtMS0xOTQ5Mjk_5fecdfeb-8292-46ee-8bd2-95b0d1aff8f0">104,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9051c125b094e389ac08453ae46745f_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfOS01LTEtMS0xOTQ5Mjk_8795876d-4813-485e-9ea3-55b5c0912703">5,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1101072b1f7f4d799ac5ea6ab0705a18_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfOS03LTEtMS0xOTQ5Mjk_f8623613-6fae-4026-8171-c1f23995dfdd">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc532b467295442c823324184b9ebe64_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTAtNS0xLTEtMTk0OTI5_de921b86-55ba-42be-a6ab-441c45ae42ac">5,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260d2a092ee24cd08e4a8a8282a56d28_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTAtNy0xLTEtMTk0OTI5_c12407c1-6921-45a4-a049-7f41dfcda11f">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib522fb2bab9949e69f42dd7e1b248159_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTEtNS0xLTEtMTk0OTI5_48ea4a4f-ad6c-4471-a0db-fcc0c5a755dc">4,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f3a6d840244f7f92937f02e11c783d_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTEtNy0xLTEtMTk0OTI5_e24b004d-a96f-4e43-9feb-869a09e90724">3,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915d046eaaee44c7881495d91a8a7d49_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTItNS0xLTEtMTk0OTI5_af2ef77f-0000-4050-885a-503d5ca6cb51">15,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id797d5aea258432e9c7d0ca865cdaee7_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTItNy0xLTEtMTk0OTI5_ad779bee-270b-4abc-8246-1ee6cd81ede7">13,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTQtNS0xLTEtMTk0OTI5_26fa2eb8-4e79-48ff-bec0-ef0141b43ad4">119,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTQtNy0xLTEtMTk0OTI5_1c2e0624-fb6e-4bf5-b162-1f21b6643cc3">117,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_82"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RleHRyZWdpb246NmFlNTE4M2JlMTFiNDgzMmE2ZGU1N2VkYTM5YzQ2NzlfNzg4_1bc520a5-ef55-44f1-a049-68236a12ac2e" continuedAt="ic5ea086314374041b44b70c830fef037" escape="true">Segments</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5ea086314374041b44b70c830fef037" continuedAt="iabb9174516cb417693a0e82e3a96f9bc">The Company&#8217;s <ix:nonFraction unitRef="segment" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RleHRyZWdpb246NmFlNTE4M2JlMTFiNDgzMmE2ZGU1N2VkYTM5YzQ2NzlfMzI_b33a6a72-3863-46fb-9654-0025beb7d500">two</ix:nonFraction> reportable segments are U.S. and International. The Company&#8217;s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#8217;s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="iabb9174516cb417693a0e82e3a96f9bc"><ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RleHRyZWdpb246NmFlNTE4M2JlMTFiNDgzMmE2ZGU1N2VkYTM5YzQ2NzlfNzg5_55392dc4-dbfa-4c15-9879-d8aabbe4693e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment adjusted EBITDA reconciled to loss before income taxes:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment adjusted EBITDA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc30004a37a84a44919da8653b8b5a85_D20230101-20230401" decimals="-3" name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMy01LTEtMS0xOTQ5Mjk_7f90831a-7333-460a-a948-5e04b3574ebc">14,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic681d0153e8d44509633594dee0fc4c2_D20220101-20220402" decimals="-3" name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMy03LTEtMS0xOTQ5Mjk_49ec7914-9fe4-41a4-bed1-108ced176b98">4,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f9608964984704ad0bc120b4fb197e_D20230101-20230401" decimals="-3" name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNC01LTEtMS0xOTQ5Mjk_e49f8b8e-838a-4e17-9db7-f77e0dbee726">2,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10818604d3f84a4b9f8471323205d604_D20220101-20220402" decimals="-3" name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNC03LTEtMS0xOTQ5Mjk_e1dd62ec-acd5-4cb7-bab1-0e3d2b215115">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNS01LTEtMS0xOTQ5Mjk_5c0828fa-d56a-4f07-ae28-792ba1d2dd93">9,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNS03LTEtMS0xOTQ5Mjk_dca77934-c84b-4323-a268-d8805e414a20">1,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNi01LTEtMS0xOTQ5Mjk_52f4af59-4a23-469e-8ff5-2efba1372273">16,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNi03LTEtMS0xOTQ5Mjk_97257d9b-4702-4daa-9d9e-c15f280dc5d0">12,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNy01LTEtMS0xOTQ5Mjk_ada21dbe-47f8-4ecf-a38b-9262d3a8c936">1,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNy03LTEtMS0xOTQ5Mjk_d277fd23-e39f-474f-9830-fed9709949cc">7,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and succession charges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfOS01LTEtMS0xOTQ5Mjk_87ea89a2-380c-44ae-99bb-df6a3964d33f">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfOS03LTEtMS0xOTQ5Mjk_4378371d-0414-4eda-8723-cf28c332d31c">577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTAtNS0xLTEtMTk0OTI5_408aab64-9e8b-45fb-8e88-40b71902e53f">1,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTAtNy0xLTEtMTk0OTI5_aaab57b2-5dd7-4d39-8dd0-50878a35d759">4,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CartiHeal divestiture and debt restructuring</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTEtNS0xLTEtMTk0OTI5_ef84a535-107e-429b-b6bc-3692baf05eb0">5,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTEtNy0xLTEtMTk0OTI5_cc9fc7f3-b2fc-4121-90b1-e2d49b1ab38b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTMtNS0xLTEtMTk0OTI5_8dae1993-045d-43d9-a76c-de6c7225a6f2">78,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTMtNy0xLTEtMTk0OTI5_96b67cf4-59a9-4ee1-b87f-0c5c810cbb09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401" decimals="-3" name="us-gaap:OtherNonrecurringExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTUtNS0xLTEtMTk0OTI5_2cff44c8-c26e-4bc2-8e58-001f6b24bcf7">3,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402" decimals="-3" name="us-gaap:OtherNonrecurringExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTUtNy0xLTEtMTk0OTI5_b0f8238f-2d13-4396-8a20-1a77541b2ded">2,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTYtNS0xLTEtMTk0OTI5_3b69d5cc-7038-4fd9-8a91-b05e40fcb029">100,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTYtNy0xLTEtMTk0OTI5_26a92ef9-6cdf-40df-96e1-629ac87383b7">19,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_544"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1XzM4NDgyOTA2OTczNTc_57b95bf2-018e-4084-ae2a-bfcb1f9b6a9b" continuedAt="iab4cb2609b9d43b09210625ed76e3dfd" escape="true">Discontinued operations</ix:nonNumeric></span></div><ix:continuation id="iab4cb2609b9d43b09210625ed76e3dfd" continuedAt="i925bf25e7a6c497dbe3837775895124d"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of <ix:nonFraction unitRef="number" contextRef="i3f75d22eb20045e4a96e961e0a09ca92_D20230227-20230227" decimals="INF" name="bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1XzE2NDkyNjc0NDM1NTY_147e4a87-ad0e-4628-8111-3b1defa1a31b">100</ix:nonFraction>% of Company&#8217;s shares in CartiHeal to a Trustee. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details concerning the CartiHeal Settlement Agreement and its deconsolidation from the Company&#8217;s financial statements. CartiHeal had no sales for the three months ended April&#160;1, 2023 and year ended December 31, 2022.</span></div><ix:continuation id="i04a0c5bba73244809e486113cdd3d807" continuedAt="ic712511996ea42f0a35accc6e8055b43"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes CartiHeal&#8217;s major classes of assets and liabilities as reported on the consolidated condensed balance sheets as of December 31, 2022 as the balances were fully deconsolidated as of April&#160;1, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major classes of assets included as part of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMtMy0xLTEtMjEyODE2_61564cfc-de35-4e48-91f4-1b848a53bfe2">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationRestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzQtMy0xLTEtMjEyODE2_581cd3ec-a486-4e5b-9b6d-8a813e8853c1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzUtMy0xLTEtMjEyODE2_a4738100-684b-4083-b935-666f722a38f2">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzYtMy0xLTEtMjEyODE2_cbe78c16-eeea-4f0f-b2e1-d4746ca97301">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzctMy0xLTEtMjEyODE2_b606d263-07fa-4078-80f5-6b8b878b9f8c">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzExLTMtMS0xLTIxMjgxNg_f3274301-72c3-4cb0-b9db-2e89f220c9dc">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzEyLTMtMS0xLTIxMjgxNg_abd9343c-5120-4b9d-b1a7-75cd6b06388e">6,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzEzLTMtMS0xLTIxMjgxNg_26d10a8e-110a-4e97-85e6-8a39ff257558">398,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzE0LTMtMS0xLTIxMjgxNg_37d6ad31-4e7a-4557-8ac8-f278350b3056">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzE2LTMtMS0xLTIxMjgxNg_5b8bbadc-54e4-44a1-980c-7112285a5034">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzEzLTEtMS0xLTIxNjE1MA_60a3a62a-3c96-4425-872c-36df2d1a56ee">408,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major liabilities included as part of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzIxLTMtMS0xLTIxMjgxNg_823028f3-e306-4850-9bee-d7aac8e7f511">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzIyLTMtMS0xLTIxMjgxNg_3bd041c1-5cf9-4d24-a4d9-391cc2f35a87">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzI1LTMtMS0xLTIxMjgxNg_fbb54b09-02c2-42fa-aeaa-0eb0204a370e">117,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzI2LTMtMS0xLTIxMjgxNg_f0ee8a56-4c38-48a1-ab24-4816a75598e4">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMwLTMtMS0xLTIxMjgxNg_48eb11c5-2c22-4ec6-a72c-e346f52ff34d">79,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMxLTMtMS0xLTIxMjgxNg_65712ebd-3f99-4c85-827d-bf2b81839a24">79,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMyLTMtMS0xLTIxMjgxNg_1ad3971d-6b80-4ad0-9ad0-88da0295ff53">67,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMzLTMtMS0xLTIxMjgxNg_18998d9f-dbd7-4f1c-80a6-77938235823a">2,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzI1LTEtMS0xLTIxNjE1NQ_58c93b36-67fb-475a-bf8a-0504913cadbe">347,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><ix:continuation id="ic712511996ea42f0a35accc6e8055b43"><ix:continuation id="i925bf25e7a6c497dbe3837775895124d"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April&#160;1, 2023 and April&#160;2, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzUtNS0xLTEtMjEyODM1_15542a28-58e5-40f5-ad11-ca43514d6db4">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzUtNy0xLTEtMjEyODM1_60fca1ce-5aa4-44d9-997b-abc34a45cac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzYtNS0xLTEtMjEyODM1_161f4a1e-2de8-4aa4-a2d3-4fd3b3fd880b">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzYtNy0xLTEtMjEyODM1_37a38f7e-67c2-44b6-b5b5-723af93dc481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzgtNS0xLTEtMjEyODM1_6f4191d4-cb97-4ddf-b0f3-1bc9c5a9912f">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzgtNy0xLTEtMjEyODM1_ef8527c5-4870-4ad8-b33d-d35a3105c54a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNS0xLTEtMjEyODM1_d4647b5a-d5ec-48b1-b631-81e93c32e583">4,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNy0xLTEtMjEyODM1_cebc1032-82f8-4c75-8397-0928bb6fa6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss from discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNS0xLTEtMjE2MTg2_29d82650-5b91-4085-b107-f3b6307a273a">8,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNy0xLTEtMjE2MTkw_d9ddc6ed-47d2-4602-8fb3-4d74b1ef8c62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEzLTUtMS0xLTIxMjgzNQ_ce67099c-4b21-443f-ad78-8371c487a788">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEzLTctMS0xLTIxMjgzNQ_142eb39e-9ccf-4ce7-b0d8-1eda76d170b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE0LTUtMS0xLTIxMjgzNQ_13d4e431-dc0e-4f30-bb79-451aa43a1880">61,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE0LTctMS0xLTIxMjgzNQ_b7ab4c7f-c531-410e-87b4-018bb10d22eb">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" sign="-" name="bvs:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEyLTUtMS0xLTIxNjE4Mw_2089a7c3-4571-461d-84f3-c3827b7139d8">66,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" sign="-" name="bvs:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEyLTctMS0xLTIxNjE5MA_86bcf8b5-b606-466b-b9f8-be3d5835333e">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" sign="-" name="bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE1LTUtMS0xLTIxNjE3OA_53107f40-7111-4f83-b4e6-1bbeed2258c5">74,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" sign="-" name="bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE1LTctMS0xLTIxNjE5MA_f918bb0d-e290-4924-b7b0-19308bb80a55">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzIxLTUtMS0xLTIxMjgzNQ_a381f496-1b68-440d-811b-e7e5529cf5a6">14,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzIxLTctMS0xLTIxMjgzNQ_3f81dbd9-42e5-44a6-a395-a9fa2eb521a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401" decimals="-3" sign="-" name="bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE3LTUtMS0xLTIxNjE3OA_35d3b498-7297-4c2a-8190-5adf48447abb">59,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402" decimals="-3" sign="-" name="bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE3LTctMS0xLTIxNjE5MA_4252c891-b091-4535-a2e7-fc2c150576e1">401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other expense includes the $<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" sign="-" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1Xzg3OTYwOTMwMzA0NTM_88a1112b-e243-4c7e-80bb-00a93c6bfade">60,639</ix:nonFraction> loss on deconsolidation, of which $<ix:nonFraction unitRef="usd" contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" decimals="-3" name="bvs:NonRefundablePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1Xzg3OTYwOTMwMzA0ODM_4f98985e-12a4-454f-ae83-a3511fbcecc9">10,150</ix:nonFraction> was attributable to non-refundable payments.</span></div></ix:continuation></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_85"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfMTYz_ae24e191-dbe2-4d50-b059-e4a15798fe69" continuedAt="ib9be858108724254a04f2dc10f9c5047" escape="true">Subsequent events</ix:nonNumeric></span></div><ix:continuation id="ib9be858108724254a04f2dc10f9c5047"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2023, Mr. Reali resigned as a director and officer of the Company, and Mr. Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023. Mr. Bihl succeeds Mr. Reali as the Company&#8217;s principal executive officer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2023, the Company repaid $<ix:nonFraction unitRef="usd" contextRef="i72a1c8e6882a4bff9613fb79fbc5344d_D20230406-20230406" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfMTY0OTI2NzQ0MjI2Nw_0b077c5c-a3ff-4ef4-8489-791b771157e7">15,000</ix:nonFraction> on its revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2023 the Company entered into a definitive agreement to sell its Wound Business, including TheraSkin and TheraGenesis, for total potential cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzIxOA_164472bd-e372-402b-b2e4-383e38ad752b">85,000</ix:nonFraction>, including $<ix:nonFraction unitRef="usd" contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzIzNQ_e5bfa610-0417-44a8-b094-8a8a581d3b6b">35,000</ix:nonFraction> at closing, $<ix:nonFraction unitRef="usd" contextRef="i6bbfa06653064902b83b28df8ecfa4bc_D20230510-20230510" decimals="-3" name="bvs:BusinessCombinationConsiderationTransferredDeferredAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzI1Nw_46089c8d-8d4c-4a25-8cca-e1b922a6d31b">5,000</ix:nonFraction> deferred for <ix:nonNumeric contextRef="i6bbfa06653064902b83b28df8ecfa4bc_D20230510-20230510" name="bvs:BusinessCombinationConsiderationTransferredDeferralPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfMjE5OTAyMzI1ODYzMA_71999852-cfa8-4a8f-a057-ff5ee8de1c97">18</ix:nonNumeric> months and $<ix:nonFraction unitRef="usd" contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzMwMg_72d303be-8462-47c2-874b-a9999ed47bad">45,000</ix:nonFraction> in potential earn-out payments. The Company expects to net approximately $<ix:nonFraction unitRef="usd" contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510" decimals="-3" name="bvs:DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzM4MA_3daeb2c1-d06b-47ec-bde3-acb65361b30e">30,000</ix:nonFraction> at closing after fees and expenses that will be used to repay existing debt. The sale of the Wound Business is expected to close approximately one week before the end of May 2023.</span></div></ix:continuation><div id="i9241aba1c0c547f8878bef4099b579e9_88"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of Bioventus Inc.&#8217;s (sometimes referred to as &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Bioventus&#8221; or &#8220;the Company&#8221;) financial condition and results of operations should be read in conjunction with the &#8220;Special Note Regarding Forward-Looking Statements&#8221; and our unaudited consolidated condensed financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 16, 2022 (&#8220;2022 10-K&#8221;).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing process. We operate our business through two reportable segments, U.S. and International, and our portfolio of products is grouped into three verticals:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Pain Treatments is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (&#8220;PNS&#8221;) products to help the patient get back to their normal activities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Surgical Solutions is comprised of bone graft substitutes (&#8220;BGS&#8221;) to fuse and grow bones, improve results following spinal and other orthopedic surgeries as well as minimally invasive ultrasonic medical devices used for precise bone sculpting, removing tumors and tissue debridement, in various surgeries.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Restorative Therapies is comprised of a bone healing system, skin allografts and products used to support healing of wounds as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed below, there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. In light of this, the Company is actively pursuing plans to mitigate these conditions and events; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part II. Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total net sales, net loss and Adjusted EBITDA for the periods presented:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per Class A common stock, basic and diluted:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per Class A common stock, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">See below under results of operations-Adjusted EBITDA for a reconciliation of net loss to Adjusted EBITDA.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_94"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Significant transactions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wound Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We routinely assess our products and businesses for alignment with our strategic focus and liquidity needs. As a result of this assessment, we decided to sell our Wound Business, specifically, those assets attributable to TheraSkin and Theragenesis (the &#8220;Wound Business&#8221; or the &#8220;Disposal Group&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also evaluated the assets of the Wound Business for impairment during the first quarter of 2023. We recorded a $78.6 million impairment ($63.3 million after tax) as a result of this evaluation to reduce the intangible assets of the Disposal Group to their respective fair values. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2023 we entered into a definitive agreement to sell our Wound Business, including TheraSkin and TheraGenesis, for total potential cash consideration of $85.0 million, including $35.0 million at closing, $5.0 million deferred for 18 months and $45.0 million in potential earn-out payments. We expect to net approximately $30.0 million at closing after fees and expenses that will be used to repay existing debt. The sale of the Wound Business is expected to close before the end of May 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CartiHeal</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2022, we acquired 100% of CartiHeal (2009) Ltd. (&#8220;CartiHeal&#8221;), a privately held company headquartered in Israel and the developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. We purchased CartiHeal (&#8220;CartiHeal Acquisition&#8221;) for an aggregate purchase price of approximately $315.0 million and an additional $135.0 million, becoming payable after closing upon the achievement of a certain sales milestone (&#8220;Sales Milestone Consideration&#8221;). We paid $100.0 million of the aggregate purchase price upon closing, consisting of a $50.0 million escrow deposit and $50.0 million from a financing arrangement. We also paid approximately $8.6 million of CartiHeal&#8217;s transaction-related fees and expenses and deferred $215.0 million (&#8220;Deferred Amount&#8221;) of the aggregate purchase price otherwise due at closing until the earlier of the achievement of certain milestones or the occurrence of certain installment payment dates. We recognized a gain of $23.7 million due to the change in fair value of our equity method investment in CartiHeal as a result of the purchase during the third quarter of 2022. The gain was recognized in other income within the consolidated statement of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously entered into an Option and Equity Purchase Agreement with CartiHeal (&#8220;Option Agreement&#8221;) in July 2020. The Option Agreement provided us with an exclusive option to acquire 100% of CartiHeal&#8217;s shares (&#8220;Call Option&#8221;), and provided CartiHeal with a put option that would require us to purchase 100% of CartiHeal&#8217;s shares under certain conditions. In August 2021, CartiHeal achieved pivotal clinical trial success, as defined in the Option Agreement, for the Agili-C implant. In order to preserve our Call Option, in accordance with the Option Agreement and upon approval of the Board of Directors (&#8220;BOD&#8221;), we deposited $50.0 million into escrow in August 2021 for the potential acquisition of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we exercised our Call Option to acquire all of the remaining shares of CartiHeal, excluding shares we already owned. Our decision to exercise the Call Option followed the FDA&#8217;s March 29, 2022 premarket approval of CartiHeal&#8217;s Agili-C implant. On June 17, 2022, the Company entered into an amendment to the Option Agreement with CartiHeal (&#8220;CartiHeal Amendment&#8221;) and Elron Ventures Limited, in its capacity as the shareholder representative, that provided for deferred payment of the consideration for CartiHeal to be paid in multiple tranches, one of which was $50.0 million due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents the results of the pivotal clinical trial (&#8220;First Paper Milestone&#8221;) or July 1, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the CartiHeal Amendment, we agreed to pay interest on each tranche of the Deferred Amount at a rate of 8.0% annually, until such tranche is paid.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The First Paper Milestone under the Option Agreement occurred on February 13, 2023, triggering our obligation to make the first $50.0 million payment, plus applicable interest, under the Option Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, we entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Elron Ventures Ltd. (&#8220;Elron&#8221; and together with the Company, the &#8220;Parties&#8221;) as representative of CartiHeal&#8217;s selling securityholders under the Option Agreement collectively, the &#8220;Former Securityholders&#8221;). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings relating to non-payment of any obligations arising under the Option Agreement during a period of 30 calendar days (the &#8220;Interim Period&#8221;) in exchange for (i) a one-time non-refundable amount of $10.0 million and (ii) a one-time non-refundable payment of $0.2 million to Elron to be used in accordance with the expense fund provisions of the Option Agreement. The Interim Period expired on March 29, 2023 and we did not exercise our right to extend the Interim Period. In addition, the Parties mutually released any further claims under the Option Agreement and related transaction documents, including without limitation a release by the Former Securityholders of any rights to enforce the provisions of the Option Agreement or make further monetary claims against us and/or our respective affiliates and representatives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the Settlement Agreement, we transferred 100% of our shares in CartiHeal to a trustee (the &#8220;Trustee&#8221;) for the benefit of the Former Securityholders. We had no ownership interest and no voting rights during the Interim Period. We have concluded that upon execution of the Settlement Agreement, the Company ceased to control CartiHeal for accounting purposes, and therefore, have deconsolidated CartiHeal (the &#8220;Deconsolidation&#8221;, or &#8220;Disposal&#8221;) effective February 27, 2023. We treated the Disposal as a discontinued operation. The loss upon disposal is estimated to be $60.6 million and was recorded within loss from discontinued operations, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended 2019 Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, we amended our Credit and Guaranty Agreement, dated as of December 6, 2019 (as amended on October 29, 2021, July 11, 2022 and March 31, 2023, the &#8220;Amended 2019 Credit Agreement&#8221;) in conjunction with the CartiHeal Acquisition to, among other things, provide for an $80.0 million term loan facility (&#8220;Term Loan Facility&#8221;). On March 31, 2023, we further amended our Amended 2019 Credit Agreement to, among other things, modify certain financial covenant provisions, waive the noncompliance at December 31, 2022 and increase the applicable interest rate. Refer to Liquidity and Capital Resources&#8212;Credit Facilities for further information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">B.O.N.E.S. Trial</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted a premarket approval (&#8220;PMA&#8221;) supplement to the FDA in December 2020 seeking approval of an expanded indication for EXOGEN, specifically, for the adjunctive treatment of acute and delayed metatarsal fractures to reduce the risk of non-union. This PMA supplement was based on and supported by clinical data in metatarsal fractures from the ongoing B.O.N.E.S. study. In April 2021, we received a letter from the FDA identifying certain deficiencies in the PMA supplement that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for re-analyses of certain data and provision of other information to support the findings. In December 2021, we completed the follow-up of all patients in the scaphoid B.O.N.E.S. study. In October 2022, we elected to withdraw our PMA submission on metatarsal fractures. Presently, we are in the process of finalizing our PMA supplement for the scaphoid indication. In the scaphoid study analysis plan, the applicable feedback received from the FDA in the prior metatarsal submission was applied prospectively and as such we believe this second filing will address the FDA&#8217;s concerns on the study design. Assuming positive outcome with the FDA of the scaphoid review, we would consider resubmitting the metatarsal data at a later date. We can, however, give no assurance that the scaphoid review will be accepted by the FDA or, if accepted, that we will be able to resolve the deficiencies in the PMA supplements identified by the FDA in a timely manner, or at all. Consequently, the FDA&#8217;s decision on the PMA supplements might be delayed beyond the time originally anticipated. Moreover, if our responses do not satisfy the FDA&#8217;s concerns, the FDA might not approve our PMA supplements seeking to expand the indications for use of EXOGEN in scaphoid and metatarsal fractures as proposed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MOTYS Update</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, prior to obtaining the results from our Phase 2 trial, we elected to discontinue the development of MOTYS, to focus our resources on other priorities, including the integration of our 2021 and 2022 acquisitions and our expanded R&amp;D and product development portfolio we inherited with these acquisitions. We incurred $0.9 million during the three months ended April&#160;1, 2023, and we expect to incur approximately $5.0 million to $6.0 million exclusively to fulfill our remaining regulatory obligations related to our Phase 2 trial (&#8220;MOTYS Costs&#8221;). We have incurred $5.2 million since the election to discontinue occurred during the second quarter of 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Appropriations Act</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, in connection with the Consolidated Appropriations Act, 2021 (&#8220;CAA&#8221;), the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) began utilizing new pricing information the Company reported to it pursuant to the newly adopted reporting obligations to adjust the Medicare payment to healthcare providers using our Durolane and Gelsyn-3 products.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_100"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the components of our results of operations, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part II. Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth components of our condensed consolidated condensed statements of operations as a percentage of net sales for the periods presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (including depreciation and amortization)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of net loss to Adjusted EBITDA for the periods presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(100,018)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,405)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and related costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and succession charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Includes for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively, depreciation and amortization of $14,339 and $9,218 in cost of sales and $2,134 and $3,261 in operating expenses presented in the consolidated condensed statements of operations and comprehensive loss. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes acquisition and integration costs related to completed acquisitions, amortization of inventory step-up associated with acquired entities, and changes in fair value of contingent consideration.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Costs incurred were the result of adopting restructuring plans to reduce headcount, reorganize management structure, and to consolidate certain facilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes compensation expense resulting from awards granted under our equity-based compensation plans.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Financial Restructuring costs which include advisory fees and debt amendment related costs.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">Represents a non-cash impairment charge for intangible assets attributable to our Wound Business due to our decision to divest the business.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other items primarily includes charges associated with strategic transactions, such as potential acquisitions or divestitures, incremental one-time consulting costs related to the recertification of certain products to comply with the new and extensive EU MDR requirements, and costs attributable to MOTYS. During the second quarter of 2022, prior to obtaining the results from our Phase 2 trial, we elected to discontinue the development of MOTYS, to focus our resources on other priorities, including the integration of our acquisitions and our expanded R&amp;D and product development portfolio we inherited with these acquisitions. We incurred $0.9 million during the three months ended April&#160;1, 2023 related to MOTYS. We expect to incur approximately $5.0 million to $6.0 million in total to fulfill our remaining regulatory obligations related to our Phase 2 trial. We have incurred $5.2 million since the election to discontinue occurred during the second quarter of 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-GAAP Financial Measures - Adjusted EBITDA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present Adjusted EBITDA, a non-GAAP financial measure, because we believe it is a useful indicator that management uses as a measure of operating performance as well as for planning purposes, including the preparation of our annual operating budget and financial projections. We believe that Adjusted EBITDA is useful to our investors because it is frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to ours. We define Adjusted EBITDA as net loss from continuing operations before depreciation and amortization, provision of income taxes and interest expense (income), net, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include acquisition and related costs, impairments on goodwill, impairments of assets, restructuring and succession charges, equity compensation expense, financial restructuring costs, and other items. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs primarily based on a ratio of net sales by segment to total consolidated net sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. These measures might exclude certain normal recurring expenses. Therefore, these measures might not provide a complete understanding of the Company's performance and should be reviewed in conjunction with the U.S. GAAP financial measures. Additionally, other companies might define their non-GAAP financial measures differently than we do. Investors are encouraged to review the reconciliation of the non-GAAP measure provided in this Quarterly Report on Form10-Q, including in the table above, to its most directly comparable U.S. GAAP measure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.85pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.85pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International net sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales remain consistent with the prior year comparable period. Changes by vertical were: (i) Pain Treatments&#8212;$6.9 million decrease due to the decline in our selling price, resulting from the impact of lower reported ASP leading due to lower reimbursement levels, partially offset with an increase in sales volume; (ii) Restorative Therapies&#8212;$3.5 million net sales increase due to net volume growth; and (iii) Surgical Solutions&#8212;$3.2 million net sales increase due volume growth.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales increased $1.9 million, or 14.2%, due to sales volume growth.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross profit and gross margin</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,110)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,783)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.573%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit decreased $2.1 million, or 3.1%, primarily due to the decrease in selling price and an increase in amortization in cost of sales. Gross margin was also negatively impacted by 4.0% from inventory step-up amortization of acquisition related assets in 2022 compared with 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased $0.3 million, or 4.0%, primarily due to the increase in net sales. Gross margin decreased due to product mix.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expense</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased $5.3 million, or 6.1%, primarily due to cost saving initiatives including (i) a decline in compensation related expenses of $4.6 million; (ii) a decrease in equity-based compensation of $2.7 million due to employee turnover and our declining stock price; (iii) a decrease of $1.8 million in other administrative and marketing related costs; (iv) a decrease in travel related expenses of $0.9 million; and (v) a decrease of $0.4 million in corporate and employee health insurance. These increases were partially offset with an increase in consulting expenses of $4.3 million and an increase in audit and legal fees of $1.3 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $3.2&#160;million, or 45.6%, primarily due to: (i) a decrease of $1.3 million in consulting costs; (ii) a decline in $0.9 million in compensation related expenses due to restructuring and cost reduction efforts; (iii) a decrease in equity-based compensation of $0.4 million due to employee turnover and our declining stock price; and (iv) a decline of $0.4 million in supplies expense due to cost reduction efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs for the three months ended April&#160;1, 2023 included costs incurred as a result of an initiative to align the Company&#8217;s organizational and management cost structure to improve profitability and cash flow through headcount reduction and cutting third-party related costs. Restructuring costs for the three months ended April&#160;2, 2022 were incurred as a result of restructuring plans for recently acquired businesses to reduce headcount and to reorganize management structure for acquired businesses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of contingent consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.52pt;text-align:left;text-indent:-11.52pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration during the three months ended April&#160;1, 2023 remained consistent with the prior year comparable period. The activity for both periods relates to contingent consideration associated with the acquisition of Bioness in March 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and amortization</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.52pt;text-align:left;text-indent:-11.52pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization decreased $1.1 million or 34.6% during the three months ended April&#160;1, 2023 compared with the prior year comparable period. The decrease was primarily due to lower amortization expense in the current year as certain customer relationship assets became fully amortized.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our decision to divest the Wound Business required us to evaluate whether certain of its assets were impaired. We recorded a $78.6 million non-cash impairment charge as a result of this evaluation to reduce the intangible assets to their fair values less costs to sell. The fair value of intangibles of the Wound Business was determined based on the consideration offered for the Wound Business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (income) expense</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,588)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(NM = Not Meaningful)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense (income), net increased $11.2 million due to: (i) an increase in interest of $4.9 million from higher interest rates; (ii) the $3.9 million in interest income resulting from the change in the fair value of our interest rate swap in 2022, which discontinued during the fourth quarter of 2022; (iii) an increase of $1.3 million due to higher margin rates associated with a high leverage ratio; (iv) an increase of $0.6 million for interest on our revolving credit borrowings; and (v) an increase of $0.5 million on the additional debt used to partially fund the acquisition of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income changed $1.2 million due to the receipt of $1.5 million from the settlement of a legal claim.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax benefit, net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,132)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective rate decrease during three months ended April&#160;1, 2023 compared to the three months ended April&#160;2, 2022 was primarily due to changes in our forecasted effective rate and a net increase in reserve for uncertain tax positions. The change in the forecasted effective rate for the 2023 compared to 2022 was primarily due to an increase in the valuation allowance applied to our net deferred tax assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing LLC Owner</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the IPO and related transactions, we are the sole managing member of BV LLC in which we own 79.8%. We have a majority economic interest, the sole voting interest in, and control the management of BV LLC. As a result, we consolidate the financial results of BV LLC and report a noncontrolling interest representing the 20.2% that is owned by the Continuing LLC Owner. Noncontrolling interest activity in 2023 was the result of large losses recorded during the period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Adjusted EBITDA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA for each of our reportable segments is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA increased $9.9 million, or 204.0%, primarily due cost saving initiatives, including a decrease in compensation related charges and declines in administrative and travel expenses as previously discussed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA remained consistent with the prior year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal liquidity needs have historically been for acquisitions, working capital, research and development, clinical trials, and capital expenditures. We expect these needs to continue as we carry out our operations, develop and commercialize our existing product candidates and any new products candidates and possibly further our expansion into international markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented previously announced restructuring initiatives to enhance our current financial position and sources of liquidity. These restructuring efforts are expected to result in $9.0 million to $10.0 million in cost savings on an annualized basis upon completion. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Financial Information&#8212;Notes to the unaudited consolidated condensed financial statements&#8212;Note 9. Restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding these cost cutting efforts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we entered into a definitive agreement on May 10, 2023 to sell our Wound Business for total potential cash consideration of $85.0 million, including $35.0 million at closing, $5.0 million deferred for 18 months and $45.0 million in potential earn-out payments. We expect to net approximately $30.0 million after fees and expenses that will be used to repay existing debt. The sale of the Wound Business is expected to close before the end of May 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that to the extent that we require additional liquidity, we will obtain funding through additional equity financings or the incurrence of other indebtedness or a combination of these potential sources of liquidity. We may explore additional divestiture opportunities for non-core assets to improve our liquidity position, as we recently did with the Wound Business. In addition, we may raise additional funds to finance future cash needs through receivables or royalty financings or corporate collaboration and licensing arrangements. If we raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. The covenants under the Amended 2019 Credit Agreement limit our ability to obtain additional debt financing. Debt financing, if allowed under the Amended 2019 Credit Agreement and if available, would result in increased payment obligations and might involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, or making capital expenditures. If we raise additional funds through collaboration and licensing arrangements with third-parties, it might be necessary to relinquish valuable rights to our products, future revenue streams or product candidates, or to grant licenses on terms that might not be favorable to us. We cannot be certain that additional funding will be available on acceptable terms, or at all. Any failure to raise capital in the future might have a negative impact on our financial condition and our ability to pursue our business strategies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared under the going concern basis of accounting, which presumes that the Company&#8217;s liquidation is not imminent; however, based on the Company&#8217;s current financial position and liquidity sources, including current cash balances, and forecasted future cash flows, the Company is at risk of violating certain of its financial covenants under the Amended 2019 Credit Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing plans to mitigate these conditions and events, such as considering various additional cost cutting measures, and exploring divestiture opportunities such as the recently announced plan to divest certain assets within its Wound Business; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. Therefore, these plans do not alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, as a part of efforts to improve our financial condition, on February 27, 2023, we reached an agreement to return the assets and liabilities of CartiHeal (2009) Ltd. (&#8220;CartiHeal&#8221;), a wholly-owned subsidiary of the Company, to its former securityholders. The deconsolidation of CartiHeal relieved deferred consideration liabilities and milestone obligations related to the acquisition of CartiHeal. See Strategic Transactions &#8211; CartiHeal above as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Financial Information&#8212;Notes to the unaudited consolidated condensed financial statements&#8212;Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding the acquisition and subsequent deconsolidation of CartiHeal. In addition, we announced a restructuring plan in December 2022 to align our organizational and management cost structure to improve profitability and cash flow. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Financial Information&#8212;Notes to the unaudited consolidated condensed financial statements&#8212;Note 9. Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If mitigating steps are not taken or are not successful, we are at substantial risk of failing to comply with the financial covenants in the Amended 2019 Credit Agreement in 2024. A breach of a financial covenant under the Amended 2019 Credit Agreement could accelerate repayment of our obligations under the agreement. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1. Financial Information&#8212;Notes to the unaudited consolidated condensed financial statements&#8212;Note 4. Financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion concerning the Company&#8217;s long-term debt obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our future cash requirements as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part II. Item 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our 2022 10-K. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with various third-parties for development, collaboration and other services for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. Certain agreements include contingent events that upon occurrence would require payment. For information regarding commitments and contingencies, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Financial Information&#8212;Notes to the unaudited consolidated condensed financial statements&#8212;Note 11. Commitments and contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BV LLC Agreement provides for the payment of certain distributions to the Continuing LLC Owner in amounts sufficient to cover the income taxes imposed with respect to the allocation of taxable income from BV LLC as well as obligations within the tax receivable agreement (&#8220;TRA&#8221;) with the Continuing LLC Owner. Under the TRA, we are required to make cash payments to the Continuing LLC Owner equal to 85% of the tax benefits, if any, that we actually realize (or in certain circumstances are deemed to realize), as a result of (1) increases in the tax basis of assets of BV LLC resulting from (a) any future redemptions or exchanges of LLC Interests, and (b) certain distributions (or deemed distributions) by BV LLC and (2) certain other tax benefits arising from payments under the TRA. We expect the amount of the cash payments required to be made under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the timing of redemptions or exchanges by the Continuing LLC Owner, the amount of gain recognized by the Continuing LLC Owner, the amount and timing of the taxable income we generate in the future, and the federal tax rates then applicable. Any payments made by us to the Continuing LLC Owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were not in compliance with certain financial covenants in the Amended 2019 Credit Agreement as of December 31, 2022. As a result, on March 31, 2023 (the &#8220;Closing Date&#8221;), we entered into another amendment to the Amended 2019 Credit Agreement to, among other things, modify certain financial covenants, waive the noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2019 Credit Agreement, as most recently amended, contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of our equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of our assets, as well as limitations on making changes to the business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of our financial statements for the fiscal quarter ending June 30, 2024, we will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January and February 2023, the Company borrowed $49.0 million on its Revolver for working capital needs. However, on the Closing Date of the March 2023 amendment to the Amended 2019 Credit Agreement, as part of the closing conditions, the Company repaid $20.0 million of these borrowings. Additionally, the Company paid $1.3 million in closing fees, and will be required to pay an additional $0.6 million by December 31, 2023 unless the Total Net Leverage Ratio as at September 30, 2023 is below 5.25 to 1.00.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Financial Information&#8212;Notes unaudited consolidated condensed financial statements&#8212;Note 1. Organization </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details on the Company&#8217;s covenant compliance and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Financial instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the Company&#8217;s indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding Commitments and Contingencies, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Financial Information&#8212;Notes to the unaudited consolidated condensed financial statements&#8212;Note 11. Commitments and Contingencies&#8212;Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this Quarterly Report on Form 10-Q</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Information regarding cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash as of April&#160;1, 2023 totaled $47.1 million, compared to $30.2 million as of December&#160;31, 2022. The decrease in cash was primarily due to the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except for percentage)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,559)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = Not Meaningful</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash in operating activities from continuing operations increased $25.7 million, primarily due to lower employee compensation and a net increase in collections. These inflows were partially offset with an increase in inventory purchases and higher interest payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities decreased $1.1 million, primarily due $1.5 million less in other investments and distribution rights in 2023 partially offset with and an increase of $0.6 million in capital expenditures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by financing activities increased $18.2 million, primarily due to (i) net revolver credit borrowings of $29.0 million compared to $15.0 million in 2022; (ii) no debt payments during the first quarter of 2023 compared to $4.5 million in the first quarter of 2022; and (iii) tax withholdings of $3.4 million in 2022 compared to none in 2023. The increase was partially offset with $2.0 million less proceeds from the issuance of stock and $1.7 million in cash payments attributable to debt refinancing in 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash flows from discontinued operations were primarily the result of $10.2 million in fees used to settle the CartiHeal disposition and $1.4 million in cash held by the CartiHeal entity at the time of disposal. </span></div><div id="i9241aba1c0c547f8878bef4099b579e9_106"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-balance Sheet Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations as disclosed in our 2022 10-K. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion of operating results is based upon the unaudited consolidated condensed financial statements and accompanying notes, which have been prepared in accordance with U.S. GAAP. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our estimates are based on our historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates. Our critical accounting estimates are detailed in Item 7 of our 2022 10-K and we have no material changes from such disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no recently issued accounting pronouncements that are expected to materially impact our financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our market risks as disclosed in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_112"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, because of ongoing material weaknesses in the Company&#8217;s internal control over financial reporting that are not fully remediated as described below, the Company&#8217;s disclosure controls and procedures were not effective as of April 1, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Weaknesses in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected and corrected on a timely basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Control Environment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company did not conduct an effective risk assessment to identify and assess changes in its business processes and internal control environment related to newly acquired companies and multiple information technology (&#8220;IT&#8221;) system implementations that occurred in 2022. Further, there was a lack of adequate personnel resources in accounting, IT and other support functions to support simultaneous system implementations and business process integrations for acquired companies, implement appropriate controls for acquired companies and to maintain focus on compliance with internal controls for legacy Bioventus processes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2022, the Company saw an unprecedented level of turnover in roles that drive execution of internal control activities. This turnover, paired with business changes, including those related to acquisitions, resulted in a disruption to the effective completion of control activities across a number of business processes. Further, management identified a gap in control design related to sufficient tracking of control performance to ensure controls operated effectively.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In considering these breakdowns in the control environment, Bioventus determined the associated Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) principles requiring further control and action by management to be:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Control environment - Establishes structure, authority, and responsibility (COSO Principle 3);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Risk assessment &#8211; Identifies and analyzes significant change (COSO Principle 9); and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Monitoring &#8211; Conducts ongoing and /or separate evaluations (COSO Principle 16).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ongoing control deficiencies have resulted in certain immaterial restatements of the Company&#8217;s financial statements as discussed in this Quarterly Report on Form 10-Q. When considered in the aggregate, they continue to create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis. Therefore, management concluded that the deficiencies continue to represent a material weakness in our internal control over financial reporting, and that disclosure controls and procedures were not effective as April 1, 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remediation Measures</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">We identified staffing gaps based on employee turnover and integration challenges. Throughout 2022, we hired personnel and temporary resources to backfill positions vacated due to employee turnover and added additional headcount in accounting, finance and IT to expand capacity.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">In the fourth quarter of 2022, we engaged third-party consultants to perform an Accounting Transformation &amp; Integration Assessment (&#8220;Project Action&#8221;). The Project Action team identified priority initiatives to enhance processes and systems to address inadequate processes, including order to cash, procure to pay and related master data processes. Further, Project Action benchmarked resources for the accounting function.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">As part of Project Action, we intend to develop mid- to long-term plans to further scale accounting, finance and IT for growth and public company requirements and continue to assess the level of resources that we need. We plan to continue to evaluate retention programs to retain key resources.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We will prioritize key projects and ensure organizational capacity, with only essential IT projects occurring during the year.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">We are reinforcing execution rigor and are establishing recurring metrics regarding internal controls in processes, and tracking current performance compared with target performance to provide additional visibility to management and the Audit Committee. We also plan to further utilize our systems to automate the tracking of internal control completion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">We will implement regular internal control certifications by control owners for all key controls.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We will drive additional accountability for control owners by tying a portion of their performance objectives to successful completion of internal controls.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We will increase training on internal controls, public company requirements and rigor through additional training requirements for new and existing control owners and tracking compliance to those training requirements.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">We will update and/or develop standard operating procedures to further document process and control performance for use in day-to-day execution and when training new employees.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Further, we plan to implement a new internal control policy that further defines expectations for internal control performance and communication of changes to financially relevant processes. This policy will require management and internal audit approval before process changes or system implementations go-live.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rebates Accrual Material Weakness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported, we identified a material weakness related to the Company&#8217;s internal controls over financial reporting that were not performed at a sufficient level of precision to ensure that the third quarter 2022 rebates accrual was complete and accurate. The process undertaken to estimate the expected reduction in revenue from rebates was consistent with the Company&#8217;s historical practice. However, subsequent to the initial calculation of the third quarter 2022 rebates accrual, an unexpectedly large invoice was received and there were not processes in place to ensure it was reviewed timely in order to update the accrual.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassessed open rebates accruals and the approach for calculating the rebate accruals based on this invoice. The Company revised its estimation methodology resulting in a decrease of revenue of $8.4 million. This adjustment was recorded subsequent to the earnings release but prior to the filing of the Company&#8217;s Quarterly Report on Form 10-Q for the third quarter of 2022. Further, this change in revenue projection related to the rebates accrual adjustment for 2022 and cascading effect on future revenue projections materially impacted the Company&#8217;s evaluation of its ability to meet debt covenants in its Amended 2019 Credit Agreement, resulting in liquidity and going concern disclosures in the Company&#8217;s Quarterly Report on Form 10-Q for the third quarter of 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remediation Measures</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed and implemented new processes and enhanced controls to address the underlying causes of the material weakness related to the rebates accrual, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reassessing open rebates accruals and changing the estimation method for calculating the rebates accruals, including enhancing the precision of the controls;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implementing enhanced controls and status tracking to ensure that rebates invoices from third-party payers are received and reviewed timely; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing rigor of documenting key conversations with payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of implementing enhanced procedures to ensure the completeness and accuracy of key reports and information used in the rebates accrual and further enhancing the precision of supporting documentation for control performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the actions described with respect to our control environment and rebates accrual processes will be sufficient to remediate the identified material weaknesses and strengthen our internal control over financial reporting. However, the new and enhanced controls have not all been fully implemented and/or have not operated for a sufficient amount of time to conclude that our material weaknesses have been fully remediated. We will continue to implement and monitor the effectiveness of our controls and will make any further changes management determines appropriate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the identified material weaknesses above, the Chief Executive Officer and Chief Financial Officer believe that the financial statements and related financial information included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our balance sheets, statements of operations and comprehensive (loss) income, statement of changes in stockholders&#8217; equity and statements of cash flows as of and for the periods presented.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the first quarter of 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting except for changes to controls resulting from the material weaknesses described above.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_115"></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_118"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina, Ciarciello v. Bioventus, Inc., No. 1:23&#8211; CV &#8211; 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserts violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees&#8217; Retirement System as lead plaintiff. The lead plaintiff&#8217;s amended consolidated complaint is due to be filed with the Court on June 12, 2023. Defendants&#8217; motion to dismiss the amended consolidated complaint is due on July 17, 2023. The Company believes the claims alleged lack merit and intends to defend itself vigorously. The outcome of the litigation is not presently determinable, and any loss is neither probable nor reasonable estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, the Company, through its subsidiary Bioness, filed a lawsuit in the United States District Court for the Eastern District of Virginia against Aretech, LLC (&#8220;Aretech&#8221;) alleging infringement by Aretech of various patents related to our Vector Gait and Safety Support System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On August 8, 2022, Aretech filed an answer to the lawsuit denying infringement and asserting various affirmative defenses and counterclaims to the Bioness complaint. Bioness filed a motion to dismiss the defendant&#8217;s counterclaims on September 28, 2022. In response to Bioness&#8217; motion to dismiss the counterclaims, on October 19, 2022, Aretech filed an amended answer and counterclaims. On November 16, 2022, Bioness filed a partial motion to dismiss certain of the amended counterclaims. On January 23, 2023, the court granted-in-part Bioness&#8217;s motion dismissing Aretech&#8217;s antitrust and inventorship-related counterclaims, but allowed certain of Aretech&#8217;s counterclaims to proceed. On March 23, 2023, the parties entered into a settlement and license agreement that resolved all claims in the litigation. The agreement also provides cross licenses to the parties for certain of their respective patents relevant to the claims asserted in the litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2017, Misonix&#8217;s former distributor in China, Cicel (Beijing) Science &amp; Technology Co., Ltd., filed a lawsuit against Misonix and certain of its officers and directors in the United States District Court for the Eastern District of New York. The complaint alleged that Misonix improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted Misonix&#8217;s motion to dismiss each of the tort claims asserted against Misonix, and also granted the individual defendants&#8217; motion to dismiss all claims asserted against them. On January 23, 2020, the court granted Cicel&#8217;s motion to amend its complaint, to include claims for alleged defamation and theft of trade secrets in addition to the breach of contract claim. Discovery in the matter ended on August 5, 2021. On January 20, 2022, the court granted Misonix&#8217;s summary judgment motion on Cicel&#8217;s breach of contract and defamation claims. Cicel&#8217;s motion for reconsideration of the court&#8217;s summary judgment ruling in Misonix&#8217;s favor was dismissed by the court on April 29, 2022. On July 18, 2022, Cicel voluntarily dismissed the remaining claim for trade secret theft and later filed an appeal in the United States Court of Appeals for the Second Circuit. We believe that we have various legal and factual defenses to these claims and intend to vigorously defend the appeal of the lower court&#8217;s summary judgement rulings in our favor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the closing of our acquisition of Bioness, Bioness had been named as a defendant in a lawsuit, for which we are indemnified under the indemnification provisions contained in the Bioness Merger Agreement. The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting our acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover approximately $3.0 million in attorney fees and other expenses incurred by the director and shareholder in connection with the matter.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, the court issued a ruling granting, in part, plaintiff&#8217;s motion for summary judgment, awarding plaintiff attorney&#8217;s fees and related expenses incurred in connection with performance of the plaintiff&#8217;s directorial duties, and denying fees and expenses incurred in a non-director capacity. In its ruling, the court&#8217;s order also directed the parties to agree upon a process that will govern the payment of and challenges to plaintiff&#8217;s payment requests and required Bioness to pay 50% of the demanded amount into escrow if more than 50% of the total invoiced amount was in dispute. Pursuant to the court&#8217;s order, Bioness paid approximately $1.3 million into escrow. On November 1, 2022, at a hearing before Delaware State Court of Chancery, the court ruled in favor of the former Bioness director awarding attorney&#8217;s fees in connection with the underlying pre-merger litigation and the advancement action in the amounts claimed, less approximately $0.1 million. On December 23, 2022, Bioness and the plaintiff entered into a settlement agreement resolving the matter for the aggregate sum of $2.5 million payable to the plaintiff. The settlement was satisfied by releasing the $1.3 million previously paid by Bioness and held in escrow and by an additional payment of $1.2 million. Pursuant to the indemnification obligations under the Bioness Merger Agreement, this subsequent payment was made on behalf of Bioness on December 28. 2022, by the selling majority shareholder under that agreement. The Company subsequently recovered the $1.3 million paid into escrow from the selling Bioness shareholders pursuant an indemnification request under the Bioness Merger Agreement. An order dismissing the case was entered by the court on January 27, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2022, the above referenced minority shareholder of Bioness filed another action in the Delaware State Court of Chancery in connection with our acquisition of Bioness. This action names the former Bioness directors, the Alfred E. Mann Trust (Trust), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of our transaction. The complaint also alleges that we aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that we breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. We believe that we are indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, we filed a motion to dismiss all claims made against us on various grounds, as did all the other named defendants in the suit. A hearing on the Bioness and other defendant&#8217;s motions was held before the Court of Chancery on January 19, 2023. We believe that there are various legal and factual defenses to the claims plaintiff made against us and intend to defend ourselves vigorously. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Stein v. Misonix, Inc., et al., Case No. 2:21-cv-05127 (E.D.N.Y.) (the Stein Complaint). The Stein Complaint named Misonix and members of its board of directors as defendants. The Stein Complaint was dismissed on April 6, 2022. On September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.) (the Ciccotelli Complaint) against Misonix, members of its board of directors, the Company, and its subsidiaries, Merger Sub I and Merger Sub II, as defendants. Plaintiff voluntarily dismissed the Ciccotelli Complaint on November 10, 2021. On October 12, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Rubin v. Misonix, Inc. et al., Case No. 1:21-cv-05672 (S.D.N.Y.) (the Rubin Complaint) and on October 15, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Taylor v. Misonix, Inc. et al., Case No. 1:21-cv-08513 (S.D.N.Y.) (the Taylor Complaint). The Rubin Complaint and the Taylor Complaint name Misonix and members of its board of directors as defendants. Plaintiffs voluntarily dismissed the Rubin and Taylor Complaints on January 21, 2022 and February 18, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the complaints relating to the Misonix Acquisition asserted claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021 or the Definitive Proxy Statement filed with the SEC on September 24, 2021, regarding Misonix and/or Bioventus&#8217; projections and J.P. Morgan&#8217;s financial analysis. The complaints sought, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger; (ii) rescission in the event that the merger is consummated; and (iii) an award of costs, including attorneys&#8217; and experts&#8217; fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2023, Bioventus LLC was named as a defendant in a lawsuit filed in the Durham, North Carolina, Superior Court, Donald Auman v. Bioventus LLC. The complaint alleges that the plaintiff suffered a m</span><span style="background-color:#ffffff;color:#080808;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ethicillin-resistant staphylococcus aureus (MRSA) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection in his left leg after using the coupling gel supplied by the Company for use with its Exogen bone healing device. The complaint also alleges that the Exogen gel used by the plaintiff was the subject of the Company&#8217;s recall in December 2020, at which time the Company initiated a voluntary recall of certain lots of the gel supplied by a third-party manufacturer due to concerns that they may have had microbial contamination. The Company is evaluating the allegations in the complaint and intends to defend itself vigorously.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part I. Item 1&#8212;Financial Information&#8212; Notes to the unaudited consolidated condensed financial statements&#8212;Note 11. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q for information pertaining to legal proceedings. In addition, we are party to legal proceedings incidental to our business. While our management currently believes the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our consolidated condensed financial statements, litigation is subject to inherent uncertainties. Were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our financial condition and results of operations.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_121"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part I. Item 1A. Risk Factors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in our 2022 10-K, which could materially affect our businesses, financial condition, or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results. Except for such additional information and the updated risk factor set forth below, we believe there have been no other material changes in our risk factors from those disclosed in our 2022 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to establish and maintain effective financial controls could cause us to have material weaknesses and financial misstatements due to error, which could adversely affect our business and stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the SEC&#8217;s rules implementing Sections 302, 404 and 906 of the Sarbanes-Oxley Act of 2002, which require management to certify financial and other information in our quarterly and annual reports, provide quarterly and annual management reports on the effectiveness of disclosure controls and procedures, and provide annual management reports on the effectiveness of internal controls over financial reporting. Though we are required to disclose changes made in our internal controls and procedures on a quarterly basis and assess internal controls over financial reporting on an annual basis, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404 until we are no longer an emerging growth company pursuant to the provisions of the JOBS Act. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To comply with the requirements of being a public company, we have undertaken various actions, and may need to take additional actions, such as implementing new financial controls and procedures and hiring additional accounting or internal audit staff. We cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent or avoid financial misstatements due to error or material weaknesses (such as those described in this Quarterly Report on Form 10-Q). In addition, our previously identified material weaknesses in financial controls related to our control environment and accounting for rebates from third-party payers have not been fully remediated. If we cannot fully remediate our ongoing material weaknesses or we identify any additional material weaknesses in the future, the accuracy and timing of our financial reporting may be adversely affected. Testing and maintaining financial controls can also divert our management&#8217;s attention from other matters that are important to the operation of our business. Ineffective disclosure controls and procedures or internal control over financial reporting could cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our Class A common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, when evaluating our financial controls, we may identify material weaknesses in our internal controls that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404. If we identify any material weaknesses in our internal controls over financial reporting or are unable to comply with the requirements of Section 404 in a timely manner, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting once we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Class A common stock could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_124"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of unregistered securities during the three months ended April 1, 2023.</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_127"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_133"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div id="i9241aba1c0c547f8878bef4099b579e9_136"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">`</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed / Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit101pavesioconsultin.htm">Consulting Agreement between Alessandra Pavesio and Bioventus LLC, dated as of January 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/0001665988/000162828022018848/exhibit101july2022amendmen.htm">10.</a>2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1665988/000162828023010151/a108damendmentno4tocredita.htm">Amendment No. 4 to Credit and Guaranty Agreement between Bioventus LLC, Wells Fargo Bank, National Association, as administrative agent, and the guarantor subsidiaries party and lenders party thereto, dated March 31, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 (d)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit103cartihealsettlem.htm">Settlement Agreement by and among CartiHeal (2009) Ltd., Bioventus LLC, Elron Ventures Ltd., and certain other parties detailed therein, dated February 27, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1665988/000119312523091610/d474824dex101.htm">Separation Agreement and Release between Kenneth Reali and Bioventus Inc., dated April 4, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/5/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1665988/000119312523097964/d480678dex101.htm">Employment Agreement between Anthony P. Bihl III and Bioventus Inc., dated as of April 5, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/11/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit311-q12023.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit311-q12023.htm">Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit312-q12023.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit312-q12023.htm">Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit32-q12023.htm">32</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit32-q12023.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">`</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed / Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160; Filed herewith</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160; Furnished herewith</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160; Submitted electronically herewith</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#94;&#160;&#160;&#160;&#160; Indicates management contract or compensatory plan</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i9241aba1c0c547f8878bef4099b579e9_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9241aba1c0c547f8878bef4099b579e9_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOVENTUS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 16, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark L. Singleton</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark L. Singleton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer<br/>(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101pavesioconsultin.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id88831293835469cbf1889b9a913e95d_1"></div><div style="min-height:95.76pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;&#124;</font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIOVENTUS LLC</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made between Bioventus LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alessandra Pavesio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effective as of January 1, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Agreement sets forth the terms and conditions by which the Company will engage Consultant to perform certain services for the Company as further described below. The Company and Consultant may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or together as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Services and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.82pt;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term of this Agreement, Consultant shall provide services to the Company which shall consist of activities related to the preparation and potential sale or other transfer of the Company&#8217;s MOTYS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> product and related assets to a third party. These services include, without limitation, assisting the Company with the following&#58; (a) finalization of all reports needed to support the Company&#8217;s 2022 financial audits in Q1 2023, (b) preparation and conduct of an End of Phase 2 (&#8220;EoP2&#8221;) meeting with the FDA by Q2-Q3 2023, (c) completion of all activities necessary to prepare the assets of the Company related to Motys for sale or transfer, including assisting with data room set up, development investor marketing materials, and participating in investor meetings, (d) identification of potential investors and&#47;or strategic partners willing to invest in the Phase 3 program, and (e) such other services within Consultant&#8217;s area of expertise and work experience as shall be reasonably requested by the Company (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Consultant shall perform the Services with the highest degree of professional skill and expertise.</font></div><div style="text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Potential Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties acknowledge and agree that the objective of the Services is to identify and engage potential third-party investors to fund the continued development of MOTYS and transfer relevant MOTYS intellectual property to a new joint venture company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Potential Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). It is indeed  the intention of the Parties that new joint venture company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NewCo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be created with equity ownership allocated among the Company, the new investors, and NewCo management in portions and subject to terms and conditions to be mutually agreed among the parties. It is also the intention of the Parties that Consultant will be offered and transition into a management employment role in NewCo upon consummation of the Potential Transaction, at which time this Agreement would terminate without the need for any further action by either Party. Without limiting the generality of the foregoing, Consultant agrees that the Company has no obligation to enter into any future agreement regarding the Potential Transaction and expressly reserves the right, in its sole discretion, to reject any and all proposals made by Consultant or any potential investor regarding a Potential Transaction, to negotiate with other interested parties, to terminate discussions and negotiations at any time, and&#47;or to terminate the pursuit of a Possible Transaction upon notice to Consultant.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Company Assistance&#59; Facilities and Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term of this Agreement, the Company shall provide Consultant with reasonable support and assistance in performance of the Services. Such support shall include reasonable access to the Company&#8217;s Research and Development, Marketing and Business Development personnel to assist in the identification and transfer of MOTYS asset, preparation of investor marketing materials and identification of potential investors. In performing the Services, Consultant will also have reasonable access to the facilities of Company and its equipment as necessary for provision of the Services, including office space and lap top computer.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;116518442.9&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Services are personal to Consultant and Consultant may not subcontract or otherwise delegate Consultant&#8217;s obligations under this Agreement without the Company&#8217;s prior written consent, and in the event the Company gives such consent, Consultant will remain fully liable to the Company for the performance of all permitted employees, independent contractors, agents or representatives of Consultant (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authorized Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Consulting Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the term of this Agreement, the Company shall compensate Consultant at an hourly rate of $&#91;300&#93; per hour and a discounted daily rate (for a minimum of eight (8) hours) at daily rate of $&#91;2,000&#93;. Consultant shall submit monthly invoices to Company describing the type and hours of Services rendered during the preceding period. Time spent travelling will not be billable to Company by Consultant. Each Invoice shall be due at least (5) days after the end of the particular month in which such Services were rendered and shall be payable by the Company within thirty 30 days of receipt. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company will reimburse Consultant for reasonable expenses incurred in the performance of the Services in accordance with the Bioventus Global Travel and Expense Policy to the extent such expenses have been approved in advance and by the Company. Approved expenses will be reimbursed within thirty (30) days of the Company&#8217;s receipt of invoices with supporting receipts.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term of this Agreement and in the course of Consultant&#8217;s performance hereunder, Consultant may receive and otherwise be exposed directly or indirectly, to technical and non-technical confidential information of the Company, including without limitation, information relating to the Company&#8217;s business, strategies, designs, products, services and technologies and any derivatives, improvements and enhancements related to any of the foregoing, or to the Company&#8217;s suppliers, customers or business partners (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whether in graphic, written, electronic or oral form. Confidential Information may be labeled or identified at the time of disclosure as confidential or proprietary, or equivalent, but Confidential Information also includes information which by its context would reasonably be deemed to be confidential and proprietary. &#8220;Confidential Information&#8221; may also include, without limitation, unpublished patent applications and other intellectual property filings, ideas, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Work Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (as defined below), techniques, works of authorship, models, inventions, compounds, compositions, processes, algorithms, software programs, software source documents, formulae, information and trade secrets as well as financial information (including sales costs, profits, pricing methods), research data, clinical data, bills of material, customer, prospect and supplier lists, investors, employees, business and contractual relationships (including with third parties), business forecasts, sales and merchandising data, and business and marketing plans and any derivatives, improvements and enhancements related to any of the above. Information the Company provides regarding third parties as to which the Company has an obligation of confidentiality also constitutes &#8220;Confidential Information.&#8221;  </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Restrictions on Use and Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Consultant acknowledges the confidential and secret character of the Confidential Information, and agrees that the Confidential Information is the sole, exclusive and extremely valuable property of the Company. Accordingly, Consultant agrees not to use or reproduce or disclose the Confidential Information except as reasonably necessary in the performance of this Agreement (including, without limitations, in connection with discussions with prospective third party investors who are bound by obligations of  confidentiality and non use substantially similar to those set forth in this Agreement) and not to lecture upon or publish all or any part of the Confidential Information in any form to any third </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party, either during or after the term of this Agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without the prior written consent of the Company. Without limiting the foregoing, Consultant shall permit access to the Confidential Information only to those Authorized Representatives having a need to know such information and who have signed, prior to the disclosure of Confidential Information to such Authorized Representative, confidentiality agreements or are otherwise bound by confidentiality obligations at least as restrictive as those contained herein. Consultant shall be responsible for the breach of this Agreement by its Authorized Representatives as if such breach were by Consultant herself. Consultant shall take, at its own expense, commercially reasonable steps to keep the Confidential Information strictly confidential and to prevent its Authorized Representatives from prohibited or unauthorized disclosure or use of the Confidential Information. Consultant agrees to institute measures to protect the Confidential Information in a manner consistent with the measures it uses to protect its own most sensitive proprietary and confidential information, which shall not be less than a reasonable standard of care. Consultant shall promptly notify the Company upon discovery of any actual or suspected loss or unauthorized disclosure of the Confidential Information by Consultant or her Authorized Representatives, and shall take all reasonable steps requested by the Company to remedy any such loss or disclosure. Upon expiration or any termination of this Agreement, Consultant agrees to cease using and to return to the Company, or at the Company&#8217;s sole option, destroy, all whole and partial copies and derivatives of the Confidential Information, whether in Consultant&#8217;s possession or under Consultant&#8217;s direct or indirect control.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Third-Party Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Consultant will not disclose or otherwise make available to the Company in any manner any confidential information received by Consultant under obligations of confidentiality from a third party.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Exceptions&#59; Compelled Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The obligations of confidentiality set forth in Section 2.2 will not apply to information Consultant can establish by competent proof&#58; (a) was generally available to the public or otherwise part of the public domain at the time of disclosure&#59; (b) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of Consultant&#59; (c) was already known to Consultant, without confidentiality restrictions, at the time of disclosure, as shown by Consultant&#8217;s files and records immediately prior to the time of disclosure&#59; (d) was disclosed to Consultant, without confidentiality restrictions, by a third party who to Consultant&#8217;s knowledge had no obligation not to disclose such information to others&#59; or (e) was developed independently by Consultant without any use of or reference to the Confidential Information. In the event a court or governmental agency legally compels Consultant to disclose Confidential Information, Consultant will provide reasonable prior written notice of such required disclosure to the Company and take reasonable and lawful actions to avoid and&#47;or minimize the extent of such disclosure.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:35.45pt;text-align:justify;text-indent:-3.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.5pt;text-decoration:underline">Assignment of Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:77.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.95pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term of this Agreement, Consultant agrees to promptly disclose to Company in writing all &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (as defined below), including the description of such Invention and any additional information necessary for Company to fulfill the purpose of this Section 3. Consultant agrees to assign, and hereby assigns, to Company all right, title, and interest in the Inventions. Further, Consultant shall cooperate with Company in the protection of such Inventions and in vesting in Company all right, title, and interest in such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inventions (including without limitation all patent, copyright, and other intellectual property rights related to the Services).  Consultant agrees to promptly execute and deliver to Company any documents as may be necessary (including but not limited to declarations, oaths, assignments, affidavits, pleadings, and powers of attorney) to carry out the purposes of this Section 3 or give effect to this Agreement in any country, territory, or jurisdiction where such is required to conform with applicable patent or other intellectual property laws. Consultant acknowledges and agrees that all Work Product shall be deemed &#8220;works made for hire&#8221; within the meaning of the United States Copyright Act, as amended. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.5pt;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company may file applications for patents covering Inventions which Company, in its sole discretion, deems to be patentable, and may file such applications. The costs associated with such patent applications shall be borne solely by Company. </font></div><div style="text-align:justify;text-indent:144pt"><font><br></font></div><div style="text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.5pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all inventions, ideas, improvements, processes, surgical techniques, devices, products, prototypes, or specifications, know-how or the like, discoveries, improvements, modifications, enhancements, and later variations which are conceived, developed, or made solely by Consultant or jointly with others, including employees or agents of Company, during the term of this Agreement, which are conceived or developed directly in the course of rendering the Services provided under this Agreement and whether patentable or not, or (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Work Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all materials, presentations, notes, and related records Consultant prepared pursuant to the Services. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This term of this Agreement will commence on the Effective Date and end on the earlier of the (i) the twelve (12)-month anniversary of the Effective Date, (ii) completion of the Potential Transaction (iii) earlier termination in accordance with this Section 4. Either party may, without prejudice to any right or remedy it may have due to any failure of Consultant to perform Consultant&#8217;s obligations under this Agreement, terminate this Agreement, with or without cause, at any time effective upon thirty (30) days written notice to the other Party. In the event of such termination by the Company, Consultant will cease work immediately after receiving notice of such termination from the Company unless otherwise advised by the Company, and will notify the Company of all costs incurred up to the effective date of termination. The Company agrees to pay Consultant for all Services actually performed for work in progress and reimburse all reasonable, non-cancellable pre-approved costs and expenses incurred by Consultant in performing such Services in compliance with this Agreement, up to the date of notice of termination of this Agreement. Sections 2-8 of this Agreement will survive expiration or any termination of this Agreement.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Consultant&#8217;s relationship with the Company pursuant to this Agreement will be that of an independent contractor and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Consultant is not the agent of the Company and is not authorized to make any representation, warranty, contract, or commitment on behalf of the Company. This Agreement shall not create any entitlement by Consultant to any of the benefits which the Company may make available to its employees, such as group insurance, equity compensation awards, or 401(k) benefits. Consultant will be solely responsible for all tax returns and payments required to be filed with or made to any federal, state or local tax authority with respect to Consultant&#8217;s performance of the Services (and those of its Authorized Representatives, if applicable) and receipt of fees under this Agreement. The Company will report amounts paid to Consultant under this Agreement by filing Form 1099-MISC with the Internal Revenue Service as required by law. Because Consultant is an independent contractor, the Company will not withhold or make payments for social security, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make unemployment insurance or disability insurance contributions, or obtain worker&#8217;s compensation insurance on Consultant&#8217;s behalf (or for any individual performing Services on behalf of Consultant, if applicable) for any payment made under this Agreement. Consultant agrees to accept exclusive liability for complying with all applicable state and federal laws governing self-employed individuals, including obligations such as payment of taxes, social security, disability and other contributions based on fees paid to Consultant under this Agreement. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">LIMITATION OF LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY LOST PROFITS OR LOST BUSINESS OR FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL OR INDIRECT DAMAGES OF ANY KIND, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE, AND REGARDLESS OF WHETHER SUCH PARTY HAS BEEN NOTIFIED BY THE OTHER OF THE POSSIBILITY OF SUCH DAMAGES. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Consultant hereby agrees to indemnify and hold the Company and its affiliates and its and their directors, officers, employees, and agents harmless from and against any and all liabilities, losses, damages, costs and expenses (including without limitation reasonable attorneys&#8217; fees) related to any third-party claim, suit, action or proceeding to the extent resulting from the willful misconduct or material breach of this Agreement by Consultant in performing Services for the Company under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Consultant will have no obligation to indemnify or hold the Company harmless with respect to any such liabilities, losses, damages, costs and expenses to the extent directly or indirectly resulting from, caused by or relating to the Company&#8217;s negligence, willful misconduct or material breach of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The Company agrees to indemnify and hold Consultant harmless from and against any and all liabilities, losses, damages, costs and expenses (including without limitation reasonable attorneys&#8217; fees) related to any third-party claim, suit, action or proceeding arising out of the provision of the Services in accordance with the provisions hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company will have no obligation to indemnify or hold Consultant harmless with respect to any such liabilities, losses, damages, costs and expenses to the extent directly or indirectly resulting from, caused by or relating to Consultant&#8217;s willful misconduct or material breach of this Agreement by Consultant in performing Services for the Company under this Agreement.</font></div><div style="margin-bottom:7.2pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties&#8217; rights and obligations under this Agreement will bind and inure to the benefit of their respective successors, heirs, executors, administrators and permitted assigns.  Consultant will not assign this Agreement or Consultant&#8217;s rights or obligations hereunder without the prior written consent of the Company. Company may assign this Agreement to any of its &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (as defined below) without the consent of Consultant. Any purported assignment not in accordance with this Section 8.1 will be null and void and a material breach of this Agreement. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean shall mean&#58; (i) the party&#8217;s parent, subsidiary or related entity&#59; and&#47;or (ii) any entity directly or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indirectly controlled or beneficially owned in whole or part by the party or the party&#8217;s parent, subsidiary or related entity.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Legal and Equitable Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Because Consultant&#8217;s Services are personal and unique and because Consultant may have access to and become acquainted with the Confidential Information of the Company, the Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All Confidential Information is provided &#8220;AS IS,&#8221; without any warranty of any kind. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law&#59; Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The rights and obligations of the Parties under this Agreement will be governed in all respects by the laws of the State of North Carolina without regard to conflict of law principles. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notices required or permitted hereunder will be given to the appropriate Party in writing and will be delivered by personal delivery, electronic mail, facsimile transmission or by certified or registered mail, return receipt requested, and will be deemed given upon personal delivery, three days after deposit in the mail, or upon acknowledgment of receipt of electronic transmission. Notices will be sent to the addresses, electronic mail or facsimile information set forth at the end of this Agreement or such other address, electronic mail or facsimile information as either Party may specify in writing.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement constitutes the Parties&#8217; final, exclusive and complete understanding and agreement with respect to the subject matter hereof, and supersede all prior and contemporaneous understandings and agreements relating to its subject matter. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Waiver and Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may not be waived, modified or amended unless mutually agreed upon in writing by both Parties. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event any provision of this Agreement is found to be legally unenforceable, such unenforceability will not prevent enforcement of any other provision of this Agreement. </font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in two or more counterparts by facsimile or other reliable electronic reproduction (including, without limitation, transmission by pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com), each of which will be considered an original, but all of which together will constitute one and the same instrument. </font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSULTANT ACKNOWLEDGES THAT CONSULTANT HAS THE RIGHT TO CONSULT WITH INDEPENDENT LEGAL COUNSEL PRIOR TO SIGNING THIS AGREEMENT AND HAVE HAD A REASONABLE OPPORTUNITY TO DO SO, AND THAT CONSULTANT EITHER HAS CONSULTED, OR ON CONSULTANT&#8217;S OWN VOLITION CHOSEN NOT TO CONSULT, WITH SUCH COUNSEL. CONSULTANT FURTHER ACKNOWLEDGES THAT CONSULTANT HAS READ THIS AGREEMENT CAREFULLY AND UNDERSTANDS AND ACCEPTS THE OBLIGATIONS WHICH IT IMPOSES UPON CONSULTANT WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO CONSULTANT TO INDUCE CONSULTANT TO SIGN THIS AGREEMENT. CONSULTANT </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SIGNS THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT THE COMPANY WILL RETAIN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BY CONSULTANT. </font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><div id="id88831293835469cbf1889b9a913e95d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Parties hereto have executed this Agreement to be effective as of the Effective Date.</font></div><div style="padding-left:12.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.089%"><tr><td style="width:1.0%"></td><td style="width:48.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIOVENTUS LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Leigh Ann Stradford</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Alessandra Pavesio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Leigh Ann Stradford</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Alessandra Pavesio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; SVP &#38; Chief Human Resources Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; 1&#47;8&#47;2023</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; 1&#47;9&#47;2023</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:10pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:10pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;116518442.9&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>exhibit103cartihealsettlem.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8f819154fad24b96b3fa4b8e3bee471f_58"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="padding-right:7.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Execution Copy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:34.65pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">February 27, 2023</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:192.47pt;padding-right:192.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Settlement Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reference is hereby made to (i) that certain Option and Equity Purchase Agreement, dated July 15, 2020, by and among CartiHeal (2009) Ltd. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Bioventus LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Elron Ventures Ltd. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securityholder Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and certain other parties detailed therein, as amended by an Amendment to the Option and Equity Purchase Agreement dated June 17, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and as may be further amended from time to time (jointly, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) that certain Amended and Restated Escrow Agreement, dated July 12, 2022, by and among the Escrow Agent, the Company, the Buyer and the Securityholder Representative, as may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Escrow Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (iii) that certain Amended and Restated Payment Agent Agreement, dated July 12, 2022, by and among the ESOP Management and Trust Services Ltd. (in its capacity as the Payment Agent under the Option Agreement), the Company, the Buyer and the Securityholder Representative, as may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payment Agent Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms used herein, which are undefined, shall have the meaning ascribed to them in the Option Agreement, the Escrow Agreement and&#47;or the Payment Agent Agreement, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, on February 13, 2022, the First Paper Milestone was achieved&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:7.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, in light of the occurrence of the First Paper Milestone and other obligations that will become due under the Option Agreement, Buyer has requested that the Securityholder Representative agree, and the Securityholder Representative has agreed, to provide Buyer with a limited-in-time interim period, in order to allow Buyer the opportunity to explore obtaining financing sufficient to pay to the Securityholders on a present basis and no later than on the expiration of the Interim Period, as defined below, an amount sufficient to extinguish the entire amount of the Post-Closing Tranches and any interest to be accrued thereon in accordance with the provisions of the Option Agreement, all pursuant to the terms and provisions of this Settlement Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:7.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS in consideration for the representations, warranties, covenants and agreements set forth herein, the Securityholder Representative has agreed that during the Interim Period, as defined below, it will forbear from initiating any legal action or proceedings relating to non-payment of any obligations arising under the Option Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms and subject to the conditions set forth herein, the Parties, intending to be legally bound hereby, agree as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.8pt;text-decoration:underline">Interim Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the period of 30 calendar days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initial Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), plus, if elected by payment of the Extension Payment pursuant to section 3.b below, up to two additional subsequent periods of 15 days each (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Optional Extension Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), commencing as of the date of this Agreement, or earlier upon the occurrence of any of Buyer Insolvency Events under the Option Agreement (except for such Insolvency Events specified under (i), (j) and (l)) with respect to Parent, Buyer, Bioventus Cooperatief, U.A, any other of their Affiliates who directly or indirectly control the Company, or the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interim Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and subject to the provisions herein below, Buyer shall be provided with the opportunity to obtain funding in order to be able to pay to the Securityholders, by the expiration of such Interim Period, the entire amount of the Post-Closing Tranches and any interest accrued thereon, while the Sales Milestone Consideration shall remain due and payable to the Securityholders in accordance with the existing provisions of the Option Agreement. In the event that Buyer shall be able to obtain such funding and transfer the same (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payoff Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Payment Agent for the benefit of the Securityholders (or directly to certain Securityholders, to the extent so provided under the Option Agreement) prior to the expiration of Interim Period, the Parties hereby agree, to the extent applicable, to enter into an additional technical amendment to the Option Agreement merely in order to reflect the same in accordance with the provisions hereof (such additional amendment, to the extent executed and delivered by the Parties, shall be referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8f819154fad24b96b3fa4b8e3bee471f_61"></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.8pt;text-decoration:underline">Return and Transfer of Escrowed Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:77pt;padding-right:7.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Concurrently with the execution of this Agreement, the Parties hereby irrevocably instruct the Escrow Agent to return the Escrowed Shares to the Securityholders as follows&#58; (i) to date (as of the date of this Agreement) and fill in the Buyer Share Transfer Deeds and transfer the Escrowed Shares to Shibolet &#38; Co. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to hold them in trust for the benefit of such Securityholder as detailed under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto and vote them in accordance with the instructions of the Securityholder Representative, (ii) deliver such Buyer Shares Transfer Deeds to the Securityholder Representative, and (iii) surrender the Escrowed Shares&#8217; Materials to the Securityholder Representative&#59; all concurrently with the execution and delivery of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:77pt;padding-right:7.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">It is agreed and acknowledged by the Parties that the transfer of the Escrowed Shares in the name of the Trustee for the benefit of such Securityholders shall be irrevocable, unless and until the Securityholders shall receive the entire Payoff Amount by the expiration of the Interim Period in accordance with the provisions hereof&#59; in which event, the Escrowed Shares shall be forthwith transferred to the Buyer and the Parties shall then, and only then, treat such transfers as if null and void to the maximum extent permissible under applicable law. If the Escrowed Shares remain with the Securityholders following the Interim Period, then such shares shall be deemed returned to the Securityholders in accordance with the terms of the Option Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77pt;padding-right:8.05pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">The Securityholder Representative undertakes not to, and shall instruct the Trustee not to, make any voluntary transactions or dispositions in the Escrowed Shares during the Interim Period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.8pt;text-decoration:underline">Transfer of One-Time Payment and Optional Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:77pt;padding-right:7.65pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Concurrently with the execution of this Agreement, Buyer shall transfer to the Payment Agent in immediately available funds a one-time non-refundable amount of US$10,000,000 for the exclusive benefit of the Securityholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">One Time Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:7.55pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">At any time prior to the expiration of the Initial Period or the first Optional Extension Period, as applicable, Buyer may elect the first Optional Extension Period or the second Optional Extension Period, as applicable, by transfer to the Payment Agent in immediately available funds an additional non-refundable amount of US$5,000,000 for the exclusive benefit of the Securityholders per each such Optional Extension Period (and US$10,000,000 in the aggregate if both Optional Extension Periods are elected) (each such US$5,000,000 payment, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Extension Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (the One Time Payment and, to the extent elected, each Extension Payment, jointly, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Settlement Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;padding-right:7.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">In addition, concurrently with the execution of this Agreement, Buyer shall transfer to the Payment Agent a one-time non-refundable payment of US$150,000 to be added to the Securityholder Representative Expense Fund and used in accordance with the provisions of the Option Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expenses Reimbursement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:7.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">The Settlement Consideration, or any part of it, may remain deposited with the Payment Agent and&#47;or distributed to the Securityholder Representative and&#47;or as it shall instruct the Payment Agent, and shall be either allocated between the Securityholders in accordance with their respective remaining Pro Rata Shares as specified in the Consideration Spreadsheet and&#47;or used to fund the operations of the Company for any period it is held and owned by the Securityholders (or by the Trustee for their benefit) and&#47;or used to reimburse the Securityholder Representative for its out-of-pocket expenses in its capacity as such&#59; in each case in accordance with the instructions to be provided by the Securityholder Representative to the Payment Agent at its sole and absolute discretion.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:7.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">It is agreed and acknowledged by the Parties that to the extent that the Securityholders shall receive the entire Post-Closing Tranches and any interest accrued thereon in accordance with and subject to the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.55pt;padding-left:77pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provisions thereof, then (i) the One-Time Payment shall be credited against payment, to be made if and when due, of the Sales Milestone Consideration, and (ii) the Extension Payment(s), if applicable, shall be credited against the amount of the Post-Closing Tranches and accrued interest thereon to be made by Buyer to the Securityholders.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.8pt;text-decoration:underline">Operation of the Company during the Interim Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree and undertake as follows&#58;</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:76.65pt;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.17pt">Upon the transfer of the Escrowed Shares to the Trustee on the date hereof as provided herein above&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:113pt;padding-right:7.6pt;text-align:justify;text-indent:-20.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.8pt">The Company shall have in its bank account an unrestricted amount of cash of US$2,000,000, as shall be evidenced in writing to the Securityholder Representative on the date of this Agreement, shall have no outstanding financial indebtedness, and all of its liabilities shall be in the ordinary course of business in accordance with past practice. Such amount, during the Interim Period, shall remain with the Company in the Company&#8217;s bank account, and be used solely to fund the Company&#8217;s operations in accordance with the provisions of this Section 4. For the avoidance of doubt, any remaining amounts of such funds shall remain in the Company&#8217;s bank account in the event that the Escrowed Shares shall be transferred to Buyer in accordance with the provisions of Section 2(b) above and at such time, the Company shall have no outstanding financial indebtedness, and all of its liabilities shall be in the ordinary course of business in accordance with past practice&#59; and</font></div><div><font><br></font></div><div style="padding-left:113pt;padding-right:7.95pt;text-align:justify;text-indent:-26.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.9pt">The Company shall have in its possession and control, as shall be coordinated and verified in advance with the Securityholder Representative, all coral inventory of the Company as existing prior to the date of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:76.65pt;padding-right:7.9pt;text-align:justify;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.55pt">During the Interim Period, the Company shall operate only in the ordinary course of business and the provisions of the Option Agreement relating to operation of the Company, and without derogating from the foregoing, the following shall apply during the Interim Period&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:7.9pt;text-align:justify;text-indent:-20.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.8pt">The incorporation documents of the Company shall be amended in order to reflect that the board members of the Company shall be appointed by the Securityholder Representative.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:7.8pt;text-align:justify;text-indent:-26.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.9pt">During the Interim Period, Mr. Nir Altschuler (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nir</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall remain consultant of Buyer in accordance with his existing Consulting Agreement, and Buyer shall allow Nir to devote all of his business time to the day-to-day operations of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;padding-right:7.7pt;text-align:justify;text-indent:-32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.9pt">During the Interim Period, any termination of engagement with, and&#47;or adverse change to the remuneration terms of, any of the Company&#8217;s personnel, and&#47;or the sale or disposal of any of the Company&#8217;s assets (except in the ordinary course of business in accordance with past practice) shall require the prior written consent of each of Buyer and the Securityholder Representative.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;padding-right:7.7pt;text-align:justify;text-indent:-31.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.3pt">During the Interim Period, Buyer shall continue to support the operations of the Company in the ordinary course of business and in accordance with past practice, including without limitation, (i) shall make available to Nir and the other members of the management of the Company any documents and files related to the Company&#8217;s intellectual property, clinical activities, FDA audits, suppliers, manufacturing, regulatory and reimbursement plans (and shall accordingly create a virtual data room during the Initial Period, which shall include all such documents and files), (ii) shall make available its applicable employees and service providers who are already engaged in the affairs of the Company to continue such operations in accordance with the requests and instructions of the management of the Company, and (iii) shall not cancel or terminate any event or conference previously planned in connection with the Company&#8217;s operations without the Securityholder Representative&#8217;s prior written approval. For the avoidance of any doubt, the management and operations of the Company during the Interim Period shall be according to the discretion of the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:80%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.55pt;padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company&#8217;s board of directors and management, and Buyer shall not engage in any activities concerning the Company except as specifically permitted hereunder.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:113pt;padding-right:7.7pt;text-align:justify;text-indent:-25.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.3pt">The Parties agree and acknowledge that, subject to Buyer&#8217;s compliance with the provisions hereof, Buyer shall not be responsible or liable for the operations of the Company during the Interim Period and thereafter (and in the event that the Escrowed Shares shall be transferred to Buyer in accordance with the provisions of Section 2(b) above, Buyer shall have no claims against the Securityholders and&#47;or the Securityholder Representative in connection with the operations of the Company during the Interim Period).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.8pt;text-decoration:underline">Mutual Release and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except with respect to the enforcement and&#47;or performance of this Agreement and subject to the provisions of the Second Amendment if and to the extent entered into between the Parties, each of the Securityholders, for themselves and their respective Affiliates and Representatives on the one hand, and the Buyer for itself and its respective Affiliates and Representatives on the other hand (and it is the intention of the Parties that the foregoing, as well as the provisions of this Agreement, shall bind also any receiver, liquidator, sequestrator, trustee, custodian or other officer having similar powers, appointed to any of the Parties, their Affiliates and&#47;or any of their assets), does hereby remise, release, waive and forever discharge each other from any and all claims, allegations, demands, actions, causes of action, disputes, arbitrations and proceedings and all duties, debts, damages, liabilities, losses, accounts, reckonings, sums of money, expenses, attorneys&#8217; fees, remedies and demands related thereto in law or equity, known or unknown, arising out of or relating to the Option Agreement, the Escrow Agreement and&#47;or the Pledge Agreement, including and without limitation, any rights to enforce the provisions of the Option Agreement and&#47;or, with respect to the Securityholders, to make any monetary claims against Buyer and&#47;or its respective Affiliates and Representatives (other than the Company), and&#47;or, with respect to the Buyer, any rights in connection with the ownership and possession of the Company, and the sole and exclusive remedy of the Securityholders and their respective Affiliates and Representatives, and the Buyer and its respective Affiliates and Representatives, pursuant to the Option Agreement, the Escrow Agreement and the Pledge Agreement, shall be as provided in this Agreement. Solely to the extent not inconsistent with the foregoing, the Securityholders retain their rights under the Pledge Agreements, as applicable. Notwithstanding the foregoing, in the event that Buyer, any of its respective Affiliates and Representatives, or any receiver, liquidator, sequestrator, trustee, custodian or other officer having similar powers, appointed to Buyer, its Affiliates and&#47;or any of their assets, successfully revokes, pursuant to a final Order of a court or tribunal of competent jurisdiction, the validity and&#47;or enforceability of the return by transfer of the Escrowed Shares to the Trustee and&#47;or the Securityholders in accordance with Section 2, and&#47;or the payment of the Settlement Consideration for the benefit of the Securityholders in accordance with Section 3, in accordance with the provisions of this Agreement, then the foregoing release by the Securityholders, their respective Affiliates and Representatives, shall not apply.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.8pt">Jurisdiction&#59; Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties hereby agree and acknowledge that this Agreement and any and all claim made pursuant to this Agreement shall be subject to the laws of Israel, and the Parties hereby irrevocably agree to the exclusive jurisdiction of the courts located in Tel Aviv, Israel. The Parties , each for itself and its respective Affiliates, hereby irrevocably consents to the jurisdiction of any such court (and the appropriate appellate courts therefrom) in any such action and irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such action in any such court or that any such action brought in any such court has been brought in an inconvenient forum</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.8pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of Section 7.14 (Confidentiality&#59; Public Announcement) of the Option Agreement shall apply with respect to this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Sections 11.02, 11.03, 11.04, 11.05, 11.06 (subject to the provisions of Section 4(b)(ii) herein), 11.09, 11.10, 11.11 and 11.12 of the Option Agreement, shall apply to this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:192.55pt;padding-right:192.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Signature Page Next</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:56.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:80%">4</font></div></div></div><div id="i8f819154fad24b96b3fa4b8e3bee471f_64"></div><hr style="page-break-after:always"><div style="min-height:81.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.65pt;padding-left:5.65pt;text-indent:36.3pt"><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first written above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.2pt;padding-left:161.92pt;padding-right:161.92pt;text-align:center"><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">BUYER</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:189.35pt;padding-right:189.35pt;text-align:center"><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">BIOVENTUS LLC</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.819%"><div style="margin-top:7.95pt;padding-left:221.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:19.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">BUYER</font></div></div><div style="display:inline-block;max-width:0.361%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.820%"></div></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:257.45pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">BIOVENTUS LLC</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:257.35pt;text-indent:0.1pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">By&#58;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:112%">________________</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">  Name&#58;  </font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ken</font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reali </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:257.3pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:108%">Title&#58;  </font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:11.5pt;font-weight:400;line-height:108%">  </font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:11pt;font-weight:400;line-height:108%">CEO</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:221.4pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">COMPANY</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:257.45pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">CARTIHEAL (2009) LTD.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:257.35pt;padding-right:103.65pt;text-indent:0.1pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">By&#58;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">_ Name&#58;  </font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:11pt;font-weight:400;line-height:129%">Ken Reali</font></div><div style="padding-left:257.3pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:106%">Title&#58;    </font><font style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:11pt;font-weight:400;line-height:106%">Chair</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:221.25pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">SECURITYHOLDER REPRESENTATIVE</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:216pt;padding-right:99.6pt;text-indent:36pt"><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">ELRON VENTURES LTD.</font></div><div style="padding-right:99.6pt"><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:261.55pt;padding-right:100pt;text-indent:0.1pt"><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">By&#58;</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">_ Name&#58;</font></div><div style="padding-left:261.55pt"><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:108%">Title&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#91;Signature Page to Settlement Agreement&#93; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i8f819154fad24b96b3fa4b8e3bee471f_70"></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:5.2pt;text-indent:35.8pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first written above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.95pt;padding-left:221.35pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">BUYER</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:257.45pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">BIOVENTUS LLC</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:257.35pt;padding-right:110.85pt;text-indent:0.1pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">By&#58;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">_ Name&#58;</font></div><div style="padding-left:257.3pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:108%">Title&#58;</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:221.4pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">COMPANY</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:257.45pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">CARTIHEAL (2009) LTD.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:257.35pt;padding-right:103.65pt;text-indent:0.1pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">By&#58;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">_ Name&#58;</font></div><div style="padding-left:257.3pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:106%">Title&#58;</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:221.25pt"><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">SECURITYHOLDER REPRESENTATIVE</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                                                                            </font><img alt="image_3a.jpg" src="image_3a.jpg" style="height:110px;margin-bottom:5pt;vertical-align:text-bottom;width:257px"></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#91;Signature Page to Settlement Agreement&#93; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i8f819154fad24b96b3fa4b8e3bee471f_73"></div><hr style="page-break-after:always"><div style="min-height:95.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.25pt;padding-left:9.95pt"><img alt="exhibit103signaturepagea.jpg" src="exhibit103signaturepagea.jpg" style="height:425px;margin-bottom:5pt;vertical-align:text-bottom;width:651px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:161.02pt;padding-right:161.02pt;text-align:center"><font><br></font></div><div style="padding-left:73.52pt;padding-right:73.52pt;text-align:center"><font><br></font></div><div style="padding-left:73.52pt;padding-right:73.52pt;text-align:center"><font><br></font></div><div style="padding-left:73.52pt;padding-right:73.52pt;text-align:center"><font><br></font></div><div style="padding-left:73.52pt;padding-right:73.52pt;text-align:center"><font><br></font></div><div style="padding-left:73.52pt;padding-right:73.52pt;text-align:center"><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Settlement </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#93;</font></div><div style="margin-top:9.8pt;padding-left:14.15pt;padding-right:14.15pt;text-align:center"><font style="color:#3a3a3a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8f819154fad24b96b3fa4b8e3bee471f_76"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-right:5.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Execution Copy</font></div><div><font><br></font></div><div style="margin-top:10.4pt;padding-left:231.27pt;padding-right:231.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 2(a)</font></div><div style="margin-top:8.7pt;padding-left:231.3pt;padding-right:231.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Securityholders</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:6.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.128%"><tr><td style="width:1.0%"></td><td style="width:31.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.77pt;padding-right:28.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:114%">Name</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:114%">I.D Number &#47; C.N.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:43pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:114%">Number and Class of Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">B.G. Negev Technologies Applications Ltd.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">510785207</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">145,339 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">aMoon 2 Fund Limited Partnership</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">540278827</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">109,654 Ordinary Shares&#59; 1,349,587 Preferred F Shares&#59; 148,987 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Prof. Razi Vago</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">54124110</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">218,008 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Nir Altschuler</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">31383904</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">919,668 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Incentive II Management Ltd.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">513878827</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">196,570 Preferred A Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Pertec Management Ltd.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">1465813</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">219,497 Preferred A Shares&#59; 35,086 Preferred C Shares&#59; 10,988 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Access Medical Ventures LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">000991888</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt;padding-right:6.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">204,666 Preferred B Shares&#59; 210,513 Preferred C Shares&#59; 102,110 Preferred D-1 Shares&#59; 559,283 Preferred D-2 Shares&#59; 46,487 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">U.M. Accelmed Medical Partners, L.P</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">550243067</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">1,446,146 Preferred D-2 Shares&#59; 334,859 Preferred E Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Elron Ventures Ltd.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">520028036</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">1,875,678 Preferred D-2 Shares&#59; 694,553 Preferred E Shares&#59; 701,786 Preferred F Shares&#59; 126,783 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Peregrine Ventures Management Ltd</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">513790196</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt;padding-right:8.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">105,481 Preferred E Shares&#59; 121,463 Preferred F Shares&#59; 21,601 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">J&#38;J Innovation- JJDC, Inc</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:11.75pt;padding-right:11.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">5106320000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt;padding-right:8.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">837,148 Preferred E Shares&#59; 304,062 Preferred F Shares&#59; 54,939 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Liat Livne</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">27464551</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">1,666 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Deborah Kammoun</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">336072087</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">2,584 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Boaz Lifschitz</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">327172110</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">58,442 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Eilat Ezra</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.9pt;padding-left:23.85pt;padding-right:23.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">58743030</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">1,535 Ordinary Shares</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.128%"><tr><td style="width:1.0%"></td><td style="width:31.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.588%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Shani Sarid</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:26.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">300093036</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">875 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Irit Segalovich</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">58636697</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">3,000 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Tslil Efron</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">28467959</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">2,000 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Anastasia Kipnis</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:26.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">323764423</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">2,500 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Caty Pearl</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">22645808</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">2,692 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Michal Alperovich</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">23663156</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">667 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Amir Kraitzer</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">25385428</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">2,500 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Dvora Darky</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">24287054</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">7,562 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">Moran Aviv</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-right:29.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">33561945</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:113%">5,125 Ordinary Shares</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Escrowed Shares previously held by Bioventus Cooperatief, U.A., to be held for the benefit of the Securityholders specified in this Schedule   2(a)   above,   in accordance with their pro-rata shares*</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt;padding-right:8.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">337,397 Preferred F Shares&#59; 1,014,267 Preferred G Shares&#59; 12,825 Preferred G-1 Shares</font></div></td></tr><tr><td colspan="6" style="background-color:#fae3d4;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:58.92pt;padding-right:58.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Total&#58;</font></div></td><td colspan="3" style="background-color:#fae3d4;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:41.72pt;padding-right:41.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">12,556,579</font></div></td></tr></table></div><div style="padding-left:6.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">* Notwithstanding anything to the contrary in the Settlement Agreement, such Escrowed Shares returned by Bioventus Cooperatief, U.A. shall be held in trust by the Trustee for the benefit of the Securityholders, however, to the extent that following the Interim Period the Escrowed Shares shall not be transferred to Buyer in accordance with the provisions of the Agreement, the Securityholder Representative may, or may instruct the Trustee, as applicable, to transfer such shares to the Company, following such transfer such Escrowed Shares shall become dormant shares.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311-q12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i89da7ae7aa8c497bb7ad3d59d5070e31_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anthony P. Bihl III, certify that&#58;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Bioventus Inc.&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony P. Bihl III</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony P. Bihl III</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer and Director (Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;16, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312-q12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie14412595fbd4bd0b8e5f8be0122f629_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark L. Singleton, certify that&#58;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Bioventus Inc.&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:18pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:3.6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:3.6pt;padding-left:54pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark L. Singleton</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark L. Singleton</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;16, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>exhibit32-q12023.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3a9a15c4c97e48129e7f95fd556df682_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, in connection with the Quarterly Report on Form 10-Q of Bioventus Inc. (the Company) for the quarter ended April&#160;1, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of Anthony P. Bihl III, Interim Chief Executive Officer and Director of the Company and Mark L. Singleton, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, that, to such officer's knowledge&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony P. Bihl III</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony P. Bihl III</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer and Director (Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark L. Singleton</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark L. Singleton</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;16, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bvs-20230401.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:082d4e54-0693-403f-8feb-755a4f49db3a,g:bca9874b-627b-4a4e-9dc7-9b090a7fd814-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bvs="http://www.bioventus.com/20230401" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bioventus.com/20230401">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bvs-20230401_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bvs-20230401_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bvs-20230401_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bvs-20230401_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.bioventus.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000002 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>0000003 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheets" roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets">
        <link:definition>0000004 - Statement - Consolidated Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofChangesinStockholdersEquity" roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Condensed Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedcondensedstatementsofcashflows" roleURI="http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows">
        <link:definition>0000007 - Statement - Consolidated condensed statements of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.bioventus.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Balancesheetinformation" roleURI="http://www.bioventus.com/role/Balancesheetinformation">
        <link:definition>0000009 - Disclosure - Balance sheet information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitionsanddivestitures" roleURI="http://www.bioventus.com/role/Acquisitionsanddivestitures">
        <link:definition>0000010 - Disclosure - Acquisitions and divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialinstruments" roleURI="http://www.bioventus.com/role/Financialinstruments">
        <link:definition>0000011 - Disclosure - Financial instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://www.bioventus.com/role/Fairvaluemeasurements">
        <link:definition>0000012 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equitybasedcompensation" roleURI="http://www.bioventus.com/role/Equitybasedcompensation">
        <link:definition>0000013 - Disclosure - Equity-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.bioventus.com/role/Stockholdersequity">
        <link:definition>0000014 - Disclosure - Stockholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.bioventus.com/role/Earningspershare">
        <link:definition>0000015 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuringcosts" roleURI="http://www.bioventus.com/role/Restructuringcosts">
        <link:definition>0000016 - Disclosure - Restructuring costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.bioventus.com/role/Incometaxes">
        <link:definition>0000017 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://www.bioventus.com/role/Commitmentsandcontingencies">
        <link:definition>0000018 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://www.bioventus.com/role/Revenuerecognition">
        <link:definition>0000019 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.bioventus.com/role/Segments">
        <link:definition>0000020 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Discontinuedoperations" roleURI="http://www.bioventus.com/role/Discontinuedoperations">
        <link:definition>0000021 - Disclosure - Discontinued operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://www.bioventus.com/role/Subsequentevents">
        <link:definition>0000022 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationPolicies" roleURI="http://www.bioventus.com/role/OrganizationPolicies">
        <link:definition>0000023 - Disclosure - Organization (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationTables" roleURI="http://www.bioventus.com/role/OrganizationTables">
        <link:definition>0000024 - Disclosure - Organization (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationTables" roleURI="http://www.bioventus.com/role/BalancesheetinformationTables">
        <link:definition>0000025 - Disclosure - Balance sheet information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresTables" roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresTables">
        <link:definition>0000026 - Disclosure - Acquisitions and divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsTables" roleURI="http://www.bioventus.com/role/FinancialinstrumentsTables">
        <link:definition>0000027 - Disclosure - Financial instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://www.bioventus.com/role/FairvaluemeasurementsTables">
        <link:definition>0000028 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitybasedcompensationTables" roleURI="http://www.bioventus.com/role/EquitybasedcompensationTables">
        <link:definition>0000029 - Disclosure - Equity-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.bioventus.com/role/StockholdersequityTables">
        <link:definition>0000030 - Disclosure - Stockholders&#8217; equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.bioventus.com/role/EarningspershareTables">
        <link:definition>0000031 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsTables" roleURI="http://www.bioventus.com/role/RestructuringcostsTables">
        <link:definition>0000032 - Disclosure - Restructuring costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesTables" roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesTables">
        <link:definition>0000033 - Disclosure - Commitments and contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionTables" roleURI="http://www.bioventus.com/role/RevenuerecognitionTables">
        <link:definition>0000034 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.bioventus.com/role/SegmentsTables">
        <link:definition>0000035 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedoperationsTables" roleURI="http://www.bioventus.com/role/DiscontinuedoperationsTables">
        <link:definition>0000036 - Disclosure - Discontinued operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://www.bioventus.com/role/OrganizationNarrativeDetails">
        <link:definition>0000037 - Disclosure - Organization - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationErrorCorrectionsDetails" roleURI="http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails">
        <link:definition>0000038 - Disclosure - Organization - Error Corrections (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationScheduleofAccountsReceivableDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails">
        <link:definition>0000039 - Disclosure - Balance sheet information - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails">
        <link:definition>0000040 - Disclosure - Balance sheet information - Components of Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails">
        <link:definition>0000041 - Disclosure - Balance sheet information - Schedule of Accounts Receivable, Allowance for Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationScheduleofInventoryDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails">
        <link:definition>0000042 - Disclosure - Balance sheet information - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>0000043 - Disclosure - Balance sheet information - Schedule of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationIntangibleAssetsDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails">
        <link:definition>0000044 - Disclosure - Balance sheet information - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationIntangiblesNarrativeDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails">
        <link:definition>0000045 - Disclosure - Balance sheet information - Intangibles (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationGoodwillNarrativeDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails">
        <link:definition>0000046 - Disclosure - Balance sheet information - Goodwill Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalancesheetinformationScheduleofAccruedLiabilitiesDetails" roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Balance sheet information - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresNarrativeDetails" roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails">
        <link:definition>0000048 - Disclosure - Acquisitions and divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails" roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails">
        <link:definition>0000049 - Disclosure - Acquisitions and divestitures - Held for Sale Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails">
        <link:definition>0000050 - Disclosure - Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000051 - Disclosure - Acquisitions and divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails">
        <link:definition>0000052 - Disclosure - Acquisitions and divestitures - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" roleURI="http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails">
        <link:definition>0000053 - Disclosure - Financial instruments - Schedule Of Long-Term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsNarrativeDetails" roleURI="http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails">
        <link:definition>0000054 - Disclosure - Financial instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>0000055 - Disclosure - Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails">
        <link:definition>0000056 - Disclosure - Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>0000057 - Disclosure - Fair value measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitybasedcompensationNarrativeDetails" roleURI="http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails">
        <link:definition>0000058 - Disclosure - Equity-based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails">
        <link:definition>0000059 - Disclosure - Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>0000060 - Disclosure - Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails">
        <link:definition>0000061 - Disclosure - Equity-based compensation - Schedule of Stock Options Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityNarrativeDetails" roleURI="http://www.bioventus.com/role/StockholdersequityNarrativeDetails">
        <link:definition>0000062 - Disclosure - Stockholders&#8217; equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityScheduleofOtherOwnershipInterestsDetails" roleURI="http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails">
        <link:definition>0000063 - Disclosure - Stockholders&#8217; equity - Schedule of Other Ownership Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareScheduleofEarningsPerShareDetails" roleURI="http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails">
        <link:definition>0000064 - Disclosure - Earnings per share - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>0000065 - Disclosure - Earnings per share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsDetails" roleURI="http://www.bioventus.com/role/RestructuringcostsDetails">
        <link:definition>0000066 - Disclosure - Restructuring costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://www.bioventus.com/role/IncometaxesDetails">
        <link:definition>0000067 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesNarrativeDetails" roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails">
        <link:definition>0000068 - Disclosure - Commitments and contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesScheduleofLeaseCostDetails" roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails">
        <link:definition>0000069 - Disclosure - Commitments and contingencies - Schedule of Lease, Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails">
        <link:definition>0000070 - Disclosure - Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionScheduleofDisaggregationofRevenueDetails" roleURI="http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails">
        <link:definition>0000071 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsDetails" roleURI="http://www.bioventus.com/role/SegmentsDetails">
        <link:definition>0000072 - Disclosure - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedoperationsScheduleofBalanceSheetDetails" roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails">
        <link:definition>0000073 - Disclosure - Discontinued operations - Schedule of Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedoperationsScheduleofStatementofOperationsDetails" roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails">
        <link:definition>0000074 - Disclosure - Discontinued operations - Schedule of Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequenteventsDetails" roleURI="http://www.bioventus.com/role/SubsequenteventsDetails">
        <link:definition>0000075 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bvs_DeferredTaxesOnEquityRebalancing" abstract="false" name="DeferredTaxesOnEquityRebalancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" abstract="false" name="ContingentConsiderationLiabilityWrittenOffForDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_ElronMember" abstract="true" name="ElronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_HAProductMember" abstract="true" name="HAProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_GrossToNetDeductionsCurrent" abstract="false" name="GrossToNetDeductionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_TrailingTwelveMonthSalesMember" abstract="true" name="TrailingTwelveMonthSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DeferredAmountPayableByJuly12023Member" abstract="true" name="DeferredAmountPayableByJuly12023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" abstract="true" name="IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" abstract="false" name="LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BVLLCMember" abstract="true" name="BVLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_AcquisitionRestructuringPlanOf2022Member" abstract="true" name="AcquisitionRestructuringPlanOf2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_HarborMember" abstract="true" name="HarborMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DeferredAmountMember" abstract="true" name="DeferredAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_PaymentOfDebtRefinancingCosts" abstract="false" name="PaymentOfDebtRefinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" abstract="true" name="EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CartiHealMember" abstract="true" name="CartiHealMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CommonStockNumberOfVotes" abstract="false" name="CommonStockNumberOfVotes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bvs_WoundBusinessMember" abstract="true" name="WoundBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" abstract="true" name="ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DeferredAmountPayableByJanuary12026Member" abstract="true" name="DeferredAmountPayableByJanuary12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_LitigationSettlementAmountRecoveredFromEscrow" abstract="false" name="LitigationSettlementAmountRecoveredFromEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_SupplierOfSingleInjectionOAProductMember" abstract="true" name="SupplierOfSingleInjectionOAProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" abstract="false" name="SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_InternationalSegmentMember" abstract="true" name="InternationalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_RestructuringPlanOf2022Member" abstract="true" name="RestructuringPlanOf2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_ContinuingLLCOwnerMember" abstract="true" name="ContinuingLLCOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_LimitedLiabilityCompanyInterestsMember" abstract="true" name="LimitedLiabilityCompanyInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRoyaltyPercentage" abstract="false" name="CollaborativeArrangementRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_BioventusAndContinuingLLCOwnerMember" abstract="true" name="BioventusAndContinuingLLCOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CartiHealLtdMember" abstract="true" name="CartiHealLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_DeferredAmountPayableByJanuary12025Member" abstract="true" name="DeferredAmountPayableByJanuary12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_NonRefundablePayments" abstract="false" name="NonRefundablePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_A2021PlanMember" abstract="true" name="A2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_RestorativeTherapiesMember" abstract="true" name="RestorativeTherapiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" abstract="false" name="BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" abstract="false" name="BusinessCombinationConsiderationTransferredDeferralPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bvs_SupplyCommitmentTerm" abstract="false" name="SupplyCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bvs_DebtInstrumentCovenantLiquidityMinimum" abstract="false" name="DebtInstrumentCovenantLiquidityMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BusinessCombinationConsiderationTransferredTransactionCosts" abstract="false" name="BusinessCombinationConsiderationTransferredTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_ThreeInjectionOAProductMember" abstract="true" name="ThreeInjectionOAProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_AccruedSalariesAndEmployeeBenefitsCurrent" abstract="false" name="AccruedSalariesAndEmployeeBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" abstract="false" name="LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" abstract="false" name="AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DeferredTaxImpactFor2022Member" abstract="true" name="DeferredTaxImpactFor2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_AssetImpairmentChargesAfterTax" abstract="false" name="AssetImpairmentChargesAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_TaxReceivableAgreementPercent" abstract="false" name="TaxReceivableAgreementPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationInventory" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_TermLoanFacilitiesMember" abstract="true" name="TermLoanFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_EquityRebalancingMember" abstract="true" name="EquityRebalancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_SurgicalSolutionsMember" abstract="true" name="SurgicalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DeferredAmountPayableByJanuary12027Member" abstract="true" name="DeferredAmountPayableByJanuary12027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" abstract="false" name="BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" abstract="false" name="CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DeferredAmountPayableBySeptember12023Member" abstract="true" name="DeferredAmountPayableBySeptember12023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" abstract="false" name="BusinessAcquisitionPercentageOfSharesTransferredToTrustee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_USSegmentMember" abstract="true" name="USSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" abstract="false" name="ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DeferredConsiderationMember" abstract="true" name="DeferredConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bvs_BusinessCombinationConsiderationTransferredDeferredAmount" abstract="false" name="BusinessCombinationConsiderationTransferredDeferredAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_TermLoanFacilityJuly2022Member" abstract="true" name="TermLoanFacilityJuly2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_CancellationRatioRequiredStockToLLCInterestRatio" abstract="false" name="CancellationRatioRequiredStockToLLCInterestRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" abstract="false" name="CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BoardOfDirectorLengthOfTerm" abstract="false" name="BoardOfDirectorLengthOfTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" abstract="false" name="SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" abstract="false" name="LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" abstract="false" name="ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" abstract="false" name="LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" abstract="false" name="AcquisitionsAndInvestmentsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BionessIncMember" abstract="true" name="BionessIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_LitigationSettlementExpenseOfClaimant" abstract="false" name="LitigationSettlementExpenseOfClaimant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" abstract="false" name="ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_SupplyCommitmentRenewalTerm" abstract="false" name="SupplyCommitmentRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bvs_StopLossInsuranceThresholdPerMemberPerYear" abstract="false" name="StopLossInsuranceThresholdPerMemberPerYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_PainTreatmentsMember" abstract="true" name="PainTreatmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bvs_CompensationAndEmployeeBenefitPlansAbstract" abstract="true" name="CompensationAndEmployeeBenefitPlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bvs_RestructuringPlanOf2021Member" abstract="true" name="RestructuringPlanOf2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>bvs-20230401_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:082d4e54-0693-403f-8feb-755a4f49db3a,g:bca9874b-627b-4a4e-9dc7-9b090a7fd814-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_14c6b9ab-4f74-4af1-aded-f0285aba7862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a5ee1b2a-f545-4e22-bca3-e32059893f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_14c6b9ab-4f74-4af1-aded-f0285aba7862" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a5ee1b2a-f545-4e22-bca3-e32059893f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_3b957c25-68ca-4eaa-b095-c06fd94486e9" xlink:href="bvs-20230401.xsd#bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_14c6b9ab-4f74-4af1-aded-f0285aba7862" xlink:to="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_3b957c25-68ca-4eaa-b095-c06fd94486e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_83d6e692-998e-4050-9f62-e3e849a1ded2" xlink:href="bvs-20230401.xsd#bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_14c6b9ab-4f74-4af1-aded-f0285aba7862" xlink:to="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_83d6e692-998e-4050-9f62-e3e849a1ded2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_136a1b14-af4e-4db5-93a8-4dc2f8bbdcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_75040f18-e4f7-4204-8adf-eeb37f7ba0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_136a1b14-af4e-4db5-93a8-4dc2f8bbdcdb" xlink:to="loc_us-gaap_OperatingIncomeLoss_75040f18-e4f7-4204-8adf-eeb37f7ba0f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4bb4d5ec-1e66-44e1-a470-fa8622bd6faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_136a1b14-af4e-4db5-93a8-4dc2f8bbdcdb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4bb4d5ec-1e66-44e1-a470-fa8622bd6faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_4b486bd4-c010-432f-8e21-615a3e246b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c6f13600-34e9-4c3a-b881-5fbf3f2f63fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_4b486bd4-c010-432f-8e21-615a3e246b2f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c6f13600-34e9-4c3a-b881-5fbf3f2f63fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8b36a402-196d-46ca-8e49-8be2ac507d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_4b486bd4-c010-432f-8e21-615a3e246b2f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8b36a402-196d-46ca-8e49-8be2ac507d5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_63856efa-0e6a-4ace-a0e1-e1eb41efafa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8492ebc1-cf13-43a2-8e9f-70cbe94bc8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_63856efa-0e6a-4ace-a0e1-e1eb41efafa1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8492ebc1-cf13-43a2-8e9f-70cbe94bc8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f3c23391-47f9-4d0b-896b-d13a066c4cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_63856efa-0e6a-4ace-a0e1-e1eb41efafa1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f3c23391-47f9-4d0b-896b-d13a066c4cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_92da7da7-90a9-4978-a584-c5bb85c720b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7146442d-917e-442d-9f14-713b33aae83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_92da7da7-90a9-4978-a584-c5bb85c720b4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7146442d-917e-442d-9f14-713b33aae83a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_91b02169-9114-44ac-9aad-88392573b100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_92da7da7-90a9-4978-a584-c5bb85c720b4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_91b02169-9114-44ac-9aad-88392573b100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3b97ee5c-1638-4855-956c-d25500d70e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_AssetImpairmentCharges_3b97ee5c-1638-4855-956c-d25500d70e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f1d712be-3b9d-4e03-9b82-56b07bc7ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f1d712be-3b9d-4e03-9b82-56b07bc7ddc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_208967b5-1854-4987-a2c3-12be1b95f27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_208967b5-1854-4987-a2c3-12be1b95f27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d09ddb3c-f9b1-45fb-bbfe-b65f68e3b710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_RestructuringCharges_d09ddb3c-f9b1-45fb-bbfe-b65f68e3b710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c9126e3e-7ebe-4035-bf16-9e05539276eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_DepreciationAndAmortization_c9126e3e-7ebe-4035-bf16-9e05539276eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_634efa20-1e97-4d30-95e1-90790c1939cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_634efa20-1e97-4d30-95e1-90790c1939cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c82f4e5f-a1cb-44a2-b15a-80b7106b4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3b2f2ec-f37a-4922-b5a7-c418f6f8859e" xlink:to="loc_us-gaap_GrossProfit_c82f4e5f-a1cb-44a2-b15a-80b7106b4d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5fc47199-c4a9-4eca-9b8c-235a4ee87d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b6722ee0-df70-4251-a7e6-09f78de7b996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5fc47199-c4a9-4eca-9b8c-235a4ee87d21" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b6722ee0-df70-4251-a7e6-09f78de7b996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_108ac28e-ffe5-44fd-9803-4896c04864c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5fc47199-c4a9-4eca-9b8c-235a4ee87d21" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_108ac28e-ffe5-44fd-9803-4896c04864c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5957a413-581f-4979-9dcf-5f507149cd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5fc47199-c4a9-4eca-9b8c-235a4ee87d21" xlink:to="loc_us-gaap_ProfitLoss_5957a413-581f-4979-9dcf-5f507149cd4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_728793cf-c2ed-472d-86a5-f43b67a0c4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_be7edec8-8296-468d-b28b-b6a13498163c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_728793cf-c2ed-472d-86a5-f43b67a0c4cd" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_be7edec8-8296-468d-b28b-b6a13498163c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4c4f4cea-b557-489f-97ba-a4f9f41b4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_728793cf-c2ed-472d-86a5-f43b67a0c4cd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4c4f4cea-b557-489f-97ba-a4f9f41b4da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_29a69c33-d346-404f-8cc3-4c9b320da9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a47a96c-fb92-45fa-9def-dc89e51fb2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_29a69c33-d346-404f-8cc3-4c9b320da9cb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a47a96c-fb92-45fa-9def-dc89e51fb2be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afc32743-9f34-4a4b-b3fd-5be39182c5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_29a69c33-d346-404f-8cc3-4c9b320da9cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afc32743-9f34-4a4b-b3fd-5be39182c5e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4822d77c-729d-417d-b548-6981c1b852f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4822d77c-729d-417d-b548-6981c1b852f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ffbee510-2ddd-419e-82a4-bd814393b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ffbee510-2ddd-419e-82a4-bd814393b134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_85c37fa4-b6c7-41af-8092-a0d5fe165a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_85c37fa4-b6c7-41af-8092-a0d5fe165a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5ab60a64-e704-4073-9341-f5e2ee3350d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:to="loc_us-gaap_LiabilitiesCurrent_5ab60a64-e704-4073-9341-f5e2ee3350d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4de75124-e7f1-4f09-a31d-b9241795fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4de75124-e7f1-4f09-a31d-b9241795fd02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_ff672700-e2e5-4123-9576-283fede9e020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_510ab274-4d88-4d90-b94d-b7a314ce9fda" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_ff672700-e2e5-4123-9576-283fede9e020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7245662d-5ad1-4ee8-a4bd-92da7f99e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_51ba683b-15c6-4a49-98de-ad4562c017b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7245662d-5ad1-4ee8-a4bd-92da7f99e8ce" xlink:to="loc_us-gaap_CommitmentsAndContingencies_51ba683b-15c6-4a49-98de-ad4562c017b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40b6ecd9-57f2-45e2-a922-7f7714a3e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7245662d-5ad1-4ee8-a4bd-92da7f99e8ce" xlink:to="loc_us-gaap_Liabilities_40b6ecd9-57f2-45e2-a922-7f7714a3e4b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e87df778-c10f-4cdf-9536-b3b9b909196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7245662d-5ad1-4ee8-a4bd-92da7f99e8ce" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e87df778-c10f-4cdf-9536-b3b9b909196c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e8b66f70-3697-4f45-8c2d-b30fe709c9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e8b66f70-3697-4f45-8c2d-b30fe709c9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ff76b514-357a-4d73-a0e8-e31214bd1cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ff76b514-357a-4d73-a0e8-e31214bd1cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c861ab1d-ef4e-4ac2-a4da-0eb2bff7a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c861ab1d-ef4e-4ac2-a4da-0eb2bff7a94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2f043a7d-218d-47a2-88d3-c696fd9aa7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_LongTermInvestments_2f043a7d-218d-47a2-88d3-c696fd9aa7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7ee6cf7e-cf4c-4547-b656-6f78cfe13eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_Goodwill_7ee6cf7e-cf4c-4547-b656-6f78cfe13eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32bcbacd-3487-41f3-abc1-80e1ade7dfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_AssetsCurrent_32bcbacd-3487-41f3-abc1-80e1ade7dfeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_c6d040bd-39c6-425b-8ec9-2f6065f1c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_477aeb58-774b-489c-8f3c-fff0a8ca5eff" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_c6d040bd-39c6-425b-8ec9-2f6065f1c7a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b0785976-3034-4641-91af-96c609368747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9f0e086b-656c-4578-a8b2-090df3f932ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b0785976-3034-4641-91af-96c609368747" xlink:to="loc_us-gaap_MinorityInterest_9f0e086b-656c-4578-a8b2-090df3f932ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_614bb08c-2e58-4ac3-ba3d-4b9c9003f9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b0785976-3034-4641-91af-96c609368747" xlink:to="loc_us-gaap_StockholdersEquity_614bb08c-2e58-4ac3-ba3d-4b9c9003f9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69797aee-de79-46a3-89ea-ddb5834e8471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b8a28e0-f366-4325-8d47-23b3ebf64b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69797aee-de79-46a3-89ea-ddb5834e8471" xlink:to="loc_us-gaap_CommonStockValue_0b8a28e0-f366-4325-8d47-23b3ebf64b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13d9a2e6-8711-4046-9f54-f28aa295deea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69797aee-de79-46a3-89ea-ddb5834e8471" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_13d9a2e6-8711-4046-9f54-f28aa295deea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_11bc73c9-7736-4756-b650-2e84293b6394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69797aee-de79-46a3-89ea-ddb5834e8471" xlink:to="loc_us-gaap_AdditionalPaidInCapital_11bc73c9-7736-4756-b650-2e84293b6394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb26cbe6-bf90-4b14-8056-1b2f55da8f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_69797aee-de79-46a3-89ea-ddb5834e8471" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cb26cbe6-bf90-4b14-8056-1b2f55da8f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_94e93d21-16ce-4459-b03a-745547dc982b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_94e93d21-16ce-4459-b03a-745547dc982b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_de49a560-8da9-45b5-ad27-d58af89d4595" xlink:href="bvs-20230401.xsd#bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:to="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_de49a560-8da9-45b5-ad27-d58af89d4595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1c62243d-6177-4008-a220-5ead46b95d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1c62243d-6177-4008-a220-5ead46b95d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b86615ed-d0ee-4d0a-a7cf-c0455c1b6f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:to="loc_us-gaap_LongTermDebtCurrent_b86615ed-d0ee-4d0a-a7cf-c0455c1b6f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_af9ad70e-086f-4da9-b32a-d86b392a8197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:to="loc_us-gaap_AccountsPayableCurrent_af9ad70e-086f-4da9-b32a-d86b392a8197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1fd4aac4-3546-461a-ba25-7c74849df025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5c5b585e-8c1a-497c-b080-1be423bda764" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1fd4aac4-3546-461a-ba25-7c74849df025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c26ba12-aa4d-4042-9c18-d4a7fcce4dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c26ba12-aa4d-4042-9c18-d4a7fcce4dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f37afb4d-864f-4953-b972-82c279e5e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:to="loc_us-gaap_InventoryNet_f37afb4d-864f-4953-b972-82c279e5e54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5ef60968-a942-46ad-b8e9-084aa6e17dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5ef60968-a942-46ad-b8e9-084aa6e17dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a8ae8f26-3aed-473d-b385-53041dc11e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a8ae8f26-3aed-473d-b385-53041dc11e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_83f758b0-480a-41f4-997a-e551a4066ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_83f758b0-480a-41f4-997a-e551a4066ef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_3920a52f-85f1-4707-88e1-081736ac378b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a67ad901-1ffb-43b9-bcb6-ee789617a673" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_3920a52f-85f1-4707-88e1-081736ac378b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows" xlink:type="simple" xlink:href="bvs-20230401.xsd#Consolidatedcondensedstatementsofcashflows"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_83f3b546-f032-4f21-b47a-481d3e1a996b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_f0acbe19-4e38-45c2-8915-fa485e0a7877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_83f3b546-f032-4f21-b47a-481d3e1a996b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_f0acbe19-4e38-45c2-8915-fa485e0a7877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_6fa018ae-77c2-4b3d-8dd7-f23943c33f00" xlink:href="bvs-20230401.xsd#bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_83f3b546-f032-4f21-b47a-481d3e1a996b" xlink:to="loc_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_6fa018ae-77c2-4b3d-8dd7-f23943c33f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da297fea-9ba3-4784-8929-89ac737659b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_83f3b546-f032-4f21-b47a-481d3e1a996b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da297fea-9ba3-4784-8929-89ac737659b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_05325c2f-640c-422f-92a6-d7e96951afc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_05325c2f-640c-422f-92a6-d7e96951afc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_84d36028-003e-4c62-936b-5a0f747a38b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_84d36028-003e-4c62-936b-5a0f747a38b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_317c60ed-9925-4ba7-810b-a8e6fede2c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_317c60ed-9925-4ba7-810b-a8e6fede2c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_4c1a1c0d-ebdd-4e29-b5dd-5d13f68e5276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_4c1a1c0d-ebdd-4e29-b5dd-5d13f68e5276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4bdd00b1-af3c-4177-8f00-b733b7127251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4bdd00b1-af3c-4177-8f00-b733b7127251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_538cb8d2-6a07-4ae2-be80-0653e87bdb04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_538cb8d2-6a07-4ae2-be80-0653e87bdb04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PaymentOfDebtRefinancingCosts_fbedfcbe-2be4-4edc-9067-fc5267ee2ee9" xlink:href="bvs-20230401.xsd#bvs_PaymentOfDebtRefinancingCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c73661-6b4b-413b-a08f-4558e1e9bec2" xlink:to="loc_bvs_PaymentOfDebtRefinancingCosts_fbedfcbe-2be4-4edc-9067-fc5267ee2ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a85d9d20-9d60-430f-b595-cb5cdd133598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_010bfd8f-2016-4787-b5f0-ef621f8cd86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a85d9d20-9d60-430f-b595-cb5cdd133598" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_010bfd8f-2016-4787-b5f0-ef621f8cd86f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48ab8f1e-9d49-483d-b96a-6823e50063a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a85d9d20-9d60-430f-b595-cb5cdd133598" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_48ab8f1e-9d49-483d-b96a-6823e50063a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b98177c-67a1-4b7a-b343-20f131cca7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a85d9d20-9d60-430f-b595-cb5cdd133598" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9b98177c-67a1-4b7a-b343-20f131cca7da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c787fde4-3bde-4f10-8da2-2fff2d5509db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a85d9d20-9d60-430f-b595-cb5cdd133598" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c787fde4-3bde-4f10-8da2-2fff2d5509db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3dbfa373-286b-4456-b0a0-d5654a2a65b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c2a9a251-b4a9-485f-a75b-bc77d7396a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3dbfa373-286b-4456-b0a0-d5654a2a65b0" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c2a9a251-b4a9-485f-a75b-bc77d7396a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_976e07fc-5fdc-4944-a7d8-39ab0ef5bcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3dbfa373-286b-4456-b0a0-d5654a2a65b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_976e07fc-5fdc-4944-a7d8-39ab0ef5bcb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cd6f947-3109-499c-9afd-45d805018d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a6b37882-7d0d-4e7c-9364-be1412307a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cd6f947-3109-499c-9afd-45d805018d73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a6b37882-7d0d-4e7c-9364-be1412307a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4c8df212-ec3a-4215-8071-1d70fc03a0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cd6f947-3109-499c-9afd-45d805018d73" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4c8df212-ec3a-4215-8071-1d70fc03a0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6319aa74-a4b2-4918-9103-280fb2c382d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_ShareBasedCompensation_6319aa74-a4b2-4918-9103-280fb2c382d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_35ee7f43-7968-46c4-ac55-fab03018685b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_35ee7f43-7968-46c4-ac55-fab03018685b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0c445e24-ae30-4396-9c1a-a0bbb9ed1f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0c445e24-ae30-4396-9c1a-a0bbb9ed1f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1cbce490-4462-494b-a7c5-53a09f211a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1cbce490-4462-494b-a7c5-53a09f211a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e9920cdb-fd6f-4f3d-92b4-beb5f38e4d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e9920cdb-fd6f-4f3d-92b4-beb5f38e4d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c7d6dc28-4875-411c-9b69-ab11039d2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c7d6dc28-4875-411c-9b69-ab11039d2d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_077fc3c0-dcb1-4ddc-9598-66ca8c2de89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_AssetImpairmentCharges_077fc3c0-dcb1-4ddc-9598-66ca8c2de89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_b181709c-6202-46ed-ba59-8bb9b90e0d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_b181709c-6202-46ed-ba59-8bb9b90e0d15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_065f2fac-9484-414c-aa99-f5e471e6c14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_065f2fac-9484-414c-aa99-f5e471e6c14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8d74275c-7e6d-43be-8e12-4643a09ad562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8d74275c-7e6d-43be-8e12-4643a09ad562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dd2ed79b-a404-4460-98ea-7e5badbfbd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dd2ed79b-a404-4460-98ea-7e5badbfbd6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a1e3985d-05a6-47c5-be7c-0c23b2714b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a1e3985d-05a6-47c5-be7c-0c23b2714b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_834b51e5-d4ed-43e5-95b4-737d5ce13d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_834b51e5-d4ed-43e5-95b4-737d5ce13d2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3b219d77-9cb4-4cdf-b4bd-43242efc90d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bdb85e9-30ba-4800-8d8f-b0eb87e04e32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3b219d77-9cb4-4cdf-b4bd-43242efc90d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_954cf9a9-117f-4608-bad3-c3ed4a9afde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_d6e24cae-8612-45ea-8044-4eb42a17b594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_954cf9a9-117f-4608-bad3-c3ed4a9afde7" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_d6e24cae-8612-45ea-8044-4eb42a17b594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_abf988e1-19a7-4536-b5b6-63ed7a67f8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_954cf9a9-117f-4608-bad3-c3ed4a9afde7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_abf988e1-19a7-4536-b5b6-63ed7a67f8c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e3886a1e-9dee-41bd-88b5-7fa93ccffc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_477120e6-bc79-4f93-8009-1e0afa55d3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e3886a1e-9dee-41bd-88b5-7fa93ccffc15" xlink:to="loc_us-gaap_InventoryFinishedGoods_477120e6-bc79-4f93-8009-1e0afa55d3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_f8575c25-8c9c-436c-ae94-86945d81018c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e3886a1e-9dee-41bd-88b5-7fa93ccffc15" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_f8575c25-8c9c-436c-ae94-86945d81018c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fbe1841a-31a3-454c-8e57-86cf54fe0e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_fcef8be8-bd5d-42dc-9610-9f2b778de7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fbe1841a-31a3-454c-8e57-86cf54fe0e4f" xlink:to="loc_us-gaap_InventoryValuationReserves_fcef8be8-bd5d-42dc-9610-9f2b778de7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_420610cd-5698-4753-9f2f-49a69f360714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fbe1841a-31a3-454c-8e57-86cf54fe0e4f" xlink:to="loc_us-gaap_InventoryGross_420610cd-5698-4753-9f2f-49a69f360714" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bf607ac-4d89-4dbf-9c02-d2e467a964a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_2eb2cebe-a2e9-4d28-8228-b9b816960b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bf607ac-4d89-4dbf-9c02-d2e467a964a5" xlink:to="loc_us-gaap_PrepaidTaxes_2eb2cebe-a2e9-4d28-8228-b9b816960b6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_bd99d73f-43f3-4936-96ca-09947b2909ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8bf607ac-4d89-4dbf-9c02-d2e467a964a5" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_bd99d73f-43f3-4936-96ca-09947b2909ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_062fff73-74d2-4d5e-8a60-0c992f831b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_22c99e29-a0cd-4886-a69a-609306a36f4c" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_062fff73-74d2-4d5e-8a60-0c992f831b33" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_22c99e29-a0cd-4886-a69a-609306a36f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_87797164-9b4b-4b9b-b738-4217aa8f9cdc" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_062fff73-74d2-4d5e-8a60-0c992f831b33" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_87797164-9b4b-4b9b-b738-4217aa8f9cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_f5f6a7c2-775a-45c3-9d79-304e862925ab" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75fc0100-7bb8-4847-937e-b75e17618b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_f5f6a7c2-775a-45c3-9d79-304e862925ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75fc0100-7bb8-4847-937e-b75e17618b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7de76db5-af11-4227-97c1-264406aacf05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_f5f6a7c2-775a-45c3-9d79-304e862925ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7de76db5-af11-4227-97c1-264406aacf05" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_e688d131-6a8f-4d92-b308-b00c4fb79ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:to="loc_us-gaap_AccruedBonusesCurrent_e688d131-6a8f-4d92-b308-b00c4fb79ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_44af2c3e-f5b2-4003-ae4e-8a4ab21a6dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:to="loc_us-gaap_TaxesPayableCurrent_44af2c3e-f5b2-4003-ae4e-8a4ab21a6dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_1bdd2fb7-4ac5-4bf6-a6e3-ec0912443bed" xlink:href="bvs-20230401.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:to="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_1bdd2fb7-4ac5-4bf6-a6e3-ec0912443bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_GrossToNetDeductionsCurrent_5eb9c69a-fd9f-4b36-8c6e-e279114456ab" xlink:href="bvs-20230401.xsd#bvs_GrossToNetDeductionsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:to="loc_bvs_GrossToNetDeductionsCurrent_5eb9c69a-fd9f-4b36-8c6e-e279114456ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_894098c9-0dfe-4375-9226-22865d828ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_894098c9-0dfe-4375-9226-22865d828ecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_d986fc1f-dd8c-4c48-bcc6-4c1e8c6c4b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12430b66-236e-48a7-90e8-61510c240ccb" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_d986fc1f-dd8c-4c48-bcc6-4c1e8c6c4b6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_aa4973c6-3b75-413f-95d7-349d79628260" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_abf1075a-2ce9-404f-a08a-66df3d3a9ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_aa4973c6-3b75-413f-95d7-349d79628260" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_abf1075a-2ce9-404f-a08a-66df3d3a9ad3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_2d68d37f-e1a0-453d-8165-2e05e93412d5" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_aa4973c6-3b75-413f-95d7-349d79628260" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_2d68d37f-e1a0-453d-8165-2e05e93412d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e3d05113-b580-46f5-8761-aa2442b24b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e3d05113-b580-46f5-8761-aa2442b24b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_68b7cf62-8bb1-4882-9b80-e8278ec64dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_68b7cf62-8bb1-4882-9b80-e8278ec64dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_06ca3936-9179-4004-b328-d7e450f1e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_06ca3936-9179-4004-b328-d7e450f1e6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f4cf5659-7550-4c2a-baac-37b3a557f418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f4cf5659-7550-4c2a-baac-37b3a557f418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_9eeb6745-c690-4e55-aefb-6e3bc03716b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_9eeb6745-c690-4e55-aefb-6e3bc03716b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_5d8ce001-91fd-41a1-95ff-a6c1731d481a" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_5d8ce001-91fd-41a1-95ff-a6c1731d481a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_a01a4dcb-30af-4ea1-b817-bdc868d61306" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_a01a4dcb-30af-4ea1-b817-bdc868d61306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_77ea554a-0c37-4e30-867f-ae75a46b3c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_77ea554a-0c37-4e30-867f-ae75a46b3c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8b352ad8-c8cf-4ed5-ae7c-d9018d2ad379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8b352ad8-c8cf-4ed5-ae7c-d9018d2ad379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_298f5952-094b-4e38-82e9-3ad6b5b6f38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_298f5952-094b-4e38-82e9-3ad6b5b6f38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_282d2202-a34d-41e8-9023-0b3379fd3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b7446e3-1da3-43c2-ad87-ffa61e68bfc7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_282d2202-a34d-41e8-9023-0b3379fd3dec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b7a223f-6b6f-4d40-8a40-82f68569da5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9d8f762b-a719-49df-a4a7-d5f4a0627692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0b7a223f-6b6f-4d40-8a40-82f68569da5f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9d8f762b-a719-49df-a4a7-d5f4a0627692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9ea69e95-ffe3-4068-806d-d5f20b4d91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0b7a223f-6b6f-4d40-8a40-82f68569da5f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9ea69e95-ffe3-4068-806d-d5f20b4d91ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_70ec907f-457e-4938-9281-e1bcfd378b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0b7a223f-6b6f-4d40-8a40-82f68569da5f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_70ec907f-457e-4938-9281-e1bcfd378b7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EarningspershareScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0fc7cc71-0af5-45d1-8947-842ea09e761e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_d1f94dcf-8384-406c-839f-baf5e0c160cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_0fc7cc71-0af5-45d1-8947-842ea09e761e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_d1f94dcf-8384-406c-839f-baf5e0c160cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_eb9313bc-0d3c-4634-94c2-5bcd2e93f80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_0fc7cc71-0af5-45d1-8947-842ea09e761e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_eb9313bc-0d3c-4634-94c2-5bcd2e93f80f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_68946672-1103-4bf9-af7c-368a3d07080b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_22a3b9b9-43dc-4197-8e6d-64c577170a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_68946672-1103-4bf9-af7c-368a3d07080b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_22a3b9b9-43dc-4197-8e6d-64c577170a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01a213fd-8386-47ad-bd8b-f958ef779e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_68946672-1103-4bf9-af7c-368a3d07080b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_01a213fd-8386-47ad-bd8b-f958ef779e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ef959013-fb10-49ff-a8b6-2f3feeb5f2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f3215754-7ce3-4f34-b6cd-36caf4a63dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ef959013-fb10-49ff-a8b6-2f3feeb5f2b2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f3215754-7ce3-4f34-b6cd-36caf4a63dc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9d94ad28-c9c6-46b0-9ec5-70313ab1767b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_ef959013-fb10-49ff-a8b6-2f3feeb5f2b2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_9d94ad28-c9c6-46b0-9ec5-70313ab1767b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_36e75096-9a1f-4058-9a05-1889aa7ac372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7b39fc77-0d0c-4aae-9372-cc941a9a86b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_36e75096-9a1f-4058-9a05-1889aa7ac372" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7b39fc77-0d0c-4aae-9372-cc941a9a86b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d2b044b2-db5a-4a86-8760-686ec1a1847e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_36e75096-9a1f-4058-9a05-1889aa7ac372" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d2b044b2-db5a-4a86-8760-686ec1a1847e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesScheduleofLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1bf8cf80-4c50-48ba-967c-0d6f315b252e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_06c8d279-ceca-4416-83f7-7b2a662e6d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1bf8cf80-4c50-48ba-967c-0d6f315b252e" xlink:to="loc_us-gaap_ShortTermLeaseCost_06c8d279-ceca-4416-83f7-7b2a662e6d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ea7bb824-db83-48e8-972c-e56f159b539b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1bf8cf80-4c50-48ba-967c-0d6f315b252e" xlink:to="loc_us-gaap_OperatingLeaseCost_ea7bb824-db83-48e8-972c-e56f159b539b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_93798672-7478-48cb-bf18-f1b08be8c0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1bf8cf80-4c50-48ba-967c-0d6f315b252e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_93798672-7478-48cb-bf18-f1b08be8c0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_86ee7fa1-abc8-40e5-ae81-0159a757d218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1bf8cf80-4c50-48ba-967c-0d6f315b252e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_86ee7fa1-abc8-40e5-ae81-0159a757d218" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_4ba037b9-d0eb-464a-9833-c0231ea98143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5d655826-5b65-4996-8851-464fb4d0bed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_4ba037b9-d0eb-464a-9833-c0231ea98143" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5d655826-5b65-4996-8851-464fb4d0bed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a68d55f8-0763-46d3-be8d-e24b8b78f510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_4ba037b9-d0eb-464a-9833-c0231ea98143" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a68d55f8-0763-46d3-be8d-e24b8b78f510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ce706d7d-baa0-4e19-933f-52197cccf309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8232d405-857f-4855-82fb-1ebd3af128cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ce706d7d-baa0-4e19-933f-52197cccf309" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8232d405-857f-4855-82fb-1ebd3af128cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_339a6bf9-babd-4d71-b5db-daf5bbe3fd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ce706d7d-baa0-4e19-933f-52197cccf309" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_339a6bf9-babd-4d71-b5db-daf5bbe3fd37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsScheduleofBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_a40969fe-76f2-436a-9b11-9f3d98bc9f37" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_a40969fe-76f2-436a-9b11-9f3d98bc9f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_c354bc33-e52a-41b1-bbc6-309f8033a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_c354bc33-e52a-41b1-bbc6-309f8033a62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_14db6116-0d4a-4bfd-bc2b-840d5a94b1f8" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_14db6116-0d4a-4bfd-bc2b-840d5a94b1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_723f150a-15e6-4e41-a6ae-665e8bd98d36" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_723f150a-15e6-4e41-a6ae-665e8bd98d36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_4927e154-5ea6-4aab-bc93-4682e0942d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_4927e154-5ea6-4aab-bc93-4682e0942d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_decd3c9b-9eb9-4722-85ee-d4966b342863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_decd3c9b-9eb9-4722-85ee-d4966b342863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_5a9b688e-2ab7-4d9e-89ad-719fc463707a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_5a9b688e-2ab7-4d9e-89ad-719fc463707a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_e14d7a70-61d5-4381-9fca-83b6d79ec3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_e14d7a70-61d5-4381-9fca-83b6d79ec3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_823502c0-f3d6-4ce1-ad47-d547951f2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_823502c0-f3d6-4ce1-ad47-d547951f2e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2c7bde3c-716f-4e42-bf55-495d8571e4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76fe771c-0344-4300-aee0-f5919755b258" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2c7bde3c-716f-4e42-bf55-495d8571e4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_ba020f84-43ee-4f92-a1f0-5ce042f32d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_ba020f84-43ee-4f92-a1f0-5ce042f32d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_a35ce82c-695e-454d-98e5-597f0e4fd96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_a35ce82c-695e-454d-98e5-597f0e4fd96f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f3fb843b-bc51-4492-be9f-11d47a06ca29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f3fb843b-bc51-4492-be9f-11d47a06ca29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8669126e-bdd2-462c-8067-5514d6c12cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8669126e-bdd2-462c-8067-5514d6c12cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_9432bff5-f9e6-4ac9-93f9-4241eb09a46a" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_9432bff5-f9e6-4ac9-93f9-4241eb09a46a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_54ac1387-0acc-4895-a90e-5d46fda4de87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_54ac1387-0acc-4895-a90e-5d46fda4de87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_a97151f5-964a-4493-b851-587c8c819f56" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_a97151f5-964a-4493-b851-587c8c819f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_24f0ee9a-0f13-4234-a45f-315f98405080" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0cf2062f-cad6-437e-b69a-6d364ded3cb8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_24f0ee9a-0f13-4234-a45f-315f98405080" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsScheduleofStatementofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_33ae11ec-d4e9-415b-a67f-bca027847602" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_4667eb29-ce81-4a34-833c-aab061194a59" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_33ae11ec-d4e9-415b-a67f-bca027847602" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_4667eb29-ce81-4a34-833c-aab061194a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_e5f844aa-33d6-409f-b444-359dc65de518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_33ae11ec-d4e9-415b-a67f-bca027847602" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_e5f844aa-33d6-409f-b444-359dc65de518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_79546ff1-8c63-4ddc-b85d-a325f2bd915d" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c1cc3387-d762-494b-a38a-80c60caea67d" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_79546ff1-8c63-4ddc-b85d-a325f2bd915d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c1cc3387-d762-494b-a38a-80c60caea67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_b5546387-24dc-4e54-a0eb-cfba571ff441" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_79546ff1-8c63-4ddc-b85d-a325f2bd915d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_b5546387-24dc-4e54-a0eb-cfba571ff441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_fb86004c-5494-4c4b-ac24-40df057a134c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c7e1ac53-f5d3-49ef-8b12-3c7cd599065f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_fb86004c-5494-4c4b-ac24-40df057a134c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c7e1ac53-f5d3-49ef-8b12-3c7cd599065f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_a649cdd8-a4b8-4c4b-a6ee-b36ce50260da" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_fb86004c-5494-4c4b-ac24-40df057a134c" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_a649cdd8-a4b8-4c4b-a6ee-b36ce50260da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_3d01e055-2969-43bf-9fdd-589882a15689" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_fb86004c-5494-4c4b-ac24-40df057a134c" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_3d01e055-2969-43bf-9fdd-589882a15689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_a8f46f81-f63a-4c4b-a7b6-4d34b1245623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_fb86004c-5494-4c4b-ac24-40df057a134c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_a8f46f81-f63a-4c4b-a7b6-4d34b1245623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a0920426-2eab-4e80-b473-f19a782b1572" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_32b1ba2e-ad86-4bfd-b98a-57938d83f887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a0920426-2eab-4e80-b473-f19a782b1572" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_32b1ba2e-ad86-4bfd-b98a-57938d83f887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_e36c240f-8330-43f6-807a-155cd203fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a0920426-2eab-4e80-b473-f19a782b1572" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_e36c240f-8330-43f6-807a-155cd203fa34" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bvs-20230401_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:082d4e54-0693-403f-8feb-755a4f49db3a,g:bca9874b-627b-4a4e-9dc7-9b090a7fd814-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bioventus.com/role/CoverPage" xlink:type="simple" xlink:href="bvs-20230401.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/CoverPage" xlink:type="extended" id="i5dd033ba16904285a03616e0a90c1ba6_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6f7fbac2-a323-4790-b9a3-90f760e70d7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentType_6f7fbac2-a323-4790-b9a3-90f760e70d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c9e5b883-c13d-4cde-a40c-ef54696aa9fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentQuarterlyReport_c9e5b883-c13d-4cde-a40c-ef54696aa9fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_be45cd8f-1019-45ac-918f-61186eb6fb46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentPeriodEndDate_be45cd8f-1019-45ac-918f-61186eb6fb46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7dfd2007-8f68-487d-9596-bb1d56206143" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentTransitionReport_7dfd2007-8f68-487d-9596-bb1d56206143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_436a13c6-b8cd-4cb5-ab44-60b00bd1a514" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityFileNumber_436a13c6-b8cd-4cb5-ab44-60b00bd1a514" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_151440e0-3350-40e7-97f3-b5d7ae7a9dfa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityRegistrantName_151440e0-3350-40e7-97f3-b5d7ae7a9dfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1d16cf9c-eb13-46a9-b76c-a4be23e6ea0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1d16cf9c-eb13-46a9-b76c-a4be23e6ea0d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_91e4521b-873a-4459-8f3a-5cde470da599" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityTaxIdentificationNumber_91e4521b-873a-4459-8f3a-5cde470da599" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d072045e-4377-47a3-8d61-e81e7c5f623d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressAddressLine1_d072045e-4377-47a3-8d61-e81e7c5f623d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b13ba53b-5b05-49e3-8ca0-df9e699f9bb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressAddressLine2_b13ba53b-5b05-49e3-8ca0-df9e699f9bb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c2c1e9d4-ecd9-4623-a84b-dbf348a55c41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressCityOrTown_c2c1e9d4-ecd9-4623-a84b-dbf348a55c41" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3f6edbd3-50bf-426f-b5da-4c88068f198c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressStateOrProvince_3f6edbd3-50bf-426f-b5da-4c88068f198c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_907d888c-7ea7-4d2c-a843-b095fd16055a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressPostalZipCode_907d888c-7ea7-4d2c-a843-b095fd16055a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_92b1837a-d4d2-4034-84e8-9b1d8b4a27fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_CityAreaCode_92b1837a-d4d2-4034-84e8-9b1d8b4a27fe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4d10fcff-cc9c-4cc2-931f-27885b36a86c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_LocalPhoneNumber_4d10fcff-cc9c-4cc2-931f-27885b36a86c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37cf84a0-3f5f-4dbd-ad5a-21bb19e8372e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_Security12bTitle_37cf84a0-3f5f-4dbd-ad5a-21bb19e8372e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_deefe101-14f2-44a6-bda0-a8b6990fdc7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_TradingSymbol_deefe101-14f2-44a6-bda0-a8b6990fdc7d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_16027c8d-424c-4dca-a8a2-940be4a3e770" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_SecurityExchangeName_16027c8d-424c-4dca-a8a2-940be4a3e770" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b36618ca-7d24-4620-a583-89cbe837173f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityCurrentReportingStatus_b36618ca-7d24-4620-a583-89cbe837173f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f2951df1-674f-4c2b-8dc6-0cca915a50c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityInteractiveDataCurrent_f2951df1-674f-4c2b-8dc6-0cca915a50c4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ec0767f8-e737-4439-8fbc-b457341de887" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityFilerCategory_ec0767f8-e737-4439-8fbc-b457341de887" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e12348e9-499a-42e7-ae33-ea390a36a4eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntitySmallBusiness_e12348e9-499a-42e7-ae33-ea390a36a4eb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f4b4e919-f175-4327-b8d5-e95fe50107bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityEmergingGrowthCompany_f4b4e919-f175-4327-b8d5-e95fe50107bb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_9da4758e-aea9-46f7-98bc-ac87b265b040" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityExTransitionPeriod_9da4758e-aea9-46f7-98bc-ac87b265b040" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_169e25a4-3a48-4e6a-9e8c-a28183b11ab6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityShellCompany_169e25a4-3a48-4e6a-9e8c-a28183b11ab6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_801bf0c9-0d75-4005-bf6f-0b37f38d0aca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_801bf0c9-0d75-4005-bf6f-0b37f38d0aca" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b7508144-eae7-4042-a0d1-e14f13da37d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_AmendmentFlag_b7508144-eae7-4042-a0d1-e14f13da37d4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49dd4701-0697-4682-89d4-c6adf20e6209" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityCentralIndexKey_49dd4701-0697-4682-89d4-c6adf20e6209" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5ea9ca7a-066d-4d72-be2f-4a8160e35ab9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_CurrentFiscalYearEndDate_5ea9ca7a-066d-4d72-be2f-4a8160e35ab9" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_51bc11e7-d92e-49e8-9718-a14d622a234c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentFiscalYearFocus_51bc11e7-d92e-49e8-9718-a14d622a234c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_42c24935-cd13-4a4f-8fef-200012310128" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentFiscalPeriodFocus_42c24935-cd13-4a4f-8fef-200012310128" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b375ef7a-1d1c-461e-a362-30d783445332_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:to="loc_us-gaap_ClassOfStockDomain_b375ef7a-1d1c-461e-a362-30d783445332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:to="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_074c7f0c-58e7-4e9f-8efa-90d8145e591d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:to="loc_us-gaap_CommonClassAMember_074c7f0c-58e7-4e9f-8efa-90d8145e591d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_db2234e6-daa1-47cf-8681-0089a6fad0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:to="loc_us-gaap_CommonClassBMember_db2234e6-daa1-47cf-8681-0089a6fad0b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended" id="i88972ebf842c4436acf009888a515c14_ConsolidatedCondensedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:to="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d7f6706-a71f-4165-b2b5-87b7d46e95ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d7f6706-a71f-4165-b2b5-87b7d46e95ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6e8b9fc6-a231-4892-b2ff-65c7de4178a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6e8b9fc6-a231-4892-b2ff-65c7de4178a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1a417510-5687-4cba-a0a2-9d72684c6813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_InventoryNet_1a417510-5687-4cba-a0a2-9d72684c6813" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1aa3d91-1a2d-4117-bc04-977899d4fdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1aa3d91-1a2d-4117-bc04-977899d4fdbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_543ce6dc-130c-4162-bb09-405d12759106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_543ce6dc-130c-4162-bb09-405d12759106" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8c026ac7-26d6-404b-8d0d-f77438c72973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8c026ac7-26d6-404b-8d0d-f77438c72973" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c6cf2a1a-2e73-4d74-9448-085677de401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AssetsCurrent_c6cf2a1a-2e73-4d74-9448-085677de401a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70ddabb6-5d35-47f0-b9b2-4d6a7dccd6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70ddabb6-5d35-47f0-b9b2-4d6a7dccd6f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_72fd2b84-ea65-4399-bdb3-d3ca88a9bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_Goodwill_72fd2b84-ea65-4399-bdb3-d3ca88a9bad1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a594575-36ad-4558-bd24-588014ac5601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a594575-36ad-4558-bd24-588014ac5601" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c72dc02-36c8-4ab4-96a4-389950e38724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c72dc02-36c8-4ab4-96a4-389950e38724" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_48c08cba-ec1e-4370-9e64-22056a7651a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_LongTermInvestments_48c08cba-ec1e-4370-9e64-22056a7651a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2e3d8f60-ecf8-4c07-a7f8-a404436f4303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2e3d8f60-ecf8-4c07-a7f8-a404436f4303" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6f37dbc6-fee5-457c-a2bd-7b45e961fc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_Assets_6f37dbc6-fee5-457c-a2bd-7b45e961fc6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_758eea60-eb0f-417f-8c2f-65dacdf02074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_AccountsPayableCurrent_758eea60-eb0f-417f-8c2f-65dacdf02074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b14ae155-35b5-48ee-ac53-4d50bd85af8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b14ae155-35b5-48ee-ac53-4d50bd85af8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c9f6da14-c82c-494b-8e4e-d7a9f015faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_LongTermDebtCurrent_c9f6da14-c82c-494b-8e4e-d7a9f015faf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_869a780d-673d-4ad0-97d1-24cc789773af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_869a780d-673d-4ad0-97d1-24cc789773af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_998206c4-a1dc-464c-93f3-3cfb0a5cf036" xlink:href="bvs-20230401.xsd#bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_998206c4-a1dc-464c-93f3-3cfb0a5cf036" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_21653515-1b55-47c2-a22f-b76311d9bba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_21653515-1b55-47c2-a22f-b76311d9bba9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c9e0953c-d134-4d48-b014-e86e44c550fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_LiabilitiesCurrent_c9e0953c-d134-4d48-b014-e86e44c550fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_937ca24e-5c00-4501-9c86-c4149f63e6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_937ca24e-5c00-4501-9c86-c4149f63e6a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a349a6b5-08c3-4d7e-9207-a92217414299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a349a6b5-08c3-4d7e-9207-a92217414299" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b2867384-0855-4e81-8ba5-9f3983c7da80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b2867384-0855-4e81-8ba5-9f3983c7da80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_59c47315-e87d-4db2-a8db-7c0299b14e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_59c47315-e87d-4db2-a8db-7c0299b14e53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_854e0d25-2a49-4305-96bf-48c5e3dd7e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_854e0d25-2a49-4305-96bf-48c5e3dd7e0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_009ecb15-fd47-414a-997c-9c2424888f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_Liabilities_009ecb15-fd47-414a-997c-9c2424888f78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f77463cd-c174-44fc-b92e-82e559a0c804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f77463cd-c174-44fc-b92e-82e559a0c804" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_85c50cfb-f8ff-41ee-9000-13d5d61acd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_CommonStockValue_85c50cfb-f8ff-41ee-9000-13d5d61acd18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_906ea564-dde3-497c-b3b7-ab185907800c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_906ea564-dde3-497c-b3b7-ab185907800c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_572ce623-ee22-4738-864e-cf9ac01e55ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_572ce623-ee22-4738-864e-cf9ac01e55ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb6ea723-f418-4307-bffe-e9dc8d5d33ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb6ea723-f418-4307-bffe-e9dc8d5d33ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fccac5c-3e70-45cd-9f22-d5563018872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_StockholdersEquity_9fccac5c-3e70-45cd-9f22-d5563018872c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_27f42926-81b7-44f6-9be9-03f9d5a50694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_MinorityInterest_27f42926-81b7-44f6-9be9-03f9d5a50694" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2ffd43f-2225-446a-aec3-f6c356fe44d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2ffd43f-2225-446a-aec3-f6c356fe44d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ead5208f-b081-497b-b3e9-cc551b2f6b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ead5208f-b081-497b-b3e9-cc551b2f6b18" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:to="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:to="loc_us-gaap_ClassOfStockDomain_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:to="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_46f56016-84d8-456d-8629-c68a5ca61449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:to="loc_us-gaap_CommonClassAMember_46f56016-84d8-456d-8629-c68a5ca61449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8443b4c7-83cc-4ee4-a9fb-a69b16359d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:to="loc_us-gaap_CommonClassBMember_8443b4c7-83cc-4ee4-a9fb-a69b16359d92" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended" id="ia02710b7e1be4522b3115e73a39dd174_ConsolidatedCondensedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12f1b4df-e0c4-4199-9efc-ec6791ba3cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12f1b4df-e0c4-4199-9efc-ec6791ba3cb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5be2dd32-0457-426b-8162-635efbfd2ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5be2dd32-0457-426b-8162-635efbfd2ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_604f3ee3-4218-4ca6-9ccf-45ae02606ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_604f3ee3-4218-4ca6-9ccf-45ae02606ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3b804e7-6921-43af-ac2d-660f422de3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3b804e7-6921-43af-ac2d-660f422de3d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c6d20f99-e82c-49fe-9f7a-0b81b34b1f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c6d20f99-e82c-49fe-9f7a-0b81b34b1f8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6c2dd5e1-7a64-40c1-ba11-fea63a36d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6c2dd5e1-7a64-40c1-ba11-fea63a36d2f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1b952a66-8401-43a5-ba5b-583ba811acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockSharesIssued_1b952a66-8401-43a5-ba5b-583ba811acc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9d85db7-c488-405a-aeba-6ccde395de1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:to="loc_us-gaap_ClassOfStockDomain_b9d85db7-c488-405a-aeba-6ccde395de1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:to="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_65bcc35f-bcae-457d-9dc1-3e75fb9457b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:to="loc_us-gaap_CommonClassAMember_65bcc35f-bcae-457d-9dc1-3e75fb9457b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_2a4683e6-fc93-4318-a98b-54bdb978fb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:to="loc_us-gaap_CommonClassBMember_2a4683e6-fc93-4318-a98b-54bdb978fb8f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="ife35b7c7f67642bfa89349ec16dd06c9_ConsolidatedCondensedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_317a1f91-5e14-4163-9c23-5ad826c60006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:href="bvs-20230401.xsd#bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317a1f91-5e14-4163-9c23-5ad826c60006" xlink:to="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_df739098-cdf8-429e-a9d0-5f6bcc9b7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_df739098-cdf8-429e-a9d0-5f6bcc9b7e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e8f71d1-728a-484e-8c77-6f3dbdb30955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e8f71d1-728a-484e-8c77-6f3dbdb30955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_449bd8b1-f438-4e10-bfe6-72958dbc26c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_449bd8b1-f438-4e10-bfe6-72958dbc26c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7c43a85-083f-4834-ba1e-034fae73d542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7c43a85-083f-4834-ba1e-034fae73d542" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredTaxesOnEquityRebalancing_c0c16f51-9849-4d99-a276-d9f1abdb2aae" xlink:href="bvs-20230401.xsd#bvs_DeferredTaxesOnEquityRebalancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_bvs_DeferredTaxesOnEquityRebalancing_c0c16f51-9849-4d99-a276-d9f1abdb2aae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c5a7f1c9-82dd-42f1-a0dc-4f27acf2276d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_ProfitLoss_c5a7f1c9-82dd-42f1-a0dc-4f27acf2276d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f058ad9f-8622-4608-b385-ef639269134c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f058ad9f-8622-4608-b385-ef639269134c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_17e3da6f-0075-4290-a626-f06add56c261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_17e3da6f-0075-4290-a626-f06add56c261" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c30f1bdb-d3ba-4cf7-8228-60e4cc158fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c30f1bdb-d3ba-4cf7-8228-60e4cc158fb5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a648f5d6-7928-4219-8aea-a80b51cf71d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b43182bf-f6ae-4c7f-ac3e-b33a492d31df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_317a1f91-5e14-4163-9c23-5ad826c60006" xlink:to="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a4f1747-eaaf-40bf-b439-88e6e6923ae2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:to="loc_us-gaap_EquityComponentDomain_6a4f1747-eaaf-40bf-b439-88e6e6923ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:to="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_faf84b27-19d0-4af4-8eeb-dbfffb41289a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_CommonStockMember_faf84b27-19d0-4af4-8eeb-dbfffb41289a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_38647da8-a572-4aa8-9883-e5654a6efea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_38647da8-a572-4aa8-9883-e5654a6efea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1cd56756-d819-4bd2-ae24-ea38b8fadbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1cd56756-d819-4bd2-ae24-ea38b8fadbab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bdaef06e-4d8d-4e7c-ad9e-d36768bdfb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_RetainedEarningsMember_bdaef06e-4d8d-4e7c-ad9e-d36768bdfb42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_caf5c149-ecfa-4078-96de-162b9e58c027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_caf5c149-ecfa-4078-96de-162b9e58c027" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ed49eb93-9bcf-42e3-9ddf-3b8083542c18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:to="loc_us-gaap_ClassOfStockDomain_ed49eb93-9bcf-42e3-9ddf-3b8083542c18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:to="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e2aad80b-09a2-4b37-a614-18eed03256cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:to="loc_us-gaap_CommonClassAMember_e2aad80b-09a2-4b37-a614-18eed03256cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8dcd104b-147c-492e-b8c0-eaf7b9c0542b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:to="loc_us-gaap_CommonClassBMember_8dcd104b-147c-492e-b8c0-eaf7b9c0542b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/OrganizationNarrativeDetails" xlink:type="extended" id="i8e76db306ec64b13a46e3ac6ad7001c1_OrganizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8cee80fb-5cfe-4017-a50e-47a2173435cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_9793941f-83af-44fc-ad6b-d0a64625b7dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cee80fb-5cfe-4017-a50e-47a2173435cf" xlink:to="loc_dei_EntityNumberOfEmployees_9793941f-83af-44fc-ad6b-d0a64625b7dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cee80fb-5cfe-4017-a50e-47a2173435cf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:to="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6dc87919-d8f4-4150-a4cd-da2b2a578c17_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:to="loc_dei_EntityDomain_6dc87919-d8f4-4150-a4cd-da2b2a578c17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b53ed72a-4e20-48a2-8e58-8186e5000cf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:to="loc_dei_EntityDomain_b53ed72a-4e20-48a2-8e58-8186e5000cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_6e70c0e9-5a48-4c20-86f4-8c371f42dbb8" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b53ed72a-4e20-48a2-8e58-8186e5000cf8" xlink:to="loc_bvs_BVLLCMember_6e70c0e9-5a48-4c20-86f4-8c371f42dbb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#OrganizationErrorCorrectionsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails" xlink:type="extended" id="i6c325e6f42654997a4140f1d08c7b7f7_OrganizationErrorCorrectionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a731baa6-85db-409e-bc2d-00563bce5549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a731baa6-85db-409e-bc2d-00563bce5549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df342918-2a48-44c1-af7f-ba651dc3766c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_Liabilities_df342918-2a48-44c1-af7f-ba651dc3766c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4ee0676b-ff2d-47be-8100-d23c71f0cfef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4ee0676b-ff2d-47be-8100-d23c71f0cfef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8e377279-0f65-416a-84d8-cfb6001672a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_MinorityInterest_8e377279-0f65-416a-84d8-cfb6001672a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c86693d9-43e9-4a1b-8dff-242839ee5ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c86693d9-43e9-4a1b-8dff-242839ee5ae4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:to="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_73f964d2-084a-4ea2-ae11-1f46bc6a0169_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:to="loc_srt_RestatementDomain_73f964d2-084a-4ea2-ae11-1f46bc6a0169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:to="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_7a148a22-c684-4aec-8a5e-68a5a85580b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_7a148a22-c684-4aec-8a5e-68a5a85580b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_cddcf62a-1bda-4479-b9a5-f702caaa0a84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:to="loc_srt_RestatementAdjustmentMember_cddcf62a-1bda-4479-b9a5-f702caaa0a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:to="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_25d327dc-6a30-4d88-a453-119bd8429721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:to="loc_us-gaap_ReclassificationTypeDomain_25d327dc-6a30-4d88-a453-119bd8429721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:to="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_EquityRebalancingMember_eb23b797-5d1f-4f35-acda-c3a4a70895e9" xlink:href="bvs-20230401.xsd#bvs_EquityRebalancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_EquityRebalancingMember_eb23b797-5d1f-4f35-acda-c3a4a70895e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_3d6fa8d0-79ec-4b02-93c8-78fbfba34e3e" xlink:href="bvs-20230401.xsd#bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_3d6fa8d0-79ec-4b02-93c8-78fbfba34e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_9ed0ad05-d5c6-413c-ba86-e1c4652681ba" xlink:href="bvs-20230401.xsd#bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_9ed0ad05-d5c6-413c-ba86-e1c4652681ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredTaxImpactFor2022Member_fdb0a19a-129e-4e64-9f9c-4df0a78c2481" xlink:href="bvs-20230401.xsd#bvs_DeferredTaxImpactFor2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_DeferredTaxImpactFor2022Member_fdb0a19a-129e-4e64-9f9c-4df0a78c2481" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" xlink:type="extended" id="i6c034efa646b4ddcbf4997c2e022af34_BalancesheetinformationScheduleofAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_3e43a169-0b0b-4d41-87ed-18cfc763677a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_3e43a169-0b0b-4d41-87ed-18cfc763677a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa38e4b8-6f20-4e40-975a-07b0587e55b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa38e4b8-6f20-4e40-975a-07b0587e55b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_17297f88-6340-4f0e-90c8-b9ef6aba936e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_17297f88-6340-4f0e-90c8-b9ef6aba936e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_48a274b6-e843-457a-8d5c-09dbbde5d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_OtherReceivables_48a274b6-e843-457a-8d5c-09dbbde5d79d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9fdb98fc-03e3-4bfb-82fe-d6c723f16365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9fdb98fc-03e3-4bfb-82fe-d6c723f16365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ba29ff1a-03e8-4ae4-893a-5b72ac4980cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ba29ff1a-03e8-4ae4-893a-5b72ac4980cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_8e2cf7e9-5431-4329-9b2d-667c12a03833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ba29ff1a-03e8-4ae4-893a-5b72ac4980cf" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_8e2cf7e9-5431-4329-9b2d-667c12a03833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8757c87-337f-4062-a4fd-012ba94f8708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8757c87-337f-4062-a4fd-012ba94f8708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c8eff240-fc11-40cb-ab75-01fca70ea718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c8eff240-fc11-40cb-ab75-01fca70ea718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_f1f668d7-72db-458b-8d7a-0e496e830d4a" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c8eff240-fc11-40cb-ab75-01fca70ea718" xlink:to="loc_bvs_CartiHealLtdMember_f1f668d7-72db-458b-8d7a-0e496e830d4a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" xlink:type="extended" id="i53403ec3398e491ea1f70361b8e9a3d7_BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e3de43ca-53b0-47ed-8a45-9f1a1a0e6d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7b8315d9-7ad7-498a-83ab-d77afe6f9221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e3de43ca-53b0-47ed-8a45-9f1a1a0e6d7d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7b8315d9-7ad7-498a-83ab-d77afe6f9221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e3de43ca-53b0-47ed-8a45-9f1a1a0e6d7d" xlink:to="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52586bce-51af-4675-8137-1ac0c5ccdbdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52586bce-51af-4675-8137-1ac0c5ccdbdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ebc140f9-a2fa-4260-b49e-d2f3daf009c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ebc140f9-a2fa-4260-b49e-d2f3daf009c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3841d9fc-0c21-41ee-93d6-af346446af06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ebc140f9-a2fa-4260-b49e-d2f3daf009c6" xlink:to="loc_us-gaap_AccountsReceivableMember_3841d9fc-0c21-41ee-93d6-af346446af06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_46a64ea8-db21-4000-a1c2-968a9029b9f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_46a64ea8-db21-4000-a1c2-968a9029b9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d231ceda-08a5-4222-ada8-12aa5d96d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d231ceda-08a5-4222-ada8-12aa5d96d6df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d63f4065-2606-4e78-bac2-b9d2a22f2168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d231ceda-08a5-4222-ada8-12aa5d96d6df" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d63f4065-2606-4e78-bac2-b9d2a22f2168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e3366f53-431f-4f49-b041-561c78cf9819_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:to="loc_srt_NameOfMajorCustomerDomain_e3366f53-431f-4f49-b041-561c78cf9819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_47359999-bb3e-466b-84b6-09be4fb55fd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:to="loc_srt_NameOfMajorCustomerDomain_47359999-bb3e-466b-84b6-09be4fb55fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CustomerOneMember_9ab2c030-ac76-4ac6-a2c4-9c43788cd336" xlink:href="bvs-20230401.xsd#bvs_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_47359999-bb3e-466b-84b6-09be4fb55fd9" xlink:to="loc_bvs_CustomerOneMember_9ab2c030-ac76-4ac6-a2c4-9c43788cd336" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" xlink:type="extended" id="ib0a663b699804a46a8aa136e30563ddc_BalancesheetinformationScheduleofInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_719e598c-c9c2-4020-9902-3ffad8a3873f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_719e598c-c9c2-4020-9902-3ffad8a3873f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_47293236-7077-4538-bb7e-f11f25dde3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryFinishedGoods_47293236-7077-4538-bb7e-f11f25dde3a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c4efbe26-eba1-425b-9d0c-8ed71c07fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryGross_c4efbe26-eba1-425b-9d0c-8ed71c07fb99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5a2a124a-df9c-4b21-b705-8c645ae7263b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryValuationReserves_5a2a124a-df9c-4b21-b705-8c645ae7263b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ea7e0870-32f2-42b8-b1b7-ffccf2d5bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryNet_ea7e0870-32f2-42b8-b1b7-ffccf2d5bf7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d7e080d8-46bc-4608-9608-52d77287bf06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d7e080d8-46bc-4608-9608-52d77287bf06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2fe69c32-e7f8-422b-8b4d-b1f8422e9787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2fe69c32-e7f8-422b-8b4d-b1f8422e9787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_fac46a15-f321-489a-b4e4-b4bdf60242f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2fe69c32-e7f8-422b-8b4d-b1f8422e9787" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_fac46a15-f321-489a-b4e4-b4bdf60242f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_153da899-25ef-40a4-ae56-5ea370b5cd68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_153da899-25ef-40a4-ae56-5ea370b5cd68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a775b4f-922b-4db3-9a46-4c4508fcd1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a775b4f-922b-4db3-9a46-4c4508fcd1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_75d338d1-a553-4966-98db-644b7aef0c01" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a775b4f-922b-4db3-9a46-4c4508fcd1f7" xlink:to="loc_bvs_CartiHealLtdMember_75d338d1-a553-4966-98db-644b7aef0c01" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended" id="i4e167535b1bc4d768cbcd543e7544320_BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_48bad10b-9d05-4b4d-b30c-0fa25eab8820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_PrepaidTaxes_48bad10b-9d05-4b4d-b30c-0fa25eab8820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_dd9839e9-b8bd-426b-ab06-a68a73871cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_dd9839e9-b8bd-426b-ab06-a68a73871cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9180e25c-27b4-4eff-90e1-66e7f5ab8edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9180e25c-27b4-4eff-90e1-66e7f5ab8edb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_adc8bf07-3705-4bd0-88a2-4b38f8351993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_adc8bf07-3705-4bd0-88a2-4b38f8351993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7d73c951-83d6-464a-9102-603cdf683c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7d73c951-83d6-464a-9102-603cdf683c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_5d8e3849-9a30-45f0-b4e4-ca8b059b50bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7d73c951-83d6-464a-9102-603cdf683c91" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_5d8e3849-9a30-45f0-b4e4-ca8b059b50bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97960a80-5c84-4c9b-9bd0-939fc813e392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97960a80-5c84-4c9b-9bd0-939fc813e392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_9a503240-256e-4068-9b34-c0f5c19c2fc8" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97960a80-5c84-4c9b-9bd0-939fc813e392" xlink:to="loc_bvs_CartiHealLtdMember_9a503240-256e-4068-9b34-c0f5c19c2fc8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails" xlink:type="extended" id="i7ed832e2ebc54eaab8e90d85743b3aa7_BalancesheetinformationIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d5b3d9f9-4af6-4346-b6b4-c91c340818a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d5b3d9f9-4af6-4346-b6b4-c91c340818a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68363cbf-9c4d-4e65-811d-5acca1f3747f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68363cbf-9c4d-4e65-811d-5acca1f3747f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_4d6bc22b-4e51-4d97-80dc-f990181208a2" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_4d6bc22b-4e51-4d97-80dc-f990181208a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_b5953540-a1b2-4e9c-b869-e7c2c91523f5" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_b5953540-a1b2-4e9c-b869-e7c2c91523f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfb80bd9-3bcd-4340-995e-0e94cb535514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfb80bd9-3bcd-4340-995e-0e94cb535514" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9d969640-5a56-4c67-bf13-bf6a0d0030d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9d969640-5a56-4c67-bf13-bf6a0d0030d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20bb8310-1960-4b11-8c78-3cf318e1a421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20bb8310-1960-4b11-8c78-3cf318e1a421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_b8cdd885-34b5-4190-af55-7440628453e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_IntellectualPropertyMember_b8cdd885-34b5-4190-af55-7440628453e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_830ecdcb-7965-4c1e-8db0-c0605d5d45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_DistributionRightsMember_830ecdcb-7965-4c1e-8db0-c0605d5d45eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3b0608e3-4fbb-4839-973e-da41e385f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3b0608e3-4fbb-4839-973e-da41e385f4c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6e3c02b2-8c84-4e83-ab26-350c97f978b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6e3c02b2-8c84-4e83-ab26-350c97f978b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_98747ee7-e904-4a94-8b5b-616b768460d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_98747ee7-e904-4a94-8b5b-616b768460d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_88d5785d-65df-4a4b-ae17-2a7d51949abe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_88d5785d-65df-4a4b-ae17-2a7d51949abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7a035051-181d-4180-9027-ade54818ff00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7a035051-181d-4180-9027-ade54818ff00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_954e78a2-5875-4ca7-b3fb-66cd814ba6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7a035051-181d-4180-9027-ade54818ff00" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_954e78a2-5875-4ca7-b3fb-66cd814ba6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dd7a70b1-5094-411a-a028-7ee06531814a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dd7a70b1-5094-411a-a028-7ee06531814a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d86f095-99a1-4625-bef0-7aadfe928340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d86f095-99a1-4625-bef0-7aadfe928340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_4710d4dc-b8ec-4526-a762-6cdf5f3e56a9" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d86f095-99a1-4625-bef0-7aadfe928340" xlink:to="loc_bvs_CartiHealLtdMember_4710d4dc-b8ec-4526-a762-6cdf5f3e56a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails" xlink:type="extended" id="i36f9ca51df704bce961b42c568e1d225_BalancesheetinformationGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_133570db-ca94-4be2-afc3-4f5c0a54d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_NumberOfReportingUnits_133570db-ca94-4be2-afc3-4f5c0a54d91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ff6082b7-605f-42e9-96e3-40ee2529f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_Goodwill_ff6082b7-605f-42e9-96e3-40ee2529f5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_193922e2-6aae-4823-8908-0f1e83238e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_193922e2-6aae-4823-8908-0f1e83238e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0b39f612-1016-4639-b6c0-df30d2430dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0b39f612-1016-4639-b6c0-df30d2430dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_95dfae91-5745-45cb-9e34-10faf5b19575_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:to="loc_us-gaap_ReportingUnitDomain_95dfae91-5745-45cb-9e34-10faf5b19575_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_22e994f5-4b86-4a86-8d00-d373bceacaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:to="loc_us-gaap_ReportingUnitDomain_22e994f5-4b86-4a86-8d00-d373bceacaf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_513672f0-de3d-4ef6-80df-7cf8df390441" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_22e994f5-4b86-4a86-8d00-d373bceacaf8" xlink:to="loc_country_US_513672f0-de3d-4ef6-80df-7cf8df390441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f1510891-66db-48a4-8fb0-2eadcbae6a86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f1510891-66db-48a4-8fb0-2eadcbae6a86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c846992c-3b8c-41b2-bb2a-9830ccff710b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c846992c-3b8c-41b2-bb2a-9830ccff710b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_cc25c202-3297-42a8-99df-1c0889ce68ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c846992c-3b8c-41b2-bb2a-9830ccff710b" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_cc25c202-3297-42a8-99df-1c0889ce68ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f08948e8-f352-4380-895b-9351eb721e69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f08948e8-f352-4380-895b-9351eb721e69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_875bcca4-2270-4952-a3c4-e28e4551fd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_875bcca4-2270-4952-a3c4-e28e4551fd64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_142f4745-05b4-42a4-89ed-f0f8b60a208c" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_875bcca4-2270-4952-a3c4-e28e4551fd64" xlink:to="loc_bvs_CartiHealLtdMember_142f4745-05b4-42a4-89ed-f0f8b60a208c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" xlink:type="extended" id="i8b98d2560e964b5c9989454814c2be25_BalancesheetinformationScheduleofAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_GrossToNetDeductionsCurrent_0ff3a7ae-da86-41e9-b11d-dcb1aa5fd6b3" xlink:href="bvs-20230401.xsd#bvs_GrossToNetDeductionsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_bvs_GrossToNetDeductionsCurrent_0ff3a7ae-da86-41e9-b11d-dcb1aa5fd6b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_6bd37135-85ee-41cc-ba2e-e478b05653d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_AccruedBonusesCurrent_6bd37135-85ee-41cc-ba2e-e478b05653d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_a5e7da30-0a40-4ceb-babb-a321f3636f5d" xlink:href="bvs-20230401.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_a5e7da30-0a40-4ceb-babb-a321f3636f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_8b1da91d-8572-45ab-a138-0bb134fd3647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_8b1da91d-8572-45ab-a138-0bb134fd3647" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_79bee6fe-d7d7-497c-a556-6963a896ede3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_TaxesPayableCurrent_79bee6fe-d7d7-497c-a556-6963a896ede3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_008bb5c8-57c2-40dc-98a9-2137917da274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_008bb5c8-57c2-40dc-98a9-2137917da274" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6a0f6318-5cc1-464d-8c95-6c1031657569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6a0f6318-5cc1-464d-8c95-6c1031657569" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0ec6e858-4cb0-44cc-a906-891431e24643_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0ec6e858-4cb0-44cc-a906-891431e24643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e88a57a1-8490-469a-a2c9-da26ca23c2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e88a57a1-8490-469a-a2c9-da26ca23c2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_e3cebe7f-932c-4101-b47a-25c8a59a1b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e88a57a1-8490-469a-a2c9-da26ca23c2e5" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_e3cebe7f-932c-4101-b47a-25c8a59a1b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99042ed7-6c7b-4024-9bad-7088315ea520_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99042ed7-6c7b-4024-9bad-7088315ea520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51bfff7a-844d-44ef-a26c-43563da3980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51bfff7a-844d-44ef-a26c-43563da3980e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_94ca6e41-6d59-4959-8b5d-55dacac3086e" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51bfff7a-844d-44ef-a26c-43563da3980e" xlink:to="loc_bvs_CartiHealLtdMember_94ca6e41-6d59-4959-8b5d-55dacac3086e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="extended" id="i9ba2834189ad43cfae47242d9f84daca_AcquisitionsanddivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7b413db6-65c1-4799-b5da-e07de342cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_AssetImpairmentCharges_7b413db6-65c1-4799-b5da-e07de342cfdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AssetImpairmentChargesAfterTax_59e6e0fe-4bd7-4ea2-8c6a-fbe312c84eb7" xlink:href="bvs-20230401.xsd#bvs_AssetImpairmentChargesAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_AssetImpairmentChargesAfterTax_59e6e0fe-4bd7-4ea2-8c6a-fbe312c84eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d62f63ea-6b85-4f3f-89c8-84998eff56ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d62f63ea-6b85-4f3f-89c8-84998eff56ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d236b27d-dc71-4679-a004-613ba002c788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_Investments_d236b27d-dc71-4679-a004-613ba002c788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5be6913e-7834-4b55-992c-c6e9e4cd3875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5be6913e-7834-4b55-992c-c6e9e4cd3875" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_be3531fe-e1c6-4343-b4d5-6e2c0509b293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_be3531fe-e1c6-4343-b4d5-6e2c0509b293" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87e667a1-de1e-4a3f-97d4-859bc246c443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87e667a1-de1e-4a3f-97d4-859bc246c443" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_76fd7f06-3769-4800-8d5e-f28298bae0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_76fd7f06-3769-4800-8d5e-f28298bae0fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_da00235e-8159-4068-96a4-072d23e0431c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_EscrowDeposit_da00235e-8159-4068-96a4-072d23e0431c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9a3229e4-05df-42bc-add4-f1727b3b12ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9a3229e4-05df-42bc-add4-f1727b3b12ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2ea7b8b6-0802-4547-a9ab-8f7a66b99624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2ea7b8b6-0802-4547-a9ab-8f7a66b99624" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_6b95436e-563d-4953-b8bd-79e011a16a35" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_6b95436e-563d-4953-b8bd-79e011a16a35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_228e4ac9-07bb-4735-8309-e3af85192582" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_228e4ac9-07bb-4735-8309-e3af85192582" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c374ae2e-7492-4ec1-a810-e4d741f822a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c374ae2e-7492-4ec1-a810-e4d741f822a1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1b031c1-1f65-4af1-af40-3794cf6db1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1b031c1-1f65-4af1-af40-3794cf6db1dc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_c81085c4-0be3-426b-aaba-1629f32f57b3" xlink:href="bvs-20230401.xsd#bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_c81085c4-0be3-426b-aaba-1629f32f57b3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_82013723-761e-4b0e-983f-17e1a88e7c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_82013723-761e-4b0e-983f-17e1a88e7c79" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0dadc91f-1be0-4644-b1ed-7aed36c582c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0dadc91f-1be0-4644-b1ed-7aed36c582c6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94196329-e991-43d1-8eb7-73b77568285c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94196329-e991-43d1-8eb7-73b77568285c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fcbda50a-e067-4cf1-a65a-9577849b40ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fcbda50a-e067-4cf1-a65a-9577849b40ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_2685ff07-8e7a-49ac-aa0a-add95f6102b4" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fcbda50a-e067-4cf1-a65a-9577849b40ec" xlink:to="loc_bvs_CartiHealLtdMember_2685ff07-8e7a-49ac-aa0a-add95f6102b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ace0231d-2bd3-46a4-ab36-783e887e387c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ace0231d-2bd3-46a4-ab36-783e887e387c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9e20145-40aa-44f1-bb01-165858c24782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9e20145-40aa-44f1-bb01-165858c24782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_3670f990-6454-4e3c-8c25-9fdb472e098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9e20145-40aa-44f1-bb01-165858c24782" xlink:to="loc_us-gaap_IntellectualPropertyMember_3670f990-6454-4e3c-8c25-9fdb472e098b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3da562dc-d5e1-4df5-9c50-0ac3c692d216_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3da562dc-d5e1-4df5-9c50-0ac3c692d216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember_7354c607-5c3a-4df8-ab7e-069196e9329c" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_SalesMilestoneMember_7354c607-5c3a-4df8-ab7e-069196e9329c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredConsiderationMember_da7572cb-0dba-48a0-a9c3-6ad0d8518cf6" xlink:href="bvs-20230401.xsd#bvs_DeferredConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredConsiderationMember_da7572cb-0dba-48a0-a9c3-6ad0d8518cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJuly12023Member_61188dd5-e092-4b9d-9bb7-3bc4cf5423d7" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJuly12023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJuly12023Member_61188dd5-e092-4b9d-9bb7-3bc4cf5423d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableBySeptember12023Member_03c72138-733a-4ad5-bd51-58f070db35ac" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableBySeptember12023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableBySeptember12023Member_03c72138-733a-4ad5-bd51-58f070db35ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12025Member_7ceaeb29-f0d0-4b8b-9dcf-72b2d4edece3" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJanuary12025Member_7ceaeb29-f0d0-4b8b-9dcf-72b2d4edece3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12026Member_5668283c-f859-479a-88b8-8c8c5f8ce1e4" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJanuary12026Member_5668283c-f859-479a-88b8-8c8c5f8ce1e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12027Member_10c36f0e-5c2e-4133-9e94-cb145c2ec2b8" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJanuary12027Member_10c36f0e-5c2e-4133-9e94-cb145c2ec2b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember_9f96d431-6eb5-4562-8dc5-cae4999a4ddb" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountMember_9f96d431-6eb5-4562-8dc5-cae4999a4ddb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TrailingTwelveMonthSalesMember_c4ce8418-43ac-425d-85b6-559d8abf1560" xlink:href="bvs-20230401.xsd#bvs_TrailingTwelveMonthSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_TrailingTwelveMonthSalesMember_c4ce8418-43ac-425d-85b6-559d8abf1560" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6ec2d91b-61b5-4e31-93a9-ad08b21fe018_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:to="loc_us-gaap_ClassOfStockDomain_6ec2d91b-61b5-4e31-93a9-ad08b21fe018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_395378a8-5f59-41f8-8052-33687c5c89e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:to="loc_us-gaap_ClassOfStockDomain_395378a8-5f59-41f8-8052-33687c5c89e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_294b0a4d-a5a9-4b33-9e78-5a653f6fce44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_395378a8-5f59-41f8-8052-33687c5c89e0" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_294b0a4d-a5a9-4b33-9e78-5a653f6fce44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0baab463-e369-4a66-9206-a031fe2583c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0baab463-e369-4a66-9206-a031fe2583c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_98de652c-bf03-4ee8-854b-45798400aa67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_98de652c-bf03-4ee8-854b-45798400aa67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_95ae3ec3-ef1e-471b-9a2d-82f97637d868" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98de652c-bf03-4ee8-854b-45798400aa67" xlink:to="loc_bvs_CartiHealLtdMember_95ae3ec3-ef1e-471b-9a2d-82f97637d868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f86e2787-10db-4125-b44c-0d5dfa108124_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f86e2787-10db-4125-b44c-0d5dfa108124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_5882944b-c646-4100-a831-3bbe18a1ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:to="loc_us-gaap_CallOptionMember_5882944b-c646-4100-a831-3bbe18a1ca2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_2cc2f919-7293-4795-9375-542c059338c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:to="loc_us-gaap_PutOptionMember_2cc2f919-7293-4795-9375-542c059338c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f029246b-5c87-436f-8038-1eacda9e3323_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:to="loc_us-gaap_ReportingUnitDomain_f029246b-5c87-436f-8038-1eacda9e3323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:to="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2a2c5fcf-8cfe-4f94-ae19-634d277545ae" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:to="loc_country_US_2a2c5fcf-8cfe-4f94-ae19-634d277545ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalMember_02c70f2e-b764-44df-bb29-4953cb08b641" xlink:href="bvs-20230401.xsd#bvs_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:to="loc_bvs_InternationalMember_02c70f2e-b764-44df-bb29-4953cb08b641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cebd8f54-bb9c-4618-939f-81c586c854ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cebd8f54-bb9c-4618-939f-81c586c854ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_adebd1c9-a350-45b1-825b-c06cba045c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_adebd1c9-a350-45b1-825b-c06cba045c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d194cb8e-b97c-4649-aec6-99dfe3ccdfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_adebd1c9-a350-45b1-825b-c06cba045c5e" xlink:to="loc_us-gaap_LineOfCreditMember_d194cb8e-b97c-4649-aec6-99dfe3ccdfd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a344602c-b041-4b3a-9ff7-d6e7b2203fb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:to="loc_us-gaap_CreditFacilityDomain_a344602c-b041-4b3a-9ff7-d6e7b2203fb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dad9d32d-2159-40d5-a949-3c90423d6e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:to="loc_us-gaap_CreditFacilityDomain_dad9d32d-2159-40d5-a949-3c90423d6e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilityMember_13b6e21d-fb19-4c0c-b6d3-ace68a5fd3bf" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dad9d32d-2159-40d5-a949-3c90423d6e9a" xlink:to="loc_bvs_TermLoanFacilityMember_13b6e21d-fb19-4c0c-b6d3-ace68a5fd3bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24419cd5-3269-486d-860a-5c9361c27c2b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24419cd5-3269-486d-860a-5c9361c27c2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ElronMember_aaa71403-4130-4381-9608-810e9b58231d" xlink:href="bvs-20230401.xsd#bvs_ElronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:to="loc_bvs_ElronMember_aaa71403-4130-4381-9608-810e9b58231d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_c3b2467c-ed36-4635-a908-fae5b513dce5" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:to="loc_bvs_CartiHealLtdMember_c3b2467c-ed36-4635-a908-fae5b513dce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d339a383-6e55-4701-a9c2-e478ea660254_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d339a383-6e55-4701-a9c2-e478ea660254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b75759d3-4daf-4097-9e1a-84538b449c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b75759d3-4daf-4097-9e1a-84538b449c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember_d045bd83-f631-4326-aedc-ae9face8fb2e" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b75759d3-4daf-4097-9e1a-84538b449c0b" xlink:to="loc_bvs_WoundBusinessMember_d045bd83-f631-4326-aedc-ae9face8fb2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ef83d819-2920-44d3-999e-32221e331ab6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ef83d819-2920-44d3-999e-32221e331ab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_62260819-1545-40a3-b2bd-f12a76529190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_62260819-1545-40a3-b2bd-f12a76529190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4ce05736-d7db-44f2-804f-0c6b6d9ab56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_62260819-1545-40a3-b2bd-f12a76529190" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4ce05736-d7db-44f2-804f-0c6b6d9ab56b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80b5fb10-4981-4826-b957-cc807dc46005_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_80b5fb10-4981-4826-b957-cc807dc46005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b9b9efb-bc51-48a7-9c6f-bb15facdc124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b9b9efb-bc51-48a7-9c6f-bb15facdc124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5a2d4278-3ee2-46d5-8d33-a459dda12955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b9b9efb-bc51-48a7-9c6f-bb15facdc124" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5a2d4278-3ee2-46d5-8d33-a459dda12955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_990f9ac1-724b-46ae-b4e8-9be6c4db98b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_990f9ac1-724b-46ae-b4e8-9be6c4db98b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d1280990-7663-4c99-9e3d-b4f0510d7a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d1280990-7663-4c99-9e3d-b4f0510d7a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cacf80a3-145a-4580-96dd-a8af4550346e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d1280990-7663-4c99-9e3d-b4f0510d7a14" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cacf80a3-145a-4580-96dd-a8af4550346e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails" xlink:type="extended" id="id1df2f4b67b44071821eac92af223f15_AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9cb74bbc-7bb2-463d-9387-8d78b04b5d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9cb74bbc-7bb2-463d-9387-8d78b04b5d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_9a34aa4c-7d05-4238-960d-b2fdf39f064e" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_9a34aa4c-7d05-4238-960d-b2fdf39f064e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0375407a-ddbb-4f06-85fb-51ff69cc5cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0375407a-ddbb-4f06-85fb-51ff69cc5cfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_6a31c805-fd6d-4329-a89f-91ca9c988cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_6a31c805-fd6d-4329-a89f-91ca9c988cbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_d2f4365c-ffbe-43bc-96b2-8f242c741b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_d2f4365c-ffbe-43bc-96b2-8f242c741b28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_621d93b8-6e4b-4498-8ac8-f7ada9252cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_621d93b8-6e4b-4498-8ac8-f7ada9252cf7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_f11f7079-8911-48bd-8572-58cf8ccb5001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_f11f7079-8911-48bd-8572-58cf8ccb5001" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8aa1c663-8b82-488a-be21-857597d5195c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8aa1c663-8b82-488a-be21-857597d5195c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2e595e13-fb55-4ddf-ac6e-24537b3aab15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2e595e13-fb55-4ddf-ac6e-24537b3aab15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c8cb2acc-454c-4869-99ba-3cb0f9497910_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c8cb2acc-454c-4869-99ba-3cb0f9497910_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_564516a7-a105-4e2d-9d9a-0b9354b6a0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_564516a7-a105-4e2d-9d9a-0b9354b6a0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_03e3326e-340b-45bc-bf11-244e2d7c56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_564516a7-a105-4e2d-9d9a-0b9354b6a0c6" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_03e3326e-340b-45bc-bf11-244e2d7c56a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23cc7607-29bb-40c2-b630-d6680fd7121e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23cc7607-29bb-40c2-b630-d6680fd7121e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9be20105-08f1-40d9-9369-7ae86b03b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9be20105-08f1-40d9-9369-7ae86b03b58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember_f4cb9355-07d0-4927-8337-2b4409c8fb3c" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9be20105-08f1-40d9-9369-7ae86b03b58a" xlink:to="loc_bvs_WoundBusinessMember_f4cb9355-07d0-4927-8337-2b4409c8fb3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="extended" id="if23ec2c569654d679d8b139277d3d0f3_AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_104dd900-e292-48ee-b6a4-9efb81a668a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_104dd900-e292-48ee-b6a4-9efb81a668a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_54d01d38-555a-4997-a611-305d125eb2ca" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_54d01d38-555a-4997-a611-305d125eb2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_d4152d27-63a9-4825-a3f4-3c09af74e3da" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_d4152d27-63a9-4825-a3f4-3c09af74e3da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_183c1c9e-2f84-4a2d-8fb7-8361d7408266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_183c1c9e-2f84-4a2d-8fb7-8361d7408266" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fcfda642-de38-4bf0-863f-f1839de7933f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fcfda642-de38-4bf0-863f-f1839de7933f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_c7ac22d0-7950-4669-897f-36530c575bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_c7ac22d0-7950-4669-897f-36530c575bad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_065e7e42-5a81-4db5-b2b6-5f01c428f65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_065e7e42-5a81-4db5-b2b6-5f01c428f65d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_62faa69a-edf7-4359-81b3-379ac7910891" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_62faa69a-edf7-4359-81b3-379ac7910891" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1229ebd5-38c6-42ba-a0aa-d8b25ad4e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1229ebd5-38c6-42ba-a0aa-d8b25ad4e42b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16f78e07-66d1-41cc-95ec-5adda82433ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16f78e07-66d1-41cc-95ec-5adda82433ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_1114824f-ef05-460e-b211-3c904cc1d723" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16f78e07-66d1-41cc-95ec-5adda82433ee" xlink:to="loc_bvs_CartiHealLtdMember_1114824f-ef05-460e-b211-3c904cc1d723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_eb7b8812-07cc-4b18-8048-f5c060ebb5a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_eb7b8812-07cc-4b18-8048-f5c060ebb5a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember_58b04245-6793-4593-90f7-93246fc4f331" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:to="loc_bvs_DeferredAmountMember_58b04245-6793-4593-90f7-93246fc4f331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember_0deb2ff6-4738-4ed6-9b75-5c5f819bfdd6" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:to="loc_bvs_SalesMilestoneMember_0deb2ff6-4738-4ed6-9b75-5c5f819bfdd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d04ac619-8a08-4362-8216-fedb4c47d254" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d04ac619-8a08-4362-8216-fedb4c47d254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_2e2d1696-6583-47c6-a53d-e79c9f591920" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d04ac619-8a08-4362-8216-fedb4c47d254" xlink:to="loc_bvs_CartiHealLtdMember_2e2d1696-6583-47c6-a53d-e79c9f591920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fae33807-3aa9-4d80-886c-8486ed707ccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fae33807-3aa9-4d80-886c-8486ed707ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_52324afe-e4a4-454b-84b5-2fc14e7d9ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_52324afe-e4a4-454b-84b5-2fc14e7d9ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c48789e1-e68a-4f21-8f34-aab0d9ea3a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_52324afe-e4a4-454b-84b5-2fc14e7d9ba5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c48789e1-e68a-4f21-8f34-aab0d9ea3a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4ea44c2-ebbd-4ec6-a366-24c5ae2a242f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c48789e1-e68a-4f21-8f34-aab0d9ea3a95" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4ea44c2-ebbd-4ec6-a366-24c5ae2a242f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="iee04db09cfb54c82b7dc9f159c73920f_AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d7fef26d-a94c-41e3-8bec-7ae6ed7509f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d7fef26d-a94c-41e3-8bec-7ae6ed7509f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5d5b60b6-d39c-412e-8545-509b51ba96a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5d5b60b6-d39c-412e-8545-509b51ba96a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_dc0edff3-84a0-45dd-8524-b36825470715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_dc0edff3-84a0-45dd-8524-b36825470715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0599df1-3d36-4bcd-89ae-4706643175df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0599df1-3d36-4bcd-89ae-4706643175df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_302cf1bd-fdba-4a6e-9563-6d24cce124e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_302cf1bd-fdba-4a6e-9563-6d24cce124e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c418c369-e5e2-492a-878c-8d9152a8bafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c418c369-e5e2-492a-878c-8d9152a8bafb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_8bfb3770-60d2-41d7-bd89-bcf1efb2ab6c" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_8bfb3770-60d2-41d7-bd89-bcf1efb2ab6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9f6a904c-4f18-4548-a58e-cefb4dcd032b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9f6a904c-4f18-4548-a58e-cefb4dcd032b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_b00f57fc-8d9a-4996-8179-b7b07f71359e" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_b00f57fc-8d9a-4996-8179-b7b07f71359e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_35f7a086-5f9a-4180-867a-644912f8251c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_35f7a086-5f9a-4180-867a-644912f8251c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f88a9e50-a08d-4361-b987-4f1ea1f3b636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f88a9e50-a08d-4361-b987-4f1ea1f3b636" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_13fcbc01-7dce-4597-998f-03f804882147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_13fcbc01-7dce-4597-998f-03f804882147" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_83eba4c5-b8a8-4f0f-8f72-502bf2541d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_83eba4c5-b8a8-4f0f-8f72-502bf2541d83" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a4d2fbe-125c-4d76-8381-898cdd7d29a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_Goodwill_9a4d2fbe-125c-4d76-8381-898cdd7d29a9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fba4a236-5ac1-428e-943a-42817df4fa1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fba4a236-5ac1-428e-943a-42817df4fa1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6331f135-93a8-476d-a1f3-2dac9730ea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6331f135-93a8-476d-a1f3-2dac9730ea7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_2246a24e-68d3-4482-90fd-9598cc6fa177" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6331f135-93a8-476d-a1f3-2dac9730ea7b" xlink:to="loc_bvs_CartiHealLtdMember_2246a24e-68d3-4482-90fd-9598cc6fa177" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="extended" id="i18574444e9ea4198bb0c41440bdaf31b_AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0ab66f7-f6ca-49c8-b4e0-b7ac769f9862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0ab66f7-f6ca-49c8-b4e0-b7ac769f9862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bad28c2b-a2bb-4d92-9918-97bda01abd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bad28c2b-a2bb-4d92-9918-97bda01abd6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7687f5bf-4534-4860-839b-3b616e312f39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7687f5bf-4534-4860-839b-3b616e312f39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d11dba37-605c-43c5-b4ec-5b1391a9f962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d11dba37-605c-43c5-b4ec-5b1391a9f962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_87c3e500-a9a1-44fa-b0a7-d81a17cb8181" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d11dba37-605c-43c5-b4ec-5b1391a9f962" xlink:to="loc_bvs_CartiHealLtdMember_87c3e500-a9a1-44fa-b0a7-d81a17cb8181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f631e13-a5de-48f5-ab2a-4fa6418191bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f631e13-a5de-48f5-ab2a-4fa6418191bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36c45f83-a629-45ac-b8ba-9c35723ace5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36c45f83-a629-45ac-b8ba-9c35723ace5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_ff257915-9197-4343-bf78-d1af507578cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36c45f83-a629-45ac-b8ba-9c35723ace5a" xlink:to="loc_us-gaap_IntellectualPropertyMember_ff257915-9197-4343-bf78-d1af507578cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:to="loc_us-gaap_SegmentDomain_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:to="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_USSegmentMember_415f3700-11fb-4a99-b109-f144c1068dd6" xlink:href="bvs-20230401.xsd#bvs_USSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:to="loc_bvs_USSegmentMember_415f3700-11fb-4a99-b109-f144c1068dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalSegmentMember_c24c7340-00d2-41af-a562-77eeeb307b63" xlink:href="bvs-20230401.xsd#bvs_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:to="loc_bvs_InternationalSegmentMember_c24c7340-00d2-41af-a562-77eeeb307b63" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" xlink:type="extended" id="if6824ca944da450ab57231b2558d0a61_FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3936b0e1-5f38-45de-8920-0f61c7d2173d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3936b0e1-5f38-45de-8920-0f61c7d2173d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c0036dea-144f-4d80-af43-59e08473b044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_LongTermDebtCurrent_c0036dea-144f-4d80-af43-59e08473b044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a84d4039-4ff9-4fa1-82ed-dda942a2b230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a84d4039-4ff9-4fa1-82ed-dda942a2b230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e04a13b-f317-447f-a71b-13959cafaeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e04a13b-f317-447f-a71b-13959cafaeba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_69143585-55cf-4fde-9d97-c32c3dc7c152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_69143585-55cf-4fde-9d97-c32c3dc7c152" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_56f46bbe-f3f1-4bcf-83e2-27f0968dc831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_56f46bbe-f3f1-4bcf-83e2-27f0968dc831" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e363135-94cf-4512-b4a5-6faaa1076874_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e363135-94cf-4512-b4a5-6faaa1076874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b28c2881-f076-4571-babc-1cd50184ccdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b28c2881-f076-4571-babc-1cd50184ccdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember_a0c2ca27-89c2-4eb3-a3b5-cd23ad6901eb" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b28c2881-f076-4571-babc-1cd50184ccdd" xlink:to="loc_bvs_TermLoanMember_a0c2ca27-89c2-4eb3-a3b5-cd23ad6901eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:to="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0dc2fe59-738f-4843-bee0-f1c60c88395f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:to="loc_us-gaap_CreditFacilityDomain_0dc2fe59-738f-4843-bee0-f1c60c88395f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_33681d16-8f96-47a8-8044-6f247325d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:to="loc_us-gaap_CreditFacilityDomain_33681d16-8f96-47a8-8044-6f247325d99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_95cc6e02-cb77-43d6-9845-ce779031a547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_33681d16-8f96-47a8-8044-6f247325d99b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_95cc6e02-cb77-43d6-9845-ce779031a547" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FinancialinstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" xlink:type="extended" id="id101af6f04dc438da19bef37da18faf2_FinancialinstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_873a80ca-bd33-45b7-b653-261684122016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_873a80ca-bd33-45b7-b653-261684122016" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7521e84-8d15-4a64-b4ec-17f202c0e07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7521e84-8d15-4a64-b4ec-17f202c0e07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_32884ed7-e85b-4290-a8c5-1108476db6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_32884ed7-e85b-4290-a8c5-1108476db6d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DebtInstrumentCovenantLiquidityMinimum_3e72670a-b60c-41c8-a4c1-af2f63026330" xlink:href="bvs-20230401.xsd#bvs_DebtInstrumentCovenantLiquidityMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_bvs_DebtInstrumentCovenantLiquidityMinimum_3e72670a-b60c-41c8-a4c1-af2f63026330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9775be0b-2bfb-401f-8d5f-04c2c5cc342d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9775be0b-2bfb-401f-8d5f-04c2c5cc342d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_b07a9df8-34f9-4330-a7a9-eeeb8df122b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_b07a9df8-34f9-4330-a7a9-eeeb8df122b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_74dfd529-a835-44dd-8b1c-f58264d2b310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_74dfd529-a835-44dd-8b1c-f58264d2b310" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0f2bc4fa-9669-4c4a-8df2-819000a6eb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0f2bc4fa-9669-4c4a-8df2-819000a6eb8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_945b6009-2380-4871-a01d-5a8fad8141db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LongTermDebt_945b6009-2380-4871-a01d-5a8fad8141db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_801ba618-80ed-414b-8206-dc079b365d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_801ba618-80ed-414b-8206-dc079b365d8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ae35e4f8-aa2d-499d-9a84-f82f9ef30fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_InterestExpenseDebt_ae35e4f8-aa2d-499d-9a84-f82f9ef30fdd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_c76cade2-2025-4bfb-8028-34b1c37de7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LineOfCredit_c76cade2-2025-4bfb-8028-34b1c37de7b1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e37a4db9-11e5-4673-9bd1-71ebe29d9e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LongTermDebtFairValue_e37a4db9-11e5-4673-9bd1-71ebe29d9e13" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_3c99fcc3-74cb-448c-b429-5451e5aea031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_3c99fcc3-74cb-448c-b429-5451e5aea031" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCashReceivedOnHedge_44df850e-16d0-4dc3-93fa-2fe1464cec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCashReceivedOnHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DerivativeCashReceivedOnHedge_44df850e-16d0-4dc3-93fa-2fe1464cec3a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_cc22f2cb-f1b5-441f-8580-a7643d79d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_cc22f2cb-f1b5-441f-8580-a7643d79d7b1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_24eed4f1-72c1-4095-a212-9a75d431d948_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:to="loc_us-gaap_CreditFacilityDomain_24eed4f1-72c1-4095-a212-9a75d431d948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_75338ea3-d1f6-44fc-8299-76a17c49f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:to="loc_us-gaap_CreditFacilityDomain_75338ea3-d1f6-44fc-8299-76a17c49f245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_330e5809-95d9-453c-8e70-e58fc2d68834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_75338ea3-d1f6-44fc-8299-76a17c49f245" xlink:to="loc_us-gaap_LineOfCreditMember_330e5809-95d9-453c-8e70-e58fc2d68834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_93d81695-7a18-4830-815b-3009f905a484_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_93d81695-7a18-4830-815b-3009f905a484_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d60c1213-0395-4ed4-976b-dd372875f04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d60c1213-0395-4ed4-976b-dd372875f04d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember_70dcb33b-94aa-451d-92fd-582c64a0614f" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:to="loc_bvs_TermLoanMember_70dcb33b-94aa-451d-92fd-582c64a0614f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f079755b-7e7f-496f-a5a6-da9c62e74201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:to="loc_us-gaap_SecuredDebtMember_f079755b-7e7f-496f-a5a6-da9c62e74201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a852a99c-1239-44d1-ae8c-8dfd85467ace_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a852a99c-1239-44d1-ae8c-8dfd85467ace_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f421a87b-05d5-412d-8d8b-5a3685ed8a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f421a87b-05d5-412d-8d8b-5a3685ed8a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11699b84-6813-45db-b5d0-af16b813cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f421a87b-05d5-412d-8d8b-5a3685ed8a98" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11699b84-6813-45db-b5d0-af16b813cafa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_424d0402-75d3-49a4-967e-14c458ff20db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_424d0402-75d3-49a4-967e-14c458ff20db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b508709f-1b27-432a-9692-a9ad15850204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b508709f-1b27-432a-9692-a9ad15850204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fb21a731-a4cd-4453-b87f-dcafad940215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b508709f-1b27-432a-9692-a9ad15850204" xlink:to="loc_us-gaap_InterestRateSwapMember_fb21a731-a4cd-4453-b87f-dcafad940215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1382918c-bcf0-4b2b-85e8-b0f4956d6497_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1382918c-bcf0-4b2b-85e8-b0f4956d6497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilityJuly2022Member_92b230c1-eb12-4da5-80c2-dd7c56f97132" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilityJuly2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:to="loc_bvs_TermLoanFacilityJuly2022Member_92b230c1-eb12-4da5-80c2-dd7c56f97132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilitiesMember_7f0ef33b-7a92-4d7f-b947-00e936aea7d6" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:to="loc_bvs_TermLoanFacilitiesMember_7f0ef33b-7a92-4d7f-b947-00e936aea7d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember_b07d968e-ed94-4b62-a389-b3762863b6aa" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:to="loc_bvs_TermLoanMember_b07d968e-ed94-4b62-a389-b3762863b6aa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="ib7c3192a7f84437aa3578c83b3915ccd_FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8604809c-76fc-4448-8161-5986d160a9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8604809c-76fc-4448-8161-5986d160a9a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b868252a-4fef-42eb-834a-2faea996bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b868252a-4fef-42eb-834a-2faea996bcd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e111c595-f5df-4c41-bce1-b940b68189e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e111c595-f5df-4c41-bce1-b940b68189e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5ee53dde-87ba-4d58-8e47-45eb0c911adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5ee53dde-87ba-4d58-8e47-45eb0c911adb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f009a189-7d94-479d-a6f6-c441936e1a28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f009a189-7d94-479d-a6f6-c441936e1a28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7f3b580-32d0-4d99-81d7-50c353fd64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7f3b580-32d0-4d99-81d7-50c353fd64b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5c00df53-8af7-4ff6-a164-3ab3eb74ffda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7f3b580-32d0-4d99-81d7-50c353fd64b4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5c00df53-8af7-4ff6-a164-3ab3eb74ffda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f84c0cf-b06b-441e-baf1-1a13d4211d5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f84c0cf-b06b-441e-baf1-1a13d4211d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8d7a3529-808c-4f53-8cba-0c4c4f885668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8d7a3529-808c-4f53-8cba-0c4c4f885668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ad95b571-25b6-47ae-9689-46cc2e067677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ad95b571-25b6-47ae-9689-46cc2e067677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01a9ffdf-8695-4d1e-a442-85060a52acba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01a9ffdf-8695-4d1e-a442-85060a52acba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_b3306708-0494-44d3-90df-55b042e70df1" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:to="loc_bvs_CartiHealLtdMember_b3306708-0494-44d3-90df-55b042e70df1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_b7cfdf52-d49c-436d-aede-61b8b7d4e608" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:to="loc_bvs_BionessIncMember_b7cfdf52-d49c-436d-aede-61b8b7d4e608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember_067b755f-95ff-438d-a39f-972937784fc7" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:to="loc_bvs_DeferredAmountMember_067b755f-95ff-438d-a39f-972937784fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember_c790b278-68be-42cd-9174-e746ccdd2603" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:to="loc_bvs_SalesMilestoneMember_c790b278-68be-42cd-9174-e746ccdd2603" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended" id="ie91f4c01e88841e885e1a911fb6721e5_FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f3ad5c53-7cb7-4d7b-9bba-b4afb0ef12c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_dd46474c-29ec-4f51-a81b-51d04a2aa0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3ad5c53-7cb7-4d7b-9bba-b4afb0ef12c1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_dd46474c-29ec-4f51-a81b-51d04a2aa0d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3ad5c53-7cb7-4d7b-9bba-b4afb0ef12c1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b1a22eb4-67b3-49af-8dc3-91d7702a3c33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b1a22eb4-67b3-49af-8dc3-91d7702a3c33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d053ad-7ba5-46db-a0c8-e32e9028013d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d053ad-7ba5-46db-a0c8-e32e9028013d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_04963b8f-93d1-40f6-a35c-e7706565b19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d053ad-7ba5-46db-a0c8-e32e9028013d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_04963b8f-93d1-40f6-a35c-e7706565b19c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbb6438a-f851-4bcc-81a9-47dcba0e1e16_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:to="loc_srt_RangeMember_cbb6438a-f851-4bcc-81a9-47dcba0e1e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:to="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_590d955c-7c56-4aa3-a59d-2bac32e5b5e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:to="loc_srt_MinimumMember_590d955c-7c56-4aa3-a59d-2bac32e5b5e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_483359fc-49b6-4955-9e2f-0d48ff8a37ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:to="loc_srt_MaximumMember_483359fc-49b6-4955-9e2f-0d48ff8a37ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_bf355da0-99de-494e-aac6-a5f3b2c05c3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_bf355da0-99de-494e-aac6-a5f3b2c05c3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d94e1a70-635a-4b8a-a2e5-f35508a9c2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d94e1a70-635a-4b8a-a2e5-f35508a9c2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_346cde56-2c7f-4b83-b872-0295fc36ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_d94e1a70-635a-4b8a-a2e5-f35508a9c2b2" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_346cde56-2c7f-4b83-b872-0295fc36ec95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_67ae19d2-6102-4858-b389-3a723db9160f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_67ae19d2-6102-4858-b389-3a723db9160f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0f9441ed-ebfd-4687-83a3-3853a430dfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0f9441ed-ebfd-4687-83a3-3853a430dfd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_13439e37-fcc3-4f88-8125-db203bc0f73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0f9441ed-ebfd-4687-83a3-3853a430dfd8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_13439e37-fcc3-4f88-8125-db203bc0f73a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf37e618-3cfc-440d-ba3f-66c754e81042_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf37e618-3cfc-440d-ba3f-66c754e81042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b413cbb-b5f3-4feb-804f-6750ef362731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b413cbb-b5f3-4feb-804f-6750ef362731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_0fddc5f9-476a-4f5b-96bd-1c9e8aa8ceb1" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b413cbb-b5f3-4feb-804f-6750ef362731" xlink:to="loc_bvs_BionessIncMember_0fddc5f9-476a-4f5b-96bd-1c9e8aa8ceb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended" id="ic1cc1490ffa140dca6da646a17ffbd96_FairvaluemeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_153cdd02-a4b4-491f-83fe-7f41826476e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_153cdd02-a4b4-491f-83fe-7f41826476e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_1e377b8d-f7c9-4ad0-92a8-8240659c7878" xlink:href="bvs-20230401.xsd#bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:to="loc_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_1e377b8d-f7c9-4ad0-92a8-8240659c7878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_15e27372-7c91-4a60-8451-3b1b011839a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_15e27372-7c91-4a60-8451-3b1b011839a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_b8363da2-2ac0-41ef-b809-978264e230fe" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:to="loc_bvs_BionessIncMember_b8363da2-2ac0-41ef-b809-978264e230fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember_abd098d7-ce4c-450e-ae48-dcbffa7c5a37" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:to="loc_bvs_CartiHealMember_abd098d7-ce4c-450e-ae48-dcbffa7c5a37" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" xlink:type="extended" id="i78f9d52842da4146b9ab96c1474c1be8_EquitybasedcompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a453263e-90e4-4697-afeb-6f69e3a44804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a453263e-90e4-4697-afeb-6f69e3a44804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c503af97-6e14-439a-9d3f-bb3239df13c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c503af97-6e14-439a-9d3f-bb3239df13c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9a7d60a2-186a-482d-a82e-84356dd77c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9a7d60a2-186a-482d-a82e-84356dd77c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1823d419-3d0f-4293-be4d-acc4ea332587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1823d419-3d0f-4293-be4d-acc4ea332587" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dcfc05c-3c04-4c2c-a8ea-a2ccfd25d701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dcfc05c-3c04-4c2c-a8ea-a2ccfd25d701" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a9e4c258-6b96-419e-9b56-54ef77d98fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a9e4c258-6b96-419e-9b56-54ef77d98fd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7890e5a6-32e8-47d3-97a7-6d6eb12d81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7890e5a6-32e8-47d3-97a7-6d6eb12d81f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e065f69-95d1-4276-89f6-359a51f670a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e065f69-95d1-4276-89f6-359a51f670a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59bf0907-8a30-4b79-b947-7f534dbefb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59bf0907-8a30-4b79-b947-7f534dbefb58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_477e109b-7870-45ca-a88a-ce8cf1de8840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_477e109b-7870-45ca-a88a-ce8cf1de8840" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_dea6cd97-6310-4806-9e87-c962df379340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_SharePrice_dea6cd97-6310-4806-9e87-c962df379340" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d3cb1c9f-7870-4473-9173-9f4f0957ff85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d3cb1c9f-7870-4473-9173-9f4f0957ff85" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33163832-0477-4e24-ad12-b5ceb3c72ffc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33163832-0477-4e24-ad12-b5ceb3c72ffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e472eea6-8b32-492d-811b-82a03ff6b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e472eea6-8b32-492d-811b-82a03ff6b1c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f2bf355c-ef96-42ca-8c35-705d4290574d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f2bf355c-ef96-42ca-8c35-705d4290574d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f3ee4da2-858c-418f-b2ec-65736fc697ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:to="loc_us-gaap_EmployeeStockMember_f3ee4da2-858c-418f-b2ec-65736fc697ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_43ec56de-85ed-406d-91a1-cb871f79629a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:to="loc_us-gaap_ClassOfStockDomain_43ec56de-85ed-406d-91a1-cb871f79629a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_27d6cd7a-9831-45f9-8afb-e30401e16298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:to="loc_us-gaap_ClassOfStockDomain_27d6cd7a-9831-45f9-8afb-e30401e16298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_aee49f6c-486a-4073-aba6-3b5e0d4a320e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_27d6cd7a-9831-45f9-8afb-e30401e16298" xlink:to="loc_us-gaap_CommonClassAMember_aee49f6c-486a-4073-aba6-3b5e0d4a320e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8fcee3c4-f743-418a-9bba-8cbeb942977a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:to="loc_us-gaap_PlanNameDomain_8fcee3c4-f743-418a-9bba-8cbeb942977a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_786c7e05-f9cb-49d2-ab98-c66a2c191e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:to="loc_us-gaap_PlanNameDomain_786c7e05-f9cb-49d2-ab98-c66a2c191e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_A2021PlanMember_0f7c2ac4-9d96-4b2f-8144-c4220896b65f" xlink:href="bvs-20230401.xsd#bvs_A2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_786c7e05-f9cb-49d2-ab98-c66a2c191e47" xlink:to="loc_bvs_A2021PlanMember_0f7c2ac4-9d96-4b2f-8144-c4220896b65f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_304c32e1-d165-421b-bc6c-af66a7e33031_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:to="loc_srt_RangeMember_304c32e1-d165-421b-bc6c-af66a7e33031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:to="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1dbc9afa-84e1-40dc-a9d8-dd7aed615aed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:to="loc_srt_MinimumMember_1dbc9afa-84e1-40dc-a9d8-dd7aed615aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86662c9a-e698-4f2a-93f0-fda05397384c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:to="loc_srt_MaximumMember_86662c9a-e698-4f2a-93f0-fda05397384c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" xlink:type="extended" id="idc7d3a0781714bbea924caf9334604b5_EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_964299ec-edce-4a57-b4fd-7bd623c46b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_964299ec-edce-4a57-b4fd-7bd623c46b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d491350b-ae71-4c24-927d-a3fb5fa0bf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d491350b-ae71-4c24-927d-a3fb5fa0bf19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_35e8b481-561c-4250-8eab-025e49a973bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_35e8b481-561c-4250-8eab-025e49a973bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7073d8-89c9-492b-b658-f0335426534a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7073d8-89c9-492b-b658-f0335426534a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58a813a7-cf70-4853-839b-88b951f226ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75eb6c8f-431d-48ea-91f8-d7a64f24210c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75eb6c8f-431d-48ea-91f8-d7a64f24210c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e167b1d9-dc2d-4162-9e53-6422a92ece0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e167b1d9-dc2d-4162-9e53-6422a92ece0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cacd8f8d-44b2-40be-abce-672c6a06e955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cacd8f8d-44b2-40be-abce-672c6a06e955" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_69284753-1396-4e40-ab3e-31b3d1ae0bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_69284753-1396-4e40-ab3e-31b3d1ae0bb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e4a4b30-d510-4e70-b2a4-7d2175dbe7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:to="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e58b6f75-7e01-4cb9-9016-e7acd896a478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e58b6f75-7e01-4cb9-9016-e7acd896a478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ef6d9f9-b112-4052-9946-70c2def6e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ef6d9f9-b112-4052-9946-70c2def6e59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec0b4ceb-755c-442d-8075-cdbb367ac39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ef6d9f9-b112-4052-9946-70c2def6e59e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec0b4ceb-755c-442d-8075-cdbb367ac39a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended" id="i6d1c61a54b60450099eeda8b0393f383_EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f185f182-3b32-4981-aef1-ca394dd79e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f185f182-3b32-4981-aef1-ca394dd79e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_38889b3b-f217-46d4-9b15-43fbee93193c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_38889b3b-f217-46d4-9b15-43fbee93193c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b4c2924c-96a1-41ec-bef4-960e67e943e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b4c2924c-96a1-41ec-bef4-960e67e943e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a98b3f-e645-44e6-b746-5149daec35ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a98b3f-e645-44e6-b746-5149daec35ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:to="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d24eb85-062f-4209-9eb2-360d3b7c3d0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d24eb85-062f-4209-9eb2-360d3b7c3d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d18e2f2-28bd-4976-b0da-412831a7ff1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d18e2f2-28bd-4976-b0da-412831a7ff1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_622d5b3c-cb8b-41b0-8c68-4afbc94b8d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d18e2f2-28bd-4976-b0da-412831a7ff1f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_622d5b3c-cb8b-41b0-8c68-4afbc94b8d27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:to="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61cbf87f-29c6-4fa1-b251-0305bc364893_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:to="loc_srt_RangeMember_61cbf87f-29c6-4fa1-b251-0305bc364893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1e148d7-0372-4adc-a91f-af8169ad6b37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:to="loc_srt_RangeMember_e1e148d7-0372-4adc-a91f-af8169ad6b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ec367bca-de86-4ecf-9308-274a22065302" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1e148d7-0372-4adc-a91f-af8169ad6b37" xlink:to="loc_srt_MaximumMember_ec367bca-de86-4ecf-9308-274a22065302" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/StockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#StockholdersequityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/StockholdersequityNarrativeDetails" xlink:type="extended" id="i8aed52d7c8a1463aa814b3f9eeabbf96_StockholdersequityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_023733a7-d2cb-4781-9ca9-7fc9104d8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_023733a7-d2cb-4781-9ca9-7fc9104d8c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_14f9f58b-9fe3-4f59-8175-fb3a6b8d0ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_14f9f58b-9fe3-4f59-8175-fb3a6b8d0ee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_b389d267-b213-4eda-aaa8-bec0d2e75d65" xlink:href="bvs-20230401.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_b389d267-b213-4eda-aaa8-bec0d2e75d65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_4dc39980-aff2-4e54-8540-118aa71e3e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_4dc39980-aff2-4e54-8540-118aa71e3e8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e9aaf204-c7ed-4fea-889a-8e4c5fda3172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e9aaf204-c7ed-4fea-889a-8e4c5fda3172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_869141b2-a90e-4b43-8474-7b3e71bccacf" xlink:href="bvs-20230401.xsd#bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_869141b2-a90e-4b43-8474-7b3e71bccacf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b779f73e-2af9-47ef-aeb6-7ca271e2721e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b779f73e-2af9-47ef-aeb6-7ca271e2721e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1c0f2ce1-25de-4215-a217-f516cc376a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1c0f2ce1-25de-4215-a217-f516cc376a9a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_84324205-efdf-47fb-aa61-40ccb7955187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_84324205-efdf-47fb-aa61-40ccb7955187" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d9d193d8-51bf-4175-a387-f875ed2f42af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d9d193d8-51bf-4175-a387-f875ed2f42af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BoardOfDirectorLengthOfTerm_5c40f0f9-cfc0-426a-892a-3e67bc5555fd" xlink:href="bvs-20230401.xsd#bvs_BoardOfDirectorLengthOfTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_BoardOfDirectorLengthOfTerm_5c40f0f9-cfc0-426a-892a-3e67bc5555fd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CommonStockNumberOfVotes_3d6a1d7d-5aa6-4c28-a6f3-22f6908701fb" xlink:href="bvs-20230401.xsd#bvs_CommonStockNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_CommonStockNumberOfVotes_3d6a1d7d-5aa6-4c28-a6f3-22f6908701fb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_772c526b-14fc-4f47-b5b3-77b2bfb87157" xlink:href="bvs-20230401.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_772c526b-14fc-4f47-b5b3-77b2bfb87157" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_9ab8f1be-43bd-4b83-9a72-42400afe3e32" xlink:href="bvs-20230401.xsd#bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_9ab8f1be-43bd-4b83-9a72-42400afe3e32" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0382414e-62c0-4e81-a44a-4d3513157c61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:to="loc_us-gaap_ClassOfStockDomain_0382414e-62c0-4e81-a44a-4d3513157c61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:to="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_57910f1c-f31b-4943-9d9c-ac2292df88ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:to="loc_us-gaap_CommonClassAMember_57910f1c-f31b-4943-9d9c-ac2292df88ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_67cca2bc-cc6d-4a9c-94d7-a480af968729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:to="loc_us-gaap_CommonClassBMember_67cca2bc-cc6d-4a9c-94d7-a480af968729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PublicOfferingMember_8a5548d6-2991-4529-b567-95d05a2d0b0a" xlink:href="bvs-20230401.xsd#bvs_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:to="loc_bvs_PublicOfferingMember_8a5548d6-2991-4529-b567-95d05a2d0b0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_f7b630a1-eacd-47be-8234-adb9f33ed964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:to="loc_us-gaap_OverAllotmentOptionMember_f7b630a1-eacd-47be-8234-adb9f33ed964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57a6adb2-318c-471b-aabc-4c3eb85172d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57a6adb2-318c-471b-aabc-4c3eb85172d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a19aeab8-9495-46e0-a897-b7b5ea0f2c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a19aeab8-9495-46e0-a897-b7b5ea0f2c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_5ef7b605-4289-4b80-83c1-b852440dab75" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a19aeab8-9495-46e0-a897-b7b5ea0f2c54" xlink:to="loc_bvs_BVLLCMember_5ef7b605-4289-4b80-83c1-b852440dab75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0301f359-b5b3-4385-b8fa-534ea338e1a2_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:to="loc_dei_EntityDomain_0301f359-b5b3-4385-b8fa-534ea338e1a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa06c0fe-cc85-481b-bcf1-db078bd2e686" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:to="loc_dei_EntityDomain_fa06c0fe-cc85-481b-bcf1-db078bd2e686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_6e93eedb-902f-42ba-b0cc-e2ca5cd7c60e" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fa06c0fe-cc85-481b-bcf1-db078bd2e686" xlink:to="loc_bvs_BVLLCMember_6e93eedb-902f-42ba-b0cc-e2ca5cd7c60e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#StockholdersequityScheduleofOtherOwnershipInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" xlink:type="extended" id="i75089a0ac2424a79a0df56e7e45262e6_StockholdersequityScheduleofOtherOwnershipInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest_e0898988-989c-421c-84c9-b89f55d1b244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest_e0898988-989c-421c-84c9-b89f55d1b244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f1464ee3-d2f3-4c82-abdc-d89b137e18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f1464ee3-d2f3-4c82-abdc-d89b137e18d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:to="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7c8233d2-8fcb-4197-83f8-77d88a0d53a1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:to="loc_srt_OwnershipDomain_7c8233d2-8fcb-4197-83f8-77d88a0d53a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b8698f3f-a9c7-45d9-b38f-e2de42fea3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:to="loc_srt_OwnershipDomain_b8698f3f-a9c7-45d9-b38f-e2de42fea3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_e33a76fb-b233-4d4e-ae96-63f1d95c0a6f" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b8698f3f-a9c7-45d9-b38f-e2de42fea3a4" xlink:to="loc_bvs_BVLLCMember_e33a76fb-b233-4d4e-ae96-63f1d95c0a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:to="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_38fad76a-e4da-43af-bfce-c2dcab26db7f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:to="loc_dei_EntityDomain_38fad76a-e4da-43af-bfce-c2dcab26db7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:to="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ContinuingLLCOwnerMember_1dc8a507-f956-4b6f-8a21-94d574addd08" xlink:href="bvs-20230401.xsd#bvs_ContinuingLLCOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:to="loc_bvs_ContinuingLLCOwnerMember_1dc8a507-f956-4b6f-8a21-94d574addd08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BioventusAndContinuingLLCOwnerMember_3f962753-8606-420c-a9e8-bcd5b7efade5" xlink:href="bvs-20230401.xsd#bvs_BioventusAndContinuingLLCOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:to="loc_bvs_BioventusAndContinuingLLCOwnerMember_3f962753-8606-420c-a9e8-bcd5b7efade5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EarningspershareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="id744ac3772e44114a0eeb4243979c509_EarningspershareScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e86ccc98-3604-4a29-ad79-9c69577b7064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478fe33c-81cd-463c-a679-8346bf25b31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e86ccc98-3604-4a29-ad79-9c69577b7064" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478fe33c-81cd-463c-a679-8346bf25b31c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e86ccc98-3604-4a29-ad79-9c69577b7064" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea7c7038-0408-4591-92b9-6f85bf31e4cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea7c7038-0408-4591-92b9-6f85bf31e4cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LimitedLiabilityCompanyInterestsMember_77220ccb-a7c0-4e42-9c34-6bbac19919f3" xlink:href="bvs-20230401.xsd#bvs_LimitedLiabilityCompanyInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:to="loc_bvs_LimitedLiabilityCompanyInterestsMember_77220ccb-a7c0-4e42-9c34-6bbac19919f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bdd6eff3-2640-4cdd-93b2-b5252af90259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bdd6eff3-2640-4cdd-93b2-b5252af90259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_303ed757-988b-433a-87bd-c7eb98b1b304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_303ed757-988b-433a-87bd-c7eb98b1b304" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/RestructuringcostsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#RestructuringcostsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/RestructuringcostsDetails" xlink:type="extended" id="i5eb385ce1d1448daa122dc05749999dd_RestructuringcostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c84bc1d-76b5-4dc0-82d1-9403c8c89e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c84bc1d-76b5-4dc0-82d1-9403c8c89e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e0972f5a-602d-4246-930b-24c300401aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_RestructuringReserve_e0972f5a-602d-4246-930b-24c300401aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f0ec4f9e-70a5-4f9d-8b19-7f4099744aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_RestructuringCharges_f0ec4f9e-70a5-4f9d-8b19-7f4099744aee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_0ecd51d5-9a53-477e-819d-6a407c786048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_PaymentsForRestructuring_0ecd51d5-9a53-477e-819d-6a407c786048" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ad810e2b-e455-4329-858b-a9588b71f8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:to="loc_us-gaap_RestructuringPlanDomain_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:to="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestructuringPlanOf2022Member_7c71d61d-4554-46bd-b979-7aeca826b50b" xlink:href="bvs-20230401.xsd#bvs_RestructuringPlanOf2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:to="loc_bvs_RestructuringPlanOf2022Member_7c71d61d-4554-46bd-b979-7aeca826b50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestructuringPlanOf2021Member_fba38b34-c89a-43fb-9d9b-701567810ce7" xlink:href="bvs-20230401.xsd#bvs_RestructuringPlanOf2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:to="loc_bvs_RestructuringPlanOf2021Member_fba38b34-c89a-43fb-9d9b-701567810ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AcquisitionRestructuringPlanOf2022Member_08abd72f-8f91-49e5-8f86-ccff7077ac1a" xlink:href="bvs-20230401.xsd#bvs_AcquisitionRestructuringPlanOf2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:to="loc_bvs_AcquisitionRestructuringPlanOf2022Member_08abd72f-8f91-49e5-8f86-ccff7077ac1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b06ab55e-f8e9-4c8a-b99b-8a65457e3171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b06ab55e-f8e9-4c8a-b99b-8a65457e3171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_7f9fb19f-c099-44b7-a021-b23d8059c00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:to="loc_us-gaap_OtherRestructuringMember_7f9fb19f-c099-44b7-a021-b23d8059c00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_840ed5a5-692b-41e8-847f-673b06e66fa9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:to="loc_srt_RangeMember_840ed5a5-692b-41e8-847f-673b06e66fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:to="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_61b7b507-e0a5-42dc-a265-82b8b7700dde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:to="loc_srt_MinimumMember_61b7b507-e0a5-42dc-a265-82b8b7700dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1253236a-9750-48f7-a8ea-c53d6b29f6fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:to="loc_srt_MaximumMember_1253236a-9750-48f7-a8ea-c53d6b29f6fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="extended" id="i4ef657c6c8204d529c7c923c017c23af_CommitmentsandcontingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc141c5c-8437-4018-b8d0-6e66ec8a7889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc141c5c-8437-4018-b8d0-6e66ec8a7889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cfc85e80-70bc-4267-bf05-ec2f680692f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cfc85e80-70bc-4267-bf05-ec2f680692f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_d2ad9dfd-1c3e-466f-be05-a9dc8514c2d9" xlink:href="bvs-20230401.xsd#bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_d2ad9dfd-1c3e-466f-be05-a9dc8514c2d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_cdbcff52-27ce-4870-85af-52b802bd158a" xlink:href="bvs-20230401.xsd#bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_cdbcff52-27ce-4870-85af-52b802bd158a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a3006623-f9a7-415d-b7f5-5dce9d36eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a3006623-f9a7-415d-b7f5-5dce9d36eceb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LitigationSettlementExpenseOfClaimant_5390ceb2-f16d-4d6b-8e07-82d6c0557b7d" xlink:href="bvs-20230401.xsd#bvs_LitigationSettlementExpenseOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LitigationSettlementExpenseOfClaimant_5390ceb2-f16d-4d6b-8e07-82d6c0557b7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_ca975292-13ae-4ea2-967f-403ed971d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_ca975292-13ae-4ea2-967f-403ed971d7cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LitigationSettlementAmountRecoveredFromEscrow_83b693f6-ec56-4827-b998-6bd003e5bd05" xlink:href="bvs-20230401.xsd#bvs_LitigationSettlementAmountRecoveredFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LitigationSettlementAmountRecoveredFromEscrow_83b693f6-ec56-4827-b998-6bd003e5bd05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3bcf8260-11e4-41a0-b7ac-def2fc8d8ded" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3bcf8260-11e4-41a0-b7ac-def2fc8d8ded" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_a264069d-4112-4c17-9b2c-87d6b8581d02" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_a264069d-4112-4c17-9b2c-87d6b8581d02" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_035cb89a-eb4c-4be2-a423-f09a47069c91" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_035cb89a-eb4c-4be2-a423-f09a47069c91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_14c81457-4549-4fce-accf-0e9e8a01d7cf" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_14c81457-4549-4fce-accf-0e9e8a01d7cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_e8cd5eda-bc82-4534-bb30-9d306211cc90" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_e8cd5eda-bc82-4534-bb30-9d306211cc90" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_3d6b3f48-42b7-4225-a219-d95a5c4afa2c" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_3d6b3f48-42b7-4225-a219-d95a5c4afa2c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRoyaltyPercentage_60e0dd42-a34c-472e-b77e-0c2c97619732" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRoyaltyPercentage_60e0dd42-a34c-472e-b77e-0c2c97619732" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_758ae316-189c-424e-ad5d-b558a374cfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_RoyaltyExpense_758ae316-189c-424e-ad5d-b558a374cfb2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplyCommitmentTerm_4b1cb31a-ba82-4c45-a969-60f29a53a778" xlink:href="bvs-20230401.xsd#bvs_SupplyCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_SupplyCommitmentTerm_4b1cb31a-ba82-4c45-a969-60f29a53a778" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplyCommitmentRenewalTerm_e2e0977c-7f4a-4957-9163-e0e8cb5c1133" xlink:href="bvs-20230401.xsd#bvs_SupplyCommitmentRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_SupplyCommitmentRenewalTerm_e2e0977c-7f4a-4957-9163-e0e8cb5c1133" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_a293ce55-007a-4566-a13b-3692f2d40113" xlink:href="bvs-20230401.xsd#bvs_StopLossInsuranceThresholdPerMemberPerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_a293ce55-007a-4566-a13b-3692f2d40113" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:to="loc_srt_RangeMember_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:to="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9eef3ad6-98ef-4d08-8446-aea7c594b58d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:to="loc_srt_MinimumMember_9eef3ad6-98ef-4d08-8446-aea7c594b58d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5394048d-eafd-4c06-8ade-e4b5387edcc4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:to="loc_srt_MaximumMember_5394048d-eafd-4c06-8ade-e4b5387edcc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6445f6a6-4290-4078-8031-0ed25d8aaec3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6445f6a6-4290-4078-8031-0ed25d8aaec3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_31a4c143-6b50-451f-a6f8-5ffa4579d645" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:to="loc_bvs_BionessIncMember_31a4c143-6b50-451f-a6f8-5ffa4579d645" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_HarborMember_4131eba7-8c84-40e1-86a5-fb32406b461c" xlink:href="bvs-20230401.xsd#bvs_HarborMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:to="loc_bvs_HarborMember_4131eba7-8c84-40e1-86a5-fb32406b461c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplierOfSingleInjectionOAProductMember_fac0fa04-ab6f-4ca7-9035-80b9e11b9343" xlink:href="bvs-20230401.xsd#bvs_SupplierOfSingleInjectionOAProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:to="loc_bvs_SupplierOfSingleInjectionOAProductMember_fac0fa04-ab6f-4ca7-9035-80b9e11b9343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_131559ce-a44a-4d29-998f-18ff750fc31f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:to="loc_dei_EntityDomain_131559ce-a44a-4d29-998f-18ff750fc31f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b577a425-b09c-489d-942d-da1a7706ec85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:to="loc_dei_EntityDomain_b577a425-b09c-489d-942d-da1a7706ec85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_11e98f19-7bc8-461f-a172-35ee3d5c59dd" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b577a425-b09c-489d-942d-da1a7706ec85" xlink:to="loc_bvs_BionessIncMember_11e98f19-7bc8-461f-a172-35ee3d5c59dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_397388b2-c1e5-44f2-b295-1dd5be5c8761_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:to="loc_srt_ProductsAndServicesDomain_397388b2-c1e5-44f2-b295-1dd5be5c8761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c67c6ef-f222-4f19-aab7-8b66489e6b17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:to="loc_srt_ProductsAndServicesDomain_5c67c6ef-f222-4f19-aab7-8b66489e6b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_HAProductMember_c57eec3a-dec5-4ad8-888a-f88d8f5e86ba" xlink:href="bvs-20230401.xsd#bvs_HAProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c67c6ef-f222-4f19-aab7-8b66489e6b17" xlink:to="loc_bvs_HAProductMember_c57eec3a-dec5-4ad8-888a-f88d8f5e86ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_8c98050a-5103-4543-9362-c182a791e424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_8c98050a-5103-4543-9362-c182a791e424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ThreeInjectionOAProductMember_9da0514b-30b4-4b9b-bcb9-5313c934463e" xlink:href="bvs-20230401.xsd#bvs_ThreeInjectionOAProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_8c98050a-5103-4543-9362-c182a791e424" xlink:to="loc_bvs_ThreeInjectionOAProductMember_9da0514b-30b4-4b9b-bcb9-5313c934463e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_694a75e6-1d10-4b39-9cce-5637b9d27393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_694a75e6-1d10-4b39-9cce-5637b9d27393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_523e369e-8e70-4047-bf93-97ccf76c9d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_694a75e6-1d10-4b39-9cce-5637b9d27393" xlink:to="loc_us-gaap_SubsequentEventMember_523e369e-8e70-4047-bf93-97ccf76c9d99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="extended" id="idb6d4fcab152496680ac099a2e10afac_CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_42074274-0283-488f-9a35-d3a5518cedf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_42074274-0283-488f-9a35-d3a5518cedf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5da617e2-2231-4a50-809e-ed6576e39174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5da617e2-2231-4a50-809e-ed6576e39174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a98137e1-6d2b-4531-a293-d84d8fc13314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a98137e1-6d2b-4531-a293-d84d8fc13314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7af6fbc3-d4ba-45da-a1b7-45ee17def880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseLiability_7af6fbc3-d4ba-45da-a1b7-45ee17def880" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_da4d76db-d7e7-46fd-acc3-18b0224236cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_da4d76db-d7e7-46fd-acc3-18b0224236cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e12c9905-a683-42b3-abc0-571c4dc7776f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e12c9905-a683-42b3-abc0-571c4dc7776f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2e2ab9d2-8ee3-40c1-afa1-9436dd562a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2e2ab9d2-8ee3-40c1-afa1-9436dd562a2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f0ea4b2e-2dd7-49a5-96eb-fcd77497b025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseLiability_f0ea4b2e-2dd7-49a5-96eb-fcd77497b025" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e88ca1f-6733-49c3-afaa-c5412c397913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e88ca1f-6733-49c3-afaa-c5412c397913" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1e7bf385-e57e-4cac-883f-60df8549f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1e7bf385-e57e-4cac-883f-60df8549f2a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fef93f51-cafe-4d05-96ab-5f641b34aa73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fef93f51-cafe-4d05-96ab-5f641b34aa73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15304412-9aaa-412e-b4c7-9d72922442cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15304412-9aaa-412e-b4c7-9d72922442cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a7c9ca7b-985c-4b26-ac95-2142eddce22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a7c9ca7b-985c-4b26-ac95-2142eddce22d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6902f007-dab6-48f8-90f8-a5e08d241122_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6902f007-dab6-48f8-90f8-a5e08d241122_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5072fc7f-eb47-4ce4-abce-d52f0d295aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5072fc7f-eb47-4ce4-abce-d52f0d295aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_b93e621a-5666-4d6a-8649-520099684fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5072fc7f-eb47-4ce4-abce-d52f0d295aa4" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_b93e621a-5666-4d6a-8649-520099684fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8557aa5e-5b36-4b42-a74f-d021a176678e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8557aa5e-5b36-4b42-a74f-d021a176678e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_dd6faf33-7b5f-48dd-afb1-131fc376c16b" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8557aa5e-5b36-4b42-a74f-d021a176678e" xlink:to="loc_bvs_CartiHealLtdMember_dd6faf33-7b5f-48dd-afb1-131fc376c16b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#RevenuerecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended" id="idc554a3807c7440eb844e23a8f5be477_RevenuerecognitionScheduleofDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8ae95e93-04d6-455d-bbfb-a8f2bc1b8f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_958f5f79-1363-4c5e-a36a-de446817e167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8ae95e93-04d6-455d-bbfb-a8f2bc1b8f7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_958f5f79-1363-4c5e-a36a-de446817e167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8ae95e93-04d6-455d-bbfb-a8f2bc1b8f7b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:to="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fda2498e-a8a4-42aa-a036-1f08eb72e28a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:to="loc_srt_SegmentGeographicalDomain_fda2498e-a8a4-42aa-a036-1f08eb72e28a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:to="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_559bc515-f96b-49db-b5bb-a3d5bd0a6b32" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:to="loc_country_US_559bc515-f96b-49db-b5bb-a3d5bd0a6b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4c24e97b-55da-4ebd-aa7c-43aa610fcf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:to="loc_us-gaap_NonUsMember_4c24e97b-55da-4ebd-aa7c-43aa610fcf00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:to="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:to="loc_srt_ProductsAndServicesDomain_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:to="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PainTreatmentsMember_b60e716b-a621-4324-880c-8e3b1b98d7ff" xlink:href="bvs-20230401.xsd#bvs_PainTreatmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:to="loc_bvs_PainTreatmentsMember_b60e716b-a621-4324-880c-8e3b1b98d7ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestorativeTherapiesMember_f8ebc622-9af1-4f2b-a496-a57e60d54d1b" xlink:href="bvs-20230401.xsd#bvs_RestorativeTherapiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:to="loc_bvs_RestorativeTherapiesMember_f8ebc622-9af1-4f2b-a496-a57e60d54d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SurgicalSolutionsMember_70d0ce9e-6332-4660-9e9c-f451e73b7da1" xlink:href="bvs-20230401.xsd#bvs_SurgicalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:to="loc_bvs_SurgicalSolutionsMember_70d0ce9e-6332-4660-9e9c-f451e73b7da1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/SegmentsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#SegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/SegmentsDetails" xlink:type="extended" id="i5c0c1adb3da64d17b1853488dd5438dc_SegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_13c4f38c-857b-434d-929f-cb1b45994068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_NumberOfReportableSegments_13c4f38c-857b-434d-929f-cb1b45994068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_a6f55941-a89c-4281-8447-62ce1fc05c7d" xlink:href="bvs-20230401.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_a6f55941-a89c-4281-8447-62ce1fc05c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ce88f616-f6a3-4d96-99b2-a772ede7f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ce88f616-f6a3-4d96-99b2-a772ede7f4fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1e1c27ca-72b3-4276-93bd-7345cd1bd876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_DepreciationAndAmortization_1e1c27ca-72b3-4276-93bd-7345cd1bd876" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ec0911b7-fbb9-4eeb-94a2-d8367ded88b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ec0911b7-fbb9-4eeb-94a2-d8367ded88b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3d8b5859-c723-4b39-a2e9-26dbedd7e193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_RestructuringCharges_3d8b5859-c723-4b39-a2e9-26dbedd7e193" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_30fc77be-d133-4f70-8ad8-0a23e4e1f332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_30fc77be-d133-4f70-8ad8-0a23e4e1f332" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_5bb97e20-e43c-483c-8c81-7492f954146a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_5bb97e20-e43c-483c-8c81-7492f954146a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_69724805-0f1e-420a-9551-52daf3755bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_AssetImpairmentCharges_69724805-0f1e-420a-9551-52daf3755bc7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringExpense_02791d33-6074-4424-b93b-77341d345d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_OtherNonrecurringExpense_02791d33-6074-4424-b93b-77341d345d90" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fd0fc3-1cd1-4439-bcbb-d563531fe4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fd0fc3-1cd1-4439-bcbb-d563531fe4ff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:to="loc_us-gaap_SegmentDomain_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:to="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_USSegmentMember_9df108d8-d929-44bb-92a5-f5273dc16a58" xlink:href="bvs-20230401.xsd#bvs_USSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:to="loc_bvs_USSegmentMember_9df108d8-d929-44bb-92a5-f5273dc16a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalSegmentMember_7233da69-26e9-49bd-a522-4b235a3b0b18" xlink:href="bvs-20230401.xsd#bvs_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:to="loc_bvs_InternationalSegmentMember_7233da69-26e9-49bd-a522-4b235a3b0b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:to="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_864ac28e-1f55-4011-908f-485d0cac46f8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:to="loc_srt_ConsolidationItemsDomain_864ac28e-1f55-4011-908f-485d0cac46f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:to="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2fdbbb46-cfdb-4cad-b16c-dee4c1d13883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:to="loc_us-gaap_OperatingSegmentsMember_2fdbbb46-cfdb-4cad-b16c-dee4c1d13883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_30f6a3ef-c68c-421d-9fad-6d1720f96509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_30f6a3ef-c68c-421d-9fad-6d1720f96509" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsScheduleofBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails" xlink:type="extended" id="iea42650c3f304461b9cc76a9483d1377_DiscontinuedoperationsScheduleofBalanceSheetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_2ab227de-d44f-4560-9a7e-b628eb7fa049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_2ab227de-d44f-4560-9a7e-b628eb7fa049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_3a3e8a65-d112-44c6-b97a-8ac79ec58749" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_3a3e8a65-d112-44c6-b97a-8ac79ec58749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d33bdf4b-21fa-487e-9cca-885463b3d468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d33bdf4b-21fa-487e-9cca-885463b3d468" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_ad38b5da-8a66-4df0-82b6-e05cf6e4ce67" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_ad38b5da-8a66-4df0-82b6-e05cf6e4ce67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_e7836564-184d-408a-af66-e283808d2f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_e7836564-184d-408a-af66-e283808d2f03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b4a40cf7-9aa9-423d-ad4d-af1cada056c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b4a40cf7-9aa9-423d-ad4d-af1cada056c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_a15856c1-90ed-4630-b166-07d9b586ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_a15856c1-90ed-4630-b166-07d9b586ddaf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_3f52d89b-fa91-4964-a88f-c0c9565b0a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_3f52d89b-fa91-4964-a88f-c0c9565b0a9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_c80b12d6-4cd8-4e00-9165-af36ca8bf6c6" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_c80b12d6-4cd8-4e00-9165-af36ca8bf6c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_565475e7-a940-432d-a868-ff4084bcd866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_565475e7-a940-432d-a868-ff4084bcd866" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5ce74e00-837c-4fc4-bf59-e27f05e4d9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5ce74e00-837c-4fc4-bf59-e27f05e4d9a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_ceff8b46-2acf-4243-8023-7fcdfebfb076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_ceff8b46-2acf-4243-8023-7fcdfebfb076" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0f1be465-8f18-4757-8e78-66b0a91e111f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0f1be465-8f18-4757-8e78-66b0a91e111f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_bb2abd46-aa93-4f5a-9830-e91f0589aae9" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_bb2abd46-aa93-4f5a-9830-e91f0589aae9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ccb70cb7-6b5c-45ac-ac36-6d2889a85762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ccb70cb7-6b5c-45ac-ac36-6d2889a85762" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1868407c-99a1-4ad7-a0d7-8108f307ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1868407c-99a1-4ad7-a0d7-8108f307ae24" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_840957ba-2107-499c-8d3e-32b57c973276" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_840957ba-2107-499c-8d3e-32b57c973276" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_73bb80b3-6fe8-4a23-8637-ec64c6654ad2" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_73bb80b3-6fe8-4a23-8637-ec64c6654ad2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_25bfa4c2-5b61-4420-a5e2-373551e5164a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_25bfa4c2-5b61-4420-a5e2-373551e5164a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_79961348-fbe1-45cb-9fff-d4460d32bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_79961348-fbe1-45cb-9fff-d4460d32bcc5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0e47fcbd-e27b-4b17-837a-babb7b88ab86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0e47fcbd-e27b-4b17-837a-babb7b88ab86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e59435e9-b895-41f3-859b-04bb3fec852d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e59435e9-b895-41f3-859b-04bb3fec852d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_524fa220-9615-4dd2-b3c9-423721a2d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e59435e9-b895-41f3-859b-04bb3fec852d" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_524fa220-9615-4dd2-b3c9-423721a2d03d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98c0a91e-eeed-44f1-9086-eb05b1d33efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98c0a91e-eeed-44f1-9086-eb05b1d33efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember_dca7baf0-3f80-4692-a6e9-43335d482a59" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98c0a91e-eeed-44f1-9086-eb05b1d33efe" xlink:to="loc_bvs_CartiHealMember_dca7baf0-3f80-4692-a6e9-43335d482a59" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsScheduleofStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails" xlink:type="extended" id="i8801304e100b4eef89b22cacc55d888e_DiscontinuedoperationsScheduleofStatementofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4702c277-e45c-4c4e-a113-a8d3c31626cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4702c277-e45c-4c4e-a113-a8d3c31626cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_7ba8a21f-484e-4cd9-ac97-2ac8db1b7212" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_7ba8a21f-484e-4cd9-ac97-2ac8db1b7212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_5d18f69a-8104-4dfb-9d46-8bdcfa643b8d" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_5d18f69a-8104-4dfb-9d46-8bdcfa643b8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_93b3a49b-0fff-4919-bafe-bf0bdfef3de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_93b3a49b-0fff-4919-bafe-bf0bdfef3de3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_09d15368-cc3e-4528-a7cd-4c63766e0769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_09d15368-cc3e-4528-a7cd-4c63766e0769" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_9b8dd4ef-9c3a-4823-af7b-9cdb0632ddac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_9b8dd4ef-9c3a-4823-af7b-9cdb0632ddac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_38251b77-47f7-4e7a-931c-2e41ce4b745b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_38251b77-47f7-4e7a-931c-2e41ce4b745b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_9ea99f50-26f2-49be-b719-7a57ed5707a5" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_9ea99f50-26f2-49be-b719-7a57ed5707a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c3a4a422-3348-49db-a56c-1fdfb26cc424" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c3a4a422-3348-49db-a56c-1fdfb26cc424" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_b8268368-c7b0-40a6-abda-6c5726b6ecb2" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_b8268368-c7b0-40a6-abda-6c5726b6ecb2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_1c97f9d2-9bd4-42c0-ace8-bcb7ec7b57b0" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_1c97f9d2-9bd4-42c0-ace8-bcb7ec7b57b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_02880fb5-8497-4fe8-aaac-290da026e677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_02880fb5-8497-4fe8-aaac-290da026e677" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_NonRefundablePayments_ab13776f-e680-4b5f-a7e4-d7490db7b6d8" xlink:href="bvs-20230401.xsd#bvs_NonRefundablePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_NonRefundablePayments_ab13776f-e680-4b5f-a7e4-d7490db7b6d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9ff2bfde-79bc-4d9b-98fe-c30440080984_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9ff2bfde-79bc-4d9b-98fe-c30440080984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_66c15bdc-d810-4b7a-adbc-9e9f5f1c7962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_66c15bdc-d810-4b7a-adbc-9e9f5f1c7962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4fd4c8a0-a39d-41c0-9771-ce80c3e4c929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_66c15bdc-d810-4b7a-adbc-9e9f5f1c7962" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4fd4c8a0-a39d-41c0-9771-ce80c3e4c929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5976f71f-b439-4845-9580-eb1febcb8b30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5976f71f-b439-4845-9580-eb1febcb8b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a6a3cb9-bde1-4809-917d-d5b6c46639a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a6a3cb9-bde1-4809-917d-d5b6c46639a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember_e4ed1e76-2827-4e43-9bdf-69be8dbab475" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a6a3cb9-bde1-4809-917d-d5b6c46639a9" xlink:to="loc_bvs_CartiHealMember_e4ed1e76-2827-4e43-9bdf-69be8dbab475" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/SubsequenteventsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#SubsequenteventsDetails"/>
  <link:definitionLink xlink:role="http://www.bioventus.com/role/SubsequenteventsDetails" xlink:type="extended" id="i3a00960433b04f1491c67921303ea6fa_SubsequenteventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_7af4b8a9-ff17-4adb-88e2-2a70532513c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_us-gaap_RepaymentsOfDebt_7af4b8a9-ff17-4adb-88e2-2a70532513c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a8be2cb0-ef77-42ce-a5a3-a2f46ebbde65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a8be2cb0-ef77-42ce-a5a3-a2f46ebbde65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_511709f8-4864-4cab-9101-fc8c97dec0c6" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_511709f8-4864-4cab-9101-fc8c97dec0c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_2facb61b-2bac-42db-9c30-65fc156aaceb" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredDeferredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_2facb61b-2bac-42db-9c30-65fc156aaceb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_a5d88420-d069-4aeb-9ff6-b28202213c36" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredDeferralPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_a5d88420-d069-4aeb-9ff6-b28202213c36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_85cb60c6-a167-4f47-92c7-2f7755778591" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_85cb60c6-a167-4f47-92c7-2f7755778591" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_3ee35bc5-6cbb-4877-ae02-cb4e75803e4e" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_3ee35bc5-6cbb-4877-ae02-cb4e75803e4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_29830739-c594-4bb2-b244-5ab1378262dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:to="loc_us-gaap_CreditFacilityDomain_29830739-c594-4bb2-b244-5ab1378262dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f28dcac2-55f4-4a36-9c35-c3502b9d530a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:to="loc_us-gaap_CreditFacilityDomain_f28dcac2-55f4-4a36-9c35-c3502b9d530a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c084741c-cfac-44b1-9be7-570d8022bf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f28dcac2-55f4-4a36-9c35-c3502b9d530a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c084741c-cfac-44b1-9be7-570d8022bf70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e0f8c729-2104-4a7b-8e76-1a4394db338c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e0f8c729-2104-4a7b-8e76-1a4394db338c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4fcac77-f48e-45e8-8721-1c993b2743a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4fcac77-f48e-45e8-8721-1c993b2743a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_86ddc776-6fa4-4224-9e6b-3c72be115a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4fcac77-f48e-45e8-8721-1c993b2743a3" xlink:to="loc_us-gaap_LineOfCreditMember_86ddc776-6fa4-4224-9e6b-3c72be115a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_87e4b409-36d4-4e90-9c58-6efcf13082d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_87e4b409-36d4-4e90-9c58-6efcf13082d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7d450a35-a917-46ce-a63b-3e61af9b862a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_87e4b409-36d4-4e90-9c58-6efcf13082d2" xlink:to="loc_us-gaap_SubsequentEventMember_7d450a35-a917-46ce-a63b-3e61af9b862a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b8de2778-4fe8-4c4c-af0e-1e1aa260d847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b8de2778-4fe8-4c4c-af0e-1e1aa260d847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7f5a3f62-0fb2-4e96-ab5d-026685bd69d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7f5a3f62-0fb2-4e96-ab5d-026685bd69d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1fc20b73-9a5e-4db8-956e-dfdbd7bebcda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7f5a3f62-0fb2-4e96-ab5d-026685bd69d3" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1fc20b73-9a5e-4db8-956e-dfdbd7bebcda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e800d77e-25e1-4a89-8b85-6d8c0f181e3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e800d77e-25e1-4a89-8b85-6d8c0f181e3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec160054-9cff-4b02-abbd-251de11e8196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec160054-9cff-4b02-abbd-251de11e8196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember_5e6864d1-8f7e-43a7-9399-5655416fd295" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec160054-9cff-4b02-abbd-251de11e8196" xlink:to="loc_bvs_WoundBusinessMember_5e6864d1-8f7e-43a7-9399-5655416fd295" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bvs-20230401_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:082d4e54-0693-403f-8feb-755a4f49db3a,g:bca9874b-627b-4a4e-9dc7-9b090a7fd814-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_ac553e09-1b8e-4e15-b12a-26a1acf5cf10_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_b1a680c9-dab5-4fb0-b30a-6b9a8c6e3c15_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_91bb6202-69b8-4b6b-8a35-a906ddde3df7_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_530fe593-84e9-4634-b48f-54359626dca1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_91af38a3-2530-4863-9029-ef870d2a1de5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_fe217125-f90b-4d59-9871-793b7a25e2d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_5ae8f7c9-e6ea-4911-8d0f-bb19c941f645_negatedLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1eccd70d-dae9-4b26-9e0b-d703bc406dc0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fc430f79-c617-40ab-b30c-e5c71ad8aa5f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_2f62550c-6e05-49ac-bd7d-73c14bf930f5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment - net (finance leases)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_7e8ba4b4-ee14-4b63-9ff8-68698eacceed_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_4360ce23-53af-4413-b38d-050b7156ca77_totalLabel_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal of cash at closing</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_label_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Gross, Including Transaction Costs</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Gross, Including Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" xlink:to="lab_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8be9776a-d551-4b3b-bec8-262eb60d19f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_00328a26-5054-4b81-a900-1acd3fbd2cf8_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_4101f091-6042-45fd-993c-70d4aa0cfce3_terseLabel_en-US" xlink:label="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued or issuable, required stock to LLC interest ratio</link:label>
    <link:label id="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_label_en-US" xlink:label="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Or Issuable, Required Stock To LLC Interest Ratio</link:label>
    <link:label id="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_documentation_en-US" xlink:label="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Or Issuable, Required Stock To LLC Interest Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:href="bvs-20230401.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:to="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c1c8e288-3aed-4448-b5fa-aa0c046ab802_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility, borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_83d5829a-6f2e-4209-9cb2-9da5dc50a356_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_07e5dc3c-54fe-4830-b862-8defbc976335_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7e0eaf57-e0d7-4d6b-b50a-970d8df7c535_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_PublicOfferingMember_589a35b1-7738-4f1a-9505-8182c1932004_terseLabel_en-US" xlink:label="lab_bvs_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_bvs_PublicOfferingMember_label_en-US" xlink:label="lab_bvs_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_bvs_PublicOfferingMember_documentation_en-US" xlink:label="lab_bvs_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PublicOfferingMember" xlink:href="bvs-20230401.xsd#bvs_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PublicOfferingMember" xlink:to="lab_bvs_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_89012b75-59eb-4ca4-bfcf-8e170e904985_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing amount</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4768e5e3-bf96-46ea-9b7e-559018fa656d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_daf83138-a025-495f-b276-39e9dc7c7289_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4ffb99f4-7f2b-467e-b6d1-24328ef90b82_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_6bfb8b14-0422-4a7d-b69b-5a00c2c7319c_terseLabel_en-US" xlink:label="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries And Employee Benefits, Current</link:label>
    <link:label id="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_documentation_en-US" xlink:label="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries And Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:href="bvs-20230401.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:to="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c2e70bb6-c051-4921-9235-12d3dea89f7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_9aebd9f5-4b96-410c-b721-4d3f6a70b03a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_193e8b42-9bc7-40cd-bc70-5030b2eadae4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3d188430-7f03-462f-8e78-bbe752419c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_226e1c81-2769-40ef-b380-cb16e15661d0_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment on revolver</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb15716e-5895-45f8-b39b-798c120185a5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b68e7168-2950-4a80-9f67-0a732ec0ba76_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bioventus Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_86d76413-7c63-47be-a967-43f91f107030_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_22f0ea7c-8d7c-4ec7-8e80-6419d12858c2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f44313f5-082b-4f89-a93a-6cdaf60f4603_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_ea584a2a-a859-403b-9e3a-8556f533bced_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12026Member_977b6733-3a9d-4410-89c9-d4075678ba17_terseLabel_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable by January 1 2026</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12026Member_label_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By January 1 2026 [Member]</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12026Member_documentation_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By January 1 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12026Member" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredAmountPayableByJanuary12026Member" xlink:to="lab_bvs_DeferredAmountPayableByJanuary12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_d780c6f5-7d90-42ff-8dc7-036a4d860f96_terseLabel_en-US" xlink:label="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest - discontinued operations</link:label>
    <link:label id="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_label_en-US" xlink:label="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations</link:label>
    <link:label id="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_documentation_en-US" xlink:label="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" xlink:href="bvs-20230401.xsd#bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" xlink:to="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_b0ea4160-283e-461c-a5e4-274cf015b2c1_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b78b5b1a-96bc-47af-b0ea-e96413dd0569_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SupplyCommitmentRenewalTerm_4483eb0a-9a07-45e3-997e-bb4f8aa13d8c_terseLabel_en-US" xlink:label="lab_bvs_SupplyCommitmentRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply commitment, renewal term</link:label>
    <link:label id="lab_bvs_SupplyCommitmentRenewalTerm_label_en-US" xlink:label="lab_bvs_SupplyCommitmentRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Renewal Term</link:label>
    <link:label id="lab_bvs_SupplyCommitmentRenewalTerm_documentation_en-US" xlink:label="lab_bvs_SupplyCommitmentRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplyCommitmentRenewalTerm" xlink:href="bvs-20230401.xsd#bvs_SupplyCommitmentRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplyCommitmentRenewalTerm" xlink:to="lab_bvs_SupplyCommitmentRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_aec67d28-50d1-403a-aa46-13f953adf35f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c1e35c65-897d-41f2-a73c-e1f6aa7befe3_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from operating activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_96147b1c-0610-42ae-a00d-7da0b81a603b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_517d6e74-fa86-49d3-909c-5d9f8c9d506c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_cdcf8491-48e3-4609-a274-935c37e0d0f1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_26f3e336-90e5-4c54-819f-85011c7a09ee_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_fa280d2f-534c-4311-896f-6033f4767c37_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_2c558b08-908a-4d30-9d0f-8d48fff97311_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_InternationalMember_ab861156-10e0-4ebc-a52d-3148bba99993_terseLabel_en-US" xlink:label="lab_bvs_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bvs_InternationalMember_label_en-US" xlink:label="lab_bvs_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_bvs_InternationalMember_documentation_en-US" xlink:label="lab_bvs_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalMember" xlink:href="bvs-20230401.xsd#bvs_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InternationalMember" xlink:to="lab_bvs_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_22a19ed1-043e-41f4-a9ca-60e4e306330a_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f5727de6-bca8-405f-a694-c2bc877226f0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_c178f661-c1e0-4a72-9f48-c7d692b9ffdb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_44e591c5-30fb-492e-b957-a2bfa16aa32e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_456e41cf-96df-4cd9-a6ac-24fc1784673b_terseLabel_en-US" xlink:label="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest - continuing operations</link:label>
    <link:label id="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_label_en-US" xlink:label="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations</link:label>
    <link:label id="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_documentation_en-US" xlink:label="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" xlink:href="bvs-20230401.xsd#bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" xlink:to="lab_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_eaf85ae3-63c6-4b77-827d-2b8a12e91fdd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_323be3cf-d83b-4fa0-b967-63286af1eb8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of Class A common stock from continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f6ded4df-8f89-4d7d-aa6f-6609b37f931e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_HarborMember_24fd2f45-388f-4372-befa-efd69116e5a5_terseLabel_en-US" xlink:label="lab_bvs_HarborMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbor</link:label>
    <link:label id="lab_bvs_HarborMember_label_en-US" xlink:label="lab_bvs_HarborMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbor [Member]</link:label>
    <link:label id="lab_bvs_HarborMember_documentation_en-US" xlink:label="lab_bvs_HarborMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_HarborMember" xlink:href="bvs-20230401.xsd#bvs_HarborMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_HarborMember" xlink:to="lab_bvs_HarborMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9aa4ba99-91e6-426f-9dca-4713baf3dae8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_6166dfd0-cbf2-46b2-a4b0-64d3a884b448_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_InternationalSegmentMember_00b0656c-512f-49eb-9e3f-6a89aa68119e_verboseLabel_en-US" xlink:label="lab_bvs_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment</link:label>
    <link:label id="lab_bvs_InternationalSegmentMember_5a576838-7979-4627-8e53-0b9159ab906c_terseLabel_en-US" xlink:label="lab_bvs_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bvs_InternationalSegmentMember_label_en-US" xlink:label="lab_bvs_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment [Member]</link:label>
    <link:label id="lab_bvs_InternationalSegmentMember_documentation_en-US" xlink:label="lab_bvs_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalSegmentMember" xlink:href="bvs-20230401.xsd#bvs_InternationalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InternationalSegmentMember" xlink:to="lab_bvs_InternationalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_21ebef54-9e07-4fbb-a4da-b66151778212_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred amount</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_label_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Deferred Amount</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Deferred Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredDeferredAmount" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredDeferredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredDeferredAmount" xlink:to="lab_bvs_BusinessCombinationConsiderationTransferredDeferredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow_2fcec33d-e5f5-4259-9d9b-4eea3ae937d6_terseLabel_en-US" xlink:label="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount recovered from escrow</link:label>
    <link:label id="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow_label_en-US" xlink:label="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Recovered From Escrow</link:label>
    <link:label id="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow_documentation_en-US" xlink:label="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Recovered From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LitigationSettlementAmountRecoveredFromEscrow" xlink:href="bvs-20230401.xsd#bvs_LitigationSettlementAmountRecoveredFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LitigationSettlementAmountRecoveredFromEscrow" xlink:to="lab_bvs_LitigationSettlementAmountRecoveredFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_56c6ba56-8066-4b4c-bd6a-e77aaf8a6400_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized compensation expense, RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6df24879-d4bc-4f0a-978e-e0d69e719324_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_fda27c04-e37b-4bb1-9e23-0990f5bc7de9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_4f8b8be4-70c9-4740-a3bb-42f78d6cdeb3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_24b4cfe8-6224-4e44-b1f1-4fc543a3b66c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_44cabe0e-9526-4ec6-9145-144e19b2788e_terseLabel_en-US" xlink:label="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, percentage under dispute</link:label>
    <link:label id="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_label_en-US" xlink:label="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Amount Under Dispute, Percentage Threshold</link:label>
    <link:label id="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_documentation_en-US" xlink:label="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Amount Under Dispute, Percentage Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" xlink:href="bvs-20230401.xsd#bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" xlink:to="lab_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_862d85e6-df5d-4185-83f1-842d7c7d660d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7a2df4f3-77ac-4bbb-8e4f-93bb769d4c55_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTypeAxis_df7b8e61-f24b-44cc-b533-15ab9c48eb63_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTypeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeAxis" xlink:to="lab_us-gaap_ReclassificationTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fd629658-f836-438d-aa21-3931f6b82e25_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_8db936d4-48b0-4841-9762-83b1bdbd2e39_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b088793e-18f9-4c95-a262-2f9adeb4598d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of Class A common stock outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_26a1b9eb-4a50-49fa-94f8-31285ceea417_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7364e1e-7b20-40b0-bc0a-6b72a70a3db7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_447e0be0-636e-4091-b693-4c258d91dc07_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Current Portion of Deferred Consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Current Portion of Deferred Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_db4b508a-547e-4b38-858d-b02f43fe1bfa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities- current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_e51260a1-92b3-4c92-b899-03726a0d3800_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRoyaltyPercentage_df21b26b-db51-47bc-a312-339f9a093ae4_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, royalty percentage</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRoyaltyPercentage_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Percentage</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRoyaltyPercentage_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:to="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTypeDomain_a5172a12-8d31-4c71-a3ad-84a9cd59be99_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeDomain" xlink:to="lab_us-gaap_ReclassificationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9ad610fb-b36f-4598-90dd-8744be48790d_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51d12fdd-fe38-41ef-b633-4c0f97dc67bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_9937cabb-330f-4850-a16b-3390652b86d5_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, sales threshold for royalties</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" xlink:to="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_d43f7947-2703-4799-bf35-be010c9ea1ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring plan, expected costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_de7f3921-c374-44da-882c-003b7d0cb573_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7d17feaf-fbf7-40f6-ad89-c64ae2888785_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_f921cb87-6ca9-4dd2-9f44-6aa0d869a678_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_abc89fcf-be95-456a-9aa9-8167b9d8b074_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f475e8ed-d673-4cbd-8371-2068d84688d1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6ad1e3c3-7b8a-47de-aa7f-92fa18c83366_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_abb26f66-1dde-4653-a64f-1a07b0e06967_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9f383082-afd6-4466-92df-144badcf9c83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_28210181-e953-4261-b569-086b9cc4ef89_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38a1dcd-e6bb-400e-9db7-e412f9b1402a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_8dc4c329-8e26-480c-869f-de1887ce3081_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7e880ca-5245-4ad7-970f-ddd7c570add9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8a5c1e08-83e2-46e8-9644-5083b7580cc8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of business acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aed21548-aa3e-4a28-ac4c-86f060dd49ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_d007620e-02da-4d8a-8fba-72c2ccff3134_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock for equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2d758309-53db-4c6f-a256-f9cb5e758513_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_921dfa2d-c7ad-41c8-bd35-0790b51a422d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_0c193691-87b7-4e32-9720-453bf0455d36_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_009deb1b-0a19-4029-a9fa-f9c41f1f18cb_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_50fa0190-5775-4291-a0ea-95799fe16bc1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_653cc9bd-82b8-410d-840f-d2dac23194e6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4dcc5b9f-ec0a-4f76-91aa-1d7469f3f811_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5d3375aa-2f14-4906-bfc8-d00bb906a9f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ea85a550-3b28-462e-af4e-115876d7e386_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_cdf7d94d-6900-46a1-bf80-1b3820bbaf63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_b4a5e298-d1c4-47a3-97f0-bd9ad5c2081c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term assets attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_107c8ca3-a07d-42a3-af97-2b2e63fba834_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c77e9e84-e9f8-4dc9-b3c5-cf93acd1c0f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_903cf127-585c-408c-bf5f-53f6a012df9f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c399991-a0d8-4a7b-af65-dcdcd8113191_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_63f2d025-0eec-466d-b053-9aa171ef302b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f9e05db8-bd5e-434a-9cba-77d534b5b1c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CartiHealMember_294ba526-a6af-4959-90bf-1ccb099b213e_terseLabel_en-US" xlink:label="lab_bvs_CartiHealMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carti Heal</link:label>
    <link:label id="lab_bvs_CartiHealMember_label_en-US" xlink:label="lab_bvs_CartiHealMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carti Heal [Member]</link:label>
    <link:label id="lab_bvs_CartiHealMember_documentation_en-US" xlink:label="lab_bvs_CartiHealMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carti Heal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CartiHealMember" xlink:to="lab_bvs_CartiHealMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_27dcbc6b-2554-46c6-9c29-de9a23b5937b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_558589bd-ac22-4642-879e-e25d94b6e5b3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c7c8d246-b9ff-426f-8ecf-3f76500469b3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_849207d6-9968-472e-9c94-997c3641fa8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredTaxImpactFor2022Member_30bfea43-1427-4f5c-870d-ba542436fd1a_terseLabel_en-US" xlink:label="lab_bvs_DeferredTaxImpactFor2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Impact For 2022</link:label>
    <link:label id="lab_bvs_DeferredTaxImpactFor2022Member_label_en-US" xlink:label="lab_bvs_DeferredTaxImpactFor2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Impact For 2022 [Member]</link:label>
    <link:label id="lab_bvs_DeferredTaxImpactFor2022Member_documentation_en-US" xlink:label="lab_bvs_DeferredTaxImpactFor2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Impact For 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredTaxImpactFor2022Member" xlink:href="bvs-20230401.xsd#bvs_DeferredTaxImpactFor2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredTaxImpactFor2022Member" xlink:to="lab_bvs_DeferredTaxImpactFor2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_bce2b9bb-b3f2-4c17-a0c8-e4cc01800d5f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_51e81c1d-f60b-4f32-b397-e1352a4c0e50_terseLabel_en-US" xlink:label="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Rebalancing for Issuance of Stock Through Equity Plans</link:label>
    <link:label id="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_label_en-US" xlink:label="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Rebalancing For Issuance Of Stock Through Equity Plans [Member]</link:label>
    <link:label id="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_documentation_en-US" xlink:label="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Rebalancing For Issuance Of Stock Through Equity Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" xlink:href="bvs-20230401.xsd#bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" xlink:to="lab_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_68007951-4cc6-4928-97a5-e1d3a87144d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Ownership Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Ownership Interests [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_edd044a9-d96f-42f1-b2f8-4761076d4c44_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_19f7288c-7795-4924-9a73-f57f9bbe85f4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ff9309ac-f07c-46a0-8861-8ef774604235_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_eee59897-7a16-4714-b00a-1610766cfc1a_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_6c0aa617-7a12-4e30-a580-3803231cf274_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_25eb3e35-fb8a-43f4-882b-282f97442974_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_7deca45b-f600-4159-b2f7-815af1d3f500_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1efd7d75-96b5-4627-a303-3b3961700350_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_7d72f60c-3860-4c9f-8e4f-ace2e5c6a6a9_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_54a96dca-b1d5-4d3b-bfea-a238117268e2_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_381245d0-e755-4b4e-b83d-7662ba584b54_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock_8d07a1a4-5165-4980-a912-259059b61cae_terseLabel_en-US" xlink:label="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions And Investments Disclosure [Text Block]</link:label>
    <link:label id="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock_documentation_en-US" xlink:label="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions And Investments Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" xlink:href="bvs-20230401.xsd#bvs_AcquisitionsAndInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" xlink:to="lab_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_58a2582d-33a8-49f7-a104-61bd79dfe401_terseLabel_en-US" xlink:label="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction in Calculation of Deferred Tax Assets</link:label>
    <link:label id="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction In Calculation Of Deferred Tax Assets [Member]</link:label>
    <link:label id="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_documentation_en-US" xlink:label="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction In Calculation Of Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" xlink:href="bvs-20230401.xsd#bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" xlink:to="lab_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_2c2232f2-1001-4c24-8911-db7e35233e06_terseLabel_en-US" xlink:label="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Lessee</link:label>
    <link:label id="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="bvs-20230401.xsd#bvs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_92c03290-dc2d-403a-99de-a891b0fda3a7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_e6331ffe-b5af-4898-a167-4b3841eee355_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_106c7b2e-73b8-42c5-a4d6-58d76df291dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of Class A common stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a2300a17-8602-4740-9a3a-d0d7ee1cc67c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_1cbc2106-25f0-4aaa-b00c-d54911915afa_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e9c56d4a-24b5-4a13-abf4-dfb763284545_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3d6d0326-6d69-4dd5-a62c-f0a121e103f4_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fe6ce6c5-51c2-4ed7-b879-51141d9ffb6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f0a9a8ca-f6b2-46aa-8b68-0b74353b6510_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f97ee5a9-b89c-42c7-8dcd-dac8b19981c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_010d9459-ba72-49ff-8651-56f45d6ebd17_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_db1ceddd-82d8-4b7a-b783-4cc3577d607f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_d1defc11-63cc-4661-b4cd-f4e461e47f2d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other assets</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_c9ace2b6-e33b-40b6-ba31-c94849d837b5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_cae65aa7-87ae-45cc-a3c0-2ee93333218b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_TaxReceivableAgreementPercent_5143f3e8-c888-40f1-b8f4-011a2d612245_terseLabel_en-US" xlink:label="lab_bvs_TaxReceivableAgreementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent</link:label>
    <link:label id="lab_bvs_TaxReceivableAgreementPercent_label_en-US" xlink:label="lab_bvs_TaxReceivableAgreementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent</link:label>
    <link:label id="lab_bvs_TaxReceivableAgreementPercent_documentation_en-US" xlink:label="lab_bvs_TaxReceivableAgreementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TaxReceivableAgreementPercent" xlink:href="bvs-20230401.xsd#bvs_TaxReceivableAgreementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TaxReceivableAgreementPercent" xlink:to="lab_bvs_TaxReceivableAgreementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cbe5b1b-0787-4167-896f-7a8009e70cb7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d1281184-1f97-428c-9c32-9e9ea6fe6282_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe6f40e6-fccd-4b70-8fcb-993b1fa9adf0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ef2b4c1-402a-4b8b-b7ce-70def2fe4d6b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_58e52b96-69ba-4860-b7ec-ac9dde94edb3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_35a8471d-9b75-4e96-a6f6-1eeffa23e89d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_083714b4-5526-48f4-b5b8-43ff057f6f84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f52c64d1-50c8-4e8d-b777-34f060d8ee3c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_98d9b28b-3744-4f82-858a-ee559072c157_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_bb604328-9776-4d94-9bbf-354e60312dbb_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_99eacdfa-d905-4fb2-a6d8-b48ac4c69621_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DebtInstrumentCovenantLiquidityMinimum_61db2c3e-abf1-4e8a-bbf3-32e8279cab04_terseLabel_en-US" xlink:label="lab_bvs_DebtInstrumentCovenantLiquidityMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, liquidity, minimum</link:label>
    <link:label id="lab_bvs_DebtInstrumentCovenantLiquidityMinimum_label_en-US" xlink:label="lab_bvs_DebtInstrumentCovenantLiquidityMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity, Minimum</link:label>
    <link:label id="lab_bvs_DebtInstrumentCovenantLiquidityMinimum_documentation_en-US" xlink:label="lab_bvs_DebtInstrumentCovenantLiquidityMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DebtInstrumentCovenantLiquidityMinimum" xlink:href="bvs-20230401.xsd#bvs_DebtInstrumentCovenantLiquidityMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentCovenantLiquidityMinimum" xlink:to="lab_bvs_DebtInstrumentCovenantLiquidityMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9f6bd995-5876-4ca0-bd65-c75fa11f57b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e3078e8a-7319-4e9e-a741-4e3e4d4bf4a2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_45520fac-c3b4-472c-9701-8d437f6e4ba2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c76b5b60-5e28-4529-a3a5-26204c400714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_21d863ca-aa7d-414a-b9ff-4d09dd60e0a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense net yet amortized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_dea7c22b-5664-4c15-b41c-89d53352b1ee_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on debt retirement</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_8cb4a5fe-0de0-4708-afa2-30dbd0b41f20_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_6388e796-1da0-4871-b81c-56f794eb8e11_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bf3b2af1-4f7b-45cd-9711-a84c6cdecbbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_47482b5d-8669-48d8-905f-a208a5cf45df_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from investing activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_cf1f11ea-6e5d-43da-b083-9585e75ab229_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_ce080288-9795-4bd4-94bf-823d5925d6f9_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_bf117bcb-90bc-4d92-b5eb-c41ca6319ced_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9ee71b68-046e-4671-acc5-960207ef8b4b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_14b2b85b-9fec-4bf3-8573-7212b5f8d1af_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, amount payable upon transfer of customer data</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" xlink:to="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_6fec4c7e-212c-403c-b41b-eba5df8432c5_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e474e606-e58c-45c6-a9dc-fe9e94e91786_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c0341c03-808c-40c2-81c1-f0969efef4bc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock for equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_6c9d4286-b7f6-4c09-8ccc-bc3408a84989_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_831e5bc0-01ef-4c67-a56f-bb581575baea_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_72cb69ba-185f-4918-b7c0-a47e2512f4d5_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0905e04a-8803-4311-8f8e-e63b16f4eddd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ed2c2cab-b134-45d6-a7a3-0f58547d42dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a9159661-51c5-40d1-9d71-f4f26931e26d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_154c0aee-df32-46ee-ab72-166063f5bb09_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_4f14b7ae-46c1-4e7d-a4b9-8334a6e493cc_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, royalty percentage, threshold one</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" xlink:to="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_491f4d58-3160-4e9e-9b2a-22e5ce822ed2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_111b73f8-1b01-43ba-9b26-75f8c9186148_negatedTerseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7b7f517c-9ed0-4762-adf0-98a868a050bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredTaxesOnEquityRebalancing_f56412b1-8e78-4581-a36f-4bd9939baf0f_negatedTerseLabel_en-US" xlink:label="lab_bvs_DeferredTaxesOnEquityRebalancing" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on equity rebalancing</link:label>
    <link:label id="lab_bvs_DeferredTaxesOnEquityRebalancing_label_en-US" xlink:label="lab_bvs_DeferredTaxesOnEquityRebalancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Taxes on Equity Rebalancing</link:label>
    <link:label id="lab_bvs_DeferredTaxesOnEquityRebalancing_documentation_en-US" xlink:label="lab_bvs_DeferredTaxesOnEquityRebalancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Taxes on Equity Rebalancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredTaxesOnEquityRebalancing" xlink:href="bvs-20230401.xsd#bvs_DeferredTaxesOnEquityRebalancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredTaxesOnEquityRebalancing" xlink:to="lab_bvs_DeferredTaxesOnEquityRebalancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ad08a3b7-b9da-4917-bc44-6a3a70faa497_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_83e4e3b2-834c-47dd-ba0a-05ea095202de_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37086bee-46d1-4034-8eea-b85c48faa7c4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d71d13d3-ddd7-48be-9b54-9822af8d9d86_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_ec7df2de-5fb0-4415-938d-eacca7a3be81_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_5887392d-319d-493f-9257-fd8136f6bf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BoardOfDirectorLengthOfTerm_0d36543f-89b6-448c-9fde-666f99568f37_terseLabel_en-US" xlink:label="lab_bvs_BoardOfDirectorLengthOfTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of board of directors term</link:label>
    <link:label id="lab_bvs_BoardOfDirectorLengthOfTerm_label_en-US" xlink:label="lab_bvs_BoardOfDirectorLengthOfTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Of Director, Length Of Term</link:label>
    <link:label id="lab_bvs_BoardOfDirectorLengthOfTerm_documentation_en-US" xlink:label="lab_bvs_BoardOfDirectorLengthOfTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Of Director, Length Of Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BoardOfDirectorLengthOfTerm" xlink:href="bvs-20230401.xsd#bvs_BoardOfDirectorLengthOfTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BoardOfDirectorLengthOfTerm" xlink:to="lab_bvs_BoardOfDirectorLengthOfTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1872131b-03fd-47d9-b78a-46a6444f46cd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest_624ae5bb-4897-496a-877f-4db500ceab59_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LLC Interests</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_33b33512-90b9-4cc5-8bb6-56667ea11639_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_645f528f-7ceb-41e8-9883-13c0dc6c9aee_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_26f1ac9e-32f5-4a8b-9941-86ac29f128d4_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred amount interest rate (in percent)</link:label>
    <link:label id="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_label_en-US" xlink:label="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Interest Rate</link:label>
    <link:label id="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" xlink:to="lab_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8bd54e97-4bae-4614-b5be-aac3585d6a12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_940fd534-1c47-4ac9-8e97-d0ba64f4318d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_4449619c-393e-4f51-b6a4-a1de443ae5d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_6e4b1718-f27d-4302-b0bd-9ced95c2fb36_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b47dc870-3393-464c-821f-25f241bdb3fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b342e478-4897-4aca-9e94-26545f5f7c91_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ab452076-8a53-4cc6-b5e3-2278ce02f79c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9efca4aa-9dff-4762-a447-e971a3c012b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock closing price, (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_11d34447-eb69-49ce-9888-507c0dbd71b6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f9fb8a85-3868-44c1-98ff-6e6fab899e06_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_TermLoanFacilityJuly2022Member_cc3deeff-a49c-4678-88db-35e34043f571_terseLabel_en-US" xlink:label="lab_bvs_TermLoanFacilityJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, July 2022</link:label>
    <link:label id="lab_bvs_TermLoanFacilityJuly2022Member_label_en-US" xlink:label="lab_bvs_TermLoanFacilityJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, July 2022 [Member]</link:label>
    <link:label id="lab_bvs_TermLoanFacilityJuly2022Member_documentation_en-US" xlink:label="lab_bvs_TermLoanFacilityJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility, July 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilityJuly2022Member" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilityJuly2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TermLoanFacilityJuly2022Member" xlink:to="lab_bvs_TermLoanFacilityJuly2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c5fefcb4-3b77-4c06-8784-82062ee10298_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization, year four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredConsiderationMember_3aa0e84a-138d-4ae4-9bbd-5c937a3e5250_terseLabel_en-US" xlink:label="lab_bvs_DeferredConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration</link:label>
    <link:label id="lab_bvs_DeferredConsiderationMember_label_en-US" xlink:label="lab_bvs_DeferredConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration [Member]</link:label>
    <link:label id="lab_bvs_DeferredConsiderationMember_documentation_en-US" xlink:label="lab_bvs_DeferredConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredConsiderationMember" xlink:href="bvs-20230401.xsd#bvs_DeferredConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredConsiderationMember" xlink:to="lab_bvs_DeferredConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_65ca8d88-28c1-4888-bc40-6baa995dfee9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_PainTreatmentsMember_ec50c462-900d-4a9b-8f81-feba389ba5a3_terseLabel_en-US" xlink:label="lab_bvs_PainTreatmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pain Treatments</link:label>
    <link:label id="lab_bvs_PainTreatmentsMember_label_en-US" xlink:label="lab_bvs_PainTreatmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pain Treatments [Member]</link:label>
    <link:label id="lab_bvs_PainTreatmentsMember_documentation_en-US" xlink:label="lab_bvs_PainTreatmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pain Treatments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PainTreatmentsMember" xlink:href="bvs-20230401.xsd#bvs_PainTreatmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PainTreatmentsMember" xlink:to="lab_bvs_PainTreatmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_883f1cba-8c53-4de7-8c49-8438b30158e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable and vested (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_264c2784-9c56-4cf7-9e49-c93adf9e5540_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51dff769-b1a6-4249-86b9-03070a4778a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_931532f3-a150-4ad0-9cfc-c8cc85c22f88_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b59a738e-5171-4210-a2d1-ae69e0956dfd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_288f640c-3af4-4f14-b69c-b0250caabd76_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3f9d7f4b-37cb-4bb6-8073-834b1fff5cf8_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_365ef3c5-e1b3-427e-9314-c3e9698f24b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CartiHealLtdMember_3eba0347-8609-4db3-8b69-744ec6d2fc5b_terseLabel_en-US" xlink:label="lab_bvs_CartiHealLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CartiHeal Ltd</link:label>
    <link:label id="lab_bvs_CartiHealLtdMember_label_en-US" xlink:label="lab_bvs_CartiHealLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CartiHeal Ltd [Member]</link:label>
    <link:label id="lab_bvs_CartiHealLtdMember_documentation_en-US" xlink:label="lab_bvs_CartiHealLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CartiHeal Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CartiHealLtdMember" xlink:to="lab_bvs_CartiHealLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5885f8f-d2a1-494e-8844-bac95f32953f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d224ea80-ac10-486c-919c-5ed93aa7fb23_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_e84bf97a-3264-4681-8b6a-efcb3bb5144a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212; continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_41600a8a-c2f0-4b53-83a9-808a3705eb55_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_0b1906d3-10c2-486c-b550-e15892fa2112_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_38fabde9-ce58-4f89-a370-c1501293f1cf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of class A common stock, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9b8cf641-2ba7-4e18-ad20-d512d6022afa_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of class A common stock, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSupplies_8ffac2f7-ea23-469a-bb0b-2ae04ffc437d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSupplies_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_484e83cc-2904-4360-9e73-6b42cf8b62bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_ec41c698-b956-4409-b407-c0822470ac2a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_TermLoanMember_e60c07af-6549-41f3-810d-6f6a15be28fc_terseLabel_en-US" xlink:label="lab_bvs_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_bvs_TermLoanMember_label_en-US" xlink:label="lab_bvs_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_bvs_TermLoanMember_documentation_en-US" xlink:label="lab_bvs_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TermLoanMember" xlink:to="lab_bvs_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_ae40b9ff-0681-401d-a933-f5fa4d9294ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CustomerOneMember_bcd124ba-bb9d-474f-a61c-f4609b162574_terseLabel_en-US" xlink:label="lab_bvs_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_bvs_CustomerOneMember_label_en-US" xlink:label="lab_bvs_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_bvs_CustomerOneMember_documentation_en-US" xlink:label="lab_bvs_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CustomerOneMember" xlink:href="bvs-20230401.xsd#bvs_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CustomerOneMember" xlink:to="lab_bvs_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_61aae815-479f-46f8-ae92-04833974721b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_51011c42-5c6c-4995-8d4c-5aa4aabd2ce4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_600be3a3-12cf-4248-884f-b49546f48c69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_01736009-5fb7-4941-a83a-7aacb642c3a2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_310ed6a6-5631-45af-9852-3c6d3739b577_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity attributable to Bioventus Inc.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_150729a1-1918-4d1e-8094-a195dc1a91df_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cd267329-2fc0-4604-aba9-8444ae107b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_d38d6b2a-1e14-420b-9091-944b234d686f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_c523dc0e-bb89-4acd-8182-acef231f841b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_14832b92-f8ea-43cb-b254-8e1fa1088ea0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d9353939-aef9-413b-954d-1a2444fbe93b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e43ec6b-fb90-4e55-86a7-b70a5c85e956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_GrossToNetDeductionsCurrent_c047b368-aa7d-4253-9beb-ee55fed4fcce_terseLabel_en-US" xlink:label="lab_bvs_GrossToNetDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net deductions</link:label>
    <link:label id="lab_bvs_GrossToNetDeductionsCurrent_label_en-US" xlink:label="lab_bvs_GrossToNetDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-To-Net Deductions, Current</link:label>
    <link:label id="lab_bvs_GrossToNetDeductionsCurrent_documentation_en-US" xlink:label="lab_bvs_GrossToNetDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-To-Net Deductions, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_GrossToNetDeductionsCurrent" xlink:href="bvs-20230401.xsd#bvs_GrossToNetDeductionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_GrossToNetDeductionsCurrent" xlink:to="lab_bvs_GrossToNetDeductionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1ec9162-7aea-4505-839c-d4563303162a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_39fd9fa4-86d2-4ec3-85ff-c01f718853a7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5ec0c13b-fff6-4428-b683-763791257718_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization, year three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_05874b24-2042-4480-bd35-2bbb06f2d0bf_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1ec77f0f-b4b6-4cad-bff8-6a10752396e9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_127618d2-cb4b-4b3a-91d0-cee30087d9b4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0fa4df25-e91c-421b-af09-185f4cb3808e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_a752cf6e-4b1b-46c0-8830-dce9701c4bd9_totalLabel_en-US" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net before currency translation</link:label>
    <link:label id="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_documentation_en-US" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" xlink:to="lab_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_96507b9d-0599-4fcc-917f-47a5f4f14590_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c4b9abaa-2060-44dd-a06d-de5e7433ca05_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_7b039140-eae6-43ec-ba7b-cd756a8bedf2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_12206259-7579-4caa-a312-8d31741a40b1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_010f409d-0468-4a63-8a5c-1b79d4c866e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available to be awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d524654d-ae3b-4884-ab2b-bcc371a9cc78_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9c8644ac-ec3d-4428-9cbd-38dfd71db1d1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_cff3307b-c837-4944-96f1-e9e3af3a762e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_50a341b5-e4bb-43d3-80d9-3cd048aea994_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_72ea5fd1-b2f2-46ee-b7d5-bfbf9931c8c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_a2d079ce-ff1c-40ee-bf86-846b88937be3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_4b236ea2-21db-4c81-b7e2-db56badd943b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held for Sale Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_c76d553c-206d-4495-b080-478ba8cbaf16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet and Statement of Operation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b51080b9-4e03-4c75-869c-75f93eddcd84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_025e8c17-278a-4827-b65f-acafb7f3ecc1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_87669a50-50b1-44e5-a28e-6ce835b46d85_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c675d4d1-5b13-4aa5-bad8-5d6a854ad80c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8ecc73e0-10f3-4e7f-bd3d-7e6271962f71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities- noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_TrailingTwelveMonthSalesMember_5899ddcb-bae6-4e86-8ab7-90035afb162e_terseLabel_en-US" xlink:label="lab_bvs_TrailingTwelveMonthSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Sales</link:label>
    <link:label id="lab_bvs_TrailingTwelveMonthSalesMember_label_en-US" xlink:label="lab_bvs_TrailingTwelveMonthSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Sales [Member]</link:label>
    <link:label id="lab_bvs_TrailingTwelveMonthSalesMember_documentation_en-US" xlink:label="lab_bvs_TrailingTwelveMonthSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Twelve Month Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TrailingTwelveMonthSalesMember" xlink:href="bvs-20230401.xsd#bvs_TrailingTwelveMonthSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TrailingTwelveMonthSalesMember" xlink:to="lab_bvs_TrailingTwelveMonthSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3465125b-dab1-44c6-8206-177ef0f983c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_caa09839-7ea0-4d90-85ba-e369248907d6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_EquityRebalancingMember_3137d78f-fc47-4fb5-bf5a-bff00733f563_terseLabel_en-US" xlink:label="lab_bvs_EquityRebalancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Rebalancing</link:label>
    <link:label id="lab_bvs_EquityRebalancingMember_label_en-US" xlink:label="lab_bvs_EquityRebalancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Rebalancing [Member]</link:label>
    <link:label id="lab_bvs_EquityRebalancingMember_documentation_en-US" xlink:label="lab_bvs_EquityRebalancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Rebalancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_EquityRebalancingMember" xlink:href="bvs-20230401.xsd#bvs_EquityRebalancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityRebalancingMember" xlink:to="lab_bvs_EquityRebalancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonrecurringExpense_17138b81-7e62-4734-bcda-fc16ce01bacf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonrecurring Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringExpense" xlink:to="lab_us-gaap_OtherNonrecurringExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_30e85384-139d-48e8-83b7-2a8d61d29ea5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_c60043bb-fd77-4eb1-bfdd-173ad8ed1dd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to noncontrolling interest - discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f8739c6b-4f5e-44fe-af19-b6cb5212497e_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_6fe37474-0132-4c5d-8aae-953dfe88c2d8_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other assets</link:label>
    <link:label id="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_label_en-US" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investment And Other Assets</link:label>
    <link:label id="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investment And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" xlink:to="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9248f63c-b321-47dd-b417-fe658264fe7f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0f94290a-7c6b-405e-b2d2-d8bbe879499f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_4629070a-bcec-4093-b685-daddd3232bf7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_dbe5f0f9-c714-476f-ae5a-cc70226265b6_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8c05cedb-2c2a-4259-a0a9-6ef369414412_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_27f298c1-a47a-4bb8-91a0-2d7d0e60efa0_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_61c4e7e0-69ef-471f-adf4-8b58fcc9c706_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_79960180-e74d-4439-ad10-5505f42a0897_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7a5ca807-295e-4683-b424-6c5bd0c88de9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c9d10a12-1f64-4680-920a-c0271f15ad30_totalLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Income (Loss)</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_5f455e1f-c369-4860-90ec-3dcbc960ef91_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_515219e6-4e46-4283-9d62-bbd3806bc511_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense (income), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_ff8534ba-182f-499a-80fe-fd3a0c8db696_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d256b391-d795-44f3-8f47-4eb8350d15b5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_d87fcf74-26c9-40e1-b3d3-e618b1c77f4a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_TermLoanFacilitiesMember_2fae1ea2-e639-4fa3-bf35-1106de074165_terseLabel_en-US" xlink:label="lab_bvs_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities</link:label>
    <link:label id="lab_bvs_TermLoanFacilitiesMember_label_en-US" xlink:label="lab_bvs_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:label id="lab_bvs_TermLoanFacilitiesMember_documentation_en-US" xlink:label="lab_bvs_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilitiesMember" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TermLoanFacilitiesMember" xlink:to="lab_bvs_TermLoanFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_e6efde90-5793-4145-84a6-ed614c36f8d7_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Consideration, Noncurrent</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Consideration, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_61ab8cbe-01cc-4d19-9ddc-14864e0f61cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6bc09642-4f2e-42e2-96b3-f458fa5dd108_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_a1cb607a-1018-44dc-8892-8b3e6490ec5d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_09da0beb-feac-4739-82ec-20f13ff90983_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ec8c693d-adfd-4bbb-bfb2-5d0f499aba9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed2fdc04-6f73-4bf6-96c7-0951695fdfcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_61e84479-2bad-434f-be84-9ee8067650cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_38ebdbb2-a1a3-4c15-8ff1-1136c0843ac2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_81db5f27-6261-4891-88c3-110a9cb0a912_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0f68e410-f2b5-41c3-be4f-3413eed12c3a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0baacdc1-b564-4e5e-8aa5-c9273757e3c9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_c8a3a643-d45a-4aad-a320-232a2b767a1d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3e9c81a2-673b-4428-a94a-14c891cad30e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_92006775-73a0-4a8a-a865-d318ea7ddcff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_HAProductMember_d2d763a5-be11-4698-8453-f05685885d57_terseLabel_en-US" xlink:label="lab_bvs_HAProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HA Product</link:label>
    <link:label id="lab_bvs_HAProductMember_label_en-US" xlink:label="lab_bvs_HAProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HA Product [Member]</link:label>
    <link:label id="lab_bvs_HAProductMember_documentation_en-US" xlink:label="lab_bvs_HAProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HA Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_HAProductMember" xlink:href="bvs-20230401.xsd#bvs_HAProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_HAProductMember" xlink:to="lab_bvs_HAProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2373379f-b85b-42d1-bc5c-f8afa3b41595_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_33b716da-0b6f-4675-950f-34cb0cb25836_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_ff88e1e2-f644-449b-b71b-34e6d56f2d9b_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration transferred percentage</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_label_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Percentage Of Members Owning Diluted Shares</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Percentage Of Members Owning Diluted Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" xlink:to="lab_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_e6a25524-aae2-4591-8448-58b8b9fc70a2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0f3c1006-9204-446c-843d-b75557f2ce2d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f12a148f-2d68-435d-8af0-abd9fe92bae0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8b7c5c52-8e20-4870-9665-8895b5635187_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_09958cfe-d4bd-4ee7-88fa-9cb6867e15f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7a38008-b068-4d47-9486-609cfed474d3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_A2021PlanMember_b077c01d-f24a-430e-bced-8a250a3ae3d9_terseLabel_en-US" xlink:label="lab_bvs_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_bvs_A2021PlanMember_label_en-US" xlink:label="lab_bvs_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan [Member]</link:label>
    <link:label id="lab_bvs_A2021PlanMember_documentation_en-US" xlink:label="lab_bvs_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_A2021PlanMember" xlink:href="bvs-20230401.xsd#bvs_A2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_A2021PlanMember" xlink:to="lab_bvs_A2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6a1f87b1-a87b-4a49-a4e7-e4e0a5a51eec_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_5d842fdf-9189-4647-b7b7-eecb878a0083_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_75db0fe6-1479-412f-ac7b-434aa52b388e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_440258e3-1c7a-46e5-8c80-2fa10a7d078d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_18fefdc0-99e3-4728-bf47-8150a2adcc73_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_e5c48c25-2313-425b-9974-aff2ac12ed54_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0892efae-dc6b-42b6-835a-ec329a05c78d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_9ba2cc41-c012-43d4-ac48-041683f9f174_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5aa4e165-5980-4d81-9b45-24cee348623d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CompensationAndEmployeeBenefitPlansAbstract_label_en-US" xlink:label="lab_bvs_CompensationAndEmployeeBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation And Employee Benefit Plans [Abstract]</link:label>
    <link:label id="lab_bvs_CompensationAndEmployeeBenefitPlansAbstract_documentation_en-US" xlink:label="lab_bvs_CompensationAndEmployeeBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation And Employee Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract" xlink:to="lab_bvs_CompensationAndEmployeeBenefitPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_344ef2eb-6ba1-43af-bf78-a193b00b4656_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_00fa2e7d-2002-4512-becb-b89dab8e657f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bce13892-6288-4e26-8c6d-5408885d4a75_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_b43bdfa4-81da-4d63-8761-85d86b015dcb_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bda88b41-607a-444a-973b-ad79d660fddd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7a84d962-dcf5-4085-986b-4712e8b25fb3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3180eaf5-a670-4b53-b9cc-25e987d4aae6_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_47b70b57-9517-4dd8-9bb9-4365bd3cc2b1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b67f412-db84-4dc0-9788-66364f3ad3c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_242c20e0-1606-46c3-aace-d7ecf1d14c1b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2b93e642-0356-420f-b168-ec466093654d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SalesMilestoneMember_a86ccc5d-c9e6-49ab-b82f-75b3edf1c59f_terseLabel_en-US" xlink:label="lab_bvs_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_bvs_SalesMilestoneMember_label_en-US" xlink:label="lab_bvs_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_bvs_SalesMilestoneMember_documentation_en-US" xlink:label="lab_bvs_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SalesMilestoneMember" xlink:to="lab_bvs_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3dab88d7-309a-45eb-a0b0-97d5fb0a76e2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_80a05fad-3940-45df-b94c-b32b0e7a6139_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_59ef8e91-02e2-4eb5-a672-286ec9c6410e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including depreciation and amortization of $14,339, $9,218, respectively)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cf007168-75ad-4335-86c4-64092ad764d8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52de70ca-1c7c-4bcd-b888-b3b6115ea0a2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of Class A common stock outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_57dfd4c2-7886-47dc-be9d-7a07e8bfceed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dfe240c3-1bf1-43d3-8696-5a51db70fc75_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of stock options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4c37d8d9-0a7c-4abd-9348-e9350af6d7f6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_1415d79d-fda3-4ca4-ae6a-022d34a7d05d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_efeaaf60-f563-47d0-acd4-3f2df70f3c4e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_03b6c3e3-93d2-49a1-8dc2-f85446308ae9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_17c2525e-ec88-486c-8d95-7996572537e9_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2ae381f6-0a55-4470-86d7-0c1bb1bf453b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ElronMember_81a1a1c5-ea75-4c30-a7d0-ac49fc4227eb_terseLabel_en-US" xlink:label="lab_bvs_ElronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elron</link:label>
    <link:label id="lab_bvs_ElronMember_label_en-US" xlink:label="lab_bvs_ElronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elron [Member]</link:label>
    <link:label id="lab_bvs_ElronMember_documentation_en-US" xlink:label="lab_bvs_ElronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ElronMember" xlink:href="bvs-20230401.xsd#bvs_ElronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ElronMember" xlink:to="lab_bvs_ElronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0eef3caa-86e5-4696-8ae2-25146d75c684_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_583dc6f7-da95-40e3-a956-2a9a49410b2d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a1d0b30c-7c26-4550-9359-82ee93cc8726_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_56f5d091-ce1a-4c04-8070-a4b23887c9d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_dbd1b9ea-4e81-4dec-9ac0-23fe3863569f_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_18a94c89-4670-4b23-8f27-7838b6961d3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ff115d1-701d-4f97-9599-8f56f7cac8ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BVLLCMember_58432b56-c9d8-4f23-8a22-3eed0118a896_terseLabel_en-US" xlink:label="lab_bvs_BVLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BV LLC</link:label>
    <link:label id="lab_bvs_BVLLCMember_label_en-US" xlink:label="lab_bvs_BVLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BV LLC [Member]</link:label>
    <link:label id="lab_bvs_BVLLCMember_documentation_en-US" xlink:label="lab_bvs_BVLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BV LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BVLLCMember" xlink:to="lab_bvs_BVLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3df6501b-078e-4da7-a2fc-5861c1287b84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_87422349-4ca2-40fe-8929-5eae2f8cef67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_b5b2b6c4-5800-4dd3-943a-d1ec4149fe29_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_389b5001-2ef0-4ffc-b19a-462a457f15f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_1592118a-0d3b-4d0a-bd09-c92898a501e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f57c240a-01c6-4d37-a200-d217db010d58_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BioventusAndContinuingLLCOwnerMember_a957c6e7-9650-4a74-9068-60e9d4119777_terseLabel_en-US" xlink:label="lab_bvs_BioventusAndContinuingLLCOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioventus and Continuing LLC Owner</link:label>
    <link:label id="lab_bvs_BioventusAndContinuingLLCOwnerMember_label_en-US" xlink:label="lab_bvs_BioventusAndContinuingLLCOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioventus And Continuing LLC Owner [Member]</link:label>
    <link:label id="lab_bvs_BioventusAndContinuingLLCOwnerMember_documentation_en-US" xlink:label="lab_bvs_BioventusAndContinuingLLCOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioventus And Continuing LLC Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BioventusAndContinuingLLCOwnerMember" xlink:href="bvs-20230401.xsd#bvs_BioventusAndContinuingLLCOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BioventusAndContinuingLLCOwnerMember" xlink:to="lab_bvs_BioventusAndContinuingLLCOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d9bc5c7e-fa5a-475c-ab03-d938ee849b35_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0aeaa6f5-288e-4968-b6de-5aaf2e1f704d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8c29dac9-04f0-4552-8c5b-0e43a273e27d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6008db93-2e87-49cc-93a1-cfa8d5afe0ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2c4c8cfd-d33a-49bd-b2b5-0c1b296ea3dc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_b5b56a9d-a1cf-4eee-84ae-71671ce429f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonus and commission</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_df812171-df12-48e0-bfd3-fa4b99521f5c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredAmountPayableBySeptember12023Member_85c6ef3b-b0a3-452a-b83c-70000d3ead00_terseLabel_en-US" xlink:label="lab_bvs_DeferredAmountPayableBySeptember12023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable by September 1 2023</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableBySeptember12023Member_label_en-US" xlink:label="lab_bvs_DeferredAmountPayableBySeptember12023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By September 1 2023 [Member]</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableBySeptember12023Member_documentation_en-US" xlink:label="lab_bvs_DeferredAmountPayableBySeptember12023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By September 1 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableBySeptember12023Member" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableBySeptember12023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredAmountPayableBySeptember12023Member" xlink:to="lab_bvs_DeferredAmountPayableBySeptember12023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f2df41b2-7030-4ce8-926e-7b8a63025144_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c86b8e69-c585-4621-be39-aba2abf975e8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_RestorativeTherapiesMember_da840261-5883-4e15-9df8-23683e5f6d0d_terseLabel_en-US" xlink:label="lab_bvs_RestorativeTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restorative Therapies</link:label>
    <link:label id="lab_bvs_RestorativeTherapiesMember_label_en-US" xlink:label="lab_bvs_RestorativeTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restorative Therapies [Member]</link:label>
    <link:label id="lab_bvs_RestorativeTherapiesMember_documentation_en-US" xlink:label="lab_bvs_RestorativeTherapiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restorative Therapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestorativeTherapiesMember" xlink:href="bvs-20230401.xsd#bvs_RestorativeTherapiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RestorativeTherapiesMember" xlink:to="lab_bvs_RestorativeTherapiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3e6f02b9-705a-48e5-9bb9-97517629f8d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a0416253-49fc-4629-afe1-06aa0335bef5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9a9a44f2-69a1-492e-83dd-94c27181915c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_6940ba36-205f-4c7e-a712-a9fc07f5cf44_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e1eda7f0-1eae-44bb-a2b0-b5d0f7ecbe5b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable for purchase of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_35839523-00c7-4632-9dd2-4d24f73e9f7d_terseLabel_en-US" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation</link:label>
    <link:label id="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_documentation_en-US" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" xlink:to="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5832212a-a479-4ca7-902f-c050199839b1_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction related fees and expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3011dbeb-d01b-4dc5-8821-3a5050b1ed8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_da1312da-6471-4952-b766-4853dd21e46d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d52e7d3-1c54-475a-9cc9-d1a628877c55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dd4cd6ee-c2fe-4238-9137-9c02a86f0c5d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bf96f82c-5380-450f-a84b-2828d3d41386_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0804b554-7f3d-484f-b060-1c32967ac290_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_071f1493-28c7-4697-80e7-e0b54fda2168_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_d61d0edf-3c8c-43d5-b229-0750d9268698_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_4ad6f1e6-2516-4b35-8dff-862efcaafaf1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_3be2f01f-9aba-4f90-9983-3d7e0548a093_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing on revolver</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AcquisitionRestructuringPlanOf2022Member_b295c757-1dbb-4f57-b615-de3ea321fa85_terseLabel_en-US" xlink:label="lab_bvs_AcquisitionRestructuringPlanOf2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Restructuring Plan Of 2022</link:label>
    <link:label id="lab_bvs_AcquisitionRestructuringPlanOf2022Member_label_en-US" xlink:label="lab_bvs_AcquisitionRestructuringPlanOf2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Restructuring Plan Of 2022 [Member]</link:label>
    <link:label id="lab_bvs_AcquisitionRestructuringPlanOf2022Member_documentation_en-US" xlink:label="lab_bvs_AcquisitionRestructuringPlanOf2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Restructuring Plan Of 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AcquisitionRestructuringPlanOf2022Member" xlink:href="bvs-20230401.xsd#bvs_AcquisitionRestructuringPlanOf2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AcquisitionRestructuringPlanOf2022Member" xlink:to="lab_bvs_AcquisitionRestructuringPlanOf2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a6806d50-2eb5-4f95-8ffd-62c6d2b82c1f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of previously held equity interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_28f4309b-f950-46d5-86f5-55e7fe2c3654_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bioventus Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_PaymentOfDebtRefinancingCosts_1ee3fa77-2e85-400e-818a-78e1ff25705c_negatedTerseLabel_en-US" xlink:label="lab_bvs_PaymentOfDebtRefinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt refinancing costs</link:label>
    <link:label id="lab_bvs_PaymentOfDebtRefinancingCosts_label_en-US" xlink:label="lab_bvs_PaymentOfDebtRefinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Debt Refinancing Costs</link:label>
    <link:label id="lab_bvs_PaymentOfDebtRefinancingCosts_documentation_en-US" xlink:label="lab_bvs_PaymentOfDebtRefinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Debt Refinancing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PaymentOfDebtRefinancingCosts" xlink:href="bvs-20230401.xsd#bvs_PaymentOfDebtRefinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PaymentOfDebtRefinancingCosts" xlink:to="lab_bvs_PaymentOfDebtRefinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_6650a47d-e44d-4b4c-8252-e307d97431bd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from operating activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_250f1731-2ba7-4b09-b84a-478ece86d57f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from investing activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7d1e7f78-3eda-42be-a799-6ca65a1c4239_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c5db51f5-fe6f-4bf2-80bc-4dae2baa5ef4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bdfff465-7109-46ac-909b-4f6453fc6ba3_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_34893abd-88f3-4f10-9d25-c364c051bde3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212; discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_befaeb6f-36d2-40a9-b110-e70bcbcf638a_terseLabel_en-US" xlink:label="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of shares transferred to trustee</link:label>
    <link:label id="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_label_en-US" xlink:label="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage Of Shares Transferred To Trustee</link:label>
    <link:label id="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_documentation_en-US" xlink:label="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage Of Shares Transferred To Trustee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" xlink:href="bvs-20230401.xsd#bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" xlink:to="lab_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_ef632af9-c5fb-48b0-a894-39c6d87e818f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_91db1be4-473d-4cd8-aa9a-07b7ac84fd67_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_2d427823-051b-4ab8-927c-891c281251db_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SupplierOfSingleInjectionOAProductMember_b4152cc5-988a-4798-9490-faaadc635d59_terseLabel_en-US" xlink:label="lab_bvs_SupplierOfSingleInjectionOAProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier of Single Injection OA Product</link:label>
    <link:label id="lab_bvs_SupplierOfSingleInjectionOAProductMember_label_en-US" xlink:label="lab_bvs_SupplierOfSingleInjectionOAProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Of Single Injection OA Product [Member]</link:label>
    <link:label id="lab_bvs_SupplierOfSingleInjectionOAProductMember_documentation_en-US" xlink:label="lab_bvs_SupplierOfSingleInjectionOAProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Of Single Injection OA Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplierOfSingleInjectionOAProductMember" xlink:href="bvs-20230401.xsd#bvs_SupplierOfSingleInjectionOAProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplierOfSingleInjectionOAProductMember" xlink:to="lab_bvs_SupplierOfSingleInjectionOAProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2e8267c3-ae43-4ad1-992a-f304ec65cddb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12025Member_d12d81a5-e3d4-4cdb-b9ac-29ea93c4695f_terseLabel_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable by January 1 2025</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12025Member_label_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By January 1 2025 [Member]</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12025Member_documentation_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By January 1 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12025Member" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredAmountPayableByJanuary12025Member" xlink:to="lab_bvs_DeferredAmountPayableByJanuary12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_31e68133-7982-470f-9b73-3d9fa2731808_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee severance and temporary labor costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_76b4dc4e-c268-48b1-8517-58a468df7d1b_negatedTotalLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f73ef196-f26b-440f-9d5a-711755353dfa_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bc13255e-a469-4ab3-af23-859e6c66410f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e83542b-cef0-4a40-8960-4ea99850367b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2c55467d-7dfe-4a23-a07b-16dc5191089b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_1c3c13bb-a5aa-4256-839e-ed19f2cecff0_terseLabel_en-US" xlink:label="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_label_en-US" xlink:label="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Stockholders' Equity And Members' Equity [Roll Forward]</link:label>
    <link:label id="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_documentation_en-US" xlink:label="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Stockholders' Equity And Members' Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:href="bvs-20230401.xsd#bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:to="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_15f82bf0-8ec3-45a1-b242-8543f87cf965_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6654cd0d-6a9f-465b-a2fb-ea602a8222d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7516b595-9741-4969-9c72-4bc0c8630d29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_f00ba057-418c-4a0f-bb5f-0628d4e4d291_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_38062d92-6d9f-49a5-942c-e881d28dcef2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_4565d428-535e-4425-b130-282babadbe84_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesGPreferredStockMember" xlink:to="lab_us-gaap_SeriesGPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_983457a7-e143-45ca-a029-942fabb246a7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e1a270ee-ab6f-4e64-a1c3-2a888016b761_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_295fe5c0-8536-42d0-8ec3-10f292b364c3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_10a85aae-2dd7-4d47-ac8e-50fc339ddae4_terseLabel_en-US" xlink:label="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability written off for deconsolidation</link:label>
    <link:label id="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_label_en-US" xlink:label="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Written Off For Deconsolidation</link:label>
    <link:label id="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_documentation_en-US" xlink:label="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Written Off For Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" xlink:href="bvs-20230401.xsd#bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" xlink:to="lab_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2d0c91f5-85bb-4420-9eed-d6fcd066f991_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_dafa454e-f3c1-4935-b7aa-2a5ab1f7bb6e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bb5bb1ad-564a-4a57-a556-06d25e70f7f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_af077bcb-29f9-441c-887c-ad9acaf880c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_d72141b4-e930-4340-9a3d-e1ffcc844ad2_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_label_en-US" xlink:label="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Number Of Tranches</link:label>
    <link:label id="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" xlink:to="lab_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c6e6d44-737d-41fc-b8be-3d475261fb2c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_2faa7860-05cb-48f0-9109-e0c392f0817a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8ffaf102-bb39-4d3b-8f1c-39343883fbf4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_b7d5d4b6-1b25-4057-bc5c-f2f45e30d4ca_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_eb04da12-32bf-4650-8253-5253a0b84442_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share in public offering (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_83d0fe6b-5343-4e96-8029-2d3f41e573f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e9037d4c-2b4d-4daa-9dfa-a947c4800fb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_67da5395-e9c2-4117-bd34-843c59c201bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4a8a89be-acaf-40d1-9dd1-8ca80064df0e_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payments</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dc3a1983-707e-43f5-8a0d-b853265fe3f1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_855aa959-80e1-48e9-bb08-136b9b1d30b3_terseLabel_en-US" xlink:label="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:label id="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_documentation_en-US" xlink:label="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="bvs-20230401.xsd#bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_77856cad-6911-4ad0-b1bf-63ebebdd22d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_31642d7b-8ad8-4cb7-95fe-774262cbf875_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense (income), net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SupplyCommitmentTerm_ad6ed815-0003-4078-9d00-c6ce085c6d82_terseLabel_en-US" xlink:label="lab_bvs_SupplyCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply commitment, term</link:label>
    <link:label id="lab_bvs_SupplyCommitmentTerm_label_en-US" xlink:label="lab_bvs_SupplyCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Term</link:label>
    <link:label id="lab_bvs_SupplyCommitmentTerm_documentation_en-US" xlink:label="lab_bvs_SupplyCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplyCommitmentTerm" xlink:href="bvs-20230401.xsd#bvs_SupplyCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplyCommitmentTerm" xlink:to="lab_bvs_SupplyCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_a5064c0e-b10e-4451-8a72-4052cb1dae3e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_199d553c-b893-420f-8b1b-3523940a62ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_USSegmentMember_d6e328c3-25dc-498c-add9-e0ff021b4231_verboseLabel_en-US" xlink:label="lab_bvs_USSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Segment</link:label>
    <link:label id="lab_bvs_USSegmentMember_24b03c17-bd3e-4dc5-8621-828ec94d7d5d_terseLabel_en-US" xlink:label="lab_bvs_USSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_bvs_USSegmentMember_label_en-US" xlink:label="lab_bvs_USSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Segment [Member]</link:label>
    <link:label id="lab_bvs_USSegmentMember_documentation_en-US" xlink:label="lab_bvs_USSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_USSegmentMember" xlink:href="bvs-20230401.xsd#bvs_USSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_USSegmentMember" xlink:to="lab_bvs_USSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_99ba931c-65cb-4a6a-9ef3-9c8496f7f8e0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8e0f9b56-7f9b-46cf-990e-e7a5b1613198_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12027Member_346f65fb-6ba1-4b31-9080-0e89e22eaa8a_terseLabel_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable by January 1 2027</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12027Member_label_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By January 1 2027 [Member]</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJanuary12027Member_documentation_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJanuary12027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By January 1 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12027Member" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredAmountPayableByJanuary12027Member" xlink:to="lab_bvs_DeferredAmountPayableByJanuary12027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_ccd0023f-07b2-4040-abb3-badca9c294a2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income and other taxes</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_d3236b6f-2ca1-43f2-ab92-c45a99784064_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_abc32576-b618-455c-9839-9e6d26d92656_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_e460c52b-fded-4cec-96dc-7c126bb33a7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_45673479-c9c2-41dc-9a9d-7d328d9f1376_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_472e2799-40ad-418d-8cd5-30cf1fba50d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_39864ef1-8f56-466e-a367-3684cdc6429e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_98220319-b950-44c2-8fcc-4d3536a55c47_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f9e0b2ff-6226-4ce2-884d-106f7af6cbf9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2c3c4ec1-6902-44d0-a3c5-7cb9f7badebf_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c85ffde6-050d-4f75-bc20-ffe77c5a3ea0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5403a86c-f218-40bb-906a-3f7f04aa3fd6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8226b123-f278-4938-86b6-e6914b1b9024_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_00390199-e2bb-4131-9604-72330f83cc37_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, royalty percentage, threshold two</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" xlink:to="lab_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_50f42474-4faa-4307-bdc8-65c122735acd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_fb6d6029-84e9-48d7-aac8-4e26aa22005c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3d01f05c-cbcb-4eeb-8fd6-281b751ebfe3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_bc1c5f43-e730-45bf-aba2-0bb09e634aa3_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out payments</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Earn-Out Payments</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Earn-Out Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1ab2d1f6-ddc5-4733-b6c0-de75e59abc0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_42e7a9c7-7d0f-4d15-9781-92b03ba09b91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionRightsMember_a832401c-533b-4b43-9e2d-19a9d56db940_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution rights</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember" xlink:to="lab_us-gaap_DistributionRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_78a7d74d-9d60-4fc1-b4d2-4f0f9f7d9d7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c2748c4f-54cf-4fab-a9f9-629f2d0aa0cf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_33b911df-042c-43b1-9ed1-4e36c74a8f0b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_5b6c6717-a6c4-430e-86ed-55b664f493f5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ed2c189d-c077-4502-ba6a-234db3a30064_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_524241ac-de15-4f8e-aee2-2bbf6f14d0ee_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_897cff94-91eb-4ce4-8e6a-d4b34f0d73c2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear_846966c8-7549-4ab3-8e91-8668e8a79748_terseLabel_en-US" xlink:label="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop loss insurance, threshold per member per year</link:label>
    <link:label id="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear_label_en-US" xlink:label="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop Loss Insurance, Threshold Per Member Per Year</link:label>
    <link:label id="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear_documentation_en-US" xlink:label="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop Loss Insurance, Threshold Per Member Per Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:href="bvs-20230401.xsd#bvs_StopLossInsuranceThresholdPerMemberPerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:to="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a2359bfd-bd96-4cbf-b62f-0a77ce94422f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_53273b3b-cd73-448e-9895-09bb07fb6c1f_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction related costs</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_label_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Transaction Costs</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts" xlink:to="lab_bvs_BusinessCombinationConsiderationTransferredTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c2547374-3f38-4371-b98f-48525df0854a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_782f4b4b-a73d-478c-8b97-dafb965c1837_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_24257c7e-d37c-4aab-b280-7f8c0408014e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_b2e73400-ebb4-4a5f-82b1-b7b8299bd332_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">As Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_39cf8c86-37b7-4392-813f-90806e6d6efd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization, year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_b00a80bb-61b4-4870-8cc3-4132b3297de0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of interest rate swap</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e7a9f6b-fde2-4c54-b83d-0421c772c7c5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_dacb1ab2-cbc9-4ee6-b13c-1504736c41cb_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_NonRefundablePayments_0973ce48-d263-49bc-a6f6-0c62ee7acf87_terseLabel_en-US" xlink:label="lab_bvs_NonRefundablePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable payments</link:label>
    <link:label id="lab_bvs_NonRefundablePayments_label_en-US" xlink:label="lab_bvs_NonRefundablePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Payments</link:label>
    <link:label id="lab_bvs_NonRefundablePayments_documentation_en-US" xlink:label="lab_bvs_NonRefundablePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_NonRefundablePayments" xlink:href="bvs-20230401.xsd#bvs_NonRefundablePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NonRefundablePayments" xlink:to="lab_bvs_NonRefundablePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62c205df-aae8-420d-9a28-93044ad96446_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_04f8b5fd-5a28-4ac7-87c1-4c2e9032e289_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCashReceivedOnHedge_aeabe48f-3ac3-4822-ac50-5c2f028a159d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCashReceivedOnHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received settlement</link:label>
    <link:label id="lab_us-gaap_DerivativeCashReceivedOnHedge_label_en-US" xlink:label="lab_us-gaap_DerivativeCashReceivedOnHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Cash Received on Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCashReceivedOnHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCashReceivedOnHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCashReceivedOnHedge" xlink:to="lab_us-gaap_DerivativeCashReceivedOnHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b6df7a41-7f10-4a0f-b9e1-bc8a087505bd_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_42a4f61f-69ee-4982-b7b0-f2aca5c60e2e_terseLabel_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, amount payable upon obtaining product certification</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_label_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification</link:label>
    <link:label id="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_documentation_en-US" xlink:label="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" xlink:to="lab_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_7146aaac-e635-4434-a5f7-aada0aaa2378_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_00f15325-d8a8-4a47-86fa-9efdbda8d18c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d17a3777-8a15-4810-8bad-fc717c9d0123_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4015f4e6-7710-4543-bf13-fbbd82633149_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_36821e3e-d4c1-404b-a36a-8a2d3c3788bb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_48a12359-a0dc-4e47-8311-e68d7b72c675_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_9fe34ea2-0693-4eea-a840-9ee99b8551e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and succession charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_5c561b7a-331c-48d1-8e8f-8dd3b4ebc0e8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_fdc7e30a-9776-4509-b662-13ac5c381f50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_feeea2ef-e87c-4fca-9e40-c4cbc4ac2461_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original issue discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_f6f75019-b3fd-4f01-ac5b-554916bc30d1_totalLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bioventus Inc.</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_RestructuringPlanOf2022Member_43f28d03-f9c6-4414-9132-d9d68abd4cd9_terseLabel_en-US" xlink:label="lab_bvs_RestructuringPlanOf2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan of 2022</link:label>
    <link:label id="lab_bvs_RestructuringPlanOf2022Member_label_en-US" xlink:label="lab_bvs_RestructuringPlanOf2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan Of 2022 [Member]</link:label>
    <link:label id="lab_bvs_RestructuringPlanOf2022Member_documentation_en-US" xlink:label="lab_bvs_RestructuringPlanOf2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan Of 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestructuringPlanOf2022Member" xlink:href="bvs-20230401.xsd#bvs_RestructuringPlanOf2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RestructuringPlanOf2022Member" xlink:to="lab_bvs_RestructuringPlanOf2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_1cb74810-658d-46e5-812a-8adf22d1d57a_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e6008da7-f615-4b31-9bcd-6ba1f15195c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of Class A common stock from continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b383da1c-d876-447d-9178-9c4166639921_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of Class A common stock from continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3c8ca377-f0f6-47f6-b82f-0406fd8696b6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_622bb608-9ba8-4440-a734-8a26fa7e8d1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Class A and B common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f7a1edbd-16a8-4f35-a83a-1fcbe1abe482_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0af0159b-5b17-431e-a9e3-e766546a903a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19737e4c-1167-48c5-a65d-b914698efbc3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of Class A common stock outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_29be351e-0e03-4596-8d21-dd41b7b00c9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_14106668-c1e9-4240-9311-9692f86fec9a_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1d04c084-0b2b-46d7-9575-9df0507c7fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable and vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredAmountPayableByJuly12023Member_d0a03114-0337-461f-9397-6a5878ccfe7d_terseLabel_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJuly12023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable by July 1 2023</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJuly12023Member_label_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJuly12023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By July 1 2023 [Member]</link:label>
    <link:label id="lab_bvs_DeferredAmountPayableByJuly12023Member_documentation_en-US" xlink:label="lab_bvs_DeferredAmountPayableByJuly12023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount Payable By July 1 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJuly12023Member" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJuly12023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredAmountPayableByJuly12023Member" xlink:to="lab_bvs_DeferredAmountPayableByJuly12023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_f6d1dc71-73db-432e-a64d-6da523aa28a9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c44f9928-0adb-439f-a141-577e7ee7c77a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_37454c78-1868-458f-926b-81d92220c543_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_6a0bb57a-32f7-4f0e-8581-de8cad5f7a37_terseLabel_en-US" xlink:label="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and acquisition of distribution rights</link:label>
    <link:label id="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_label_en-US" xlink:label="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments</link:label>
    <link:label id="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_documentation_en-US" xlink:label="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" xlink:href="bvs-20230401.xsd#bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" xlink:to="lab_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_91251954-434c-4137-9e28-b4dbf70b69dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_155d7a6a-1fe9-4ab3-90a3-90b996ff92f4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ad60138b-f603-4c2d-82be-7abce4eebe05_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8bad248-a7b5-487a-bba8-74507caab3b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_c027c788-4929-44cb-a1b0-dffe2b117a4f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CartiHeal divestiture and debt restructuring</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_82edb6a5-edb9-4bc2-9f42-0eb2e64cf938_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2c0ec7ca-fb79-4265-94a2-94104a55eeee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets attributable to discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_f082961f-c5b5-4113-b4d6-8c8d215f0356_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_23ed56e6-1066-4aff-b8a4-99a7435e01a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ffe368f8-bd81-40e0-b39c-71c96ddf8752_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3e8ce20-bfbc-4d54-901e-bfc7ad9e67f1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_895e6592-3be1-4485-8032-f7f78cadfc61_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b987165f-dc68-4b9d-9826-c022650fab07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_eb1c782e-f34b-4899-9713-e375ef765d4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_TermLoanFacilityMember_32ad915b-6f7e-4842-9d72-d8b99304233d_terseLabel_en-US" xlink:label="lab_bvs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_bvs_TermLoanFacilityMember_label_en-US" xlink:label="lab_bvs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_bvs_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_bvs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilityMember" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TermLoanFacilityMember" xlink:to="lab_bvs_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_70f7cce6-da0e-4835-b77d-3c215a63a2fc_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_67fcf68a-87db-4ecc-ab78-2f2b788ccba8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_df35e1ee-b34d-4006-9b4f-18173a29da55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c1142eca-53b5-45a0-8060-7677f7843c8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_831fe48d-394a-421a-b5b0-4f72bfbca43b_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_13955315-fcc4-439a-9f34-6986a9057e8d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_8814ebc8-abe7-4a10-a9cd-2a1b7af515f9_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_72055022-26f3-472b-9107-18f27e35e359_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, weighted average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f95b2def-59d1-4e6e-a88b-4d40be300bc5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_fddb5fe5-4ca7-4986-bfad-d8513171de5e_terseLabel_en-US" xlink:label="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued or issuable, redemption of LLC interest ratio</link:label>
    <link:label id="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_label_en-US" xlink:label="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Or Issuable, Redemption Of LLC Interest Ratio</link:label>
    <link:label id="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_documentation_en-US" xlink:label="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Or Issuable, Redemption Of LLC Interest Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" xlink:href="bvs-20230401.xsd#bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" xlink:to="lab_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_4912f078-b603-4b0c-b569-2f2636bbf7be_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_a5eae4c5-9f7e-40e4-a92d-2701526d895d_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_7d028b0f-498f-4de9-87fc-48b7e0c0ff1e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4dfb980a-ac6f-4180-98b3-96322f2f522e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_13c3951c-9f3a-460b-8083-e0fc127b58f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_SurgicalSolutionsMember_4aaf2ace-3c1e-4b71-a4e6-d1b817ccbd18_terseLabel_en-US" xlink:label="lab_bvs_SurgicalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Solutions</link:label>
    <link:label id="lab_bvs_SurgicalSolutionsMember_label_en-US" xlink:label="lab_bvs_SurgicalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Solutions [Member]</link:label>
    <link:label id="lab_bvs_SurgicalSolutionsMember_documentation_en-US" xlink:label="lab_bvs_SurgicalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SurgicalSolutionsMember" xlink:href="bvs-20230401.xsd#bvs_SurgicalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SurgicalSolutionsMember" xlink:to="lab_bvs_SurgicalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25237b31-7896-4e8c-9aec-487f16cd0013_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholdings on equity-based compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d3e27429-1c3c-4802-8c60-7c9ef1f836d2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_9c73d225-4636-4de5-9cd5-3aaa23872d55_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d8dc14a3-31bb-42a0-835f-f4d2a8b77bce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency fluctuations</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b01ea6b5-4edc-495b-96b3-4b027c7140b2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fd946b3a-ebf6-45d4-913a-7a9e53edf885_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_2d13eed0-70ba-4da6-98fb-d56c7e06bc93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on revolver</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_66b83586-7525-4aff-a5e3-e2e3c725deea_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_8a6d2670-a61e-45ef-95a8-609a554d6251_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4d9127df-98ba-4f07-b8a0-78a230ec921f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fbf543ba-45ad-4629-b93a-018527572844_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing arrangement</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_61a02237-c494-4d43-8f81-4852111e6229_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4fb40317-85b9-4ac6-a764-faa45f779bf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_73465252-84ed-4627-ba9e-b9024d3fb496_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8393d419-7823-4bec-ba68-45b6a8b02587_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BionessIncMember_4181010e-3544-46f2-8ca1-9dd36edeab1e_terseLabel_en-US" xlink:label="lab_bvs_BionessIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioness, Inc</link:label>
    <link:label id="lab_bvs_BionessIncMember_e71b15eb-54af-4cd2-ac02-3e1dc3c2fa31_verboseLabel_en-US" xlink:label="lab_bvs_BionessIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioness contingent consideration</link:label>
    <link:label id="lab_bvs_BionessIncMember_label_en-US" xlink:label="lab_bvs_BionessIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioness, Inc [Member]</link:label>
    <link:label id="lab_bvs_BionessIncMember_documentation_en-US" xlink:label="lab_bvs_BionessIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioness, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BionessIncMember" xlink:to="lab_bvs_BionessIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_RestructuringPlanOf2021Member_fcb0aa2c-37c7-4357-b28c-9bae2aa17996_terseLabel_en-US" xlink:label="lab_bvs_RestructuringPlanOf2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan of 2021</link:label>
    <link:label id="lab_bvs_RestructuringPlanOf2021Member_label_en-US" xlink:label="lab_bvs_RestructuringPlanOf2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan of 2021 [Member]</link:label>
    <link:label id="lab_bvs_RestructuringPlanOf2021Member_documentation_en-US" xlink:label="lab_bvs_RestructuringPlanOf2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan of 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestructuringPlanOf2021Member" xlink:href="bvs-20230401.xsd#bvs_RestructuringPlanOf2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RestructuringPlanOf2021Member" xlink:to="lab_bvs_RestructuringPlanOf2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1c60a1a5-3574-4f41-a9dd-33daac184108_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f4a5e6b5-b5cf-488f-8cc0-46cf2cba2e8c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_450ecd13-f0f5-469d-a120-29d859fd7994_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3712857b-fa75-4e5d-8092-1b03d92098ef_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7959b6d9-3e5a-4d79-899e-7a099eec23fd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share of class A common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_42a97526-2a55-4cf1-8eef-2f78ea55e478_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of class A common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d8b8c727-6eaf-451e-80a4-a097df58f3c6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_04f1e2ee-5cfb-495a-8618-0f756def3e09_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_99ef21aa-4e35-4a41-afbb-91ddd79f1c8a_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb28be7e-097f-4a26-88fe-47df8a748ef9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6a61e59-d736-4cfd-b108-36084ebec69c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e53eba22-35c4-4431-9321-d8c889aa1b5a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_24b21299-33a1-4f49-bb35-4d9d3730f0a1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cf3424e7-7134-419e-86b5-d7cba5f12503_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_46c38914-91c1-4d4b-998f-030f8638fc9d_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_e0f0cfcb-2000-4f4d-a974-a3da0298bda7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other charges</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_cd6eaf8d-8440-49c4-a0eb-860c458cb0c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_fbaa398d-e90d-46bc-9dfc-363f5c04baec_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2525ad1e-3cc8-4023-9002-227fab6c48c6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_da2cf81c-98f9-4097-a31d-1c58e0b58620_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_a89b487c-e4ed-4cda-ac53-981753e98ed4_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LitigationSettlementExpenseOfClaimant_995a5c22-bd40-4fb5-8d9a-8e4028be4e6f_terseLabel_en-US" xlink:label="lab_bvs_LitigationSettlementExpenseOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense of claimant</link:label>
    <link:label id="lab_bvs_LitigationSettlementExpenseOfClaimant_label_en-US" xlink:label="lab_bvs_LitigationSettlementExpenseOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense Of Claimant</link:label>
    <link:label id="lab_bvs_LitigationSettlementExpenseOfClaimant_documentation_en-US" xlink:label="lab_bvs_LitigationSettlementExpenseOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense Of Claimant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LitigationSettlementExpenseOfClaimant" xlink:href="bvs-20230401.xsd#bvs_LitigationSettlementExpenseOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LitigationSettlementExpenseOfClaimant" xlink:to="lab_bvs_LitigationSettlementExpenseOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_94885465-a548-4b1f-854e-53d36dad1e05_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ContinuingLLCOwnerMember_1a505700-1d04-4e90-a78d-b244eeb29752_terseLabel_en-US" xlink:label="lab_bvs_ContinuingLLCOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing LLC Owner</link:label>
    <link:label id="lab_bvs_ContinuingLLCOwnerMember_label_en-US" xlink:label="lab_bvs_ContinuingLLCOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing LLC Owner [Member]</link:label>
    <link:label id="lab_bvs_ContinuingLLCOwnerMember_documentation_en-US" xlink:label="lab_bvs_ContinuingLLCOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing LLC Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ContinuingLLCOwnerMember" xlink:href="bvs-20230401.xsd#bvs_ContinuingLLCOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ContinuingLLCOwnerMember" xlink:to="lab_bvs_ContinuingLLCOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_980c6ce1-7a6b-438d-8881-795c7e36c9d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_31aeb20d-8cbf-4e47-8b30-0e6edb596ca8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable and vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_c24b5655-d243-401f-aa62-63e38b5c0d18_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_ThreeInjectionOAProductMember_5b46a565-7176-42f9-8717-8521031b42b9_terseLabel_en-US" xlink:label="lab_bvs_ThreeInjectionOAProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Injection OA Product</link:label>
    <link:label id="lab_bvs_ThreeInjectionOAProductMember_label_en-US" xlink:label="lab_bvs_ThreeInjectionOAProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Injection OA Product [Member]</link:label>
    <link:label id="lab_bvs_ThreeInjectionOAProductMember_documentation_en-US" xlink:label="lab_bvs_ThreeInjectionOAProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Injection OA Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ThreeInjectionOAProductMember" xlink:href="bvs-20230401.xsd#bvs_ThreeInjectionOAProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ThreeInjectionOAProductMember" xlink:to="lab_bvs_ThreeInjectionOAProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4490ef6e-b463-48ef-b22a-0d290604ea11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ac81563a-48fb-49b8-9051-a8015ccc43cd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_30193890-ec1a-480e-835f-3e2496bdc230_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_8c2b7af3-0310-49b1-bd4b-09fd1881a390_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance of $898</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4fcc17c3-4096-4ad5-adcc-81fc64ce3a1e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_518ad92b-d4cf-4cad-a2c0-25a2af845a99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_49efc981-9646-487f-a164-fda99d92b180_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_877b5c56-e870-4d73-9f0b-8b6a953c71d0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_77afec23-1217-4ced-b432-faa4f77baade_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6d0b8d79-04f3-46c3-8064-1fe3aed0b009_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cda8cbd8-ab36-4d19-bffa-c5e6c285bef1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases, weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0e108002-5f1f-4bcd-a626-deb24c4674a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable and vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_ec104dc2-6f14-4e1a-b503-2244e534c0e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8729fbfd-7687-491f-8ef0-0fc30d593f93_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae591f47-563f-4ea3-bbd0-0dc746b8a6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_69257907-a9fb-4796-a2de-b3cecd6028c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess and obsolete reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c8f8648f-299a-4466-81a8-6a40a9d8c914_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_1453406f-daaf-4e08-ad8f-eb7f35e6157c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_75298342-a393-417f-b080-3d77ae87c796_terseLabel_en-US" xlink:label="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of LLC interest held (in shares)</link:label>
    <link:label id="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_label_en-US" xlink:label="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Number Of Interests Held</link:label>
    <link:label id="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_documentation_en-US" xlink:label="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Number Of Interests Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:href="bvs-20230401.xsd#bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:to="lab_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78de23e3-c93a-4cfd-add0-47ba00a7e73b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_8a04c47e-acff-4082-a300-cbf28318e83b_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership %</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_fd177ae3-6d5c-48a6-96fc-40842077afe3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f7271415-a4eb-43b1-9eb6-573ed7586f06_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_56d93ae9-47a4-48f4-a7a1-1d7f5d00792a_terseLabel_en-US" xlink:label="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment adjusted EBITDA</link:label>
    <link:label id="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_label_en-US" xlink:label="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items</link:label>
    <link:label id="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_documentation_en-US" xlink:label="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:href="bvs-20230401.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:to="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2f7589a9-5bea-4cd2-ad83-04247987c5c5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_31df44dd-f389-46b3-af2e-2671c3ec5363_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized to be awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio_c67ef3d8-d401-4af2-b9fd-b5b0e70f5916_terseLabel_en-US" xlink:label="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation ratio, required stock to LLC interest ratio</link:label>
    <link:label id="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio_label_en-US" xlink:label="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation Ratio, Required Stock To LLC Interest Ratio</link:label>
    <link:label id="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio_documentation_en-US" xlink:label="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation Ratio, Required Stock To LLC Interest Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:href="bvs-20230401.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:to="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AssetImpairmentChargesAfterTax_39c76615-8ab3-4ee0-8a1b-d8d6595ad195_terseLabel_en-US" xlink:label="lab_bvs_AssetImpairmentChargesAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges, after tax</link:label>
    <link:label id="lab_bvs_AssetImpairmentChargesAfterTax_label_en-US" xlink:label="lab_bvs_AssetImpairmentChargesAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges, After Tax</link:label>
    <link:label id="lab_bvs_AssetImpairmentChargesAfterTax_documentation_en-US" xlink:label="lab_bvs_AssetImpairmentChargesAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges, After Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AssetImpairmentChargesAfterTax" xlink:href="bvs-20230401.xsd#bvs_AssetImpairmentChargesAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AssetImpairmentChargesAfterTax" xlink:to="lab_bvs_AssetImpairmentChargesAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a43219be-3bf3-4587-a32b-bd130834f740_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_WoundBusinessMember_797de3f5-1164-4410-88cd-dde3ae057236_terseLabel_en-US" xlink:label="lab_bvs_WoundBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Business</link:label>
    <link:label id="lab_bvs_WoundBusinessMember_label_en-US" xlink:label="lab_bvs_WoundBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Business [Member]</link:label>
    <link:label id="lab_bvs_WoundBusinessMember_documentation_en-US" xlink:label="lab_bvs_WoundBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_WoundBusinessMember" xlink:to="lab_bvs_WoundBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b895c3e0-4130-4549-b46c-a7936fed610f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization, remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DeferredAmountMember_b07160ef-0a4e-489c-a599-3ddc8709bccd_terseLabel_en-US" xlink:label="lab_bvs_DeferredAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount</link:label>
    <link:label id="lab_bvs_DeferredAmountMember_label_en-US" xlink:label="lab_bvs_DeferredAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount [Member]</link:label>
    <link:label id="lab_bvs_DeferredAmountMember_documentation_en-US" xlink:label="lab_bvs_DeferredAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredAmountMember" xlink:to="lab_bvs_DeferredAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_3681b9ac-0ef6-4811-be90-5b9afdef3531_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on deconsolidation</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_e73dde39-7e95-416d-bee7-d089b8b57953_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f7aeea56-67c7-4161-864b-941b6fbdcb2b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_7c3acb91-f267-403a-be18-2ee71169cee4_terseLabel_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral period</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_label_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Deferral Period</link:label>
    <link:label id="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_documentation_en-US" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Deferral Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredDeferralPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" xlink:to="lab_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f787c607-1349-4ea2-b2e5-3ba2c71649f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_474fab6f-563e-4b0f-928a-d0671c7c08b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_10e3208d-fe35-4e40-b2c9-6419ec2d3052_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c6560c7e-9478-4fdb-8fb4-19400d1b0640_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LimitedLiabilityCompanyInterestsMember_de6aa8b4-005d-49c2-a5a1-0f708932d669_terseLabel_en-US" xlink:label="lab_bvs_LimitedLiabilityCompanyInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LLC Interests</link:label>
    <link:label id="lab_bvs_LimitedLiabilityCompanyInterestsMember_label_en-US" xlink:label="lab_bvs_LimitedLiabilityCompanyInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company Interests [Member]</link:label>
    <link:label id="lab_bvs_LimitedLiabilityCompanyInterestsMember_documentation_en-US" xlink:label="lab_bvs_LimitedLiabilityCompanyInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LimitedLiabilityCompanyInterestsMember" xlink:href="bvs-20230401.xsd#bvs_LimitedLiabilityCompanyInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LimitedLiabilityCompanyInterestsMember" xlink:to="lab_bvs_LimitedLiabilityCompanyInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ac16c82d-7bcb-4eec-b002-1cd8ca4e7f32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_d1872c74-ad8f-4a96-9e52-43b0e4aa00eb_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees and expenses</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Fees and Expenses</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Fees and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb1fc64d-4b6a-4eb2-aac4-d39fa3670f51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9c142c3-2711-4ba2-8090-b7495a6f983f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d4091cb1-addb-4cbe-96db-c4f1b851f5f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholdings on equity compensation awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639bce4f-b731-48d4-88a1-f8a613e787c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_CommonStockNumberOfVotes_c87d4180-8a61-4a2a-89c7-862286b8afea_terseLabel_en-US" xlink:label="lab_bvs_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common share</link:label>
    <link:label id="lab_bvs_CommonStockNumberOfVotes_label_en-US" xlink:label="lab_bvs_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:label id="lab_bvs_CommonStockNumberOfVotes_documentation_en-US" xlink:label="lab_bvs_CommonStockNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CommonStockNumberOfVotes" xlink:href="bvs-20230401.xsd#bvs_CommonStockNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CommonStockNumberOfVotes" xlink:to="lab_bvs_CommonStockNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_6894a437-832f-4ea4-adfc-4f953de28181_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_622f312f-8a58-495d-8f42-19681562d09f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7c33205c-badc-4891-bf46-135fef528706_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_6f03cd9f-a5b0-4dfe-8f9c-22ab8ddc9f8d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_66e699c6-abcf-4ace-b978-fed3b23b3cec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_47bd5092-ef2e-4803-9441-96d07f5ffe38_terseLabel_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_label_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Assets</link:label>
    <link:label id="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_documentation_en-US" xlink:label="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" xlink:to="lab_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_becdd2c5-ceac-45a7-8519-dfe1ab852fcb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_25073851-e2ac-436d-b7ea-1fd6699199fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current and noncurrent assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_56b40ae2-c5f0-47f4-a679-dfb82af64977_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_260377d4-b4d6-4c17-8809-fb55a2acc4c7_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_f522fdae-2aca-42dd-ad18-09b09faf2d43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_575a5e46-56f7-4911-afc7-0e501c5f57b6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_a79796a4-19c5-4e59-a328-ba0f3832eab3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_235cd0a8-f08b-4b3a-ab2a-b611f41e30fe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_04c4b535-172d-487a-96e0-0fffaab6273f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cb5796a-f1b2-4eb2-ab6f-8820845abaeb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0fe84a07-4a0f-4d1c-b40d-95ca0c16383a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9c2b6a28-7afa-4f52-8f90-d7d0670d0891_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_94cf80a9-fcc8-4140-843b-ef49f7c7432b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_011846fc-2898-45b2-b5ca-1d932b352e5b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ab1884ac-388a-49b6-a546-218adc5e9db3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_dc19350c-a7b3-4003-9e2e-3d4af755dadb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_ddf5c5da-cbcc-4b2f-85d2-4b10164556c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_791a3cb4-9341-4eb2-9b02-af71e332a227_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fa42d463-01fd-4c25-b8a0-8ffa13a123b4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_5282c231-307b-4125-80e8-3d119dbe17ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fce2a72a-683d-4a71-8b05-4b26ef9142e7_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_80a558d5-181c-4f2b-82bf-6a05be82badd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_26f384c0-6c29-4dcd-8444-79f507ad4ba7_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale_1837b136-b4eb-4e30-b264-80cc64e172a3_terseLabel_en-US" xlink:label="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to held for sale</link:label>
    <link:label id="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale_label_en-US" xlink:label="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Reclassification To Held For Sale</link:label>
    <link:label id="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale_documentation_en-US" xlink:label="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Reclassification To Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" xlink:href="bvs-20230401.xsd#bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" xlink:to="lab_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d780ed3e-3a14-4c1b-a4fd-1462f23c34f8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization, year one</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d12e55ee-b329-475d-a8a8-cef9dd83caa0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e443d073-01d2-4b07-b36b-84f6d71beabb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_ae932d0f-6239-4f6d-9743-0c366866040f_terseLabel_en-US" xlink:label="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, percentage of demanded amount to be paid</link:label>
    <link:label id="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_label_en-US" xlink:label="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Percentage Of Demanded Amount To Be Paid</link:label>
    <link:label id="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_documentation_en-US" xlink:label="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Percentage Of Demanded Amount To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" xlink:href="bvs-20230401.xsd#bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" xlink:to="lab_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_fb634d12-abd2-47fc-9c6f-9a4e180e8ee3_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_4c4f4ee9-1e56-456b-a8eb-d405d5cf5354_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to noncontrolling interest - continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bvs-20230401_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:082d4e54-0693-403f-8feb-755a4f49db3a,g:bca9874b-627b-4a4e-9dc7-9b090a7fd814-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bioventus.com/role/CoverPage" xlink:type="simple" xlink:href="bvs-20230401.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ffb9b474-116c-4035-be1c-6b4cf950c1d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffb9b474-116c-4035-be1c-6b4cf950c1d0" xlink:to="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b375ef7a-1d1c-461e-a362-30d783445332" xlink:to="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_074c7f0c-58e7-4e9f-8efa-90d8145e591d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:to="loc_us-gaap_CommonClassAMember_074c7f0c-58e7-4e9f-8efa-90d8145e591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_db2234e6-daa1-47cf-8681-0089a6fad0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6f8a1d4e-5da1-4c6e-b624-71c824f1218a" xlink:to="loc_us-gaap_CommonClassBMember_db2234e6-daa1-47cf-8681-0089a6fad0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8b8c4b91-6634-4446-8cca-042b237af5e2" xlink:to="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6f7fbac2-a323-4790-b9a3-90f760e70d7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentType_6f7fbac2-a323-4790-b9a3-90f760e70d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c9e5b883-c13d-4cde-a40c-ef54696aa9fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentQuarterlyReport_c9e5b883-c13d-4cde-a40c-ef54696aa9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_be45cd8f-1019-45ac-918f-61186eb6fb46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentPeriodEndDate_be45cd8f-1019-45ac-918f-61186eb6fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7dfd2007-8f68-487d-9596-bb1d56206143" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentTransitionReport_7dfd2007-8f68-487d-9596-bb1d56206143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_436a13c6-b8cd-4cb5-ab44-60b00bd1a514" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityFileNumber_436a13c6-b8cd-4cb5-ab44-60b00bd1a514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_151440e0-3350-40e7-97f3-b5d7ae7a9dfa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityRegistrantName_151440e0-3350-40e7-97f3-b5d7ae7a9dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1d16cf9c-eb13-46a9-b76c-a4be23e6ea0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1d16cf9c-eb13-46a9-b76c-a4be23e6ea0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_91e4521b-873a-4459-8f3a-5cde470da599" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityTaxIdentificationNumber_91e4521b-873a-4459-8f3a-5cde470da599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d072045e-4377-47a3-8d61-e81e7c5f623d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressAddressLine1_d072045e-4377-47a3-8d61-e81e7c5f623d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b13ba53b-5b05-49e3-8ca0-df9e699f9bb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressAddressLine2_b13ba53b-5b05-49e3-8ca0-df9e699f9bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c2c1e9d4-ecd9-4623-a84b-dbf348a55c41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressCityOrTown_c2c1e9d4-ecd9-4623-a84b-dbf348a55c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3f6edbd3-50bf-426f-b5da-4c88068f198c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressStateOrProvince_3f6edbd3-50bf-426f-b5da-4c88068f198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_907d888c-7ea7-4d2c-a843-b095fd16055a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityAddressPostalZipCode_907d888c-7ea7-4d2c-a843-b095fd16055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_92b1837a-d4d2-4034-84e8-9b1d8b4a27fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_CityAreaCode_92b1837a-d4d2-4034-84e8-9b1d8b4a27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4d10fcff-cc9c-4cc2-931f-27885b36a86c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_LocalPhoneNumber_4d10fcff-cc9c-4cc2-931f-27885b36a86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37cf84a0-3f5f-4dbd-ad5a-21bb19e8372e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_Security12bTitle_37cf84a0-3f5f-4dbd-ad5a-21bb19e8372e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_deefe101-14f2-44a6-bda0-a8b6990fdc7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_TradingSymbol_deefe101-14f2-44a6-bda0-a8b6990fdc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_16027c8d-424c-4dca-a8a2-940be4a3e770" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_SecurityExchangeName_16027c8d-424c-4dca-a8a2-940be4a3e770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b36618ca-7d24-4620-a583-89cbe837173f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityCurrentReportingStatus_b36618ca-7d24-4620-a583-89cbe837173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f2951df1-674f-4c2b-8dc6-0cca915a50c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityInteractiveDataCurrent_f2951df1-674f-4c2b-8dc6-0cca915a50c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ec0767f8-e737-4439-8fbc-b457341de887" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityFilerCategory_ec0767f8-e737-4439-8fbc-b457341de887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e12348e9-499a-42e7-ae33-ea390a36a4eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntitySmallBusiness_e12348e9-499a-42e7-ae33-ea390a36a4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f4b4e919-f175-4327-b8d5-e95fe50107bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityEmergingGrowthCompany_f4b4e919-f175-4327-b8d5-e95fe50107bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_9da4758e-aea9-46f7-98bc-ac87b265b040" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityExTransitionPeriod_9da4758e-aea9-46f7-98bc-ac87b265b040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_169e25a4-3a48-4e6a-9e8c-a28183b11ab6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityShellCompany_169e25a4-3a48-4e6a-9e8c-a28183b11ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_801bf0c9-0d75-4005-bf6f-0b37f38d0aca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_801bf0c9-0d75-4005-bf6f-0b37f38d0aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b7508144-eae7-4042-a0d1-e14f13da37d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_AmendmentFlag_b7508144-eae7-4042-a0d1-e14f13da37d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49dd4701-0697-4682-89d4-c6adf20e6209" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_EntityCentralIndexKey_49dd4701-0697-4682-89d4-c6adf20e6209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5ea9ca7a-066d-4d72-be2f-4a8160e35ab9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_CurrentFiscalYearEndDate_5ea9ca7a-066d-4d72-be2f-4a8160e35ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_51bc11e7-d92e-49e8-9718-a14d622a234c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentFiscalYearFocus_51bc11e7-d92e-49e8-9718-a14d622a234c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_42c24935-cd13-4a4f-8fef-200012310128" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_934ace7a-8dc8-497a-abfb-171fb4b68004" xlink:to="loc_dei_DocumentFiscalPeriodFocus_42c24935-cd13-4a4f-8fef-200012310128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a063ef8a-cc8e-45ae-8da3-e9408d1200c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a063ef8a-cc8e-45ae-8da3-e9408d1200c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3338be96-304f-4807-b47f-645acad2e5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3338be96-304f-4807-b47f-645acad2e5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2c3d68c7-9cff-415b-abd8-92ca9787ddcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_GrossProfit_2c3d68c7-9cff-415b-abd8-92ca9787ddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_df16c4fe-48a0-40b3-a7a2-9980cbf7f10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_df16c4fe-48a0-40b3-a7a2-9980cbf7f10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1cf225bc-202b-497a-807c-97045a1a8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1cf225bc-202b-497a-807c-97045a1a8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_574061c6-7315-415d-9757-aeddea1203ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_RestructuringCharges_574061c6-7315-415d-9757-aeddea1203ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a021a567-96fa-4551-bb2a-a4a94aa73820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a021a567-96fa-4551-bb2a-a4a94aa73820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b599fb85-4ca9-4383-b0c0-ed115a931438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_DepreciationAndAmortization_b599fb85-4ca9-4383-b0c0-ed115a931438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_654c6c9d-c9ba-44b7-b2a6-fe0f68a7566c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_AssetImpairmentCharges_654c6c9d-c9ba-44b7-b2a6-fe0f68a7566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85d15b0f-fb39-4d8e-9d59-2e4e3fc62296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_OperatingIncomeLoss_85d15b0f-fb39-4d8e-9d59-2e4e3fc62296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_af4c3868-1853-418e-ad05-ac4c2bea6f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_af4c3868-1853-418e-ad05-ac4c2bea6f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0300b999-76e4-4d6d-a197-691cb3e0669c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0300b999-76e4-4d6d-a197-691cb3e0669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_33a8119e-22ec-4786-89a0-543ba3978ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_33a8119e-22ec-4786-89a0-543ba3978ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48a1dba8-64d3-4597-a6ad-35a98bd04905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48a1dba8-64d3-4597-a6ad-35a98bd04905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ce980ca-5226-45c7-9d84-0c48e7e02bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ce980ca-5226-45c7-9d84-0c48e7e02bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_73de337a-762c-4afa-97e0-9ac06137df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_73de337a-762c-4afa-97e0-9ac06137df0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8e141ffc-ab86-44ec-a227-3a4270db28a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8e141ffc-ab86-44ec-a227-3a4270db28a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_841072db-dcc1-4040-ab4e-e2a7f4eee6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_ProfitLoss_841072db-dcc1-4040-ab4e-e2a7f4eee6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b2a9a576-18b3-43d9-ac39-027bdaecaafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b2a9a576-18b3-43d9-ac39-027bdaecaafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_934c2924-b3f8-4e14-857a-b9ae1365fff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_934c2924-b3f8-4e14-857a-b9ae1365fff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_266c5961-0ecd-4702-8dc8-a7da562fc017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_NetIncomeLoss_266c5961-0ecd-4702-8dc8-a7da562fc017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_27d970d4-6ba6-40db-a446-d976a8b6c050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_27d970d4-6ba6-40db-a446-d976a8b6c050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_74e6dbf7-56d0-4da7-ad10-08704bc1128a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_74e6dbf7-56d0-4da7-ad10-08704bc1128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_1f0e36f7-95af-425e-92d8-7cbf9fc0c513" xlink:href="bvs-20230401.xsd#bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations_1f0e36f7-95af-425e-92d8-7cbf9fc0c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_9d28a50c-1c24-43a7-90c8-4d265777da09" xlink:href="bvs-20230401.xsd#bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations_9d28a50c-1c24-43a7-90c8-4d265777da09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9cf309b-a0f5-4ea1-bacd-74545ce2e5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9cf309b-a0f5-4ea1-bacd-74545ce2e5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f998813e-eab9-4004-9c77-44d273bf7d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f998813e-eab9-4004-9c77-44d273bf7d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d592e736-1c80-4122-bd72-38479e8d1cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d592e736-1c80-4122-bd72-38479e8d1cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d748813e-2a84-4533-a9aa-4ec358541fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d748813e-2a84-4533-a9aa-4ec358541fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_5cce06d9-d4e8-4644-ae66-7dd79c66f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_5cce06d9-d4e8-4644-ae66-7dd79c66f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1d793431-4cf3-46e4-9bcc-ce2a7cc8b586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_1d793431-4cf3-46e4-9bcc-ce2a7cc8b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02817902-c7a2-4f0e-9a29-d5d6004aedf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a96e0a4-ea25-422b-b4ac-a9556985c1aa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02817902-c7a2-4f0e-9a29-d5d6004aedf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_ce09331e-0fd4-49f7-bbf9-614154db8ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6022af13-c7ec-4f1e-b839-1213c473b251" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_ce09331e-0fd4-49f7-bbf9-614154db8ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c4f5c21-e31d-4d10-8541-eee64ad43bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_ce09331e-0fd4-49f7-bbf9-614154db8ec7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c4f5c21-e31d-4d10-8541-eee64ad43bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3372ecaf-4cb2-43f1-bf41-f474242379aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_ce09331e-0fd4-49f7-bbf9-614154db8ec7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3372ecaf-4cb2-43f1-bf41-f474242379aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a36aca53-69f2-4892-9413-91d0ccb95a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_634621db-a32d-452f-96c7-6273efc350ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a36aca53-69f2-4892-9413-91d0ccb95a40" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_634621db-a32d-452f-96c7-6273efc350ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_38b4c656-5c53-465d-8941-1d3d42ba723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_38b4c656-5c53-465d-8941-1d3d42ba723f" xlink:to="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0972e6a2-7bbb-4d0a-9559-9579beb7b9d2" xlink:to="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_46f56016-84d8-456d-8629-c68a5ca61449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:to="loc_us-gaap_CommonClassAMember_46f56016-84d8-456d-8629-c68a5ca61449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8443b4c7-83cc-4ee4-a9fb-a69b16359d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e1587df-c250-4af6-9acc-f01bb5f6efa2" xlink:to="loc_us-gaap_CommonClassBMember_8443b4c7-83cc-4ee4-a9fb-a69b16359d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca47e063-5c57-4780-9d5d-0d64e3180d04" xlink:to="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:to="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d7f6706-a71f-4165-b2b5-87b7d46e95ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d7f6706-a71f-4165-b2b5-87b7d46e95ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6e8b9fc6-a231-4892-b2ff-65c7de4178a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6e8b9fc6-a231-4892-b2ff-65c7de4178a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1a417510-5687-4cba-a0a2-9d72684c6813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_InventoryNet_1a417510-5687-4cba-a0a2-9d72684c6813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1aa3d91-1a2d-4117-bc04-977899d4fdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1aa3d91-1a2d-4117-bc04-977899d4fdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_543ce6dc-130c-4162-bb09-405d12759106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_543ce6dc-130c-4162-bb09-405d12759106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8c026ac7-26d6-404b-8d0d-f77438c72973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8c026ac7-26d6-404b-8d0d-f77438c72973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c6cf2a1a-2e73-4d74-9448-085677de401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_51b07896-97fb-4272-ae3a-a1e2daf33905" xlink:to="loc_us-gaap_AssetsCurrent_c6cf2a1a-2e73-4d74-9448-085677de401a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70ddabb6-5d35-47f0-b9b2-4d6a7dccd6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70ddabb6-5d35-47f0-b9b2-4d6a7dccd6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_72fd2b84-ea65-4399-bdb3-d3ca88a9bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_Goodwill_72fd2b84-ea65-4399-bdb3-d3ca88a9bad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a594575-36ad-4558-bd24-588014ac5601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a594575-36ad-4558-bd24-588014ac5601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c72dc02-36c8-4ab4-96a4-389950e38724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c72dc02-36c8-4ab4-96a4-389950e38724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_48c08cba-ec1e-4370-9e64-22056a7651a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_LongTermInvestments_48c08cba-ec1e-4370-9e64-22056a7651a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2e3d8f60-ecf8-4c07-a7f8-a404436f4303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2e3d8f60-ecf8-4c07-a7f8-a404436f4303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6f37dbc6-fee5-457c-a2bd-7b45e961fc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edf636e9-94b1-4b8c-af4b-86b3b6ed3acc" xlink:to="loc_us-gaap_Assets_6f37dbc6-fee5-457c-a2bd-7b45e961fc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a595d765-a9bc-47c4-8c3e-87f2515c9ad4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_758eea60-eb0f-417f-8c2f-65dacdf02074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_AccountsPayableCurrent_758eea60-eb0f-417f-8c2f-65dacdf02074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b14ae155-35b5-48ee-ac53-4d50bd85af8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b14ae155-35b5-48ee-ac53-4d50bd85af8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c9f6da14-c82c-494b-8e4e-d7a9f015faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_LongTermDebtCurrent_c9f6da14-c82c-494b-8e4e-d7a9f015faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_869a780d-673d-4ad0-97d1-24cc789773af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_869a780d-673d-4ad0-97d1-24cc789773af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_998206c4-a1dc-464c-93f3-3cfb0a5cf036" xlink:href="bvs-20230401.xsd#bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent_998206c4-a1dc-464c-93f3-3cfb0a5cf036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_21653515-1b55-47c2-a22f-b76311d9bba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_21653515-1b55-47c2-a22f-b76311d9bba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c9e0953c-d134-4d48-b014-e86e44c550fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14ffcf5e-e4bd-42d2-b0b6-6b619157043c" xlink:to="loc_us-gaap_LiabilitiesCurrent_c9e0953c-d134-4d48-b014-e86e44c550fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_937ca24e-5c00-4501-9c86-c4149f63e6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_937ca24e-5c00-4501-9c86-c4149f63e6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a349a6b5-08c3-4d7e-9207-a92217414299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a349a6b5-08c3-4d7e-9207-a92217414299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b2867384-0855-4e81-8ba5-9f3983c7da80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b2867384-0855-4e81-8ba5-9f3983c7da80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_59c47315-e87d-4db2-a8db-7c0299b14e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_59c47315-e87d-4db2-a8db-7c0299b14e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_854e0d25-2a49-4305-96bf-48c5e3dd7e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_854e0d25-2a49-4305-96bf-48c5e3dd7e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_009ecb15-fd47-414a-997c-9c2424888f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_Liabilities_009ecb15-fd47-414a-997c-9c2424888f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f77463cd-c174-44fc-b92e-82e559a0c804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f77463cd-c174-44fc-b92e-82e559a0c804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_85c50cfb-f8ff-41ee-9000-13d5d61acd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_CommonStockValue_85c50cfb-f8ff-41ee-9000-13d5d61acd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_906ea564-dde3-497c-b3b7-ab185907800c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_906ea564-dde3-497c-b3b7-ab185907800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_572ce623-ee22-4738-864e-cf9ac01e55ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_572ce623-ee22-4738-864e-cf9ac01e55ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb6ea723-f418-4307-bffe-e9dc8d5d33ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb6ea723-f418-4307-bffe-e9dc8d5d33ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fccac5c-3e70-45cd-9f22-d5563018872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_StockholdersEquity_9fccac5c-3e70-45cd-9f22-d5563018872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_27f42926-81b7-44f6-9be9-03f9d5a50694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_MinorityInterest_27f42926-81b7-44f6-9be9-03f9d5a50694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2ffd43f-2225-446a-aec3-f6c356fe44d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_55611253-d901-494e-8bd6-50bc4ef086d3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2ffd43f-2225-446a-aec3-f6c356fe44d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ead5208f-b081-497b-b3e9-cc551b2f6b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9dd529a9-dc84-44c2-b84e-939c8f87ef77" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ead5208f-b081-497b-b3e9-cc551b2f6b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e7bf6a67-2910-4f8a-8ee6-f53519720db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7bf6a67-2910-4f8a-8ee6-f53519720db8" xlink:to="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b9d85db7-c488-405a-aeba-6ccde395de1b" xlink:to="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_65bcc35f-bcae-457d-9dc1-3e75fb9457b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:to="loc_us-gaap_CommonClassAMember_65bcc35f-bcae-457d-9dc1-3e75fb9457b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_2a4683e6-fc93-4318-a98b-54bdb978fb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b5e2d5f-4502-4ba0-b4aa-cb83d3932166" xlink:to="loc_us-gaap_CommonClassBMember_2a4683e6-fc93-4318-a98b-54bdb978fb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d4507b4b-d16b-4541-b684-221cbf85b4dc" xlink:to="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12f1b4df-e0c4-4199-9efc-ec6791ba3cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12f1b4df-e0c4-4199-9efc-ec6791ba3cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5be2dd32-0457-426b-8162-635efbfd2ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5be2dd32-0457-426b-8162-635efbfd2ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_604f3ee3-4218-4ca6-9ccf-45ae02606ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_604f3ee3-4218-4ca6-9ccf-45ae02606ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3b804e7-6921-43af-ac2d-660f422de3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3b804e7-6921-43af-ac2d-660f422de3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c6d20f99-e82c-49fe-9f7a-0b81b34b1f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c6d20f99-e82c-49fe-9f7a-0b81b34b1f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6c2dd5e1-7a64-40c1-ba11-fea63a36d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6c2dd5e1-7a64-40c1-ba11-fea63a36d2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1b952a66-8401-43a5-ba5b-583ba811acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789dccd8-8a1f-44fb-9ddc-242232aeedb4" xlink:to="loc_us-gaap_CommonStockSharesIssued_1b952a66-8401-43a5-ba5b-583ba811acc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="bvs-20230401.xsd#ConsolidatedCondensedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_162148d2-8a95-4acd-b474-b10c661d8b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_162148d2-8a95-4acd-b474-b10c661d8b93" xlink:to="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a4f1747-eaaf-40bf-b439-88e6e6923ae2" xlink:to="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_faf84b27-19d0-4af4-8eeb-dbfffb41289a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_CommonStockMember_faf84b27-19d0-4af4-8eeb-dbfffb41289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_38647da8-a572-4aa8-9883-e5654a6efea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_38647da8-a572-4aa8-9883-e5654a6efea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1cd56756-d819-4bd2-ae24-ea38b8fadbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1cd56756-d819-4bd2-ae24-ea38b8fadbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bdaef06e-4d8d-4e7c-ad9e-d36768bdfb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_RetainedEarningsMember_bdaef06e-4d8d-4e7c-ad9e-d36768bdfb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_caf5c149-ecfa-4078-96de-162b9e58c027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e2d5cb58-45db-46f4-8ee9-6a7a1a72e93b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_caf5c149-ecfa-4078-96de-162b9e58c027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed49eb93-9bcf-42e3-9ddf-3b8083542c18" xlink:to="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e2aad80b-09a2-4b37-a614-18eed03256cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:to="loc_us-gaap_CommonClassAMember_e2aad80b-09a2-4b37-a614-18eed03256cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8dcd104b-147c-492e-b8c0-eaf7b9c0542b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_68865983-d348-43d1-9ca0-f44b8a0eefed" xlink:to="loc_us-gaap_CommonClassBMember_8dcd104b-147c-492e-b8c0-eaf7b9c0542b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_317a1f91-5e14-4163-9c23-5ad826c60006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be0c5a70-0da2-422e-8533-57390b744858" xlink:to="loc_us-gaap_StatementLineItems_317a1f91-5e14-4163-9c23-5ad826c60006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:href="bvs-20230401.xsd#bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317a1f91-5e14-4163-9c23-5ad826c60006" xlink:to="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_df739098-cdf8-429e-a9d0-5f6bcc9b7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_df739098-cdf8-429e-a9d0-5f6bcc9b7e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e8f71d1-728a-484e-8c77-6f3dbdb30955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e8f71d1-728a-484e-8c77-6f3dbdb30955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_449bd8b1-f438-4e10-bfe6-72958dbc26c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_449bd8b1-f438-4e10-bfe6-72958dbc26c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7c43a85-083f-4834-ba1e-034fae73d542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7c43a85-083f-4834-ba1e-034fae73d542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredTaxesOnEquityRebalancing_c0c16f51-9849-4d99-a276-d9f1abdb2aae" xlink:href="bvs-20230401.xsd#bvs_DeferredTaxesOnEquityRebalancing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_bvs_DeferredTaxesOnEquityRebalancing_c0c16f51-9849-4d99-a276-d9f1abdb2aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c5a7f1c9-82dd-42f1-a0dc-4f27acf2276d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_ProfitLoss_c5a7f1c9-82dd-42f1-a0dc-4f27acf2276d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f058ad9f-8622-4608-b385-ef639269134c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f058ad9f-8622-4608-b385-ef639269134c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_17e3da6f-0075-4290-a626-f06add56c261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_17e3da6f-0075-4290-a626-f06add56c261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c30f1bdb-d3ba-4cf7-8228-60e4cc158fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c30f1bdb-d3ba-4cf7-8228-60e4cc158fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a648f5d6-7928-4219-8aea-a80b51cf71d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a648f5d6-7928-4219-8aea-a80b51cf71d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b43182bf-f6ae-4c7f-ac3e-b33a492d31df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_e7c25961-e8b4-416d-a3bc-e53f249eea19" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b43182bf-f6ae-4c7f-ac3e-b33a492d31df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows" xlink:type="simple" xlink:href="bvs-20230401.xsd#Consolidatedcondensedstatementsofcashflows"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_06dc4f60-01bf-4d8a-b5ad-8f934ec25dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_ProfitLoss_06dc4f60-01bf-4d8a-b5ad-8f934ec25dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c00bdea3-bf83-483c-ad76-c455c66fe4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c00bdea3-bf83-483c-ad76-c455c66fe4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d61ad139-0a6c-4ef3-b61f-b304314eb90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d61ad139-0a6c-4ef3-b61f-b304314eb90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_820884bf-8816-46bc-8262-aaf9a1d38659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_820884bf-8816-46bc-8262-aaf9a1d38659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_3aea9061-e17d-4c27-a5ab-06c4a04449f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_3aea9061-e17d-4c27-a5ab-06c4a04449f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c8c05249-7059-4c24-a741-99fd7d51164b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_ShareBasedCompensation_c8c05249-7059-4c24-a741-99fd7d51164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c01dac27-aac9-479d-985b-1db2079f5dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c01dac27-aac9-479d-985b-1db2079f5dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3b661226-96c4-462a-a42d-b66aacc06214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3b661226-96c4-462a-a42d-b66aacc06214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b2f73c9c-9705-4d41-9e7b-83dfe24dbde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b2f73c9c-9705-4d41-9e7b-83dfe24dbde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_34b45685-f584-4695-8de1-41d7d9e34f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_AssetImpairmentCharges_34b45685-f584-4695-8de1-41d7d9e34f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_024d2a8e-fa05-479d-96d5-805a65e4a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_024d2a8e-fa05-479d-96d5-805a65e4a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_03de16f2-7978-4523-b12e-ef942d79dc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_03de16f2-7978-4523-b12e-ef942d79dc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bcaa9859-5590-4554-a358-f9ff2b722b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86a45272-365a-4bb3-837b-f420c05e0651" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bcaa9859-5590-4554-a358-f9ff2b722b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_32df3b7c-ffbd-43a8-83bf-0e8dd00a1b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bcaa9859-5590-4554-a358-f9ff2b722b08" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_32df3b7c-ffbd-43a8-83bf-0e8dd00a1b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bcfea8a8-bf48-46b8-88ba-7f94dd40837b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bcaa9859-5590-4554-a358-f9ff2b722b08" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bcfea8a8-bf48-46b8-88ba-7f94dd40837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1a562981-7d46-459f-96cd-55b7deb0e7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bcaa9859-5590-4554-a358-f9ff2b722b08" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1a562981-7d46-459f-96cd-55b7deb0e7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8fec64e4-d951-4431-a7de-1c0ab941387d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bcaa9859-5590-4554-a358-f9ff2b722b08" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8fec64e4-d951-4431-a7de-1c0ab941387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a49abb0-353e-41c9-821a-1dfda4eb29d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a49abb0-353e-41c9-821a-1dfda4eb29d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_debfdd0b-4944-4fc2-bdec-1ae75e98429d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_debfdd0b-4944-4fc2-bdec-1ae75e98429d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_970077fc-cc09-4197-8fcc-ea8b4a52410e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5d7fe7ad-2419-497e-8040-74b77ceecb2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_970077fc-cc09-4197-8fcc-ea8b4a52410e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_d4f0d3b5-b48e-44c7-a671-c55ec7340d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_d4f0d3b5-b48e-44c7-a671-c55ec7340d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7da541fd-4a9f-427b-add1-ced47a84ce66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7da541fd-4a9f-427b-add1-ced47a84ce66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_a4a6574e-92fb-4793-a2c4-e1c4a9fbe6bb" xlink:href="bvs-20230401.xsd#bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:to="loc_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments_a4a6574e-92fb-4793-a2c4-e1c4a9fbe6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_148b1c25-d2b5-4630-83f0-95fce9027799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_148b1c25-d2b5-4630-83f0-95fce9027799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_01e9d02d-f626-4d58-a7c0-ba126d726df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_01e9d02d-f626-4d58-a7c0-ba126d726df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6a66b15f-5402-48e0-8780-0011d4181e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7ef8f26-2c95-4b4c-832c-d4a10fa6cb32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6a66b15f-5402-48e0-8780-0011d4181e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f94f4c18-aa08-4726-a836-22967dfeaad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f94f4c18-aa08-4726-a836-22967dfeaad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9cf6529c-2ce5-46a0-8b25-6915c060da61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9cf6529c-2ce5-46a0-8b25-6915c060da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_bc42ab8b-9a80-4832-bae5-ff37b1bbcf96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_bc42ab8b-9a80-4832-bae5-ff37b1bbcf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_7689dc89-302d-4321-b4e7-d2d86ed5fa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_7689dc89-302d-4321-b4e7-d2d86ed5fa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PaymentOfDebtRefinancingCosts_3f24e7ea-5b91-4816-be64-2dc334241e08" xlink:href="bvs-20230401.xsd#bvs_PaymentOfDebtRefinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_bvs_PaymentOfDebtRefinancingCosts_3f24e7ea-5b91-4816-be64-2dc334241e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_156c459c-c5a9-437b-a426-a99ed04ec013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_156c459c-c5a9-437b-a426-a99ed04ec013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_52e9c131-145b-46a8-a74a-445b58a15858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_52e9c131-145b-46a8-a74a-445b58a15858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a8cf3736-4995-4ba6-ae4f-abfe0a621234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2dff29b6-c37a-4024-84a3-598aae7d4081" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a8cf3736-4995-4ba6-ae4f-abfe0a621234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe39f422-f128-4a9c-9398-a7e8ed82db82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe39f422-f128-4a9c-9398-a7e8ed82db82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f946de1e-ab61-4f61-8452-c421fcaebf92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f946de1e-ab61-4f61-8452-c421fcaebf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77ec7e52-38cf-47e8-9576-dc3faffb5c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77ec7e52-38cf-47e8-9576-dc3faffb5c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67198d88-8689-463c-8786-bcb76178172e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67198d88-8689-463c-8786-bcb76178172e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5592eab4-ddaf-43d5-9870-6419913b367c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2a7d96ea-d6b2-460c-ae64-c0e018631927" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5592eab4-ddaf-43d5-9870-6419913b367c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_76ffccf6-865d-4fe4-ac01-309d84921f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5592eab4-ddaf-43d5-9870-6419913b367c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_76ffccf6-865d-4fe4-ac01-309d84921f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Organization" xlink:type="simple" xlink:href="bvs-20230401.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90f3f6b7-e06d-40c4-b514-fa451d646f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_73dd28f8-aea1-486d-8734-638902a27344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90f3f6b7-e06d-40c4-b514-fa451d646f72" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_73dd28f8-aea1-486d-8734-638902a27344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Balancesheetinformation" xlink:type="simple" xlink:href="bvs-20230401.xsd#Balancesheetinformation"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Balancesheetinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e7f3cfc-4951-4e94-b4ee-94c71706cad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_20e70013-4b89-4ad9-8bf5-89b2e09106fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e7f3cfc-4951-4e94-b4ee-94c71706cad3" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_20e70013-4b89-4ad9-8bf5-89b2e09106fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Acquisitionsanddivestitures" xlink:type="simple" xlink:href="bvs-20230401.xsd#Acquisitionsanddivestitures"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Acquisitionsanddivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_30707922-f20e-4421-b9c1-9265a2675006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock_04ab529c-5fa4-484c-8cf2-39d05846095f" xlink:href="bvs-20230401.xsd#bvs_AcquisitionsAndInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_30707922-f20e-4421-b9c1-9265a2675006" xlink:to="loc_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock_04ab529c-5fa4-484c-8cf2-39d05846095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Financialinstruments" xlink:type="simple" xlink:href="bvs-20230401.xsd#Financialinstruments"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Financialinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4985e933-295c-410f-9c8e-e9f538171b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_51228825-172d-446e-a153-2faee79a4998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4985e933-295c-410f-9c8e-e9f538171b32" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_51228825-172d-446e-a153-2faee79a4998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="bvs-20230401.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c12fd0a7-676b-4b64-b70d-ea6d7641b0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_07f2286b-a660-444e-90f4-436598e57c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c12fd0a7-676b-4b64-b70d-ea6d7641b0de" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_07f2286b-a660-444e-90f4-436598e57c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Equitybasedcompensation" xlink:type="simple" xlink:href="bvs-20230401.xsd#Equitybasedcompensation"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Equitybasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_cbceb399-7418-43a9-9925-ed0c87bba73d" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_83a739c8-50b4-403d-86cc-b1c56c86cac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_cbceb399-7418-43a9-9925-ed0c87bba73d" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_83a739c8-50b4-403d-86cc-b1c56c86cac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Stockholdersequity" xlink:type="simple" xlink:href="bvs-20230401.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e71b3614-3f8f-4e09-b88f-e464ae896463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8accc787-834c-4f54-af6f-251ba6736738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e71b3614-3f8f-4e09-b88f-e464ae896463" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8accc787-834c-4f54-af6f-251ba6736738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Earningspershare" xlink:type="simple" xlink:href="bvs-20230401.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b0a841bb-aa5d-4676-9acb-912a13ffd0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cdf2d62e-c3af-4ad5-ba3f-e14eed8f8c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0a841bb-aa5d-4676-9acb-912a13ffd0fb" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cdf2d62e-c3af-4ad5-ba3f-e14eed8f8c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Restructuringcosts" xlink:type="simple" xlink:href="bvs-20230401.xsd#Restructuringcosts"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Restructuringcosts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_94fdd798-f2d4-4037-8a74-e6ebb2b9b82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4e14c2a6-e650-435f-90f2-eb9f258d99d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_94fdd798-f2d4-4037-8a74-e6ebb2b9b82b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4e14c2a6-e650-435f-90f2-eb9f258d99d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Incometaxes" xlink:type="simple" xlink:href="bvs-20230401.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_393af065-9772-447a-b298-2a2df116047c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_768555ca-2a76-4cad-8cd6-eb174eb20fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393af065-9772-447a-b298-2a2df116047c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_768555ca-2a76-4cad-8cd6-eb174eb20fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="bvs-20230401.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_540602b2-1602-48de-a5d4-1dac8730f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5d3a8b25-b7d8-4008-a864-be67a43400e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_540602b2-1602-48de-a5d4-1dac8730f99b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5d3a8b25-b7d8-4008-a864-be67a43400e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Revenuerecognition" xlink:type="simple" xlink:href="bvs-20230401.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b63216a-c1b8-47e2-960c-2496020a9004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5b9937e7-f26d-49cd-93c4-ab6ba33a4735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b63216a-c1b8-47e2-960c-2496020a9004" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5b9937e7-f26d-49cd-93c4-ab6ba33a4735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Segments" xlink:type="simple" xlink:href="bvs-20230401.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1057e751-c843-4e74-8721-01d37d013efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_7676f6b4-042b-4d99-8ed8-6fbd894b6116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1057e751-c843-4e74-8721-01d37d013efd" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_7676f6b4-042b-4d99-8ed8-6fbd894b6116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Discontinuedoperations" xlink:type="simple" xlink:href="bvs-20230401.xsd#Discontinuedoperations"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Discontinuedoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8b3e0114-c1d3-4650-b77b-030813a58e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3ed2352a-e208-496d-a8ef-286a93a6395a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8b3e0114-c1d3-4650-b77b-030813a58e5b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3ed2352a-e208-496d-a8ef-286a93a6395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/Subsequentevents" xlink:type="simple" xlink:href="bvs-20230401.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_71d378d8-a014-41d7-801d-caf0d68eb146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_51fc789c-0e7b-48b8-aa67-8c777b34a26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_71d378d8-a014-41d7-801d-caf0d68eb146" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_51fc789c-0e7b-48b8-aa67-8c777b34a26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/OrganizationPolicies" xlink:type="simple" xlink:href="bvs-20230401.xsd#OrganizationPolicies"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/OrganizationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f79062e-b4ea-4620-9370-352958a58dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ead6cea5-1ea4-44eb-a19d-9d401848e48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f79062e-b4ea-4620-9370-352958a58dc3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ead6cea5-1ea4-44eb-a19d-9d401848e48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_87b00713-2195-4d90-afc3-371cfcbddc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f79062e-b4ea-4620-9370-352958a58dc3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_87b00713-2195-4d90-afc3-371cfcbddc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/OrganizationTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#OrganizationTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/OrganizationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6cbda07-e067-4c91-abef-de656ef7c79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_fb266868-903c-49c2-afea-eab2ca48ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6cbda07-e067-4c91-abef-de656ef7c79b" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_fb266868-903c-49c2-afea-eab2ca48ea11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_32a884d9-86ba-4e72-b571-6291aa5ceb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_32a884d9-86ba-4e72-b571-6291aa5ceb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_bc1ccb4c-0f98-47a3-a292-31bbec0642c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_bc1ccb4c-0f98-47a3-a292-31bbec0642c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_23d8f398-8735-4e5c-9101-45c8b08e132f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_23d8f398-8735-4e5c-9101-45c8b08e132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_72f76d5a-2865-48d3-8a04-2054f0772302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_72f76d5a-2865-48d3-8a04-2054f0772302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_73c8d7d3-b2ed-480f-a9a4-cf80a39f21dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_73c8d7d3-b2ed-480f-a9a4-cf80a39f21dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0f302c41-818a-4995-b3d9-0a2099535001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8b85e16-2750-4c22-b14b-2f139533ef92" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0f302c41-818a-4995-b3d9-0a2099535001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1318cd3f-b749-4253-b466-faf2b89e1b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b8d75768-24ba-409f-9ea4-6be2bdeeec5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1318cd3f-b749-4253-b466-faf2b89e1b31" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b8d75768-24ba-409f-9ea4-6be2bdeeec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ce9421a1-123e-4151-902f-c780c61022f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1318cd3f-b749-4253-b466-faf2b89e1b31" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ce9421a1-123e-4151-902f-c780c61022f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_123a1f6a-a446-4178-842e-9a91db48f6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1318cd3f-b749-4253-b466-faf2b89e1b31" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_123a1f6a-a446-4178-842e-9a91db48f6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_27495615-9d5b-48e6-90b4-4cba15c027c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1318cd3f-b749-4253-b466-faf2b89e1b31" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_27495615-9d5b-48e6-90b4-4cba15c027c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FinancialinstrumentsTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#FinancialinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FinancialinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_02edacfd-21d7-4055-a228-57cd915a6ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e4be9a1b-b802-4ffd-9df7-34ebe4bda553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_02edacfd-21d7-4055-a228-57cd915a6ea4" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e4be9a1b-b802-4ffd-9df7-34ebe4bda553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a72b55c2-9866-4df6-8251-2b53b51e3423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_419c6633-55db-4459-b306-6ed5a242c606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a72b55c2-9866-4df6-8251-2b53b51e3423" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_419c6633-55db-4459-b306-6ed5a242c606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_4df0f5c1-612a-455a-8127-2602dc73d579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a72b55c2-9866-4df6-8251-2b53b51e3423" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_4df0f5c1-612a-455a-8127-2602dc73d579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_f60a3e89-c879-492b-96ed-31c00e14d82d" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_87a073b7-c1f3-4703-bc4d-1a42b1305908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_f60a3e89-c879-492b-96ed-31c00e14d82d" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_87a073b7-c1f3-4703-bc4d-1a42b1305908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_589810e4-031b-4532-a88c-493720f5060a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_f60a3e89-c879-492b-96ed-31c00e14d82d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_589810e4-031b-4532-a88c-493720f5060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_c027d104-837a-4c79-9c57-ad907a213586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_f60a3e89-c879-492b-96ed-31c00e14d82d" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_c027d104-837a-4c79-9c57-ad907a213586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_85757548-9447-4000-b512-9091ec48b528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_6975be46-e7f2-4d07-812d-6bc0e29fa846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85757548-9447-4000-b512-9091ec48b528" xlink:to="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock_6975be46-e7f2-4d07-812d-6bc0e29fa846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EarningspershareTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8e16dc26-b241-4662-9e0a-3126b065fb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7ce4cea9-1b6c-4003-ba22-b6a3ea759f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e16dc26-b241-4662-9e0a-3126b065fb98" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7ce4cea9-1b6c-4003-ba22-b6a3ea759f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c64c1437-8365-4e51-bfcf-42338c416e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8e16dc26-b241-4662-9e0a-3126b065fb98" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c64c1437-8365-4e51-bfcf-42338c416e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/RestructuringcostsTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#RestructuringcostsTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/RestructuringcostsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_42141a73-071e-4218-9b53-36530fe8defc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_8381c81e-0d02-42ae-8544-26cb2af0d7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_42141a73-071e-4218-9b53-36530fe8defc" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_8381c81e-0d02-42ae-8544-26cb2af0d7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_def14a45-fa89-4991-a613-3e519631de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c8f02ffb-fb8b-406a-8456-c597443c9059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_def14a45-fa89-4991-a613-3e519631de3c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c8f02ffb-fb8b-406a-8456-c597443c9059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_5c0f2f32-1385-4188-8006-56042b8a162b" xlink:href="bvs-20230401.xsd#bvs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_def14a45-fa89-4991-a613-3e519631de3c" xlink:to="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_5c0f2f32-1385-4188-8006-56042b8a162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/RevenuerecognitionTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#RevenuerecognitionTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/RevenuerecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cd6037d9-1d31-4192-aede-be27d3700e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a6075226-58b0-4ac1-886d-06d9b7d7fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cd6037d9-1d31-4192-aede-be27d3700e75" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a6075226-58b0-4ac1-886d-06d9b7d7fce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/SegmentsTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_47323716-e912-4fe2-acfa-707ca8693417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f3fdc007-95ac-4593-98e1-4e1c2a9cf118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_47323716-e912-4fe2-acfa-707ca8693417" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f3fdc007-95ac-4593-98e1-4e1c2a9cf118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsTables" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsTables"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c99b14a5-b299-4744-aece-72f075d7860f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_7a5ca51c-87a3-4b41-bc82-c051f7e85a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c99b14a5-b299-4744-aece-72f075d7860f" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_7a5ca51c-87a3-4b41-bc82-c051f7e85a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d3eb0d-46e8-4d13-bdb8-38178a863414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35d3eb0d-46e8-4d13-bdb8-38178a863414" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:to="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b53ed72a-4e20-48a2-8e58-8186e5000cf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6dc87919-d8f4-4150-a4cd-da2b2a578c17" xlink:to="loc_dei_EntityDomain_b53ed72a-4e20-48a2-8e58-8186e5000cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_6e70c0e9-5a48-4c20-86f4-8c371f42dbb8" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b53ed72a-4e20-48a2-8e58-8186e5000cf8" xlink:to="loc_bvs_BVLLCMember_6e70c0e9-5a48-4c20-86f4-8c371f42dbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8cee80fb-5cfe-4017-a50e-47a2173435cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3ca562af-429c-4f75-b64e-99ae7c906f2d" xlink:to="loc_us-gaap_ClassOfStockLineItems_8cee80fb-5cfe-4017-a50e-47a2173435cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_9793941f-83af-44fc-ad6b-d0a64625b7dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cee80fb-5cfe-4017-a50e-47a2173435cf" xlink:to="loc_dei_EntityNumberOfEmployees_9793941f-83af-44fc-ad6b-d0a64625b7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#OrganizationErrorCorrectionsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27ca1a1f-8e32-4a2e-bf9a-3959a9a643c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27ca1a1f-8e32-4a2e-bf9a-3959a9a643c0" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:to="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_73f964d2-084a-4ea2-ae11-1f46bc6a0169" xlink:to="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_7a148a22-c684-4aec-8a5e-68a5a85580b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_7a148a22-c684-4aec-8a5e-68a5a85580b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_cddcf62a-1bda-4479-b9a5-f702caaa0a84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d063e227-37b4-4505-97cc-dc9cb6235527" xlink:to="loc_srt_RestatementAdjustmentMember_cddcf62a-1bda-4479-b9a5-f702caaa0a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:to="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeAxis_25d327dc-6a30-4d88-a453-119bd8429721" xlink:to="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_EquityRebalancingMember_eb23b797-5d1f-4f35-acda-c3a4a70895e9" xlink:href="bvs-20230401.xsd#bvs_EquityRebalancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_EquityRebalancingMember_eb23b797-5d1f-4f35-acda-c3a4a70895e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_3d6fa8d0-79ec-4b02-93c8-78fbfba34e3e" xlink:href="bvs-20230401.xsd#bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember_3d6fa8d0-79ec-4b02-93c8-78fbfba34e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_9ed0ad05-d5c6-413c-ba86-e1c4652681ba" xlink:href="bvs-20230401.xsd#bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember_9ed0ad05-d5c6-413c-ba86-e1c4652681ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredTaxImpactFor2022Member_fdb0a19a-129e-4e64-9f9c-4df0a78c2481" xlink:href="bvs-20230401.xsd#bvs_DeferredTaxImpactFor2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_fa09cb6e-e791-4968-b2e0-381a2605faf5" xlink:to="loc_bvs_DeferredTaxImpactFor2022Member_fdb0a19a-129e-4e64-9f9c-4df0a78c2481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_24df69ca-c0da-4522-8c94-9378a114b99c" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a731baa6-85db-409e-bc2d-00563bce5549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a731baa6-85db-409e-bc2d-00563bce5549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df342918-2a48-44c1-af7f-ba651dc3766c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_Liabilities_df342918-2a48-44c1-af7f-ba651dc3766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4ee0676b-ff2d-47be-8100-d23c71f0cfef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4ee0676b-ff2d-47be-8100-d23c71f0cfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8e377279-0f65-416a-84d8-cfb6001672a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_MinorityInterest_8e377279-0f65-416a-84d8-cfb6001672a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c86693d9-43e9-4a1b-8dff-242839ee5ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_eb59221d-06e1-484d-a3e6-3b00c9c0aa70" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c86693d9-43e9-4a1b-8dff-242839ee5ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7cd03387-ba61-4cce-ad81-d2007c389d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7cd03387-ba61-4cce-ad81-d2007c389d68" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ba29ff1a-03e8-4ae4-893a-5b72ac4980cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9fdb98fc-03e3-4bfb-82fe-d6c723f16365" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ba29ff1a-03e8-4ae4-893a-5b72ac4980cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_8e2cf7e9-5431-4329-9b2d-667c12a03833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ba29ff1a-03e8-4ae4-893a-5b72ac4980cf" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_8e2cf7e9-5431-4329-9b2d-667c12a03833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c8eff240-fc11-40cb-ab75-01fca70ea718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e8757c87-337f-4062-a4fd-012ba94f8708" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c8eff240-fc11-40cb-ab75-01fca70ea718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_f1f668d7-72db-458b-8d7a-0e496e830d4a" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c8eff240-fc11-40cb-ab75-01fca70ea718" xlink:to="loc_bvs_CartiHealLtdMember_f1f668d7-72db-458b-8d7a-0e496e830d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f652cfdc-6af5-495d-830c-58a3b9d57fec" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_3e43a169-0b0b-4d41-87ed-18cfc763677a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_3e43a169-0b0b-4d41-87ed-18cfc763677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa38e4b8-6f20-4e40-975a-07b0587e55b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa38e4b8-6f20-4e40-975a-07b0587e55b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_17297f88-6340-4f0e-90c8-b9ef6aba936e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_17297f88-6340-4f0e-90c8-b9ef6aba936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_48a274b6-e843-457a-8d5c-09dbbde5d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_222eeeb9-95a5-4fd8-8ab1-ad1cbf8899e9" xlink:to="loc_us-gaap_OtherReceivables_48a274b6-e843-457a-8d5c-09dbbde5d79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_e16a3735-6bc7-40d3-ab14-ec575eabea85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e16a3735-6bc7-40d3-ab14-ec575eabea85" xlink:to="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ebc140f9-a2fa-4260-b49e-d2f3daf009c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_52586bce-51af-4675-8137-1ac0c5ccdbdf" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ebc140f9-a2fa-4260-b49e-d2f3daf009c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3841d9fc-0c21-41ee-93d6-af346446af06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ebc140f9-a2fa-4260-b49e-d2f3daf009c6" xlink:to="loc_us-gaap_AccountsReceivableMember_3841d9fc-0c21-41ee-93d6-af346446af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d231ceda-08a5-4222-ada8-12aa5d96d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_46a64ea8-db21-4000-a1c2-968a9029b9f4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d231ceda-08a5-4222-ada8-12aa5d96d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d63f4065-2606-4e78-bac2-b9d2a22f2168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d231ceda-08a5-4222-ada8-12aa5d96d6df" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d63f4065-2606-4e78-bac2-b9d2a22f2168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_47359999-bb3e-466b-84b6-09be4fb55fd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e3366f53-431f-4f49-b041-561c78cf9819" xlink:to="loc_srt_NameOfMajorCustomerDomain_47359999-bb3e-466b-84b6-09be4fb55fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CustomerOneMember_9ab2c030-ac76-4ac6-a2c4-9c43788cd336" xlink:href="bvs-20230401.xsd#bvs_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_47359999-bb3e-466b-84b6-09be4fb55fd9" xlink:to="loc_bvs_CustomerOneMember_9ab2c030-ac76-4ac6-a2c4-9c43788cd336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e3de43ca-53b0-47ed-8a45-9f1a1a0e6d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_4214dd08-6e84-4fbf-a0bf-9eece76b19b0" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e3de43ca-53b0-47ed-8a45-9f1a1a0e6d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7b8315d9-7ad7-498a-83ab-d77afe6f9221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e3de43ca-53b0-47ed-8a45-9f1a1a0e6d7d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7b8315d9-7ad7-498a-83ab-d77afe6f9221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632fea07-5a31-4e58-aec9-ec9acdd4a34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632fea07-5a31-4e58-aec9-ec9acdd4a34a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_fc110b73-366a-4f9c-8ee7-c03a36d5c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_fc110b73-366a-4f9c-8ee7-c03a36d5c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ede715c0-bca2-488e-90f7-624c14bfc5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ede715c0-bca2-488e-90f7-624c14bfc5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_158b5a9d-3e9f-4a2b-8afb-e7d907a677a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_158b5a9d-3e9f-4a2b-8afb-e7d907a677a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_db602677-3667-4b87-b546-9a38c33afe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_db602677-3667-4b87-b546-9a38c33afe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale_86cc3fc1-991d-4198-96e3-98170f0b4ee1" xlink:href="bvs-20230401.xsd#bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:to="loc_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale_86cc3fc1-991d-4198-96e3-98170f0b4ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_75fe3d52-d72e-4561-8feb-bed74ad77081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2ff4896c-33bd-4b84-ade2-e3dbe1418f87" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_75fe3d52-d72e-4561-8feb-bed74ad77081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1e234b2-fc79-45f5-859d-865e72295b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1e234b2-fc79-45f5-859d-865e72295b2b" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2fe69c32-e7f8-422b-8b4d-b1f8422e9787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d7e080d8-46bc-4608-9608-52d77287bf06" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2fe69c32-e7f8-422b-8b4d-b1f8422e9787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_fac46a15-f321-489a-b4e4-b4bdf60242f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2fe69c32-e7f8-422b-8b4d-b1f8422e9787" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_fac46a15-f321-489a-b4e4-b4bdf60242f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a775b4f-922b-4db3-9a46-4c4508fcd1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_153da899-25ef-40a4-ae56-5ea370b5cd68" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a775b4f-922b-4db3-9a46-4c4508fcd1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_75d338d1-a553-4966-98db-644b7aef0c01" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a775b4f-922b-4db3-9a46-4c4508fcd1f7" xlink:to="loc_bvs_CartiHealLtdMember_75d338d1-a553-4966-98db-644b7aef0c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9d824597-a7e6-42db-9658-29804e56f383" xlink:to="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_719e598c-c9c2-4020-9902-3ffad8a3873f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_719e598c-c9c2-4020-9902-3ffad8a3873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_47293236-7077-4538-bb7e-f11f25dde3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryFinishedGoods_47293236-7077-4538-bb7e-f11f25dde3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c4efbe26-eba1-425b-9d0c-8ed71c07fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryGross_c4efbe26-eba1-425b-9d0c-8ed71c07fb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5a2a124a-df9c-4b21-b705-8c645ae7263b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryValuationReserves_5a2a124a-df9c-4b21-b705-8c645ae7263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ea7e0870-32f2-42b8-b1b7-ffccf2d5bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_01bad1b0-b0ce-4e95-b130-a70c1750f400" xlink:to="loc_us-gaap_InventoryNet_ea7e0870-32f2-42b8-b1b7-ffccf2d5bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95f7c6bf-5dbb-4b77-a3cc-50c4f5afcb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95f7c6bf-5dbb-4b77-a3cc-50c4f5afcb5a" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7d73c951-83d6-464a-9102-603cdf683c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_adc8bf07-3705-4bd0-88a2-4b38f8351993" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7d73c951-83d6-464a-9102-603cdf683c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_5d8e3849-9a30-45f0-b4e4-ca8b059b50bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7d73c951-83d6-464a-9102-603cdf683c91" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_5d8e3849-9a30-45f0-b4e4-ca8b059b50bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97960a80-5c84-4c9b-9bd0-939fc813e392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5744f5a-5de4-4cdc-b98d-1b1c149f3f05" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97960a80-5c84-4c9b-9bd0-939fc813e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_9a503240-256e-4068-9b34-c0f5c19c2fc8" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97960a80-5c84-4c9b-9bd0-939fc813e392" xlink:to="loc_bvs_CartiHealLtdMember_9a503240-256e-4068-9b34-c0f5c19c2fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c8f33c1f-67b5-4027-81de-f8b283260c8e" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_48bad10b-9d05-4b4d-b30c-0fa25eab8820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_PrepaidTaxes_48bad10b-9d05-4b4d-b30c-0fa25eab8820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_dd9839e9-b8bd-426b-ab06-a68a73871cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_dd9839e9-b8bd-426b-ab06-a68a73871cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9180e25c-27b4-4eff-90e1-66e7f5ab8edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_53965e03-91ba-48ec-8275-f51c81dab024" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9180e25c-27b4-4eff-90e1-66e7f5ab8edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_b2b3f60c-b376-4abf-baa2-b603a5d42cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_b2b3f60c-b376-4abf-baa2-b603a5d42cb1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_20bb8310-1960-4b11-8c78-3cf318e1a421" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_b8cdd885-34b5-4190-af55-7440628453e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_IntellectualPropertyMember_b8cdd885-34b5-4190-af55-7440628453e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_830ecdcb-7965-4c1e-8db0-c0605d5d45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_DistributionRightsMember_830ecdcb-7965-4c1e-8db0-c0605d5d45eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3b0608e3-4fbb-4839-973e-da41e385f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3b0608e3-4fbb-4839-973e-da41e385f4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6e3c02b2-8c84-4e83-ab26-350c97f978b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6e3c02b2-8c84-4e83-ab26-350c97f978b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_98747ee7-e904-4a94-8b5b-616b768460d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6cbc9292-cd71-4980-987a-5bdf39044362" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_98747ee7-e904-4a94-8b5b-616b768460d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7a035051-181d-4180-9027-ade54818ff00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_88d5785d-65df-4a4b-ae17-2a7d51949abe" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7a035051-181d-4180-9027-ade54818ff00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_954e78a2-5875-4ca7-b3fb-66cd814ba6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7a035051-181d-4180-9027-ade54818ff00" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_954e78a2-5875-4ca7-b3fb-66cd814ba6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d86f095-99a1-4625-bef0-7aadfe928340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dd7a70b1-5094-411a-a028-7ee06531814a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d86f095-99a1-4625-bef0-7aadfe928340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_4710d4dc-b8ec-4526-a762-6cdf5f3e56a9" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d86f095-99a1-4625-bef0-7aadfe928340" xlink:to="loc_bvs_CartiHealLtdMember_4710d4dc-b8ec-4526-a762-6cdf5f3e56a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4440f8cd-449f-4dfb-bcfd-094a7bc2dae8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d5b3d9f9-4af6-4346-b6b4-c91c340818a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d5b3d9f9-4af6-4346-b6b4-c91c340818a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68363cbf-9c4d-4e65-811d-5acca1f3747f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68363cbf-9c4d-4e65-811d-5acca1f3747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_4d6bc22b-4e51-4d97-80dc-f990181208a2" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss_4d6bc22b-4e51-4d97-80dc-f990181208a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_b5953540-a1b2-4e9c-b869-e7c2c91523f5" xlink:href="bvs-20230401.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss_b5953540-a1b2-4e9c-b869-e7c2c91523f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfb80bd9-3bcd-4340-995e-0e94cb535514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bfb80bd9-3bcd-4340-995e-0e94cb535514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9d969640-5a56-4c67-bf13-bf6a0d0030d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9ac1b2c7-dfd3-496a-87ec-9a9f802f7387" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9d969640-5a56-4c67-bf13-bf6a0d0030d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_6a57e5ba-ed69-46e4-b3fe-f337a3d932c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6e592e47-715a-4826-ac0a-7fc7420a7def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6a57e5ba-ed69-46e4-b3fe-f337a3d932c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6e592e47-715a-4826-ac0a-7fc7420a7def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_632f3fee-b461-4927-83b2-e1fb647518dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6a57e5ba-ed69-46e4-b3fe-f337a3d932c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_632f3fee-b461-4927-83b2-e1fb647518dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cc1ff7bc-8f72-410d-abd9-e0d30f4773a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6a57e5ba-ed69-46e4-b3fe-f337a3d932c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cc1ff7bc-8f72-410d-abd9-e0d30f4773a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_47585c09-22c3-4b8d-be49-09227dbbc8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6a57e5ba-ed69-46e4-b3fe-f337a3d932c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_47585c09-22c3-4b8d-be49-09227dbbc8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d15fde32-50f8-4fb4-8dac-36d2c516d3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6a57e5ba-ed69-46e4-b3fe-f337a3d932c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d15fde32-50f8-4fb4-8dac-36d2c516d3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_7efdaa3e-8af3-46ca-a583-501e05ade815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_7efdaa3e-8af3-46ca-a583-501e05ade815" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_22e994f5-4b86-4a86-8d00-d373bceacaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_95dfae91-5745-45cb-9e34-10faf5b19575" xlink:to="loc_us-gaap_ReportingUnitDomain_22e994f5-4b86-4a86-8d00-d373bceacaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_513672f0-de3d-4ef6-80df-7cf8df390441" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_22e994f5-4b86-4a86-8d00-d373bceacaf8" xlink:to="loc_country_US_513672f0-de3d-4ef6-80df-7cf8df390441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c846992c-3b8c-41b2-bb2a-9830ccff710b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f1510891-66db-48a4-8fb0-2eadcbae6a86" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c846992c-3b8c-41b2-bb2a-9830ccff710b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_cc25c202-3297-42a8-99df-1c0889ce68ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c846992c-3b8c-41b2-bb2a-9830ccff710b" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_cc25c202-3297-42a8-99df-1c0889ce68ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_875bcca4-2270-4952-a3c4-e28e4551fd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f08948e8-f352-4380-895b-9351eb721e69" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_875bcca4-2270-4952-a3c4-e28e4551fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_142f4745-05b4-42a4-89ed-f0f8b60a208c" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_875bcca4-2270-4952-a3c4-e28e4551fd64" xlink:to="loc_bvs_CartiHealLtdMember_142f4745-05b4-42a4-89ed-f0f8b60a208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7f8c0c3e-0821-412a-9dec-d683b12c9cfd" xlink:to="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_133570db-ca94-4be2-afc3-4f5c0a54d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_NumberOfReportingUnits_133570db-ca94-4be2-afc3-4f5c0a54d91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ff6082b7-605f-42e9-96e3-40ee2529f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_Goodwill_ff6082b7-605f-42e9-96e3-40ee2529f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_193922e2-6aae-4823-8908-0f1e83238e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_193922e2-6aae-4823-8908-0f1e83238e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0b39f612-1016-4639-b6c0-df30d2430dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5fa37d84-a545-4a51-8858-d41354eb2c98" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0b39f612-1016-4639-b6c0-df30d2430dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#BalancesheetinformationScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ebd91e83-060f-4999-8b73-cea414e15706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ebd91e83-060f-4999-8b73-cea414e15706" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e88a57a1-8490-469a-a2c9-da26ca23c2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0ec6e858-4cb0-44cc-a906-891431e24643" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e88a57a1-8490-469a-a2c9-da26ca23c2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_e3cebe7f-932c-4101-b47a-25c8a59a1b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e88a57a1-8490-469a-a2c9-da26ca23c2e5" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_e3cebe7f-932c-4101-b47a-25c8a59a1b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51bfff7a-844d-44ef-a26c-43563da3980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_99042ed7-6c7b-4024-9bad-7088315ea520" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51bfff7a-844d-44ef-a26c-43563da3980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_94ca6e41-6d59-4959-8b5d-55dacac3086e" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_51bfff7a-844d-44ef-a26c-43563da3980e" xlink:to="loc_bvs_CartiHealLtdMember_94ca6e41-6d59-4959-8b5d-55dacac3086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0cb10e1e-73b9-49fb-8f77-c7fd59d41929" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_GrossToNetDeductionsCurrent_0ff3a7ae-da86-41e9-b11d-dcb1aa5fd6b3" xlink:href="bvs-20230401.xsd#bvs_GrossToNetDeductionsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_bvs_GrossToNetDeductionsCurrent_0ff3a7ae-da86-41e9-b11d-dcb1aa5fd6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_6bd37135-85ee-41cc-ba2e-e478b05653d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_AccruedBonusesCurrent_6bd37135-85ee-41cc-ba2e-e478b05653d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_a5e7da30-0a40-4ceb-babb-a321f3636f5d" xlink:href="bvs-20230401.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_a5e7da30-0a40-4ceb-babb-a321f3636f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_8b1da91d-8572-45ab-a138-0bb134fd3647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_8b1da91d-8572-45ab-a138-0bb134fd3647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_79bee6fe-d7d7-497c-a556-6963a896ede3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_TaxesPayableCurrent_79bee6fe-d7d7-497c-a556-6963a896ede3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_008bb5c8-57c2-40dc-98a9-2137917da274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_008bb5c8-57c2-40dc-98a9-2137917da274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6a0f6318-5cc1-464d-8c95-6c1031657569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_99fea546-14cd-4c91-afa8-4c5e7a673ee0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6a0f6318-5cc1-464d-8c95-6c1031657569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f319c668-c1ec-40cf-8dde-74217b15016c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f319c668-c1ec-40cf-8dde-74217b15016c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fcbda50a-e067-4cf1-a65a-9577849b40ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_94196329-e991-43d1-8eb7-73b77568285c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fcbda50a-e067-4cf1-a65a-9577849b40ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_2685ff07-8e7a-49ac-aa0a-add95f6102b4" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fcbda50a-e067-4cf1-a65a-9577849b40ec" xlink:to="loc_bvs_CartiHealLtdMember_2685ff07-8e7a-49ac-aa0a-add95f6102b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9e20145-40aa-44f1-bb01-165858c24782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ace0231d-2bd3-46a4-ab36-783e887e387c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9e20145-40aa-44f1-bb01-165858c24782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_3670f990-6454-4e3c-8c25-9fdb472e098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c9e20145-40aa-44f1-bb01-165858c24782" xlink:to="loc_us-gaap_IntellectualPropertyMember_3670f990-6454-4e3c-8c25-9fdb472e098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3da562dc-d5e1-4df5-9c50-0ac3c692d216" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember_7354c607-5c3a-4df8-ab7e-069196e9329c" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_SalesMilestoneMember_7354c607-5c3a-4df8-ab7e-069196e9329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredConsiderationMember_da7572cb-0dba-48a0-a9c3-6ad0d8518cf6" xlink:href="bvs-20230401.xsd#bvs_DeferredConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredConsiderationMember_da7572cb-0dba-48a0-a9c3-6ad0d8518cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJuly12023Member_61188dd5-e092-4b9d-9bb7-3bc4cf5423d7" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJuly12023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJuly12023Member_61188dd5-e092-4b9d-9bb7-3bc4cf5423d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableBySeptember12023Member_03c72138-733a-4ad5-bd51-58f070db35ac" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableBySeptember12023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableBySeptember12023Member_03c72138-733a-4ad5-bd51-58f070db35ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12025Member_7ceaeb29-f0d0-4b8b-9dcf-72b2d4edece3" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJanuary12025Member_7ceaeb29-f0d0-4b8b-9dcf-72b2d4edece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12026Member_5668283c-f859-479a-88b8-8c8c5f8ce1e4" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12026Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJanuary12026Member_5668283c-f859-479a-88b8-8c8c5f8ce1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountPayableByJanuary12027Member_10c36f0e-5c2e-4133-9e94-cb145c2ec2b8" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountPayableByJanuary12027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountPayableByJanuary12027Member_10c36f0e-5c2e-4133-9e94-cb145c2ec2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember_9f96d431-6eb5-4562-8dc5-cae4999a4ddb" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_DeferredAmountMember_9f96d431-6eb5-4562-8dc5-cae4999a4ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TrailingTwelveMonthSalesMember_c4ce8418-43ac-425d-85b6-559d8abf1560" xlink:href="bvs-20230401.xsd#bvs_TrailingTwelveMonthSalesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd228727-a778-41a9-a936-3d850a738ba7" xlink:to="loc_bvs_TrailingTwelveMonthSalesMember_c4ce8418-43ac-425d-85b6-559d8abf1560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_395378a8-5f59-41f8-8052-33687c5c89e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ec2d91b-61b5-4e31-93a9-ad08b21fe018" xlink:to="loc_us-gaap_ClassOfStockDomain_395378a8-5f59-41f8-8052-33687c5c89e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_294b0a4d-a5a9-4b33-9e78-5a653f6fce44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_395378a8-5f59-41f8-8052-33687c5c89e0" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_294b0a4d-a5a9-4b33-9e78-5a653f6fce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_98de652c-bf03-4ee8-854b-45798400aa67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0baab463-e369-4a66-9206-a031fe2583c1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_98de652c-bf03-4ee8-854b-45798400aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_95ae3ec3-ef1e-471b-9a2d-82f97637d868" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98de652c-bf03-4ee8-854b-45798400aa67" xlink:to="loc_bvs_CartiHealLtdMember_95ae3ec3-ef1e-471b-9a2d-82f97637d868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_f86e2787-10db-4125-b44c-0d5dfa108124" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_5882944b-c646-4100-a831-3bbe18a1ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:to="loc_us-gaap_CallOptionMember_5882944b-c646-4100-a831-3bbe18a1ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_2cc2f919-7293-4795-9375-542c059338c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_f9d3c4c4-e5ca-4081-b43e-ebc9b2472e82" xlink:to="loc_us-gaap_PutOptionMember_2cc2f919-7293-4795-9375-542c059338c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_f029246b-5c87-436f-8038-1eacda9e3323" xlink:to="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2a2c5fcf-8cfe-4f94-ae19-634d277545ae" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:to="loc_country_US_2a2c5fcf-8cfe-4f94-ae19-634d277545ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalMember_02c70f2e-b764-44df-bb29-4953cb08b641" xlink:href="bvs-20230401.xsd#bvs_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_c33fcdcb-9657-4ac8-a5da-4807f6628466" xlink:to="loc_bvs_InternationalMember_02c70f2e-b764-44df-bb29-4953cb08b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_adebd1c9-a350-45b1-825b-c06cba045c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cebd8f54-bb9c-4618-939f-81c586c854ca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_adebd1c9-a350-45b1-825b-c06cba045c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d194cb8e-b97c-4649-aec6-99dfe3ccdfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_adebd1c9-a350-45b1-825b-c06cba045c5e" xlink:to="loc_us-gaap_LineOfCreditMember_d194cb8e-b97c-4649-aec6-99dfe3ccdfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dad9d32d-2159-40d5-a949-3c90423d6e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a344602c-b041-4b3a-9ff7-d6e7b2203fb8" xlink:to="loc_us-gaap_CreditFacilityDomain_dad9d32d-2159-40d5-a949-3c90423d6e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilityMember_13b6e21d-fb19-4c0c-b6d3-ace68a5fd3bf" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dad9d32d-2159-40d5-a949-3c90423d6e9a" xlink:to="loc_bvs_TermLoanFacilityMember_13b6e21d-fb19-4c0c-b6d3-ace68a5fd3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_24419cd5-3269-486d-860a-5c9361c27c2b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ElronMember_aaa71403-4130-4381-9608-810e9b58231d" xlink:href="bvs-20230401.xsd#bvs_ElronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:to="loc_bvs_ElronMember_aaa71403-4130-4381-9608-810e9b58231d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_c3b2467c-ed36-4635-a908-fae5b513dce5" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97385f0b-46ee-42e6-8cca-8091ba17a6bf" xlink:to="loc_bvs_CartiHealLtdMember_c3b2467c-ed36-4635-a908-fae5b513dce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b75759d3-4daf-4097-9e1a-84538b449c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d339a383-6e55-4701-a9c2-e478ea660254" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b75759d3-4daf-4097-9e1a-84538b449c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember_d045bd83-f631-4326-aedc-ae9face8fb2e" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b75759d3-4daf-4097-9e1a-84538b449c0b" xlink:to="loc_bvs_WoundBusinessMember_d045bd83-f631-4326-aedc-ae9face8fb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_62260819-1545-40a3-b2bd-f12a76529190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ef83d819-2920-44d3-999e-32221e331ab6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_62260819-1545-40a3-b2bd-f12a76529190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4ce05736-d7db-44f2-804f-0c6b6d9ab56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_62260819-1545-40a3-b2bd-f12a76529190" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_4ce05736-d7db-44f2-804f-0c6b6d9ab56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b9b9efb-bc51-48a7-9c6f-bb15facdc124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_80b5fb10-4981-4826-b957-cc807dc46005" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b9b9efb-bc51-48a7-9c6f-bb15facdc124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5a2d4278-3ee2-46d5-8d33-a459dda12955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b9b9efb-bc51-48a7-9c6f-bb15facdc124" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5a2d4278-3ee2-46d5-8d33-a459dda12955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d1280990-7663-4c99-9e3d-b4f0510d7a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_990f9ac1-724b-46ae-b4e8-9be6c4db98b2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d1280990-7663-4c99-9e3d-b4f0510d7a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cacf80a3-145a-4580-96dd-a8af4550346e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d1280990-7663-4c99-9e3d-b4f0510d7a14" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cacf80a3-145a-4580-96dd-a8af4550346e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f83e2c41-a445-4f35-a437-4a8c31644898" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7b413db6-65c1-4799-b5da-e07de342cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_AssetImpairmentCharges_7b413db6-65c1-4799-b5da-e07de342cfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AssetImpairmentChargesAfterTax_59e6e0fe-4bd7-4ea2-8c6a-fbe312c84eb7" xlink:href="bvs-20230401.xsd#bvs_AssetImpairmentChargesAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_AssetImpairmentChargesAfterTax_59e6e0fe-4bd7-4ea2-8c6a-fbe312c84eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d62f63ea-6b85-4f3f-89c8-84998eff56ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d62f63ea-6b85-4f3f-89c8-84998eff56ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d236b27d-dc71-4679-a004-613ba002c788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_Investments_d236b27d-dc71-4679-a004-613ba002c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5be6913e-7834-4b55-992c-c6e9e4cd3875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5be6913e-7834-4b55-992c-c6e9e4cd3875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_be3531fe-e1c6-4343-b4d5-6e2c0509b293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_be3531fe-e1c6-4343-b4d5-6e2c0509b293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87e667a1-de1e-4a3f-97d4-859bc246c443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87e667a1-de1e-4a3f-97d4-859bc246c443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_76fd7f06-3769-4800-8d5e-f28298bae0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_76fd7f06-3769-4800-8d5e-f28298bae0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_da00235e-8159-4068-96a4-072d23e0431c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_EscrowDeposit_da00235e-8159-4068-96a4-072d23e0431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9a3229e4-05df-42bc-add4-f1727b3b12ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9a3229e4-05df-42bc-add4-f1727b3b12ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2ea7b8b6-0802-4547-a9ab-8f7a66b99624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2ea7b8b6-0802-4547-a9ab-8f7a66b99624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_6b95436e-563d-4953-b8bd-79e011a16a35" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches_6b95436e-563d-4953-b8bd-79e011a16a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_228e4ac9-07bb-4735-8309-e3af85192582" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate_228e4ac9-07bb-4735-8309-e3af85192582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c374ae2e-7492-4ec1-a810-e4d741f822a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c374ae2e-7492-4ec1-a810-e4d741f822a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1b031c1-1f65-4af1-af40-3794cf6db1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e1b031c1-1f65-4af1-af40-3794cf6db1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_c81085c4-0be3-426b-aaba-1629f32f57b3" xlink:href="bvs-20230401.xsd#bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee_c81085c4-0be3-426b-aaba-1629f32f57b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_82013723-761e-4b0e-983f-17e1a88e7c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_82013723-761e-4b0e-983f-17e1a88e7c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0dadc91f-1be0-4644-b1ed-7aed36c582c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3d40573a-d91c-473c-98b2-53d6d3008cb1" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0dadc91f-1be0-4644-b1ed-7aed36c582c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d7efd807-528b-41d7-8e6a-9cc548b29f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d7efd807-528b-41d7-8e6a-9cc548b29f3b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_564516a7-a105-4e2d-9d9a-0b9354b6a0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c8cb2acc-454c-4869-99ba-3cb0f9497910" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_564516a7-a105-4e2d-9d9a-0b9354b6a0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_03e3326e-340b-45bc-bf11-244e2d7c56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_564516a7-a105-4e2d-9d9a-0b9354b6a0c6" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_03e3326e-340b-45bc-bf11-244e2d7c56a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9be20105-08f1-40d9-9369-7ae86b03b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_23cc7607-29bb-40c2-b630-d6680fd7121e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9be20105-08f1-40d9-9369-7ae86b03b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember_f4cb9355-07d0-4927-8337-2b4409c8fb3c" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9be20105-08f1-40d9-9369-7ae86b03b58a" xlink:to="loc_bvs_WoundBusinessMember_f4cb9355-07d0-4927-8337-2b4409c8fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba199f05-c740-4d8a-9ddb-3b3c4a12ce5a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9cb74bbc-7bb2-463d-9387-8d78b04b5d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9cb74bbc-7bb2-463d-9387-8d78b04b5d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_9a34aa4c-7d05-4238-960d-b2fdf39f064e" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_9a34aa4c-7d05-4238-960d-b2fdf39f064e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0375407a-ddbb-4f06-85fb-51ff69cc5cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0375407a-ddbb-4f06-85fb-51ff69cc5cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_6a31c805-fd6d-4329-a89f-91ca9c988cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_6a31c805-fd6d-4329-a89f-91ca9c988cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_d2f4365c-ffbe-43bc-96b2-8f242c741b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_d2f4365c-ffbe-43bc-96b2-8f242c741b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_621d93b8-6e4b-4498-8ac8-f7ada9252cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_621d93b8-6e4b-4498-8ac8-f7ada9252cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_f11f7079-8911-48bd-8572-58cf8ccb5001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_f11f7079-8911-48bd-8572-58cf8ccb5001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8aa1c663-8b82-488a-be21-857597d5195c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8aa1c663-8b82-488a-be21-857597d5195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2e595e13-fb55-4ddf-ac6e-24537b3aab15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43478ea4-2c3f-4e5e-b30c-9497dc1c8057" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2e595e13-fb55-4ddf-ac6e-24537b3aab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3d5aac06-62c6-43b5-912d-c75543a283fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3d5aac06-62c6-43b5-912d-c75543a283fd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16f78e07-66d1-41cc-95ec-5adda82433ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19c10a7e-f9e6-4971-9b0b-3c3e2ea0b002" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16f78e07-66d1-41cc-95ec-5adda82433ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_1114824f-ef05-460e-b211-3c904cc1d723" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16f78e07-66d1-41cc-95ec-5adda82433ee" xlink:to="loc_bvs_CartiHealLtdMember_1114824f-ef05-460e-b211-3c904cc1d723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_eb7b8812-07cc-4b18-8048-f5c060ebb5a0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember_58b04245-6793-4593-90f7-93246fc4f331" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:to="loc_bvs_DeferredAmountMember_58b04245-6793-4593-90f7-93246fc4f331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember_0deb2ff6-4738-4ed6-9b75-5c5f819bfdd6" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_d3cd28be-6d3e-4cfd-9626-535b2d9d1c9a" xlink:to="loc_bvs_SalesMilestoneMember_0deb2ff6-4738-4ed6-9b75-5c5f819bfdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d04ac619-8a08-4362-8216-fedb4c47d254" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_03a04fc7-a1d0-4ca7-8f29-d7221501d4f7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d04ac619-8a08-4362-8216-fedb4c47d254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_2e2d1696-6583-47c6-a53d-e79c9f591920" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d04ac619-8a08-4362-8216-fedb4c47d254" xlink:to="loc_bvs_CartiHealLtdMember_2e2d1696-6583-47c6-a53d-e79c9f591920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_52324afe-e4a4-454b-84b5-2fc14e7d9ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_fae33807-3aa9-4d80-886c-8486ed707ccc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_52324afe-e4a4-454b-84b5-2fc14e7d9ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c48789e1-e68a-4f21-8f34-aab0d9ea3a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_52324afe-e4a4-454b-84b5-2fc14e7d9ba5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c48789e1-e68a-4f21-8f34-aab0d9ea3a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4ea44c2-ebbd-4ec6-a366-24c5ae2a242f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c48789e1-e68a-4f21-8f34-aab0d9ea3a95" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4ea44c2-ebbd-4ec6-a366-24c5ae2a242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_16e5baa0-6e92-4e66-bc78-a95f6e71ab56" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_104dd900-e292-48ee-b6a4-9efb81a668a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_104dd900-e292-48ee-b6a4-9efb81a668a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_54d01d38-555a-4997-a611-305d125eb2ca" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredTransactionCosts_54d01d38-555a-4997-a611-305d125eb2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_d4152d27-63a9-4825-a3f4-3c09af74e3da" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts_d4152d27-63a9-4825-a3f4-3c09af74e3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_183c1c9e-2f84-4a2d-8fb7-8361d7408266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_183c1c9e-2f84-4a2d-8fb7-8361d7408266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fcfda642-de38-4bf0-863f-f1839de7933f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fcfda642-de38-4bf0-863f-f1839de7933f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_c7ac22d0-7950-4669-897f-36530c575bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_c7ac22d0-7950-4669-897f-36530c575bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_065e7e42-5a81-4db5-b2b6-5f01c428f65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_065e7e42-5a81-4db5-b2b6-5f01c428f65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_62faa69a-edf7-4359-81b3-379ac7910891" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares_62faa69a-edf7-4359-81b3-379ac7910891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1229ebd5-38c6-42ba-a0aa-d8b25ad4e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cea49c5e-f3b3-4cc2-b312-b4dd125a0987" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1229ebd5-38c6-42ba-a0aa-d8b25ad4e42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a9a8cbc5-83a1-45b5-bfce-31430f62e843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a9a8cbc5-83a1-45b5-bfce-31430f62e843" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6331f135-93a8-476d-a1f3-2dac9730ea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fba4a236-5ac1-428e-943a-42817df4fa1b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6331f135-93a8-476d-a1f3-2dac9730ea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_2246a24e-68d3-4482-90fd-9598cc6fa177" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6331f135-93a8-476d-a1f3-2dac9730ea7b" xlink:to="loc_bvs_CartiHealLtdMember_2246a24e-68d3-4482-90fd-9598cc6fa177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1b86492-d251-4c82-a470-b160228940c8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d7fef26d-a94c-41e3-8bec-7ae6ed7509f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_d7fef26d-a94c-41e3-8bec-7ae6ed7509f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5660895a-89fb-45fb-9dbf-51a989512dbb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5d5b60b6-d39c-412e-8545-509b51ba96a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5d5b60b6-d39c-412e-8545-509b51ba96a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_dc0edff3-84a0-45dd-8524-b36825470715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_dc0edff3-84a0-45dd-8524-b36825470715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0599df1-3d36-4bcd-89ae-4706643175df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0599df1-3d36-4bcd-89ae-4706643175df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_302cf1bd-fdba-4a6e-9563-6d24cce124e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_302cf1bd-fdba-4a6e-9563-6d24cce124e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c418c369-e5e2-492a-878c-8d9152a8bafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c418c369-e5e2-492a-878c-8d9152a8bafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_8bfb3770-60d2-41d7-bd89-bcf1efb2ab6c" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets_8bfb3770-60d2-41d7-bd89-bcf1efb2ab6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9f6a904c-4f18-4548-a58e-cefb4dcd032b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9f6a904c-4f18-4548-a58e-cefb4dcd032b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_b00f57fc-8d9a-4996-8179-b7b07f71359e" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_b00f57fc-8d9a-4996-8179-b7b07f71359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_35f7a086-5f9a-4180-867a-644912f8251c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_35f7a086-5f9a-4180-867a-644912f8251c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f88a9e50-a08d-4361-b987-4f1ea1f3b636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f88a9e50-a08d-4361-b987-4f1ea1f3b636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_13fcbc01-7dce-4597-998f-03f804882147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_13fcbc01-7dce-4597-998f-03f804882147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_83eba4c5-b8a8-4f0f-8f72-502bf2541d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_83eba4c5-b8a8-4f0f-8f72-502bf2541d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a4d2fbe-125c-4d76-8381-898cdd7d29a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_5bcef6d9-66c7-4e6d-a82c-d91b0404c2aa" xlink:to="loc_us-gaap_Goodwill_9a4d2fbe-125c-4d76-8381-898cdd7d29a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0e76ba90-73b3-4e52-a19b-df08eb235c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0e76ba90-73b3-4e52-a19b-df08eb235c6f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d11dba37-605c-43c5-b4ec-5b1391a9f962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7687f5bf-4534-4860-839b-3b616e312f39" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d11dba37-605c-43c5-b4ec-5b1391a9f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_87c3e500-a9a1-44fa-b0a7-d81a17cb8181" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d11dba37-605c-43c5-b4ec-5b1391a9f962" xlink:to="loc_bvs_CartiHealLtdMember_87c3e500-a9a1-44fa-b0a7-d81a17cb8181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36c45f83-a629-45ac-b8ba-9c35723ace5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4f631e13-a5de-48f5-ab2a-4fa6418191bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36c45f83-a629-45ac-b8ba-9c35723ace5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_ff257915-9197-4343-bf78-d1af507578cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_36c45f83-a629-45ac-b8ba-9c35723ace5a" xlink:to="loc_us-gaap_IntellectualPropertyMember_ff257915-9197-4343-bf78-d1af507578cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4f9c17b0-7405-47e2-a9f9-c15f6ea0aa6e" xlink:to="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_USSegmentMember_415f3700-11fb-4a99-b109-f144c1068dd6" xlink:href="bvs-20230401.xsd#bvs_USSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:to="loc_bvs_USSegmentMember_415f3700-11fb-4a99-b109-f144c1068dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalSegmentMember_c24c7340-00d2-41af-a562-77eeeb307b63" xlink:href="bvs-20230401.xsd#bvs_InternationalSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a4f548e5-66d6-4b2f-a4e3-3eb0833125c9" xlink:to="loc_bvs_InternationalSegmentMember_c24c7340-00d2-41af-a562-77eeeb307b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e42f4d02-eabf-4af3-a8ca-229bf8cc1d78" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0ab66f7-f6ca-49c8-b4e0-b7ac769f9862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0ab66f7-f6ca-49c8-b4e0-b7ac769f9862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bad28c2b-a2bb-4d92-9918-97bda01abd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ba58e119-5050-4b22-ab52-04fee2bd95b8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bad28c2b-a2bb-4d92-9918-97bda01abd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f0659286-bab3-4a8f-be65-44e0705c0146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f0659286-bab3-4a8f-be65-44e0705c0146" xlink:to="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b28c2881-f076-4571-babc-1cd50184ccdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3e363135-94cf-4512-b4a5-6faaa1076874" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b28c2881-f076-4571-babc-1cd50184ccdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember_a0c2ca27-89c2-4eb3-a3b5-cd23ad6901eb" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b28c2881-f076-4571-babc-1cd50184ccdd" xlink:to="loc_bvs_TermLoanMember_a0c2ca27-89c2-4eb3-a3b5-cd23ad6901eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:to="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_33681d16-8f96-47a8-8044-6f247325d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0dc2fe59-738f-4843-bee0-f1c60c88395f" xlink:to="loc_us-gaap_CreditFacilityDomain_33681d16-8f96-47a8-8044-6f247325d99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_95cc6e02-cb77-43d6-9845-ce779031a547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_33681d16-8f96-47a8-8044-6f247325d99b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_95cc6e02-cb77-43d6-9845-ce779031a547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bd3c7492-a888-4b79-b0dd-8f53b3717187" xlink:to="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3936b0e1-5f38-45de-8920-0f61c7d2173d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3936b0e1-5f38-45de-8920-0f61c7d2173d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c0036dea-144f-4d80-af43-59e08473b044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_LongTermDebtCurrent_c0036dea-144f-4d80-af43-59e08473b044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a84d4039-4ff9-4fa1-82ed-dda942a2b230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a84d4039-4ff9-4fa1-82ed-dda942a2b230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e04a13b-f317-447f-a71b-13959cafaeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e04a13b-f317-447f-a71b-13959cafaeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_69143585-55cf-4fde-9d97-c32c3dc7c152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_69143585-55cf-4fde-9d97-c32c3dc7c152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_56f46bbe-f3f1-4bcf-83e2-27f0968dc831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40fe4e4f-f26e-4534-bd30-1894e8a2a38b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_56f46bbe-f3f1-4bcf-83e2-27f0968dc831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FinancialinstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_45e6714e-7e29-49e6-b20b-eaf219b453f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45e6714e-7e29-49e6-b20b-eaf219b453f8" xlink:to="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_75338ea3-d1f6-44fc-8299-76a17c49f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_24eed4f1-72c1-4095-a212-9a75d431d948" xlink:to="loc_us-gaap_CreditFacilityDomain_75338ea3-d1f6-44fc-8299-76a17c49f245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_330e5809-95d9-453c-8e70-e58fc2d68834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_75338ea3-d1f6-44fc-8299-76a17c49f245" xlink:to="loc_us-gaap_LineOfCreditMember_330e5809-95d9-453c-8e70-e58fc2d68834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93d81695-7a18-4830-815b-3009f905a484" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d60c1213-0395-4ed4-976b-dd372875f04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d60c1213-0395-4ed4-976b-dd372875f04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember_70dcb33b-94aa-451d-92fd-582c64a0614f" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:to="loc_bvs_TermLoanMember_70dcb33b-94aa-451d-92fd-582c64a0614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f079755b-7e7f-496f-a5a6-da9c62e74201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68e9096a-a9ca-4749-a0c6-421fb1c2b97f" xlink:to="loc_us-gaap_SecuredDebtMember_f079755b-7e7f-496f-a5a6-da9c62e74201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f421a87b-05d5-412d-8d8b-5a3685ed8a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a852a99c-1239-44d1-ae8c-8dfd85467ace" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f421a87b-05d5-412d-8d8b-5a3685ed8a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11699b84-6813-45db-b5d0-af16b813cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f421a87b-05d5-412d-8d8b-5a3685ed8a98" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11699b84-6813-45db-b5d0-af16b813cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b508709f-1b27-432a-9692-a9ad15850204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_424d0402-75d3-49a4-967e-14c458ff20db" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b508709f-1b27-432a-9692-a9ad15850204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fb21a731-a4cd-4453-b87f-dcafad940215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b508709f-1b27-432a-9692-a9ad15850204" xlink:to="loc_us-gaap_InterestRateSwapMember_fb21a731-a4cd-4453-b87f-dcafad940215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1382918c-bcf0-4b2b-85e8-b0f4956d6497" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilityJuly2022Member_92b230c1-eb12-4da5-80c2-dd7c56f97132" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilityJuly2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:to="loc_bvs_TermLoanFacilityJuly2022Member_92b230c1-eb12-4da5-80c2-dd7c56f97132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanFacilitiesMember_7f0ef33b-7a92-4d7f-b947-00e936aea7d6" xlink:href="bvs-20230401.xsd#bvs_TermLoanFacilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:to="loc_bvs_TermLoanFacilitiesMember_7f0ef33b-7a92-4d7f-b947-00e936aea7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TermLoanMember_b07d968e-ed94-4b62-a389-b3762863b6aa" xlink:href="bvs-20230401.xsd#bvs_TermLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c04107e9-adb7-4445-918c-090abd42ec3c" xlink:to="loc_bvs_TermLoanMember_b07d968e-ed94-4b62-a389-b3762863b6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_951a94c3-f8b0-427f-a08f-c1ebef324033" xlink:to="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_873a80ca-bd33-45b7-b653-261684122016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_873a80ca-bd33-45b7-b653-261684122016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7521e84-8d15-4a64-b4ec-17f202c0e07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7521e84-8d15-4a64-b4ec-17f202c0e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_32884ed7-e85b-4290-a8c5-1108476db6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_32884ed7-e85b-4290-a8c5-1108476db6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DebtInstrumentCovenantLiquidityMinimum_3e72670a-b60c-41c8-a4c1-af2f63026330" xlink:href="bvs-20230401.xsd#bvs_DebtInstrumentCovenantLiquidityMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_bvs_DebtInstrumentCovenantLiquidityMinimum_3e72670a-b60c-41c8-a4c1-af2f63026330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9775be0b-2bfb-401f-8d5f-04c2c5cc342d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9775be0b-2bfb-401f-8d5f-04c2c5cc342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_b07a9df8-34f9-4330-a7a9-eeeb8df122b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_b07a9df8-34f9-4330-a7a9-eeeb8df122b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_74dfd529-a835-44dd-8b1c-f58264d2b310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_74dfd529-a835-44dd-8b1c-f58264d2b310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0f2bc4fa-9669-4c4a-8df2-819000a6eb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0f2bc4fa-9669-4c4a-8df2-819000a6eb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_945b6009-2380-4871-a01d-5a8fad8141db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LongTermDebt_945b6009-2380-4871-a01d-5a8fad8141db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_801ba618-80ed-414b-8206-dc079b365d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_801ba618-80ed-414b-8206-dc079b365d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ae35e4f8-aa2d-499d-9a84-f82f9ef30fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_InterestExpenseDebt_ae35e4f8-aa2d-499d-9a84-f82f9ef30fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_c76cade2-2025-4bfb-8028-34b1c37de7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LineOfCredit_c76cade2-2025-4bfb-8028-34b1c37de7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_e37a4db9-11e5-4673-9bd1-71ebe29d9e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_LongTermDebtFairValue_e37a4db9-11e5-4673-9bd1-71ebe29d9e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_3c99fcc3-74cb-448c-b429-5451e5aea031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_3c99fcc3-74cb-448c-b429-5451e5aea031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCashReceivedOnHedge_44df850e-16d0-4dc3-93fa-2fe1464cec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCashReceivedOnHedge"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_DerivativeCashReceivedOnHedge_44df850e-16d0-4dc3-93fa-2fe1464cec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_cc22f2cb-f1b5-441f-8580-a7643d79d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_34f3afdf-60ba-485b-b8b5-4a80403eabbd" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_cc22f2cb-f1b5-441f-8580-a7643d79d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_807967b5-bedf-4a1f-b0d9-45b594776bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_807967b5-bedf-4a1f-b0d9-45b594776bf6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7f3b580-32d0-4d99-81d7-50c353fd64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f009a189-7d94-479d-a6f6-c441936e1a28" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7f3b580-32d0-4d99-81d7-50c353fd64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5c00df53-8af7-4ff6-a164-3ab3eb74ffda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d7f3b580-32d0-4d99-81d7-50c353fd64b4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5c00df53-8af7-4ff6-a164-3ab3eb74ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f84c0cf-b06b-441e-baf1-1a13d4211d5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8d7a3529-808c-4f53-8cba-0c4c4f885668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8d7a3529-808c-4f53-8cba-0c4c4f885668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ad95b571-25b6-47ae-9689-46cc2e067677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5cc7337e-954f-4303-b4ed-002f42b77a13" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ad95b571-25b6-47ae-9689-46cc2e067677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01a9ffdf-8695-4d1e-a442-85060a52acba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_b3306708-0494-44d3-90df-55b042e70df1" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:to="loc_bvs_CartiHealLtdMember_b3306708-0494-44d3-90df-55b042e70df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_b7cfdf52-d49c-436d-aede-61b8b7d4e608" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f5ab265-4647-4f5c-9427-8cd60d34f775" xlink:to="loc_bvs_BionessIncMember_b7cfdf52-d49c-436d-aede-61b8b7d4e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_09f148a0-b947-4d7c-a1e9-5e6630c1dfc7" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DeferredAmountMember_067b755f-95ff-438d-a39f-972937784fc7" xlink:href="bvs-20230401.xsd#bvs_DeferredAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:to="loc_bvs_DeferredAmountMember_067b755f-95ff-438d-a39f-972937784fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SalesMilestoneMember_c790b278-68be-42cd-9174-e746ccdd2603" xlink:href="bvs-20230401.xsd#bvs_SalesMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b62555c6-fa9d-4d14-aeb9-7311a107f7e0" xlink:to="loc_bvs_SalesMilestoneMember_c790b278-68be-42cd-9174-e746ccdd2603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_41b3d1c0-5cec-4920-bf93-051158acd39f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8604809c-76fc-4448-8161-5986d160a9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8604809c-76fc-4448-8161-5986d160a9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b868252a-4fef-42eb-834a-2faea996bcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b868252a-4fef-42eb-834a-2faea996bcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e111c595-f5df-4c41-bce1-b940b68189e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e111c595-f5df-4c41-bce1-b940b68189e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5ee53dde-87ba-4d58-8e47-45eb0c911adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50e753d4-f5e1-4db5-b026-765c00ddb59f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5ee53dde-87ba-4d58-8e47-45eb0c911adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85afa6fe-422f-4edb-9506-d382ed71092d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85afa6fe-422f-4edb-9506-d382ed71092d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d053ad-7ba5-46db-a0c8-e32e9028013d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b1a22eb4-67b3-49af-8dc3-91d7702a3c33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d053ad-7ba5-46db-a0c8-e32e9028013d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_04963b8f-93d1-40f6-a35c-e7706565b19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d053ad-7ba5-46db-a0c8-e32e9028013d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_04963b8f-93d1-40f6-a35c-e7706565b19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cbb6438a-f851-4bcc-81a9-47dcba0e1e16" xlink:to="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_590d955c-7c56-4aa3-a59d-2bac32e5b5e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:to="loc_srt_MinimumMember_590d955c-7c56-4aa3-a59d-2bac32e5b5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_483359fc-49b6-4955-9e2f-0d48ff8a37ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7d0b1b9-d402-4f18-9051-98a7de815e9c" xlink:to="loc_srt_MaximumMember_483359fc-49b6-4955-9e2f-0d48ff8a37ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d94e1a70-635a-4b8a-a2e5-f35508a9c2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bf355da0-99de-494e-aac6-a5f3b2c05c3e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d94e1a70-635a-4b8a-a2e5-f35508a9c2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_346cde56-2c7f-4b83-b872-0295fc36ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_d94e1a70-635a-4b8a-a2e5-f35508a9c2b2" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_346cde56-2c7f-4b83-b872-0295fc36ec95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0f9441ed-ebfd-4687-83a3-3853a430dfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_67ae19d2-6102-4858-b389-3a723db9160f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0f9441ed-ebfd-4687-83a3-3853a430dfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_13439e37-fcc3-4f88-8125-db203bc0f73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0f9441ed-ebfd-4687-83a3-3853a430dfd8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_13439e37-fcc3-4f88-8125-db203bc0f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b413cbb-b5f3-4feb-804f-6750ef362731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cf37e618-3cfc-440d-ba3f-66c754e81042" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b413cbb-b5f3-4feb-804f-6750ef362731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_0fddc5f9-476a-4f5b-96bd-1c9e8aa8ceb1" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b413cbb-b5f3-4feb-804f-6750ef362731" xlink:to="loc_bvs_BionessIncMember_0fddc5f9-476a-4f5b-96bd-1c9e8aa8ceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f3ad5c53-7cb7-4d7b-9bba-b4afb0ef12c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1dff19f7-331a-44d8-b2b7-9662864526fc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f3ad5c53-7cb7-4d7b-9bba-b4afb0ef12c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_dd46474c-29ec-4f51-a81b-51d04a2aa0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f3ad5c53-7cb7-4d7b-9bba-b4afb0ef12c1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_dd46474c-29ec-4f51-a81b-51d04a2aa0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54811c74-cfae-4ef0-9d33-206f874b7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54811c74-cfae-4ef0-9d33-206f874b7e6a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_15e27372-7c91-4a60-8451-3b1b011839a3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_b8363da2-2ac0-41ef-b809-978264e230fe" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:to="loc_bvs_BionessIncMember_b8363da2-2ac0-41ef-b809-978264e230fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember_abd098d7-ce4c-450e-ae48-dcbffa7c5a37" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cf22fef-79db-44e5-995c-a946100ce8a6" xlink:to="loc_bvs_CartiHealMember_abd098d7-ce4c-450e-ae48-dcbffa7c5a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7da3c8d1-b056-499a-b899-cc8548f4e5e9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_153cdd02-a4b4-491f-83fe-7f41826476e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_153cdd02-a4b4-491f-83fe-7f41826476e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_1e377b8d-f7c9-4ad0-92a8-8240659c7878" xlink:href="bvs-20230401.xsd#bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ceea0fbb-725f-49f9-a499-192063d1ad76" xlink:to="loc_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation_1e377b8d-f7c9-4ad0-92a8-8240659c7878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_02ba267e-4a3e-4cda-97dc-624e84057643" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_02ba267e-4a3e-4cda-97dc-624e84057643" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_33163832-0477-4e24-ad12-b5ceb3c72ffc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e472eea6-8b32-492d-811b-82a03ff6b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e472eea6-8b32-492d-811b-82a03ff6b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f2bf355c-ef96-42ca-8c35-705d4290574d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f2bf355c-ef96-42ca-8c35-705d4290574d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f3ee4da2-858c-418f-b2ec-65736fc697ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9206921-8c6f-474b-8004-71474dfd4095" xlink:to="loc_us-gaap_EmployeeStockMember_f3ee4da2-858c-418f-b2ec-65736fc697ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_27d6cd7a-9831-45f9-8afb-e30401e16298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43ec56de-85ed-406d-91a1-cb871f79629a" xlink:to="loc_us-gaap_ClassOfStockDomain_27d6cd7a-9831-45f9-8afb-e30401e16298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_aee49f6c-486a-4073-aba6-3b5e0d4a320e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_27d6cd7a-9831-45f9-8afb-e30401e16298" xlink:to="loc_us-gaap_CommonClassAMember_aee49f6c-486a-4073-aba6-3b5e0d4a320e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_786c7e05-f9cb-49d2-ab98-c66a2c191e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8fcee3c4-f743-418a-9bba-8cbeb942977a" xlink:to="loc_us-gaap_PlanNameDomain_786c7e05-f9cb-49d2-ab98-c66a2c191e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_A2021PlanMember_0f7c2ac4-9d96-4b2f-8144-c4220896b65f" xlink:href="bvs-20230401.xsd#bvs_A2021PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_786c7e05-f9cb-49d2-ab98-c66a2c191e47" xlink:to="loc_bvs_A2021PlanMember_0f7c2ac4-9d96-4b2f-8144-c4220896b65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_304c32e1-d165-421b-bc6c-af66a7e33031" xlink:to="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1dbc9afa-84e1-40dc-a9d8-dd7aed615aed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:to="loc_srt_MinimumMember_1dbc9afa-84e1-40dc-a9d8-dd7aed615aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86662c9a-e698-4f2a-93f0-fda05397384c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d3210bd-3ffc-4412-8af4-87b319aee9ee" xlink:to="loc_srt_MaximumMember_86662c9a-e698-4f2a-93f0-fda05397384c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6639aeb-a8a0-4759-9b42-d0b23158bfb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a453263e-90e4-4697-afeb-6f69e3a44804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a453263e-90e4-4697-afeb-6f69e3a44804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c503af97-6e14-439a-9d3f-bb3239df13c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c503af97-6e14-439a-9d3f-bb3239df13c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9a7d60a2-186a-482d-a82e-84356dd77c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9a7d60a2-186a-482d-a82e-84356dd77c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1823d419-3d0f-4293-be4d-acc4ea332587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1823d419-3d0f-4293-be4d-acc4ea332587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dcfc05c-3c04-4c2c-a8ea-a2ccfd25d701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dcfc05c-3c04-4c2c-a8ea-a2ccfd25d701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a9e4c258-6b96-419e-9b56-54ef77d98fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a9e4c258-6b96-419e-9b56-54ef77d98fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7890e5a6-32e8-47d3-97a7-6d6eb12d81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7890e5a6-32e8-47d3-97a7-6d6eb12d81f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e065f69-95d1-4276-89f6-359a51f670a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e065f69-95d1-4276-89f6-359a51f670a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59bf0907-8a30-4b79-b947-7f534dbefb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59bf0907-8a30-4b79-b947-7f534dbefb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_477e109b-7870-45ca-a88a-ce8cf1de8840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_477e109b-7870-45ca-a88a-ce8cf1de8840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_dea6cd97-6310-4806-9e87-c962df379340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_SharePrice_dea6cd97-6310-4806-9e87-c962df379340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d3cb1c9f-7870-4473-9173-9f4f0957ff85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac3d6caf-d13e-4159-85f9-c3eb7bbec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d3cb1c9f-7870-4473-9173-9f4f0957ff85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_29a0a155-1bcb-4174-ad66-57082f4a1fea" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_29a0a155-1bcb-4174-ad66-57082f4a1fea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:to="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ef6d9f9-b112-4052-9946-70c2def6e59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e58b6f75-7e01-4cb9-9016-e7acd896a478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ef6d9f9-b112-4052-9946-70c2def6e59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec0b4ceb-755c-442d-8075-cdbb367ac39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ef6d9f9-b112-4052-9946-70c2def6e59e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec0b4ceb-755c-442d-8075-cdbb367ac39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0107b7a0-c7f7-4320-a21e-d99a09627974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_964299ec-edce-4a57-b4fd-7bd623c46b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_964299ec-edce-4a57-b4fd-7bd623c46b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d491350b-ae71-4c24-927d-a3fb5fa0bf19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d491350b-ae71-4c24-927d-a3fb5fa0bf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_35e8b481-561c-4250-8eab-025e49a973bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_35e8b481-561c-4250-8eab-025e49a973bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7073d8-89c9-492b-b658-f0335426534a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2a7073d8-89c9-492b-b658-f0335426534a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58a813a7-cf70-4853-839b-88b951f226ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59d8db8d-62be-45bf-a0b8-5dbb88a1200e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58a813a7-cf70-4853-839b-88b951f226ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e84dcf-ca53-4604-b61c-f1c9415ad6b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75eb6c8f-431d-48ea-91f8-d7a64f24210c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75eb6c8f-431d-48ea-91f8-d7a64f24210c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e167b1d9-dc2d-4162-9e53-6422a92ece0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e167b1d9-dc2d-4162-9e53-6422a92ece0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cacd8f8d-44b2-40be-abce-672c6a06e955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cacd8f8d-44b2-40be-abce-672c6a06e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_69284753-1396-4e40-ab3e-31b3d1ae0bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_69284753-1396-4e40-ab3e-31b3d1ae0bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e4a4b30-d510-4e70-b2a4-7d2175dbe7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39b163cf-863e-456c-b4fc-90b583a1e94a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e4a4b30-d510-4e70-b2a4-7d2175dbe7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_b1246c60-c2ca-4864-9784-4e9ea69d88c2" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_b1246c60-c2ca-4864-9784-4e9ea69d88c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:to="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d18e2f2-28bd-4976-b0da-412831a7ff1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8d24eb85-062f-4209-9eb2-360d3b7c3d0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d18e2f2-28bd-4976-b0da-412831a7ff1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_622d5b3c-cb8b-41b0-8c68-4afbc94b8d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d18e2f2-28bd-4976-b0da-412831a7ff1f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_622d5b3c-cb8b-41b0-8c68-4afbc94b8d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:to="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1e148d7-0372-4adc-a91f-af8169ad6b37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_61cbf87f-29c6-4fa1-b251-0305bc364893" xlink:to="loc_srt_RangeMember_e1e148d7-0372-4adc-a91f-af8169ad6b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ec367bca-de86-4ecf-9308-274a22065302" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1e148d7-0372-4adc-a91f-af8169ad6b37" xlink:to="loc_srt_MaximumMember_ec367bca-de86-4ecf-9308-274a22065302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e4e9f2-c0bb-47e4-8f00-d3773897f193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f185f182-3b32-4981-aef1-ca394dd79e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f185f182-3b32-4981-aef1-ca394dd79e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_38889b3b-f217-46d4-9b15-43fbee93193c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_38889b3b-f217-46d4-9b15-43fbee93193c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b4c2924c-96a1-41ec-bef4-960e67e943e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b4c2924c-96a1-41ec-bef4-960e67e943e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a98b3f-e645-44e6-b746-5149daec35ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_faa7c5bb-8156-4dd9-9bcd-6883928fff84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06a98b3f-e645-44e6-b746-5149daec35ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:href="bvs-20230401.xsd#bvs_CompensationAndEmployeeBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d987ace-bc8d-4217-9553-c88508404cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d987ace-bc8d-4217-9553-c88508404cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e52d3be5-5422-4f92-bcd3-87f4bbc3e3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d987ace-bc8d-4217-9553-c88508404cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e52d3be5-5422-4f92-bcd3-87f4bbc3e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11750553-ad7d-45ec-8284-997a5022b572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d987ace-bc8d-4217-9553-c88508404cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11750553-ad7d-45ec-8284-997a5022b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f4c0b80a-29ca-43fc-9d51-5033db54e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d987ace-bc8d-4217-9553-c88508404cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f4c0b80a-29ca-43fc-9d51-5033db54e4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8244035c-aa26-4d3d-81e7-fda39152d680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d987ace-bc8d-4217-9553-c88508404cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8244035c-aa26-4d3d-81e7-fda39152d680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6221821f-8bee-4b9d-ae81-ac0441c00d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6221821f-8bee-4b9d-ae81-ac0441c00d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_685572a4-0ac9-40da-a624-b6cfc8538b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_685572a4-0ac9-40da-a624-b6cfc8538b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3743990-4899-481b-8d2a-e0f8ee82ebe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_685572a4-0ac9-40da-a624-b6cfc8538b43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3743990-4899-481b-8d2a-e0f8ee82ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26d073c9-b364-4c77-a849-4fcd3161361e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_685572a4-0ac9-40da-a624-b6cfc8538b43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26d073c9-b364-4c77-a849-4fcd3161361e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bf1f70bb-88d8-4407-bde5-7ab9b0d3e4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_685572a4-0ac9-40da-a624-b6cfc8538b43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bf1f70bb-88d8-4407-bde5-7ab9b0d3e4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_afd7dec8-925a-446f-8079-2876fa77c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_685572a4-0ac9-40da-a624-b6cfc8538b43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_afd7dec8-925a-446f-8079-2876fa77c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0443c202-97ce-4240-94a3-a9a3d2aa389e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0443c202-97ce-4240-94a3-a9a3d2aa389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ae78866b-e32f-4c5a-adeb-305226cba836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ae78866b-e32f-4c5a-adeb-305226cba836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_161f6115-d8ba-4828-9b37-6354c6d9e945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_161f6115-d8ba-4828-9b37-6354c6d9e945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9286f777-df61-49ee-9f04-ce367224276c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9286f777-df61-49ee-9f04-ce367224276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_73676603-8def-44ad-b4ac-5cba49e3216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CompensationAndEmployeeBenefitPlansAbstract_5f6e2a0f-e850-4e8c-809c-58e6c80e891c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_73676603-8def-44ad-b4ac-5cba49e3216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/StockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#StockholdersequityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/StockholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fed6415d-678d-4060-b432-1a85126f7949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fed6415d-678d-4060-b432-1a85126f7949" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0382414e-62c0-4e81-a44a-4d3513157c61" xlink:to="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_57910f1c-f31b-4943-9d9c-ac2292df88ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:to="loc_us-gaap_CommonClassAMember_57910f1c-f31b-4943-9d9c-ac2292df88ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_67cca2bc-cc6d-4a9c-94d7-a480af968729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_84b7ba6b-efb7-48cc-aaa3-11273319e07a" xlink:to="loc_us-gaap_CommonClassBMember_67cca2bc-cc6d-4a9c-94d7-a480af968729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2b7fc1d-ff4a-49cc-95a8-c858bf60287f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PublicOfferingMember_8a5548d6-2991-4529-b567-95d05a2d0b0a" xlink:href="bvs-20230401.xsd#bvs_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:to="loc_bvs_PublicOfferingMember_8a5548d6-2991-4529-b567-95d05a2d0b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_f7b630a1-eacd-47be-8234-adb9f33ed964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a685d24-116b-4d17-8c66-0d87c1fbce11" xlink:to="loc_us-gaap_OverAllotmentOptionMember_f7b630a1-eacd-47be-8234-adb9f33ed964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a19aeab8-9495-46e0-a897-b7b5ea0f2c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_57a6adb2-318c-471b-aabc-4c3eb85172d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a19aeab8-9495-46e0-a897-b7b5ea0f2c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_5ef7b605-4289-4b80-83c1-b852440dab75" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a19aeab8-9495-46e0-a897-b7b5ea0f2c54" xlink:to="loc_bvs_BVLLCMember_5ef7b605-4289-4b80-83c1-b852440dab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa06c0fe-cc85-481b-bcf1-db078bd2e686" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0301f359-b5b3-4385-b8fa-534ea338e1a2" xlink:to="loc_dei_EntityDomain_fa06c0fe-cc85-481b-bcf1-db078bd2e686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_6e93eedb-902f-42ba-b0cc-e2ca5cd7c60e" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fa06c0fe-cc85-481b-bcf1-db078bd2e686" xlink:to="loc_bvs_BVLLCMember_6e93eedb-902f-42ba-b0cc-e2ca5cd7c60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b03f862d-3052-4c90-8ed6-df6b1edd6bd3" xlink:to="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_023733a7-d2cb-4781-9ca9-7fc9104d8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_023733a7-d2cb-4781-9ca9-7fc9104d8c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_14f9f58b-9fe3-4f59-8175-fb3a6b8d0ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_14f9f58b-9fe3-4f59-8175-fb3a6b8d0ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_b389d267-b213-4eda-aaa8-bec0d2e75d65" xlink:href="bvs-20230401.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_b389d267-b213-4eda-aaa8-bec0d2e75d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_4dc39980-aff2-4e54-8540-118aa71e3e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_4dc39980-aff2-4e54-8540-118aa71e3e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e9aaf204-c7ed-4fea-889a-8e4c5fda3172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e9aaf204-c7ed-4fea-889a-8e4c5fda3172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_869141b2-a90e-4b43-8474-7b3e71bccacf" xlink:href="bvs-20230401.xsd#bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld_869141b2-a90e-4b43-8474-7b3e71bccacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b779f73e-2af9-47ef-aeb6-7ca271e2721e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b779f73e-2af9-47ef-aeb6-7ca271e2721e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1c0f2ce1-25de-4215-a217-f516cc376a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1c0f2ce1-25de-4215-a217-f516cc376a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_84324205-efdf-47fb-aa61-40ccb7955187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_84324205-efdf-47fb-aa61-40ccb7955187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d9d193d8-51bf-4175-a387-f875ed2f42af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d9d193d8-51bf-4175-a387-f875ed2f42af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BoardOfDirectorLengthOfTerm_5c40f0f9-cfc0-426a-892a-3e67bc5555fd" xlink:href="bvs-20230401.xsd#bvs_BoardOfDirectorLengthOfTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_BoardOfDirectorLengthOfTerm_5c40f0f9-cfc0-426a-892a-3e67bc5555fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CommonStockNumberOfVotes_3d6a1d7d-5aa6-4c28-a6f3-22f6908701fb" xlink:href="bvs-20230401.xsd#bvs_CommonStockNumberOfVotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_CommonStockNumberOfVotes_3d6a1d7d-5aa6-4c28-a6f3-22f6908701fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_772c526b-14fc-4f47-b5b3-77b2bfb87157" xlink:href="bvs-20230401.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_772c526b-14fc-4f47-b5b3-77b2bfb87157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_9ab8f1be-43bd-4b83-9a72-42400afe3e32" xlink:href="bvs-20230401.xsd#bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae0fe97d-9aaf-472a-b053-bae0f1695607" xlink:to="loc_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio_9ab8f1be-43bd-4b83-9a72-42400afe3e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#StockholdersequityScheduleofOtherOwnershipInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0920e612-3808-4e25-8148-63dc4093b6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0920e612-3808-4e25-8148-63dc4093b6b5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:to="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b8698f3f-a9c7-45d9-b38f-e2de42fea3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_7c8233d2-8fcb-4197-83f8-77d88a0d53a1" xlink:to="loc_srt_OwnershipDomain_b8698f3f-a9c7-45d9-b38f-e2de42fea3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BVLLCMember_e33a76fb-b233-4d4e-ae96-63f1d95c0a6f" xlink:href="bvs-20230401.xsd#bvs_BVLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b8698f3f-a9c7-45d9-b38f-e2de42fea3a4" xlink:to="loc_bvs_BVLLCMember_e33a76fb-b233-4d4e-ae96-63f1d95c0a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:to="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_38fad76a-e4da-43af-bfce-c2dcab26db7f" xlink:to="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ContinuingLLCOwnerMember_1dc8a507-f956-4b6f-8a21-94d574addd08" xlink:href="bvs-20230401.xsd#bvs_ContinuingLLCOwnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:to="loc_bvs_ContinuingLLCOwnerMember_1dc8a507-f956-4b6f-8a21-94d574addd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BioventusAndContinuingLLCOwnerMember_3f962753-8606-420c-a9e8-bcd5b7efade5" xlink:href="bvs-20230401.xsd#bvs_BioventusAndContinuingLLCOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9ffd19f7-fbc5-4f77-abae-5d27d3f7086c" xlink:to="loc_bvs_BioventusAndContinuingLLCOwnerMember_3f962753-8606-420c-a9e8-bcd5b7efade5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7005737-600a-44db-8449-34ff7a354018" xlink:to="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest_e0898988-989c-421c-84c9-b89f55d1b244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest_e0898988-989c-421c-84c9-b89f55d1b244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f1464ee3-d2f3-4c82-abdc-d89b137e18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e326bbb5-7c8d-4189-b2b6-5ea7493d36d8" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f1464ee3-d2f3-4c82-abdc-d89b137e18d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EarningspershareScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fca90d96-8011-452c-9d19-645d9947980c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fca90d96-8011-452c-9d19-645d9947980c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ad5feb6b-c353-40f7-a37c-acfd0c5fdfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ad5feb6b-c353-40f7-a37c-acfd0c5fdfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_29a6eeb4-0b9c-4f83-a85b-141b60d8219d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_29a6eeb4-0b9c-4f83-a85b-141b60d8219d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_889e170f-5773-4dba-93a7-88bb3c78ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_889e170f-5773-4dba-93a7-88bb3c78ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_67c83cb4-7cf2-4271-b44d-ec06446d0641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_67c83cb4-7cf2-4271-b44d-ec06446d0641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_dbcdccee-3ccd-4cb1-a588-a9b0b2f54e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_dbcdccee-3ccd-4cb1-a588-a9b0b2f54e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_17adce8a-31e9-4e6a-92bf-6615e8aaad8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_125843e7-abe1-4585-83f8-11d034706620" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_17adce8a-31e9-4e6a-92bf-6615e8aaad8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fca90d96-8011-452c-9d19-645d9947980c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93b49ffb-2ba3-43a2-8f2c-b33f9a9cc242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93b49ffb-2ba3-43a2-8f2c-b33f9a9cc242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ff004381-8e96-46a2-b64c-455edb9071dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ff004381-8e96-46a2-b64c-455edb9071dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_adeaae4f-5dcd-4f30-952f-514d6ac6e773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_adeaae4f-5dcd-4f30-952f-514d6ac6e773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3f0a67c5-09a4-4c10-9338-d76f3b4b025b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3f0a67c5-09a4-4c10-9338-d76f3b4b025b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_7ad0f6af-bdd1-4cc0-9734-41550147343e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_7ad0f6af-bdd1-4cc0-9734-41550147343e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3a8c0f00-ffe8-4ea9-a5e5-650d24fae4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3a8c0f00-ffe8-4ea9-a5e5-650d24fae4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6c43450e-2336-412e-b5da-6227df7f6ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_EarningsPerShareBasic_6c43450e-2336-412e-b5da-6227df7f6ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ede29134-0f1e-417a-a37c-fd4d7d56890f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b83aa53b-0c71-492f-8a34-5c48230f4934" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ede29134-0f1e-417a-a37c-fd4d7d56890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#EarningspershareScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eb45e844-d9e4-40ba-855a-6649f8cd60a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eb45e844-d9e4-40ba-855a-6649f8cd60a4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ea7c7038-0408-4591-92b9-6f85bf31e4cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LimitedLiabilityCompanyInterestsMember_77220ccb-a7c0-4e42-9c34-6bbac19919f3" xlink:href="bvs-20230401.xsd#bvs_LimitedLiabilityCompanyInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:to="loc_bvs_LimitedLiabilityCompanyInterestsMember_77220ccb-a7c0-4e42-9c34-6bbac19919f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bdd6eff3-2640-4cdd-93b2-b5252af90259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bdd6eff3-2640-4cdd-93b2-b5252af90259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_303ed757-988b-433a-87bd-c7eb98b1b304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b3dbc8c2-f8c9-4084-a518-c03ad71763f8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_303ed757-988b-433a-87bd-c7eb98b1b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e86ccc98-3604-4a29-ad79-9c69577b7064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6d48bd5c-6c2b-4ab0-8408-e0b1b0453616" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e86ccc98-3604-4a29-ad79-9c69577b7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478fe33c-81cd-463c-a679-8346bf25b31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e86ccc98-3604-4a29-ad79-9c69577b7064" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478fe33c-81cd-463c-a679-8346bf25b31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/RestructuringcostsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#RestructuringcostsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/RestructuringcostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7f15bdc1-a7ad-4321-9f72-6c06cd9967a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7f15bdc1-a7ad-4321-9f72-6c06cd9967a6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_16fa328b-2d02-4de0-8fc6-d40e39bcc5c0" xlink:to="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestructuringPlanOf2022Member_7c71d61d-4554-46bd-b979-7aeca826b50b" xlink:href="bvs-20230401.xsd#bvs_RestructuringPlanOf2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:to="loc_bvs_RestructuringPlanOf2022Member_7c71d61d-4554-46bd-b979-7aeca826b50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestructuringPlanOf2021Member_fba38b34-c89a-43fb-9d9b-701567810ce7" xlink:href="bvs-20230401.xsd#bvs_RestructuringPlanOf2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:to="loc_bvs_RestructuringPlanOf2021Member_fba38b34-c89a-43fb-9d9b-701567810ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AcquisitionRestructuringPlanOf2022Member_08abd72f-8f91-49e5-8f86-ccff7077ac1a" xlink:href="bvs-20230401.xsd#bvs_AcquisitionRestructuringPlanOf2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_718207a6-b7f9-4e20-8893-f9c8beab3f68" xlink:to="loc_bvs_AcquisitionRestructuringPlanOf2022Member_08abd72f-8f91-49e5-8f86-ccff7077ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8d55fbd9-1f97-4f3e-94aa-6c7ce8a40560" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b06ab55e-f8e9-4c8a-b99b-8a65457e3171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b06ab55e-f8e9-4c8a-b99b-8a65457e3171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_7f9fb19f-c099-44b7-a021-b23d8059c00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4e6da254-7aad-4b93-bc94-f98e1597fab3" xlink:to="loc_us-gaap_OtherRestructuringMember_7f9fb19f-c099-44b7-a021-b23d8059c00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_840ed5a5-692b-41e8-847f-673b06e66fa9" xlink:to="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_61b7b507-e0a5-42dc-a265-82b8b7700dde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:to="loc_srt_MinimumMember_61b7b507-e0a5-42dc-a265-82b8b7700dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1253236a-9750-48f7-a8ea-c53d6b29f6fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a819055-d527-4bce-850b-68ddc1c65722" xlink:to="loc_srt_MaximumMember_1253236a-9750-48f7-a8ea-c53d6b29f6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5a40bd32-57d5-4f81-b395-7ec4929bb6fc" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c84bc1d-76b5-4dc0-82d1-9403c8c89e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c84bc1d-76b5-4dc0-82d1-9403c8c89e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51e24b2b-c60d-4c74-be89-217e354d7ea5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e0972f5a-602d-4246-930b-24c300401aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_RestructuringReserve_e0972f5a-602d-4246-930b-24c300401aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f0ec4f9e-70a5-4f9d-8b19-7f4099744aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_RestructuringCharges_f0ec4f9e-70a5-4f9d-8b19-7f4099744aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_0ecd51d5-9a53-477e-819d-6a407c786048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_PaymentsForRestructuring_0ecd51d5-9a53-477e-819d-6a407c786048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_ad810e2b-e455-4329-858b-a9588b71f8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_2ce718f8-c403-4d5e-99ab-8e8956fc1f8c" xlink:to="loc_us-gaap_RestructuringReserve_ad810e2b-e455-4329-858b-a9588b71f8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f0542b6a-4c06-4ba6-9f85-95af615befd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db6e6ee5-bfdd-449e-9f3e-adf1e55f6b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0542b6a-4c06-4ba6-9f85-95af615befd5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db6e6ee5-bfdd-449e-9f3e-adf1e55f6b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_TaxReceivableAgreementPercent_59a84940-5616-4fb8-a845-92c97784d2ec" xlink:href="bvs-20230401.xsd#bvs_TaxReceivableAgreementPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0542b6a-4c06-4ba6-9f85-95af615befd5" xlink:to="loc_bvs_TaxReceivableAgreementPercent_59a84940-5616-4fb8-a845-92c97784d2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36f6fc0e-ee6d-4c19-a45c-b8251c55b385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36f6fc0e-ee6d-4c19-a45c-b8251c55b385" xlink:to="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e0eb5f28-a3da-4613-a4cb-fc5fe79a688f" xlink:to="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9eef3ad6-98ef-4d08-8446-aea7c594b58d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:to="loc_srt_MinimumMember_9eef3ad6-98ef-4d08-8446-aea7c594b58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5394048d-eafd-4c06-8ade-e4b5387edcc4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad3ca4ae-5872-492d-8442-68b0c088277c" xlink:to="loc_srt_MaximumMember_5394048d-eafd-4c06-8ade-e4b5387edcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6445f6a6-4290-4078-8031-0ed25d8aaec3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_31a4c143-6b50-451f-a6f8-5ffa4579d645" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:to="loc_bvs_BionessIncMember_31a4c143-6b50-451f-a6f8-5ffa4579d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_HarborMember_4131eba7-8c84-40e1-86a5-fb32406b461c" xlink:href="bvs-20230401.xsd#bvs_HarborMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:to="loc_bvs_HarborMember_4131eba7-8c84-40e1-86a5-fb32406b461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplierOfSingleInjectionOAProductMember_fac0fa04-ab6f-4ca7-9035-80b9e11b9343" xlink:href="bvs-20230401.xsd#bvs_SupplierOfSingleInjectionOAProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c5ab7e2-a562-48de-a475-8e4cd9e9d1ec" xlink:to="loc_bvs_SupplierOfSingleInjectionOAProductMember_fac0fa04-ab6f-4ca7-9035-80b9e11b9343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b577a425-b09c-489d-942d-da1a7706ec85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_131559ce-a44a-4d29-998f-18ff750fc31f" xlink:to="loc_dei_EntityDomain_b577a425-b09c-489d-942d-da1a7706ec85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BionessIncMember_11e98f19-7bc8-461f-a172-35ee3d5c59dd" xlink:href="bvs-20230401.xsd#bvs_BionessIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b577a425-b09c-489d-942d-da1a7706ec85" xlink:to="loc_bvs_BionessIncMember_11e98f19-7bc8-461f-a172-35ee3d5c59dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c67c6ef-f222-4f19-aab7-8b66489e6b17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_397388b2-c1e5-44f2-b295-1dd5be5c8761" xlink:to="loc_srt_ProductsAndServicesDomain_5c67c6ef-f222-4f19-aab7-8b66489e6b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_HAProductMember_c57eec3a-dec5-4ad8-888a-f88d8f5e86ba" xlink:href="bvs-20230401.xsd#bvs_HAProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c67c6ef-f222-4f19-aab7-8b66489e6b17" xlink:to="loc_bvs_HAProductMember_c57eec3a-dec5-4ad8-888a-f88d8f5e86ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_8c98050a-5103-4543-9362-c182a791e424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_2ad5a64b-f7d1-4cb7-b189-517e3b1d6acf" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_8c98050a-5103-4543-9362-c182a791e424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_ThreeInjectionOAProductMember_9da0514b-30b4-4b9b-bcb9-5313c934463e" xlink:href="bvs-20230401.xsd#bvs_ThreeInjectionOAProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_8c98050a-5103-4543-9362-c182a791e424" xlink:to="loc_bvs_ThreeInjectionOAProductMember_9da0514b-30b4-4b9b-bcb9-5313c934463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_694a75e6-1d10-4b39-9cce-5637b9d27393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_108bad1d-0404-4f0d-a853-bfeb8f0a7ee7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_694a75e6-1d10-4b39-9cce-5637b9d27393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_523e369e-8e70-4047-bf93-97ccf76c9d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_694a75e6-1d10-4b39-9cce-5637b9d27393" xlink:to="loc_us-gaap_SubsequentEventMember_523e369e-8e70-4047-bf93-97ccf76c9d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d5383f83-cc93-4537-a1aa-4b452b431afd" xlink:to="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc141c5c-8437-4018-b8d0-6e66ec8a7889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc141c5c-8437-4018-b8d0-6e66ec8a7889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cfc85e80-70bc-4267-bf05-ec2f680692f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cfc85e80-70bc-4267-bf05-ec2f680692f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_d2ad9dfd-1c3e-466f-be05-a9dc8514c2d9" xlink:href="bvs-20230401.xsd#bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid_d2ad9dfd-1c3e-466f-be05-a9dc8514c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_cdbcff52-27ce-4870-85af-52b802bd158a" xlink:href="bvs-20230401.xsd#bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold_cdbcff52-27ce-4870-85af-52b802bd158a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a3006623-f9a7-415d-b7f5-5dce9d36eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a3006623-f9a7-415d-b7f5-5dce9d36eceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LitigationSettlementExpenseOfClaimant_5390ceb2-f16d-4d6b-8e07-82d6c0557b7d" xlink:href="bvs-20230401.xsd#bvs_LitigationSettlementExpenseOfClaimant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LitigationSettlementExpenseOfClaimant_5390ceb2-f16d-4d6b-8e07-82d6c0557b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_ca975292-13ae-4ea2-967f-403ed971d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_ca975292-13ae-4ea2-967f-403ed971d7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_LitigationSettlementAmountRecoveredFromEscrow_83b693f6-ec56-4827-b998-6bd003e5bd05" xlink:href="bvs-20230401.xsd#bvs_LitigationSettlementAmountRecoveredFromEscrow"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_LitigationSettlementAmountRecoveredFromEscrow_83b693f6-ec56-4827-b998-6bd003e5bd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3bcf8260-11e4-41a0-b7ac-def2fc8d8ded" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment_3bcf8260-11e4-41a0-b7ac-def2fc8d8ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_a264069d-4112-4c17-9b2c-87d6b8581d02" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData_a264069d-4112-4c17-9b2c-87d6b8581d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_035cb89a-eb4c-4be2-a423-f09a47069c91" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification_035cb89a-eb4c-4be2-a423-f09a47069c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_14c81457-4549-4fce-accf-0e9e8a01d7cf" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne_14c81457-4549-4fce-accf-0e9e8a01d7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_e8cd5eda-bc82-4534-bb30-9d306211cc90" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold_e8cd5eda-bc82-4534-bb30-9d306211cc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_3d6b3f48-42b7-4225-a219-d95a5c4afa2c" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo_3d6b3f48-42b7-4225-a219-d95a5c4afa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CollaborativeArrangementRoyaltyPercentage_60e0dd42-a34c-472e-b77e-0c2c97619732" xlink:href="bvs-20230401.xsd#bvs_CollaborativeArrangementRoyaltyPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_CollaborativeArrangementRoyaltyPercentage_60e0dd42-a34c-472e-b77e-0c2c97619732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_758ae316-189c-424e-ad5d-b558a374cfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_us-gaap_RoyaltyExpense_758ae316-189c-424e-ad5d-b558a374cfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplyCommitmentTerm_4b1cb31a-ba82-4c45-a969-60f29a53a778" xlink:href="bvs-20230401.xsd#bvs_SupplyCommitmentTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_SupplyCommitmentTerm_4b1cb31a-ba82-4c45-a969-60f29a53a778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SupplyCommitmentRenewalTerm_e2e0977c-7f4a-4957-9163-e0e8cb5c1133" xlink:href="bvs-20230401.xsd#bvs_SupplyCommitmentRenewalTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_SupplyCommitmentRenewalTerm_e2e0977c-7f4a-4957-9163-e0e8cb5c1133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_a293ce55-007a-4566-a13b-3692f2d40113" xlink:href="bvs-20230401.xsd#bvs_StopLossInsuranceThresholdPerMemberPerYear"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fba6be29-9751-4740-b3db-9d11ed322471" xlink:to="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_a293ce55-007a-4566-a13b-3692f2d40113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesScheduleofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_78eef4d6-3daa-470c-9405-9fe4a3990c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_OperatingLeaseCost_78eef4d6-3daa-470c-9405-9fe4a3990c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9b724a67-3b1c-447b-9fe7-988da27d06af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_ShortTermLeaseCost_9b724a67-3b1c-447b-9fe7-988da27d06af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_6d554d9b-7002-4923-8107-9467dd20abaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_6d554d9b-7002-4923-8107-9467dd20abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9caf4dfd-e5b2-4e9a-a0d6-070f781c5d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9caf4dfd-e5b2-4e9a-a0d6-070f781c5d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7a378469-2a2f-450a-8031-32f23423b2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_LeaseCost_7a378469-2a2f-450a-8031-32f23423b2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d3875302-5350-4511-a18f-14ddc6320c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_OperatingLeasePayments_d3875302-5350-4511-a18f-14ddc6320c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_28a48e6b-d8e4-476f-a603-3f67d225166e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_28a48e6b-d8e4-476f-a603-3f67d225166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ff400552-83d1-49a2-bab1-c2d3738bc184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ff400552-83d1-49a2-bab1-c2d3738bc184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_383a55ca-a769-4ccb-8858-855b5d38b6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_383a55ca-a769-4ccb-8858-855b5d38b6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_8bfaa5fd-6718-4b62-8405-eef633dd0bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910a4435-aa1e-4ae3-80dc-9586d1cd6a70" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_8bfaa5fd-6718-4b62-8405-eef633dd0bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_058ca948-5984-4c67-aa80-c3362e9f0e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_058ca948-5984-4c67-aa80-c3362e9f0e32" xlink:to="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5072fc7f-eb47-4ce4-abce-d52f0d295aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6902f007-dab6-48f8-90f8-a5e08d241122" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5072fc7f-eb47-4ce4-abce-d52f0d295aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_b93e621a-5666-4d6a-8649-520099684fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5072fc7f-eb47-4ce4-abce-d52f0d295aa4" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_b93e621a-5666-4d6a-8649-520099684fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8557aa5e-5b36-4b42-a74f-d021a176678e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8fefdd4f-6a0c-4c8f-b62d-e5c11f75cfb5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8557aa5e-5b36-4b42-a74f-d021a176678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealLtdMember_dd6faf33-7b5f-48dd-afb1-131fc376c16b" xlink:href="bvs-20230401.xsd#bvs_CartiHealLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8557aa5e-5b36-4b42-a74f-d021a176678e" xlink:to="loc_bvs_CartiHealLtdMember_dd6faf33-7b5f-48dd-afb1-131fc376c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e7dd887f-ee9f-432d-9cca-18e96015a4db" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_42074274-0283-488f-9a35-d3a5518cedf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_42074274-0283-488f-9a35-d3a5518cedf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5da617e2-2231-4a50-809e-ed6576e39174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5da617e2-2231-4a50-809e-ed6576e39174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a98137e1-6d2b-4531-a293-d84d8fc13314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a98137e1-6d2b-4531-a293-d84d8fc13314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7af6fbc3-d4ba-45da-a1b7-45ee17def880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseLiability_7af6fbc3-d4ba-45da-a1b7-45ee17def880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_da4d76db-d7e7-46fd-acc3-18b0224236cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_da4d76db-d7e7-46fd-acc3-18b0224236cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e12c9905-a683-42b3-abc0-571c4dc7776f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e12c9905-a683-42b3-abc0-571c4dc7776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2e2ab9d2-8ee3-40c1-afa1-9436dd562a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2e2ab9d2-8ee3-40c1-afa1-9436dd562a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f0ea4b2e-2dd7-49a5-96eb-fcd77497b025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseLiability_f0ea4b2e-2dd7-49a5-96eb-fcd77497b025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e88ca1f-6733-49c3-afaa-c5412c397913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e88ca1f-6733-49c3-afaa-c5412c397913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1e7bf385-e57e-4cac-883f-60df8549f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1e7bf385-e57e-4cac-883f-60df8549f2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fef93f51-cafe-4d05-96ab-5f641b34aa73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fef93f51-cafe-4d05-96ab-5f641b34aa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15304412-9aaa-412e-b4c7-9d72922442cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_15304412-9aaa-412e-b4c7-9d72922442cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a7c9ca7b-985c-4b26-ac95-2142eddce22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_3f03c80c-de03-49d9-abd2-861037d140fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a7c9ca7b-985c-4b26-ac95-2142eddce22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#RevenuerecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0c1950d-218d-466c-adb5-741ce029c30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e0c1950d-218d-466c-adb5-741ce029c30c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:to="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fda2498e-a8a4-42aa-a036-1f08eb72e28a" xlink:to="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_559bc515-f96b-49db-b5bb-a3d5bd0a6b32" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:to="loc_country_US_559bc515-f96b-49db-b5bb-a3d5bd0a6b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4c24e97b-55da-4ebd-aa7c-43aa610fcf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_be0a8133-e283-4e07-8b77-ecbd7454e2d0" xlink:to="loc_us-gaap_NonUsMember_4c24e97b-55da-4ebd-aa7c-43aa610fcf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:to="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dd30cafe-9c38-4f5f-a219-90d20c7dcfcb" xlink:to="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_PainTreatmentsMember_b60e716b-a621-4324-880c-8e3b1b98d7ff" xlink:href="bvs-20230401.xsd#bvs_PainTreatmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:to="loc_bvs_PainTreatmentsMember_b60e716b-a621-4324-880c-8e3b1b98d7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_RestorativeTherapiesMember_f8ebc622-9af1-4f2b-a496-a57e60d54d1b" xlink:href="bvs-20230401.xsd#bvs_RestorativeTherapiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:to="loc_bvs_RestorativeTherapiesMember_f8ebc622-9af1-4f2b-a496-a57e60d54d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_SurgicalSolutionsMember_70d0ce9e-6332-4660-9e9c-f451e73b7da1" xlink:href="bvs-20230401.xsd#bvs_SurgicalSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0aaf8341-ca9e-44de-8629-d6fa833a1a52" xlink:to="loc_bvs_SurgicalSolutionsMember_70d0ce9e-6332-4660-9e9c-f451e73b7da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8ae95e93-04d6-455d-bbfb-a8f2bc1b8f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_402e5d43-d215-4fdd-8f10-580cc386dfdc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8ae95e93-04d6-455d-bbfb-a8f2bc1b8f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_958f5f79-1363-4c5e-a36a-de446817e167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8ae95e93-04d6-455d-bbfb-a8f2bc1b8f7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_958f5f79-1363-4c5e-a36a-de446817e167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/SegmentsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#SegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/SegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ba4a2998-4d2d-4669-80e6-887d6a61f080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ba4a2998-4d2d-4669-80e6-887d6a61f080" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_735cc95c-a3bb-45ab-a6e5-9b4f640ffafb" xlink:to="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_USSegmentMember_9df108d8-d929-44bb-92a5-f5273dc16a58" xlink:href="bvs-20230401.xsd#bvs_USSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:to="loc_bvs_USSegmentMember_9df108d8-d929-44bb-92a5-f5273dc16a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_InternationalSegmentMember_7233da69-26e9-49bd-a522-4b235a3b0b18" xlink:href="bvs-20230401.xsd#bvs_InternationalSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_86d0f3e7-7010-440e-89fa-269cada6dea0" xlink:to="loc_bvs_InternationalSegmentMember_7233da69-26e9-49bd-a522-4b235a3b0b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:to="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_864ac28e-1f55-4011-908f-485d0cac46f8" xlink:to="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2fdbbb46-cfdb-4cad-b16c-dee4c1d13883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:to="loc_us-gaap_OperatingSegmentsMember_2fdbbb46-cfdb-4cad-b16c-dee4c1d13883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_30f6a3ef-c68c-421d-9fad-6d1720f96509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fe2c6826-6b74-4e6a-a099-f26afb39a571" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_30f6a3ef-c68c-421d-9fad-6d1720f96509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_792ca30e-ce41-4d82-bc52-2b019017aed5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_13c4f38c-857b-434d-929f-cb1b45994068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_NumberOfReportableSegments_13c4f38c-857b-434d-929f-cb1b45994068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_a6f55941-a89c-4281-8447-62ce1fc05c7d" xlink:href="bvs-20230401.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_a6f55941-a89c-4281-8447-62ce1fc05c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ce88f616-f6a3-4d96-99b2-a772ede7f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ce88f616-f6a3-4d96-99b2-a772ede7f4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1e1c27ca-72b3-4276-93bd-7345cd1bd876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_DepreciationAndAmortization_1e1c27ca-72b3-4276-93bd-7345cd1bd876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ec0911b7-fbb9-4eeb-94a2-d8367ded88b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ec0911b7-fbb9-4eeb-94a2-d8367ded88b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3d8b5859-c723-4b39-a2e9-26dbedd7e193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_RestructuringCharges_3d8b5859-c723-4b39-a2e9-26dbedd7e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_30fc77be-d133-4f70-8ad8-0a23e4e1f332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_30fc77be-d133-4f70-8ad8-0a23e4e1f332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_5bb97e20-e43c-483c-8c81-7492f954146a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_5bb97e20-e43c-483c-8c81-7492f954146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_69724805-0f1e-420a-9551-52daf3755bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_AssetImpairmentCharges_69724805-0f1e-420a-9551-52daf3755bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringExpense_02791d33-6074-4424-b93b-77341d345d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonrecurringExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_OtherNonrecurringExpense_02791d33-6074-4424-b93b-77341d345d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fd0fc3-1cd1-4439-bcbb-d563531fe4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_867f4ae6-1b5b-496c-8193-dd6e0747b3fe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6fd0fc3-1cd1-4439-bcbb-d563531fe4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsScheduleofBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c96250ac-b36c-43c2-87c3-2df86c3f5b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c96250ac-b36c-43c2-87c3-2df86c3f5b92" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e59435e9-b895-41f3-859b-04bb3fec852d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0e47fcbd-e27b-4b17-837a-babb7b88ab86" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e59435e9-b895-41f3-859b-04bb3fec852d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_524fa220-9615-4dd2-b3c9-423721a2d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e59435e9-b895-41f3-859b-04bb3fec852d" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_524fa220-9615-4dd2-b3c9-423721a2d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98c0a91e-eeed-44f1-9086-eb05b1d33efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d06312ba-fc7c-4815-8ddc-ec535cfd1cbe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98c0a91e-eeed-44f1-9086-eb05b1d33efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember_dca7baf0-3f80-4692-a6e9-43335d482a59" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_98c0a91e-eeed-44f1-9086-eb05b1d33efe" xlink:to="loc_bvs_CartiHealMember_dca7baf0-3f80-4692-a6e9-43335d482a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b26da2be-1c20-4bb8-844f-f33480d97a2d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_2ab227de-d44f-4560-9a7e-b628eb7fa049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash_2ab227de-d44f-4560-9a7e-b628eb7fa049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_3a3e8a65-d112-44c6-b97a-8ac79ec58749" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_3a3e8a65-d112-44c6-b97a-8ac79ec58749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d33bdf4b-21fa-487e-9cca-885463b3d468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d33bdf4b-21fa-487e-9cca-885463b3d468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_ad38b5da-8a66-4df0-82b6-e05cf6e4ce67" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationInventory_ad38b5da-8a66-4df0-82b6-e05cf6e4ce67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_e7836564-184d-408a-af66-e283808d2f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_e7836564-184d-408a-af66-e283808d2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b4a40cf7-9aa9-423d-ad4d-af1cada056c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b4a40cf7-9aa9-423d-ad4d-af1cada056c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_a15856c1-90ed-4630-b166-07d9b586ddaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_a15856c1-90ed-4630-b166-07d9b586ddaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_3f52d89b-fa91-4964-a88f-c0c9565b0a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_3f52d89b-fa91-4964-a88f-c0c9565b0a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_c80b12d6-4cd8-4e00-9165-af36ca8bf6c6" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets_c80b12d6-4cd8-4e00-9165-af36ca8bf6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_565475e7-a940-432d-a868-ff4084bcd866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_565475e7-a940-432d-a868-ff4084bcd866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5ce74e00-837c-4fc4-bf59-e27f05e4d9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5ce74e00-837c-4fc4-bf59-e27f05e4d9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_ceff8b46-2acf-4243-8023-7fcdfebfb076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_ceff8b46-2acf-4243-8023-7fcdfebfb076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0f1be465-8f18-4757-8e78-66b0a91e111f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0f1be465-8f18-4757-8e78-66b0a91e111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_bb2abd46-aa93-4f5a-9830-e91f0589aae9" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration_bb2abd46-aa93-4f5a-9830-e91f0589aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ccb70cb7-6b5c-45ac-ac36-6d2889a85762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ccb70cb7-6b5c-45ac-ac36-6d2889a85762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1868407c-99a1-4ad7-a0d7-8108f307ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_1868407c-99a1-4ad7-a0d7-8108f307ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_840957ba-2107-499c-8d3e-32b57c973276" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent_840957ba-2107-499c-8d3e-32b57c973276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_73bb80b3-6fe8-4a23-8637-ec64c6654ad2" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_73bb80b3-6fe8-4a23-8637-ec64c6654ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_25bfa4c2-5b61-4420-a5e2-373551e5164a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_25bfa4c2-5b61-4420-a5e2-373551e5164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_79961348-fbe1-45cb-9fff-d4460d32bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_db3ab39c-87e0-4055-8fc5-c265632665a8" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_79961348-fbe1-45cb-9fff-d4460d32bcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#DiscontinuedoperationsScheduleofStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cc1b1afd-fe58-4aaa-9e52-ac5c41898039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cc1b1afd-fe58-4aaa-9e52-ac5c41898039" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_66c15bdc-d810-4b7a-adbc-9e9f5f1c7962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9ff2bfde-79bc-4d9b-98fe-c30440080984" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_66c15bdc-d810-4b7a-adbc-9e9f5f1c7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4fd4c8a0-a39d-41c0-9771-ce80c3e4c929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_66c15bdc-d810-4b7a-adbc-9e9f5f1c7962" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4fd4c8a0-a39d-41c0-9771-ce80c3e4c929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a6a3cb9-bde1-4809-917d-d5b6c46639a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5976f71f-b439-4845-9580-eb1febcb8b30" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a6a3cb9-bde1-4809-917d-d5b6c46639a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_CartiHealMember_e4ed1e76-2827-4e43-9bdf-69be8dbab475" xlink:href="bvs-20230401.xsd#bvs_CartiHealMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a6a3cb9-bde1-4809-917d-d5b6c46639a9" xlink:to="loc_bvs_CartiHealMember_e4ed1e76-2827-4e43-9bdf-69be8dbab475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1268ba01-4fd6-4e70-8895-3af80a68d7a1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4702c277-e45c-4c4e-a113-a8d3c31626cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_4702c277-e45c-4c4e-a113-a8d3c31626cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_7ba8a21f-484e-4cd9-ac97-2ac8db1b7212" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_7ba8a21f-484e-4cd9-ac97-2ac8db1b7212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_5d18f69a-8104-4dfb-9d46-8bdcfa643b8d" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration_5d18f69a-8104-4dfb-9d46-8bdcfa643b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_93b3a49b-0fff-4919-bafe-bf0bdfef3de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_93b3a49b-0fff-4919-bafe-bf0bdfef3de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_09d15368-cc3e-4528-a7cd-4c63766e0769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_09d15368-cc3e-4528-a7cd-4c63766e0769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_9b8dd4ef-9c3a-4823-af7b-9cdb0632ddac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_9b8dd4ef-9c3a-4823-af7b-9cdb0632ddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_38251b77-47f7-4e7a-931c-2e41ce4b745b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_38251b77-47f7-4e7a-931c-2e41ce4b745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_9ea99f50-26f2-49be-b719-7a57ed5707a5" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_9ea99f50-26f2-49be-b719-7a57ed5707a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c3a4a422-3348-49db-a56c-1fdfb26cc424" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss_c3a4a422-3348-49db-a56c-1fdfb26cc424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_b8268368-c7b0-40a6-abda-6c5726b6ecb2" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest_b8268368-c7b0-40a6-abda-6c5726b6ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_1c97f9d2-9bd4-42c0-ace8-bcb7ec7b57b0" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent_1c97f9d2-9bd4-42c0-ace8-bcb7ec7b57b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_02880fb5-8497-4fe8-aaac-290da026e677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_02880fb5-8497-4fe8-aaac-290da026e677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_NonRefundablePayments_ab13776f-e680-4b5f-a7e4-d7490db7b6d8" xlink:href="bvs-20230401.xsd#bvs_NonRefundablePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be469ac-e3da-4fc9-89ee-cb30ff88e568" xlink:to="loc_bvs_NonRefundablePayments_ab13776f-e680-4b5f-a7e4-d7490db7b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioventus.com/role/SubsequenteventsDetails" xlink:type="simple" xlink:href="bvs-20230401.xsd#SubsequenteventsDetails"/>
  <link:presentationLink xlink:role="http://www.bioventus.com/role/SubsequenteventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_143f8437-d7fc-41b2-9156-54ff5d16cd02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_143f8437-d7fc-41b2-9156-54ff5d16cd02" xlink:to="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f28dcac2-55f4-4a36-9c35-c3502b9d530a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_29830739-c594-4bb2-b244-5ab1378262dd" xlink:to="loc_us-gaap_CreditFacilityDomain_f28dcac2-55f4-4a36-9c35-c3502b9d530a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c084741c-cfac-44b1-9be7-570d8022bf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f28dcac2-55f4-4a36-9c35-c3502b9d530a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c084741c-cfac-44b1-9be7-570d8022bf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4fcac77-f48e-45e8-8721-1c993b2743a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e0f8c729-2104-4a7b-8e76-1a4394db338c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4fcac77-f48e-45e8-8721-1c993b2743a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_86ddc776-6fa4-4224-9e6b-3c72be115a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4fcac77-f48e-45e8-8721-1c993b2743a3" xlink:to="loc_us-gaap_LineOfCreditMember_86ddc776-6fa4-4224-9e6b-3c72be115a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_87e4b409-36d4-4e90-9c58-6efcf13082d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66bbb586-7aaa-4a3e-bc3c-9be3c6720a7a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_87e4b409-36d4-4e90-9c58-6efcf13082d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7d450a35-a917-46ce-a63b-3e61af9b862a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_87e4b409-36d4-4e90-9c58-6efcf13082d2" xlink:to="loc_us-gaap_SubsequentEventMember_7d450a35-a917-46ce-a63b-3e61af9b862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7f5a3f62-0fb2-4e96-ab5d-026685bd69d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b8de2778-4fe8-4c4c-af0e-1e1aa260d847" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7f5a3f62-0fb2-4e96-ab5d-026685bd69d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1fc20b73-9a5e-4db8-956e-dfdbd7bebcda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7f5a3f62-0fb2-4e96-ab5d-026685bd69d3" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1fc20b73-9a5e-4db8-956e-dfdbd7bebcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec160054-9cff-4b02-abbd-251de11e8196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e800d77e-25e1-4a89-8b85-6d8c0f181e3e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec160054-9cff-4b02-abbd-251de11e8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_WoundBusinessMember_5e6864d1-8f7e-43a7-9399-5655416fd295" xlink:href="bvs-20230401.xsd#bvs_WoundBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ec160054-9cff-4b02-abbd-251de11e8196" xlink:to="loc_bvs_WoundBusinessMember_5e6864d1-8f7e-43a7-9399-5655416fd295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_78b94f74-5c3d-45f7-915e-25664ee53795" xlink:to="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_7af4b8a9-ff17-4adb-88e2-2a70532513c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_us-gaap_RepaymentsOfDebt_7af4b8a9-ff17-4adb-88e2-2a70532513c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a8be2cb0-ef77-42ce-a5a3-a2f46ebbde65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a8be2cb0-ef77-42ce-a5a3-a2f46ebbde65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_511709f8-4864-4cab-9101-fc8c97dec0c6" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount_511709f8-4864-4cab-9101-fc8c97dec0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_2facb61b-2bac-42db-9c30-65fc156aaceb" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredDeferredAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredDeferredAmount_2facb61b-2bac-42db-9c30-65fc156aaceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_a5d88420-d069-4aeb-9ff6-b28202213c36" xlink:href="bvs-20230401.xsd#bvs_BusinessCombinationConsiderationTransferredDeferralPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod_a5d88420-d069-4aeb-9ff6-b28202213c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_85cb60c6-a167-4f47-92c7-2f7755778591" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments_85cb60c6-a167-4f47-92c7-2f7755778591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_3ee35bc5-6cbb-4877-ae02-cb4e75803e4e" xlink:href="bvs-20230401.xsd#bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e9ccc1eb-97f2-4431-9749-a8dc02e7df2d" xlink:to="loc_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses_3ee35bc5-6cbb-4877-ae02-cb4e75803e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exhibit103signaturepagea.jpg
<TEXT>
begin 644 exhibit103signaturepagea.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" /1!=<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BH[C[G?KT!QG\?KBH7N<R*NX;FR>.1QPV!D$X./SH
M M45%"2TA.>/3/3Z5+0 4444 %%%% !11377<N.1[B@!U%<Y\1OBGX;^$VD0
M:AXH\1Z%X:L+BY2VBN-5OXK.&65L[8P\C*"[8.%!R<'WJ7P'\0-$^(VGR7N@
M:YI6O6<3F"2?3[R.YB20 ';N3(W;64D9XXH WJ*** "BBB@ HJ.Z?RXL_IG&
M:\V^-7[6GPW_ &==8TW3_'?COPIX/O-9@FFL5UK5HM/%PL0&]@TI"@ NHR3U
M(X/8 ]-HK$\">.M&^)'AVTUKP_K.G:_H]^A>UO\ 3[I+JVN5!P2DD9*,,C&1
MZ&MN@ HHHH **9.Q"<9Y...H]ZX'P9^U#\-OB)XWG\-:!\0O!.N>([<,TVEV
M&O6UQ?1A#M8F!7+C!P#QU/- 'H-%10R;F R<XW<CUJ6@ HHHH **** "BF3_
M .K[X')QUQ7)_$[XY>#/@G9077C/Q=X9\(VEY(88+C6=4BL(II ,E5:5E4MC
M^$'/!]* .OHK&\$^-M'^(V@6NLZ!JUCK6DWR>9;7EC<+/;SJ>,JZY4].QK9H
M **H>)_$=CX0\/W>J:I>VVFZ;I\37%W=W,RPPVL2@LTCNQ"JH )))X%<-\(_
MVLOAE\>]:>R\$_$GP)XQNXHC/);Z%K]IJ#I'NVAB(7<X!R"<X!^M 'I%%(#D
M_2EH ***CN"1'P>_.#U% $E%><^(OVJOAIX5\2W6C:G\1_ NGZKI\B17EE<Z
M]:PW-J[@%4>-I0ZLV00".<UW]E=I>PI)'(LJ.H8.G*,#R"#R/UH GHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH BNV*QC !^89&!T]>>!CK^%?BS_ ,%M?^"ES^#O
M^"DO@'0?"5_97$WP#\GQ'J862W=C>RL6GMV0L'?_ $15SM"A1-*2P?8#^KG[
M9W[3&F_L<?LN>-?B=JUI=:E:>#]->]2PM4=I]3N.$M[6/:CD/-.\40;:0ID#
M-\H-?BGXE_9C_:$UO_@EIJ.@>,_V2_'<?BIO$-_\6]=\7V_C;0C=3:A,'FGD
M33_--V&-J=@MBGF;HT!5F4  '[J> O'=EX^\$:-XATYY/[.\0V,.HV3/RYCF
MC613M'7AUZ9Z9)SG/A/[6/\ P5J^"W[%WCRW\)^,-<UR\\4RV_VPZ+X?T*^U
MF]A@ 8F246T;K& $!(=PV'!VX.:^7?\ @V;_ &N&^*O[)-W\-;Z2YEO_  *R
M7.G@QC$>GW*B38[ N6=+AIP=QR%>, %5#U\\Q?''1_\ @F3_ ,%U?BGXR^,M
MGK!M]5T74=3TS5-*L5UF[U&"X>-K2V86YE>"0I:RP@3^2BJJEBBL)) #]#?V
M;/\ @MM^SG^UK\4-'\&^ _'5]KVOZ_Y@TZ)/#FI0)=^5&97*L\&$Q&KG]X5S
MY; 5'X0_X+>?LX^-/%.IZ+_PL$:#J.D6UW<W<6N:9=:<(Q:J7G17F10\JA7Q
M$N7;RGPO!KYH_P"#</\ 8U\=_"J?QY\6/%.BZSX,T;XAQK'I.A:K:"ROI8EF
M:1+F>W+-)"<%U1'V_(<C>K*U?/W[,G[,?@?]IG_@NIXZL_&.B:7KVC0:]KVJ
MSZ??VB3VVIS),ZJLRMPZ[I2Y4YWE=I!#-0!^GOPF_P""LGP)^-/P \1?$_2_
M'L%EX+\*72VFK7^J6EQ8"SE8*8T"RQ*79U8,%3<22![5S_[-7_!:CX"_M2_%
MW2_!/AWQ%XALO$OB*WDN=$M==\.WVE1:[%$"97M9IHEBDVXS@/R,;0<FOC'_
M (+Y?L[^$_V1OV1]#\%_#+PK8^$_"GQ!\63:WX@T_2U<)J=W#:1B(!26"I\@
M81#"AT5@-Q.="#_@F%KW[2OP;_9B^+'Q&_:%^'7A+PU\)M.TF/1TTSPB;**6
MWFN;+[/93WDFIK#YS.D%N"EO%^\;'ELV* /M#]MG_@KQ\%/^"?OCO1_"OQ#\
M2WR>*=?MGNK72M(TZ;4[Q8U!/F/%"K,BMM<KD<B-CSP#Z=^RC^UYX$_;:^".
ME?$7X;>($\0^%]9.V.;R)()('0XDBEB<"2-U_NL.00PRC*3^/WP5\=>/_B)_
MP7W^*S:'\0O _@'Q=<W^L>'+'5_%^@'5RUI;W82UL[6W-S;DW#QI RCS(\()
M"-Q<*_J/CO\ X)^ZY_P3J_96_:XOD^/%G\1==\>:19:GXBT/3-)32;JP^U7T
MB"[:,7DK1PSQM?)MQM=8W WB+RR >C?M]?\ !7O]DW]I_P#9C^,?A*>[O_&1
M\)VM]8V>JGPCJ-QHUAXA2WE^Q0Q:B+?R(KAIE?RV\P*X63:[1D;K/_!KYH-]
MI_[*WCV[N(XH+>7Q.+9(O-5I8Y([.W9U9478JA9(]NUVS\_) #-Q?_!/KP/X
M.UC_ (-U_BE;/;:.;?5-*\37VIQW"QA#J021H-R[F!?Y+?J,N?P+=[_P;*7D
M\_[-'Q!2629@/$X<H\A8*[6L.X^YP%RW4@*/X10!^B_C[QOI?PW\(7^NZWJ%
MMI6D:7"US=WEPVV.WC4$DDX/IC'4YP.2!7Q'J_\ P</_   \/Z?_ &O)!\3_
M /A#)+N:QLO%[>#KU=!U2>)RLD4%PX 9]P<;2,C8<@<9^E/V_-%\!^(OV-_B
M'9?$Z[N[#P'<:/*FLW5HQ%Q;Q8X>+ ;,@?;M4JP9L J02*_#_P"*GQ/\:_%_
M_@E[X1L?#/A33_#/[+WACQC-I6F-XAUW^V/%.OZB3<RM-(T<2P):1RM=($ 5
ME/E@*57( /V;_:%_X*0?#[]G3]F+0?B_J:^)-7\!Z_):B/4M'TY[M;..Y ,4
MUP%R8H2S)&7/ =T4_>KYZF_X.7/V8KC2$GTW7O%&IW;W C-BNAW$,RQ ;C/N
M=1&4W?*,-DD],<UP^L36TG_!M/!!)9F[M_\ A%K2V>U4)(B@WJ+C:#]T @X/
M\)%?)?PV\!:7H/\ P;S^/I[>TMTGO?B+#>2;HD0PN$M(\  ==B8/^\WK0!^R
M6D?MK^ -;_9,'QNCUQO^%?#3CJ;W9A8R"('84:, GS/,RFT#KCG%?EY_P5J_
MX*??#?\ ;L_8LMM/T;P)\2;"2\U>&;PAXHUK0C;Z1J4T+F*[%M=;CO\ +)V,
M-HR5SDXK.^,]WJ%I_P &T7PSC6&22R/B55U,QR91;475](6D&Y?E+B,8Y(9E
M(&0#71_M*2:;JO\ P;?_  F%B(+@P7VGK;O GE^7<*]RCC;C&\$3*V#UW'H:
M /M[_@AO8_V=_P $P_AA&/*(%M=Y*=#_ *9-T]LY/XU]!?M!?M >#OV7_A3J
M?C;Q[X@LO#/A?14\R\OKIFVKUVJJHK.[L<!40%F) 4$D ^%?\$55C_X=E?"I
M8BN!I\P;9CAOM$F>G3G/'O69_P %N/$WP<TC]@G7K3XW7>OQ>$]6GCM[>TT0
MQC4=3O@KR6]O 9$=-[-'GYE*_*=V5R" <1:_\' WP>T[QMI>E^*_#'Q?\!:=
MXCMX=1T?6?$WA:2PM-1MI ")X_GWF%3A=P0J<]3SGZ7_ &M/VR? O[$WP;F\
M>?$#6VT[P^LL<*-! \\TSR'"!(D!=N.3C' )ZX!_"S_@H+\4?B1\9?V6_@1=
MZKHWA'P9\(#I4\?@?1)_$<^N>+)H(TAC^VWDC1I$\<B[-L:J&C^YV.?>?^#A
M'7=6TB\_9O.I66_P7I^CIJ"A93)%/>Q21-<)L;Y05C$.&)&?,(SQ0!^A/[-G
M_!8CX(_M2?'T_"_0M8\1Z=XZEM#=Q:-X@\/7FE3S1A=Q($T:\[<-CC*LI /)
MKX"^$GPVT7P7_P '*]UI6DZ38Z=I$&H74T=M;0QQV\3-IADW*H  )=B<CG<V
M>M?HG)\ ?@%/\>?!7[0.H6V@6?Q&U:QAT_0M:GUI[5]1$T!1(DA698)Y&1F7
M[CM@+@X7C\N_VD-?^)7A;_@NQX\U/X1:5;Z[XXTU;N2RMIHU8,!I1#%5(&^1
M 3LC7_6.BJ3ACD _3^S_ ."IGPYOOVP+[X$V=GX\UCXB:3*B:I:Z;X<N+BVT
MJ-\%)YKA1Y<<#*\9#D_=E0G'..#F_P""_/[-NA>-]9\/:_XOUOPYJ_A]YX[Z
MWU3PW?6DD$L3LK0-&8RXE!##;C)*-TP0/"/^#<+]IZ+XN1?%G2/%$SW_ ,4-
M3U]_$.JZI>R*;O5DD5(AP0"HB,0!B7Y8]PP &%>/_LQ?#NU\2_\ !PIX@74[
M2VNAIOB;7;_==6_G+)*(S'N0OG#<+SU^4>E 'Z7?L7?\%+/A1^WO<:U#\-]=
MO=6ET&.&XNQ<V$EKB.8OLV[P-P^0].1E<]:Q?VI/^"KGPG_95^,%G\.]5F\8
M>*/']U8G4I/#OA#P]=Z_J5E9@J&N)X;5',:*K;\GLIZG:#^?W_!"/PGI^@_\
M%-OBM':V5O;+I^F:A;VP"J&1?[14':<?*,*BX'8+Z"M7_@AO=2^,O^"J?[0&
MN>(D\_Q?+:/;7EW.B1W%RJWKC&,;MJJ$3KT0>M 'W)9?\%=/@KJG[)6O_&VR
M\2:IJ/@OPG(MOK<=KHEVVIZ1,753'/9>7YL;*74MN  4@Y[GE=._X+G_  *\
M7>'O&>L>';WQSXE\/_#^$3:_JFD>$=0EM],4X&YG:+) SGA>BD\@-CXR_P""
M*KQ>*O\ @I)^T+X;BM[^Y\(:];:BNK6,BM]CO))+QE'FJQ.X^6TB GH&QT->
M _!KX7_$_P#8I_;O^(_[,OPRGL;-OB5,?#;W=Q:!8;73V83_ &[R0I1I!9M.
MHR!S,6SN44 ?K7^S5_P5X^%7[7NG>,]0\"0^-M8TWP%I#ZOK%S_PCUPBQJJ.
MX@2-@LKW#!&*Q+&2P _O"OCK_@K=^U-X4_;^_P""9_AWXH^#])UV+PK:^+O[
M/TZ]UO2FLYK^,PR!KB!'R_D,T;*2VTDH..,U\C?#WP'\:_V+/VK_ (K_ +-W
MPXUF[7Q3\0T_X16'6+DF-E@D=&.K.D6X)-]C:9BX8,@?</G K[V_X+8?"'3_
M -G3_@EI\.O /AM)AI/AC4+'2+*WFN'GW)#:2QH'8G<P&.N<YQ[T >K_ +#O
M[2_@;]C/_@CWX*\?>/M<CT/PEH.E;YKP!G,A:8B..-%!D=F8A0J@]>?E!(T?
MV/\ _@MK\,/VPOC?%\.X/#WQ+\">*=8M#J>@VOB_0'TH>([' 87%JQ8[E,9+
MKG;N525SAL?F/_P4W\3ZE:?\$SOV4M#C8_V%<Z3<W=Q-&FY))HS"(V9P"I*D
MEERI(+9QW'TAX_\ V'-.^,'AWX*?'7XI_MB&ROHTTVS\'ZA/H.G::S2S2H\%
MC%Y$D;S,78;@2S8+%MJJQ !]A?';_@K-\+?A7\>Y/A1%8>-/B3XGA@>77=.\
M):$^MMHMOA59[I(^JC>H<("5\Q05Y./@7_@@8-"U[_@I#\1M4\,1BRT*YTN[
MN+:'[#]BWQ_:UV@1G[NT;1MPFWH0>UG_ (-V[.\N_P!OGXV7_B&2,>*+>R==
M0,B>7-<327;F9L2!9,!XSG?DYSG!'-K_ ((M^&K?5/\ @HW\9+15\B.^TK4K
M5Q -DD:M>E#M.<#"E<8!'3CT /L7]J/_ (+J_!O]F;XN:AX(AM?&?Q$U[PY$
MMYXG'@W2'U6W\*6I8!KF]D4@)&F1NQDC(X].I_8]_P""O_P;_;J\9:AH7P^U
M'Q5<W&E:<VIW5QJ.@76G644(V'+7$J;%W*ZN 6R5W$<*:_+_ /91O]7_ ."=
M'Q2_:G^&,W@;Q5\3M:\56LFD6J>!K*XU#[==S+,@\V2$$1,(I=TCR;'CV.&.
M5 'L_P %/V)/BG_P3W_X(I?':ZUBS;1_&/BVUAN#I6GM'>7.G63&"WDBDDB$
MB,PMS(K@!@B@X<XW4 ?1MQ_P<5?LYP_$NVT<:GXUE\.2Z^?#,WC%/#-Z/#EO
MJ')6V>ZV'YV78PVK]V1&)"YQ](?M;_MV?#+]B?X=V/B/XB>(XM(LM7N(X-,@
MCC>ZO-4<E21!!$&DDVAE+$*0,C.-RY_(7]@W]B+6?^"@?_!.;6O"=Y\?O!/@
MGX3Z'?7&HZWX7D\"V$\]A*A>8W]QJ#7"L%+;Y-Y08 9=^%K)_:LO7\,_MB_L
MA^'IO&L/Q0\'^%+3P^NC>*)+D&QUZ+[?G[?&B[EB*\QY:1F/D+N9N30 O_!4
MW]H+X:?MC_MW^#]7\&Z1=:%XFL[;3;+Q-;^(?#,^AZK9W+W;^2;M985+Y@2+
M:V]AM5,< 8_7_P#:A_;H^'W["/PO\/:YX^U6>VL]4V6EF+6T:Y:X<1AB04P
MH ZGU%?G;_P7HGM[#_@H=\'I4D2Q$FGV-U-=)&'7(U"1?,8#AB%4 9Y( '11
M7VW_ ,% ?"W[,GC[1/ FD?M$3^'8DU*;RM!DU._N=.+RE!N!G@DC*KC'WGV^
MM 'TMX"\:Z?\1/"FG:WI-W'?:;JENES;S*X;S(W 93QQT-;5<K\'-.\.:3\/
M='M?![Z<_A>TM$ATS[!*LUJ+=5"IY;J2&7 ZY8^]=50 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXGBO)+G[7_;8UR5-249&85((B$9Z;5B &<C! ->Q_$;_ ()B?"SXJ_L?Z/\
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M!UU#'_;-NV-XGBFAD3S/E!#+CE03DX(^N"@;J!^5)Y:_W1UST[T >#?L-?L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD;IZ4R.X623:,
MY STH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]BT_1M"LY+V[N)3PD:*6.!W)Q@ <DD <FMZ\D\F+<-W3G:,FOS>_:TUW4?\
M@K;^TY:_!'PKJDEO\(O =ZE]X\U&VF+1:ZT;C99@H5(0D.-RMC()_A0UZ&68
M)8FK^\?+3CK*79+IZOH959VT6YL?\$P?#7B+]N7XZ>(?VGO'5M=)HM[NTSX>
M6-S))$UA8)(^9/+^Z0^?E?&6Y;G=D_H5;H%/'UXZ5F>%?#]GX1TBTTZPMXK.
MRLX%@MX4.%2-  H QZ?YYK50AG'3=C\JG,,=]:K<\5:*TBNR73_,J$5!<JW)
M****XBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX6\/:_\ %7XC^(9[[4/%'CG24O(+C?Y96.&Y9,:>B/)(./*C"K@R?*$'ZO\
M[2?_  4%\,?L]W'Q3TNVL;[7/%'PK^&U[\1M2LXE\NV2VA68P6LEQRL<TYAE
M\M",[4+$ %=WR%\?O^"*GPE_X*2_ GPC\7?A),?A/JOCKP]#XF@A\@R:=J*7
MT*W423Q!QY)7SBI:' 4/]R3:$(![!_P3I_80M_\ @F[\0?VB-;TO[':_"?Q#
M>V&K>$UAN%N)XK*&V>:>-6)8^2K3F&%9&+$0EL[74CXF_9%TAO\ @NW_ ,%(
MM:USXWV-OXA^%'@C3Y=3\/\ A">7-C:K]JVV4<J1LJRL(WE,DC@^80%.4* ;
M?_!&"T^(]Q\5_P!H7]D+X@W\]]HV@>%[[3M3TYY7>+2I[EEAC:.X _U5U%.\
M@VN3A<;%V%5B_P"#=R>7X ?M[?$_X6>*%M='\6#0%EGT^]S;7JM!- /DCE"O
M(CBXR&4$?NB">* /<O\ @LE_P2T^%7AK]C?4/B+\*_!/A/X9>/OAI)#K&F:C
MX4T&&Q:X"/LDBDCM5 =/G5\[2T9B!&5W(U']C/X[:-_P58_X).^.=(^+?AC2
M_%?B+X6:3=V$MWJGEW\UQ<PV#M#J499-\4[ LADW$L8W(;YF ^E/^"TOQ(TS
MX<_\$TOB==:E=VML-2L%TV$32>2;J6615\M 67<VW>2G(=492"":^3/^",GP
M>U?PG_P2 ^,^O7NESP:9X[L-6U'2X(Y7M[FXMX].,0*EE&W<R,JR;LY&<\ T
M ?/_ /P0<_8<^%/[5OAOXV:1\3_ GAO7='BT_2_*O;RPC$^G_-=EY;>X8;[9
MU$:Y9"N=O.:U?^#;+XQ:_P"&_P!L?Q+\.O#UY?7GPTFTR[NQ ^3#:F*6)+:5
M?[A:,@;??':LW_@A#^Q3X/\ VM=:^,.E>*M4\>_V$D.EFXTG1_%VH:/8ZG%(
M)M\5T+:6,SQF5'RK9P#@<&OV(_9;_8O^&'['?AJ72OAMX/TSPS97*H)FB\R:
M>X"J OF3S,TLOKEF/+,>I- '9_%#X:>'?C'X"U#PWXNT'2/$WA_5@BWNF:K:
M)=VDX5E<;XW!5MK(K+D<,JD<@&OYM?VE_P!GZ^_9Z\51^-_!FD0VWA6T^)&O
M6'A^\NMOFV<FEW\BI:7*A67$J@.!CE%>OZ;&^0]LD_GQ7Y:_##]DZ+]K'_@D
MQ\</#MGI<C>)D^)?BW7='5%Q<SZA;:K<,@781N>2-6A!;.-ZG&5& #Z#^.'_
M  4TT[P?_P $Y?"_Q7\/PVT/BCXFG3_#_A'2KY'E^V:W>DQQ6GR@;@I$IW$
M8B.>M?E-^PW^SWI&E_\ !4;P/X,\>>&-,\1:AH'B6_M?$*:G"+B"\NUAN 'V
MOD2%)\,I.2"H(Z5Z/_P;]?LR>*OVKOC)I^M>/;^]O_AW^S[J]SJ?AG39U#Q0
MZS>J@;EPKYB2-'"[<(\F003FKG[/UFVL?\' 5Z+.'F3X@:Y*J+M79&@N9&()
MX VJQ..?EXYQ0!^WUIID&B:;';V\26=K JQI%"H6.%%4  = % '3I@8]J_ #
MXC_\%@[GQ=_P6>T3XRZ<)_\ A7^DM-X8TB_FT:86^H^'8[@Q7%S'LVO<#S9)
M;D '<'1%(4* ?T]_X+?_ !RUCPC^R')\+_ R_;?BG\>;C_A"?"M@M\UHQ:=3
M]JN3*OS+'# 69FS_ !+ZFOS@_;S_ &4?VA--_9+\ 0>(?V:?!7P^^'WP"TE[
M..X\.^++?6-0%K-Y".TL>S?)M9!)*X)+-*TA.06 !^[6GW%GXIT%9@T5_I^I
M6^XEL/%-&ZY(9>@4@].X/.:_GR_X*"?LCZWX0_:;^.?Q#^$7A>UT30O@_P"-
M+&VGDT<+:S:"S6T%RDL4* *8A)*&&W#;RHR S&OT]_X(,?MD1_M3_L76.CZA
M?F]\1_#UTT>Y65H%GDMB-UK(8HP-JB(F(,<E_(=BS$YJ7]@#PS9>-?VM_P!M
M[1]6M[?5-(U;QY;V=U:RQB2&XADT2TCDB93P05)5@>O(H \&^#_[<G@O_@K1
M_P $JOB]I'Q2\,^'M7\=?#;P5J6H7%Q?:5!=Q/)_9MRL.JV@D4B.<;'R8P&1
MA\I"LHKZ[_X([_"3PW\(_P#@FU\(_P#A&]#TK19-=\+Z=JVJ/:64=LVH7LEI
M#YEQ.5 +RD*JEVRV$49PHK\G/^"JW_!.G6?^";/Q7\0>,/ R^(8OAEX^M+K3
MK:329YD_LN2[7;+IUQ(&W-;F,L 7^61,*V6C8G]J?@'K&F_"C]C/PCJ&IS-8
MZ1X>\)V]U=.T9E-M!%:*SD+&"S8"G 4%CT R: /S_P#^#EK]M;2?"/PRT/X+
MZ9?+=^*=6GB\2:G!!O>;3+&"3$$KD#;$S3M\N3DF)<=:^Q/^"4G[4G_#7'["
M7@/Q1/=O/K,5DNFZK)(?WC7-N?+=V';>$W\]G'K7YO\ P=^%O[0W[5'@3X_^
M.+G]F&P\?:9^UGY>KZ!XMU#X@:38W&B:1Y$9T:/[*JO(PM<13 &4%C'M9<@L
MV1_P18_;6L?^":'C3XH?#7XUZA>^$=-M)/M7E7,$DL<.J0%H)XE$<3*\DJK&
M1^\ Q$ !S32E)VCN&G4]>_X.*?V[_&6DZYI'P&^'6L+87.OV\=YKSP?)<3+*
MSQP6@F\S:@8C>PV9("<C)!^A_@I_P20_90_8_P#V9;(^./AO\*=:>PLEO-<\
M3>*=)L]0N;BX\O=)*;BY1I$7AF5$("C.!7YC?\%3_B/=_'[]JQ?C-'X=\1^!
M/ ^OO866B:QXQTJ6VM[V:U:V>22.&,-/+"T0)5@N"0%W 5^A_P 8/^":7B#X
M]_LP67C&7XVR^+O&T%M#XAM]4U7PU9ZCX<O(HXS*L,>G3 A8V7 !:1SR3MR>
M.N&%HT:KCC&X\O97;_1$2E*UH'SI^QKH&@?L_?\ !1+QMXC_ &2? GB#XG^"
M[_PRFDZ=I\DD^GZ-X;N7NB9HDO;K(^R$6S2)L!R[-'Q@,/E?_@I[^R%<_"O]
MISP_%\2?!_PZT76O&L6GZ@=#\!6S:9I-A;FYDC=22I/VAO)?.WY5,F=S9X^J
M_P#@C;^W)^T]^UG^UGIG@SQ#XW\':3\/_"-@]_=Z;I/ANSC:[MD"Q0V:JD0$
M"@MG<K<>6 !S6)_P<H^&H/%O[9GP\TFX::*+5/#NGVIE3<\L*G59_,9<$$-Y
M0?\ B7)(R<9JL7BJ$KPP]-17=MMOY_\  '%2WDSUCXC_ /!-7X"?M&6_QZ_9
M]^$'PGT+X>>// GAW2[FW\;-<7*32:C>Q?:;>W:4'SWB_<Q"1C(RY<'8Y3!]
M)_X+"_LL:?=?\$D6'BK1_"NM>.O VFZ/IUOK LPKVDTEW:VTK6\C[I(XW9LD
M!N!W)&:WO^";'_!/:3_@G5^T=\=;K3+">Q^#.L:5HE_X<N[W53J5T)8;61+V
M)BTK3;8]D9'F*.)"H9PO$7[?7[5/AK]K?_@B7XO^)7A[[98Z%XFCL&L&U"W,
M4HD_MBU@C+(H+*/,"$'J,@\8KALBCX3_ ."./Q$UC]@+_@J3K'PI\66$.B1^
M+81H5];VTQ:WCN8@TMI.KMRT4F94CP0=TP). <_1?_!>3QCJG[37BK5?A5H?
MFKHWP;\,IX\\5:AY:RP"\NYUMM-L&4LK+(T8N9MZEAM..*\V_P"#B[X#:E\)
M_'/PP^._ASS=-E>*WTJXO+92CPZC 3-;3LYVX=E&$P<DP"O6X/V8-:^#O_!(
M7XU?$;QU<W&H?%3XS6R>)O$MS<P+:S1!Y(EM[7"L0!##\H ZL#W- ''_ /!M
MI^R[X%\>?!WXG^*/$7AGP]KM_?:[_94:WVDI<K;6HMX9FB625"0&:0Y4-@[%
MR.!7S1X]_8\^']O_ ,%^(O '_"+:,W@6^\4*SZ*T>RUPT!F,(1-H$8<#"?=P
M "".#]L?\&Q'C.SO_P!FKXA: -[:AIWB<7<I$>(VCEM8$1@?<Q-E>W%?(7[7
MOPE\/?'G_@OO=^%_%D+7?AG7?$=M;7\$=U+!]H0VZ@1[XOG7<VP$@CC/-&VP
M'U%\-_V)/A1^W?>V?Q"^!7PZ\/\ PIUCX+_%Q-/M-6L;B/[#XMTNQND%W*JQ
MH4(DC+[0PW*Z$;B "=;_ (+T_LJ^%/B]\4O@K;:;X9\,0?$7XA:S=Z1!K%U:
M^5]M$%D9([>YGC5G*$A47(PI*\J!7I?[+^G:=_P19_81^*M[X_MVTWP?X*\4
M:IJ.AO!=Q75SK6G7%R6LPB[QME<R;!&6!W ]JJ_\%'?&D7C#]I/]B/5#9W.G
M-K'C.XO8X+L*)K<-I_\ JW"L?F&]0<;AG'/J7ON!\@_\$;/V^[S]FSXK:Q^R
M]\;="GM=)US4Y]*MK+4F6ZBT>>5O+.G/"%93!,S.N=Q3=GAA(67VOX._\$S/
M WCK1?VU_ W@7POX+T7Q-J?B>?2-#U:[T4-#HMI=:?97 @@D',<2O(Y"1M@$
M [5&!71?\%R/^"5%C\=? U[\8O!.EV\?C;PY;F;7;*.$;]>LD !8D<+/$@)W
M\ED4CLM;O_!N9K%UXL_9:\<:[J$LEQJ>M^,)[FZN;J=Y;R\E6VMXS).7))?Y
M0/\ ="GO2;L@/ O^"L'_  2T^#G[%W_!/WP4WAKP;IL7BK2=4LM.N]<2/_2=
M3'V>42M.S,V[<R(1G)X/-:O[-?\ P1L^%_[97_!(7PZUAX9\,Z/\4;V&6YTS
MQ8\$H>"X2Z8J9PI_?H4!0JX< ,"!E5(]X_X.'[F$?L9:';KL6YG\3PF%21EM
ML4NX@=P <D#TYXS7RQ^R!^U/\8_VD/V4?#W[//[.VGRZ1J&BV+V_B_QO??NH
M- 6>X?,4&X$F7RFSD9<[OW97:)#T8?#>VER-V75OH9SK."NE=GV'^VO_ ,%0
M_P#AG'4M,^#_ ,+=!/Q4^-^H00V%KHMA\T&G2E,"2YDQL4+MW%7:/ (+,HRP
M\W3]CG2_V0_AYXC_ &G?VL?%EM\3/B?X;M7U.VCN9-FAZ7<(A%M;6]N$17FW
M$*K%  2&51MWU].?L%_\$Z/!7[!/@F2WT6.75_%6K)&VO>);Z222^UB8<EB7
M9C''N)(C4XSR2S,Q/RU_P55\6:]^U%^W5\)_@[X$\$:I\5HOA3<0_$#QEX>L
M]?MM&@=Q_P @V.:XN <,K;I?+! D24 Y'%>GB,QHT8?5<M6GVIOXI?\ R*\D
M1&DY>_5^X\8_X-Q_VL-8UK]H;QGX7U?4[>ZL?B#:OXJM89+AQ)#<;\R(L9<K
MN(<9PH^Y]YNWZ)_\%1?AQX4\??L)?$V3Q3X:T?Q+#HGA^_U*T6]6,&QGC@=D
MGB9AE95ZC;RV-O(;%?CC^W18_&S]C[]NVU^/E[\,;[X//XCU<ZE86:ZW::S#
M/,H47(>2W9HU,BECLR/O<#K7ZZ_M7_%UOCO_ ,$F/B1XP\(7$<Y\1?#J_OH=
MIC8K&]BYE'/&=F_W&..17B[FY^)_[.7[1'Q5_P""0WC;X>>/#:O#X6^(NC6>
MO7&G6VHQ3Z;XITZ9 -S-EE2Y0\;@-VY0%RK_ #?H%^U/\'/AA^U'_P %1_V2
MOB!9>#O!6O>&OBEIFL/J\TME!=P:ZT%M$\:W2%2DSQ"10'<%OX<_( /7?AU^
MP-X._;A_X(]?"CP-J=O%%+IGA*S?P_J(GFE.CW MU57!5@\B_P )5L@@9QD*
M:^$O^"4'A7Q-\+?^"F/P_P#A3XQ;7HKOX9'5XX-/U)W-K9M.@\R2U5B53S/E
MR8\!@ 3UH H_\'('[)'@+X+?'?P*_@7P=X3\(VFJZ&?M%EI&DQ6,,DJS2 R>
M7"J@L4(&>O'!R!7MG_!0?_@CI\)M-_X)_P!G\9OACX<M?AE\3?"GAVUNCJ?A
MUFTQ-3C(CWI<1Q* SY.X2 ;R1EV; K _X.@XVN_C1\-85.W_ (DDP:,G[Z_:
M' QWYP?RK[)_;]\5Z?X'_P""+'B*?49XX8I/"-G;1Y'S2,_DJJHH(+')_(&C
M<#R/_@E+_P %9M<\;_L ^+O$7Q7N;>_UOX7;+1M0A 275U=0("8410/F8)O'
MWMK-BJ/B7_@EGXD_;5_9/\/6E^- TF7QQXPM/$?BNXU'?_:*:7$7816GE#"R
M2!B.2I7S203MVGY'_P""/GP43X^?$'3?"UI>N=%O+BVUS7[0R-&DZVRC9+@=
M68N>O0,17[X:=8Q6%K'#$H6.)0B =@!@?IBO:J5:>'RY48K]Y5=Y/M%;+YLQ
M@^9\Y_/]_P %YO\ @G#\$_V*?&7P[M?A/X0L?"U[JUA<"_\ ])N+V2X6,@+*
MS3NQ+L=P8^9DX)*Y&3]<>+O^#>CX3_$?X9?!KQ9\-?!7A'POXKTJ\TJ_\0?;
MI+FXM]=L-T<ES!("TB%V ;DI\^[:QP,5YW_P= P*WQ7^&K$1_+I,V6<<*/./
M7VS@Y[=>U?27[17_  5(7X#_  S\(?"7X4:4_C[X[:WHMG#I^D6R>=%IA>,#
MS[EE^1=H^?:Q QAF(7->=A<+6Q,W2HQ\V^B\V:S<(6YMV?EQ_P %!/@?X*^!
M_P#P6?O]&\*_";P[K.D0ZC9-:>$;&UBL[749Y$1C"H4A4C>1DS'LVX^4@ FM
M3_@H_P#L/:S_ ,$Y;3X<?%$:A8^$/B7XRU6[U Z/X:6.VM/"ACV-'%;E>3@2
M%2H&/E95)&16-\5/V8/%%[_P5BTOP/\ %KQCJ6M>(M?U>Q?6M<T4I:WT4\T8
M8"W8@B,Q%@-P!R%R%&*Z_P#:$\'7G_!/G_@JGX3N_CPGB3XI^&=*U*%K'Q!X
MFDN+S^T--^Y%-N)82/!D%HP2,QD;02,S*7L^>E#9O?J_+T!*ZN?I#^T]\%-&
M_;2_X(Z1^*OBCX5TS4O'&G^#/[4@U#4;)9;W3+@1B1BDF-Z%MO)!&<\UX)_P
M;"_LY^!;[X:^,_&UYX<\.7?C/1];6UL+][2*2ZTR+[*A+0,REX]Q=P<$9Q7W
MO^W%K-C\0/\ @GG\0K_0+^V;3=1\+33V5Y;QK/!-;M&""@&<@KQCMFOC_P#X
M-A=4TV__ &>OB*RJT>J0:_''*LH:/;$+:/;U)!&[=SCKFL-MAFE\0_V%_@YH
MW_!=?P$+;X8^!H[;4? 5YK]S:0:7;K!-J27P1+IX=FPR!1G=MW%P"3GFOD']
MKSXX>%A_P71U*^_:7\.67CWX:^$)6T71-(U*Q,]IX;MG7Y+E[,H\=YN+-O7:
M<<.I;"K7Z(>)Y!XU_P""]7AI-.FCG'@WX43)JB%OFM'N;]S" &/+%58Y],<'
MMROC7X!_!_\ X+:?\+*TKQ3X?;PSX^^%OB2Z\*+K.E7C"\A1&#!R"%299$/2
M1&"ECCD4 <EX:_X)M?"7XD?M)?!S]H']E:S\$V_@ZP\22W/BK3-"N39Z;=J;
M>6$3I;$>5')$S &()&>%.W.<.^)O_!#KX;>)-;_:5^+/QO\ #.A>/-6\47.I
M:WX=074Y.CV<<+RQ#($9$NX'(Y4# %?(FB_LC?$W_@CS_P %,_AKH^D^+[G4
M-#\=:C!:VFHVSBVBU>S\S;);W4.<>:@);K(""""O?]N/VCK*UOOV>/'<=TT?
MV67PY?I.[MA=AMI 22.V": /P8_X(*_\$Z?@[^U5\9OB'IGQ)\ ^&?%FAV6F
M026%O<9B%F[R2 ONC*'D8 YR,5^OG_!*_P#8:U/_ ()]? S7O %SJ&F7VDP^
M(KVZT$VP=/*TYY"8(Y%95PZH0" 7&1]\]:^"_P#@VCAC_P"&A?B+L^:./28/
M*;[PQYL@^4]2, =:_9:4"*/A1SV'&Z@#\GO^#E?QY?Z7XA^"V@:[IUUK/PKO
M]5%WKVEAFBCUCRI5#0.ZD9^0@JI."6QQFL7]HS]@G]F3_@J9^RN^J?LHVO@C
MP9\4M#@CFM-(T**VT$WK*Z@PZE:^6!,BC>1*5/(X=@>/J_\ :Q\2?";]K;]K
M,?LO?%+PIIE_]L\/?\)+H^J7&IFVNYIF9XGCM=B*5D0 $[7.0!E&Q7Y<?\%-
MO^"5_C'_ ()17MC\3O /C75+KPG-?+:07L,TEKJNF3MED21HL+)&P4@,&'*G
M*+SD ^VO^"\/[(_@G4_V"-+\6ZQX-\-3?$+0_P"S;$ZY#9HMZ(EC*21>:!N=
M/EX!X&W@CO\ *O["?[$_[*L_[$WPUU?XH_![1?&?C/XQ>-;GPY9W U"2VN(D
M623$\1C:-BD:1H2(TQEN6YY^L?\ @I]\0=7^+'_!%SPKKFO[8M9UK^S9;M3N
M4-*5RQ8MRI.,\YYZUX%_P37_ .">5SJ'A']FSXY^ ]/U?5]3TKQI?_\ "4VU
MQK;O9QV31S1"X@AE)BC93C+1J&.<9YH ^G?@'_P2,\,? ']A3XO?#/XB:#X5
M\6>$K&]U/5O"DU[8P336-MY#&*XR5+0RKMZYR N,XXK\^_\ @@__ ,$[?@_^
MUY\8_B+HGQ)\#^'_ !IH5CIL,FGQN[QK"WG.&D5H=K+G '7/!SU-?LMXP_:O
M\$_%.]^-?PWT?7#-XF^'OAZ6372FUH=.,]K(R8D(,>]0,LI'RD?,,YK\5O\
M@EQ^S?\ $?\ :*U?XPQ?##XHZWX&\9Z?I$=SI?V&_2%-<D,C_N96P%V%1QT
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MKVM_#W]G[QWJF@P>.OAKIR+/K6C:H^VSU"[D5'C$\<;*5W)O&X$ 9X[5Z?\
M\&_EG\'-9^(/Q"\2_"6XU7PM::O96@NO <ZSO;:%*/\ 6/!,[NLD9; 7'(!.
M>,4 ?>_[7/PBU/XX? #Q%X>T?QCXB\!:G=VK-:ZWH=P(+RSD7YE(8JW!( (
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MGU\!?CY^US_P3HUWX9^ ;_X7^#/AUXDUBYL]:\1WTE]=ZV$D$?FI;VD02('
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M^"?VAS_\(=_;]YXGU&Q2RO\ Q#J=ZUS=76TD[PG^HC^8E\*GH#QQ7S]\>?\
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MC]<>+YY#<C74\2VT&HQS@?+,DT-HC*R?P\X&!QP*^_0@4\ >O2E5 HX 'T%
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M;.U@5)%??4AQ]1R..]?*'_!3?6[GXD:=X-^$>GR>4WC[5H?[2=9,,MC&^YU
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M Z5ZC&@7H .,<5P8K%T_X6%7+'OUEZE1BWK/<_-#XD_\&\]Q\5OB\WQ*UO\
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ML:=X3\11>$?$-Y;M%8:R]@E\NFRGI*8'95DQ_=8X-=*D*1D[55<]<#K2XP*
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MQJ\6^/O"7AV#0O$'CM$.O26<LJ6VIRH<B9H-WDB7L750Q[DUZJ$ [#GKQUH
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M22!VK]4R@8\@'\*3RUW9VC/KB@#,TO3+?1M,AM+=%AAMHEAB4#&U0  ,'/0
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M!$LGE)#/;@+#N(P, J <X![\5]*B-0#\H^8Y/'6D$"+T1>.1QTH _.OXJ?\
M!(_5/$7_  1HM?@?HL2CQK;6D>IQI)J20!]2#"1D\]$V[0<H"5(P!R1U^L/V
M#?V<XOV4/V4? _@=-.2PN]&TR*.^C6;[1_I+ --F0* _SD_,, U[+Y2[B=JY
M/4XZT+&$)P ,]<#K0!P/[3?B#QSX8^"VN77PX\-6'BKQCY!33]/O-473(9';
MC<T[*P7;G/W><8KY/_X(_P#[-/Q,^#'P<\3^$OC/\)_#NC7VIZM/KMYK8U^V
MUT^)9[F1I&,D2Q*8C'\J@L6!Z@"OO"D*!NH''3B@#\:/B3_P3,_:1\&?M]:E
M\9OA'\*O!GA]-.UT7]AI[>*X3'J4"\/'A0@B$X )4D*N\UYU_P %L/CMXC\9
M?M@?##2/BU\*+?Q#H=AH$=_<^"1>B47%[)O^T;;JT/G%5VIM/'3.".:_=BY3
M]WP=G.,A<X_S^5?%_P"T_P#\$G=5\??M/R_&?X,_&C7_ ()?%&^M5LM0O?[&
MM_$>GZA". 'L[E@JG'&588[<T ?$O_!-S_@JG\"_V6_BUIG@K1/V8)O@N/&6
MH1V7]K1:B^I2 2%0"\LZ^>\88Y.UMGMFO1?VK?\ @FI\??V9OV[+SX]_LT1:
M/XAG\23O+>:1>-#";0S;5<,LS*&C<Y8D.A7GYAUKW[3/^"2WQ ^,OQV\+>+O
MVA?V@=1^+VG^!YS>Z%X?TOP9:>&-.CN>AEN=DDS7''0;E /MQ7W-! L6 H.%
MXQCCUH _.V[_ &0OVI_'O[-'QEUGXC>,K?Q3\1OB5IC:1HO@:QOX[/POX:A8
M(#(HE+[IAR22QR"1DY!'RG\ /^":_P"US\!OV._B-\)IOA)X?UX^/;JVF_MF
M;QU:1?V:L625$&R0R9['>N,_A7[AA #G YX/'6@H#V''M0!\ ?L#_L6_%/2_
M^"<OCKX'?%#0[7PG>:A!=V.FZA::I!J8FCN$/S;4 *%&P?F/._VK,_X(P?LB
M_M,?L6ZGK?A'XB7'A"+X81O)=V,%NJW=]/<N%!9)D9"B?+DB5'/\(QU'Z(F-
M<=!@=..E-5$\S.T9Z9Q02XW=SYQ_X*K?L^>-?VI/V,/$_@SP+=VMOJ^IB/,-
MPR(M]$KAGAWN0J[@",D@<]17Y>^(_P#@AQ^U3XM_8_T+PBS?#O1(?"6K27FF
M^&-/9$O;\3 ^9/<WV\0[P=@"!=N%!SD ']TP,?C2"-1_"/RH*/S=^-?[+/[2
MGQ8_X)1Z)\+-4\)?#^^\;B\M;&6/2]7$$%E86X4I-F5?*-P638R(P7#9SGY1
MX+\0OV /VG?'/_!/OPU\$)O@O:2W/AG6FU2/61X\L$MYE(?"&'.[=E_NME<U
M^S@B4?PCICI2A !C Q]* /RP^*7_  25^)'[4?\ P2O\'>!=:TZW\&?%[X72
MRC1'&J)<V^I1Y+;796*KO! ^8<,F?NDBO(OVNOV+_P!NC]MWX3>"O!_B;X8?
M#_1QX!MA;)K5OXPM_/U5PB#S3$L96/A&#+YBJ=QP.!7[5^2N[.U<^N*#$IQ\
MJ_+TXZ4[BL>/_L5^'_%O@3]EGP3H?C#1M+T+Q%I&EQ65S96&HB]@7RP$5EE*
MK]X -@!L;L!FQD^'?\%;O!_QC_:"^#U[\,/AW\*(_%.G:]%#-/XCNO$MC8Q:
M;)',K>6L$W[R0L%QG*8W<%J^T$@2-<!% /4 =:=L'H/RI#/SX_X(W^ /CS^R
MAIT_PM\>_ BYT+PR]S<:I_PF,/BW2[N!I61,0FTB<SC., \]!VKU#_@LO\!_
MB7^T5^Q1JWA/X76<NIZK?W,*7VG0WB6K:A99/F1;W=5 /<9)(!P">*^MM@ST
M'7/2CRE*XVKCTQ0!^!_[1'_!(/\ ;"\9?LC^!=)B\'?#&%/AX\D6E>&](N$3
M6'^T$>==SSAUA:1?E ,<@X&64D9/ZU? 70?$OQ._8QL/"7QX\+^&_#/B#6M)
MDTV_T"VU47\?E",H<R!55F*#>0N0-V,\5]!W6$@8Y"^^!S]:^)/^"C/_  2H
MU3]MOXW^#/'7AKXK:W\,-8\-0M97$UC8"Z9[=R6987WQ^4[?.I9R?O XR "
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M7\_N-526\M6.\I1_"OKTI0@'8?E2T5Y?F6)M]J @!S@9^E+10 4444 %%%%
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MQJ,N2./Q_.O/_"GP@TW4_BY=^/[Q;NZU6]M([2R2Z&$TRW"J&CC7)&7<,Y;
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M "BBB@ HHHH **** "BBB@ HHHH 0J#V%+110 4444 %%%% !1110 BH%'
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M_(OQ[LR]C*5I3U\CZ*T'P[9^'=*MM/LK>WM;&TA6"&V@B"111*,*BH.%55X
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M$3[_ .M #Z*** "F*[&3&./6GT4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[QQXATKPKX3DF86NZ*W@LA;*8I(#.D0G+3NDN(LX&,AC@UR'[;_QW\;?'O\
MX)R_L\^-+CQ%?:CI%KJ8T7Q XF2UNAK*[A#*<(I(7R9<.AR &SR]?0__  3R
M\/S77_!27]LU;==MF9DLXVMDB_UA-TS,$4#<QWKG<.3GFOE;5]6^V_\ !'SP
MWH]A%!<1Z;\<H($^V*L<<B;KB4!V_P"6&,@97& N.AJ0/U:_X)]_";X@_![]
MGRTL/B7XSOO&/B2[N#=^;<-YKV<3A2L(D/,F,9+$]6(Z 5\ ?MQ?'WQ'\*/^
M"COQO\ >"+C3=>UCXW:#IOA5-/:5[<^'[NZTY[>*X>7<-IQ\_P GS!0."0HK
M]9-"CSX=M0&"_P"C)C# JF5XQV./Y8S7XP_!_P#8S3]MCX%_'/QKHEXK?'_P
M!\4[SQ)I.KR7P::<1&*1+:3)VK;N$ R!D-%P>M 'W_\ \$\?$G@/]E&S\/?L
MH#Q7<:W\4?A_X6MM5UM&L+A(KDS',DR3.FPAI&W8#G < =&"_/W_  <!>%O&
M\?B/X5:UIVI74GA2>^&B+I,-U]G\O4YV(CN)),$89"8P6QL(8@C<08?^"-?Q
M^\8?MO?MP?%+XJ^.5T[3;RT\)Z+X?T_2K'S)8+14-Q).?-?KNG+L ./FKUC_
M (+HSI9?"+X/S%8S+'\3]&,1>,.H8,Y&0>".!P>#T/% 'S3^UA??M ? +P?\
M!_A9)XR\0ZWX_P#'D&K6-Y!IFH.XDCE>-H(I+F9SYK1*Y#/L7Y$."<"NH_9P
ML_C;^S]^V[^R_P#"SQ?XOU>*>'PIKU[XCTB/44N+"[A2Y9;8DK@O(JE<[LA?
ME]Z]R_;%DMV_X*A_LHM+%;1^7'K!\UF&\;K8!5P>!R.,>_85'^T'HS2?\%P/
M@C>R20_9SX&U1;?S(E"B59R7V2_>+LLB_*> %R.2U'6X;[G"?M!?\%&?&_[.
M7Q7_ &Q+B6_GOX?A7X=T2\\/V 6.6SL)+W]VL@0XD+;I%9RQ*':-HQD'E?@#
M\"/VW=:^$GB*.]^(5CK$'Q)\(_VG:ZW>7\,G]D7TDJ9L8XBA$9>W,BK(J2(I
M(;<#T]6_9H^'6B>(/^"I'[76EW8MO$MKXGTW0EEM=7M5U"SC3[*\<ENZ,2&B
MW!LQ\#MQ7-_LZ?%CX_?LP_M.W_[/WQ&_X0K6?#NI^$;O4O VJ>$]+BT?[$D"
M;$@%I$%6%!DJ/E&"@"LPY !G?\$ _ ?Q1O?A/:^-]:\1Z#;?#W4X)[73O#>F
MH8_L]S'<,LLTJA A<L&^96.>.%Z5#_P57_:#^-^N?M9?\*Y^%?BB#P=I/A#P
M5<>,M5N9;F2W>^*%L1AHP6W84;5^Z3NSBO6_^"!>G3:3_P $M_ ,-U)OG@FU
M!9GWELM]LFW$D^^37D__  7K_9LU&PT;3?CUX8\5WGA_7O#VD/X1U.RCF>./
M6M-N9F<P;U8<[V?<N/G5N?N5K1ASU%$3V/!_@U\3?BWH7[*7PQ^%?PKU,:/\
M6_C]?W^N:AK.K,\?V*TC8JLOF$N49EBR=L9]A7TC^Q]\>/C5\$?A[\>/AC\7
M/%.C:YXL^$OA5]?M/$%K>M<W"1RVDTD;%6@1Y54QE]S+NYV[3C%?+?A=-<_:
M3_:<_9@7X0_$:R\"ZY#\-CIT^L6ZVVI+IAB>3SK-K.3;N92?NDG/#<[:^G-8
M_P"">'B7]G+PG\>/BO\ $3XPZA\2/$7BGX=ZAH>H7 T"/3]BF"18Y/*B<IA5
M<?(% 'S'^*C$5?:5IRUU>E][+8(Z*R/EGPG^U;^U;JO[/6M_M!1>*_$<'@W2
MM!65=5N/(>PU+RKJ",LEJ[(R;@Q9G$9++&X!);;7W9^VA^UAXNT[6_V9M+\"
M:_<V=S\5]=6:Y,,$0DO[*&".:?"3@%8]KDL N0O)P<5RO[)'P<G^+/\ P0$T
MSP9'8OK-[>^ Y[?3[6!$+7=Q'$SVR8;Y26D2,$'@Y(/%?/'_  3Z\=:C^U?^
MW3^S+-J.DZ7I\?PA^%U_::I81PQI+IFLK.+=RBIE5A,2G;MP/FX8Y(K(9WUA
M^V'XP_9R_8:_:,\46NM7VI^)K;X@WNE:)+>3O=M:++(%18U(8!47<40;5X'7
M[IO?LX>/OVD_V'K'QSXX^-<]_KGPTB\%7/B2*ZN]:M[U;2_B :.U=_+CDC:;
M< -L9C' 5L\5\Z^(O#_B3Q7X+\86EE&U_8?\-5Z;>6,<VI6ULAM%;S)( US+
M$)I&S(!&K.3@]@:_1;_@L;\2XOA1_P $SOBMJ4T5\[Q:,%2TLP//*M-$C%1D
M9"!P3@D "@#Y!T?QQ^T1\#+GX>?M$>,_'/AC4_#'C?6K2#4+":2Z@33]/N_F
MR481*HC4X51'NW!<[LY';_ML#]H;]KS]K7QMX<^"7CB+PQ+\,;'3[RTM?[4E
ML8M7,\:3JKA8W5\@D'>4P" ".:S_ (/_ /!)_P")?[1G[)O@2/6OVGO%ESX2
MUBUT_5[W1+_1([^*39LD6))3."F,#!Y ;DJW2K/_  5._9P^(7[#OB;4OVK?
M@YXOU**Y\/V=K_PEWAV\NO\ 0]5L[<+$F$.Q'4*>8V.4W,R,.@ /T.TA-;O_
M (4Q1ZE!Y.N/I6R>..0.$N#%ABKYP?F/J:^8?^"(=YIM[^P_$EK%'%=0:]J<
M-\G\2R)=2!=W;.T+R*^B_ ?Q,3X@_!/2?$>H+!8P:MHT=_=)#*EW';*\(D;]
MX-R.%!)& P..<YKYV_X(=:=)'^P5HVHFSO+*VU?4]1O[<7$$<32PR74C)( G
M/*X^\>.W% &3\ G@@_X+G?'B'[1]GF;P/X>G%H/+47)/GAI "-[$< LI YY[
M5S6F17,W_!>C5SX?GM(/)\+Q+K\4SN#*K1)M,:C@O\J'GL375Q_#V;X??\%M
MG\20:QI6I0^/? 'V>ZTZVM0MWI LY1LED99-[I*9&PS+G*LN< 5R.@WUZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYUR+1-*M^%W@O-<M@D)%&H+,QP0 !]2.M?''A3P%\1/^"R%Q9:Q\2[&]\ _
M"&5I+/PDLL\.H^*I(W;9-<OA&CA /W2>60$ <,>\_9J_8K\7_'OQ]#\7OVDF
ML=;\0><MYX8\'H%DTOPA"&5X]Z[<2W0(!WDMM.<%NH^R[<"/Y,*.N.,9 _\
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M\,?%KXY_\(KKMKH?A34-*N9=#NQ!>:/:D><BLL8C5Y7<.<PAL8'[P[17Z,A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/3OUJ7%0QMEOH2,?C4B')KY_9V-!U%%%4 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E5_P<Q_LN>"O
M'GPJ^&OBTZ-8V_C+4/&=EH-QJ\4"?:I].:WNGDC9L9<J40KD_* V*V?VS?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_X+P_MP:=X-\%Z=\*=*UR<:MK$JS^(;*U5&>.R&&57=N$8D;AS_  C-:8+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.[MW?;R[CC)-M%3XC_MG:#\*OVIO"WPOUBWO;:Z\9:<]YIFIL<VLLX=E^RG
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MQ@'Z6_8'_9(\ _LA>.O%^@>!?%=[JJ>5:G4=)NK]KN;3Y_+&97+L6W2CYL8
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M7GCKP!\./A=IUTT-S\0_%=M;3B*5MS0(VT[D'WD#2;SGC,0]*^NK?X;:=/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDY(3C/?D#..#V[T /H
MKG[SXD:!IFO#3+C7=)M]2>18_LLM[&LVYL%5V%MVXAA@8H\0_$;0?"-VD&K:
M[I&F3RIO2*\O8X'=>>5#%?[IYQV- '045S/C+XM>&?AWX(D\4Z]XDT+1/#,
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M!]T_ O\ X+!_ #]H7XZGX:>'?'LR>-9D$]AINKZ+?Z1)J\)02":V:[MXQ*C
M\;,DX8J&7:U>H>)?VQ?AWX0_:+T+X27?B>T3XB^([<W=CH8#/<& ),_FN1E5
M4B"3&2&XZ5\9?M-_\$\M(L-#\/\ Q8_:R_:*U3Q7;?"RXCET'5-(\%Z=H)MF
MEN(GV20Q0W4MTSR1VX"1*!@/B/YR1]UW7PB\'^*O'N@>-;_PUHE]XJT*U>#2
MM<GLXWU"TBD4[TCE*AU5@S':N!RW H [&%LMC)..,'MCBI:@@PL^,@-LP5R,
M@ \''7UJ>@ HHHH *1NWUI:1NWUH BNXPT?.1[CJ*_.CX\_&'P[^R+_P6:@\
M6_$F:73_  [XC\(-#I.L7!+6VG!2 5 C0GADER&[SJ>]?HUG<*XGXZ_L\^"O
MVC?!IT+QMX;TOQ'I@D$R17D?^ID'\:./F1L9&Y2#@]:[<MQD:$I*HO=E%Q=M
M[,B<6]5N<S:?ML?"*Z\)6VN1_$KP/'I5U&)8II=9MXRX*E@-K.'WX!.W&>.E
M>(_%O_@MA\*/!^IQZ1X)T_QG\6O$]PS0V^D^$=&ENI)90,@%F"C;R,L,XX[9
M(WO#/_!&']GKPYX@DU-/!!G\UG9;2;5;J:UCW8SA"_/3OG@D5[U\,/V?O!'P
M6LC;>$O"?A_PY!(<R#3["*W,AXY8JH+'@<G/05UWRBCJHSJ/M=17W[DQ52_O
M/0^6+VU_:I_;2$ECJ,>F_LX_#V^A02-;7:ZMXOO8WSO5)!B&U.,*?D+)N)#D
MCCYH^#=O\-?^"9W_  5#\>:3\3FU'^P-?T6V_L#7O$K2:I+( %,KR2LKLYD=
M2,C@&$@_PU^MWE+&<C SU]ZX/XW?LR^ ?VB=-BM/&OA'0/$D42E(3?6:220
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!,48Q2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]AGV2F"W@@A"7$*X>:YC!W.%4$GH,']%OV&_^"2^F?LR?&+]H'PA?:%%XB^
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M\')*1:O^W9X$L8X%O+G_ (16SB,$4GEF1GU"\/EE_P" N&7YNV[- 'TJO_!
M/P)\&?VC?@C\4O@'I%MX(N_#.J0R^*K675;J5=0L2F6*-(9&$F2R% X1EDY'
M K\[/^"S'['7@+P3_P %0=4\/^#_  YX>\'6&O/8O>-;VNZWAN+G89Y1&$ 1
M?G4X7@D$XK^BGP?&J^%-+)PQ^R1-EAC)VC)_E^5?A;_P7L\.W/A__@J/!<31
MC&M:5IMQI[[C'M"?N>&[8:)NGJ: /UF^(W[$OPC_ .&)O$?PTN?A_P"'(OA[
M-I4UU/H=G MK") AD\V)\8BFWJI60#*L-U?!7_!,?P=I/['/_! /Q=\8OAOX
M;@T[XE^*=!OY[[4H/->>X>"[NK>WG((<?Z/$[2?*FT[78CYB:_3GXFZK9>'/
MV;/$&H:Y?+8V&F>&[FYU"\9PPMX4M6:1R7=5.%#$DNO0_,O4?#'_  3N_:0\
M+_L8_P#!OCX#^(7C'2)]5\*:9HP;4K*VMT=KF&\U+R&)CD8"1?WX9]WWE#>O
M(!\O_P#!*#X%_L._MH?LY7'P_P#B;X7TZ3XO:Q?F[UO4_$>LR6NJ^(;R0L%F
MT^\6=)!&0P'V>/8NY/FC<_O&_1[_ ()5?LF^+_V// GQ'\,^+;V_U=;KQSJ.
MI:+J]_JC:A>ZSITHB,%Q<.W[P3D JX<L<QYSS7QK^VM_P;JZ1XZBO/B+^SIK
M,&BZO?0G4HO#5W-ML9RRF6,65RI#VSDYVA]R9=071$->M_\ !O-^V'\0/VCO
MA%XV\->/[W6=8O? 5_!;V]]JA>6\"S*Q-O+*47>T90GYCOQ(,A5VB@#ZF_X*
M&_MH:7^P=^RUKWQ!U"W:^GM56VT^TXVW%U)D1!R67" _,QSG:K8!.*_-W_@G
M=_P33/\ P5]M-2_:"_:G\8>)_B);ZOJ%Y8^&_"46IS:7I6C6L<Y4Y-N48R!E
M*@0LB@#YVE;E/I[_ (.)?A;?>/?V _[6MH7NK;P=KUKJE[#%"97,!66W)4#I
M@SKDG@#.>*T/^#?+X@:=XN_X)N^'M-L'0R>&=3O[*[$;@@2RW#W(&5 &"MQ&
M0>I!Y[T >+_M<_\ !!+0/@U<^ /%'[,\7COPQ/H/C+1K[Q%X3TOQ==M8ZS:)
M>1M+<'[9-*5FB7D$'&S>=I8**\X_X+D_M_?$;QO^T=IO[-/PY\6R^ M(NY--
MTSQ+K%D=NHW!O98T>-)0P\M8XI,90$-(6!Q]Z/\ 8:^UF"P,,<LT$<EP_E1(
MTBKYKC)*J#RQ !.!Z5^#W_!4CP;?_"/_ (+2PZCJNF.-.\7^(]#U'3+R.W<1
MJH:..0AV 7.0=^#P8SZB@#[Y\+_\&ZO[*MG^SQ;>!KOP%)J][LC>X\47=R[>
M(I[@8<SM=J$PQ8;B JQG/W.17SO_ ,$2OVO?B%\"_P!KCQ'^S5\3/%FI^+[6
M"[N]/\.7E[<R7TME<6F_S(?,8EUA:*/<JN<*4PN-U?K?8A5M49U.%1>GW54'
MCOCW/X5^'O["ND?\-*_\%X/$>H:5'JAT?PMXDU?5KV[CA$ENVTND?[SL'+*1
M@\X- '5?\%2/VK/'O_!0;_@H9H7[,/@;QGJWA7X=G7H]!\50V,JP3ZOY3.U]
M&71A(P58R @<9V$XZU]>_&?_ (-^_P!F;QE^SS)X4\/?##2_"6LZ1:N=#U_2
M9Y+?5H;L+B.1[HL9)_FP,3LW!)!5OF'PE<1M\ /^#BI(=7:33SJWC>ZU&*\:
M/R8I8;])&BVR<%@3+Y9&<$AA7[A>*M9M_"WAO4=4NKR.RM;&VDN9[F92\=O&
M@9V=@""5 !. >@H _*W_ ((1_M\>(/CEHVK_ +.'QA^S^*FT[2)[?3;S4LN^
MKVB_N;BSN0^?.P"1D\E2=XZ$_)NB_L3_  U\8_\ !=Z^^%&H^#-+U'X;R>)-
M0M_[ /[J!(Q:SNH0*5("MM8;&4@(<'M7>?\ !O%X)N_BE_P4 U[Q1IUI?QZ-
MX7LKS[1=26.V%);B0;(2_9\;S@DDJ%)J3XQ?!Y?VBO\ @XCU/PK8^*O%?@N*
M^U2=I]:\*ZF=,U6T"Z=(6\B=48*S. #N&"K,.I% '-_&KP7<?\$:/^"R6DZ5
M\!M9O=$\&^)$L$N?"%U>W%[IT9NY%CEB<22,0!A'C?#,/,(W  YZ/_@Y&_96
M\$_"SXP_#[Q9X1\*^'_"FK^*["Y&KMI=FMG#>RHZ'S',:A2^'.YR,G"\\5^G
M7P1_X)*?!SX)_%R/X@#3_$GB[QXOENOB+Q7KUSJ^HLZ(5$IDE8@.0Q!('0 #
M XKX3_X.E-,-YXG^$D4&(F2VO<%1@D;XAM7D9/) Z@9)Q0!C>)/^"6_[/'Q?
ML-*^#_@GX:ZGX:^-/B?X31^/K#QMI^L3K;/=!S"EO,DLSK^]E4%AL"["S<%1
M7H?_  5=_8?T:#_@D;X7\4^,O".F:?\ &'P#H^DZ9<:G;.)[N' 2*:W:>-29
MXB22-W^R1CFO0O\ @F?^PKXL_9&_;9N==\WQCXN\%^.?AKI=P?$.M:H+LZ9?
M6[;7T\;R)%0@[XUQL1<CBKG_  5:_:>\)_M>?\$<?&/CGP3>R:KX:FU,6<%V
MUNT273VVH&W=T!YV;XV()[;30!\T_P#!.'_@BQ^SY^UC_P $MV\:^+?"\5U\
M0=1M]7)UZ#5;J)]/:*686[>3'(L/RJB$K(AR<YKH?^#9S]J;XD:MXN\5?"KQ
M#K%[XF\)Z+9+>:=->2///I;A]AC$A) C<8(C_A*G Y-?//AWX&?'W_ASK:^.
M_"7Q;\6WWPT$]TOB+P.EG!:01VIN)%$UO/%MGDBRX\Y-PW$[CPA(^X_^#<;X
ML?"76OV89O#WA6WMM$^)%BQ/B.WFR+W4(P[F*XRS$.@5@"1]QB5;G!(!]J_M
MP_M.Z5^QK^RIXU^)&L26JQ>%]-EN;:.X;"7%R5*P1GD9#2%0<'."<5^>O_!L
M5^VC>?&_X<_$3PCXCU*2Z\0KK!\26(GN\LUG<A24",S$;) V?+RH#+DC-=;_
M ,%4?V@M6^+7[>?PR^%?@WP!\1/BSIWP?N+7Q]XUTKPC>V2""X8O_9D-VURR
M;"IC,X7=EQ(/[HK\_+CX]Z_^P#_P5WL_B!/\+/%'P9TSQ%>_;5\/^(W1UGTZ
MY8+=-YT$DL6U#F3;NR"L:XQ0!^O/_!2S_@G&W_!17XD?!G3]<DM)/AIX4U.^
MU'Q58&XEANM1#11BU2%T (^=7W_,#@]:_(C_ (*4?\$^OAU\%O\ @J7X3^&W
M@W1K;PW\/M3N]'BO+.2_O+Q56>6-)V\R:1W_ (F'$B[<Y&,9']$?AS5;;Q#H
M5K?6LT=U:7T"S0RH_F(Z,H((;N,$<]Z_#[_@M-')-_P5[T%89?(FDN-$C64+
MDH2\0!_ XH ^NM,_X(2^ ?@5^V9\//'7PAT?3M#\&C3[_1/'6@ZCJ=Y=PZM9
MW$$B!XO-DEWNS,J/$65-B@XR>?S0_;@_86\$_#W_ (+%P?##PQX>TK1/A[J/
MB+1[:YTJ.\DABDMKEK=KJ/<SE@'!( 5P1QM'3']'>BQ>7I-KDG(A4%L?>X%?
MB-_P4:US3+__ (+Z>%H6TF9OL.NZ!%<-;H=\KYAVN=N#P63)/9: /4O^"^7[
M"OPI^#W[/7P]\1^%/"]EX;U_PW-;^%[%K&%\RZ;'&PCAEE#%BD6U-N[+8ZG
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MEX?N+VV>WNK&2RDD1;J15G*. V9%_>%N =V0 #7T?X&^*GA?XB:G?VNA>)M
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M$])_:+^!OBOP+K,<?]G^+-+N=,DE,"3-:F:-D6=%;CS(V(D4]F0'J*[1(UC
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M+M6\6W%[=M?7$MR#%;6TA4 QVT.3Y<?&3EF+,2Q/.!]*;1Z#GVHQB@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***:YP* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4=:** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!1]YMPPO?GFC7H2Y16Y8!8=\TJN<_P"-8@^(N@H>=9TM>-Q#7<?3_OJLJ_\
MCYX)M-4%DWB_PLEYN"K VK0AV/7INST!K982ONH-_)F#Q="+LYI?-'8[L_\
MUJ$;)JMIU_%?V\4D$L,T,J;T='R&4]"#SD>^:L)_K/PK#5.UC=.ZO<DHHHIE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[$$A$4L&9B%8A1DD*>.*^"O!/[7?[9?[;4]XW@'P1H?PS\,%W-IK6M6#PNZ
MC 'VDN9<@\M' 4!'WAWZGX=_\$.M)\7:W%XC^.?CWQ1\3_$LLFZY@^W%+)@0
M<H69?.9<'@(8P/[M>U_86&PFN:8A1M]F'OR]'T1X4N(<5BX_\)="4O[T_<C\
MNY8^(7_!>WP-K-]'HGPE\+^,/B=XGN&_<6=KI\L"R*,9*@(\SX) ^5,=>1WH
MQ?M,?MP?%CQ/;VVD?"CPSX#TR]),=SJR._V9&'#3,TY;(_V8@1G!4]OK/PIX
M0^$W['7@NVL[.'P7\/M'C'EQR3/#8!\Y/S22$%F/).XDG!/:ODW]KC_@O-X#
M^&4TNA?"BUD^)7BL;XS-'%*NF6C+PI=N'E!/3R_E(_C' /J99R5)\F6X%37\
MU2[2\WM'Y7/)S*GB*<?:YICW%_R4U^'=LR]6_8(_:Z^+NL7M_P",/V@H/#*J
MX,<7A^[NTA8>I55A50 >G.>_K7CO[5?[)_@W]F"S,'C[]KGQ=:ZM=J/.LK1Y
M[K4)XRN3OMX[C>JD$<L<-QQ3-.NOV[/^"C.JDP?VG\*/"LGF+NDAFT&S,,BK
MPH(>ZG4@\'YEX;D9KT_X$?\ !NKX4T?Q3;:Q\2O'.N>,[E2)KFUL4%K;74G<
M22.9)70\@D-&Q]J^DJX]X%*./Q,%;_EW2C%M?]O6T/F:66RQ<N;+\+4G?[=6
M<DO6UT?FUIGA#1?B5\8!X>^%.E_$[X@131PQ1->VZ"YDN,#S&\J$E88]P.W?
MR!G) R:^R_V6_P#@WN\7?$&^;6_BQXA?PG#<2G_B2:>RW=]Y)&-KS<Q1OS_!
MYH'<D]/U1^"7[/O@G]GWPS%HO@WPSI'AZP1<%+.U5"^./G;DL?=F)KMI5"L.
M&'/4 5XF8^(V.G3^KX-<D.[LY/\ 0][*O#?#4JOUG&R<Y/[*;Y4<C\"O@_I?
M[/WPMT7P?HC7+:5H5JEI;F[=6F95&,L5"@D^H45V#'!R"!67XE\3:?X/TR6_
MU34+#3[& ;I;B[F$440'.2S$!1]<"OB?]IG_ (+Z_!SX(7-S8>'/[3^(6I6S
M;&;3 J6"N/X?M#<-TZQAZ^+P>68W,ZS^KP<Y;MK3\7H?;8O-,%EU)*O-1BME
MU/NQY-O\0'XU6N]1CME+R3I'&@)+-(%4?4YK\:]1_P""KW[6'[9^JWEE\+/"
M-_8:=+,%1_#NC2W;608':LUW*IC4XSSM3D4O@C_@D3^U'^T?I[WOC3Q)'X>%
M[= 7D>OZ]/<7CKR6?RH4>(CT4LO7M7U=/@B-)<V8XRG1\OB?X'RM7C>K5GR9
M9A)U?/X5^.Y^RFFZO!JL2RVTZW$4@RKQG<IQ[]*N*>:^0?\ @G5_P3(U+]@K
MQ-JMX?B-J?B6SUJSCBN-.:T\BV6=2?WJY=CG'';K7UZA^?OTKX['T:%*NX8:
MISP76S5_DS[/ 5ZU6BIXBGR2?2]Q]%%%<IVA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M15;[1E\;^,X8$\DG'';'4>_-"W $V"<,1G83SWQWQV/Y&@"S135.3_GBG4 %
M'6BB@!,4C*,=*=39#Q0P&#!JMJA,=O\ (P0YZ[L'] ?QXZ9SQ7GO[2O[5'@;
M]E/P5_;GCGQ'::#9-*L48*O-<3NV<+'#&#(^<'.T?* 6) 4D?EI\??V^?C5_
MP5@^)&J?#SX'Z/KUIX*@!2\^RR);F\C,GRRW=RX40)A21$KC<H.?,8JM?09'
MPSB,Q?M9?NZ2WJ2TC\NY\OG?$V'R_P#=03J57M"._P ^Q]0?M]?\%O\ PC^S
M/JNL^$?!5O\ \)EXVM%,32HZ_P!D6$O/$DH+%Y$P/DC4KNW*SHX95^=OV3/^
M"8?Q&_X*"_$$_%?]I+4?$4>F23 66D3AK#4=5 *,"Z!0MO:.A=2D.R0A6QMX
M9OH[_@G;_P $8O"7[-MC8^)OB+;:?XQ^(HG:Y0NIFTW27#(\8A1P TJ%01-(
MH;)^4+BO>OVD?^"A/PF_98*V_BKQ?;0ZDQ,8TRP0W=XA ).Z*($QCC&7('(Y
MKZ7Z_2PO_"=PU2E.H])5+7;_ ,-MEYGS?U&OB$LQXDJJ%-:QIW]U>O=^1ZOX
M,\+:;X)\/66C:38V6EZ/ID"V5I9V\ BA@B50B(JCC 48QCMQT-,\<?$OP_\
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MQ#8O\1_$%O)O-UKJ@VBG P$M0/*(X!^<.V<_-R:^T+>VBM8]L:1QK@ *J@#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)6Y:%*UEY2?3^K'G9'&M4O+)*-V]Z]56;\XKJ>%ZO\9?VL_^"C@EM_ .C_\
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M:N+@L3B[PH]+*\I/^['KZ[=3XK/>,*6#G]6PR4ZG=OW8_P")]_(]%_X*3_\
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MO->M;=!^ZB@\(7T:@=?E00\#I5H_\%I_@)$N[^U?%6/0>%-0Y_\ (5>GP_\
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M /@?)$D9^$_@/9&[2*O]BPX5FSN(&WJ=QR>^3ZT >.'_ (+=? \I]WQTWS(
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M,4@3PK(/LTHX\M\O]X]NW%?0+_\ !/[X-N^X_#SP^<+L'[MN!G.,9]>:C/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%?
M\%(/C1XT^ /[(_B3Q-\/]'NM9\469B^SK!9-=_94W@RS/&O)58P_/\)()& :
M]UID\0E3# $9[BNC"5H4:T:M2'/%--I[/R,,33E4HRIP=FU:_8_G4^#/@SXK
M?'GXGF_\'^%]=\9?$22[%[+J=_8"[M[*0KD7#R3@1H^X@B60[1CY,' /WA\
M/^""7_"::R?&'[0'C+5_%/B34[GSKBPT^Z.URK?()[J53+/E%4801XP ,@5^
MF:Z?%%(62-$9NI50-V/6I$C"8[8&.*^[SOQ(Q^-2CAHJDK6TUE;M>VQ^?Y/X
M<8+"MU,5-UFW>SVO^ISWPR^&OA_X2>$K30/#>C:=H>CZ:@C@LK.W2&.+IT50
M.3U)/)/-=&B*TF=HR5 )QU'^30.>.PIZ_>_"OSR4W4?--W;W;/T2$%!*$%:*
MT20NP>@_*@( <X&?7%+106%)C%+10 4444 )BC:#VI:* $V#T'Y4;0.PI:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<<QX)P"<$XS
M4E1W/*KS_$#C.-V.?\_2@#X\^'=_9^/O^"N?QVTJ[L8-6L;#X<^'--O5N4:2
M"U$TNHRFV(<F%DD261V&TYPW!R0?CW]HWP;XL_X(.?'7Q1XC\*V']I_LK?&B
M66TO](MHVDNO".I2VDB(82/^66Y%*Y^7RMRG)C#-]\?#_P#X)W6?PX_:[\2?
M&6P^)_Q7F\0>+]D>KZ9=7NGR:1?V\1S! 8?L6]4BY",KK(F6"N [ ^S?$_X;
MZ+\:OA[KOA3Q'8P:EHOB"RFT^^MI(U?S(I$92"""JD!LJ3WYH _/CX(^)_AC
M\!O^#;3PK<_&IM2E^';>"[<:M9Z3/LO=1CEE\Q;:']Y&6=RP1DWKD;\D+N(^
M1_\ @HKX;^-?B_\ X)[_  FO/$G@OX9?"+X1VNN:3IW@'P=9!K_Q#I:M93^1
M<WEZ-D4>4!#111DDLI9@1@_K#XZ_X)M_#/XE?L$O^SOJD.K7G@ :;'IT$DD\
M<M_9"-P\<L<K1LHFC8 JQ0],$$$U\Y^)O^#=+X>>//!&C>'?$GQQ_:?\06/A
MQ(8M"BU#QO#)'H21A%3[/ MJL (5-H=HF;!VD[5 H Y[_@M-X!TSQU\0/V+[
M/6++2=2DD\?6MKG4;,7T#J\EB)8RO4H^P!E) ;'/2N;_ ."OW[/'@?QC_P %
M+_V4K#4O"'A.\T_5KX6FIPRZ7&4O8(IH%CAF4+EHPK%523*X9EQ@G/T/XI_X
M(I?#_P ?)\.!J?Q$^-U]#\,;^75K*&_\3)?-J5Y)=+<F>[>XMY))'!1$4JR;
M8QCKDUU_[0W_  3#\.?M'_M1^%OBSJ?C[XFZ3K_@OR#HUCI]_9'2;)HSN\R.
M">UEY?(WG<,X'H* /E_]M[3[;X(_\%T/V:];\/:)8Z>MUHO]E3K;VL-O'<":
M2ZMOF,8#L8TD!P3M&Q<"N#\>Z#K_ ,=O^#AKQ]I-_P#%?5OA#K6C>$H-,\'W
MEK;:?<W-_:O'!+):VQN8G0[S+--M1?/R6*LNQF'WI\=_^"<_A#]H;]JGP-\7
M-6\0^,[;Q#\/88HM+L+.[@CTR9HYI90\B/;NQ+&4ABCJ,(@["L[]M_\ X)6_
M";]OC7-+UGQ?8:KI?BO24\NVUS0KM;#40@Y56D9&$@C8;TW*<,!_"6! /%OV
M;?V+OA%^QK_P4C@GU7XZ?$KQ?^T%\2=&FU6XTC5KN%;76K.)O+^V30VUHJH8
MP72,RR!6*R[%X;;]H_"#X!>"?@8=7_X0SPEX=\*CQ!>-J6I_V5IT=G]ON6"@
MS2!%4,Y"KDUX;^Q#_P $IOA7^PEK'B;7/"C>*=:\6^+[6.QU3Q/XBU%KW66M
MXXPL<,<F%6)1MW;4C!/[L$E8XU7K?V&/V"?#'[!^E>*++P[XB\;^(W\7:D=7
MOKCQ-J$-Y.9B,,59(HVP>IW[FR>M 'O5(1G\.1[4M,G8JHQGKVZT >+_ /!1
MW3[:\_X)_?&V.XMH9H?^$$UIF5XPX&RPG=3@@CY2,C/0@'GH?R$_8<_:QT3_
M (*.?#OX+?L2)K>M?"OPUIOA*.Z\8IJ$<FF7_P 18(]CIIVCRJQ)MVC\QY7)
M#21;_+0JK2K^E?\ P68_:W\-_LV?L-^-])U6]9?$7Q"T#4?#WA[38[*>[GU2
MYFA\B18Q'T*+,6RQ'0GD*:^'?@O^R%\./^"OW_!)3X<VG@B_M]#_ &C_ -G_
M $FQM='UQR]EJ/AK4[0AHH+F7RVS;EHPZD!@I 9,<@@'ZU_#;X?^'/@7\.=/
M\,^'-+T[PYX:\-6:6]I:6J+!;VD$:X7"KPJ_*/<\YK\Q_C3_ ,%ZO&GC:S^)
MGBKX,^,_V5M)\*?#^]GM=.T;Q_KT\7B3QK';+NENK*&.XAVQ2?,L(*EG9&&"
M66NW_84_X*?ZQ^UO\/?$_P"S7\>-.\3?#3]HR33+_P -^=;Z9=00ZP_V9HGO
M[6XBB,<$B[Q(<G:"0Z,RG:ORK_P3?_:&^$W_  37^'>M_ +]I3]G'7%^*OAK
M6[W^QK^V^'D7B"X^(+33^;;QV\Z(SRW)!*1EB(6BA0B3JJ@'V1^U%_P6$^(G
M@/\ X):?#C]I/X<^!/"6M0>+?L7]L:5JVK2C^S)+HK"L-O(!$+@"X8KYI*#:
MF[!#%EQ/BI_P5$_:G_9B^(?PW\2?&'X-_#KP?\'?B+XFL?#"Q67B&6_\1:'-
M=,PCEN9(LVK*5 ?9'O(\MQO;-<E_P7'_ &J=-U__ ()9^&-#U;PGXC\ >*O&
MVHZ1?V/@NZL/-O\ 3;.VNTED:=;972 (B+N4%BF4&W).,S_@N=^V9\./B5^Q
MW^SMJN@:_-K6FW7CK2/%L?V'3[J99M,L5D%W=':F46$LH*L%8[B #S0!^LUK
M,+B-23GS5WJ&YXX/Z9'Z5^;'_!P3\1=!^#WQ=_9)\5>)KN+3= T'XA/>W]X\
M3R"UB40DR$("?EZ\@CCUQ7Z%_#/QGIOCSP+I6MZ+<I?Z3JUG#=6ES$-JSQL@
M*LJGG!!&,\^O2OR:_P""W?\ P4(^''_#>/P"\/V][XBU*Y^!OC8:OXY-EHMW
M+#H5O(+<*\CK&PD^4.^(@QPK>IH W/VI?BKX(_X+V_M=?"SX>_""7_A(O!_P
M5\16OB[QGXO%Z;**"%FW0VEHHD$TK3/!\S!!Y8"G(.*^J_\ @J;_ ,%-]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'FBB@!-@/
M8<]>*&0,.0#WY%+10 F,G-(8E9<%00>V*=10 FP>@_*D\I<GY5^;@\=:=10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,F)"
M\=<T /HJM+=!%P-^T C@?W>O/_U\_D:B.IQ?;FMQ*CW"*'>)2=ZJ<X.!G&<'
M]!0!>HKEO&WQ<\-_#>?2(-?\1:'H-QXAU!=*TB+4K^*UDU>[92RV]N)73S92
M 2$3+$*<"N@CE#MD,Y!) !.,\\^AX- %FBN>\??$G0_A=H+ZGXCUO1] T])!
M']KU6^CL;;<Q 5=[D#D\#UK7M)_-FQNS@%NO4$\'@GCTSZ&@"U1110 4444
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M(JO8QK##&J*%14 50N /RX'X58H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#!<3QQH7[57[%WP<\;:#9Z]+97OQ LM.AM-6T6\TBZG\R.=FC>VNHXWX>
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M]LW]FS4/VM_@K=>![;QMJO@O2=;WVVM2Z=8VUS<:E9/%)'+:@SHRQA]ZDR*
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MV#%LC:,Y,<:Y6*,C$8=N6R,?4A0%@<#(Y!QTH$2JN JXQC&.U #((O*;J2,
M<^H[GWJ6DQ@TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !37;:.A/TIU% #4?<>A'UIU%% !2,<"EIKG H
M3)]Z53SWJ"YD.SY"/1CG[OZBN5\-^$O$-O\ %34M8O/%#7N@SVRP6>C):JB6
M;#&YVDW%G8\U4(W3<I6(E-II)'9T445)84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %(R[Q_GBEHH BM[..V4[5'
M)R3CK4@4 ]!^5+THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 R0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]0/$::Q)H
MMPN@2V,&K';Y$FI1/) /F&[<J,K'Y=V,$<X^E?G!^TS_ ,%,_B]^R_\ %G4/
M FO^!O!^HW-O#%<PWME<W7EW$,@RK ,05/!!!Z%3@D8)_3*OPW_X+#_\G@'_
M +%ZQ_\ 0I: /MS]G[]JW]I;]I7X>IXS\'_#WX>#1VNI;0#4-6NH9=\>-WRA
M6X^8=ZR_CQ^V%^U3^SMH+Z]XI^"GA>X\/1D";5M(U&:Z@@).!Y@5M\8)(&YE
M"Y(&<\5TO_!'[_DSNV_[#M]_[3KW[X3>/[#]H_P9X_@U*TL;_P .QZ_JOA@1
MQ*3'=VD)\EB^6.[?E^1@$$8% $W[.'Q:U;X\?L\^%O'DUG9:5K&N6,DXMDWO
M;Q2!W1>IW%?E!/.>O-?*_P"V3^W5\8_V.?$N@V&K^%?!GB'3M<@EFLK^SDNH
MB3$5$B/&S':1YB'@D$-]17U=^S'\*;SX'? KPIX%OYXKJYT2*6W\Z%BRNAGD
M9#D@<[67/'7-?GK_ ,%S/^/WX,?]<]8_G94 >R?L9_MO_&3]LG6/$<.E>%_!
MGAS2] C@:\OKM[J9B\Q?RT2-6&[/E.22PQ@=<U]WZ<+M=/M1?M"]\(E%PUNI
M6(R8&XH"20N<X!)..YK\OO\ @AK_ ,@GXQ_]=])_]!NZ_4F@ KXR_;2_:I^,
M7[(7AS3?%+Z!X-\3>&M0U'^S4>-KJ"X@E9'DC#J6((*1O\P/4=.17V;7P3_P
M6@_Y-1T+_L;;3_TENZ .*_9K_P""CGQR_:J\8ZEX:\%_#[P/'J-A8-J,QU34
M+J&,Q"1(S@J&R=TB\8Z9KL?C?^W!^T/^R]9V^K_$7X':%>^&I91#_:N@:X[0
M!ST1F*.T9/8N@!Z#)KY<_P"")_\ R<=XS_[%27_TLM:_2O\ ;CT_3=3_ &0O
MBY#JJQM;+X=NID$N,>?&F^ _7S5CQ[XH YG]D;]OCP!^UN+G3=*BN?#GB^TB
M\^?0=1=6=X\@&2&1>)4!(!X5AGE0""?IBOYS/V%M3U?2OVO_ (2RZ*TBW<GB
M"V@D\K.3;2-LN <=O):3/MFOZ!?BY\1[#X0?##Q3XUU-3)9:#IT]^\*MM:8H
MA*QJ3_$[84>["@#S/]J7]M'X=_LFZ-#)XIO)=0U^[0O9>'M-VO=SKR-[ D".
M/(QO8\X.T,017COP,_:3_::_:FT<^*_!G@'P+X"\$3,RV=YXOGO+N:[VG!:)
M83'N4'(W%54D$ G!Q^0MSKWB;]J[]HK3I_$>HR7GB#QGKMM9//GB+SIDB1$!
M^ZB!@JKT 45_2)X;\.Z=X0\/:9H>D6L=CI6FVT=G:6T0PL44:A44>P  H ^*
M_C9^V#\>_P!D:6RU;XJ?#?PMXM\$74ZVYUWP3>7%O]G<]%DCN Y#$ X!PIQC
M?FOI#]GC]IKP#^T_X//B#P/JIN1"0E[IMTHCO+%SG"S1Y.,X.&!*M@X)P<;/
MQY^&5E\9?@UXR\%7\"SQ:SIDUM&&&=DVTF&0>Z2!&'NHK^?']E;]H?6OV8_C
M1H?C+2YIC91RK!JUA&V%O;)F'FQ$="<#<I/1E4]J /W]^.FL?%7P[X:N=5^&
M.D>'O$5Y:6[ROH^L/-%-=,.=L,B':&(X"L "<?,*_,Y?^"VGQ M+\17OPT\/
MJ(I-L\(N;B.08.&7DG:W4<@X/:OUWL+^WU2QMKRTE6>UN8UFAE0Y5T895A[$
M$&OPJ^*G[%E]X@_9?M/CIX1BFO+B#4]7C\2Z>N780QZC<(EW&/1$55<#H 'Q
MPYH _:;X+_&+PU\>OAMHWC;PG>"[TC4HMP5L"6WD'#PR*/NNC9!'XC(()X[]
MI+QK\5_AKX,USQ9X"TKPQXAT_1K![ZYTO56N(KN1(U9I3$Z':Q"C(4@$X/))
M K\;_P#@GU^VE>?LI?$G[%K$TUQ\.M=E2/5K5<M]D?[JW<:_WE'# ?>3C!*I
MC]Q/B%J=EKWP:\3:CI]U#?Z=>:!=3V]S X>.:-[=F5U8<%2""".H- 'E'[(?
MQA^+7Q]\"Z+X\\6Z%X6\->&-7BDFM+.PDN);Z1 2J2-N.Q%)7('S$KCIFOHN
MO#OV'@!^R%\(\<?\4[:?^@5[C0!Y)^TEXQ^)GP\^'^H^)_ASHNA>(Y-)M)KR
M]TK56G2>>-!N/D&,X+!0QVD?-P <\'\W-._X+6_$+4M0M;0?#_PI 9Y5B$L]
MU<+&FX@;F.> ,Y)]*_7TC(((R#VK^=[]O7X!?\,[?M,^*/#]I;?9_#^H2?VO
MHX PHM9R2$7VC<21?]L_>@#]_/ J^,5TZ1O&4VARWS%3&NA13+$@Q\P)E8EN
M>APOTJG\2V\?QZ6DOP_'AR74$20O;^(A.L<S8&P+)$<I_%DE6ZCI@UXI_P $
MY_CY_P +]_9>\-WEY<^?XAT ?V%JFYLNTD*J(Y#W.^(QL3W8OZ5VW[7?Q9OO
MA#\$-7O-"5I_&.M21>'_  Y:QGYYM2NF\J';ZE<M)CTC- 'B/[&O[6/QP_:I
MU>_OKKP+X6\,^"M(OOL5_J;W%P\LTJD&2&V4$AF4$98D*-PZ]*D_;1_:M^,?
M[('A[2?$LWA_P9XG\.:E?G3EEB-U!/!,4>1%="Y!!2-_F!ZKT&17T=^S[\'=
M.^ 7P;\*^!--V/'I%FL<]PHQ]IN&^:>8_P"_(SM[9 [5\A_\%J_^36/"W_8Y
MVO\ Z0WU ''_ +-__!2+XX_M3^-;_P +>"OAYX)74[+3WU.4ZGJ%S#'Y*R1Q
MG!&[)W2IQCIFO;/&GQ:_;'\'Z/<:C#\&_ WB)8%+O;Z+K4TDY4==L;E"Y_V5
MR3V!KX=_X(I?\G.^+?\ L3[C_P!+;*OU7N/B\?\ AI?3_A=;BU=3X2NO$EZQ
M!,\;"\M[>W .[ 5@UP2""253!&#D \/_ & OVT?%'[6]Y\1+3Q1X6L?"UUX5
M>QB$%H9=Y>8W(D619#E2IMP,>YS5K]LS]HCXU_LO^&[GQIHWA+PMXM\$0W B
MGEWW,=W8*[!8VF7=M92Q"[U/!(R!G->J?#7X%)\./V@OBUXYL4MH=+\<6VCR
MM#$2'%[;"[2=BN, ,LD#9!R6,A('4\+_ ,%*>?V(?BA_U[6G_I;;T ?)OP2_
MX+/77B;XEZ-I'Q$\)Z3X=\+7TGV>?5]/GE9K-FX21U<D&,'&['(!)YQ@_J1!
M/'=01S0R)+#(H=)(V#*RD9!!'4&OP&_;_P#V+;[]D_XD?:M)BFNOAWKDK2:1
M>MEC;-U:TE;^^H^Z3]]1GDA\?6?_  2E_;G^W16'P0\=ZA_I$:^7X7U*Y?\
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MS8_^B5KHO#'P8L?"GQU\;_$6RDCBD\5Z9IUG>6JQX+3VK3CSBW?='+$F,?\
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M(]Y,K@98,TD2#DKB$,H&\D_#/_!<S_C]^#'_ %SUC^=E0!I?\$-?^03\8_\
MKOI/_H-W7ZDU^6W_  0V_P"05\9!W\_2?_0;ROU)H *^"?\ @M!_R:CH?_8V
MVG_I+=UZ[KWQO;Q9^W=X0^%F@ZI*;7PSH%_KGB&&VF(C>:58XK>&4 X)19/,
MP<C,L9ZBO(O^"T'_ ":CH7_8VVG_ *2W= 'PM_P2]\2?$/PK\8/&-_\ #;PE
MIWC+64\,S&;3M1U$V0,(N(&)C;:VYRP10IP/F/(Q53]K#_@H]\3OVD_#MQX&
MU/2[#P3X<^T#^T--L5D-Q.\;Y"3NYSM5U!V!5^91G.!CTW_@B?\ \G'>,_\
ML4Y?_2RUKK?^"MO[&/\ PCVJ2_&_P?8XTR_E5/$UI G$%PQ 2\ '19"0K_[9
M5N2Y( /H?_@GI^P/X&^"^GZ3\58_$T/Q!\0:K8"73-3MH3%9V<,J?,85)+&0
MJ2I=L$ LNU?FSZ+_ ,%.Q<G]AOXF_9<E_+L-^.NS^T+;?_X[G\,U\,?\$F_V
MSO\ A7WB>/X-^+[[9X;UJX+:#=3O\ME>N>8,GHDQZ>DG;]X2/U>^+?PYL/B]
M\,?%/@K5&*6.NZ=-822J,M%O0A9 /56PP]U% '\]G[%AC'[6WP@\W[O_  D]
MAC_>\Y=OZXK^D"OYI9]$\2_LK?M#V,'B&P>T\0^#-=M[N2 ' E,$RRHR,>J.
M%#*W<,#7])'AOQ%IWB_P]IFNZ1=1WVE:E;1WEI<Q'*RQ2*&1A[$$&@#2K^6;
MQ"(QK^I^5CROM4NS'3&\XK^E?]H+XI6?P5^"GC/QK>SI FCZ9-/#O./,N"NV
M",>[R,BCW:OY^_V3OV=]8_:=^-N@^#]/@E_LUIEN=8OD!VVEDK RN6[,1\JY
MZNRCWH _?W]F=;E?V</A2+T$7@\)Z4)@1@[_ +'%N_7->5_\$[X([K]E3389
MHUEADUG7$>-U#*RG4[D$$'J"*^EK*S@TZS@M+:)8+:"-8HHD& B*, #V  KY
ML_X)S,&_9:TK!!_XG>M]/^PG<T ?F7_P4F_8;D_9N\:'QEX1LG;X:Z[<'RXX
MP2-)NFR3;M_TS;DQGT!4\J"W7?\ !/[]N?\ X1/P!XC^"WCO4,:+>Z7>)X;U
M*Y?BTG:)_P#1&)_Y9NQ^0_PN=O1AM_7_ .(/@#0?BEX+UCPGXGTZ+5="U:W:
MVNK64<,IZ$'JK @,K#D$ C!%?SW?MB?LIZ]^R9\5[GPY?^9?>'[S=<Z)K!7"
MWEOGHV.!*F0KKZX(^5E) /W"_8>_Y-"^$7_8N6G_ * *]PKP_P#8>_Y-"^$7
M_8N6G_H KW"@ KX!_P""POP"_P"%@_ S3_B'IMMYFL>#)\W)1?F>PF*K)G')
MV2")O93(?6OOZLOQ3X:T[QGX9U;P_J]LMYI6JVDME=V[])(9$*.OXJQ% 'XI
M?\$C/CY_PJ_]HA_!>H7/E:'XWA%F [85+Z/<UNW_  +,D>.YD3TK]'G'_"__
M -M=1_K_  =\'+3<>\=QX@O$X]F\BW_%'D[5^(?Q5^'GB']F_P"/>M>%EFG@
MU[POJX%E=QKB1]CB2VG0?[2F-Q_O"OWZ_9)^$U_\(O@KI=IK[F?QGK<TOB#Q
M)=./GFU.Z;S)MV.NS*QCVC% 'LM? '_!:O\ Y-8\+?\ 8YVO_I#?5]_U\ ?\
M%J_^36/"W_8YVO\ Z0WU 'PM_P $Q-/^*&I?&WQ1#\)=5\.:1XE_X1B<RS^)
MH)9;<P?:K7(41Y(??Y9!((P&XZ5]4_L&Z/\ %/1/^"BWQ2@^,=Q)>^.&\)2R
M3W>X&&>$W=EY3P;0%\K:,*% Q@@@$$#QG_@BD?\ C)[Q:/\ J3[C_P!+;*OU
MFN?A1;R_'S3OB9'-''=0>&;KPY<0^7\\R/=6]Q$V[/ 0Q3#&.?-[8.0#OZ^9
M?^"E/_)D7Q0_Z]K3_P!+;>NE^)?Q\73OVD_A9\(O#^H1_P!M:M-=:KKR1JDA
MM]-AM)F1'R#L:6;RL$8.V-N@89YK_@I40/V(?BADX_T:TZ_]?MO0!['\9_@]
MX:^//PWUGP3XLLQ=Z1J46TLN!+;R#E)HF/W71L$'\#D$@_ST?M%? +Q;^R?\
M8;OPMK+RQ75G(MWI6L6VZ-;N#=F*XB8'*G(Y .592,\9K^DT'(SU'K7@'[:'
M[)6B?M:_"F?0[GRK'Q1IX>YT+5W7FVGQS&Y')BDP%8<]%8 E10!\1>&?VVK?
M]J'X'?"G0/$=S''\2= ^(WAH7Z'"_P!HP"ZVK=H/7.!(!P&(/ =0/U=K^;OX
M0>"=;^&_[7GP_P##'B33Y=*US2O&>F6UW9SC#1NMY%^!!&"&&00002"*_I$H
M *_G&_;?_P"3O/B[_P!C'=_^AFOZ.:_G&_;?_P"3O/B[_P!C'=_^C#0!^Y_[
M%/\ R:/\(?\ L6;'_P!$K7M5>*_L4_\ )H_PA_[%FQ_]$K7M5 'X\?\ !;G_
M )+'\.O^P#+_ .E#5[5_P1(_Y(E\0?\ L84_])HZ\P_X+?\ A:\B\7_"_P 2
M")FL)[&\T\R@?*DB2)( 3V)$AQZ[3Z5W_P#P1"UJVF^&7Q,TA95-Y;:Q;7;Q
M9^8))"54X],Q-^5 'Z6U\H_#$9_X*.?&D]AX2T8?J:^KJ^2/V9M0B^(7[9G[
M2OC73V%QH=G)I/ABUO$Y26>V@;[4H/0[)-H_X$* /I#XH_\ ),_%W_8(O/\
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M9U3]D;X(ZMX0EU:PUW6[S5+C5!=Q1O' 7>&*.-&SEL#RAG'J<5XI^V)^P?\
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MZG K[*HH _.3]E3_ ()Q?%K]DSXG2>,?#OCSPEJKW%C)IUW8W]C<B.:!W1R
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MT?Q[\5/"'@+0)U\N\E\"6,LFIS1_Q(LLRJ(21_&AR/0]*^E/@_\ !_PM\"O
M&F^#O!^GC3]&L02-S;Y9Y&Y>65^KR,>23[ 8  ':44 >4_'KPO\ $WQQX5UC
MP[X%U+PUHMMJNG264NHZQ%/-<0F0,CM&B87(0C:6)P<Y! Y_.70/^"+WQ#\,
MZ[IVL:?\3_#\-_I]S'=V\AL)SMDC8,IQWP0*_7"B@#D_AZOCE-/E3QR_A^6]
M54$<WA]9TC<X.\LDI)7G;@!CWYKXE_;)_P""5D7[0GQ7E\=>"O$.G^$;O4X]
MVL6EW;.\<]P.!.FSHS#[X[E=W5FK]!J* /C/]C[]ECXW?LG:%>>&4\=>%O%?
MA&5WN(--O;:Y1[.<@Y,,@/RHS8+*01G)&"6W<-^U]^P#\6_VP/&NE:YKGC;P
MCH=II5J;2RT^QM+EP@9MSN[L<LQ.!P ,*..I/Z"T4 ?G;^S9^P+\?_V4Y=:_
MX07XL>$DMM8$1O+/4='FGB=H]VQQR&4@.PX(!SR#@8]%^(GP'_:\^(>CSZ6W
MQW\+^'+2=2DIT#19+:9E/83'=(GU1E/O7V;10!\C?L"?L2:M^Q]'XYFUWQ)9
M>)M0\226A$]I$Z>6L/G$[B_)+&8G\*XOXI?\$U+SXO\ [27COXMS_$34/!6K
M75Y9S>')="C#RVQALX(S-*25.?,C<!$(X );YL#[MIDLJ01M)(ZQQJ"S.YP
M!U)- 'S%ID/[7GA&S&E2-\+/'HC79#KU[->Z;<2#L\\$<;)N]HR!7A5_^S3J
MFI_'"7XH?&WQ99>,OB'IBP/8:5I5BR:%HZ(^8U7S?WDNUFRH*8W.68L<D?6>
ML?&>VUN\DLK*UOK?3$;9/?N%6)P6Q\K@G@@=<CAQ7':I8V^G7=W=1VOG:5=2
M"7<I,PWLBG<6;KG&-N<#.10!FZ-?WFI27&L6"+/>WMHZ7<G"ARVWD D  %2.
MW;K7JG@(76AB6V=]\$$H X!*@KNQT&>6)_&N0T/1EOXH(BFTA$DCGA3'E$@'
MH,8'(/7^&O1;'1KE)7^WW NV7&9ESD#D_C_]:@#X=_X*;2>*_$WP]TC3?%6I
MZ#:>'8=26^MM.TNVGENKJ?RYQ"9)),(%"B4%0/O,#GBN2_9R_P""<'Q:^$'C
M&T^(GPZ^)N@:-?/!+:^1J&FO.LD+':Z.HX(+(&XP1@<US_[=/C,_$3]H+POX
M-L9=R6]];6LJ;<[E6ZN8SU52/O <-WZ]Z_5G0;!=,TN&!!@+G]6)_K7?6HJC
M2@WNS&$^:3/FJ_\  /[7=Y:20P_%;X>6,C# N+?PW,73W =V7/U!KR3X'_\
M!.OXD>$/VJ]#^,_Q&^)]EXYO[*6XFN08)1-,SVTL,84GY45"ZD*   N !7Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/\73T /6_AYI(TFPCC3E"20WE[-W+<X_3\*[:L?PT4ETY'4#()&,8QR>E;%
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MY&S)5,@ <$<-Z'!]9\*G[5?OYT4,R0KL,D;[VD!88). >B^IKS72?#UOX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLUA%(EWN2W5F)?Y]W&-P]_2J][,;214A<JK2#.,')+<\FKEB0-3,<3*JE&?
MY_CYJ66.&9'C\IF57#* Q.&R>?I7BG64KJX'V96)3<JC<1C<>#Z"IF<+IGSP
MA%,7[N5!D_=ZGC^E-E5($G65EC?8 %0\' )]*?9W#PVQ9I!Y)3.Y?F*<#VP*
M ,>\D>WL;IP^XAB2@&2Q^7' %9MPK2.T[*6!(SN5LK\X]JY#XR?';2?AAI4P
MN+F*6Z=B5173=PT?\)=><-FLKX#_ !5N?C+X/369[2:U$DIC\B\C,; "0C.-
M[>GK5N$E'G:T)NF['=_8TDGM)8F:158?+L. 26.?TJ"836FF1E8A'YK AP#\
MW#>IJ4Z5)&8PGSH&4JA7!Z/P<<XJ.^F9+"*$M&9XSS">=HV'GKTJ"C%:9XY)
MRT:EDB)W/@D'RU]_>F:B&FOYEVG"AVX P/EB'K4J +;:A)*1MPXS@<D!!@5!
M=R^5>WC.I#-&W"]OGC _04#,[5+..&QN)G "-/(#C'(,JJI_\=Q4%\5DU&>Y
M!)7:HSGUN&/3\*V1:I-8QQ.HVSS9<MUR9VY_05FV\+72( PPS+&6&,\2.>10
M!3F@ ZR8$LL3;D/8S2-SC\*P])E\UA"A$LJ-&,#(8#:Y]/>NGD"G588VD,BF
M&/'. ,*[$<5@HJ1>7.'*J^&X)!&(?7ZF@1[M\)2/^%>:/@Y 1Q_Y$:NOKDOA
M2''@+2Q)C>/-!V]/]:]=;0 4444 %%%% !1110 4444 %%%% !1110 4444
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MH?)6DOMR+)D>:3&_RKQ_=% 'LOP["+X0LA&24#S8)_ZZO725S7PZ5E\'6&\
M,3*>/>5ZZ6@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)F="%P?[TC9_2M 6[F\A:.,QQ2*@8-SG!D.?UK$$H73]*5&8.Q4$G'/[N0T
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M1(6=E11U+' J'[?:_P#/S#_WV* +%%0QW<$K;4FC=O16!-34 %%%% !1110
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M);PR2RL$CC4LS-T ')-/K@OC=XDN_#?P\U273S&E_,BP0M,NY 7D1#G'LYH
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MX9ATNS@B<F5HQW48SG-;72EHH A*G[4K9XVD8_*IJJE&_M%&Q\GEL,^^1_\
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MSI6CQ\QYR9"1^&*TWWP I*/D\]'^4$\>=(16/I]M%)<I+Y)R-FPXQ_RS8YH
M]L^'HQX,TL?],S_Z$:Z*N>\ !5\(:<%)("MUZ_?:NAH$%%%% !1110 4444
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M6PIZ@@@G(/:@#J/A#XDT'QKX=AUOP[?1ZAIEV1+%- ^=P/&<X![=,5P?CO\
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M@U^>^I>']*^//_!1JZ^'?Q8N;BZ\'Z9;/;:/H<MR]O%)&MNSIRC*>J[LYR2
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M6OSU^"7PN\7_  2T2]\&>)-?MY=#T/5)?[)%G.0A7>?,A8D#[Q525Y(XZ\8
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M3I@\-^(9I%\:>#];BT?5;><8ES',XA8Y]4V@GK\K&OU0\#G/@W0S_P!.4/\
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MO&MNL/P20WA73R&#90G*],[C6Y0(**** "BBB@ HHHH **** "BBB@ HHHH
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MJBOE(_LN?'PS*_\ PUCK> I!7_A$;#G..?O8[>G?MSE__#+_ ,>_^CK]<_\
M"1L/\: /JJBOE7_AE_X]_P#1U^N?^$C8?XTR3]ESX^.T9'[6.M@*V2/^$1L.
M>",<-[]\_P B #ZMHKY5_P"&7_CW_P!'7ZY_X2-A_C1_PR_\>_\ HZ_7/_"1
ML/\ &@#ZJHKY1E_9;^/DB@+^UCK:D,IS_P (C8]B#V8?YZYZ5)_PR_\ 'O\
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M7]U#96D*[Y)[B0(B#U)/ KBO%WQ@T?1+F72M*E77O$:$YTNP=))4"E=Y<%U
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M]>U5O"MY93QM%+:W/V6&(QO<Q+\RDN"AY.""%(X!ZCI79^%[0L1'"K0V=O*
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M'\J?7Y;?\$3==U+Q+K7QRU/5]0NM5U*Y.BO/>7LS332M_IW+.Q)8^Y-?J30
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M$P,@/F,H(_ND"+_Z]:5R&;4+><RJBQ0!1G!_Y9L<]?>J)C\NTAAW$F)6(*@
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M]XI^+OQ3E^,?CSP==^"EU+7_ !&+C5)/%-O=RW/*L\2(89% C42. "..<<4
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MI:JH9FEG".[$ KD*N?F R6)4>L?#CPK<Z=I)O;S4KA0SYCL';:LN7<A=I/<
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MQ?>^"_#MSK=MIT5_;6D+R72RWAMRB#8/E_=L&/L2OMGI7S?\"[N7X(_'37O
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M[*&WPQ;8B8Y]3^5 &=9^$K.]TVSM9(7:"W15#,^"0%QV/TKI[:UBM(PD2[5
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M/O0!]!T45A^,?"Y\7Z.=/&L:KH>7#FZT>Y$$_ (V[\'@Y_04 ?D-\:+J$_\
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M(%>!_P#!'[Q[X=\._LO75AJ6L6EG?WGC6>RMK224>=/-);6I140?,<@,<@8
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MG2K8FTF\6V44B_+%!X@F5<\D\# '04S4O^">OPLDN(6GD\0W3$$YN]8EE*D
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MKS#]F;X-6W[/_P "?!O@2W">=I5BHO)8^DMV^9+A\]P9&?'M@=J]/H ****
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M,2Q)YW \^XSZ?E716]I#:)LAC6-?84 0:=I,&FJPB!&XYY.:NT44 %%%(>E
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M[2?4;L'W!KI: "BBB@ HHHH *K:GJ-MH^FW5_>S);6=K$\\\TAPL<:@LS'V
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M,GTQV%?0O[&V@06O[/G@[6+JX66.XTI(XS=S!41RY 5"5.#N &!WQ0!\Q_\
M!0ZRL-%^%?@.S@9&O8]1N6O6A@\M#*T$8)7ID91N@ Z<5]I>#IW^&WP8;Q'/
M<+<:%I&@?VG-IP9F5@EFLI^\,=17SA_P6%TN'2_A_P##^6%+;]_JUP_FP1A6
M<>4#\Q'4]_Q-?;US\*W\;_LG:AH-HWF:GKO@>33H,@ "2:P\M.?JPH ^/_\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413003200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOVENTUS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-0980861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4721 Emperor Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">474-6700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001665988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,486,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413279616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 119,059<span></span>
</td>
<td class="nump">$ 117,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including depreciation and amortization of $14,339, $9,218, respectively)</a></td>
<td class="nump">45,140<span></span>
</td>
<td class="nump">41,588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">73,919<span></span>
</td>
<td class="nump">75,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">80,858<span></span>
</td>
<td class="nump">86,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">78,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(92,058)<span></span>
</td>
<td class="num">(21,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense (income), net</a></td>
<td class="nump">9,694<span></span>
</td>
<td class="num">(1,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(1,588)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">8,106<span></span>
</td>
<td class="num">(1,913)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(100,164)<span></span>
</td>
<td class="num">(19,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit, net</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(5,132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">(100,018)<span></span>
</td>
<td class="num">(14,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net (loss) income from discontinued operations, net of tax</a></td>
<td class="num">(74,429)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(174,447)<span></span>
</td>
<td class="num">(14,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Loss attributable to noncontrolling interest - continuing operations</a></td>
<td class="nump">20,360<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest - discontinued operations</a></td>
<td class="nump">14,937<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bioventus Inc.</a></td>
<td class="num">(139,150)<span></span>
</td>
<td class="num">(11,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustments</a></td>
<td class="nump">657<span></span>
</td>
<td class="num">(682)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(99,361)<span></span>
</td>
<td class="num">(15,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations', window );">Comprehensive loss attributable to noncontrolling interest - continuing operations</a></td>
<td class="nump">20,226<span></span>
</td>
<td class="nump">3,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations', window );">Comprehensive loss attributable to noncontrolling interest - discontinued operations</a></td>
<td class="nump">14,937<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bioventus Inc.</a></td>
<td class="num">$ (64,198)<span></span>
</td>
<td class="num">$ (11,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share of Class A common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per share of Class A common stock from continuing operations, basic (in dollars per share)</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per share of Class A common stock from continuing operations, diluted (in dollars per share)</a></td>
<td class="num">(1.28)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)</a></td>
<td class="num">(0.96)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)</a></td>
<td class="num">(0.96)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share of class A common stock, basic (in dollars per share)</a></td>
<td class="num">(2.24)<span></span>
</td>
<td class="num">(0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share of class A common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average shares of Class A common stock outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">62,124,752<span></span>
</td>
<td class="nump">60,484,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">62,124,752<span></span>
</td>
<td class="nump">60,484,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951598240576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 14,339<span></span>
</td>
<td class="nump">$ 9,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951411770448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,102<span></span>
</td>
<td class="nump">$ 30,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">118,544<span></span>
</td>
<td class="nump">136,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">87,953<span></span>
</td>
<td class="nump">84,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">17,192<span></span>
</td>
<td class="nump">18,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">37,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets attributable to discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">308,664<span></span>
</td>
<td class="nump">272,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">36,556<span></span>
</td>
<td class="nump">27,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,462<span></span>
</td>
<td class="nump">7,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">516,039<span></span>
</td>
<td class="nump">639,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">16,063<span></span>
</td>
<td class="nump">16,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investment and other assets</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Long-term assets attributable to discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">405,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">887,404<span></span>
</td>
<td class="nump">1,372,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">32,828<span></span>
</td>
<td class="nump">36,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">115,769<span></span>
</td>
<td class="nump">111,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">41,320<span></span>
</td>
<td class="nump">33,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,273<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities attributable to discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">196,063<span></span>
</td>
<td class="nump">304,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">404,265<span></span>
</td>
<td class="nump">385,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">17,718<span></span>
</td>
<td class="nump">17,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">28,645<span></span>
</td>
<td class="nump">22,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Long-term liabilities attributable to discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">228,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">647,042<span></span>
</td>
<td class="nump">960,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">492,475<span></span>
</td>
<td class="nump">490,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,456)<span></span>
</td>
<td class="num">(165,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">413<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity attributable to Bioventus Inc.</a></td>
<td class="nump">188,511<span></span>
</td>
<td class="nump">325,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">51,851<span></span>
</td>
<td class="nump">86,984<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">240,362<span></span>
</td>
<td class="nump">412,222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">887,404<span></span>
</td>
<td class="nump">1,372,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities Held-for-sale, Not Part of Disposal Group, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951417038304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">62,507,917<span></span>
</td>
<td class="nump">62,063,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">62,507,917<span></span>
</td>
<td class="nump">62,063,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951407979952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Class A</div></th>
<th class="th"><div>Common Class B</div></th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class B</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated other comprehensive (loss) income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,548,504<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 607,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 473,318<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="num">$ (6,602)<span></span>
</td>
<td class="nump">$ 140,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A common stock for equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,808,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock for equity plans</a></td>
<td class="nump">2,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DeferredTaxesOnEquityRebalancing', window );">Deferred taxes on equity rebalancing</a></td>
<td class="num">(1,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(14,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,277)<span></span>
</td>
<td class="num">(3,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="nump">4,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholdings on equity compensation awards</a></td>
<td class="num">(3,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="num">(682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 02, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,357,270<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 02, 2022</a></td>
<td class="nump">593,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">476,661<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(17,879)<span></span>
</td>
<td class="nump">135,311<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,063,014<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">62,063,014<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">412,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">490,576<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(165,306)<span></span>
</td>
<td class="nump">86,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A common stock for equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock for equity plans</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(174,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139,150)<span></span>
</td>
<td class="num">(35,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 01, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,507,917<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">62,507,917<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 01, 2023</a></td>
<td class="nump">$ 240,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 492,475<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="num">$ (304,456)<span></span>
</td>
<td class="nump">$ 51,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DeferredTaxesOnEquityRebalancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Taxes on Equity Rebalancing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DeferredTaxesOnEquityRebalancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Stockholders' Equity And Members' Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416977680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated condensed statements of cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (174,447)<span></span>
</td>
<td class="num">$ (14,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Less: Loss from discontinued operations, net of tax</a></td>
<td class="num">(74,429)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(100,018)<span></span>
</td>
<td class="num">(14,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">16,473<span></span>
</td>
<td class="nump">12,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit losses</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">4,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(2,664)<span></span>
</td>
<td class="num">(17,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">78,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign currency fluctuations</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">13,162<span></span>
</td>
<td class="nump">4,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,294)<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="num">(7,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other current and noncurrent assets and liabilities</a></td>
<td class="num">(2,129)<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash from operating activities - continuing operations</a></td>
<td class="nump">4,659<span></span>
</td>
<td class="num">(21,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash from operating activities - discontinued operations</a></td>
<td class="num">(2,169)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash from operating activities</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="num">(21,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3,560)<span></span>
</td>
<td class="num">(2,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments', window );">Investments and acquisition of distribution rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,478)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash from investing activities - continuing operations</a></td>
<td class="num">(3,560)<span></span>
</td>
<td class="num">(4,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash from investing activities - discontinued operations</a></td>
<td class="num">(11,506)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash from investing activities</a></td>
<td class="num">(15,066)<span></span>
</td>
<td class="num">(4,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class A and B common stock</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">2,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholdings on equity-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing on revolver</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payment on revolver</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_PaymentOfDebtRefinancingCosts', window );">Debt refinancing costs</a></td>
<td class="num">(1,668)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="nump">27,380<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">461<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">15,265<span></span>
</td>
<td class="num">(16,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">31,837<span></span>
</td>
<td class="nump">99,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">47,102<span></span>
</td>
<td class="nump">82,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable for purchase of property, plant and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PaymentOfDebtRefinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Debt Refinancing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PaymentOfDebtRefinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414312272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioventus Inc. (together with its subsidiaries, the &#8220;Company&#8221;) was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (&#8220;BV LLC&#8221;). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company completed its initial public offering (&#8220;IPO&#8221;), which was conducted through what is commonly referred to as an umbrella partnership C Corporation (&#8220;UP-C&#8221;) structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC held by its continuing LLC owner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately 1,040 employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim periods</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2023 end on April 1, July 1 and September 30. Comparable periods for 2022 ended on April 2, July 2 and October 1. The fourth and first quarters may vary in length depending on the calendar year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) considered necessary for a fair statement of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The consolidated balance sheet at December&#160;31, 2022 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Correction of immaterial misstatements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended April 1, 2023 and as part of the balance sheet review process, the Company identified misstatements in its calculation of the carrying amount of noncontrolling interest as it applies to the Company&#8217;s complex UP-C tax and ownership structure as prescribed in the amended and restated limited liability company agreement of BV LLC. Specifically, the Company failed to adjust the carrying amount of its noncontrolling interest to reflect changes in ownership interests relating to BV LLC. As a result, the previously issued consolidated financial statements reflect an understatement of noncontrolling interest and an overstatement of additional paid-in capital. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of further research conducted, the Company discovered an additional error related to historical deferred income tax balances. The Company concluded that it had inappropriately calculated deferred income taxes by using an incorrect book basis in its investment of BV LLC during the Company&#8217;s IPO, which resulted in an overstatement of deferred tax liabilities, an understatement of noncontrolling interest and an understatement of additional paid-in capital.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The statements affected by these errors include the consolidated balance sheets and consolidated statements of stockholders&#8217; and members&#8217; equity issued in the Company&#8217;s Annual Report on Form 10-K for the years ended December 31, 2022 and December 31, 2021. There was no impact to any other financial statements for the periods presented. The Company concluded that these misstatements were not material, individually or in the aggregate, as evaluated under the Securities and Exchange Commission Staff Bulletin No. 99, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Materiality;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> No. 108, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Considering the Effects of Prior Year Misstatements in Current Year Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">; and Financial Accounting Standards Board ASC 250-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting Changes and Error Corrections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. However, because of the significance of these items, and to facilitate comparison among periods, the Company has decided to revise its previously issued consolidated financial statements on a prospective basis. The Company will correct its prior period presentation for this error in its future 2023 quarterly financial statements included in its Forms 10-Q and 2023 Annual Report on Form 10-K for the period ended December 31, 2023. The adjustments did not have an impact on revenues, total assets or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are selected line items from our aforementioned impacted financial statements illustrating the effect of the error corrections thereon:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets &#8212; December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (b)(d)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,890)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital (a)(b)(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest (a)(c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets &#8212; December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (b)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,867)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital (a)(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated statements of changes in stockholders&#8217; and members equity as of December 31, 2022 and December 31, 2021 have been corrected to reflect the above adjustments. The Company revised the amounts originally reported for the years ended December 31, 2022 and December 31, 2021 for the following items:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Recorded a $65,821 decrease to additional paid-in capital and a corresponding increase to noncontrolling interest. This action effectively rebalanced equity appropriately between the Company and its noncontrolling interests according to their respective BV LLC ownership interests.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Recorded a $73,867 decrease to deferred income tax balances and an increase to additional paid in capital to reflect the correction of an error that occurred during the calculation of deferred taxes at the Company&#8217;s IPO.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Reflects the entry as discussed in (a) above and additional rebalancing activity of $2,588 relating to the issuance of Class A common stock for equity plans during the year ended December 31, 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects the entry as discussed in (b) and an additional $1,977 increase to deferred income tax balances and a reduction to additional paid in capital to reflect the deferred tax impact during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared under the going concern basis of accounting, which presumes that the Company&#8217;s liquidation is not imminent; however, based on the Company&#8217;s current financial position and liquidity sources, including current cash balances, and forecasted future cash flows, the Company is at risk of violating certain of its financial covenants under the Credit and Guaranty Agreement, dated December 6, 2019 (as amended on October 29, 2021, July 11, 2022 and March 31, 2023).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If mitigating steps are not taken or are not successful, the Company is at substantial risk of failing its covenants in 2024. A breach of a financial covenant under the Credit and Guaranty Agreement could accelerate repayment of our obligations under the agreement. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion concerning the Company&#8217;s long-term debt obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing plans to mitigate these conditions and events, such as considering various additional cost cutting measures, and exploring additional divestiture opportunities such as the recently announced plan to divest certain assets within its Wound Business; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. Therefore, these plans do not alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of efforts to improve its financial condition, on February 27, 2023, the Company reached an agreement to return the assets and liabilities of CartiHeal (2009) Ltd. (&#8220;CartiHeal&#8221;), a wholly-owned subsidiary of the Company, to its former securityholders. The deconsolidation of CartiHeal relieved deferred consideration liabilities and milestone obligations related to the acquisition of CartiHeal. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding the acquisition and subsequent deconsolidation of CartiHeal. In addition, the Company announced a restructuring plan in December 2022 to align the Company&#8217;s organizational and management cost structure to improve profitability and cash flow. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an accelerated public company filer. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when emerging growth companies are required to adopt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414005632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance sheet information</a></td>
<td class="text">Balance sheet information<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net of allowances, consisted of the following as of:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Other receivables of $350 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Accounts receivable of $5,012 was reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding assets held for sale and the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Allowance for credit losses of $898 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding assets held for sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of the Company&#8217;s receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately 11.8% of the accounts receivable balance as of April&#160;1, 2023. Historically, the Company&#8217;s reserves have been adequate to cover credit losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in credit losses were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to held for sale</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,401)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following as of:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess and obsolete reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Raw material inventory of $642 attributable to CartiHeal has been reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Finished goods inventory of $1,481 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid and other current assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following as of:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Prepaid and other current assets of $134 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 balance sheet. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following as of:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,204)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net before currency translation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Intellectual property and accumulated depreciation attributable to CartiHeal totaling $410,200 and $11,327, respectively, were reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Net intellectual property and customer relationships of $23,458 and $8,377, respectively, were reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding assets held for sale.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Company recorded an impairment loss of $78,615 in the U.S. reporting segment of net intellectual property attributable to a business held for sale. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding businesses held for sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for intangibles subsequent to reclassifications and impairment for the remainder of 2023 and for the years ended December 31, 2024 through 2027 is expected to be $22,041, $26,347, $22,874, $20,030 and $19,652, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company assesses goodwill impairment by applying a quantitative impairment analysis comparing the carrying value of the Company&#8217;s reporting units to their respective fair values. A goodwill impairment exists if the carrying value of the reporting unit exceeds its fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two reporting units and assesses impairment based upon qualitative factors and if necessary, quantitative factors. A reporting unit's fair value is determined using the income approach and discounted cash flow models by utilizing Level 3 inputs and assumptions such as future cash flows, discount rates, long-term growth rates, market value and income tax considerations. Specifically, the value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company then reconciles the values of all reporting units to the market capitalization of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill resides within the International segment, of which $6,297 related to CartiHeal and was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. The amount was recorded in discontinued operations, net of tax on the consolidated condensed statements of operations for the three months ended April 1, 2023 as a result of CartiHeal&#8217;s deconsolidation. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details concerning the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022, due to a significant decline in the Company&#8217;s Class A common stock price, circumstances became evident that a possible goodwill impairment existed as of the third quarter 2022 balance sheet date. The Company concluded that the carrying value of the U.S. reporting unit exceeded its fair value and recorded a non-cash goodwill impairment charge of $189,197 during the year ended December 31, 2022. There were no accumulated impairment losses prior to the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following as of:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus and commission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Bonus and commissions of $588 were reclassified into liabilities held for sale within the April&#160;1, 2023 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other liabilities attributable to CartiHeal of $384 were reclassified into current liabilities attributable to discontinued operations within December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414231504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock', window );">Acquisitions and divestitures</a></td>
<td class="text">Acquisitions and divestitures<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Wound Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its businesses and products in order to calibrate its strategic focus, enhance liquidity, prioritize investments and allocate capital to its core business units. As a result of this assessment, the Company has committed to a plan to divest certain assets within its Wound Business, specifically those attributable to TheraSkin and Theragenesis (the &#8220;Wound Business&#8221; or  the &#8220;Disposal Group&#8221;). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified the identifiable net assets of the Disposal Group as held for sale. Assets and liabilities determined to be part of the Disposal Group have been recorded as single amounts within the Company&#8217;s consolidated financial statements. Assets held for sale are reported at the lower of the carrying amount or fair value less costs to sell, which is expected to occur within one year. The Company has ceased the depreciation and amortization attributable to assets classified as held for sale. Assets and liabilities held for sale are reviewed each reporting period to determine whether existing carrying values are fully recoverable in comparison to estimated fair values less costs to sell.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Wound Business for impairment during the first quarter of 2023. The Company recorded a $78,615 ($63,337 after tax) impairment as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values less any costs to sell. The fair value of intangibles of the Wound Business was determined based on the consideration offered for the Wound Business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the major classes of assets and liabilities of the Wound Business that were classified as held for sale were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of assets classified as held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance of $898</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of liabilities classified as held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CartiHeal (2009) Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2022, the Company completed the acquisition of 100% of the remaining shares in CartiHeal, a privately held company headquartered in Israel and the developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. The Company previously held an equity interest in CartiHeal&#8217;s fully diluted shares with a carrying value of $15,768 and $16,771 as of July 12, 2022 and December&#160;31, 2022, respectively. Net equity losses associated with CartiHeal for the three months ended April&#160;2, 2022 totaled $401, which was included in discontinued operations, net on the consolidated condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired CartiHeal (the &#8220;CartiHeal Acquisition&#8221;) for an aggregate purchase price of approximately $315,000 and an additional $135,000, payable after closing upon the achievement of a certain sales milestone (&#8220;Sales Milestone&#8221;, or &#8220;CartiHeal Contingent Consideration&#8221;). The Company paid $100,000 of the aggregate purchase price upon closing consisting of a $50,000 deposit held in trust and $50,000 from a financing arrangement (Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding financing arrangements). The Company also paid approximately $8,622 of CartiHeal&#8217;s transaction-related fees and expenses and deferred $215,000 (&#8220;Deferred Amount&#8221;) of the aggregate purchase price otherwise due at closing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Deferred Amount was to be paid in five tranches commencing in 2023 and ending no later than 2027 as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$50,000 due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents the results of the pivotal clinical trial (&#8220;First Paper Milestone&#8221;) or July 1, 2023; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$50,000 due upon the earliest to occur &#8212; the implantation of Agili-C devices in 100 patients in the United States or September 1, 2023;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$25,000 due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents any new or additional clinical data subsequent to the First Paper Milestone with respect to Agili-C (&#8220;Second Paper Milestone&#8221;) or January 1, 2025;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$25,000 due upon the earliest to occur &#8212; the publication in a peer-reviewed orthopedic journal of an article that presents any new or additional clinical data subsequent to the First and Second Paper Milestone with respect to Agili-C or January 1, 2026; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$65,000 due upon the earliest to occur &#8212; obtaining a U.S. Category 1 Current Procedural Terminology (&#8220;CPT&#8221;) code from Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for Agili-C or January 1, 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the CartiHeal Amendment (as defined below), the Company owed interest on each tranche of the Deferred Amount at a rate of 8.0% annually, until such tranche is paid. The Sales Milestone was payable upon the achievement of $75,000 in trailing twelve month sales pursuant to the CartiHeal Amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had entered into an Option and Equity Purchase Agreement with CartiHeal (&#8220;Option Agreement&#8221;) in January 2020 and a subsequent amendment in June 2022 (&#8220;CartiHeal Amendment&#8221;). The Option Agreement provided the Company with an exclusive option to acquire 100% of CartiHeal&#8217;s shares (&#8220;Call Option&#8221;), and provided CartiHeal with a put option that would require the Company to purchase 100% of CartiHeal&#8217;s shares under certain conditions. In August 2021, CartiHeal achieved pivotal clinical trial success, as defined in the Option Agreement, for the Agili-C implant. In order to preserve the Company&#8217;s Call Option, in accordance with the Option Agreement and upon approval of the Company&#8217;s Board of Directors (&#8220;BOD&#8221;), the Company deposited $50,000 into escrow in August 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The First Paper Milestone under the Option Agreement occurred on February 13, 2023, which obligated the Company to make the first $50,000 payment, plus applicable interest, under the Option Agreement. On February 27, 2023, the Company entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Elron Ventures Ltd. (&#8220;Elron&#8221; and together with the Company, the &#8220;Parties&#8221;) as representative of CartiHeal&#8217;s selling securityholders under the Option Agreement collectively, the &#8220;Former Securityholders&#8221;). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings relating to non-payment of any obligations arising under the Option Agreement during a period of 30 calendar days (the &#8220;Interim Period&#8221;) in exchange for (i) a one-time non-refundable amount of $10,000 and (ii) a one-time non-refundable payment of $150 to Elron to be used in accordance with the expense fund provisions of the Option Agreement. The Interim Period expired on March 29, 2023 and the Company did not exercise its right to extend the Interim Period. In addition, the Parties mutually released any further claims under the Option Agreement and related transaction documents, including without limitation a release by the Former Securityholders of any rights to enforce the provisions of the Option Agreement or make further monetary claims against the Company and/or its respective affiliates and representatives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company transferred 100% of its shares in CartiHeal to a trustee (the &#8220;Trustee&#8221;) for the benefit of the Former Securityholders pursuant to the Settlement Agreement. The Company had no ownership interest and no voting rights during the Interim Period. Accordingly, the Company concluded that upon execution of the Settlement Agreement, the Company ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Company&#8217;s international reporting segment. The Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss upon disposal was $60,639 and was recorded within discontinued operations, net within the consolidated condensed statements of operations and comprehensive loss. The loss on disposal is comprised of the book value of CartiHeal&#8217;s net assets at the time of disposal, goodwill attributable to CartiHeal and the previously discussed non-refundable payments made to Elron. The Company allowed the Interim Period to expire on March 29, 2023 as the Company was not able to find a financing solution to fund the payment obligations under the Option and Equity Purchase Agreement on terms the Company believed to be favorable to it and its shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of consideration for the CartiHeal Acquisition was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal of cash at closing</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales Milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Remeasurement of the Company&#8217;s equity method investment in CartiHeal, net of equity losses as a result of the purchase. The remeasurement included a gain of $23,709 calculated as the difference between the fair value and the carrying value of the Company&#8217;s investment in CartiHeal at the acquisition date and was recognized in other income during the third quarter of 2022 on the consolidated condensed statements of operations and comprehensive loss. The fair value was based upon: (i) the consideration transferred to members owning 89.97% of CartiHeal&#8217;s fully diluted shares; (ii) calculating the value of CartiHeal&#8217;s fully diluted shares based upon the transferred consideration; and (iii) applying the calculated value to the Company&#8217;s 10.03% ownership in CartiHeal&#8217;s fully diluted shares at the acquisition date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the CartiHeal Acquisition using the acquisition method of accounting whereby the total purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,106&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resulting goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly 100% of the goodwill represents estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized and is attributable to expected revenue growth in new markets. The goodwill was not deductible for tax purposes and $55,295 and $4,999 was allocated to the U.S. and International reporting units, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CartiHeal&#8217;s intangibles consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual Property - US Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual Property - International Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired CartiHeal intangibles was determined using an income approach, a valuation technique that estimates the fair value of an asset based on market participant expectations of the cash flows that an asset would generate over its remaining useful life. The determination of the useful lives was based upon consideration of market participant assumptions and transaction specific factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AcquisitionsAndInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisitions And Investments Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AcquisitionsAndInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413977792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financial instruments</a></td>
<td class="text">Financial instruments<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended Term Loan due October 2026 (9.19% at April&#160;1, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver due October 2025 (9.28% at April&#160;1, 2023)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the &#8220;2019 Credit Agreement&#8221;) that was comprised of a $200,000 term loan (&#8220;Original Term Loan&#8221;) and a $50,000 revolving facility (the &#8220;Revolver&#8221;). The Company amended the 2019 Credit Agreement on October 29, 2021 in connection with the Misonix Acquisition in which the Company prepaid $80,000 on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $360,750 term loan (&#8220;Term Loan&#8221;) and the Revolver.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, the Company further amended the 2019 Credit Agreement, as amended on October 29, 2021 (the &#8220;First Amended 2019 Credit Agreement&#8221;), in conjunction with the CartiHeal Acquisition. Pursuant to the First Amended 2019 Credit Agreement, an $80,000 term loan facility (the &#8220;July 2022 Term Loan&#8221; and, together with the Term Loan, the &#8220;Term Loan Facilities&#8221;) was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was not in compliance with certain financial covenants as of December 31, 2022. As a result, on March 31, 2023 (the &#8220;Closing Date&#8221;), the Company entered into another amendment to the 2019 Credit Agreement (collectively, with the October 2021 and July 2022 amendments, the &#8220;Amended 2019 Credit Agreement&#8221;) to, among other things, modify certain financial covenants, waive the noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLC&#8217;s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending June 30, 2024, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2019 Credit Agreement had deferred financing costs of $3,661, of which $1,617 were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $2,044 were capitalized on the consolidated condensed balance sheets. There was no loss on debt refinancing and modification as a result of the March 2023 amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;1, 2023, $416,585 was outstanding on the Term Loan Facilities, net of original issue discount of $2,876 and deferred financing costs of $1,251. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. The Company recorded $223 and $203 for deferred cost amortization in interest expense for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively. The Company had $29,000 and no outstanding borrowings on its Revolver as of April&#160;1, 2023 and December&#160;31, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Term Loan Facilities was $414,402 as of April&#160;1, 2023. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instruments within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically entered into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company had one non-designated interest rate swap agreement that was terminated on October 28, 2022. The Company received $7,738 upon the swap&#8217;s termination. The swap was carried at fair value on the balance sheet with changes in fair value recorded as interest income or expense within the consolidated condensed statements of operations and comprehensive loss. Net interest income of $3,924 was recorded related to the change in fair value of the interest rate swap for the three months ended April&#160;2, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414036752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurementsThe process for determining fair value has not changed from that described in the Annual Report on Form 10-K for the year ended December 31, 2022.<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 inputs. The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount - Current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount - Long Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CartiHeal contingent consideration- Sales Milestone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioness contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Deferred Amount and contingent consideration attributable to CartiHeal have been reclassified to discontinued operations within the December 31, 2022 balance sheet. CartiHeal was fully deconsolidated during the first quarter of 2023. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Amount</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Deferred Amount that resulted from the CartiHeal Acquisition was calculated based on the total amount payable on each due date for the five payment tranches including applicable interest. As previously discussed, the Company reached a settlement Agreement with the Former Securityholders. Pursuant to the Settlement Agreement, the Company was relieved of the obligations under the Deferred Amount. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs. As previously discussed, the Company reached a settlement agreement with the Former Securityholders and was relieved of the CartiHeal Contingent Consideration obligations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures and Note 14. Discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unobservable inputs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioness contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4% - 6.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2025</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness totaled $287 and $269 for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss. Changes in contingent consideration related to the CartiHeal Acquisition totaled $1,710 for the three months ended April&#160;1, 2023 and is reported within discontinued operations, net within the consolidated condensed statements of operations and comprehensive loss. Pursuant to the Settlement Agreement, the Company was relieved of CartiHeal related obligations. The Company deconsolidated the remaining $68,961 contingent consideration liability as a result. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding the deconsolidation of CartiHeal.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414039984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CompensationAndEmployeeBenefitPlansAbstract', window );"><strong>Compensation And Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Equity-based compensation</a></td>
<td class="text">Equity-based compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates an equity-based compensation plan (the &#8220;2021 Plan&#8221;), which allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;), other stock-based awards, and cash awards (collectively, &#8220;Awards&#8221;). As of April&#160;1, 2023, 11,278,656 shares of Class A common stock were authorized to be awarded and 2,762,266 shares were available for Awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense for Awards granted under the 2021 Plan for the three months ended April&#160;1, 2023 and April&#160;2, 2022, totaled $1,718 and $4,731, respectively. The expense is primarily included in selling, general and administrative expense with a nominal amount in research and development expense on the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were $430 and $1,225 income tax benefit related to this expense for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;1, 2023, the Company granted time-based RSUs which vest at various dates through January&#160;3, 2027. RSU compensation expense is recognized over the vesting period, which is typically between 1 and 4 years. Unamortized compensation expense related to the RSUs totaled $2,265 at April&#160;1, 2023, and is expected to be recognized over a weighted average period of approximately 2.50 years. A summary of the RSU award activity for the three months ended April&#160;1, 2023 is as follows (number of units in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant-date fair value per unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at April 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;1, 2023, the Company granted time-based stock options which vest over 2 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 2 to 4 years, net of actual forfeitures. A summary of the Company&#8217;s assumptions used in determining the fair value of the stock options granted during the three months ended April&#160;1, 2023 is shown in the following table.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of stock options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended April&#160;1, 2023 was $1.10 per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company&#8217;s peers&#8217; common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $9,614 at April&#160;1, 2023, and is expected to be recognized over a weighted average period of approximately 3.78 years. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows for the three months ended April&#160;1, 2023 (number of options in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.44 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and vested at April 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.74 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#8217;s Class A common stock for options that had exercise prices lower than $1.07 per share, the closing price of the Company&#8217;s Class A common stock on March&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates a non-qualified Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which provides for the issuance of shares of the Company&#8217;s Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of April&#160;1, 2023, the aggregate number of shares reserved for issuance under the ESPP was 1,181,830. A total of 222,076 shares were issued and $128 of expense was recognized during the three months ended April&#160;1, 2023. A total of 48,993 shares were issued and $158 of expense was recognized during the three months ended April&#160;2, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CompensationAndEmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation And Employee Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CompensationAndEmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414075728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; equity</a></td>
<td class="text">Stockholders&#8217; equity<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company closed an IPO of 9,200,000 shares of Class A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters' over-allotment option. In connection with the IPO, the Company completed the following transactions (&#8220;Transactions&#8221;).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amended and restated the limited liability company agreement of BV LLC (&#8220;BV LLC Agreement&#8221;), to, among other things, (i) provide for a new single class of common membership interests in BV LLC (&#8220;LLC Interests&#8221;); (ii) exchange all of the existing membership interests in BV LLC (&#8220;Original BV LLC Owners&#8221;) for new LLC Interests; and (iii) appoint Bioventus Inc. as the sole managing member of BV LLC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amended and restated the Bioventus Inc. certificate of incorporation to, among other things, (i) provide for an increase in the authorized shares of Class A common stock; (ii) provide for Class B common stock with voting rights but no economic interest, which shares were issued to the Original BV LLC Owners on a one-for-one basis with the number of LLC Interests they owned; and (iii) provide for undesignated preferred stock.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquired, by merger, ten entities that were Original BV LLC Owners (&#8220;Former LLC Owners&#8221;), for which the Company issued 31,838,589 shares of Class A common stock as merger consideration (&#8220;IPO Mergers&#8221;). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the IPO Mergers, the 31,838,589 shares of Class B common stock were canceled, and the Company recognized the 31,838,589 LLC Interests at carrying value, as the IPO Mergers are considered to be a recapitalization transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment and restatement of certificate of incorporation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company amended and restated its certificate of incorporation to, among other things, provide for: (i) the authorization of 250,000,000 shares of Class A common stock with a par value of $0.001 per share; (ii) the authorization of 50,000,000 shares of Class B common stock with a par value of $0.001 per share; (iii) the authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the BOD in one or more series; and (iv) the establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by the Smith &amp; Nephew, Inc. (the &#8220;Continuing LLC Owner&#8221;). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis upon the redemption or exchange of any outstanding LLC Interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must, at all times, maintain a one-to-one ratio between the number of outstanding shares of Class A common stock and the number of LLC Interests owned by the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BV LLC recapitalization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BV LLC Agreement provides that holders of LLC Interests may, from time to time, require the Company to redeem all or a portion of their LLC Interests for newly-issued shares of Class A common stock on a one-for-one basis. The Company may elect to settle any such redemption in shares of Class A common stock or in cash.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment also requires that the Company, at all times, maintain (i) a one-to-one ratio between the number of outstanding shares of Class A common stock and the number of LLC Interests owned by the Company and (ii) a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with any redemption, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the three months ended April 1, 2023 or during the year ended December&#160;31, 2022. The following table summarizes the ownership interest in BV LLC as of April&#160;1, 2023 and December&#160;31, 2022 (number of units in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LLC Interests</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ownership %</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LLC Interests</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ownership %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of LLC Interests owned</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioventus Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing LLC Owner</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,850&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414102256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income from continuing operations, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests &#8212; continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212;<br/>&#160;&#160;&#160;&#160;continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,876)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests &#8212; discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212;<br/>&#160;&#160;&#160;&#160;discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of Class A common stock outstanding - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,124,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,484,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock from continuing operations, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock from discontinued operations, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following number of weighted-average potentially dilutive shares as of April&#160;1, 2023 and April&#160;2, 2022 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LLC Interests held by Continuing LLC Owner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,786,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,786,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,517,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,757,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,373,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,006,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414063712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring costs</a></td>
<td class="text">Restructuring costs<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs are not allocated to the Company&#8217;s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company announced a restructuring plan in December 2022 (the &#8220;2022 Restructuring Plan&#8221;) that is intended to align the Company&#8217;s organizational and management cost structure to improve profitability and cash flow. The Company expects to incur $4,000 to $5,000 of pre-tax costs under the 2022 Restructuring Plan primarily consisting of employee severance and additional expenses for third-party and other related costs. Pre-tax charges recognized during the three months ended April&#160;1, 2023 and the year ended December&#160;31, 2022 totaled $262 and $4,581, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted restructuring plans for businesses acquired to reduce headcount, reorganize management structure and consolidate certain facilities during the second half of 2021 (the &#8220;2021 Acquisition Restructuring Plan&#8221;) and during the first quarter of 2022 (the &#8220;2022 Acquisition Restructuring Plan&#8221;). The Company planned total pre-tax charges for the 2021 Acquisition Restructuring Plan and 2022 Acquisition Restructuring Plan are $3,500 and $2,300, respectively. There was nominal activity related to the 2021 Acquisition Restructuring Plan during the three months ended April&#160;1, 2023 and $377, $719 and $2,487 recognized during the three months ended April&#160;2, 2022, and the years ended December 31, 2022 and 2021, respectively. The 2021 Acquisition Restructuring Plan is essentially completed. Costs incurred attributable to the 2022 Acquisition Restructuring Plan totaled $84, $200 and $1,479 during the three months ended April&#160;1, 2023 and April&#160;2, 2022, and the year ended December 31, 2022, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restructuring charges and payments for plans related to businesses recently acquired comprised of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">severance and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">temporary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">labor costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">charges </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at April 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413969488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company's annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended April&#160;1, 2023 and April&#160;2, 2022, the Company's effective tax rate was 0.1% and 26.3%, respectively. The decrease for the three months ended April&#160;1, 2023 was primarily due to changes in our forecasted effective rate and a net increase in reserve for uncertain tax positions. The change in the forecasted effective rate for the three months ended April&#160;1, 2023 compared to three months ended April 2, 2022 was primarily due to an increase in the valuation allowance applied to our net deferred tax assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company entered into a tax receivable agreement (&#8220;TRA&#8221;) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. As of April&#160;1, 2023, the Continuing LLC Owner had not exchanged LLC Interests for shares of Class A common stock and therefore the Company had not recorded any liabilities under the TRA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414121472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">Commitments and contingencies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 10 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of finance lease assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Includes variable lease cost and sublease income, which are immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to operating leases were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from financing leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet and other information related to operating leases were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,690</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities- current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities- noncurrent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,455</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,355</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,309</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,907</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524">Property, plant and equipment - net (finance leases)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities - current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years) for leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate for leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Operating lease assets totaling $618 attributable to CartiHeal was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Operating lease liabilities-current totaling $176 and operating lease liabilities-noncurrent of $442 were reclassified into current liabilities attributable to discontinued operations and long-term liabilities attributable to discontinued operations, respectively, within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental and legal contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Company&#8217;s complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bioventus shareholder litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina, Ciarciello v. Bioventus, Inc., No. 1:23&#8211; CV &#8211; 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserts violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees&#8217; Retirement System as lead plaintiff. The lead plaintiff&#8217;s amended consolidated complaint is due to be filed with the Court on June 12, 2023. Defendants&#8217; motion to dismiss the amended consolidated complaint is due on July 17, 2023. The Company believes the claims alleged lack merit and intends to defend itself vigorously. The outcome of the litigation is not presently determinable, and any loss is neither probable nor reasonably estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bioness patent litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, the Company, through its subsidiary Bioness, filed a lawsuit in the United States District Court for the Eastern District of Virginia against Aretech, LLC (&#8220;Aretech&#8221;) alleging infringement by Aretech of various patents related the Bioness&#8217; Vector Gait and Safety Support System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On August 8, 2022, Aretech filed an answer to the lawsuit denying infringement and asserting various affirmative defenses and counterclaims to the Bioness complaint. Bioness filed a motion to dismiss the defendant&#8217;s counterclaims on September 28, 2022. In response to Bioness&#8217; motion to dismiss the counterclaims, on October 19, 2022, Aretech filed an amended answer and counterclaims. On November 16, 2022, Bioness filed a partial motion to dismiss certain of the amended counterclaims. On January 23, 2023, the court granted-in-part Bioness&#8217; motion dismissing Aretech&#8217;s antitrust and inventorship-related counterclaims, but allowed certain of Aretech&#8217;s counterclaims to proceed. On March 23, 2023, the parties entered into a settlement and license agreement that resolved all claims in the litigation. The agreement also provides cross licenses to the parties for certain of their respective patents relevant to the claims asserted in the litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Misonix stockholder</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Stein v. Misonix, Inc., et al., Case No. 2:21-cv-05127 (E.D.N.Y.) (the &#8220;Stein Complaint&#8221;). The Stein Complaint named Misonix and members of its board of directors as defendants. The Stein Complaint was dismissed on April 6, 2022. On September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.) (the &#8220;Ciccotelli Complaint&#8221;) against Misonix, members of its board of directors, the Company, and its subsidiaries, Merger Sub I and Merger Sub II, as defendants. Plaintiff voluntarily dismissed the Ciccotelli Complaint on November 10, 2021. On October 12, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Rubin v. Misonix, Inc. et al., Case No. 1:21-cv-05672 (S.D.N.Y.) (the &#8220;Rubin Complaint&#8221;) and on October 15, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Taylor v. Misonix, Inc. et al., Case No. 1:21-cv-08513 (S.D.N.Y.) (the &#8220;Taylor Complaint&#8221;). The Rubin Complaint and the Taylor Complaint name Misonix and members of its board of directors as defendants. Plaintiffs voluntarily dismissed the Rubin and Taylor Complaints on January 21, 2022 and February 18, 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaints asserted claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021 or the Definitive Proxy Statement filed with the SEC on September 24, 2021, regarding Misonix and/or Bioventus&#8217; projections and J.P. Morgan&#8217;s financial analysis. The complaints had sought, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger; (ii) rescission in the event that the merger is consummated; and (iii) an award of costs, including attorneys&#8217; and experts&#8217; fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Misonix former distributor</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2017, Misonix&#8217;s former distributor in China, Cicel (Beijing) Science &amp; Technology Co., Ltd., filed a lawsuit against Misonix and certain of its officers and directors in the United States District Court for the Eastern District of New York. The complaint alleged that Misonix improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted Misonix&#8217;s motion to dismiss each of the tort claims asserted against Misonix, and also granted the individual defendants&#8217; motion to dismiss all claims asserted against them. On January 23, 2020, the court granted Cicel&#8217;s motion to amend its complaint, to include claims for alleged defamation and theft of trade secrets in addition to the breach of contract claim. Discovery in the matter ended on August 5, 2021. On January 20, 2022, the court granted Misonix&#8217;s summary judgment motion on Cicel&#8217;s breach of contract and defamation claims. Cicel&#8217;s motion for reconsideration of the court&#8217;s summary judgment ruling in Misonix&#8217;s favor was dismissed by the Court on April 29, 2022. On July 18, 2022, Cicel voluntarily dismissed the remaining claim for trade secret theft and later filed an appeal to the United States Court of Appeals for the Second Circuit. The Company believes that it has various legal and factual defenses to these claims and intends to vigorously defend the appeal of the lower court&#8217;s summary judgment rulings in its favor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bioness shareholder</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to closing the Bioness Acquisition, Bioness had been named as a defendant in a lawsuit, for which the Company is indemnified under the indemnification provisions contained in the Bioness Merger Agreement. The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting the acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover attorney fees and other expenses totaling approximately $3,000 incurred by the director and shareholder in connection with the matter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, the court issued a ruling granting, in part, plaintiff&#8217;s motion for summary judgment, awarding plaintiff attorney&#8217;s fees and related expenses incurred in connection with performance of the plaintiff&#8217;s directorial duties, and denying fees and expenses incurred in a non-director capacity. In its ruling, the court&#8217;s order also directed the parties to agree upon a process that will govern the payment of and challenges to plaintiff&#8217;s payment requests and required Bioness to pay 50% of the demanded amount into escrow if more than 50% of the total invoiced amount was in dispute. Pursuant to the court&#8217;s order, Bioness paid approximately $1,300 into escrow. On November 1, 2022, at a hearing before Delaware State Court of Chancery, the court ruled in favor of the former Bioness director awarding attorney&#8217;s fees in connection with the underlying pre-merger litigation and the advancement action in the amounts claimed, less approximately $50. On December 23, 2022, Bioness and the plaintiff entered into a settlement agreement resolving the matter for the aggregate sum of $2,500 payable to the plaintiff. The settlement was satisfied by releasing the $1,300 previously paid by Bioness and held in escrow and by an additional payment of $1,200. Pursuant to the indemnification obligations under the Bioness Merger Agreement, this subsequent payment was made on behalf of Bioness on December 28. 2022, by the selling majority shareholder under that agreement. The Company subsequently recovered the $1,300 paid into escrow from the selling Bioness shareholders pursuant an indemnification request under the Bioness Merger Agreement. An order dismissing the case was entered by the court on January 27, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2022, the above referenced minority shareholder of Bioness filed another action in the Delaware State Court of Chancery in connection with the Company&#8217;s acquisition of Bioness. This action names the former Bioness directors, the Alfred E. Mann Trust (Trust), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Company&#8217;s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bioness&#8217; and other the defendant&#8217;s motions was held before the Court of Chancery on January 19, 2023. The Company believes that there are various legal and factual defenses to the claims plaintiff made against us and intend to defend ourselves vigorously. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $853. An additional payment of $853 was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $1,707 will be paid to the seller within five days. The Company is required to pay royalties through 2026 of 5.0% on the first $569 in sales and 2.5% thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed, but during the second quarter of 2022, the Company elected to discontinue the development of MOTYS, the initial product candidate under development. On October 21, 2022, the Company provided notice to MTF of termination of the Development Agreement and the related cGTP Commercial Supply Agreement with MTF for MOTYS, effective December 20, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#8217;s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended April&#160;1, 2023 and April&#160;2, 2022 totaled $2,321 and $3,332, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a supply agreement entered on February 9, 2016 for the Company&#8217;s three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a supply agreement for the Company&#8217;s five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company causes letters of credit (&#8220;LOCs&#8221;) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of April&#160;1, 2023 and December&#160;31, 2022, the Company had one LOC outstanding for a nominal amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#8220;claims made&#8221; basis for expenses in excess of $200 per member per year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414075728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policies for recognizing sales have not changed from those described in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. The following table presents the Company&#8217;s net sales disaggregated by major products (Vertical) within each segment as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413565680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">SegmentsThe Company&#8217;s two reportable segments are U.S. and International. The Company&#8217;s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#8217;s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment adjusted EBITDA reconciled to loss before income taxes:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and related costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and succession charges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CartiHeal divestiture and debt restructuring</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,164)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,537)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414109552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued operations</a></td>
<td class="text">Discontinued operations<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of 100% of Company&#8217;s shares in CartiHeal to a Trustee. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details concerning the CartiHeal Settlement Agreement and its deconsolidation from the Company&#8217;s financial statements. CartiHeal had no sales for the three months ended April&#160;1, 2023 and year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes CartiHeal&#8217;s major classes of assets and liabilities as reported on the consolidated condensed balance sheets as of December 31, 2022 as the balances were fully deconsolidated as of April&#160;1, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major classes of assets included as part of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major liabilities included as part of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April&#160;1, 2023 and April&#160;2, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,492)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414073296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text">Subsequent events<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2023, Mr. Reali resigned as a director and officer of the Company, and Mr. Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023. Mr. Bihl succeeds Mr. Reali as the Company&#8217;s principal executive officer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2023, the Company repaid $15,000 on its revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2023 the Company entered into a definitive agreement to sell its Wound Business, including TheraSkin and TheraGenesis, for total potential cash consideration of $85,000, including $35,000 at closing, $5,000 deferred for 18 months and $45,000 in potential earn-out payments. The Company expects to net approximately $30,000 at closing after fees and expenses that will be used to repay existing debt. The sale of the Wound Business is expected to close approximately one week before the end of May 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413987152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared under the going concern basis of accounting, which presumes that the Company&#8217;s liquidation is not imminent; however, based on the Company&#8217;s current financial position and liquidity sources, including current cash balances, and forecasted future cash flows, the Company is at risk of violating certain of its financial covenants under the Credit and Guaranty Agreement, dated December 6, 2019 (as amended on October 29, 2021, July 11, 2022 and March 31, 2023).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If mitigating steps are not taken or are not successful, the Company is at substantial risk of failing its covenants in 2024. A breach of a financial covenant under the Credit and Guaranty Agreement could accelerate repayment of our obligations under the agreement. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4. Financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion concerning the Company&#8217;s long-term debt obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing plans to mitigate these conditions and events, such as considering various additional cost cutting measures, and exploring additional divestiture opportunities such as the recently announced plan to divest certain assets within its Wound Business; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. Therefore, these plans do not alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of efforts to improve its financial condition, on February 27, 2023, the Company reached an agreement to return the assets and liabilities of CartiHeal (2009) Ltd. (&#8220;CartiHeal&#8221;), a wholly-owned subsidiary of the Company, to its former securityholders. The deconsolidation of CartiHeal relieved deferred consideration liabilities and milestone obligations related to the acquisition of CartiHeal. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding the acquisition and subsequent deconsolidation of CartiHeal. In addition, the Company announced a restructuring plan in December 2022 to align the Company&#8217;s organizational and management cost structure to improve profitability and cash flow. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an accelerated public company filer. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when emerging growth companies are required to adopt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414219552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are selected line items from our aforementioned impacted financial statements illustrating the effect of the error corrections thereon:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets &#8212; December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (b)(d)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,890)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital (a)(b)(c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest (a)(c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets &#8212; December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (b)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,867)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital (a)(b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated statements of changes in stockholders&#8217; and members equity as of December 31, 2022 and December 31, 2021 have been corrected to reflect the above adjustments. The Company revised the amounts originally reported for the years ended December 31, 2022 and December 31, 2021 for the following items:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Recorded a $65,821 decrease to additional paid-in capital and a corresponding increase to noncontrolling interest. This action effectively rebalanced equity appropriately between the Company and its noncontrolling interests according to their respective BV LLC ownership interests.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Recorded a $73,867 decrease to deferred income tax balances and an increase to additional paid in capital to reflect the correction of an error that occurred during the calculation of deferred taxes at the Company&#8217;s IPO.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Reflects the entry as discussed in (a) above and additional rebalancing activity of $2,588 relating to the issuance of Class A common stock for equity plans during the year ended December 31, 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects the entry as discussed in (b) and an additional $1,977 increase to deferred income tax balances and a reduction to additional paid in capital to reflect the deferred tax impact during the year ended December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951418155968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net of allowances, consisted of the following as of:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Other receivables of $350 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Accounts receivable of $5,012 was reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding assets held for sale and the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Allowance for credit losses of $898 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details regarding assets held for sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in credit losses were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to held for sale</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,401)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following as of:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess and obsolete reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Raw material inventory of $642 attributable to CartiHeal has been reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Finished goods inventory of $1,481 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following as of:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Prepaid and other current assets of $134 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 balance sheet. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following as of:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,204)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net before currency translation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Intellectual property and accumulated depreciation attributable to CartiHeal totaling $410,200 and $11,327, respectively, were reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Net intellectual property and customer relationships of $23,458 and $8,377, respectively, were reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding assets held for sale.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Company recorded an impairment loss of $78,615 in the U.S. reporting segment of net intellectual property attributable to a business held for sale. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding businesses held for sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following as of:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus and commission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Bonus and commissions of $588 were reclassified into liabilities held for sale within the April&#160;1, 2023 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other liabilities attributable to CartiHeal of $384 were reclassified into current liabilities attributable to discontinued operations within December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951417700272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Held for Sale Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the major classes of assets and liabilities of the Wound Business that were classified as held for sale were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of assets classified as held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance of $898</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of liabilities classified as held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes CartiHeal&#8217;s major classes of assets and liabilities as reported on the consolidated condensed balance sheets as of December 31, 2022 as the balances were fully deconsolidated as of April&#160;1, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major classes of assets included as part of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major liabilities included as part of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April&#160;1, 2023 and April&#160;2, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,492)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of consideration for the CartiHeal Acquisition was comprised of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal of cash at closing</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales Milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Remeasurement of the Company&#8217;s equity method investment in CartiHeal, net of equity losses as a result of the purchase. The remeasurement included a gain of $23,709 calculated as the difference between the fair value and the carrying value of the Company&#8217;s investment in CartiHeal at the acquisition date and was recognized in other income during the third quarter of 2022 on the consolidated condensed statements of operations and comprehensive loss. The fair value was based upon: (i) the consideration transferred to members owning 89.97% of CartiHeal&#8217;s fully diluted shares; (ii) calculating the value of CartiHeal&#8217;s fully diluted shares based upon the transferred consideration; and (iii) applying the calculated value to the Company&#8217;s 10.03% ownership in CartiHeal&#8217;s fully diluted shares at the acquisition date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,106&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resulting goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CartiHeal&#8217;s intangibles consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual Property - US Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual Property - International Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413981584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended Term Loan due October 2026 (9.19% at April&#160;1, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver due October 2025 (9.28% at April&#160;1, 2023)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414058576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount - Current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Amount - Long Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CartiHeal contingent consideration- Sales Milestone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioness contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Deferred Amount and contingent consideration attributable to CartiHeal have been reclassified to discontinued operations within the December 31, 2022 balance sheet. CartiHeal was fully deconsolidated during the first quarter of 2023. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioness contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4% - 6.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2025</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413223392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CompensationAndEmployeeBenefitPlansAbstract', window );"><strong>Compensation And Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text">A summary of the RSU award activity for the three months ended April&#160;1, 2023 is as follows (number of units in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant-date fair value per unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at April 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">A summary of the Company&#8217;s assumptions used in determining the fair value of the stock options granted during the three months ended April&#160;1, 2023 is shown in the following table.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of stock options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows for the three months ended April&#160;1, 2023 (number of options in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at April 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.44 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable and vested at April 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.74 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CompensationAndEmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation And Employee Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CompensationAndEmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414156752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock', window );">Schedule of Other Ownership Interests</a></td>
<td class="text">The following table summarizes the ownership interest in BV LLC as of April&#160;1, 2023 and December&#160;31, 2022 (number of units in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LLC Interests</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ownership %</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LLC Interests</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ownership %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of LLC Interests owned</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioventus Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing LLC Owner</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,850&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other units or shares or classes of ownership in a partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415799168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income from continuing operations, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests &#8212; continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212;<br/>&#160;&#160;&#160;&#160;continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,876)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests &#8212; discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212;<br/>&#160;&#160;&#160;&#160;discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of Class A common stock outstanding - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,124,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,484,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock from continuing operations, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock from discontinued operations, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of Class A common stock, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following number of weighted-average potentially dilutive shares as of April&#160;1, 2023 and April&#160;2, 2022 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LLC Interests held by Continuing LLC Owner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,786,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,786,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,517,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,757,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,373,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,006,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414231504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restructuring charges and payments for plans related to businesses recently acquired comprised of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">severance and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">temporary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">labor costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">charges </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at April 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415758784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of finance lease assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Includes variable lease cost and sublease income, which are immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to operating leases were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from financing leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Assets and Liabilities, Lessee</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet and other information related to operating leases were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,690</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities- current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,854</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities- noncurrent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,455</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,355</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,309</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,907</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524">Property, plant and equipment - net (finance leases)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities - current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years) for leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate for leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Operating lease assets totaling $618 attributable to CartiHeal was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Operating lease liabilities-current totaling $176 and operating lease liabilities-noncurrent of $442 were reclassified into current liabilities attributable to discontinued operations and long-term liabilities attributable to discontinued operations, respectively, within the December 31, 2022 consolidated balance sheets. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. Acquisitions and divestitures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14. Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details regarding the deconsolidation of CartiHeal.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414056352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">The following table presents the Company&#8217;s net sales disaggregated by major products (Vertical) within each segment as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pain Treatments</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restorative Therapies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical Solutions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414166512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment adjusted EBITDA reconciled to loss before income taxes:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and related costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and succession charges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CartiHeal divestiture and debt restructuring</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,164)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,537)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414041568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Balance Sheet and Statement of Operation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the major classes of assets and liabilities of the Wound Business that were classified as held for sale were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of assets classified as held for sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance of $898</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying amounts of liabilities classified as held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes CartiHeal&#8217;s major classes of assets and liabilities as reported on the consolidated condensed balance sheets as of December 31, 2022 as the balances were fully deconsolidated as of April&#160;1, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major classes of assets included as part of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amounts of major liabilities included as part of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April&#160;1, 2023 and April&#160;2, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bioventus Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,492)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951417053616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>employee</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BVLLCMember', window );">BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">1,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416110432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Error Corrections (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 2,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">647,042<span></span>
</td>
<td class="nump">960,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">492,475<span></span>
</td>
<td class="nump">490,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">51,851<span></span>
</td>
<td class="nump">86,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="nump">$ 240,362<span></span>
</td>
<td class="nump">412,222<span></span>
</td>
<td class="nump">$ 593,808<span></span>
</td>
<td class="nump">607,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Equity Rebalancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Error Correction in Calculation of Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (73,867)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Equity Rebalancing for Issuance of Stock Through Equity Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Deferred Tax Impact For 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=bvs_EquityRebalancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=bvs_EquityRebalancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=bvs_DeferredTaxImpactFor2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=bvs_DeferredTaxImpactFor2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951588149552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Schedule of Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 125,945<span></span>
</td>
<td class="nump">$ 143,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: Allowance for credit losses</a></td>
<td class="num">(7,401)<span></span>
</td>
<td class="num">(7,022)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">118,544<span></span>
</td>
<td class="nump">136,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: Allowance for credit losses</a></td>
<td class="num">$ (898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951414176464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Components of Accounts Receivable (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">11.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bvs_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bvs_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415989888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Schedule of Accounts Receivable, Allowance for Credit Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="num">$ (7,022)<span></span>
</td>
<td class="num">$ (3,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale', window );">Reclassification to held for sale</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="num">$ (7,401)<span></span>
</td>
<td class="num">$ (4,254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Reclassification To Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416137088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials and supplies</a></td>
<td class="nump">$ 24,729<span></span>
</td>
<td class="nump">$ 19,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">65,461<span></span>
</td>
<td class="nump">67,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross</a></td>
<td class="nump">90,190<span></span>
</td>
<td class="nump">86,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Excess and obsolete reserves</a></td>
<td class="num">(2,237)<span></span>
</td>
<td class="num">(1,851)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">87,953<span></span>
</td>
<td class="nump">84,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415962176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Schedule of Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 4,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">12,792<span></span>
</td>
<td class="nump">14,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 17,192<span></span>
</td>
<td class="nump">18,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951411692704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying amount</a></td>
<td class="nump">$ 815,322<span></span>
</td>
<td class="nump">$ 938,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(298,194)<span></span>
</td>
<td class="num">(297,204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss', window );">Intangible assets, net before currency translation</a></td>
<td class="nump">517,128<span></span>
</td>
<td class="nump">641,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss', window );">Currency translation</a></td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">516,039<span></span>
</td>
<td class="nump">639,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying amount</a></td>
<td class="nump">676,549<span></span>
</td>
<td class="nump">790,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(188,094)<span></span>
</td>
<td class="num">(187,767)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">23,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">78,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property | Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,327)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying amount</a></td>
<td class="nump">61,325<span></span>
</td>
<td class="nump">61,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(45,563)<span></span>
</td>
<td class="num">(44,319)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying amount</a></td>
<td class="nump">57,950<span></span>
</td>
<td class="nump">67,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(57,950)<span></span>
</td>
<td class="num">(58,842)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">8,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying amount</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying amount</a></td>
<td class="nump">13,998<span></span>
</td>
<td class="nump">13,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">$ (6,587)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951412742720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Intangibles (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization, remainder of fiscal year</a></td>
<td class="nump">$ 22,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization, year one</a></td>
<td class="nump">26,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization, year two</a></td>
<td class="nump">22,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization, year three</a></td>
<td class="nump">20,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization, year four</a></td>
<td class="nump">$ 19,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951417008768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Goodwill Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,462,000<span></span>
</td>
<td class="nump">$ 7,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of assets</a></td>
<td class="num">$ (189,197,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415327808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_GrossToNetDeductionsCurrent', window );">Gross-to-net deductions</a></td>
<td class="nump">$ 66,557<span></span>
</td>
<td class="nump">$ 71,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus and commission</a></td>
<td class="nump">9,462<span></span>
</td>
<td class="nump">9,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AccruedSalariesAndEmployeeBenefitsCurrent', window );">Compensation and benefits</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">11,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">6,210<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income and other taxes</a></td>
<td class="nump">4,496<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">22,201<span></span>
</td>
<td class="nump">16,947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">115,769<span></span>
</td>
<td class="nump">111,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus and commission</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AccruedSalariesAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Salaries And Employee Benefits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AccruedSalariesAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_GrossToNetDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross-To-Net Deductions, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_GrossToNetDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951406787424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,615,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">$ 60,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember', window );">Wound Business | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AssetImpairmentChargesAfterTax', window );">Impairment charges, after tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_ElronMember', window );">Elron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G Preferred Stock | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction related fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee', window );">Business acquisition, percentage of shares transferred to trustee</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Line of Credit | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Call Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Amount Payable by July 1 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Amount Payable by September 1 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Amount Payable by January 1 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Amount Payable by January 1 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Amount Payable by January 1 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Deferred Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate', window );">Deferred amount interest rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Trailing Twelve Month Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Intellectual Property | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Intellectual Property | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AssetImpairmentChargesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges, After Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AssetImpairmentChargesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Percentage Of Shares Transferred To Trustee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_ElronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_ElronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bvs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bvs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJuly12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJuly12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableBySeptember12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableBySeptember12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJanuary12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJanuary12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJanuary12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJanuary12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJanuary12027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountPayableByJanuary12027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_TrailingTwelveMonthSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_TrailingTwelveMonthSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bvs_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bvs_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415933488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and divestitures - Held for Sale Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, allowance</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 7,022<span></span>
</td>
<td class="nump">$ 4,254<span></span>
</td>
<td class="nump">$ 3,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | Wound Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net of allowance of $898</a></td>
<td class="nump">4,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationInventory', window );">Inventory</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">31,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="nump">37,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">1,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, allowance</a></td>
<td class="nump">$ 898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951406749088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details) - CartiHeal Ltd - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total consideration</a></td>
<td class="nump">$ 393,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Remeasurement gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares', window );">Contingent consideration transferred percentage</a></td>
<td class="nump">89.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationConsiderationTransferredTransactionCosts', window );">Transaction related costs</a></td>
<td class="nump">8,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts', window );">Subtotal of cash at closing</a></td>
<td class="nump">108,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously held equity interest</a></td>
<td class="nump">39,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total consideration</a></td>
<td class="nump">393,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">Deferred Amount | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">183,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">Sales Milestone | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 61,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Gross, Including Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Percentage Of Members Owning Diluted Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationConsiderationTransferredTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationConsiderationTransferredTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951411698928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,462<span></span>
</td>
<td class="nump">$ 7,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Fair value of consideration</a></td>
<td class="nump">$ 393,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="nump">3,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangibles</a></td>
<td class="nump">410,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets', window );">Investment and other assets</a></td>
<td class="nump">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="num">(171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="num">(79,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(2,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">333,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 60,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investment And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416800624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and divestitures - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) - CartiHeal Ltd<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 12, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Fair Value</a></td>
<td class="nump">$ 410,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">Intellectual Property | US Segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Fair Value</a></td>
<td class="nump">$ 351,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">Intellectual Property | International Segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Fair Value</a></td>
<td class="nump">$ 58,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951406734464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Schedule Of Long-Term Debt Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">$ (41,320)<span></span>
</td>
<td class="num">$ (33,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(1,251)<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(2,876)<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">404,265<span></span>
</td>
<td class="nump">385,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">9.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 420,712<span></span>
</td>
<td class="nump">$ 420,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">9.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951407354784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>USD ($) </div>
<div>derivative</div>
</th>
<th class="th">
<div>Apr. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 06, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing on revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of interest rate swap agreements | derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCashReceivedOnHedge', window );">Received settlement</a></td>
<td class="nump">$ 7,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember', window );">Term Loan | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DebtInstrumentCovenantLiquidityMinimum', window );">Debt instrument, covenant, liquidity, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit facility, borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings on line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt | Term Loan Facility, July 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing on revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt | Term Loan Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,000<span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentCovenantLiquidityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentCovenantLiquidityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCashReceivedOnHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period on settlement of a hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCashReceivedOnHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityJuly2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityJuly2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416821280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 17,718<span></span>
</td>
<td class="nump">$ 17,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember', window );">CartiHeal Ltd | Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities:</a></td>
<td class="nump">17,718<span></span>
</td>
<td class="nump">281,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | CartiHeal Ltd | Deferred Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of deferred consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | CartiHeal Ltd | Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="nump">17,718<span></span>
</td>
<td class="nump">17,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities:</a></td>
<td class="nump">17,718<span></span>
</td>
<td class="nump">281,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | CartiHeal Ltd | Deferred Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of deferred consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | CartiHeal Ltd | Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="nump">$ 17,718<span></span>
</td>
<td class="nump">$ 17,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_DeferredAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415016224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details) - Level 3 - Valuation Technique, Discounted Cash Flow - Payment discount rate - Bioness contingent consideration<br></strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Payment discount rate</a></td>
<td class="nump">0.064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Payment discount rate</a></td>
<td class="nump">0.068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416044672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember', window );">Carti Heal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation', window );">Contingent consideration liability written off for deconsolidation</a></td>
<td class="nump">$ 68,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Liability Written Off For Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951406848064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (146)<span></span>
</td>
<td class="num">$ (5,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized compensation expense, options</a></td>
<td class="nump">9,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bvs_A2021PlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">4,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (430)<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price, (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be awarded (in shares)</a></td>
<td class="nump">11,278,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available to be awarded (in shares)</a></td>
<td class="nump">2,762,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unamortized compensation expense, RSUs</a></td>
<td class="nump">$ 2,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense net yet amortized, period for recognition</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense net yet amortized, period for recognition</a></td>
<td class="text">3 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available to be awarded (in shares)</a></td>
<td class="nump">1,181,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares)</a></td>
<td class="nump">222,076<span></span>
</td>
<td class="nump">48,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bvs_A2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bvs_A2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416954848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) - RSUs<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 01, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled (in shares) | shares</a></td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant-date fair value per unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">12.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">12.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415027744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">35.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of stock options (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416956544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Schedule of Stock Options Roll Forward (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">8,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/canceled (in shares) | shares</a></td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">8,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable and vested (in shares) | shares</a></td>
<td class="nump">5,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">12.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">11.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable and vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term</a></td>
<td class="text">7 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable and vested (in years)</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable and vested | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415615648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in public offering (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BoardOfDirectorLengthOfTerm', window );">Length of board of directors term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio', window );">Shares issued or issuable, redemption of LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BVLLCMember', window );">BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Number of LLC interest held (in shares)</a></td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio', window );">Shares issued or issuable, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of entities acquired | segment</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares issued in acquisition (in shares)</a></td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio', window );">Shares issued or issuable, required stock to LLC interest ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares cancelled (in shares)</a></td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio', window );">Cancellation ratio, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BoardOfDirectorLengthOfTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Board Of Director, Length Of Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BoardOfDirectorLengthOfTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellation Ratio, Required Stock To LLC Interest Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CancellationRatioRequiredStockToLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CommonStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CommonStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Number Of Interests Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Or Issuable, Redemption Of LLC Interest Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Or Issuable, Required Stock To LLC Interest Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bvs_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bvs_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415586848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity - Schedule of Other Ownership Interests (Details) - BV LLC - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">LLC Interests</a></td>
<td class="nump">$ 62,508<span></span>
</td>
<td class="nump">$ 62,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">79.80%<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bvs_BVLLCMember', window );">Continuing LLC Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">LLC Interests</a></td>
<td class="nump">$ 15,787<span></span>
</td>
<td class="nump">$ 15,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">20.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bvs_BVLLCMember', window );">Bioventus and Continuing LLC Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">LLC Interests</a></td>
<td class="nump">$ 78,295<span></span>
</td>
<td class="nump">$ 77,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of ownership interest in a limited liability company (LLC), including portions attributable to both the parent and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70191-108054<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_ContinuingLLCOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_ContinuingLLCOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusAndContinuingLLCOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusAndContinuingLLCOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415580864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">$ (100,018)<span></span>
</td>
<td class="num">$ (14,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Loss attributable to noncontrolling interest - continuing operations</a></td>
<td class="nump">20,360<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212; continuing operations</a></td>
<td class="num">(79,658)<span></span>
</td>
<td class="num">(10,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net (loss) income from discontinued operations, net of tax</a></td>
<td class="num">(74,429)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest - discontinued operations</a></td>
<td class="nump">14,937<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss attributable to Bioventus Inc. Class A common stockholders &#8212; discontinued operations</a></td>
<td class="num">$ (59,492)<span></span>
</td>
<td class="num">$ (401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of Class A common stock outstanding - basic (in shares)</a></td>
<td class="nump">62,124,752<span></span>
</td>
<td class="nump">60,484,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of Class A common stock outstanding - diluted (in shares)</a></td>
<td class="nump">62,124,752<span></span>
</td>
<td class="nump">60,484,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share)</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share of Class A common stock from continuing operations, basic (in dollars per share)</a></td>
<td class="num">(1.28)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)</a></td>
<td class="num">(0.96)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)</a></td>
<td class="num">(0.96)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of class A common stock, basic (in dollars per share)</a></td>
<td class="num">(2.24)<span></span>
</td>
<td class="num">(0.19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of class A common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951417703696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">25,373,887<span></span>
</td>
<td class="nump">25,006,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember', window );">LLC Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">8,517,045<span></span>
</td>
<td class="nump">8,757,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,070,105<span></span>
</td>
<td class="nump">462,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415849232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="num">(1,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee severance and temporary labor costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="num">(1,653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2022Member', window );">Restructuring Plan of 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2022Member', window );">Restructuring Plan of 2022 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring plan, expected costs</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2022Member', window );">Restructuring Plan of 2022 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring plan, expected costs</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2021Member', window );">Restructuring Plan of 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring plan, expected costs</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">$ 2,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_AcquisitionRestructuringPlanOf2022Member', window );">Acquisition Restructuring Plan Of 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring plan, expected costs</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=bvs_RestructuringPlanOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=bvs_AcquisitionRestructuringPlanOf2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=bvs_AcquisitionRestructuringPlanOf2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951506905520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">26.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_TaxReceivableAgreementPercent', window );">Tax receivable agreement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_TaxReceivableAgreementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_TaxReceivableAgreementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951408368432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2022</div></th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
<th class="th"><div>Aug. 19, 2021</div></th>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Aug. 23, 2019</div></th>
<th class="th"><div>Feb. 09, 2016</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_StopLossInsuranceThresholdPerMemberPerYear', window );">Stop loss insurance, threshold per member per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember', window );">Three Injection OA Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_SupplyCommitmentTerm', window );">Supply commitment, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_SupplyCommitmentRenewalTerm', window );">Supply commitment, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bvs_HAProductMember', window );">HA Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData', window );">Collaborative arrangement, amount payable upon transfer of customer data</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification', window );">Collaborative arrangement, amount payable upon obtaining product certification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne', window );">Collaborative arrangement, royalty percentage, threshold one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold', window );">Collaborative arrangement, sales threshold for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo', window );">Collaborative arrangement, royalty percentage, threshold two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid', window );">Loss contingency, damages sought, percentage of demanded amount to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold', window );">Loss contingency, damages sought, percentage under dispute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_LitigationSettlementExpenseOfClaimant', window );">Expense of claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Accrual payments</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_LitigationSettlementAmountRecoveredFromEscrow', window );">Amount recovered from escrow</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_HarborMember', window );">Harbor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_CollaborativeArrangementRoyaltyPercentage', window );">Collaborative agreement, royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_SupplyCommitmentTerm', window );">Supply commitment, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember', window );">Supplier of Single Injection OA Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,321<span></span>
</td>
<td class="nump">$ 3,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LitigationSettlementAmountRecoveredFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Recovered From Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LitigationSettlementAmountRecoveredFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LitigationSettlementExpenseOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Expense Of Claimant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LitigationSettlementExpenseOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Sought, Amount Under Dispute, Percentage Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Sought, Percentage Of Demanded Amount To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_StopLossInsuranceThresholdPerMemberPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stop Loss Insurance, Threshold Per Member Per Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_StopLossInsuranceThresholdPerMemberPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SupplyCommitmentRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SupplyCommitmentRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SupplyCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SupplyCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_HAProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_HAProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_HarborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_HarborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413298736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Schedule of Lease, Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease assets</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from financing leases</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 9,141<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413062240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 16,063<span></span>
</td>
<td class="nump">$ 16,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities- current</a></td>
<td class="nump">3,854<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities- noncurrent</a></td>
<td class="nump">13,455<span></span>
</td>
<td class="nump">14,355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">17,309<span></span>
</td>
<td class="nump">17,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Property, plant and equipment - net (finance leases)</a></td>
<td class="nump">9,034<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities - current</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities - noncurrent</a></td>
<td class="nump">6,602<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="nump">$ 7,021<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, weighted average remaining lease term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (in percent)</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate (in percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities- current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities- noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951406753632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">$ 119,059<span></span>
</td>
<td class="nump">$ 117,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">103,978<span></span>
</td>
<td class="nump">104,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Pain Treatments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">40,995<span></span>
</td>
<td class="nump">47,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Restorative Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">32,488<span></span>
</td>
<td class="nump">28,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Surgical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">30,495<span></span>
</td>
<td class="nump">27,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">15,081<span></span>
</td>
<td class="nump">13,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International | Pain Treatments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">5,331<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International | Restorative Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">5,614<span></span>
</td>
<td class="nump">5,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International | Surgical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">$ 4,136<span></span>
</td>
<td class="nump">$ 3,616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_PainTreatmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_PainTreatmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_RestorativeTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_RestorativeTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_SurgicalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_SurgicalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951408320336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Apr. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income, net</a></td>
<td class="num">$ (9,694)<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(2,129)<span></span>
</td>
<td class="num">(3,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and succession charges</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="num">(78,615)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(100,164)<span></span>
</td>
<td class="num">(19,537)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income, net</a></td>
<td class="num">(9,694)<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(16,473)<span></span>
</td>
<td class="num">(12,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition and related costs</a></td>
<td class="num">(1,175)<span></span>
</td>
<td class="num">(7,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and succession charges</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="num">(1,846)<span></span>
</td>
<td class="num">(4,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">CartiHeal divestiture and debt restructuring</a></td>
<td class="num">(5,330)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="num">(78,615)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Other items</a></td>
<td class="num">(3,665)<span></span>
</td>
<td class="num">(2,336)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember', window );">U.S. | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems', window );">Segment adjusted EBITDA</a></td>
<td class="nump">14,712<span></span>
</td>
<td class="nump">4,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember', window );">International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems', window );">Segment adjusted EBITDA</a></td>
<td class="nump">$ 2,239<span></span>
</td>
<td class="nump">$ 2,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951413065024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued operations - Schedule of Balance Sheet (Details) - Disposed of by Sale - Carti Heal<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash', window );">Cash</a></td>
<td class="nump">$ 1,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Other receivables</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationInventory', window );">Inventory</a></td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">6,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">398,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="nump">408,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration', window );">Current portion of deferred consideration</a></td>
<td class="nump">117,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="nump">79,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent', window );">Deferred consideration</a></td>
<td class="nump">79,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">67,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">$ 347,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Current Portion of Deferred Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Deferred Consideration, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951416008896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued operations - Schedule of Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Loss on deconsolidation</a></td>
<td class="nump">$ 60,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_NonRefundablePayments', window );">Non-refundable payments</a></td>
<td class="nump">10,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Disposed of by Sale | Carti Heal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">1,728<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss from discontinued operations</a></td>
<td class="num">(8,098)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense (income), net</a></td>
<td class="nump">4,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other expense</a></td>
<td class="nump">61,442<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">66,331<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,429)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="nump">14,937<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent', window );">Net loss attributable to Bioventus Inc.</a></td>
<td class="num">$ (59,492)<span></span>
</td>
<td class="num">$ (401)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NonRefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Refundable Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NonRefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_CartiHealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139951415303936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events (Details) - Subsequent Event - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>Apr. 06, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Discontinued Operations, Held-for-sale | Wound Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount', window );">Closing amount</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationConsiderationTransferredDeferredAmount', window );">Deferred amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod', window );">Deferral period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments', window );">Earn-out payments</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses', window );">Fees and expenses</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment on revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationConsiderationTransferredDeferralPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Deferral Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationConsiderationTransferredDeferralPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationConsiderationTransferredDeferredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Deferred Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationConsiderationTransferredDeferredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Earn-Out Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Fees and Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_WoundBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>bvs-20230401_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bvs="http://www.bioventus.com/20230401"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bvs-20230401.xsd" xlink:type="simple"/>
    <context id="i52374b540ac247b597e34da4fa742209_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="iaeb6a37547344ac9aad38b881bb074fc_I20230512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="i97dc12b8bc0f49cea30123f6d5847691_I20230512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="if08a873c6cd84f99985971869a2e69d5_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i98f850194f2743b69d130043cb5b83f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf9ff7993c944b92a4bd359489e2eaa2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie046b8a033654588aa416481153be819_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i1493c3a9bf294032a142cf4e7b1411f1_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i8f5136a92c314002a0d0deb5ff33d794_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a77552c277241be958f7a79b2d31cfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia42904e813fb462d9dc6296126b6c027_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65a95c8964854c0ea4aa51dff316c9de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac87cf08602645f0945125525d86864a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc3dce8230ba45119afeb7423bdc2a1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35eb85bfb0344959b05e48db02d1b900_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4c947a790104295ae50f5e97a83a1ab_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i22d0b8a085484d5a96145656d90e23f7_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="if617eff8c0b4423a8de0547fb060a911_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i29ffafbcd14f4f3491e4973003291b92_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="id808e9e13e51453cba22d69e6a1554cb_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i87ab2fcc47d94402b6ff38f1493add69_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i38144d2db4094669a2e5d9b194b1693f_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i28d0b867fa5943ee856db6daa307d849_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i75851ee9fae0477786892678243e9687_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="id4ad4457b2c747a98ed6638c8f80b5d0_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i1cc622914d7b4479b2f4c07410226853_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfc88da3e7a54c03802bbbf690e497ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53d734f3503d4c13a2b1d964e624c27c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i213ccc4548494407ab148000e45c5ee6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fe3f930f8964d73927338dd023b5b3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9135fb165b2b49eb9e44a33009bf3cba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f04a78cee4c46279f51766a4be3f9e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i951147d4bd5642aabe42d38fc7311981_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="id23499e24e764f54b220fbe6a3325161_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ieb5615fc08d24ff491b3bbb101a069f3_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i7aa0f2fc11fb4924a6e04334ad932d5a_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i2accf9b821314f3bad4a25bd77746a1c_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="ice6503af7f6a41e696df5e32d186a5ab_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="i3c005cdfc09f429a8813448058fdbe09_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="i2d6267e834a1443ea11cee027905e439_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="ie45a988315ec4dc5bee4e8ba6723c8a4_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="ib9ddf2d069db4849bee3aa72aa59d848_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="i34aedf09bd844e088614ef324e5b1a3e_I20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="ia9c0fbba09b6496a91ab1685ca96483a_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i96799592dc2f46ce951da575359089fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b737d439dfc4c049b11e5aa48820383_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8306c6c2e0b4d1497206736d20693f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i178bff9b64ed42ff81776518c4189b1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66988f17121f479d987ec3f6a81fa043_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:EquityRebalancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i673ea96088114535bb4f91785d7e72e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:EquityRebalancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib42fe425b80941f48b28aca4ecd33ade_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:ErrorCorrectionInCalculationOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7a4b0b14d204b00844c680753360a35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:ErrorCorrectionInCalculationOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9117991cb301409cb832cbb9dd88871a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:EquityRebalancingForIssuanceOfStockThroughEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i109b3bd8eade44d394a7ae03c62fed13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">bvs:DeferredTaxImpactFor2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i688306a9d855467ca189676c7d19b6cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i7ebfe75a99584627ab0c086aca856452_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bvs:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ib35b3d444a98478a89240114e08c3916_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i5da15f6d37344cae8110d560e17ae77c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15da563fbc3546a19bdbbb85a92d1730_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i764545bc9ad949eea69c3be558616715_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62641fead14343468e0f3d886ba7a6ca_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i70245e2f7da94059ae58287036f79af6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i98809c525a964717bfbdd03b0ff34ad8_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ib032dbd53db04880ad76314b46e1e9e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa5c981648904e9b80b64c023d15fa42_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i0a4af42355014f9cba9ef136263bb498_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b54bc099ff64cdf83d289598ea44468_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49ccfda1a2d4406197267d9884f36892_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i0829461c73da4cc59c0a31bf4e8fdc00_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i1fad609af52e483890feb9ddbe45ddcc_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i00ae122881df443da212c3e259b30aac_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ia6e7f859e2de4e2e9bea8834f864b660_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i3fa935ec3263472594eb58a3df3c2f65_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i8c00fe1120844212b2fb0039b542d999_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i2e2d5c54e1f649d99de1b04258d57249_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="ic4a9d2699d26472ebf9e64d62424696d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a2781c3a6a04fffb4599cdde6001d9a_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="ibcd6603021274a84ba8c4328e971097b_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="iaf3b97bb69794fb5a74d6264e30703c9_D20220712-20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bvs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="i18d2594349e442f5aa4558186daaac0f_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i975eb89011db4560ba2bcc2086c60016_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJuly12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i49db16cff51046329cf250fb5ac89e34_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableBySeptember12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i5f444d9528924284aadcb1788007ff06_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJanuary12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="ibe7aa5cbcd4e4539a13ab3abf8e8c9f7_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJanuary12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i99f4d905bbb34b16a050cfc582ff2ea9_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJanuary12027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="icd90e131a7bf4a278b55541190ffe001_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i22f12085d4424a5b9d5157232a465367_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:TrailingTwelveMonthSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5248f80680c045179f84e361ed1ba3cc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1247f024a75548eba0514a747599cee5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6ac987576c674d6cbf92d74ed2df1b8b_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i2f97030445ee47889c1b38177e4a3a23_D20230213-20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountPayableByJuly12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="i80bae10979d2454580adedb3b2a6c481_D20230227-20230227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="iebb5d183410449b1908570eb5651c0ca_D20230227-20230227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:ElronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="i3f75d22eb20045e4a96e961e0a09ca92_D20230227-20230227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="ib6a06c7e9385495f98dce248522deff1_D20230227-20230227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="iad8c492357214f09a0573977291f320f_D20220712-20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="ie2752ec5905e4a858220620c6f6f6ab1_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="iff82fadf30aa4ced9c49563731d130d5_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="i4dafe4682a984e7cb23b5b32626f258b_D20220703-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-03</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="id9f99c0f111c40f4b35d75accc7a326e_I20220711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="i387d0ba33ecf49d4ae4397e0b83f1636_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="if9202c7ec716435aaa3082106434860a_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bvs:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i61effdba045e47f7bcb546d32bcd31c3_D20220712-20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="iabe5797c14874b5fa84ef6a0757f4034_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="id56740f57a5e43aca22cc898a646c454_D20220712-20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-12</endDate>
        </period>
    </context>
    <context id="i88bdab0f0d4d463fa6398c22775dd54e_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="if35ea5d41b5b485f883e49f6ae8fdc25_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="icaa1cdc09860462383a3492205a224d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad26eeedf4bb4bbda6790671a5bdff05_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ie7c79358e91348e084baee11c93bc142_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9d9f38043fa4c028d7126e56c12e67d_I20191206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="i0a847747334d4e8ba6cc594e9dcdc9df_I20191206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="i047d1c54f41c47e5b83b854cf55d776f_D20220711-20220711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="i76987f19a9c44ee4a8433bbef3cdc2e3_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="ibfe65f363fbb4e1787d372f14d6ed933_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c898ba97cad4ab6b65934419909f8e3_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="if392e17bdeab412496b7af16131a7aba_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityJuly2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ie47412cb505a4ad484457826df28f027_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ic5b6613394184391936737b585ea4d43_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefdfaf8115ec421eb8f0d09f38e11095_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i5252c9ad17db48d1988ebc871c1bdd70_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="idaa95b5adcef4db8a8cea991408aafb7_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ie42967b0b3404880892fef4d2d36f92f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8df20ba54290443e83e1927334a06e3b_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i031d0465b2ad444390d6fdd9eb9e80b5_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="idd2c5ab49e734e9bb3b79cadbd93c30d_D20221028-20221028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-28</startDate>
            <endDate>2022-10-28</endDate>
        </period>
    </context>
    <context id="idd8a6fd92ded42a9ae62df80dfacd5bc_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i6bff1a06928a49e684d3ba0fc962346e_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="iebfb6349253c4e3280459ada7054fafc_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ic9956bf782d64ea1bd2b96df630c6d75_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3cb0bc9269646a2a591dda918400054_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:DeferredAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93ef7632e5b4407e87abff23d73b268c_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="iad35dc89c0f44e299cceeb0f722b12ee_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i961477208dd54a26b2ccf6e64c912305_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2705284e689b4650bdc0ab6b3be0e86e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice6df20213a847689d562669ec8c0eb2_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i848696f930194e1d8e9f0ab3b2518dab_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="iabedf0c4173d4d219e5a4a7c97ef7c6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief782f56b0bd4c4ba52ecbb991a64e23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7804b256d26143329ce8b1c8bfdeb7ee_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i13a1162e408641aeb42666f59ea6e3c1_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i04b95fd7a3234324ac4b5f9ada511b59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5fb4f2d80cc44287b347cfd75169b5a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i323f1175cc564a45a27343e1faec2e7a_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i87246041109544cf8fb41b557c4513b7_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i7dd7797604384c719b067b4dc6cf3c42_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i41945a367312405a869c8711b228f155_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i2479f6ea4f13427d9a5c83ccd6ec9614_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="iaf9b7a1c5154425c8c24265aade7743e_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="id47714ccd1064cd1b7ff9cd499c1fc55_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i094ee1c434914509890caa47833deaa5_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i13e007318d4e4feaa4ef8dfd98ef3932_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i61c0aac0923c4bc7a1174492aa74af25_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="idcb624597b214504b42d1ecb52e98a8c_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ib4fed2036ec84bff9a6d9d643492a512_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia114f5984aa5487d94a7e5a2f9dd47c1_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i7c391ae2f04e49239fb30fb662e626cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7a367805653149a6bd4c69f62610cedd_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i90132788802142b1b654aab8435a8fb6_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i977440bad8ac48adba402f0ac93702bf_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i455ecc502ecd43c8a0240143ce3f7613_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bvs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="ibd867d34482345439425ee5ab5255266_I20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="i9b2195c740e24fa3b47460484cabe3cd_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i24e141c8e8054b31a54f133d51dc223c_I20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="ifa4f6b39d2a74a85bb0d2edd723d8a7b_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i77db743857a644e9a0320ade7e6a5d2a_I20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="i8504a2e91ba84dfd8a6e426662ca386d_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="id407ba4965db4b79a8fd6e8dc15e23b0_I20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="id9ca1d77ddbc4f598510ff5ccb96d1ee_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i4f28a6c8e2a44fe9b2c8149437d14601_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i81b082e001c941259cd51349877d6268_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i00441e04d2f34f5aa2bc5b4cd5b53c4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3508c22776a24e489023f7a0f04b1e3e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ad3381ddd884b6e8d796b931cdf5c98_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i6f9f122c646249b6ba80f94f1d27ce49_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ideca15b277be4a5a80bfeb0ef5169075_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb4089d2b0824f41a82aadcb2951f8f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:ContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7cc806e7a00b4d2aa28a38d41193abfe_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i621e34ed2397424fbf3217653350ee1d_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i4bda7af6c3f04de89092466d5c2c03b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifaac88ea486b416ea279e01dd9088634_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusAndContinuingLLCOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ab3e51b5150437a9922627be2e141bb_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i9bd02248ff5a4c349ca283983f6fb643_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i826a2b73e7024f2bbb971c7170189c53_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i11cb3b3b1ef8485b8260800eb571e90a_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i3ec54bc3bcce4e0cba062fc969afa5c3_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i8e76064517ae4b5e9d9e3a322bd12ee1_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="iab463c35574b4f8ca9e4c2daa0b62cf5_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ie37855daa1184dc78d7515b03e113ea3_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i7889eb67185b4a7fb1f2a59966756eb0_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ie6c1ba06aa134309858a469840e28937_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i544e8c2721cb486fa712dc07d475a475_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i6cafecddd27a4b469315f336ef3ed50d_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="if5b22816b48c442798421ebd10c98786_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i8eab176afd194ef687ade1014da11d08_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bd943395fc7408b9c20e3013b149ed9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:RestructuringPlanOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief777ae06245484290df025fea9e0d3d_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i96d6024603534c5ea5af4d437fd6040e_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i2c209e0543284533a6ae897763a26743_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:AcquisitionRestructuringPlanOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i471155b226eb40c690334fd2874e4f56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad9c750d3df948a0bfe95f8639979859_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73d4aa340243422abe25f197db4c3b59_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="idc2830275f954d0484c2c3f9c65710b4_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="iaa741b924a3549099b1b5111321fbba2_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="iac4cade8aa8d459cab8ee8fe3bbf1bdd_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i7304128a25744503b8891660f963b710_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="ieb6cde82adad47b0938be5a986d174e9_I20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="i75a9b09aeea047d997e35f25ccf68400_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0195281e11e649b9b130d85d5763b801_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i269ccd94849d4d2ba444fb9e4e51782b_I20210819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-19</instant>
        </period>
    </context>
    <context id="i2e70fc04918244f2994b165f1a124430_D20210819-20210819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-19</startDate>
            <endDate>2021-08-19</endDate>
        </period>
    </context>
    <context id="id46b7f3929c94e30aa38e125d5c1fb3a_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i270d95a5216e45eca0d7972f80ac3edb_D20221223-20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="i095df0e9d3b640bdad1576e09c931392_D20221228-20221228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="if8a13de58ac44d4ca44be08ddc84b03b_D20221228-20221228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:HAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-10</startDate>
            <endDate>2021-11-10</endDate>
        </period>
    </context>
    <context id="i76920cf66e21420bb4f0e4336311f5de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:HAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6c32e79d61845d9a2b670c38ccad90a_D20190823-20190823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-23</startDate>
            <endDate>2019-08-23</endDate>
        </period>
    </context>
    <context id="ia7b5a733f4024b57989f06cbdb94c545_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i3cc6602c201f442ea229c5c1441c0506_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-09</startDate>
            <endDate>2016-02-09</endDate>
        </period>
    </context>
    <context id="if1c5e680b22440109145605beffbd285_D20201222-20201222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="i85686a2c0fc64b148872e20370023dd3_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i0c67e34f91494006b4a5bd61a96084e8_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ie6a1353106cf447ca65be040ed56b6d0_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i6030c2e18bb140f29cddb91bd8f88824_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="if757a0e5be5f42b2b08f3b701abff4af_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i671287cbd69c46ef9a385740e8dbd49c_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i8b7e30af75d7460f92fef399bf827f6b_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i5376f01c85d24e8cb1ee7b9a3e0894e7_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ib9051c125b094e389ac08453ae46745f_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i1101072b1f7f4d799ac5ea6ab0705a18_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="idc532b467295442c823324184b9ebe64_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i260d2a092ee24cd08e4a8a8282a56d28_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ib522fb2bab9949e69f42dd7e1b248159_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ia4f3a6d840244f7f92937f02e11c783d_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:SurgicalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i915d046eaaee44c7881495d91a8a7d49_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="id797d5aea258432e9c7d0ca865cdaee7_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ibc30004a37a84a44919da8653b8b5a85_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="ic681d0153e8d44509633594dee0fc4c2_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="id7f9608964984704ad0bc120b4fb197e_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i10818604d3f84a4b9f8471323205d604_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i221faa30c740451eb553a94e1f7b7017_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:CartiHealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-02</endDate>
        </period>
    </context>
    <context id="i72a1c8e6882a4bff9613fb79fbc5344d_D20230406-20230406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-06</startDate>
            <endDate>2023-04-06</endDate>
        </period>
    </context>
    <context id="i852f13a0b8994a0b9c4197a33edb508f_I20230510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="i6bbfa06653064902b83b28df8ecfa4bc_D20230510-20230510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:WoundBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-10</startDate>
            <endDate>2023-05-10</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>bvs:employee</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bvs:reporting_unit</measure>
    </unit>
    <unit id="tranche">
        <measure>bvs:tranche</measure>
    </unit>
    <unit id="derivative">
        <measure>bvs:derivative</measure>
    </unit>
    <unit id="segment">
        <measure>bvs:segment</measure>
    </unit>
    <unit id="vote">
        <measure>bvs:vote</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl8yLTEtMS0xLTE5NDkyOQ_1f65354c-a697-4039-a719-c98001b24b6e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl81LTEtMS0xLTE5NDkyOQ_ebe66632-90b4-417b-8e31-592cdc5a088d">0001665988</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl84LTEtMS0xLTE5NDkyOQ_77546604-b736-4b7f-893f-1babe6b17c79">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl8xNi0xLTEtMS0xOTQ5Mjk_0af18a71-71af-4c45-9399-2c6f9321c9d9">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80L2ZyYWc6M2I1MTQzZDE1ZmI0NGIzYzk4ZGNkYTg2MDZmMzc1ZWUvdGFibGU6NDdlN2EyODZmOTcxNGI5Njk1YThhZWExNzIyMGFhNGIvdGFibGVyYW5nZTo0N2U3YTI4NmY5NzE0Yjk2OTVhOGFlYTE3MjIwYWE0Yl8xNy0xLTEtMS0xOTQ5Mjk_783558cb-1acc-4aca-bfe7-98c378db45d9">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDI5_1dcfb747-1997-4f62-88db-84a86e44c996">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NjEzZmM4MjcyYWY3NGY4NWExOGQwYzU2Nzk3NWQ4MzIvdGFibGVyYW5nZTo2MTNmYzgyNzJhZjc0Zjg1YTE4ZDBjNTY3OTc1ZDgzMl8wLTAtMS0xLTE5NDkyOQ_db7be0c1-5f52-4156-9e62-b96dd55ccdbf">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18xNjc_e2e37d07-13d8-4f5e-9870-fe54c4c86506">2023-04-01</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6M2UxODI0NzM5MmM5NDhhNzhkYzYxYzA1ZWE4ZjFhZjkvdGFibGVyYW5nZTozZTE4MjQ3MzkyYzk0OGE3OGRjNjFjMDVlYThmMWFmOV8wLTAtMS0xLTE5NDkyOQ_b3fb16d0-94f5-405d-938b-f12053be90e7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMz_367f6484-9c77-4284-9c04-bdc6878e3708">001-37844</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMw_75d63c1a-3333-4b17-b02c-8ab39206720a">BIOVENTUS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18wLTAtMS0xLTE5NDkyOQ_be7012ad-cff3-426a-9dbd-5233c47efcbf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18wLTItMS0xLTE5NDkyOQ_ed5faaee-cfda-444c-b316-1381caef3741">81-0980861</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18zLTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOjYyNzViYTE2MGFkZjQ1MjI4MTg3N2ZjYjAxYWYzMmRmXzQ_1c74a39b-a7a5-48e6-b58c-58709c19020a">4721 Emperor Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y18zLTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOjYyNzViYTE2MGFkZjQ1MjI4MTg3N2ZjYjAxYWYzMmRmXzg_de7a295a-07f1-4b1d-b6c7-5a35ac66838d">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y180LTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOmE3NWI1ODYzMzM5YTQxNmFiMWEwZGE5ZDkxZGQ4YzgzXzQ_c7e12db7-8050-4895-af9f-109b734ba442">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y180LTAtMS0xLTE5NDkyOS90ZXh0cmVnaW9uOmE3NWI1ODYzMzM5YTQxNmFiMWEwZGE5ZDkxZGQ4YzgzXzg_9cc1d233-b372-4b75-94c4-a2e8b9155c54">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6NGE2YTA3MGM2ODdiNGY5OGJmNDY4MmIyMjYxZDJmNGMvdGFibGVyYW5nZTo0YTZhMDcwYzY4N2I0Zjk4YmY0NjgyYjIyNjFkMmY0Y180LTItMS0xLTE5NDkyOQ_53865b20-a675-4056-a84d-3e13bf6da12c">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDM0_b093a719-4e77-4853-a33e-6266d3781939">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMx_d37d6fea-70f1-4093-8dbd-3b6f2788fa59">474-6700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6ZDkxY2RmYjgwZGVlNDc3ZjgzNjk5NGUxODBiMmUzNDkvdGFibGVyYW5nZTpkOTFjZGZiODBkZWU0NzdmODM2OTk0ZTE4MGIyZTM0OV8xLTAtMS0xLTE5NDkyOQ_fe465e07-05b2-41ae-a048-b443fd28e7ab">Class A Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6ZDkxY2RmYjgwZGVlNDc3ZjgzNjk5NGUxODBiMmUzNDkvdGFibGVyYW5nZTpkOTFjZGZiODBkZWU0NzdmODM2OTk0ZTE4MGIyZTM0OV8xLTEtMS0xLTE5NDkyOQ_acbc4e00-fb55-47bb-8bef-1eb16e59bf9e">BVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6ZDkxY2RmYjgwZGVlNDc3ZjgzNjk5NGUxODBiMmUzNDkvdGFibGVyYW5nZTpkOTFjZGZiODBkZWU0NzdmODM2OTk0ZTE4MGIyZTM0OV8xLTItMS0xLTE5NDkyOQ_fd21cadd-7b82-49c5-96fa-0fa30063ef58">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDM1_2fef7d53-7981-412d-a123-75d2f2e9f362">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDMy_8d42b3d3-2bba-4951-a714-fa6ab8020718">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6MmE3OTBmMGQ2NTc2NGEzYWE0NDcxNjQ3NzdiOTViOGQvdGFibGVyYW5nZToyYTc5MGYwZDY1NzY0YTNhYTQ0NzE2NDc3N2I5NWI4ZF8wLTMtMS0xLTIyNjU2Ng_9741b8bd-c9d5-4074-8f92-eda4e01ab358">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6MmE3OTBmMGQ2NTc2NGEzYWE0NDcxNjQ3NzdiOTViOGQvdGFibGVyYW5nZToyYTc5MGYwZDY1NzY0YTNhYTQ0NzE2NDc3N2I5NWI4ZF8xLTQtMS0xLTE5NDkyOQ_04870ba7-d902-43e7-b4bd-f5df5d4661a8">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGFibGU6MmE3OTBmMGQ2NTc2NGEzYWE0NDcxNjQ3NzdiOTViOGQvdGFibGVyYW5nZToyYTc5MGYwZDY1NzY0YTNhYTQ0NzE2NDc3N2I5NWI4ZF8yLTQtMS0xLTE5NDkyOQ_ffc6d98e-720b-464e-9775-48bc0a2cfe7d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18yMDM2_3c8f9df9-65fb-43fe-8144-8ae397605f16">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM180OTQ3ODAyMzI3MDMw_f0040b2e-a21c-47b4-96b8-ab7d8401649c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iaeb6a37547344ac9aad38b881bb074fc_I20230512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18xOTMy_8587f332-f51f-44e3-b889-a6501ed551f2"
      unitRef="shares">62486725</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i97dc12b8bc0f49cea30123f6d5847691_I20230512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xL2ZyYWc6NzIwY2ZkYjhmMTQ1NDg1MWEyMTMyY2U2MzU3OTEzMzMvdGV4dHJlZ2lvbjo3MjBjZmRiOGYxNDU0ODUxYTIxMzJjZTYzNTc5MTMzM18xOTgy_24891739-7ae7-414d-a2c5-80de1b79e3aa"
      unitRef="shares">15786737</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMi01LTEtMS0xOTQ5Mjk_6f78b36e-9fe6-4adf-8462-d173ff5ce7f9"
      unitRef="usd">119059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMi03LTEtMS0xOTQ5Mjk_56d3c6e2-66e6-46ae-a53a-327c1fc4b14e"
      unitRef="usd">117290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjo0YjQyODdjM2Y3YWM0MzBhODcyZGRiZDAyOWJmZDI4OF82NA_4959689f-4a5e-471c-b15c-8c4a0f02cb59"
      unitRef="usd">14339000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjo0YjQyODdjM2Y3YWM0MzBhODcyZGRiZDAyOWJmZDI4OF82OA_a3d4891b-4e27-4c46-b894-e6b59463b8e1"
      unitRef="usd">9218000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy01LTEtMS0xOTQ5Mjk_4ebf14b6-43d0-4189-9477-99b3e2cdc663"
      unitRef="usd">45140000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMy03LTEtMS0xOTQ5Mjk_8598e660-aa20-4dc1-b9bb-cbbde3786a26"
      unitRef="usd">41588000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNC01LTEtMS0xOTQ5Mjk_73578f0e-7371-48a6-9693-31bb31f7337a"
      unitRef="usd">73919000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNC03LTEtMS0xOTQ5Mjk_91900987-5934-4a63-ac98-f53f51fae2fe"
      unitRef="usd">75702000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNS01LTEtMS0xOTQ5Mjk_69798614-c9c0-44d2-9f19-67afa124564f"
      unitRef="usd">80858000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNS03LTEtMS0xOTQ5Mjk_04240f13-ca59-4f2f-8eb0-1b100213de8d"
      unitRef="usd">86124000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNi01LTEtMS0xOTQ5Mjk_e44ea684-5789-44f0-b7e5-de551b730db3"
      unitRef="usd">3771000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNi03LTEtMS0xOTQ5Mjk_e87fc751-fc5f-4aee-8d7a-4dc8a7ec11f9"
      unitRef="usd">6928000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNy01LTEtMS0xOTQ5Mjk_6b361373-ed6b-43ae-a000-b9dc70550b53"
      unitRef="usd">317000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfNy03LTEtMS0xOTQ5Mjk_984d0adf-0810-43fe-86f1-a3fab4acadb7"
      unitRef="usd">577000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOC01LTEtMS0xOTQ5Mjk_a6069c35-32c6-4122-ad93-c94ebe6782fe"
      unitRef="usd">287000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOC03LTEtMS0xOTQ5Mjk_8b855133-61dc-4b3d-a14b-ed2fca5b7b23"
      unitRef="usd">269000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DepreciationAndAmortization
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOS01LTEtMS0xOTQ5Mjk_b85bab56-222d-4a4c-a86b-3973f6ea6b6e"
      unitRef="usd">2129000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfOS03LTEtMS0xOTQ5Mjk_cb317be1-91e4-4de4-a7ab-32be0334d059"
      unitRef="usd">3254000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTAtNS0xLTEtMTk0OTI5_806bba9c-3d8a-4e02-a8e1-d5b9695444ef"
      unitRef="usd">78615000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTAtNy0xLTEtMTk0OTI5_822cf4d9-da5a-47fb-ac02-bb0600813d4e"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingIncomeLoss
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTItNS0xLTEtMTk0OTI5_e50af166-cb5f-46a4-b1d4-267a50cce74a"
      unitRef="usd">-92058000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTItNy0xLTEtMTk0OTI5_8c93989b-4409-4717-97b4-99c610ecd6df"
      unitRef="usd">-21450000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTMtNS0xLTEtMTk0OTI5_b9f7b372-1e8e-43c5-97d6-184187f5da60"
      unitRef="usd">-9694000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTMtNy0xLTEtMTk0OTI5_23b38b28-e018-42b8-9967-689264e1933c"
      unitRef="usd">1550000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTQtNS0xLTEtMTk0OTI5_c1167361-def5-4648-bd33-9c03bfa08e29"
      unitRef="usd">1588000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTQtNy0xLTEtMTk0OTI5_761dba21-981f-4be1-ad09-9a18ae9389fb"
      unitRef="usd">363000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTUtNS0xLTEtMTk0OTI5_cb188ee0-685e-43b3-80f8-a5878e81d056"
      unitRef="usd">-8106000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTUtNy0xLTEtMTk0OTI5_80d003d9-cce0-47fe-a73f-87a930e01472"
      unitRef="usd">1913000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTYtNS0xLTEtMTk0OTI5_d3a90ef9-dfc4-4d2c-9d0b-ee13fe0a1f4d"
      unitRef="usd">-100164000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTYtNy0xLTEtMTk0OTI5_7c833e57-4701-43cc-bf93-b4eb0a208420"
      unitRef="usd">-19537000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTctNS0xLTEtMTk0OTI5_15f3b1ea-cd82-4125-a5e8-037f3bbf491e"
      unitRef="usd">-146000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTctNy0xLTEtMTk0OTI5_2799c544-b93c-444e-a6b4-406bff307624"
      unitRef="usd">-5132000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTgtNS0xLTEtMTk0OTI5_929fb60e-c54a-443f-ab74-4c296278ea1c"
      unitRef="usd">-100018000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTgtNy0xLTEtMTk0OTI5_008990f6-ae09-4731-a377-b2e9f8e79859"
      unitRef="usd">-14405000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNS0xLTEtMjA1Mjc0_af781833-2b37-451a-ac76-29e7a666aa65"
      unitRef="usd">-74429000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNy0xLTEtMjA1Mjc0_5cf943f4-c3bb-46f9-9771-8679b2eb67dd"
      unitRef="usd">-401000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNS0xLTEtMjA5MDQ3_592145ee-eeaf-4e78-b49c-ce35b3866124"
      unitRef="usd">-174447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNy0xLTEtMjA5MDQ3_9fd9c572-0e75-4d69-9d38-2934f3f35ee6"
      unitRef="usd">-14806000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNS0xLTEtMTk0OTI5_bd4cb1ac-2b26-44f1-aaea-644af287b0e0"
      unitRef="usd">-20360000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMTktNy0xLTEtMTk0OTI5_7faa21e0-efaf-490c-8f3d-87dcf687b84b"
      unitRef="usd">-3529000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjEtNS0xLTEtMjE0MDIy_ab3cb1ad-cbb3-4f0d-877e-8821caff0db3"
      unitRef="usd">-14937000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjEtNy0xLTEtMjE0MDIy_28a4f071-46b8-453b-817e-4741252193ad"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNS0xLTEtMTk0OTI5_d88dca1a-cc0e-424c-8014-91361b41d509"
      unitRef="usd">-139150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjAtNy0xLTEtMTk0OTI5_199f45e6-ca60-4bb0-9245-d88c8e9cf055"
      unitRef="usd">-11277000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjItNS0xLTEtMTk0OTI5_8ebdc0a9-2895-4e40-a475-9cd2e63cc073"
      unitRef="usd">-100018000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjItNy0xLTEtMTk0OTI5_9a668a94-79ed-47dc-a07e-22fcd5fb8620"
      unitRef="usd">-14405000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjQtNS0xLTEtMTk0OTI5_9505799e-b459-4eb5-b4e5-c4e59aa6f5d1"
      unitRef="usd">657000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjQtNy0xLTEtMTk0OTI5_dea767e0-271f-42a4-83fc-f077f608d5cf"
      unitRef="usd">-682000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjUtNS0xLTEtMTk0OTI5_b5c501ea-8d83-4e88-9cbe-5da35260d1e4"
      unitRef="usd">-99361000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjUtNy0xLTEtMTk0OTI5_4430e4bd-d432-457c-b8a7-b5803163444b"
      unitRef="usd">-15087000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjYtNS0xLTEtMTk0OTI5_625a5283-1d86-43ee-a54b-aaa91aa427ba"
      unitRef="usd">20226000</bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations>
    <bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjYtNy0xLTEtMTk0OTI5_b8e25166-1cb4-47fa-bce4-511d020fc522"
      unitRef="usd">3669000</bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations>
    <bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNS0xLTEtMjE0MDg3_3ea709e3-18e7-49f4-a057-2a6509505392"
      unitRef="usd">14937000</bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations>
    <bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNy0xLTEtMjE0MDg3_7a80705a-d7f0-4414-866a-a8fcbca89e3a"
      unitRef="usd">0</bvs:ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjctNS0xLTEtMTk0OTI5_241f9c73-87ba-4e55-aafc-3385cf53bb4d"
      unitRef="usd">-64198000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjctNy0xLTEtMTk0OTI5_31957620-e0e6-427d-893c-bdf1198ba53a"
      unitRef="usd">-11418000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNS0xLTEtMTk0OTI5_b03ca516-a186-4d40-849c-eb9ace7928a3"
      unitRef="usdPerShare">-1.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNS0xLTEtMTk0OTI5_bfb43913-de54-4f88-b4f5-ce965cb8a414"
      unitRef="usdPerShare">-1.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNy0xLTEtMTk0OTI5_6bf7111d-b123-46c9-b2aa-d40ff044536d"
      unitRef="usdPerShare">-0.18</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMjktNy0xLTEtMTk0OTI5_86e755d4-e6d8-46c4-988e-26c6a5191f82"
      unitRef="usdPerShare">-0.18</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjE1ODU1_6912ab97-5cb9-4f1b-9bfa-c86e7c4bb957"
      unitRef="usdPerShare">-0.96</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjE1ODU1_bf19b76c-fbb6-4429-830b-fd60fd4bf1ee"
      unitRef="usdPerShare">-0.96</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjE1ODU1_33d39feb-c3c9-4a12-adea-e68d77910a22"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjE1ODU1_a9e84df8-b77a-4536-9d7d-fccf19836603"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjA5MDUz_272cc204-4587-4c3c-a262-11cc17e13591"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNS0xLTEtMjA5MDUz_6fe78d61-0066-4983-97d9-ab96a48a7db9"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjA5MDU5_23282a4a-c2e8-449e-83b0-9e8f6e0d5e38"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzMtNy0xLTEtMjA5MDU5_b737bd29-b5fe-421c-b928-038b3a0e0f93"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNS0xLTEtMTk0OTI5_c4eaa163-8f6a-4e02-b5e8-1cb8bb7acab3"
      unitRef="shares">62124752</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNS0xLTEtMTk0OTI5_f7c58b2f-8d1d-42b4-9980-6b3abd15c221"
      unitRef="shares">62124752</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNy0xLTEtMTk0OTI5_669abd42-75ee-4bbc-9606-eff35b4b53cf"
      unitRef="shares">60484969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8xOS9mcmFnOjRhMWZkMTlmNzg0MjRhODZiNTY1MWM3NDU3NGIwMTNhL3RhYmxlOmZmNTRjM2M2ZjdhNDRiYzJhNjhlZjYzNTFhMGQ1MWVmL3RhYmxlcmFuZ2U6ZmY1NGMzYzZmN2E0NGJjMmE2OGVmNjM1MWEwZDUxZWZfMzEtNy0xLTEtMTk0OTI5_c6c358ab-6275-4192-a14b-b78b567f820e"
      unitRef="shares">60484969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMy0xLTEtMS0xOTQ5Mjk_d4d4adea-6c93-4abb-83a1-e6554b614bd8"
      unitRef="usd">47102000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMy0zLTEtMS0xOTQ5Mjk_ae47e722-e6ef-4904-80c0-2c814788d157"
      unitRef="usd">30186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNS0xLTEtMS0xOTQ5Mjk_ff18c16c-cf0c-46bc-a817-390472ebb8ec"
      unitRef="usd">118544000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNS0zLTEtMS0xOTQ5Mjk_776fb93c-38e1-4586-96e7-7d7dab246c96"
      unitRef="usd">136295000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNi0xLTEtMS0xOTQ5Mjk_55d8a95b-97c8-43c8-af65-cc6bd17bc6a3"
      unitRef="usd">87953000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNi0zLTEtMS0xOTQ5Mjk_1975ba56-dd80-4bd2-b470-fd40345f80c0"
      unitRef="usd">84766000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNy0xLTEtMS0xOTQ5Mjk_0be00cc2-4db2-4441-88e7-858b3ccc6834"
      unitRef="usd">17192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNy0zLTEtMS0xOTQ5Mjk_25d918e6-8990-4953-ac75-7fc1c9d327d1"
      unitRef="usd">18551000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0xLTEtMS0yMTQyNDQ_da23a49e-233b-4d19-b6ba-c700d84f558e"
      unitRef="usd">37873000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0zLTEtMS0yMTQyNDQ_262d4916-db9c-4bf8-be40-ed1ef1851d79"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0xLTEtMS0yMTQyMDM_e62ea808-a942-4fc5-a240-1aace90164ca"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0zLTEtMS0yMTQyMDM_6fb2c322-3172-4f93-ba21-973e2e663f01"
      unitRef="usd">2777000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0xLTEtMS0xOTQ5Mjk_de2b5a50-a3b4-44fc-b1b1-41ba575907a4"
      unitRef="usd">308664000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfOC0zLTEtMS0xOTQ5Mjk_2170d361-f551-4411-b4bf-f243037bc5d2"
      unitRef="usd">272575000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTEtMS0xLTEtMTk0OTI5_b236cfcf-2668-4d8e-98f5-31386d2a01fa"
      unitRef="usd">36556000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTEtMy0xLTEtMTk0OTI5_c8d06013-03e9-4c85-bbf4-862bb480be26"
      unitRef="usd">27456000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Goodwill
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTItMS0xLTEtMTk0OTI5_b85af913-7946-4b73-b29f-2a22e84e31a2"
      unitRef="usd">7462000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTItMy0xLTEtMTk0OTI5_4164b726-5ffc-43c2-9fc2-b1c4e9ae4d16"
      unitRef="usd">7462000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTMtMS0xLTEtMTk0OTI5_4f64f907-bbb1-4153-a3ee-3b0018bc6de0"
      unitRef="usd">516039000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTMtMy0xLTEtMTk0OTI5_ee9d4da8-485c-4247-bd98-7780057aca36"
      unitRef="usd">639851000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTQtMS0xLTEtMTk0OTI5_a02711dc-2568-4e09-8117-a2cf95529023"
      unitRef="usd">16063000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTQtMy0xLTEtMTk0OTI5_dbe1c2a7-d9cc-47b3-8e65-4904d7ffc071"
      unitRef="usd">16690000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTYtMS0xLTEtMTk0OTI5_d7f3b0ca-99ba-43c7-97f2-236a3f798aaa"
      unitRef="usd">2620000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTYtMy0xLTEtMTk0OTI5_c064a074-a6b3-4854-b5bc-4fe7dfc2ef35"
      unitRef="usd">2621000</us-gaap:LongTermInvestments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTgtMS0xLTEtMjE0MjEz_0c953616-047c-40f7-8aaf-eab9925d65c7"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTgtMy0xLTEtMjE0MjEz_693a7856-c5dc-4605-a2a8-5aad6a990ebc"
      unitRef="usd">405994000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTctMS0xLTEtMTk0OTI5_60040d30-ef7f-4baf-8b48-f86f66b0ae50"
      unitRef="usd">887404000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMTctMy0xLTEtMTk0OTI5_7e13ec81-bc21-428d-b093-f1b04cf8ada8"
      unitRef="usd">1372649000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjEtMS0xLTEtMTk0OTI5_bad16082-672b-4954-8fe5-91c21a1c27bf"
      unitRef="usd">32828000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjEtMy0xLTEtMTk0OTI5_cec3ed7d-346b-426f-96a6-798c60ff8146"
      unitRef="usd">36697000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjItMS0xLTEtMTk0OTI5_03797d1a-b5f2-4f22-8d78-0206edccd60f"
      unitRef="usd">115769000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjItMy0xLTEtMTk0OTI5_3dd529be-ba08-4780-bc4f-3ce6a7805820"
      unitRef="usd">111570000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjQtMS0xLTEtMTk0OTI5_c5e7927c-1d9e-49b0-a956-c161fa2c2355"
      unitRef="usd">41320000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjQtMy0xLTEtMTk0OTI5_3ac88680-369d-4498-a53c-6711ee6427fd"
      unitRef="usd">33056000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjYtMS0xLTEtMTk0OTI5_8ef7b633-f684-4609-bcd1-6b5607d8229b"
      unitRef="usd">4273000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjYtMy0xLTEtMTk0OTI5_5f0b9445-4352-488e-b240-2892fdb0a45f"
      unitRef="usd">3607000</us-gaap:OtherLiabilitiesCurrent>
    <bvs:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMS0xLTEtMjE0MjU4_07e119b1-e333-4bab-b141-ad7969f0dde8"
      unitRef="usd">1873000</bvs:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent>
    <bvs:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMy0xLTEtMjE0MjU4_7a2a923d-34b8-46d5-a6d5-609784e561b5"
      unitRef="usd">0</bvs:LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMS0xLTEtMjE0MjIx_e110c76b-248b-4170-8764-975cdb9b56dd"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMy0xLTEtMjE0MjIx_9d91fb50-7011-4920-805a-bfe28bb5a1af"
      unitRef="usd">119087000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjctMS0xLTEtMTk0OTI5_091c6520-ab1c-45a1-ac07-df1dc76dd0f9"
      unitRef="usd">196063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjctMy0xLTEtMTk0OTI5_786fcc40-f3ef-496b-af70-9bfb354378a0"
      unitRef="usd">304017000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMS0xLTEtMTk0OTI5_942f1686-c813-4c5a-aebf-0d6731f4f10c"
      unitRef="usd">404265000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMjktMy0xLTEtMTk0OTI5_15540c26-a8de-49db-aa59-2b339a169147"
      unitRef="usd">385010000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzAtMS0xLTEtMTk0OTI5_bdd35038-4c09-4f09-9ac1-02e818ed2a55"
      unitRef="usd">351000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzAtMy0xLTEtMTk0OTI5_4a22d40c-bf5c-47df-8cd0-96ba077ed961"
      unitRef="usd">2248000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzItMS0xLTEtMTk0OTI5_aa8efe7d-0ab6-4df2-af5b-77873a7b49d6"
      unitRef="usd">17718000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzItMy0xLTEtMTk0OTI5_f7829a9d-b011-43d3-91b4-0982b8126ec1"
      unitRef="usd">17431000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzMtMS0xLTEtMTk0OTI5_3fee3a16-5422-4dd1-8f03-b9e78ada6406"
      unitRef="usd">28645000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzMtMy0xLTEtMTk0OTI5_574f56e6-3045-4649-8650-7142dfda5b7a"
      unitRef="usd">22810000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzctMS0xLTEtMjE0MjMx_39dfcc4e-2ecf-4172-bc63-0b46ac69a604"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzctMy0xLTEtMjE0MjMx_59b29e9d-749b-4a80-9613-0662506b62d6"
      unitRef="usd">228911000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzQtMS0xLTEtMTk0OTI5_74525c9a-5421-4811-96db-a448a17d3289"
      unitRef="usd">647042000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzQtMy0xLTEtMTk0OTI5_0ee6b307-e506-4d9a-8fea-649dee00a3c9"
      unitRef="usd">960427000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzYtMS0xLTEtMTk0OTI5_9ea9ab36-eef5-4ec7-af8a-110be2a0b789"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzYtMy0xLTEtMTk0OTI5_23f6d2fd-7108-49fb-b3e6-83d9c01ea79a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMjE_1832993b-0964-49c3-bd78-5f499fefdd6d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMjE_787230e3-3f95-4f0d-b1b9-6631939ca16a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMzU_449aea91-4b38-44a2-a6a4-659fda2433ef"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfMzU_82c349aa-a8b1-48a7-9ade-6f98d104c7a6"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfNTc_06775ce2-e69a-43f2-a479-2781aaf90010"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfMzktMC0xLTEtMTk0OTI5L3RleHRyZWdpb246YWFmMjE1NDU5N2NkNGZjZmFhZWMwZTE2NTYyZGI5OWRfNTc_5f32de10-4caf-45d2-86e3-03391499b332"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMjY_21f251a9-91c6-4dc4-a8e5-11bca5ee6616"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMjY_9a7ce701-0344-4d83-87bd-c4978aeb83c0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfNDA_c931e119-8891-4938-a484-5593899b5f25"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfNDA_cd375da6-7365-47ef-8367-df76d9eb4cef"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfOTc_0d3b61c7-1e5c-4abd-8766-a81479032cdb"
      unitRef="shares">62507917</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfOTc_6c60294c-60e8-42d8-a4b7-0c65239968da"
      unitRef="shares">62507917</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMTA0_2a496aa7-d817-4b98-8a84-cb849a860edb"
      unitRef="shares">62063014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246MDhkYjQwNTE2MDIyNGIwMWIxNDk4ODBhZjkxZGUzNTFfMTA0_cbf0440d-74d3-4108-98f5-c287b1998ecd"
      unitRef="shares">62063014</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMS0xLTEtMTk0OTI5_5d32e2aa-eda4-4281-973c-8d7b0fe72dcf"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idf9ff7993c944b92a4bd359489e2eaa2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDAtMy0xLTEtMTk0OTI5_704b3b58-58e4-48c9-bd19-c69c2c66e2fc"
      unitRef="usd">62000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfMjY_ac56d0f9-ff85-41b4-9ae2-c6e86931389f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfMjY_c1e8247e-cbc0-4b10-a639-fab82fdada5b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNDA_0fbc4fb1-8e4d-42a0-880a-6a979827b7ba"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNDA_622eb6ec-029a-43bd-84f2-cff4f2545b19"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_2fce4d3a-0c39-4d53-8413-26a37b41f9c7"
      unitRef="shares">15786737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_3b5542e8-8290-461b-b7af-c054687adba1"
      unitRef="shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_56e9f9dc-2d1c-42a5-968c-8801514b4c57"
      unitRef="shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMC0xLTEtMTk0OTI5L3RleHRyZWdpb246ZmE0MTA4MTc5NzVjNGU3MmI3MDQ2M2QwMDQ0OGRiNzlfNjc_828ce548-1e4d-4650-9934-307a86ea8192"
      unitRef="shares">15786737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMS0xLTEtMTk0OTI5_20374194-6515-4037-836a-ecdb523b8ae8"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8f5136a92c314002a0d0deb5ff33d794_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDEtMy0xLTEtMTk0OTI5_465134a7-712d-49e6-ae56-1a06a0fda0d9"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDItMS0xLTEtMTk0OTI5_0563a5a6-aac2-442c-8308-f2c0a338973b"
      unitRef="usd">492475000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDItMy0xLTEtMTk0OTI5_8068cf2e-eaf1-418d-afcd-b90dbb3ac252"
      unitRef="usd">490576000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDMtMS0xLTEtMTk0OTI5_07c9dff9-9491-446d-a984-e0bb398b5651"
      unitRef="usd">-304456000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDMtMy0xLTEtMTk0OTI5_348cdff5-a9d7-41ac-a1f2-1c6c39e3c403"
      unitRef="usd">-165306000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDQtMS0xLTEtMTk0OTI5_9f5860d8-16f2-4d66-94f1-7656fa1bf88a"
      unitRef="usd">413000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDQtMy0xLTEtMTk0OTI5_8b89febb-3c98-4f87-8ee3-195010357d7d"
      unitRef="usd">-110000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDUtMS0xLTEtMTk0OTI5_284f8f23-4d46-4df0-8d29-b685f887f9a2"
      unitRef="usd">188511000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDUtMy0xLTEtMTk0OTI5_428e74c1-d032-40e9-b67c-12a488f0e262"
      unitRef="usd">325238000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDYtMS0xLTEtMTk0OTI5_5f294efa-3d38-4567-9541-eeae45592702"
      unitRef="usd">51851000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDYtMy0xLTEtMTk0OTI5_47b08bbc-0254-4bc4-bbe7-3bc9a754d4d7"
      unitRef="usd">86984000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDctMS0xLTEtMTk0OTI5_80e5b187-5aa5-42bc-8d1e-ed33c38852cf"
      unitRef="usd">240362000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDctMy0xLTEtMTk0OTI5_4b8e2517-de03-450c-baa4-32e61d36c171"
      unitRef="usd">412222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDgtMS0xLTEtMTk0OTI5_d50dc02c-d71e-43ee-a0f0-064254eb241d"
      unitRef="usd">887404000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yNS9mcmFnOjhhZTgxMjUzZjdhNTQyMDVhZjFlOGZjODBjYzRiZmNlL3RhYmxlOjgzYzI3NDIwZWVhZTRiMjE4MWYyZjQzZjJmYjNlMTM5L3RhYmxlcmFuZ2U6ODNjMjc0MjBlZWFlNGIyMTgxZjJmNDNmMmZiM2UxMzlfNDgtMy0xLTEtMTk0OTI5_09326ae2-7ceb-4e23-b399-617ac3951070"
      unitRef="usd">1372649000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3a77552c277241be958f7a79b2d31cfe_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xLTEtMS0xOTQ5Mjk_ddcbc87c-02e5-4b2c-a506-b4f1cc004a20"
      unitRef="shares">62063014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a77552c277241be958f7a79b2d31cfe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0yLTEtMS0xOTQ5Mjk_a4501166-456b-4f33-8e70-1d00f4dabcbb"
      unitRef="usd">62000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia42904e813fb462d9dc6296126b6c027_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy00LTEtMS0xOTQ5Mjk_209d37a7-2c38-4125-85cc-b5d21254e368"
      unitRef="shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia42904e813fb462d9dc6296126b6c027_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy01LTEtMS0xOTQ5Mjk_003ea853-0662-49e9-8c49-db4a8963e2fe"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65a95c8964854c0ea4aa51dff316c9de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy03LTEtMS0xOTQ5Mjk_0542432a-0e20-4c24-81f4-1a4795d2a578"
      unitRef="usd">490576000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac87cf08602645f0945125525d86864a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy05LTEtMS0xOTQ5Mjk_cec40da3-6324-42a2-8b8a-1bfdbde866cc"
      unitRef="usd">-110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc3dce8230ba45119afeb7423bdc2a1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xMS0xLTEtMTk0OTI5_cd0a29ba-c162-4798-810f-8669a85bf087"
      unitRef="usd">-165306000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35eb85bfb0344959b05e48db02d1b900_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xMy0xLTEtMTk0OTI5_3912dd0a-3963-4861-ae9f-3639d37f27e9"
      unitRef="usd">86984000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMy0xNS0xLTEtMTk0OTI5_cf484776-3719-4aaa-960a-86d12e887ebb"
      unitRef="usd">412222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic4c947a790104295ae50f5e97a83a1ab_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0xLTEtMS0xOTQ5Mjk_fe61e6d8-8d4a-4e63-8416-759a1d057b3f"
      unitRef="shares">444903</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic4c947a790104295ae50f5e97a83a1ab_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0yLTEtMS0xOTQ5Mjk_f76296c3-6c4a-4366-8307-7390e22c6689"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i22d0b8a085484d5a96145656d90e23f7_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC03LTEtMS0xOTQ5Mjk_30170b72-2d1c-4a08-b6be-7a96697e06d3"
      unitRef="usd">360000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0xMy0xLTEtMTk0OTI5_df04f010-28f3-4b7a-8875-5f590c2a8366"
      unitRef="usd">-277000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNC0xNS0xLTEtMTk0OTI5_0d69b5cb-3a21-483f-bab0-d0381f00c064"
      unitRef="usd">84000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="if617eff8c0b4423a8de0547fb060a911_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNS0xMS0xLTEtMTk0OTI5_5e68431e-4a3e-42d8-9be7-2964446038b3"
      unitRef="usd">-139150000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNS0xMy0xLTEtMTk0OTI5_1cbbf7bc-54bc-4cd0-beb2-ce837705ceef"
      unitRef="usd">-35297000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNS0xNS0xLTEtMTk0OTI5_991bcf0f-07c1-406b-a9ba-5ea727026bf0"
      unitRef="usd">-174447000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i22d0b8a085484d5a96145656d90e23f7_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNi03LTEtMS0xOTQ5Mjk_db659739-d8b3-446e-af68-9ad7c3ab79eb"
      unitRef="usd">1539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNi0xMy0xLTEtMTk0OTI5_60ca3e26-e1b8-43cd-bce9-1054ec45cbe7"
      unitRef="usd">307000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfNi0xNS0xLTEtMTk0OTI5_0e9f7bbe-5f5e-4623-ac23-3c6a420deaba"
      unitRef="usd">1846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i29ffafbcd14f4f3491e4973003291b92_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfOS05LTEtMS0xOTQ5Mjk_d5013ebf-38b1-48d4-9355-94fbe0e38414"
      unitRef="usd">523000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i22ffb60d01754fda9faba19d74c3993a_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfOS0xMy0xLTEtMTk0OTI5_b9d2d218-c63d-4430-9d29-879c9a888a49"
      unitRef="usd">134000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfOS0xNS0xLTEtMTk0OTI5_3bcfd8f9-5888-4b96-ba1d-9221a8da9aff"
      unitRef="usd">657000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id808e9e13e51453cba22d69e6a1554cb_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMS0xLTEtMTk0OTI5_92295b8f-a1fe-4394-908f-aaa423d61772"
      unitRef="shares">62507917</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id808e9e13e51453cba22d69e6a1554cb_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMi0xLTEtMTk0OTI5_523f721b-3bab-43c5-b6cf-7d84f62950b6"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i87ab2fcc47d94402b6ff38f1493add69_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtNC0xLTEtMTk0OTI5_29af4abe-1f08-4f0c-9868-1ae1b113afc3"
      unitRef="shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87ab2fcc47d94402b6ff38f1493add69_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtNS0xLTEtMTk0OTI5_6eb616cb-d66c-4ebd-93bd-95242c061c9f"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38144d2db4094669a2e5d9b194b1693f_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtNy0xLTEtMTk0OTI5_81795cba-5e04-4f0c-8c97-826f5d6fcc32"
      unitRef="usd">492475000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28d0b867fa5943ee856db6daa307d849_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtOS0xLTEtMTk0OTI5_39ffbc35-6e2f-44b1-ba2e-daede38f41a3"
      unitRef="usd">413000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75851ee9fae0477786892678243e9687_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMTEtMS0xLTE5NDkyOQ_f703c215-7819-4b17-91c8-610929ed8b0d"
      unitRef="usd">-304456000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4ad4457b2c747a98ed6638c8f80b5d0_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMTMtMS0xLTE5NDkyOQ_5a50573d-d8b4-4856-a2ac-f1dec9900d33"
      unitRef="usd">51851000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOjE1NmUxNWJmNzk4OTRlNTU4MWZjYzM0ZmEwZmExOGUyL3RhYmxlcmFuZ2U6MTU2ZTE1YmY3OTg5NGU1NTgxZmNjMzRmYTBmYTE4ZTJfMTAtMTUtMS0xLTE5NDkyOQ_ad139635-ecc2-4d77-84e6-5cbad192be3a"
      unitRef="usd">240362000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1cc622914d7b4479b2f4c07410226853_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xLTEtMS0yMDU0OTc_a291a187-3a46-497d-9994-1e9538f776e6"
      unitRef="shares">59548504</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cc622914d7b4479b2f4c07410226853_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0yLTEtMS0yMDU0OTc_7973541e-5a8c-4127-ad7d-5ed1285d326e"
      unitRef="usd">59000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibfc88da3e7a54c03802bbbf690e497ca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy00LTEtMS0yMDU0OTc_60047545-6793-41ea-b277-b73b7e9a5633"
      unitRef="shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfc88da3e7a54c03802bbbf690e497ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy01LTEtMS0yMDU0OTc_b25a6269-c20f-43f0-9b02-d318158ca1da"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53d734f3503d4c13a2b1d964e624c27c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy03LTEtMS0yMDU0OTc_59ee2ee3-c332-4afb-9a4b-86601287bb28"
      unitRef="usd">473318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i213ccc4548494407ab148000e45c5ee6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy05LTEtMS0yMDU0OTc_6be76368-70b4-45d2-b40f-49ffcf91b497"
      unitRef="usd">179000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1fe3f930f8964d73927338dd023b5b3d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xMS0xLTEtMjA1NDk3_827e6fe8-fcf5-4ea0-9381-d81b8a679998"
      unitRef="usd">-6602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9135fb165b2b49eb9e44a33009bf3cba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xMy0xLTEtMjA1NDk3_886a7251-e32a-4bc9-a12d-c3d252c76ed1"
      unitRef="usd">140686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfMy0xNS0xLTEtMjA1NzQ1_6154db04-2022-4c1d-85eb-08d4288a2f6a"
      unitRef="usd">607656000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i951147d4bd5642aabe42d38fc7311981_D20220101-20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0xLTEtMS0yMDU0OTc_ace9b7a1-ac1c-4b2c-b4c1-0bfb2464a503"
      unitRef="shares">1808766</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i951147d4bd5642aabe42d38fc7311981_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0yLTEtMS0yMDU0OTc_c42f7a8b-baac-4a56-a322-518be474e084"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC03LTEtMS0yMDU0OTc_ec4b5a9a-ce82-47bb-933d-abac5d5b999a"
      unitRef="usd">4729000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0xMy0xLTEtMjA1NDk3_18edd23f-ea1c-49c9-bb2b-c8124677a684"
      unitRef="usd">-2652000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNC0xNS0xLTEtMjA1NzQ1_63349cf3-54ef-4bbd-b508-defa395c2821"
      unitRef="usd">2080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bvs:DeferredTaxesOnEquityRebalancing
      contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS03LTEtMS0yMjkxNjg_646b93fc-0aab-4079-9834-04626cca2be0"
      unitRef="usd">1977000</bvs:DeferredTaxesOnEquityRebalancing>
    <bvs:DeferredTaxesOnEquityRebalancing
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xNS0xLTEtMjI5Mjk5_f5d3b171-4a49-4484-9984-7c04f56ea5a1"
      unitRef="usd">1977000</bvs:DeferredTaxesOnEquityRebalancing>
    <us-gaap:ProfitLoss
      contextRef="ieb5615fc08d24ff491b3bbb101a069f3_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xMS0xLTEtMjA1NDk3_e24a5148-ca3b-46a5-afe3-1c908f57a097"
      unitRef="usd">-11277000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xMy0xLTEtMjA1NDk3_56ed39a1-9589-4bf0-add5-647ce1026507"
      unitRef="usd">-3529000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNS0xNS0xLTEtMjA1NzQ1_42c9259f-345a-487d-a357-13f22d0b1727"
      unitRef="usd">-14806000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNi03LTEtMS0yMDU0OTc_a8053492-9e27-47ee-93f5-3c94ed7dcfe9"
      unitRef="usd">3943000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNi0xMy0xLTEtMjA1NDk3_ebc5a205-0d0d-43d6-90ac-5b8f399d538a"
      unitRef="usd">946000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNi0xNS0xLTEtMjA1NzQ1_48b5d702-8855-4744-9655-ba5511528a4c"
      unitRef="usd">4889000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id23499e24e764f54b220fbe6a3325161_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOC03LTEtMS0yMDU0OTc_28ea32f4-5004-4bd8-8620-ea6e995e3f8f"
      unitRef="usd">3352000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfNy0xNS0xLTEtMjA1NzUw_7f780756-9687-4697-8e0e-51c9a11d16e8"
      unitRef="usd">3352000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7aa0f2fc11fb4924a6e04334ad932d5a_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS05LTEtMS0yMDU0OTc_38272f74-e6af-4afd-bf02-d1d50258f8ff"
      unitRef="usd">-542000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3682dbebbc3749a488ea240e00fcb097_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xMy0xLTEtMjA1NDk3_cb8e0683-223f-416f-8dab-d9e85356eda0"
      unitRef="usd">-140000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOC0xNS0xLTEtMjA1NzUw_744b862d-4730-44ae-9401-e2279aeae1a6"
      unitRef="usd">-682000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2accf9b821314f3bad4a25bd77746a1c_I20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xLTEtMS0yMDU3NTA_5fe63325-0c9c-4271-9e11-4880b89d7642"
      unitRef="shares">61357270</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2accf9b821314f3bad4a25bd77746a1c_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0yLTEtMS0yMDU3NTA_9a11df44-1552-4e33-83f7-74afac937226"
      unitRef="usd">62000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ice6503af7f6a41e696df5e32d186a5ab_I20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS00LTEtMS0yMDU3NTA_1e9b582e-fa93-42ad-b66b-0451f1528c12"
      unitRef="shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice6503af7f6a41e696df5e32d186a5ab_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS01LTEtMS0yMDU3NTA_af139b9c-6a02-4531-ad32-9facb9ac7ce2"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3c005cdfc09f429a8813448058fdbe09_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS03LTEtMS0yMDU3NTA_2b41c6f5-16ca-43b2-8496-ad3dd2d043c5"
      unitRef="usd">476661000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d6267e834a1443ea11cee027905e439_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS05LTEtMS0yMDU3NTA_2d1a711a-61a5-422e-9dce-89a3f0a991a4"
      unitRef="usd">-363000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie45a988315ec4dc5bee4e8ba6723c8a4_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xMS0xLTEtMjA1NzUw_e1050470-58cd-4d42-9a18-dffa299b585a"
      unitRef="usd">-17879000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9ddf2d069db4849bee3aa72aa59d848_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xMy0xLTEtMjA1NzUw_6aa05080-4e93-478d-98a2-083c9df8de4f"
      unitRef="usd">135311000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34aedf09bd844e088614ef324e5b1a3e_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8yOC9mcmFnOjcyZTI5M2ZhMGIxOTQ3NTVhYmRhM2Y1MjJhMWU2OTcwL3RhYmxlOmZmZGRjYjI0N2U1YTQzMDc5NGY5MjAzNTJmMjUyYzVlL3RhYmxlcmFuZ2U6ZmZkZGNiMjQ3ZTVhNDMwNzk0ZjkyMDM1MmYyNTJjNWVfOS0xNS0xLTEtMjA1NzUw_9302bec7-5b2f-4e00-bccb-bcaaded2becb"
      unitRef="usd">593808000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMy0xLTEtMS0xOTQ5Mjk_c22a7d0c-2ff6-4b20-b027-0ff3ce036135"
      unitRef="usd">-174447000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMy0zLTEtMS0xOTQ5Mjk_20991158-845d-4ec1-9afc-d07eeb6d9d24"
      unitRef="usd">-14806000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNC0xLTEtMS0yMjExNTI_fec0b1bd-e472-4b4d-bf11-79c6cad501b2"
      unitRef="usd">-74429000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNC0zLTEtMS0yMjExNTI_ecbe3be4-b6bb-4c60-ab9f-afca68eb951a"
      unitRef="usd">-401000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0xLTEtMS0yMjIyMjU_da2ebc14-9758-4c4d-8d67-9d805961ac41"
      unitRef="usd">-100018000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0zLTEtMS0yMjIyMjU_a2216c96-7aaa-4253-beb9-591a03bcf7a0"
      unitRef="usd">-14405000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0xLTEtMS0xOTQ5Mjk_a6c4cbae-f004-4d9b-8aca-dc980fffce9d"
      unitRef="usd">16473000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNS0zLTEtMS0xOTQ5Mjk_97ac337a-91c0-4128-aaa3-4f5622b05422"
      unitRef="usd">12479000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNi0xLTEtMS0xOTQ5Mjk_4757e3a4-e66a-4133-b35f-b146785bdf15"
      unitRef="usd">1079000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNi0zLTEtMS0xOTQ5Mjk_5a36dbb8-3ea0-4e7f-844d-211365d99fc3"
      unitRef="usd">1152000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNy0xLTEtMS0xOTQ5Mjk_3d0fcda4-1203-4dee-87a6-4014d7177fba"
      unitRef="usd">1846000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNy0zLTEtMS0xOTQ5Mjk_56fb20b1-d271-43fb-b0b7-5e0d421c5398"
      unitRef="usd">4889000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfOS0xLTEtMS0xOTQ5Mjk_e409a443-6ec2-4120-a261-ee89fe24dd31"
      unitRef="usd">287000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfOS0zLTEtMS0xOTQ5Mjk_f78e9ada-7242-44a3-9530-3c18f703aa8c"
      unitRef="usd">269000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTAtMS0xLTEtMTk0OTI5_2f76a6d4-0ada-4849-a8b4-1470fb652a70"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTAtMy0xLTEtMTk0OTI5_776ed11f-181d-4ef6-8e67-2f4665c53996"
      unitRef="usd">3924000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTEtMS0xLTEtMTk0OTI5_2a0de218-939b-4217-a060-eab90ae8bef6"
      unitRef="usd">-2664000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTEtMy0xLTEtMTk0OTI5_7de61231-35c7-4990-8e69-bef0fb74a660"
      unitRef="usd">-17018000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:AssetImpairmentCharges
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTMtMS0xLTEtMTk0OTI5_a52416a0-630f-4cb2-8290-7c803b1944a8"
      unitRef="usd">78615000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTMtMy0xLTEtMTk0OTI5_670fd253-75f5-47a1-b7ed-36f6b083c786"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTYtMS0xLTEtMTk0OTI5_628a8bab-0bc6-43e2-910f-8c853496fb15"
      unitRef="usd">-747000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTYtMy0xLTEtMTk0OTI5_19568fd8-352b-4a55-869d-a4a7ce1e2827"
      unitRef="usd">-44000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTctMS0xLTEtMTk0OTI5_5c6e1149-74c0-4583-9c9d-e5d30eeb34e1"
      unitRef="usd">224000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTctMy0xLTEtMTk0OTI5_83fac994-47a7-4033-b101-43af1d749329"
      unitRef="usd">203000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTktMS0xLTEtMTk0OTI5_1034b071-8e92-4288-9913-66ee54945e7c"
      unitRef="usd">-13162000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMTktMy0xLTEtMTk0OTI5_c24c6cb5-7d76-45de-94d6-07f4ae452ddc"
      unitRef="usd">-4416000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjAtMS0xLTEtMTk0OTI5_c053bf15-b253-48ef-a123-3d8d34a70756"
      unitRef="usd">5294000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjAtMy0xLTEtMTk0OTI5_c426e92a-94d2-4ed9-8951-5e7c960987ca"
      unitRef="usd">-326000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMS0xLTEtMTk0OTI5_e04c071a-c475-48d9-95ce-cdb95740aaa0"
      unitRef="usd">2331000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMy0xLTEtMTk0OTI5_d311d62d-b21a-4dbf-bd55-1a8927800108"
      unitRef="usd">-7915000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMS0xLTEtMTk0OTI5_253ab342-df66-4a30-aa31-cae6c2e90eef"
      unitRef="usd">2129000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMy0xLTEtMTk0OTI5_90f96cca-f98f-4102-b07a-7687b3c4c5fc"
      unitRef="usd">1535000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjMtMS0xLTEtMTk0OTI5_78556f9c-eb7e-4020-8961-8e33687de3a8"
      unitRef="usd">4659000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjMtMy0xLTEtMTk0OTI5_77dc10a8-9f65-41f9-b6eb-d200b5f6d223"
      unitRef="usd">-21019000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMS0xLTEtMjA1Njk5_eb5ae84c-5083-4bbe-bca7-49a3930ea04a"
      unitRef="usd">-2169000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjEtMy0xLTEtMjA1Njk5_fadb9ef2-7b65-4ad7-b558-7dc0e81286ee"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMS0xLTEtMjA5MDY1_8bbafd3f-ddca-41d2-9905-8de372152c2a"
      unitRef="usd">2490000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjItMy0xLTEtMjA5MDcy_ec68eb82-d7b9-4544-ab73-6c5c004bebd8"
      unitRef="usd">-21019000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjYtMS0xLTEtMTk0OTI5_52f10118-e1e9-4e85-99a2-911b54056e07"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjYtMy0xLTEtMTk0OTI5_cc44d4c1-64b1-4a78-83ab-6d3fd1992feb"
      unitRef="usd">236000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjctMS0xLTEtMTk0OTI5_9dfbeb82-fdaf-4cb7-bb41-6cd2ca260024"
      unitRef="usd">3560000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjctMy0xLTEtMTk0OTI5_c650ece2-56de-411c-a90a-46fd17b162d4"
      unitRef="usd">2960000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <bvs:ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjgtMS0xLTEtMTk0OTI5_aa66a23b-dc5e-4311-9c71-c100e576de89"
      unitRef="usd">0</bvs:ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments>
    <bvs:ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjgtMy0xLTEtMTk0OTI5_6bcf8a5e-d569-4ec7-8333-cada97f9aff0"
      unitRef="usd">-1478000</bvs:ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMS0xLTEtMTk0OTI5_21dca16d-8176-408a-b440-06e5a0ca1b7d"
      unitRef="usd">-3560000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMy0xLTEtMTk0OTI5_5b5ca455-ef22-4f04-97c2-ea6769d94cb4"
      unitRef="usd">-4674000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjktMS0xLTEtMjA1NzIx_38e08659-bcf3-49fe-826b-89ea6c7be2c8"
      unitRef="usd">-11506000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMjktMy0xLTEtMjA1NzIx_e66d62dd-edfd-4297-81d9-2e8f10c89dd7"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMS0xLTEtMjA5MDc0_07ab95cf-8559-4fb6-b37c-f8271f2cc30c"
      unitRef="usd">-15066000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzAtMy0xLTEtMjA5MDgx_72af5757-aade-48f3-9bd9-9387c855dfe9"
      unitRef="usd">-4674000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzMtMS0xLTEtMTk0OTI5_8546e83f-d973-4315-b2e3-20314d715dff"
      unitRef="usd">84000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzMtMy0xLTEtMTk0OTI5_6e1cf93a-347f-42f1-9d8e-06db578423a5"
      unitRef="usd">2080000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzQtMS0xLTEtMTk0OTI5_1e16af37-b7e9-4e37-a07e-e4a4c20dfedc"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzQtMy0xLTEtMTk0OTI5_36b09565-0876-4d14-a0b2-04b589333ea6"
      unitRef="usd">3352000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzUtMS0xLTEtMTk0OTI5_b69a4615-79ee-4474-b42f-e4d8980f20df"
      unitRef="usd">49000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzUtMy0xLTEtMTk0OTI5_f8894f84-c473-4be7-82d1-9d5b267ba9d4"
      unitRef="usd">15000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzYtMS0xLTEtMTk0OTI5_fc0e75a4-a8e2-4ca8-b52e-1706c3846663"
      unitRef="usd">20000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzYtMy0xLTEtMTk0OTI5_f11d7125-7041-490e-ac58-fb71e90a032b"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <bvs:PaymentOfDebtRefinancingCosts
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzctMS0xLTEtMTk0OTI5_f35e89f8-fbf2-40d4-9ae5-cc7e0c7afbfe"
      unitRef="usd">1668000</bvs:PaymentOfDebtRefinancingCosts>
    <bvs:PaymentOfDebtRefinancingCosts
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzctMy0xLTEtMTk0OTI5_3f67be15-77dc-43e1-96fd-79179245ba7c"
      unitRef="usd">0</bvs:PaymentOfDebtRefinancingCosts>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzgtMS0xLTEtMTk0OTI5_36fea623-35e6-49b2-9e18-861d83f51e73"
      unitRef="usd">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfMzgtMy0xLTEtMTk0OTI5_98c046b2-0856-4206-a212-86dfbec58367"
      unitRef="usd">4509000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDAtMS0xLTEtMTk0OTI5_c906803a-a284-48a8-b4bd-aadacde06ed0"
      unitRef="usd">-36000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDAtMy0xLTEtMTk0OTI5_ab450336-ea94-4358-ba3e-2a8c9469ef4e"
      unitRef="usd">-14000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDEtMS0xLTEtMTk0OTI5_6f321e70-51b5-4287-9328-3e6742f25167"
      unitRef="usd">27380000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDEtMy0xLTEtMTk0OTI5_28c82b39-f9b4-4f54-a348-0adbd53b87cb"
      unitRef="usd">9205000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDItMS0xLTEtMTk0OTI5_138d5eb3-f16e-438e-842d-e0aa9daa4247"
      unitRef="usd">461000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDItMy0xLTEtMTk0OTI5_e9caeb79-4dee-4925-8dc0-7beadfca773e"
      unitRef="usd">-71000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDMtMS0xLTEtMTk0OTI5_7cc7f738-b501-4469-b479-229b94b30dfc"
      unitRef="usd">15265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDMtMy0xLTEtMTk0OTI5_30eb61ff-3c95-43fa-ba74-18bdbc4e0105"
      unitRef="usd">-16559000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDQtMS0xLTEtMTk0OTI5_f40b4eab-ed6f-4e59-bdc3-50351698cbb1"
      unitRef="usd">31837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDQtMy0xLTEtMTk0OTI5_56c4cd3f-347e-4136-907d-ebf0ed8381a2"
      unitRef="usd">99213000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDUtMS0xLTEtMTk0OTI5_8821a0b5-b105-47d5-b5eb-8cc6be10896f"
      unitRef="usd">47102000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i34aedf09bd844e088614ef324e5b1a3e_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDUtMy0xLTEtMTk0OTI5_973c508f-e842-49e6-ab37-e2c68d1262a4"
      unitRef="usd">82654000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDgtMS0xLTEtMTk0OTI5_5992052b-c01b-4bb7-a333-11b52192149c"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zMS9mcmFnOjJmN2Y1MDRmNjliNzRkYmQ5YzJkZGMyNThhYTRmMjRlL3RhYmxlOjA3ZDJlMTNjMzE2NjRhMmRiNzM5N2JkM2YxY2U4YjAwL3RhYmxlcmFuZ2U6MDdkMmUxM2MzMTY2NGEyZGI3Mzk3YmQzZjFjZThiMDBfNDgtMy0xLTEtMTk0OTI5_64e3c82b-6a3c-4fdd-a017-1195b9d4b83b"
      unitRef="usd">76000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfODMxNg_cd3cc40e-e4f5-4010-8577-a26a4cbf1af6">Organization&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bioventus Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (&#x201c;BV LLC&#x201d;). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;), which was conducted through what is commonly referred to as an umbrella partnership C Corporation (&#x201c;UP-C&#x201d;) structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC held by its continuing LLC owner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#x2019;s natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately 1,040 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interim periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2023 end on April 1, July 1 and September 30. Comparable periods for 2022 ended on April 2, July 2 and October 1. The fourth and first quarters may vary in length depending on the calendar year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1. Organization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) considered necessary for a fair statement of the Company&#x2019;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022. The consolidated balance sheet at December&#160;31, 2022 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Correction of immaterial misstatements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended April 1, 2023 and as part of the balance sheet review process, the Company identified misstatements in its calculation of the carrying amount of noncontrolling interest as it applies to the Company&#x2019;s complex UP-C tax and ownership structure as prescribed in the amended and restated limited liability company agreement of BV LLC. Specifically, the Company failed to adjust the carrying amount of its noncontrolling interest to reflect changes in ownership interests relating to BV LLC. As a result, the previously issued consolidated financial statements reflect an understatement of noncontrolling interest and an overstatement of additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of further research conducted, the Company discovered an additional error related to historical deferred income tax balances. The Company concluded that it had inappropriately calculated deferred income taxes by using an incorrect book basis in its investment of BV LLC during the Company&#x2019;s IPO, which resulted in an overstatement of deferred tax liabilities, an understatement of noncontrolling interest and an understatement of additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The statements affected by these errors include the consolidated balance sheets and consolidated statements of stockholders&#x2019; and members&#x2019; equity issued in the Company&#x2019;s Annual Report on Form 10-K for the years ended December 31, 2022 and December 31, 2021. There was no impact to any other financial statements for the periods presented. The Company concluded that these misstatements were not material, individually or in the aggregate, as evaluated under the Securities and Exchange Commission Staff Bulletin No. 99, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Materiality;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; No. 108, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Considering the Effects of Prior Year Misstatements in Current Year Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;; and Financial Accounting Standards Board ASC 250-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accounting Changes and Error Corrections&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. However, because of the significance of these items, and to facilitate comparison among periods, the Company has decided to revise its previously issued consolidated financial statements on a prospective basis. The Company will correct its prior period presentation for this error in its future 2023 quarterly financial statements included in its Forms 10-Q and 2023 Annual Report on Form 10-K for the period ended December 31, 2023. The adjustments did not have an impact on revenues, total assets or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are selected line items from our aforementioned impacted financial statements illustrating the effect of the error corrections thereon:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets &#x2014; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes (b)(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital (a)(b)(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest (a)(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets &#x2014; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes (b)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital (a)(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated statements of changes in stockholders&#x2019; and members equity as of December 31, 2022 and December 31, 2021 have been corrected to reflect the above adjustments. The Company revised the amounts originally reported for the years ended December 31, 2022 and December 31, 2021 for the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Recorded a $65,821 decrease to additional paid-in capital and a corresponding increase to noncontrolling interest. This action effectively rebalanced equity appropriately between the Company and its noncontrolling interests according to their respective BV LLC ownership interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Recorded a $73,867 decrease to deferred income tax balances and an increase to additional paid in capital to reflect the correction of an error that occurred during the calculation of deferred taxes at the Company&#x2019;s IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Reflects the entry as discussed in (a) above and additional rebalancing activity of $2,588 relating to the issuance of Class A common stock for equity plans during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Reflects the entry as discussed in (b) and an additional $1,977 increase to deferred income tax balances and a reduction to additional paid in capital to reflect the deferred tax impact during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared under the going concern basis of accounting, which presumes that the Company&#x2019;s liquidation is not imminent; however, based on the Company&#x2019;s current financial position and liquidity sources, including current cash balances, and forecasted future cash flows, the Company is at risk of violating certain of its financial covenants under the Credit and Guaranty Agreement, dated December 6, 2019 (as amended on October 29, 2021, July 11, 2022 and March 31, 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If mitigating steps are not taken or are not successful, the Company is at substantial risk of failing its covenants in 2024. A breach of a financial covenant under the Credit and Guaranty Agreement could accelerate repayment of our obligations under the agreement. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4. Financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further discussion concerning the Company&#x2019;s long-term debt obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is actively pursuing plans to mitigate these conditions and events, such as considering various additional cost cutting measures, and exploring additional divestiture opportunities such as the recently announced plan to divest certain assets within its Wound Business; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. Therefore, these plans do not alleviate the substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of efforts to improve its financial condition, on February 27, 2023, the Company reached an agreement to return the assets and liabilities of CartiHeal (2009) Ltd. (&#x201c;CartiHeal&#x201d;), a wholly-owned subsidiary of the Company, to its former securityholders. The deconsolidation of CartiHeal relieved deferred consideration liabilities and milestone obligations related to the acquisition of CartiHeal. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding the acquisition and subsequent deconsolidation of CartiHeal. In addition, the Company announced a restructuring plan in December 2022 to align the Company&#x2019;s organizational and management cost structure to improve profitability and cash flow. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an accelerated public company filer. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when emerging growth companies are required to adopt.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="ia9c0fbba09b6496a91ab1685ca96483a_I20230401"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfOTA1_48cf55e4-50b0-4b70-9664-66d0898a84b6"
      unitRef="employee">1040</dei:EntityNumberOfEmployees>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfNDk0NzgwMjM2OTQzMg_440f231b-a455-4dca-b9d2-9776d8fd7a5d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are selected line items from our aforementioned impacted financial statements illustrating the effect of the error corrections thereon:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets &#x2014; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes (b)(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71,890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital (a)(b)(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest (a)(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets &#x2014; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes (b)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital (a)(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated statements of changes in stockholders&#x2019; and members equity as of December 31, 2022 and December 31, 2021 have been corrected to reflect the above adjustments. The Company revised the amounts originally reported for the years ended December 31, 2022 and December 31, 2021 for the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Recorded a $65,821 decrease to additional paid-in capital and a corresponding increase to noncontrolling interest. This action effectively rebalanced equity appropriately between the Company and its noncontrolling interests according to their respective BV LLC ownership interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Recorded a $73,867 decrease to deferred income tax balances and an increase to additional paid in capital to reflect the correction of an error that occurred during the calculation of deferred taxes at the Company&#x2019;s IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Reflects the entry as discussed in (a) above and additional rebalancing activity of $2,588 relating to the issuance of Class A common stock for equity plans during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Reflects the entry as discussed in (b) and an additional $1,977 increase to deferred income tax balances and a reduction to additional paid in capital to reflect the deferred tax impact during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i96799592dc2f46ce951da575359089fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMS0xLTEtMS0yMjc2NTM_85d03cf8-68c7-4a91-bb2c-9304f5bb9471"
      unitRef="usd">74138000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMS0zLTEtMS0yMjc2NTM_a8c9fdeb-591e-4e2e-a804-30469cf8f5fa"
      unitRef="usd">-71890000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMS01LTEtMS0yMjc2ODg_57ec7ad4-d242-4ca6-b680-8ab534b39635"
      unitRef="usd">2248000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i96799592dc2f46ce951da575359089fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0xLTEtMS0yMjk0MjM_a32495a7-8ab9-4751-800c-bf9945eb844a"
      unitRef="usd">1032317000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0zLTEtMS0yMjk0MjM_7c92afb3-9fe7-428f-a34f-ce9b9956a818"
      unitRef="usd">-71890000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi01LTEtMS0yMjk0MjM_7f31e268-4635-4ffa-9912-61a4c95e50ac"
      unitRef="usd">960427000</us-gaap:Liabilities>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i96799592dc2f46ce951da575359089fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0xLTEtMS0yMjc2NTM_5e770ec2-bc2c-4f69-b3c7-3bf639053bef"
      unitRef="usd">481919000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi0zLTEtMS0yMjc2NTM_9d187e9d-9bf6-4504-abdc-c5b939533ad0"
      unitRef="usd">8657000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMi01LTEtMS0yMjc2ODg_b3e4853a-1291-4001-abd4-e65ce0344244"
      unitRef="usd">490576000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:MinorityInterest
      contextRef="i96799592dc2f46ce951da575359089fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMy0xLTEtMS0yMjc2NTM_284559f5-7928-4231-bbe6-9d92eeb86a46"
      unitRef="usd">23751000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMy0zLTEtMS0yMjc2NTM_6382ddb4-fcea-433c-bab2-3fb2c7619a54"
      unitRef="usd">63233000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfMy01LTEtMS0yMjc2ODg_0f99c1f4-7171-4514-b0e9-41dcd5fa0cf1"
      unitRef="usd">86984000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96799592dc2f46ce951da575359089fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfNS0xLTEtMS0yMjk0MzY_fcd3c759-8702-496b-af8d-54f730dbd315"
      unitRef="usd">340332000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b737d439dfc4c049b11e5aa48820383_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfNS0zLTEtMS0yMjk0MzY_78c412b7-5c14-4b71-a36c-8b99fc78ac99"
      unitRef="usd">71890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjliNDViODVmMWJmYjQ0MDBhNzE2OWE4NTQ1NzFhOGRiL3RhYmxlcmFuZ2U6OWI0NWI4NWYxYmZiNDQwMGE3MTY5YTg1NDU3MWE4ZGJfNS01LTEtMS0yMjk1MTg_7551063a-ea95-497d-bafc-d3f7d10bfd90"
      unitRef="usd">412222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMS0xLTEtMS0yMjc2NjE_7248716a-a289-4b88-93ac-0420d9492a78"
      unitRef="usd">133518000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMS0zLTEtMS0yMjc2NjE_abee2060-8818-40dc-ba55-e64140e7ccb0"
      unitRef="usd">-73867000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMS01LTEtMS0yMjc2OTI_271fd6dc-3b7e-4b9b-a5df-e45640ae9a70"
      unitRef="usd">59651000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0xLTEtMS0yMjk0NTA_9668c6ff-da6a-4c25-8514-514370e555bf"
      unitRef="usd">692073000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0zLTEtMS0yMjk0NTA_09f1d06f-7ce5-4ae7-8c17-3949a2a79830"
      unitRef="usd">-73867000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi01LTEtMS0yMjk1MjE_385c2c1f-943e-499f-a6d3-48f51e7a15d1"
      unitRef="usd">618206000</us-gaap:Liabilities>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0xLTEtMS0yMjc2NjE_f922582e-8808-40ff-bf5a-0cbfe212e413"
      unitRef="usd">465272000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi0zLTEtMS0yMjc2NjE_fb427fa4-f034-42e6-849e-1bfae1a6172c"
      unitRef="usd">8046000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMi01LTEtMS0yMjc2OTI_f849bd43-98b9-4cac-b01e-2e721b19b7c8"
      unitRef="usd">473318000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:MinorityInterest
      contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMy0xLTEtMS0yMjc2NjE_0b7f73c4-b304-4a76-ab7f-8d15cf1dbdf3"
      unitRef="usd">74865000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMy0zLTEtMS0yMjc2NjE_cd1b0399-86d4-49ff-9f33-e88643f5f938"
      unitRef="usd">65821000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfMy01LTEtMS0yMjc2OTI_a9915564-8c50-4e4d-bc05-08840b4d0301"
      unitRef="usd">140686000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8306c6c2e0b4d1497206736d20693f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfNS0xLTEtMS0yMjk0NTk_cee11484-aa95-484b-a36e-ffc457799125"
      unitRef="usd">533789000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i178bff9b64ed42ff81776518c4189b1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfNS0zLTEtMS0yMjk0NTk_ee8eca04-3908-425e-86f3-63091061d550"
      unitRef="usd">73867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RhYmxlOjk0YjMxOTc2YTY5NDQwMjJhZDFjOGY3ODI5NWQwYjlmL3RhYmxlcmFuZ2U6OTRiMzE5NzZhNjk0NDAyMmFkMWM4Zjc4Mjk1ZDBiOWZfNS01LTEtMS0yMjk1MjE_06c28f3b-a20b-40aa-a712-dae73e872193"
      unitRef="usd">607656000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="i66988f17121f479d987ec3f6a81fa043_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_10a7bac9-e3c3-4dc8-858a-8d80f955e246"
      unitRef="usd">65821000</us-gaap:MinorityInterest>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i66988f17121f479d987ec3f6a81fa043_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_17f39e94-e0d2-4612-88bb-74f020835565"
      unitRef="usd">-65821000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i673ea96088114535bb4f91785d7e72e6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_585b19f9-1f38-49e4-bc4f-1475d8996729"
      unitRef="usd">-65821000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:MinorityInterest
      contextRef="i673ea96088114535bb4f91785d7e72e6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MDcwOA_e6ad43af-c616-4b60-83fc-c6d5aacd782c"
      unitRef="usd">65821000</us-gaap:MinorityInterest>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib42fe425b80941f48b28aca4ecd33ade_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MTU2OA_b7d0fce3-35ac-495f-87c0-455771f7403b"
      unitRef="usd">-73867000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib7a4b0b14d204b00844c680753360a35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MTU2OA_c3e0c611-0f42-4f47-bf83-1ef0163ef428"
      unitRef="usd">-73867000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9117991cb301409cb832cbb9dd88871a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MjU0NQ_17ad9802-693e-4728-9d0c-4ff6bf4b26ee"
      unitRef="usd">2588000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:MinorityInterest
      contextRef="i9117991cb301409cb832cbb9dd88871a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5MjU0NQ_418dda73-6dcb-4e8b-a8ff-245176f04125"
      unitRef="usd">2588000</us-gaap:MinorityInterest>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i109b3bd8eade44d394a7ae03c62fed13_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5NzY5OA_20101671-f1e7-48e9-b3b2-4c125873dad2"
      unitRef="usd">-1977000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i109b3bd8eade44d394a7ae03c62fed13_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfMTY0OTI2NzQ5NzY5OA_4c5ccd6e-e78a-4c6c-969d-15b2da77eb9d"
      unitRef="usd">1977000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfODMxNw_4d571af7-e801-4269-b131-7f145ebc5312">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared under the going concern basis of accounting, which presumes that the Company&#x2019;s liquidation is not imminent; however, based on the Company&#x2019;s current financial position and liquidity sources, including current cash balances, and forecasted future cash flows, the Company is at risk of violating certain of its financial covenants under the Credit and Guaranty Agreement, dated December 6, 2019 (as amended on October 29, 2021, July 11, 2022 and March 31, 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If mitigating steps are not taken or are not successful, the Company is at substantial risk of failing its covenants in 2024. A breach of a financial covenant under the Credit and Guaranty Agreement could accelerate repayment of our obligations under the agreement. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4. Financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further discussion concerning the Company&#x2019;s long-term debt obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is actively pursuing plans to mitigate these conditions and events, such as considering various additional cost cutting measures, and exploring additional divestiture opportunities such as the recently announced plan to divest certain assets within its Wound Business; however, there can be no assurances that it is probable these plans will be successfully implemented or that they will successfully mitigate these conditions and events. Therefore, these plans do not alleviate the substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of efforts to improve its financial condition, on February 27, 2023, the Company reached an agreement to return the assets and liabilities of CartiHeal (2009) Ltd. (&#x201c;CartiHeal&#x201d;), a wholly-owned subsidiary of the Company, to its former securityholders. The deconsolidation of CartiHeal relieved deferred consideration liabilities and milestone obligations related to the acquisition of CartiHeal. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding the acquisition and subsequent deconsolidation of CartiHeal. In addition, the Company announced a restructuring plan in December 2022 to align the Company&#x2019;s organizational and management cost structure to improve profitability and cash flow. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV8zNy9mcmFnOjhiNjUzYjdlYmM3ZDQ0NTNhZjBkZjQ1MWQ4ZmJlYTNkL3RleHRyZWdpb246OGI2NTNiN2ViYzdkNDQ1M2FmMGRmNDUxZDhmYmVhM2RfODMxOA_6ac81bc4-1093-4097-845b-c79b7d145ad0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an accelerated public company filer. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when emerging growth companies are required to adopt.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3Ng_4f5fc942-15be-4f61-9b6f-8da3373d3deb">Balance sheet information&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net of allowances, consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Other receivables of $350 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Accounts receivable of $5,012 was reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding assets held for sale and the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Allowance for credit losses of $898 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further details regarding assets held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of the Company&#x2019;s receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately 11.8% of the accounts receivable balance as of April&#160;1, 2023. Historically, the Company&#x2019;s reserves have been adequate to cover credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in credit losses were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess and obsolete reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Raw material inventory of $642 attributable to CartiHeal has been reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Finished goods inventory of $1,481 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Prepaid and other current assets of $134 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 balance sheet. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(298,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net before currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Intellectual property and accumulated depreciation attributable to CartiHeal totaling $410,200 and $11,327, respectively, were reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Net intellectual property and customer relationships of $23,458 and $8,377, respectively, were reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding assets held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;The Company recorded an impairment loss of $78,615 in the U.S. reporting segment of net intellectual property attributable to a business held for sale. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding businesses held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense for intangibles subsequent to reclassifications and impairment for the remainder of 2023 and for the years ended December 31, 2024 through 2027 is expected to be $22,041, $26,347, $22,874, $20,030 and $19,652, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company assesses goodwill impairment by applying a quantitative impairment analysis comparing the carrying value of the Company&#x2019;s reporting units to their respective fair values. A goodwill impairment exists if the carrying value of the reporting unit exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two reporting units and assesses impairment based upon qualitative factors and if necessary, quantitative factors. A reporting unit's fair value is determined using the income approach and discounted cash flow models by utilizing Level 3 inputs and assumptions such as future cash flows, discount rates, long-term growth rates, market value and income tax considerations. Specifically, the value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company then reconciles the values of all reporting units to the market capitalization of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s goodwill resides within the International segment, of which $6,297 related to CartiHeal and was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. The amount was recorded in discontinued operations, net of tax on the consolidated condensed statements of operations for the three months ended April 1, 2023 as a result of CartiHeal&#x2019;s deconsolidation. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further details concerning the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 8, 2022, due to a significant decline in the Company&#x2019;s Class A common stock price, circumstances became evident that a possible goodwill impairment existed as of the third quarter 2022 balance sheet date. The Company concluded that the carrying value of the U.S. reporting unit exceeded its fair value and recorded a non-cash goodwill impairment charge of $189,197 during the year ended December 31, 2022. There were no accumulated impairment losses prior to the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross-to-net deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonus and commission&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income and other taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Bonus and commissions of $588 were reclassified into liabilities held for sale within the April&#160;1, 2023 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Other liabilities attributable to CartiHeal of $384 were reclassified into current liabilities attributable to discontinued operations within December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM4MA_c29ad0f9-4ee8-408e-9efc-427fe646406e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net of allowances, consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Allowance for credit losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Other receivables of $350 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Accounts receivable of $5,012 was reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding assets held for sale and the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Allowance for credit losses of $898 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further details regarding assets held for sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMS0xLTEtMS0xOTQ5Mjk_cf5caad8-369a-402d-98a3-911ef6da7e32"
      unitRef="usd">125945000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMS0zLTEtMS0xOTQ5Mjk_e5607546-b163-412f-9a6f-43f1fddaa7e8"
      unitRef="usd">143317000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMi0xLTEtMS0xOTQ5Mjk_15b49ff7-3caa-4952-b179-4d3577ca9b73"
      unitRef="usd">7401000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMi0zLTEtMS0xOTQ5Mjk_17b70b49-c1f8-46d6-bf4d-db3b03eb2bda"
      unitRef="usd">7022000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMy0xLTEtMS0xOTQ5Mjk_df84b14b-51d5-4dcb-84d8-b5196eb260ab"
      unitRef="usd">118544000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmUxOGIwMzAwNGQxMjQ3ZjY5MzcyODVlMmViODUxNGI1L3RhYmxlcmFuZ2U6ZTE4YjAzMDA0ZDEyNDdmNjkzNzI4NWUyZWI4NTE0YjVfMy0zLTEtMS0xOTQ5Mjk_880c5935-7e10-4dad-adba-4ebb4b7162c7"
      unitRef="usd">136295000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivables
      contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzA5Mg_06ff59a8-a3c5-463f-b825-30ff443a3ac7"
      unitRef="usd">350000</us-gaap:OtherReceivables>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzEyMw_8b9fe9d4-6136-4848-8816-eb55a2b14af7"
      unitRef="usd">5012000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfODc5NjA5MzA1MDQxNw_01181ec7-9169-44e9-a804-a84f084da0e1"
      unitRef="usd">898000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ebfe75a99584627ab0c086aca856452_D20230101-20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTgyMg_8877fbae-d543-4a78-bd1b-fc0bd3400565"
      unitRef="number">0.118</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3OQ_18fe389e-c129-4df0-a3bb-0721aa8d68a7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in credit losses were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMi01LTEtMS0xOTQ5Mjk_66758c8b-4a87-431e-b6e5-6fac754e70c8"
      unitRef="usd">7022000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMi03LTEtMS0xOTQ5Mjk_e2dc5820-84df-4b1c-9dd1-5c9da18af5d3"
      unitRef="usd">3402000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMy01LTEtMS0xOTQ5Mjk_5ec26220-3957-4b4e-8c9f-738a69abdb7c"
      unitRef="usd">1079000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfMy03LTEtMS0xOTQ5Mjk_371aad8a-57ff-48ed-aa53-4a818681d34b"
      unitRef="usd">1152000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNC01LTEtMS0xOTQ5Mjk_58a9d274-f31d-46cf-948d-2d35f42dbc9b"
      unitRef="usd">286000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNC03LTEtMS0xOTQ5Mjk_74f8ee07-2815-4ce0-8d69-a0f86d48ac8c"
      unitRef="usd">369000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNS01LTEtMS0xOTQ5Mjk_31603083-1e7f-4cf0-9171-50e8950c73e6"
      unitRef="usd">484000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNS03LTEtMS0xOTQ5Mjk_f356f6a8-5be3-4142-b261-ed8d9f4b80d6"
      unitRef="usd">69000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bvs:AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi01LTEtMS0yMjA4MzE_7b370d97-e449-467f-a8a7-8016d5bb73f2"
      unitRef="usd">898000</bvs:AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale>
    <bvs:AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi03LTEtMS0yMjA4MzE_55d1e47e-544e-4c7f-801c-00a43a6ba94b"
      unitRef="usd">0</bvs:AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi01LTEtMS0xOTQ5Mjk_48c93884-23ff-4ba0-a2b7-0d31c1b99e05"
      unitRef="usd">7401000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i34aedf09bd844e088614ef324e5b1a3e_I20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmE5YTQxYjhiYjNlMzQ1YjdiMzQ1ZTRkMzVlMDVlY2ZhL3RhYmxlcmFuZ2U6YTlhNDFiOGJiM2UzNDViN2IzNDVlNGQzNWUwNWVjZmFfNi03LTEtMS0xOTQ5Mjk_c5d77038-f720-4f17-8607-613b83336e16"
      unitRef="usd">4254000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3NQ_8f6cddd6-250e-42ec-a964-e4d64db7ef2f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess and obsolete reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Raw material inventory of $642 attributable to CartiHeal has been reclassified to current assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Finished goods inventory of $1,481 was reclassified to assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMS0xLTEtMS0xOTQ5Mjk_de186ad7-53fe-4744-b04c-4457fa3078d5"
      unitRef="usd">24729000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMS0zLTEtMS0xOTQ5Mjk_3526546a-91b4-497b-a4fc-e050c90c1619"
      unitRef="usd">19133000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMi0xLTEtMS0xOTQ5Mjk_df76bae2-9114-444e-b4c1-848203cedb1d"
      unitRef="usd">65461000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMi0zLTEtMS0xOTQ5Mjk_dea3d011-a50a-425c-9e1b-20f2a8adea65"
      unitRef="usd">67484000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMy0xLTEtMS0xOTQ5Mjk_fb80fce8-f014-4f64-818e-b82d69ca32b2"
      unitRef="usd">90190000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfMy0zLTEtMS0xOTQ5Mjk_069edabe-78aa-4b9c-969c-09735b65c185"
      unitRef="usd">86617000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNC0xLTEtMS0xOTQ5Mjk_a2c8ead4-fee1-403f-a44f-159cf1c4da17"
      unitRef="usd">2237000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNC0zLTEtMS0xOTQ5Mjk_cdfe41e9-00f5-4013-a7c2-7de78e0fd732"
      unitRef="usd">1851000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNS0xLTEtMS0xOTQ5Mjk_230d91b6-308f-4db0-a388-f96029e7b032"
      unitRef="usd">87953000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjU3OGMyNmM4MDg1MDQwZTg4NTM0OTBjZTA1Mzc3M2Q2L3RhYmxlcmFuZ2U6NTc4YzI2YzgwODUwNDBlODg1MzQ5MGNlMDUzNzczZDZfNS0zLTEtMS0xOTQ5Mjk_dd84416d-5dc3-46b5-80b7-1e1022753652"
      unitRef="usd">84766000</us-gaap:InventoryNet>
    <us-gaap:InventoryFinishedGoods
      contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NDEyNw_690eb1c3-b684-4dc1-983d-061190c7ada8"
      unitRef="usd">642000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3NzIyNA_d662a991-a58d-42b4-885a-0b8bf6b91522"
      unitRef="usd">1481000</us-gaap:InventoryFinishedGoods>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3Nw_e9412efa-20bb-41df-b5fe-f49d12288441">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Prepaid and other current assets of $134 attributable to CartiHeal was reclassified to current assets attributable to discontinued operations within the December 31, 2022 balance sheet. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidTaxes
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMS0xLTEtMS0xOTQ5Mjk_f8e7dae5-b9ef-45b7-89d6-d0fae88d45d0"
      unitRef="usd">4400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMS0zLTEtMS0xOTQ5Mjk_754a84e4-8dc4-45a8-ad1b-4252e1ff3ca8"
      unitRef="usd">4442000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMi0xLTEtMS0xOTQ5Mjk_85c0f72c-2da0-4b27-a1ed-4cf9ee97b07d"
      unitRef="usd">12792000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMi0zLTEtMS0xOTQ5Mjk_253fd5c9-6113-4b23-bb52-f5670c89757f"
      unitRef="usd">14109000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMy0xLTEtMS0xOTQ5Mjk_b3f79bae-ffd7-4247-ac74-17ea9704acaf"
      unitRef="usd">17192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmJhNDY4YTc5N2Q2MDRmNTU5YjI1MzMzM2Y0ZTE0M2Q3L3RhYmxlcmFuZ2U6YmE0NjhhNzk3ZDYwNGY1NTliMjUzMzMzZjRlMTQzZDdfMy0zLTEtMS0xOTQ5Mjk_bbff2765-2607-465f-8d81-05466849fbd8"
      unitRef="usd">18551000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ2OTM0MQ_c53e27ea-d2da-4b23-9a84-1bd47e855ab5"
      unitRef="usd">134000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDk0NzgwMjM1MzEzMQ_75274965-7ff0-4d93-b8ec-adc6d0b39258">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(298,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net before currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Intellectual property and accumulated depreciation attributable to CartiHeal totaling $410,200 and $11,327, respectively, were reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Net intellectual property and customer relationships of $23,458 and $8,377, respectively, were reclassified into assets held for sale within the April&#160;1, 2023 consolidated condensed balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding assets held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;The Company recorded an impairment loss of $78,615 in the U.S. reporting segment of net intellectual property attributable to a business held for sale. The loss was recorded in impairment of assets within the consolidated condensed statements of operations and comprehensive loss. Refer to Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding businesses held for sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib35b3d444a98478a89240114e08c3916_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMS0xLTEtMS0yMTgxNzY_4ffb9247-047f-4b48-9ae8-ececc0c29aca"
      unitRef="usd">676549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5da15f6d37344cae8110d560e17ae77c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMS0zLTEtMS0yMTgxNzY_4c6b7795-4795-4521-979c-eeff1cdb4796"
      unitRef="usd">790049000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i15da563fbc3546a19bdbbb85a92d1730_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMi0xLTEtMS0yMTgxNzY_39247d63-743d-4b15-98ee-bda1b76ead19"
      unitRef="usd">61325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i764545bc9ad949eea69c3be558616715_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMi0zLTEtMS0yMTgxNzY_ac7c9242-cd49-4c35-9989-f8b87babf8ad"
      unitRef="usd">61325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i62641fead14343468e0f3d886ba7a6ca_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMy0xLTEtMS0yMTgxNzY_fb8d28c7-c0b6-4d6e-951d-2338c741a067"
      unitRef="usd">57950000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i70245e2f7da94059ae58287036f79af6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMy0zLTEtMS0yMTgxNzY_0e5fc975-c98c-4b7b-9ca0-e41de95a58c1"
      unitRef="usd">67450000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i98809c525a964717bfbdd03b0ff34ad8_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNC0xLTEtMS0yMTgxNzY_0b89c3fe-47bf-437a-a8e2-29d429aabea0"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib032dbd53db04880ad76314b46e1e9e6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNC0zLTEtMS0yMTgxNzY_5d8676bd-2250-46cc-80f1-71ee79ebca66"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaa5c981648904e9b80b64c023d15fa42_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNS0xLTEtMS0yMTgxNzY_54a570cd-7fbe-4455-b239-559d1490972a"
      unitRef="usd">13998000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a4af42355014f9cba9ef136263bb498_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNS0zLTEtMS0yMTgxNzY_525ae0e4-ff53-4373-ae1d-f4b5d0ccd1b9"
      unitRef="usd">13998000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNi0xLTEtMS0yMTkxNDM_348eb240-7777-408b-9cad-8be282eed8ad"
      unitRef="usd">815322000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfNi0zLTEtMS0yMTkxNDM_abf124c0-3691-468d-bf98-ddb6f4a38352"
      unitRef="usd">938322000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib35b3d444a98478a89240114e08c3916_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOC0xLTEtMS0yMTgxNzY_a1a54f62-ccb6-4553-86ac-a98ec30dd04e"
      unitRef="usd">188094000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5da15f6d37344cae8110d560e17ae77c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOC0zLTEtMS0yMTgxNzY_408ad1b4-930c-45a1-a18a-9a69d9aa17f6"
      unitRef="usd">187767000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i15da563fbc3546a19bdbbb85a92d1730_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOS0xLTEtMS0yMTgxNzY_3c4eba73-8e9c-47ab-a827-ab2d490d1580"
      unitRef="usd">45563000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i764545bc9ad949eea69c3be558616715_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfOS0zLTEtMS0yMTgxNzY_5a5d54e0-e78e-4635-b567-e74e46583352"
      unitRef="usd">44319000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i62641fead14343468e0f3d886ba7a6ca_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTAtMS0xLTEtMjE4MTc2_0955bf45-1024-496e-bc17-b8c19d121c1e"
      unitRef="usd">57950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i70245e2f7da94059ae58287036f79af6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTAtMy0xLTEtMjE4MTc2_16d1889c-ce5b-4d23-bb7b-f44fbdf4a020"
      unitRef="usd">58842000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa5c981648904e9b80b64c023d15fa42_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTEtMS0xLTEtMjE4MTc2_53698820-1ab0-4193-a4c1-d7254b2af55a"
      unitRef="usd">6587000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a4af42355014f9cba9ef136263bb498_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTEtMy0xLTEtMjE4MTc2_f7791ee7-68f6-4bec-9c75-db493d13dcca"
      unitRef="usd">6276000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTItMS0xLTEtMjE5MTQz_90cc6ebc-88dc-4d1a-8df1-2dccab221780"
      unitRef="usd">298194000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTItMy0xLTEtMjE5MTQz_f2b354a9-0a58-4037-99f8-2d3f4383902e"
      unitRef="usd">297204000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <bvs:FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTMtMS0xLTEtMjE5MTQz_1d319fa2-fffb-474b-8060-9c4cfbc9b13d"
      unitRef="usd">517128000</bvs:FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss>
    <bvs:FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTMtMy0xLTEtMjE5MTQz_aec5228f-dbd7-4ef8-a994-d8c516d9a3ca"
      unitRef="usd">641118000</bvs:FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss>
    <bvs:FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTQtMS0xLTEtMjE4MTc2_3034171e-57f8-4616-9d2d-3883773b3fb9"
      unitRef="usd">-1089000</bvs:FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss>
    <bvs:FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTQtMy0xLTEtMjE4MTc2_91f15f8c-f68e-4f37-ab7c-d813c90306b6"
      unitRef="usd">-1267000</bvs:FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTUtMS0xLTEtMjE5MTQz_56ff39e2-09b0-4c8c-867a-c55eda861fc8"
      unitRef="usd">516039000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOjJhMjhhZmQ4ZjQ0ZDRiYTBiZTYyZTI0MWRmZjk2NTQyL3RhYmxlcmFuZ2U6MmEyOGFmZDhmNDRkNGJhMGJlNjJlMjQxZGZmOTY1NDJfMTUtMy0xLTEtMjE5MTQz_9141611b-4c5e-44ba-8703-68121a44b4e6"
      unitRef="usd">639851000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6b54bc099ff64cdf83d289598ea44468_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3MzQ5OQ_fff3eede-f78d-438d-a88f-38d070a10a3d"
      unitRef="usd">410200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6b54bc099ff64cdf83d289598ea44468_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3MzUwNw_59ae2330-0f94-4a10-9c9a-2cdcc3b7fc4a"
      unitRef="usd">11327000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i49ccfda1a2d4406197267d9884f36892_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfODc5NjA5MzA1MzM0OQ_8cbc9f62-029e-4638-a9f3-23f54dcc3e40"
      unitRef="usd">23458000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0829461c73da4cc59c0a31bf4e8fdc00_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfODc5NjA5MzA1MzQwNQ_00a26cca-e66a-4776-a2b8-058d2b789ccd"
      unitRef="usd">8377000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i1fad609af52e483890feb9ddbe45ddcc_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3MzEwMA_d89309b7-75fb-4489-a186-fc96621b19b5"
      unitRef="usd">78615000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzA2NQ_c04ef67d-37ce-4ca3-acb4-48655647f862"
      unitRef="usd">22041000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAxMA_52970d6e-cb35-4e37-8a7c-90e54aad126e"
      unitRef="usd">26347000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAxNQ_1f47c4a1-574d-4cae-a350-f39a04708fe2"
      unitRef="usd">22874000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAyMA_f8e230ac-8dd2-4ef6-8981-76fe97650c5f"
      unitRef="usd">20030000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1NzAyNA_6785fb9a-9dfd-41f5-b3e3-e63f11a6752b"
      unitRef="usd">19652000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:NumberOfReportingUnits
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMjYwMg_28d68b32-76f8-4276-8f42-739da70200a9"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:Goodwill
      contextRef="i00ae122881df443da212c3e259b30aac_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ1MDAyNQ_19a744c8-c69a-4454-82a2-dbeb7d2765bc"
      unitRef="usd">6297000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia6e7f859e2de4e2e9bea8834f864b660_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3NDM5MA_b043f424-3e2b-4489-80fa-7993a3f44568"
      unitRef="usd">189197000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i5f04a78cee4c46279f51766a4be3f9e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3NDQ0Ng_3d6c6496-6ca1-49d7-b0e2-415304411ee5"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfNDM3OA_8c66f3c3-38f1-403a-b4a2-20a0d532eca9">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross-to-net deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonus and commission&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income and other taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Bonus and commissions of $588 were reclassified into liabilities held for sale within the April&#160;1, 2023 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Other liabilities attributable to CartiHeal of $384 were reclassified into current liabilities attributable to discontinued operations within December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bvs:GrossToNetDeductionsCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMS0xLTEtMS0xOTQ5Mjk_dce1f7c2-e32e-4260-a06d-fb6ab72603a0"
      unitRef="usd">66557000</bvs:GrossToNetDeductionsCurrent>
    <bvs:GrossToNetDeductionsCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMS0zLTEtMS0xOTQ5Mjk_98033d1b-a035-4bb5-89b3-5d8e18e10154"
      unitRef="usd">71227000</bvs:GrossToNetDeductionsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMi0xLTEtMS0xOTQ5Mjk_bbef86ad-5b66-4600-8a60-5dcee14cd3af"
      unitRef="usd">9462000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMi0zLTEtMS0xOTQ5Mjk_1de87d01-c528-4c30-929f-8d3f6386d976"
      unitRef="usd">9179000</us-gaap:AccruedBonusesCurrent>
    <bvs:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMy0xLTEtMS0xOTQ5Mjk_14aefbd7-3f42-4850-8aeb-31430d8b099c"
      unitRef="usd">6843000</bvs:AccruedSalariesAndEmployeeBenefitsCurrent>
    <bvs:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfMy0zLTEtMS0xOTQ5Mjk_38d8d5d9-df0b-4f7c-868b-c9f4156f34af"
      unitRef="usd">11428000</bvs:AccruedSalariesAndEmployeeBenefitsCurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0xLTEtMS0yMjU4NDg_9ddb00b3-96c7-40de-abde-dbdee65975fa"
      unitRef="usd">6210000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0zLTEtMS0yMjU4NDg_6a6b6f60-ddc2-4fd9-8140-0ea5fc9a11d5"
      unitRef="usd">217000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0xLTEtMS0xOTQ5Mjk_96357458-c79d-4fd9-b209-91153b57b1c2"
      unitRef="usd">4496000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNC0zLTEtMS0xOTQ5Mjk_4c514d31-0321-4467-a8c9-a06e49db1247"
      unitRef="usd">2572000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNS0xLTEtMS0xOTQ5Mjk_8942487b-67a2-4785-a3f2-445dad439227"
      unitRef="usd">22201000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNS0zLTEtMS0xOTQ5Mjk_744f88e8-19cd-4aaf-9f16-014b795707bb"
      unitRef="usd">16947000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNi0xLTEtMS0xOTQ5Mjk_79dd636b-1219-4417-a3b8-c1b769c1b999"
      unitRef="usd">115769000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RhYmxlOmI5NGFhZDZkN2I0MDQ3ODdiOTBkYzQ5Mzc1Yzg0NzAxL3RhYmxlcmFuZ2U6Yjk0YWFkNmQ3YjQwNDc4N2I5MGRjNDkzNzVjODQ3MDFfNi0zLTEtMS0xOTQ5Mjk_1d5f94c2-7269-48ec-b681-256926300f98"
      unitRef="usd">111570000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i96bf92cb92254a4ab3b4c7931ae92c61_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3ODkyOA_d3eb9a20-d22a-4d32-9677-1baf08e7a969"
      unitRef="usd">588000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80MC9mcmFnOmVkYzBhMzA4Zjk3MDQ4NDg5NTEwYzEyNDBkOWM5ZDk4L3RleHRyZWdpb246ZWRjMGEzMDhmOTcwNDg0ODk1MTBjMTI0MGQ5YzlkOThfMTY0OTI2NzQ3OTQ2MQ_a49a3f9f-cb4f-4828-9209-2a91ae8e9a57"
      unitRef="usd">384000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <bvs:AcquisitionsAndInvestmentsDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyNzc_a65084a3-5895-4572-8306-b67f14814702">Acquisitions and divestitures&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Wound Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses its businesses and products in order to calibrate its strategic focus, enhance liquidity, prioritize investments and allocate capital to its core business units. As a result of this assessment, the Company has committed to a plan to divest certain assets within its Wound Business, specifically those attributable to TheraSkin and Theragenesis (the &#x201c;Wound Business&#x201d; or  the &#x201c;Disposal Group&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has classified the identifiable net assets of the Disposal Group as held for sale. Assets and liabilities determined to be part of the Disposal Group have been recorded as single amounts within the Company&#x2019;s consolidated financial statements. Assets held for sale are reported at the lower of the carrying amount or fair value less costs to sell, which is expected to occur within one year. The Company has ceased the depreciation and amortization attributable to assets classified as held for sale. Assets and liabilities held for sale are reviewed each reporting period to determine whether existing carrying values are fully recoverable in comparison to estimated fair values less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Wound Business for impairment during the first quarter of 2023. The Company recorded a $78,615 ($63,337 after tax) impairment as a result of this evaluation to reduce the intangible assets of the Wound Business to reflect their respective fair values less any costs to sell. The fair value of intangibles of the Wound Business was determined based on the consideration offered for the Wound Business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the major classes of assets and liabilities of the Wound Business that were classified as held for sale were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying amounts of assets classified as held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net of allowance of $898&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying amounts of liabilities classified as held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CartiHeal (2009) Ltd&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2022, the Company completed the acquisition of 100% of the remaining shares in CartiHeal, a privately held company headquartered in Israel and the developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. The Company previously held an equity interest in CartiHeal&#x2019;s fully diluted shares with a carrying value of $15,768 and $16,771 as of July 12, 2022 and December&#160;31, 2022, respectively. Net equity losses associated with CartiHeal for the three months ended April&#160;2, 2022 totaled $401, which was included in discontinued operations, net on the consolidated condensed statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired CartiHeal (the &#x201c;CartiHeal Acquisition&#x201d;) for an aggregate purchase price of approximately $315,000 and an additional $135,000, payable after closing upon the achievement of a certain sales milestone (&#x201c;Sales Milestone&#x201d;, or &#x201c;CartiHeal Contingent Consideration&#x201d;). The Company paid $100,000 of the aggregate purchase price upon closing consisting of a $50,000 deposit held in trust and $50,000 from a financing arrangement (Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4. Financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding financing arrangements). The Company also paid approximately $8,622 of CartiHeal&#x2019;s transaction-related fees and expenses and deferred $215,000 (&#x201c;Deferred Amount&#x201d;) of the aggregate purchase price otherwise due at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Deferred Amount was to be paid in five tranches commencing in 2023 and ending no later than 2027 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;$50,000 due upon the earliest to occur &#x2014; the publication in a peer-reviewed orthopedic journal of an article that presents the results of the pivotal clinical trial (&#x201c;First Paper Milestone&#x201d;) or July 1, 2023; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;$50,000 due upon the earliest to occur &#x2014; the implantation of Agili-C devices in 100 patients in the United States or September 1, 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;$25,000 due upon the earliest to occur &#x2014; the publication in a peer-reviewed orthopedic journal of an article that presents any new or additional clinical data subsequent to the First Paper Milestone with respect to Agili-C (&#x201c;Second Paper Milestone&#x201d;) or January 1, 2025;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;$25,000 due upon the earliest to occur &#x2014; the publication in a peer-reviewed orthopedic journal of an article that presents any new or additional clinical data subsequent to the First and Second Paper Milestone with respect to Agili-C or January 1, 2026; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;$65,000 due upon the earliest to occur &#x2014; obtaining a U.S. Category 1 Current Procedural Terminology (&#x201c;CPT&#x201d;) code from Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) for Agili-C or January 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the CartiHeal Amendment (as defined below), the Company owed interest on each tranche of the Deferred Amount at a rate of 8.0% annually, until such tranche is paid. The Sales Milestone was payable upon the achievement of $75,000 in trailing twelve month sales pursuant to the CartiHeal Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had entered into an Option and Equity Purchase Agreement with CartiHeal (&#x201c;Option Agreement&#x201d;) in January 2020 and a subsequent amendment in June 2022 (&#x201c;CartiHeal Amendment&#x201d;). The Option Agreement provided the Company with an exclusive option to acquire 100% of CartiHeal&#x2019;s shares (&#x201c;Call Option&#x201d;), and provided CartiHeal with a put option that would require the Company to purchase 100% of CartiHeal&#x2019;s shares under certain conditions. In August 2021, CartiHeal achieved pivotal clinical trial success, as defined in the Option Agreement, for the Agili-C implant. In order to preserve the Company&#x2019;s Call Option, in accordance with the Option Agreement and upon approval of the Company&#x2019;s Board of Directors (&#x201c;BOD&#x201d;), the Company deposited $50,000 into escrow in August 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The First Paper Milestone under the Option Agreement occurred on February 13, 2023, which obligated the Company to make the first $50,000 payment, plus applicable interest, under the Option Agreement. On February 27, 2023, the Company entered into a settlement agreement (the &#x201c;Settlement Agreement&#x201d;) with Elron Ventures Ltd. (&#x201c;Elron&#x201d; and together with the Company, the &#x201c;Parties&#x201d;) as representative of CartiHeal&#x2019;s selling securityholders under the Option Agreement collectively, the &#x201c;Former Securityholders&#x201d;). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings relating to non-payment of any obligations arising under the Option Agreement during a period of 30 calendar days (the &#x201c;Interim Period&#x201d;) in exchange for (i) a one-time non-refundable amount of $10,000 and (ii) a one-time non-refundable payment of $150 to Elron to be used in accordance with the expense fund provisions of the Option Agreement. The Interim Period expired on March 29, 2023 and the Company did not exercise its right to extend the Interim Period. In addition, the Parties mutually released any further claims under the Option Agreement and related transaction documents, including without limitation a release by the Former Securityholders of any rights to enforce the provisions of the Option Agreement or make further monetary claims against the Company and/or its respective affiliates and representatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company transferred 100% of its shares in CartiHeal to a trustee (the &#x201c;Trustee&#x201d;) for the benefit of the Former Securityholders pursuant to the Settlement Agreement. The Company had no ownership interest and no voting rights during the Interim Period. Accordingly, the Company concluded that upon execution of the Settlement Agreement, the Company ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Company&#x2019;s international reporting segment. The Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss upon disposal was $60,639 and was recorded within discontinued operations, net within the consolidated condensed statements of operations and comprehensive loss. The loss on disposal is comprised of the book value of CartiHeal&#x2019;s net assets at the time of disposal, goodwill attributable to CartiHeal and the previously discussed non-refundable payments made to Elron. The Company allowed the Interim Period to expire on March 29, 2023 as the Company was not able to find a financing solution to fund the payment obligations under the Option and Equity Purchase Agreement on terms the Company believed to be favorable to it and its shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of consideration for the CartiHeal Acquisition was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal of cash at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of previously held equity interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Remeasurement of the Company&#x2019;s equity method investment in CartiHeal, net of equity losses as a result of the purchase. The remeasurement included a gain of $23,709 calculated as the difference between the fair value and the carrying value of the Company&#x2019;s investment in CartiHeal at the acquisition date and was recognized in other income during the third quarter of 2022 on the consolidated condensed statements of operations and comprehensive loss. The fair value was based upon: (i) the consideration transferred to members owning 89.97% of CartiHeal&#x2019;s fully diluted shares; (ii) calculating the value of CartiHeal&#x2019;s fully diluted shares based upon the transferred consideration; and (iii) applying the calculated value to the Company&#x2019;s 10.03% ownership in CartiHeal&#x2019;s fully diluted shares at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for the CartiHeal Acquisition using the acquisition method of accounting whereby the total purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired and liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Resulting goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nearly 100% of the goodwill represents estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized and is attributable to expected revenue growth in new markets. The goodwill was not deductible for tax purposes and $55,295 and $4,999 was allocated to the U.S. and International reporting units, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CartiHeal&#x2019;s intangibles consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual Property - US Segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual Property - International Segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the acquired CartiHeal intangibles was determined using an income approach, a valuation technique that estimates the fair value of an asset based on market participant expectations of the cash flows that an asset would generate over its remaining useful life. The determination of the useful lives was based upon consideration of market participant assumptions and transaction specific factors.&lt;/span&gt;&lt;/div&gt;</bvs:AcquisitionsAndInvestmentsDisclosureTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3fa935ec3263472594eb58a3df3c2f65_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ4MDc4Mg_7245cf5a-0c1c-4c39-bbf0-895f4e159af4"
      unitRef="usd">78615000</us-gaap:AssetImpairmentCharges>
    <bvs:AssetImpairmentChargesAfterTax
      contextRef="i3fa935ec3263472594eb58a3df3c2f65_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ4MDkzNQ_5b22d88b-aec1-484d-8f54-b70d06ce7128"
      unitRef="usd">63337000</bvs:AssetImpairmentChargesAfterTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDk0NzgwMjM1MjE5Nw_1586423b-4e40-4da2-92e4-dcfdac7b3bc6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the major classes of assets and liabilities of the Wound Business that were classified as held for sale were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying amounts of assets classified as held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net of allowance of $898&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying amounts of liabilities classified as held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes CartiHeal&#x2019;s major classes of assets and liabilities as reported on the consolidated condensed balance sheets as of December 31, 2022 as the balances were fully deconsolidated as of April&#160;1, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amounts of major classes of assets included as part of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amounts of major liabilities included as part of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April&#160;1, 2023 and April&#160;2, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bioventus Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMi0wLTEtMS0yMTc1MDkvdGV4dHJlZ2lvbjpiNzRjOTYzMGNmMDQ0YzA4OTBiNzYyYTg5NzVlY2Q2OV8xNjQ5MjY3NDQxNzA5_86d0c0ed-df43-43b9-b2ad-e3996f6b0711"
      unitRef="usd">898000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMi0xLTEtMS0yMTc1MDI_5cc95a4b-a495-42b7-a5f7-dedf1113f3ac"
      unitRef="usd">4114000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <bvs:DisposalGroupIncludingDiscontinuedOperationInventory
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMy0xLTEtMS0yMTc1MDI_f7ed63e8-042e-4243-bc4c-53cc6819b730"
      unitRef="usd">1481000</bvs:DisposalGroupIncludingDiscontinuedOperationInventory>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfNC0xLTEtMS0yMTc1MDI_0c76bec5-ed44-430e-8a23-743cfd8866e1"
      unitRef="usd">443000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfNS0xLTEtMS0yMTc1MDI_ba0b3257-650e-427f-a9f9-94337712b5a5"
      unitRef="usd">31835000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfNi0xLTEtMS0yMTc0OTg_33310649-7d3f-4b95-a023-c360372175a7"
      unitRef="usd">37873000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfOS0xLTEtMS0yMTc1MDM_c5c0780d-2cc0-462d-bf50-dba9a2c1cbde"
      unitRef="usd">1285000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMTAtMS0xLTEtMjE3NTAz_01b5d852-ade5-4f13-817a-3728d6028ebe"
      unitRef="usd">588000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i8c00fe1120844212b2fb0039b542d999_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmRmNWU4ZWI0M2NkOTQxYTQ4M2Q0YzE5YTA2YTRkMjMwL3RhYmxlcmFuZ2U6ZGY1ZThlYjQzY2Q5NDFhNDgzZDRjMTlhMDZhNGQyMzBfMTEtMS0xLTEtMjE3NTAw_af36eb34-4e58-472b-85e6-de76061038ba"
      unitRef="usd">1873000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTE3_96d6b7e2-4965-414e-8330-908edae653bf"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:Investments
      contextRef="i2e2d5c54e1f649d99de1b04258d57249_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDc1_c2033e53-bc62-4e6a-8252-d3da61696ee5"
      unitRef="usd">15768000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="ic4a9d2699d26472ebf9e64d62424696d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDgy_a6249e02-3437-4347-97bf-2d71827885a3"
      unitRef="usd">16771000</us-gaap:Investments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6a2781c3a6a04fffb4599cdde6001d9a_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNjM3_0fb9ac46-7a15-464f-a74c-d44e86f917e5"
      unitRef="usd">-401000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfODQ3_918b3479-4e9a-444f-bdce-4df90222ba8c"
      unitRef="usd">315000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibcd6603021274a84ba8c4328e971097b_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfODY4_36102905-ff92-4d3d-8e12-b79b84d38e33"
      unitRef="usd">135000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTAyOA_d88aee28-1950-4250-a29e-167a2697f5d9"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:EscrowDeposit
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTA5Mg_806778aa-a6cc-4635-b75c-5676324eaadc"
      unitRef="usd">50000000</us-gaap:EscrowDeposit>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iaf3b97bb69794fb5a74d6264e30703c9_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTEyMQ_cebfc6a4-7406-45a3-bc19-ec5140780e65"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTI4OA_fa4c8f59-0c74-46e6-ba2d-e59b5744dde2"
      unitRef="usd">8622000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i18d2594349e442f5aa4558186daaac0f_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTM1Nw_819e195a-36ba-4421-870b-5b9734e2bdda"
      unitRef="usd">215000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bvs:BusinessCombinationContingentConsiderationLiabilityNumberOfTranches
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTQ3Mg_79ab5f3c-fe9f-4315-9c61-b22bac5ce9d4"
      unitRef="tranche">5</bvs:BusinessCombinationContingentConsiderationLiabilityNumberOfTranches>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i975eb89011db4560ba2bcc2086c60016_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTU0NQ_372b7c1b-24ce-4186-82bd-5b097c051cf6"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i49db16cff51046329cf250fb5ac89e34_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTc0Nw_5c3c684e-deb5-4bed-a6d8-c60bc4ccaab0"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5f444d9528924284aadcb1788007ff06_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTg3OA_b1dbea08-0cbc-427d-8689-4429ba31e4f4"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibe7aa5cbcd4e4539a13ab3abf8e8c9f7_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjE0MQ_5989d551-322b-41b2-bdf3-5d33b8bc365e"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i99f4d905bbb34b16a050cfc582ff2ea9_I20220712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjM5NA_7d02ef34-6738-4721-8256-b1af60e8101f"
      unitRef="usd">65000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bvs:BusinessCombinationContingentConsiderationLiabilityInterestRate
      contextRef="icd90e131a7bf4a278b55541190ffe001_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjcyNA_f7ac38f3-ebd1-4adf-9315-f8fdd4bb7477"
      unitRef="number">0.080</bvs:BusinessCombinationContingentConsiderationLiabilityInterestRate>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i22f12085d4424a5b9d5157232a465367_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMjgyNQ_af36d542-b4b7-4989-b4c8-3a1ce087c37f"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i5248f80680c045179f84e361ed1ba3cc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMzE1NA_e0384fab-4650-4d07-a91e-7fb196e2b2e3"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i1247f024a75548eba0514a747599cee5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMzI3OA_3e7331a7-6ff2-495e-b630-ce7fd43eff01"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EscrowDeposit
      contextRef="i6ac987576c674d6cbf92d74ed2df1b8b_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMzYyOA_58ee2cf1-b2a5-4ed5-b01e-2928ad6643ad"
      unitRef="usd">50000000</us-gaap:EscrowDeposit>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i2f97030445ee47889c1b38177e4a3a23_D20230213-20230213"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2NzI4OQ_fe04328f-e66f-4fc2-9ca1-d85db8207528"
      unitRef="usd">50000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i80bae10979d2454580adedb3b2a6c481_D20230227-20230227"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2Nzc1Mg_ea3f9e85-ccb5-42b9-be91-b5f4088aacd1"
      unitRef="usd">10000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="iebb5d183410449b1908570eb5651c0ca_D20230227-20230227"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2Nzc1OQ_38e30f53-b41f-43d4-aec5-81dba78c68b5"
      unitRef="usd">150000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee
      contextRef="i3f75d22eb20045e4a96e961e0a09ca92_D20230227-20230227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2NzY4MA_147e4a87-ad0e-4628-8111-3b1defa1a31b"
      unitRef="number">1</bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="ib6a06c7e9385495f98dce248522deff1_D20230227-20230227"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2Nzc3MA_ea587dca-1159-4058-9578-9a61d2871c6c"
      unitRef="usd">-60639000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyNzg_ddcdacc0-9f5e-4e4b-ae62-374e28be0197">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of consideration for the CartiHeal Acquisition was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal of cash at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of previously held equity interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Remeasurement of the Company&#x2019;s equity method investment in CartiHeal, net of equity losses as a result of the purchase. The remeasurement included a gain of $23,709 calculated as the difference between the fair value and the carrying value of the Company&#x2019;s investment in CartiHeal at the acquisition date and was recognized in other income during the third quarter of 2022 on the consolidated condensed statements of operations and comprehensive loss. The fair value was based upon: (i) the consideration transferred to members owning 89.97% of CartiHeal&#x2019;s fully diluted shares; (ii) calculating the value of CartiHeal&#x2019;s fully diluted shares based upon the transferred consideration; and (iii) applying the calculated value to the Company&#x2019;s 10.03% ownership in CartiHeal&#x2019;s fully diluted shares at the acquisition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMC0xLTEtMS0xOTQ5Mjk_96019e31-9290-4e1a-b567-033cb1b73bc9"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <bvs:BusinessCombinationConsiderationTransferredTransactionCosts
      contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMS0xLTEtMS0xOTQ5Mjk_5a6ade91-206a-4bb6-af8e-c9c76904d3c7"
      unitRef="usd">8622000</bvs:BusinessCombinationConsiderationTransferredTransactionCosts>
    <bvs:BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts
      contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMi0xLTEtMS0xOTQ5Mjk_8ecab0ba-2d8f-4fc1-924f-07327e949d6b"
      unitRef="usd">108622000</bvs:BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie2752ec5905e4a858220620c6f6f6ab1_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfMy0xLTEtMS0xOTQ5Mjk_6a22fffe-2515-4998-8f11-e3998973606d"
      unitRef="usd">183400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iff82fadf30aa4ced9c49563731d130d5_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfNC0xLTEtMS0xOTQ5Mjk_8b545ef9-7334-423c-a2e2-2a8778ae5218"
      unitRef="usd">61901000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfNS0xLTEtMS0xOTQ5Mjk_a83d5e29-b8a7-4f5d-8300-593cdcef55c1"
      unitRef="usd">39477000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="iad8c492357214f09a0573977291f320f_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjZhZjdiNGViNjc0MzRiZGM5YTYyNjkwMDFjOWUzODI3L3RhYmxlcmFuZ2U6NmFmN2I0ZWI2NzQzNGJkYzlhNjI2OTAwMWM5ZTM4MjdfNi0xLTEtMS0xOTQ5Mjk_d93feb64-9399-44f3-97ad-67c79bae7612"
      unitRef="usd">393400000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i4dafe4682a984e7cb23b5b32626f258b_D20220703-20221001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTY0OTI2NzQ2ODQ4NA_4dae2b0a-0239-4859-96d0-ef8afb5cba07"
      unitRef="usd">23709000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <bvs:BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares
      contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDM2OQ_9b11cabf-ba4a-4492-843b-78f6373ad56d"
      unitRef="number">0.8997</bvs:BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id9f99c0f111c40f4b35d75accc7a326e_I20220711"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNDU3MQ_a126934f-684d-4ed2-bec2-6c35f913304c"
      unitRef="number">0.1003</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyODQ_75b4e3bd-0af0-41c4-a3b1-ee9442b38325">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets acquired and liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Resulting goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="i38e424db57644fffa0b3eb6330265e74_D20220712-20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMC0xLTEtMS0xOTQ5Mjk_b8c57df0-0379-4d00-8fa5-e2540db4863c"
      unitRef="usd">393400000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMi0xLTEtMS0xOTQ5Mjk_01d68fe1-1f5a-41f9-a1ba-3e60b1ecfa42"
      unitRef="usd">3781000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMy0xLTEtMS0xOTQ5Mjk_fb7221ed-2ecb-4b59-9560-082ededab4bf"
      unitRef="usd">642000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNC0xLTEtMS0xOTQ5Mjk_d1416fcf-9b65-417f-a84c-c81b3b5dbc2d"
      unitRef="usd">552000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNS0xLTEtMS0xOTQ5Mjk_7b947b4a-836a-4431-ad2a-f56571968631"
      unitRef="usd">259000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNi0xLTEtMS0xOTQ5Mjk_5a9b7b88-26e1-462e-b9e5-5f8acb12c4f6"
      unitRef="usd">410200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfNy0xLTEtMS0xOTQ5Mjk_5e9f166a-0649-4ba2-9cf1-ef1a613463b9"
      unitRef="usd">727000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfOC0xLTEtMS0xOTQ5Mjk_19136628-00d9-4478-9093-ad6b120d2079"
      unitRef="usd">18000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfOS0xLTEtMS0xOTQ5Mjk_197d3c34-7861-48ec-97e1-4546a9a0986a"
      unitRef="usd">459000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTAtMS0xLTEtMTk0OTI5_8548faae-0d56-438b-bdba-3bacdcd8b130"
      unitRef="usd">171000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTEtMS0xLTEtMTk0OTI5_e858cc0e-343e-484c-854a-f95510b882a0"
      unitRef="usd">79863000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTItMS0xLTEtMTk0OTI5_83f7ffc1-b0a9-4994-a5f1-fc02c6c47d9d"
      unitRef="usd">2544000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTMtMS0xLTEtMTk0OTI5_1416bbdd-6e4c-4c8d-a7a6-7ccec9c6bdce"
      unitRef="usd">333106000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOmI5ODM5NjlhZGZlZjQ4NWM5OGQ0NjdhMjg2ZDU3Y2Q3L3RhYmxlcmFuZ2U6Yjk4Mzk2OWFkZmVmNDg1Yzk4ZDQ2N2EyODZkNTdjZDdfMTQtMS0xLTEtMTk0OTI5_93200637-60e0-4c03-bdf6-b730ce3ffc1d"
      unitRef="usd">60294000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i387d0ba33ecf49d4ae4397e0b83f1636_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNTY5OA_f50d352b-1e41-45cd-af91-db8569cd6d2e"
      unitRef="usd">55295000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="if9202c7ec716435aaa3082106434860a_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfNTcwNQ_98cadecb-becf-4e52-a260-aefbec8422aa"
      unitRef="usd">4999000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RleHRyZWdpb246ZjM5MWFjYjIyMWJjNGRlM2E3MzNjM2Y3N2FmODE2ZjRfMTMyODM_aad23bce-90d0-4d2b-9bad-3e766e63848c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CartiHeal&#x2019;s intangibles consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual Property - US Segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual Property - International Segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i61effdba045e47f7bcb546d32bcd31c3_D20220712-20220712"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMS0xLTEtMS0xOTQ5Mjk_941249de-6705-4b2a-9def-eef2df3579c1">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iabe5797c14874b5fa84ef6a0757f4034_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMS0zLTEtMS0xOTQ5Mjk_a0e5adbd-4e7a-4f11-9b63-afe075fdec40"
      unitRef="usd">351500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id56740f57a5e43aca22cc898a646c454_D20220712-20220712"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMi0xLTEtMS0xOTQ5Mjk_e81d01dd-cccf-4cb3-b22c-0a41b908b512">P8Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i88bdab0f0d4d463fa6398c22775dd54e_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMi0zLTEtMS0xOTQ5Mjk_9c2ce2ed-92f2-4b4d-80cb-ff2b4edaf3c0"
      unitRef="usd">58700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80My9mcmFnOmYzOTFhY2IyMjFiYzRkZTNhNzMzYzNmNzdhZjgxNmY0L3RhYmxlOjEwY2FkYTRlNDVhNzQ5ZDRiOWUzYjE0ODYwZGFlMThmL3RhYmxlcmFuZ2U6MTBjYWRhNGU0NWE3NDlkNGI5ZTNiMTQ4NjBkYWUxOGZfMy0zLTEtMS0xOTQ5Mjk_deee3e39-eec5-4a0c-a5cd-a356d8226fbf"
      unitRef="usd">410200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMzE0OQ_569280bc-dba1-478c-bff4-535c12d41115">Financial instruments&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amended Term Loan due October 2026 (9.19% at April&#160;1, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver due October 2025 (9.28% at April&#160;1, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the &#x201c;2019 Credit Agreement&#x201d;) that was comprised of a $200,000 term loan (&#x201c;Original Term Loan&#x201d;) and a $50,000 revolving facility (the &#x201c;Revolver&#x201d;). The Company amended the 2019 Credit Agreement on October 29, 2021 in connection with the Misonix Acquisition in which the Company prepaid $80,000 on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $360,750 term loan (&#x201c;Term Loan&#x201d;) and the Revolver.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 11, 2022, the Company further amended the 2019 Credit Agreement, as amended on October 29, 2021 (the &#x201c;First Amended 2019 Credit Agreement&#x201d;), in conjunction with the CartiHeal Acquisition. Pursuant to the First Amended 2019 Credit Agreement, an $80,000 term loan facility (the &#x201c;July 2022 Term Loan&#x201d; and, together with the Term Loan, the &#x201c;Term Loan Facilities&#x201d;) was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was not in compliance with certain financial covenants as of December 31, 2022. As a result, on March 31, 2023 (the &#x201c;Closing Date&#x201d;), the Company entered into another amendment to the 2019 Credit Agreement (collectively, with the October 2021 and July 2022 amendments, the &#x201c;Amended 2019 Credit Agreement&#x201d;) to, among other things, modify certain financial covenants, waive the noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLC&#x2019;s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending June 30, 2024, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended 2019 Credit Agreement had deferred financing costs of $3,661, of which $1,617 were recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $2,044 were capitalized on the consolidated condensed balance sheets. There was no loss on debt refinancing and modification as a result of the March 2023 amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;1, 2023, $416,585 was outstanding on the Term Loan Facilities, net of original issue discount of $2,876 and deferred financing costs of $1,251. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. The Company recorded $223 and $203 for deferred cost amortization in interest expense for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively. The Company had $29,000 and no outstanding borrowings on its Revolver as of April&#160;1, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Term Loan Facilities was $414,402 as of April&#160;1, 2023. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instruments within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically entered into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company had one non-designated interest rate swap agreement that was terminated on October 28, 2022. The Company received $7,738 upon the swap&#x2019;s termination. The swap was carried at fair value on the balance sheet with changes in fair value recorded as interest income or expense within the consolidated condensed statements of operations and comprehensive loss. Net interest income of $3,924 was recorded related to the change in fair value of the interest rate swap for the three months ended April&#160;2, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMzE1MA_4a8cdd7e-6d6e-4e25-abbb-7f0213406fb4">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amended Term Loan due October 2026 (9.19% at April&#160;1, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver due October 2025 (9.28% at April&#160;1, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if35ea5d41b5b485f883e49f6ae8fdc25_I20230401"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMS0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjoyNGUxMmZjZWQyNjk0NjM0Yjg3NGU0NzExNTMyNTQ1ZV80MA_20f49a38-a5ff-412a-a569-04984cee06ad"
      unitRef="number">0.0919</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if35ea5d41b5b485f883e49f6ae8fdc25_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMS0xLTEtMS0xOTQ5Mjk_d3a5aea8-0596-4695-9ce6-b2f87dbe5d2c"
      unitRef="usd">420712000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icaa1cdc09860462383a3492205a224d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMS0zLTEtMS0xOTQ5Mjk_801edd19-d216-41c9-95d8-88f25003e887"
      unitRef="usd">420712000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iad26eeedf4bb4bbda6790671a5bdff05_I20230401"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMy0wLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpjY2YzN2EzYzc2OGM0M2UzODdjZDVlNGQ0MDY4OWZkY18zMg_2557ba11-4182-4e26-bea3-c7ddcbc3aea3"
      unitRef="number">0.0928</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iad26eeedf4bb4bbda6790671a5bdff05_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMy0xLTEtMS0xOTQ5Mjk_bd0a369b-9fb6-4145-92be-8f39060957a7"
      unitRef="usd">29000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie7c79358e91348e084baee11c93bc142_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfMy0zLTEtMS0xOTQ5Mjk_f85ba94d-42cf-4c69-8cdf-af2d9a8b7395"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNS0xLTEtMS0xOTQ5Mjk_2075f7bc-716d-43ad-98cd-257ea68df8cf"
      unitRef="usd">41320000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNS0zLTEtMS0xOTQ5Mjk_7446df9d-aa94-4d32-8d59-168e43acc52d"
      unitRef="usd">33056000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNi0xLTEtMS0xOTQ5Mjk_3c8242de-a983-4778-bb8b-c3df3e849a35"
      unitRef="usd">1251000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNi0zLTEtMS0xOTQ5Mjk_4c476855-a29f-4e5e-80bb-ad834e88f81f"
      unitRef="usd">1338000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNy0xLTEtMS0xOTQ5Mjk_f1adc969-ce72-4fc6-a0e4-aa707d2a9479"
      unitRef="usd">2876000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfNy0zLTEtMS0xOTQ5Mjk_ffafa1cb-91dc-4f99-80cf-a6e1e1406f8d"
      unitRef="usd">1308000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfOC0xLTEtMS0xOTQ5Mjk_e278190e-2f07-4926-be26-4c27bd55564a"
      unitRef="usd">404265000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RhYmxlOjFmZjg4NWE3NTQ4MjQ2MmNiNWVjMjU0NDQ5Zjg2ZjI1L3RhYmxlcmFuZ2U6MWZmODg1YTc1NDgyNDYyY2I1ZWMyNTQ0NDlmODZmMjVfOC0zLTEtMS0xOTQ5Mjk_3ac38454-6b69-4e61-a979-3a44c77e0b6a"
      unitRef="usd">385010000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id9d9f38043fa4c028d7126e56c12e67d_I20191206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ0NjA3Nw_d6920178-296f-4d8d-b8d8-3ab47e1261d4"
      unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0a847747334d4e8ba6cc594e9dcdc9df_I20191206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ0NjA4Nw_a4fab3c6-f2b4-43a8-a13c-23e8e844f337"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i047d1c54f41c47e5b83b854cf55d776f_D20220711-20220711"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYwMA_7875e3e3-b258-42ca-a353-822aed13949c"
      unitRef="usd">80000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i76987f19a9c44ee4a8433bbef3cdc2e3_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjU5MA_ef209a97-6cb0-4d9e-acf0-dc6f1881016a"
      unitRef="usd">360750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i047d1c54f41c47e5b83b854cf55d776f_D20220711-20220711"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYwNA_0fa0ba87-a00a-4a69-bc0b-431ea25632ec"
      unitRef="usd">80000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <bvs:DebtInstrumentCovenantLiquidityMinimum
      contextRef="ibfe65f363fbb4e1787d372f14d6ed933_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA1Mw_f096b5bc-57f3-4f1d-8157-d16f5fcd4fa4"
      unitRef="usd">10000000</bvs:DebtInstrumentCovenantLiquidityMinimum>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i4c898ba97cad4ab6b65934419909f8e3_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDc4Mg_62740e22-2855-48e0-852c-530049041051"
      unitRef="usd">3661000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if392e17bdeab412496b7af16131a7aba_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDkyNg_1b7d722e-bdc3-4aa9-83c2-3be44b2d34e2"
      unitRef="usd">1617000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i4c898ba97cad4ab6b65934419909f8e3_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDkzMw_021f2782-23c6-4b43-99d0-7f2bc2884891"
      unitRef="usd">2044000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie47412cb505a4ad484457826df28f027_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjIxOQ_43ec7c23-5f15-4c7d-bb71-6e56ac55c848"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LongTermDebt
      contextRef="ic5b6613394184391936737b585ea4d43_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA2NA_43eef2ef-320b-446a-9945-c00878f03b2a"
      unitRef="usd">416585000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic5b6613394184391936737b585ea4d43_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA3NA_11ec51ca-ebb9-483b-98cc-be699d25a58b"
      unitRef="usd">2876000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic5b6613394184391936737b585ea4d43_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfODc5NjA5MzA2MTA4NA_97d60a46-613e-4bec-ad1c-d72fbfde370c"
      unitRef="usd">1251000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="iefdfaf8115ec421eb8f0d09f38e11095_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ4NDc2Mw_a34788f3-ac12-4c59-8018-ebc07ff34bbe"
      unitRef="usd">223000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i5252c9ad17db48d1988ebc871c1bdd70_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ4NDc1Ng_71fe65ef-cf82-412e-aaf5-adc0f2a9eac5"
      unitRef="usd">203000</us-gaap:InterestExpenseDebt>
    <us-gaap:LineOfCredit
      contextRef="idaa95b5adcef4db8a8cea991408aafb7_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYyNg_37aadce1-7bc4-48d0-bdd7-3ded59f7d963"
      unitRef="usd">29000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie42967b0b3404880892fef4d2d36f92f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MjYyMA_f78abcc9-e4f2-4d4e-a867-0ff025f0aac5"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtFairValue
      contextRef="i8df20ba54290443e83e1927334a06e3b_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ5MDYyMg_b0ddd72e-588d-4342-a88a-9d6d90bec8b2"
      unitRef="usd">414402000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i031d0465b2ad444390d6fdd9eb9e80b5_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMjM2NQ_b79a9fad-8dad-447a-a0cb-062e193d7ece"
      unitRef="derivative">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeCashReceivedOnHedge
      contextRef="idd2c5ab49e734e9bb3b79cadbd93c30d_D20221028-20221028"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMTY0OTI2NzQ0NjM0NQ_109902c6-d166-42b4-ba9f-9ef46624b0b5"
      unitRef="usd">7738000</us-gaap:DerivativeCashReceivedOnHedge>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="idd8a6fd92ded42a9ae62df80dfacd5bc_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV80OS9mcmFnOjk2Y2JjZWYzNDkwMzRjYTBiNzhlYmQ3OTI2ZWJkN2JjL3RleHRyZWdpb246OTZjYmNlZjM0OTAzNGNhMGI3OGViZDc5MjZlYmQ3YmNfMjcxMA_a020cd7a-4cef-4248-9d3f-6d2ef0ce5924"
      unitRef="usd">3924000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfNDMyNg_88a776f9-4289-461a-80b5-26e3d5850fb3">Fair value measurementsThe process for determining fair value has not changed from that described in the Annual Report on Form 10-K for the year ended December 31, 2022.&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 inputs. The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Amount - Current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Amount - Long Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CartiHeal contingent consideration- Sales Milestone&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioness contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;The Deferred Amount and contingent consideration attributable to CartiHeal have been reclassified to discontinued operations within the December 31, 2022 balance sheet. CartiHeal was fully deconsolidated during the first quarter of 2023. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Deferred Amount that resulted from the CartiHeal Acquisition was calculated based on the total amount payable on each due date for the five payment tranches including applicable interest. As previously discussed, the Company reached a settlement Agreement with the Former Securityholders. Pursuant to the Settlement Agreement, the Company was relieved of the obligations under the Deferred Amount. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs. As previously discussed, the Company reached a settlement agreement with the Former Securityholders and was relieved of the CartiHeal Contingent Consideration obligations. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures and Note 14. Discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioness contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4% - 6.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 - 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness totaled $287 and $269 for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss. Changes in contingent consideration related to the CartiHeal Acquisition totaled $1,710 for the three months ended April&#160;1, 2023 and is reported within discontinued operations, net within the consolidated condensed statements of operations and comprehensive loss. Pursuant to the Settlement Agreement, the Company was relieved of CartiHeal related obligations. The Company deconsolidated the remaining $68,961 contingent consideration liability as a result. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfNDMyNw_3b94c5ab-a48f-4353-8eaa-380971961209">The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Amount - Current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Amount - Long Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CartiHeal contingent consideration- Sales Milestone&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioness contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;The Deferred Amount and contingent consideration attributable to CartiHeal have been reclassified to discontinued operations within the December 31, 2022 balance sheet. CartiHeal was fully deconsolidated during the first quarter of 2023. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i6bff1a06928a49e684d3ba0fc962346e_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS0xLTEtMS0xOTQ5Mjk_8316b098-cc35-44ad-961e-49c1f14b296c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iebfb6349253c4e3280459ada7054fafc_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS01LTEtMS0xOTQ5Mjk_a150ba4a-4b0f-4ea1-958f-80487e32e81e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ic9956bf782d64ea1bd2b96df630c6d75_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS03LTEtMS0xOTQ5Mjk_a014bf3c-f816-4c91-8ec8-3cbca5f6417b"
      unitRef="usd">117615000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ic3cb0bc9269646a2a591dda918400054_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNS0xMS0xLTEtMTk0OTI5_7193333c-5af9-40f0-8249-768d3ab0b10f"
      unitRef="usd">117615000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6bff1a06928a49e684d3ba0fc962346e_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi0xLTEtMS0xOTQ5Mjk_563cebf1-0d4b-4fa9-b49e-8fcb5742d7c1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iebfb6349253c4e3280459ada7054fafc_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi01LTEtMS0xOTQ5Mjk_8de50d41-39d9-4c75-a877-8df8d5b620c3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic9956bf782d64ea1bd2b96df630c6d75_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi03LTEtMS0xOTQ5Mjk_49d48353-a33b-42d8-a28d-4db8a46c0229"
      unitRef="usd">79269000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic3cb0bc9269646a2a591dda918400054_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNi0xMS0xLTEtMTk0OTI5_2d7ae156-8a0f-428b-8424-e1ccc9e92ac3"
      unitRef="usd">79269000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i93ef7632e5b4407e87abff23d73b268c_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy0xLTEtMS0xOTQ5Mjk_c1d02257-0b57-47dd-9bcf-fb42380d5cd4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iad35dc89c0f44e299cceeb0f722b12ee_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy01LTEtMS0xOTQ5Mjk_0e558235-5e58-47ab-af4e-5d96da45aed8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i961477208dd54a26b2ccf6e64c912305_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy03LTEtMS0xOTQ5Mjk_3ab366e6-5035-480b-a5ca-a53ce6d309e3"
      unitRef="usd">67251000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2705284e689b4650bdc0ab6b3be0e86e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfNy0xMS0xLTEtMTk0OTI5_e30f596a-6197-4d4f-be7b-f97b5389e17d"
      unitRef="usd">67251000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ice6df20213a847689d562669ec8c0eb2_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC0xLTEtMS0xOTQ5Mjk_f6575ea2-0516-4fe0-b5f7-2c31e5922f85"
      unitRef="usd">17718000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i848696f930194e1d8e9f0ab3b2518dab_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC01LTEtMS0xOTQ5Mjk_461cb467-e110-42e3-b814-6f5afee84237"
      unitRef="usd">17718000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iabedf0c4173d4d219e5a4a7c97ef7c6d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC03LTEtMS0xOTQ5Mjk_45a5b3fc-6620-4c8c-9c12-5ff7057bbb45"
      unitRef="usd">17431000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ief782f56b0bd4c4ba52ecbb991a64e23_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOC0xMS0xLTEtMTk0OTI5_23ab0951-4557-44cc-be61-06c899fe4b99"
      unitRef="usd">17431000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7804b256d26143329ce8b1c8bfdeb7ee_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS0xLTEtMS0xOTQ5Mjk_2878387d-75be-4251-9c5a-093b29129782"
      unitRef="usd">17718000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i13a1162e408641aeb42666f59ea6e3c1_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS01LTEtMS0xOTQ5Mjk_954aa1e1-a947-4348-9920-425f6ce71bfc"
      unitRef="usd">17718000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i04b95fd7a3234324ac4b5f9ada511b59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS03LTEtMS0xOTQ5Mjk_daeb060c-f502-4daf-bb96-4b78a1eaadee"
      unitRef="usd">281566000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5fb4f2d80cc44287b347cfd75169b5a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjdlYTU2M2E1MzU0ODRhOGRiNjI3Njc4N2Y1YWI1OTIzL3RhYmxlcmFuZ2U6N2VhNTYzYTUzNTQ4NGE4ZGI2Mjc2Nzg3ZjVhYjU5MjNfOS0xMS0xLTEtMTk0OTI5_9e629854-6ce2-4366-9c8c-c96b7c37d535"
      unitRef="usd">281566000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfNDMyOA_b5db0740-c7b9-4294-96eb-17aa443fa0bb">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioness contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4% - 6.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 - 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i323f1175cc564a45a27343e1faec2e7a_I20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjQ0MGFhNzI2NDEyNTQ4Njc5YjcxODM1OGY4Njk3ZmQ1L3RhYmxlcmFuZ2U6NDQwYWE3MjY0MTI1NDg2NzliNzE4MzU4Zjg2OTdmZDVfNS01LTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpjODcwODA5NzM2NzY0ZGVkYjk3YTk3ZWU3NzYyOWI3Nl80_beec15d8-f081-4040-8a39-775c73c3aa04"
      unitRef="number">0.064</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i87246041109544cf8fb41b557c4513b7_I20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RhYmxlOjQ0MGFhNzI2NDEyNTQ4Njc5YjcxODM1OGY4Njk3ZmQ1L3RhYmxlcmFuZ2U6NDQwYWE3MjY0MTI1NDg2NzliNzE4MzU4Zjg2OTdmZDVfNS01LTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpjODcwODA5NzM2NzY0ZGVkYjk3YTk3ZWU3NzYyOWI3Nl85_52399048-adfc-4a66-8b54-35f04a37bbd6"
      unitRef="number">0.068</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7dd7797604384c719b067b4dc6cf3c42_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMjgwNw_fd057231-014d-4dad-9700-04774ee8b75a"
      unitRef="usd">287000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i41945a367312405a869c8711b228f155_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMTY0OTI2NzQ1MDg4OQ_a974684d-7af2-4073-9543-5c249237bc09"
      unitRef="usd">269000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2479f6ea4f13427d9a5c83ccd6ec9614_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMTY0OTI2NzQ1MTExMQ_e7179251-e30f-4494-83e3-887bbf5c20ce"
      unitRef="usd">1710000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bvs:ContingentConsiderationLiabilityWrittenOffForDeconsolidation
      contextRef="i2479f6ea4f13427d9a5c83ccd6ec9614_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81Mi9mcmFnOjZjMTdlM2IxNDM0OTQyYzA5NjNjMmZiMDYyZTMyMTdkL3RleHRyZWdpb246NmMxN2UzYjE0MzQ5NDJjMDk2M2MyZmIwNjJlMzIxN2RfMTY0OTI2NzQ1MTMxMQ_7cb619dc-7a0c-4bca-a6e3-f6aea6a447e7"
      unitRef="usd">68961000</bvs:ContingentConsiderationLiabilityWrittenOffForDeconsolidation>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0NQ_f7022b3a-61a5-47df-86a6-ded375f6c467">Equity-based compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates an equity-based compensation plan (the &#x201c;2021 Plan&#x201d;), which allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (&#x201c;RSUs&#x201d;), other stock-based awards, and cash awards (collectively, &#x201c;Awards&#x201d;). As of April&#160;1, 2023, 11,278,656 shares of Class A common stock were authorized to be awarded and 2,762,266 shares were available for Awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based compensation expense for Awards granted under the 2021 Plan for the three months ended April&#160;1, 2023 and April&#160;2, 2022, totaled $1,718 and $4,731, respectively. The expense is primarily included in selling, general and administrative expense with a nominal amount in research and development expense on the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were $430 and $1,225 income tax benefit related to this expense for the three months ended April&#160;1, 2023 and April&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended April&#160;1, 2023, the Company granted time-based RSUs which vest at various dates through January&#160;3, 2027. RSU compensation expense is recognized over the vesting period, which is typically between 1 and 4 years. Unamortized compensation expense related to the RSUs totaled $2,265 at April&#160;1, 2023, and is expected to be recognized over a weighted average period of approximately 2.50 years. A summary of the RSU award activity for the three months ended April&#160;1, 2023 is as follows (number of units in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average grant-date fair value per unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended April&#160;1, 2023, the Company granted time-based stock options which vest over 2 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 2 to 4 years, net of actual forfeitures. A summary of the Company&#x2019;s assumptions used in determining the fair value of the stock options granted during the three months ended April&#160;1, 2023 is shown in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of stock options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the three months ended April&#160;1, 2023 was $1.10 per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company&#x2019;s peers&#x2019; common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $9,614 at April&#160;1, 2023, and is expected to be recognized over a weighted average period of approximately 3.78 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity is as follows for the three months ended April&#160;1, 2023 (number of options in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.44 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and vested at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.74 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#x2019;s Class A common stock for options that had exercise prices lower than $1.07 per share, the closing price of the Company&#x2019;s Class A common stock on March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates a non-qualified Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which provides for the issuance of shares of the Company&#x2019;s Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of April&#160;1, 2023, the aggregate number of shares reserved for issuance under the ESPP was 1,181,830. A total of 222,076 shares were issued and $128 of expense was recognized during the three months ended April&#160;1, 2023. A total of 48,993 shares were issued and $158 of expense was recognized during the three months ended April&#160;2, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iaf9b7a1c5154425c8c24265aade7743e_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTE5NQ_c6be1e4b-c1ee-4f16-ae09-6522118b86f0"
      unitRef="shares">11278656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iaf9b7a1c5154425c8c24265aade7743e_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTI2Mw_1923be53-cf3a-4af3-a7db-c07d363b3130"
      unitRef="shares">2762266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id47714ccd1064cd1b7ff9cd499c1fc55_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTQzMg_fc25ed25-7a42-464f-b766-dc156c30153d"
      unitRef="usd">1718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i094ee1c434914509890caa47833deaa5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTQzOQ_77f68325-4d0c-46ba-bcc1-ab47042606d1"
      unitRef="usd">4731000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id47714ccd1064cd1b7ff9cd499c1fc55_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTcxNg_1ef1115c-bded-4002-8e3f-4efe3c41079a"
      unitRef="usd">-430000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i094ee1c434914509890caa47833deaa5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMTY0OTI2NzQ0NzE1MQ_4b25d3fd-04cb-488b-8621-23eb59545e0b"
      unitRef="usd">1225000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i13e007318d4e4feaa4ef8dfd98ef3932_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjA5OA_7945e421-9e6b-4ef6-b057-9135123dba74">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i61c0aac0923c4bc7a1174492aa74af25_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjEwNQ_9c5d2898-fe2a-4dc2-ab93-f66fc725f7b0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="idcb624597b214504b42d1ecb52e98a8c_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjE3MA_f9118b6e-e218-44d3-b3a1-8c407769c180"
      unitRef="usd">2265000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjI2MQ_d5dffc3b-1c14-4e4e-aa75-fdaed9d26773">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0Ng_ba676761-3cb0-400b-9dd5-f7bf89038d75">A summary of the RSU award activity for the three months ended April&#160;1, 2023 is as follows (number of units in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average grant-date fair value per unit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib4fed2036ec84bff9a6d9d643492a512_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMS0xLTEtMS0xOTQ5Mjk_2e7d56e4-e033-4c8b-87d6-c17e6e99c6ac"
      unitRef="shares">1189000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib4fed2036ec84bff9a6d9d643492a512_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMS0zLTEtMS0xOTQ5Mjk_619c1710-6fc1-4f74-b3f1-32736af5a371"
      unitRef="usdPerShare">11.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMi0xLTEtMS0xOTQ5Mjk_c39d88db-af31-4f69-a6ee-58ba736838e0"
      unitRef="shares">39000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMi0zLTEtMS0xOTQ5Mjk_969be3a7-4268-4cac-9b85-ca984428f81e"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMy0xLTEtMS0xOTQ5Mjk_8e8a1c43-8633-4f42-8a62-63824ba54188"
      unitRef="shares">223000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfMy0zLTEtMS0xOTQ5Mjk_ab35691a-e5e9-4f55-bf4a-5bf762d31d27"
      unitRef="usdPerShare">12.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNC0xLTEtMS0xOTQ5Mjk_2f481c96-168f-4407-a2f3-b632ed13ce48"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i31eb5c9cc83744b4b75a799605d651d0_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNC0zLTEtMS0xOTQ5Mjk_a1ab470b-3719-4940-b4cf-0504eddd5fef"
      unitRef="usdPerShare">12.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idcb624597b214504b42d1ecb52e98a8c_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNS0xLTEtMS0xOTQ5Mjk_bc09b8b2-272c-4064-aceb-201546d4a2c4"
      unitRef="shares">905000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idcb624597b214504b42d1ecb52e98a8c_I20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOjU0ZDViODkyNDIwNjRkMzNhOTg4ODE4MGM3NTNhZDg2L3RhYmxlcmFuZ2U6NTRkNWI4OTI0MjA2NGQzM2E5ODg4MTgwYzc1M2FkODZfNS0zLTEtMS0xOTQ5Mjk_6633fdd8-6ce3-42d7-b0e1-10aa1f8f68c4"
      unitRef="usdPerShare">11.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia114f5984aa5487d94a7e5a2f9dd47c1_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjQ2Mg_e36e0955-cb9d-42b4-96a6-3e883aac4db6">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjQ2OA_68e4aaaa-640f-4861-be05-3c7639d151a6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjUxNw_aaad5bd7-dbfd-43ef-9110-c7f1af16a183">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia114f5984aa5487d94a7e5a2f9dd47c1_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjcwMQ_e36e0955-cb9d-42b4-96a6-3e883aac4db6">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjcwNw_68e4aaaa-640f-4861-be05-3c7639d151a6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0Nw_53942260-ab2f-4b96-abfa-bac0c0403789">A summary of the Company&#x2019;s assumptions used in determining the fair value of the stock options granted during the three months ended April&#160;1, 2023 is shown in the following table.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of stock options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMC0xLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjoyOWIwOWEyNGI0MjA0NWFiYmEzZjEwNzdlNzgyMTU5Yl85_e307afe2-9dff-421e-b23c-7dda90eabc64"
      unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMS0xLTEtMS0xOTQ5Mjk_b0cd2cca-06bc-4327-8048-ffdaf9e120fe"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMi0xLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjo4YTJmNmZkMDA2ZTg0MDk4OTgwY2QwZThhZTQ2Y2M0N185_70a1fbef-695f-4b66-8930-414f9efb9b38"
      unitRef="number">0.352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i60e77c9e6b2a43fcb6fa31c38629388a_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmViZDcwNzlmMDUyZjRiNzM5YjExMTdiZjNiZDNjZjE2L3RhYmxlcmFuZ2U6ZWJkNzA3OWYwNTJmNGI3MzliMTExN2JmM2JkM2NmMTZfMy0xLTEtMS0xOTQ5MjkvdGV4dHJlZ2lvbjpmMjkyZDA3OTU3MmI0NmJmOGVjZjQ1ZGM4NmZiMzM2N180_f6798dc5-cd7c-4dd9-8c5a-1c8f71f0a9d6">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMjk3Ng_0dc55b54-facd-4a2a-b235-46b2c7d5dd9d"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMzM5OQ_9db80acc-d7a7-4c64-802e-cb7911dfcc31"
      unitRef="usd">9614000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMzQ5MA_82d22d43-6d76-4a1f-a398-6f2aa729adf9">P3Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDU0OA_c74c32b4-15a2-4b03-a553-b36989a4c026">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity is as follows for the three months ended April&#160;1, 2023 (number of options in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.44 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable and vested at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.74 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMS0xLTEtMS0xOTQ5Mjk_5432f590-18dc-404c-be8f-cad7ed0d6c29"
      unitRef="shares">8910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMS0zLTEtMS0xOTQ5Mjk_6243866d-44fb-4d81-a257-07a74fd8c850"
      unitRef="usdPerShare">11.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMi0xLTEtMS0xOTQ5Mjk_46b6c646-d780-4ddf-bc46-1eea971440bf"
      unitRef="shares">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfMi0zLTEtMS0xOTQ5Mjk_3a0dd0c7-6aef-48f6-9718-f592fc9b468e"
      unitRef="usdPerShare">2.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNC0xLTEtMS0xOTQ5Mjk_f66225eb-4928-4535-880e-98855e504457"
      unitRef="shares">636000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNC0zLTEtMS0xOTQ5Mjk_b6a9d516-33be-404f-ac37-890c588ea145"
      unitRef="usdPerShare">12.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS0xLTEtMS0xOTQ5Mjk_cd57779e-2cad-47eb-b369-cb723286055d"
      unitRef="shares">8296000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS0zLTEtMS0xOTQ5Mjk_fed3a0dc-6adb-4734-bea9-14ac67d17b7e"
      unitRef="usdPerShare">11.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS01LTEtMS0xOTQ5Mjk_d2700611-6fb0-4f92-ab81-ad7f225548c2">P7Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNS03LTEtMS0xOTQ5Mjk_240cf713-2bc1-4a3e-bd25-3730d7d96245"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi0xLTEtMS0xOTQ5Mjk_888115e4-abb7-4bd5-bbcd-5bd2f703480b"
      unitRef="shares">5026000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi0zLTEtMS0xOTQ5Mjk_36e051f6-c7f9-4a45-a754-18f8427e3416"
      unitRef="usdPerShare">10.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi01LTEtMS0xOTQ5Mjk_d027dd3d-f1f3-461a-ab34-8346345ef5e1">P6Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RhYmxlOmFjMmIyMjc3OWQ4NzQzM2M5Mjk0MjgwZWJhNzNmOTFhL3RhYmxlcmFuZ2U6YWMyYjIyNzc5ZDg3NDMzYzkyOTQyODBlYmE3M2Y5MWFfNi03LTEtMS0xOTQ5Mjk_b52f2467-1584-4b45-b09a-2d2d3dbffcd2"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="i7c391ae2f04e49239fb30fb662e626cb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfMzgyMg_b7bf2eb3-56e9-4eae-952a-2f40606bfa42"
      unitRef="usdPerShare">1.07</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i7a367805653149a6bd4c69f62610cedd_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDMzMw_358e53ae-dc73-4b09-8aca-34479a84bfd6"
      unitRef="shares">1181830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i90132788802142b1b654aab8435a8fb6_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDM1NQ_d32f57be-e3b4-4a04-80c7-5f07df73bc8c"
      unitRef="shares">222076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i90132788802142b1b654aab8435a8fb6_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDM4OA_faabf218-3903-4e88-bd1d-8dc098e6f507"
      unitRef="usd">128000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i977440bad8ac48adba402f0ac93702bf_D20220101-20220402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDQ2Nw_fbd81999-75c4-4d45-b62c-6eca315f9e4c"
      unitRef="shares">48993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i977440bad8ac48adba402f0ac93702bf_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81OC9mcmFnOjZjM2JmYTY3ZjUyMTQ5MmRiMmYxN2IwY2M4NWQ4YzU0L3RleHRyZWdpb246NmMzYmZhNjdmNTIxNDkyZGIyZjE3YjBjYzg1ZDhjNTRfNDUwMA_aa27d502-5f27-4564-ad20-9765a75bcb61"
      unitRef="usd">158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzM1MQ_747acf5b-6963-46ea-a5e6-1063838cf575">Stockholders&#x2019; equity&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2021, the Company closed an IPO of 9,200,000 shares of Class A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters' over-allotment option. In connection with the IPO, the Company completed the following transactions (&#x201c;Transactions&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Amended and restated the limited liability company agreement of BV LLC (&#x201c;BV LLC Agreement&#x201d;), to, among other things, (i) provide for a new single class of common membership interests in BV LLC (&#x201c;LLC Interests&#x201d;); (ii) exchange all of the existing membership interests in BV LLC (&#x201c;Original BV LLC Owners&#x201d;) for new LLC Interests; and (iii) appoint Bioventus Inc. as the sole managing member of BV LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Amended and restated the Bioventus Inc. certificate of incorporation to, among other things, (i) provide for an increase in the authorized shares of Class A common stock; (ii) provide for Class B common stock with voting rights but no economic interest, which shares were issued to the Original BV LLC Owners on a one-for-one basis with the number of LLC Interests they owned; and (iii) provide for undesignated preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Acquired, by merger, ten entities that were Original BV LLC Owners (&#x201c;Former LLC Owners&#x201d;), for which the Company issued 31,838,589 shares of Class A common stock as merger consideration (&#x201c;IPO Mergers&#x201d;). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the IPO Mergers, the 31,838,589 shares of Class B common stock were canceled, and the Company recognized the 31,838,589 LLC Interests at carrying value, as the IPO Mergers are considered to be a recapitalization transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment and restatement of certificate of incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2021, the Company amended and restated its certificate of incorporation to, among other things, provide for: (i) the authorization of 250,000,000 shares of Class A common stock with a par value of $0.001 per share; (ii) the authorization of 50,000,000 shares of Class B common stock with a par value of $0.001 per share; (iii) the authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the BOD in one or more series; and (iv) the establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Class A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by the Smith &amp;amp; Nephew, Inc. (the &#x201c;Continuing LLC Owner&#x201d;). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis upon the redemption or exchange of any outstanding LLC Interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must, at all times, maintain a one-to-one ratio between the number of outstanding shares of Class A common stock and the number of LLC Interests owned by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BV LLC recapitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BV LLC Agreement provides that holders of LLC Interests may, from time to time, require the Company to redeem all or a portion of their LLC Interests for newly-issued shares of Class A common stock on a one-for-one basis. The Company may elect to settle any such redemption in shares of Class A common stock or in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendment also requires that the Company, at all times, maintain (i) a one-to-one ratio between the number of outstanding shares of Class A common stock and the number of LLC Interests owned by the Company and (ii) a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with any redemption, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the three months ended April 1, 2023 or during the year ended December&#160;31, 2022. The following table summarizes the ownership interest in BV LLC as of April&#160;1, 2023 and December&#160;31, 2022 (number of units in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;LLC Interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ownership %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;LLC Interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ownership %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of LLC Interests owned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioventus Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing LLC Owner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i455ecc502ecd43c8a0240143ce3f7613_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NzIwMQ_990b29a5-4c03-475a-b28d-0bb7e537a8b8"
      unitRef="shares">9200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ibd867d34482345439425ee5ab5255266_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NzIyMw_753af6c1-f554-460e-85f1-abb34023068a"
      unitRef="usdPerShare">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9b2195c740e24fa3b47460484cabe3cd_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NzIxNA_693e04de-10c1-4476-823e-9385a86220cc"
      unitRef="shares">1200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="i24e141c8e8054b31a54f133d51dc223c_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0Njc4NA_a36d7ccc-54bb-46b6-8832-856edf562c42"
      unitRef="number">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ifa4f6b39d2a74a85bb0d2edd723d8a7b_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0Njc5Mg_7598f89d-1168-45f2-86ab-a56dfc2c9a93"
      unitRef="segment">10</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ifa4f6b39d2a74a85bb0d2edd723d8a7b_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjIwMw_c2e47b77-a55c-47cd-a228-bd3ec63c2499"
      unitRef="shares">31838589</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <bvs:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="i77db743857a644e9a0320ade7e6a5d2a_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjMyOA_f4cbc1fa-b83a-4fa0-a6d8-ece9c051aaa7"
      unitRef="shares">31838589</bvs:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i8504a2e91ba84dfd8a6e426662ca386d_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjQ1MA_e6074dfd-4e48-4970-9c0f-cbf8dbacbd50"
      unitRef="shares">31838589</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <bvs:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="i77db743857a644e9a0320ade7e6a5d2a_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTY0OTI2NzQ0NjUzMQ_f4cbc1fa-b83a-4fa0-a6d8-ece9c051aaa7"
      unitRef="shares">31838589</bvs:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id407ba4965db4b79a8fd6e8dc15e23b0_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjM3_8bba0eae-1d4c-48a8-8872-9d8eb6c4df8c"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id407ba4965db4b79a8fd6e8dc15e23b0_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjkx_13858c42-c27d-4f15-b189-6c9f9b29733a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i24e141c8e8054b31a54f133d51dc223c_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzMx_53a5e4b7-bc91-4e28-a488-7c420bf1a9d5"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i24e141c8e8054b31a54f133d51dc223c_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzg1_87eb60e1-6fb2-49bb-b616-763a6691fdba"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibd867d34482345439425ee5ab5255266_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfNDI2_68e219b6-9bc1-42a4-8eb5-f29c838d8915"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <bvs:BoardOfDirectorLengthOfTerm
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzM1Mg_4a4dda13-be7e-45b1-8257-343d5b2d4c5d">P3Y</bvs:BoardOfDirectorLengthOfTerm>
    <bvs:CommonStockNumberOfVotes
      contextRef="id9ca1d77ddbc4f598510ff5ccb96d1ee_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfNzM3_2e0b85c9-8e09-4b7f-9ea7-6f3e8bf2fc90"
      unitRef="vote">1</bvs:CommonStockNumberOfVotes>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTE3NA_00ebfb48-36e7-4c29-844c-e25957eee3ee"
      unitRef="number">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:CancellationRatioRequiredStockToLLCInterestRatio
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTQ2Mw_cd6fd32e-f938-465c-b7fb-df91c1190574"
      unitRef="number">1</bvs:CancellationRatioRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMTU4OQ_1a59b0dc-81d7-4729-a5c9-1cd5e7201dde"
      unitRef="number">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRedemptionOfLLCInterestRatio
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjMyMg_fbbc0a01-31b9-4468-af9f-ec5e0f85e471"
      unitRef="number">1</bvs:SharesIssuedOrIssuableRedemptionOfLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="ie046b8a033654588aa416481153be819_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjUxMw_6d9b6924-e477-4047-8859-426f92d908f2"
      unitRef="number">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="i1493c3a9bf294032a142cf4e7b1411f1_I20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMjY1OA_1c9eb68d-9c1a-4c75-8d57-cb8d08757140"
      unitRef="number">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RleHRyZWdpb246MTU5MWMyMjUyM2Y4NDQ5Y2EzYWMwZWQwZjZlMTI3M2VfMzM1Mw_9f6340c3-5ae3-41d9-ac76-814afb829de7">The following table summarizes the ownership interest in BV LLC as of April&#160;1, 2023 and December&#160;31, 2022 (number of units in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;LLC Interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ownership %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;LLC Interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ownership %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of LLC Interests owned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioventus Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing LLC Owner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock>
    <us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f28a6c8e2a44fe9b2c8149437d14601_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy0xLTEtMS0xOTQ5Mjk_ec20c26f-8565-472f-af44-b79ef5ad5b29"
      unitRef="usd">62508000</us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i81b082e001c941259cd51349877d6268_D20230101-20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy0zLTEtMS0xOTQ5Mjk_e28945ea-fad7-4c93-be67-83767944e8eb"
      unitRef="number">0.798</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00441e04d2f34f5aa2bc5b4cd5b53c4a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy01LTEtMS0xOTQ5Mjk_d205b40d-9a5e-42c9-83b6-db1e504cf71d"
      unitRef="usd">62063000</us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i3508c22776a24e489023f7a0f04b1e3e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfMy03LTEtMS0xOTQ5Mjk_29cc78a6-1625-41f7-aeae-90ea8eb045ff"
      unitRef="number">0.797</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ad3381ddd884b6e8d796b931cdf5c98_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC0xLTEtMS0xOTQ5Mjk_36f719c8-a97a-4259-b435-e282f6aa573b"
      unitRef="usd">15787000</us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i6f9f122c646249b6ba80f94f1d27ce49_D20230101-20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC0zLTEtMS0xOTQ5Mjk_59b92ae9-99ef-48b1-968b-12487c5b60e4"
      unitRef="number">0.202</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideca15b277be4a5a80bfeb0ef5169075_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC01LTEtMS0xOTQ5Mjk_08c75029-76b4-4ef1-9300-53f21ca70608"
      unitRef="usd">15787000</us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="ibb4089d2b0824f41a82aadcb2951f8f4_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNC03LTEtMS0xOTQ5Mjk_6b4e6bf2-04d3-4263-a413-d7463e95a33f"
      unitRef="number">0.203</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cc806e7a00b4d2aa28a38d41193abfe_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS0xLTEtMS0xOTQ5Mjk_32a54703-8971-4784-b596-b667cff2afd3"
      unitRef="usd">78295000</us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i621e34ed2397424fbf3217653350ee1d_D20230101-20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS0zLTEtMS0xOTQ5Mjk_784facc4-387d-45b1-873f-0a74c4598677"
      unitRef="number">1.000</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bda7af6c3f04de89092466d5c2c03b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS01LTEtMS0xOTQ5Mjk_6bbc67ba-8966-4ea2-904d-c52cd0ba6aaa"
      unitRef="usd">77850000</us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="ifaac88ea486b416ea279e01dd9088634_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82MS9mcmFnOjE1OTFjMjI1MjNmODQ0OWNhM2FjMGVkMGY2ZTEyNzNlL3RhYmxlOjM0MmQxYjdhYWE5YTRlZjZhYWMxZmU0MTA1MTE5MzNkL3RhYmxlcmFuZ2U6MzQyZDFiN2FhYTlhNGVmNmFhYzFmZTQxMDUxMTkzM2RfNS03LTEtMS0xOTQ5Mjk_6e295749-9d92-420c-9682-66aec26a4520"
      unitRef="number">1.000</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RleHRyZWdpb246NGZjY2I0ZDg3NWMzNDg1MDhjZjkwMmIyNmU0YThlZWJfODYx_1e20e611-8fdf-4aa9-a259-6743d78a8b07">Earnings per share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income from continuing operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests &#x2014; continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bioventus Inc. Class A common stockholders &#x2014;&lt;br/&gt;&#160;&#160;&#160;&#160;continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests &#x2014; discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bioventus Inc. Class A common stockholders &#x2014;&lt;br/&gt;&#160;&#160;&#160;&#160;discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of Class A common stock outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,124,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,484,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of Class A common stock from continuing operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of Class A common stock from discontinued operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following number of weighted-average potentially dilutive shares as of April&#160;1, 2023 and April&#160;2, 2022 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LLC Interests held by Continuing LLC Owner&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,786,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,786,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,517,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,757,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,373,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,006,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RleHRyZWdpb246NGZjY2I0ZDg3NWMzNDg1MDhjZjkwMmIyNmU0YThlZWJfODYy_34548fa4-9787-4bf2-b073-c0d4d9feb3dc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income from continuing operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests &#x2014; continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bioventus Inc. Class A common stockholders &#x2014;&lt;br/&gt;&#160;&#160;&#160;&#160;continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests &#x2014; discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bioventus Inc. Class A common stockholders &#x2014;&lt;br/&gt;&#160;&#160;&#160;&#160;discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of Class A common stock outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,124,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,484,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of Class A common stock from continuing operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of Class A common stock from discontinued operations, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNC01LTEtMS0xOTQ5Mjk_5c1f37cb-f2d8-458d-bc80-2336b651e6d7"
      unitRef="usd">-100018000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNC03LTEtMS0xOTQ5Mjk_c93e5039-e1cf-47b4-89b9-4829172570c0"
      unitRef="usd">-14405000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNS01LTEtMS0xOTQ5Mjk_ac405912-24a6-4f49-a9fc-673761973c20"
      unitRef="usd">-20360000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNS03LTEtMS0xOTQ5Mjk_cc4a3a4b-b543-4f42-8e21-4f34ffcdbb2c"
      unitRef="usd">-3529000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNi01LTEtMS0xOTQ5Mjk_4f7265d4-25ae-4ada-8ca7-6509fb706177"
      unitRef="usd">-79658000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNi03LTEtMS0xOTQ5Mjk_94b34fc7-9e1c-4b49-b05f-49e8e426b697"
      unitRef="usd">-10876000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNy01LTEtMS0yMDU4NDc_554d0be0-8a67-4fc9-896c-6f5e5c805329"
      unitRef="usd">-74429000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfNy03LTEtMS0yMDU4NDc_54beabfa-eba6-4151-a112-aab9f696f291"
      unitRef="usd">-401000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOC01LTEtMS0yMDU4NDc_4c652b70-4a68-44d5-9aac-434b7c77c8dc"
      unitRef="usd">-14937000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOC03LTEtMS0yMDU4NDc_d00a63f4-4b50-4a41-a8a2-5fd384ee6f16"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTAtNS0xLTEtMjA4Mzk3_8d53dbda-daa2-4e04-85ec-bd6c84f66bbb"
      unitRef="usd">-59492000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTAtNy0xLTEtMjA4NDE3_16f144cc-4167-404f-bffd-220c70fe6da1"
      unitRef="usd">-401000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS01LTEtMS0xOTQ5Mjk_71e12476-c79d-4087-8d6d-7dcbc00b0dc5"
      unitRef="shares">62124752</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS01LTEtMS0xOTQ5Mjk_adc8dc81-f911-47e1-94c3-c10c1d23b0b5"
      unitRef="shares">62124752</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS03LTEtMS0xOTQ5Mjk_77fdd71a-f32d-41af-a36b-e1ad0bcb5600"
      unitRef="shares">60484969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfOS03LTEtMS0xOTQ5Mjk_f88a63c9-ebe5-4a31-828c-ca66a9afeb58"
      unitRef="shares">60484969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNS0xLTEtMTk0OTI5_1050414d-088e-4810-ae5b-0786d6a86618"
      unitRef="usdPerShare">-1.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNS0xLTEtMTk0OTI5_56b5a6a4-6f97-460d-b068-df762fed5273"
      unitRef="usdPerShare">-1.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNy0xLTEtMTk0OTI5_16fbcf89-4770-4690-8b57-ed30c7a16a3b"
      unitRef="usdPerShare">-0.18</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTEtNy0xLTEtMTk0OTI5_ac927454-802c-4344-83b1-f3f378c609a0"
      unitRef="usdPerShare">-0.18</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNS0xLTEtMjA1OTEx_12371584-2406-4711-a734-ec6de401e62b"
      unitRef="usdPerShare">-0.96</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNS0xLTEtMjA1OTEx_e77a9596-c911-4efc-a22c-6b12c60843b5"
      unitRef="usdPerShare">-0.96</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNy0xLTEtMjA1OTEx_39be4774-2959-4be1-a3e6-eab27b9c071e"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTUtNy0xLTEtMjA1OTEx_76b3e5a2-6781-482a-882e-6daea7649b26"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNS0xLTEtMjA4NDE5_8859b6f7-5e9d-4c46-99a7-30f8f87d5725"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNS0xLTEtMjA4NDE5_d26df951-4a80-4872-be61-2fbe520f63ba"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNy0xLTEtMjA4NDI0_3a34c45a-3a12-4601-b7e8-4ba42a0f94f6"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjg5YWYxMTczYWRjNTRkM2Q4MjViNmQ0NTFmMjJhODAzL3RhYmxlcmFuZ2U6ODlhZjExNzNhZGM1NGQzZDgyNWI2ZDQ1MWYyMmE4MDNfMTctNy0xLTEtMjA4NDI0_3f2591c7-30a1-4599-b661-b2e4d44b27e0"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RleHRyZWdpb246NGZjY2I0ZDg3NWMzNDg1MDhjZjkwMmIyNmU0YThlZWJfODYw_b6c9088b-141a-4bb6-accc-9a8627622336">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following number of weighted-average potentially dilutive shares as of April&#160;1, 2023 and April&#160;2, 2022 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LLC Interests held by Continuing LLC Owner&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,786,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,786,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,517,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,757,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,373,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,006,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ab3e51b5150437a9922627be2e141bb_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMi01LTEtMS0xOTQ5Mjk_e6e54bba-26af-4e0e-b7a7-5ffe2c80e71a"
      unitRef="shares">15786737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9bd02248ff5a4c349ca283983f6fb643_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMi03LTEtMS0xOTQ5Mjk_14302b47-65a7-42dd-a121-7b92da884ac9"
      unitRef="shares">15786737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i826a2b73e7024f2bbb971c7170189c53_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMy01LTEtMS0xOTQ5Mjk_4984d1b6-7250-4927-b4b0-0b29c10bea87"
      unitRef="shares">8517045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11cb3b3b1ef8485b8260800eb571e90a_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfMy03LTEtMS0xOTQ5Mjk_087fc10b-ba5f-4ec4-b7eb-9fac7f10e2ad"
      unitRef="shares">8757706</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ec54bc3bcce4e0cba062fc969afa5c3_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNC01LTEtMS0xOTQ5Mjk_7bcc7d16-b10d-4408-8984-f46f8b1d97f0"
      unitRef="shares">1070105</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e76064517ae4b5e9d9e3a322bd12ee1_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNC03LTEtMS0xOTQ5Mjk_0fe54166-33ce-41f5-bb6a-a2558565184b"
      unitRef="shares">462404</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNi01LTEtMS0xOTQ5Mjk_979d25f2-437c-4dbd-bcf0-54aa9c9de903"
      unitRef="shares">25373887</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82NC9mcmFnOjRmY2NiNGQ4NzVjMzQ4NTA4Y2Y5MDJiMjZlNGE4ZWViL3RhYmxlOjhhZTIxNjM1YzE0NzQ3MDM5MTdlZTYyNDhlNTUxOTFkL3RhYmxlcmFuZ2U6OGFlMjE2MzVjMTQ3NDcwMzkxN2VlNjI0OGU1NTE5MWRfNi03LTEtMS0xOTQ5Mjk_6470052f-4d20-45c7-8a01-1e3cf508060e"
      unitRef="shares">25006847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTAzNw_836ac42a-66a0-4522-bead-953c858c80e7">Restructuring costs&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs are not allocated to the Company&#x2019;s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company announced a restructuring plan in December 2022 (the &#x201c;2022 Restructuring Plan&#x201d;) that is intended to align the Company&#x2019;s organizational and management cost structure to improve profitability and cash flow. The Company expects to incur $4,000 to $5,000 of pre-tax costs under the 2022 Restructuring Plan primarily consisting of employee severance and additional expenses for third-party and other related costs. Pre-tax charges recognized during the three months ended April&#160;1, 2023 and the year ended December&#160;31, 2022 totaled $262 and $4,581, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted restructuring plans for businesses acquired to reduce headcount, reorganize management structure and consolidate certain facilities during the second half of 2021 (the &#x201c;2021 Acquisition Restructuring Plan&#x201d;) and during the first quarter of 2022 (the &#x201c;2022 Acquisition Restructuring Plan&#x201d;). The Company planned total pre-tax charges for the 2021 Acquisition Restructuring Plan and 2022 Acquisition Restructuring Plan are $3,500 and $2,300, respectively. There was nominal activity related to the 2021 Acquisition Restructuring Plan during the three months ended April&#160;1, 2023 and $377, $719 and $2,487 recognized during the three months ended April&#160;2, 2022, and the years ended December 31, 2022 and 2021, respectively. The 2021 Acquisition Restructuring Plan is essentially completed. Costs incurred attributable to the 2022 Acquisition Restructuring Plan totaled $84, $200 and $1,479 during the three months ended April&#160;1, 2023 and April&#160;2, 2022, and the year ended December 31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s restructuring charges and payments for plans related to businesses recently acquired comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;severance and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;temporary&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;labor costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;charges &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="iab463c35574b4f8ca9e4c2daa0b62cf5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDMzOA_319bbef8-ef62-4697-b7c3-358969cfc1ea"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ie37855daa1184dc78d7515b03e113ea3_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDM0Nw_67ad2bc3-f1f8-4d42-a49b-bdc1b513a3b9"
      unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges
      contextRef="i7889eb67185b4a7fb1f2a59966756eb0_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDUxMg_3b780c82-6a89-4f3b-b1e6-9d40e39e3c1f"
      unitRef="usd">262000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie6c1ba06aa134309858a469840e28937_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDUyMA_a7f7c3fd-568e-4de8-a459-3f7d22176924"
      unitRef="usd">4581000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i544e8c2721cb486fa712dc07d475a475_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDg2OA_63519f08-858e-4e32-a406-0617f6202050"
      unitRef="usd">3500000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i6cafecddd27a4b469315f336ef3ed50d_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0Njc2Mg_133f1b60-8590-4ebf-bbd3-fd31420df198"
      unitRef="usd">2300000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges
      contextRef="if5b22816b48c442798421ebd10c98786_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzU3Mg_9c5dc467-4269-4e7d-af3c-410cd88bb781"
      unitRef="usd">377000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i8eab176afd194ef687ade1014da11d08_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzIwMg_eaa3f6f9-0782-4127-a01a-4bdefe4e4b28"
      unitRef="usd">719000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1bd943395fc7408b9c20e3013b149ed9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzIxMA_988d386d-c62f-4f8c-826d-8dbfa0fa8446"
      unitRef="usd">2487000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ief777ae06245484290df025fea9e0d3d_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NDk1NQ_291abcef-3b5a-4d57-bbe8-4da5fe503933"
      unitRef="usd">84000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i96d6024603534c5ea5af4d437fd6040e_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzYwOQ_5e3222ff-e74b-4376-aa60-716bf7298dd8"
      unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2c209e0543284533a6ae897763a26743_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTY0OTI2NzQ0NzQ0OA_44a5065b-f450-47c7-8ba5-fc99d7ac7020"
      unitRef="usd">1479000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RleHRyZWdpb246MzY5MmMyY2RjMDdhNGYxOTgxNGI2MDVlOTM2NTE2YTdfMTAzOA_4e021099-14d3-4df7-9fa3-e5084af105af">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s restructuring charges and payments for plans related to businesses recently acquired comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;severance and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;temporary&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;labor costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;charges &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i471155b226eb40c690334fd2874e4f56_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMS0xLTEtMS0xOTQ5Mjk_a386d694-2def-473a-ac79-b8fb76c90818"
      unitRef="usd">3760000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iad9c750d3df948a0bfe95f8639979859_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMS0zLTEtMS0xOTQ5Mjk_2f359a54-09c7-43f4-ae31-59aa3c74af82"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMS01LTEtMS0xOTQ5Mjk_11ad120c-ac91-45b0-979f-d36350ffd0a6"
      unitRef="usd">3760000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i73d4aa340243422abe25f197db4c3b59_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMi0xLTEtMS0xOTQ5Mjk_71460a50-8c03-4c43-b702-0f86500cf304"
      unitRef="usd">125000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="idc2830275f954d0484c2c3f9c65710b4_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMi0zLTEtMS0xOTQ5Mjk_22022868-b176-4cbc-9be4-7768da7ca7d2"
      unitRef="usd">192000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMi01LTEtMS0xOTQ5Mjk_b25dc8d9-48ee-4510-af8e-ef4f38f46767"
      unitRef="usd">317000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i73d4aa340243422abe25f197db4c3b59_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMy0xLTEtMS0xOTQ5Mjk_17fb1742-42db-4ab0-8f2a-78edb5ad1765"
      unitRef="usd">1653000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="idc2830275f954d0484c2c3f9c65710b4_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMy0zLTEtMS0xOTQ5Mjk_39987a64-6cb3-48f6-b8d6-b42bb930ddbc"
      unitRef="usd">192000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfMy01LTEtMS0xOTQ5Mjk_82119ea3-4edd-4d66-87cf-bd861eb5d0cb"
      unitRef="usd">1845000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="iaa741b924a3549099b1b5111321fbba2_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfNC0xLTEtMS0xOTQ5Mjk_d7b3b0ac-84a4-46a2-9cad-0f0f7df941ac"
      unitRef="usd">2232000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iac4cade8aa8d459cab8ee8fe3bbf1bdd_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfNC0zLTEtMS0xOTQ5Mjk_e60f5fa7-9d8f-4ce0-985e-feb0c150fc83"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV82Ny9mcmFnOjM2OTJjMmNkYzA3YTRmMTk4MTRiNjA1ZTkzNjUxNmE3L3RhYmxlOjA2OGE3ZjUzYjZkNTQ2NGI5OWFmNmNkYWUwODQ2YTJhL3RhYmxlcmFuZ2U6MDY4YTdmNTNiNmQ1NDY0Yjk5YWY2Y2RhZTA4NDZhMmFfNC01LTEtMS0xOTQ5Mjk_a82422e5-812d-4d5b-a9bb-c026f32298c8"
      unitRef="usd">2232000</us-gaap:RestructuringReserve>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMzQzMQ_96078492-21f0-41dc-aba8-611dadb5a49f">Income taxes&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company's annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended April&#160;1, 2023 and April&#160;2, 2022, the Company's effective tax rate was 0.1% and 26.3%, respectively. The decrease for the three months ended April&#160;1, 2023 was primarily due to changes in our forecasted effective rate and a net increase in reserve for uncertain tax positions. The change in the forecasted effective rate for the three months ended April&#160;1, 2023 compared to three months ended April 2, 2022 was primarily due to an increase in the valuation allowance applied to our net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2021, the Company entered into a tax receivable agreement (&#x201c;TRA&#x201d;) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. As of April&#160;1, 2023, the Continuing LLC Owner had not exchanged LLC Interests for shares of Class A common stock and therefore the Company had not recorded any liabilities under the TRA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMTU0NQ_1faee7d2-f5ea-4be5-947e-fb3d7e061e75"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMTU0OQ_b693afe4-b7bf-49e4-80ee-c60943c6919c"
      unitRef="number">0.263</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <bvs:TaxReceivableAgreementPercent
      contextRef="ibd867d34482345439425ee5ab5255266_I20210216"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83MC9mcmFnOjE1Y2M4YjZhNGIyNjRlNzI4ZWJiMTc3MjFiODE4YTM3L3RleHRyZWdpb246MTVjYzhiNmE0YjI2NGU3MjhlYmIxNzcyMWI4MThhMzdfMjY1Mg_3e35dcdc-aa23-4bb1-9494-a61e3eb9ce1a"
      unitRef="number">0.85</bvs:TaxReceivableAgreementPercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ2MTQ_0b86d73a-e52b-482c-aeb8-7e9bde10ef04">Commitments and contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Includes variable lease cost and sublease income, which are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from financing leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet and other information related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities- current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities- noncurrent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,455&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,355&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,309&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,907&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524"&gt;Property, plant and equipment - net (finance leases)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities - noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years) for leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate for leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Operating lease assets totaling $618 attributable to CartiHeal was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Operating lease liabilities-current totaling $176 and operating lease liabilities-noncurrent of $442 were reclassified into current liabilities attributable to discontinued operations and long-term liabilities attributable to discontinued operations, respectively, within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Governmental and legal contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#x2019;s standard practice is to cooperate with regulators and investigators in responding to inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Company&#x2019;s complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bioventus shareholder litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina, Ciarciello v. Bioventus, Inc., No. 1:23&#x2013; CV &#x2013; 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserts violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees&#x2019; Retirement System as lead plaintiff. The lead plaintiff&#x2019;s amended consolidated complaint is due to be filed with the Court on June 12, 2023. Defendants&#x2019; motion to dismiss the amended consolidated complaint is due on July 17, 2023. The Company believes the claims alleged lack merit and intends to defend itself vigorously. The outcome of the litigation is not presently determinable, and any loss is neither probable nor reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bioness patent litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2022, the Company, through its subsidiary Bioness, filed a lawsuit in the United States District Court for the Eastern District of Virginia against Aretech, LLC (&#x201c;Aretech&#x201d;) alleging infringement by Aretech of various patents related the Bioness&#x2019; Vector Gait and Safety Support System&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On August 8, 2022, Aretech filed an answer to the lawsuit denying infringement and asserting various affirmative defenses and counterclaims to the Bioness complaint. Bioness filed a motion to dismiss the defendant&#x2019;s counterclaims on September 28, 2022. In response to Bioness&#x2019; motion to dismiss the counterclaims, on October 19, 2022, Aretech filed an amended answer and counterclaims. On November 16, 2022, Bioness filed a partial motion to dismiss certain of the amended counterclaims. On January 23, 2023, the court granted-in-part Bioness&#x2019; motion dismissing Aretech&#x2019;s antitrust and inventorship-related counterclaims, but allowed certain of Aretech&#x2019;s counterclaims to proceed. On March 23, 2023, the parties entered into a settlement and license agreement that resolved all claims in the litigation. The agreement also provides cross licenses to the parties for certain of their respective patents relevant to the claims asserted in the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Misonix stockholder&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Stein v. Misonix, Inc., et al., Case No. 2:21-cv-05127 (E.D.N.Y.) (the &#x201c;Stein Complaint&#x201d;). The Stein Complaint named Misonix and members of its board of directors as defendants. The Stein Complaint was dismissed on April 6, 2022. On September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.) (the &#x201c;Ciccotelli Complaint&#x201d;) against Misonix, members of its board of directors, the Company, and its subsidiaries, Merger Sub I and Merger Sub II, as defendants. Plaintiff voluntarily dismissed the Ciccotelli Complaint on November 10, 2021. On October 12, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Eastern District of New York, captioned Rubin v. Misonix, Inc. et al., Case No. 1:21-cv-05672 (S.D.N.Y.) (the &#x201c;Rubin Complaint&#x201d;) and on October 15, 2021, another purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Taylor v. Misonix, Inc. et al., Case No. 1:21-cv-08513 (S.D.N.Y.) (the &#x201c;Taylor Complaint&#x201d;). The Rubin Complaint and the Taylor Complaint name Misonix and members of its board of directors as defendants. Plaintiffs voluntarily dismissed the Rubin and Taylor Complaints on January 21, 2022 and February 18, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The complaints asserted claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021 or the Definitive Proxy Statement filed with the SEC on September 24, 2021, regarding Misonix and/or Bioventus&#x2019; projections and J.P. Morgan&#x2019;s financial analysis. The complaints had sought, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger; (ii) rescission in the event that the merger is consummated; and (iii) an award of costs, including attorneys&#x2019; and experts&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Misonix former distributor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2017, Misonix&#x2019;s former distributor in China, Cicel (Beijing) Science &amp;amp; Technology Co., Ltd., filed a lawsuit against Misonix and certain of its officers and directors in the United States District Court for the Eastern District of New York. The complaint alleged that Misonix improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted Misonix&#x2019;s motion to dismiss each of the tort claims asserted against Misonix, and also granted the individual defendants&#x2019; motion to dismiss all claims asserted against them. On January 23, 2020, the court granted Cicel&#x2019;s motion to amend its complaint, to include claims for alleged defamation and theft of trade secrets in addition to the breach of contract claim. Discovery in the matter ended on August 5, 2021. On January 20, 2022, the court granted Misonix&#x2019;s summary judgment motion on Cicel&#x2019;s breach of contract and defamation claims. Cicel&#x2019;s motion for reconsideration of the court&#x2019;s summary judgment ruling in Misonix&#x2019;s favor was dismissed by the Court on April 29, 2022. On July 18, 2022, Cicel voluntarily dismissed the remaining claim for trade secret theft and later filed an appeal to the United States Court of Appeals for the Second Circuit. The Company believes that it has various legal and factual defenses to these claims and intends to vigorously defend the appeal of the lower court&#x2019;s summary judgment rulings in its favor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Bioness shareholder&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to closing the Bioness Acquisition, Bioness had been named as a defendant in a lawsuit, for which the Company is indemnified under the indemnification provisions contained in the Bioness Merger Agreement. The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting the acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover attorney fees and other expenses totaling approximately $3,000 incurred by the director and shareholder in connection with the matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2021, the court issued a ruling granting, in part, plaintiff&#x2019;s motion for summary judgment, awarding plaintiff attorney&#x2019;s fees and related expenses incurred in connection with performance of the plaintiff&#x2019;s directorial duties, and denying fees and expenses incurred in a non-director capacity. In its ruling, the court&#x2019;s order also directed the parties to agree upon a process that will govern the payment of and challenges to plaintiff&#x2019;s payment requests and required Bioness to pay 50% of the demanded amount into escrow if more than 50% of the total invoiced amount was in dispute. Pursuant to the court&#x2019;s order, Bioness paid approximately $1,300 into escrow. On November 1, 2022, at a hearing before Delaware State Court of Chancery, the court ruled in favor of the former Bioness director awarding attorney&#x2019;s fees in connection with the underlying pre-merger litigation and the advancement action in the amounts claimed, less approximately $50. On December 23, 2022, Bioness and the plaintiff entered into a settlement agreement resolving the matter for the aggregate sum of $2,500 payable to the plaintiff. The settlement was satisfied by releasing the $1,300 previously paid by Bioness and held in escrow and by an additional payment of $1,200. Pursuant to the indemnification obligations under the Bioness Merger Agreement, this subsequent payment was made on behalf of Bioness on December 28. 2022, by the selling majority shareholder under that agreement. The Company subsequently recovered the $1,300 paid into escrow from the selling Bioness shareholders pursuant an indemnification request under the Bioness Merger Agreement. An order dismissing the case was entered by the court on January 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2022, the above referenced minority shareholder of Bioness filed another action in the Delaware State Court of Chancery in connection with the Company&#x2019;s acquisition of Bioness. This action names the former Bioness directors, the Alfred E. Mann Trust (Trust), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Company&#x2019;s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bioness&#x2019; and other the defendant&#x2019;s motions was held before the Court of Chancery on January 19, 2023. The Company believes that there are various legal and factual defenses to the claims plaintiff made against us and intend to defend ourselves vigorously. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $853. An additional payment of $853 was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $1,707 will be paid to the seller within five days. The Company is required to pay royalties through 2026 of 5.0% on the first $569 in sales and 2.5% thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed, but during the second quarter of 2022, the Company elected to discontinue the development of MOTYS, the initial product candidate under development. On October 21, 2022, the Company provided notice to MTF of termination of the Development Agreement and the related cGTP Commercial Supply Agreement with MTF for MOTYS, effective December 20, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#x2019;s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended April&#160;1, 2023 and April&#160;2, 2022 totaled $2,321 and $3,332, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a supply agreement entered on February 9, 2016 for the Company&#x2019;s three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a supply agreement for the Company&#x2019;s five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated condensed statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company causes letters of credit (&#x201c;LOCs&#x201d;) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of April&#160;1, 2023 and December&#160;31, 2022, the Company had one LOC outstanding for a nominal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#x201c;claims made&#x201d; basis for expenses in excess of $200 per member per year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i7304128a25744503b8891660f963b710_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMjc3_b66bfb0d-16c4-4634-8cd6-1e49a203849f">P1M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ieb6cde82adad47b0938be5a986d174e9_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMjgz_560d2b06-0ad8-4fa8-a3e9-790381f544b8">P10Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ2MTU_0e9aef88-77aa-4ac0-b11b-34b928f416c6">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Includes variable lease cost and sublease income, which are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from financing leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMi01LTEtMS0xOTQ5Mjk_c0d096a7-877c-4b3d-b602-21aae44a2b71"
      unitRef="usd">1069000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMi03LTEtMS0xOTQ5Mjk_01a3dbff-2f5a-419e-b73f-ed012051603a"
      unitRef="usd">1126000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMy01LTEtMS0xOTQ5Mjk_3d450174-a0ee-4c6d-a6ec-40f04d48b6ba"
      unitRef="usd">206000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfMy03LTEtMS0xOTQ5Mjk_c1932e72-f667-4177-9844-be2e3553fa76"
      unitRef="usd">183000</us-gaap:ShortTermLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNS01LTEtMS0xOTQ5Mjk_f773334e-33b4-4956-949c-e32ffb288af2"
      unitRef="usd">235000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNS03LTEtMS0xOTQ5Mjk_2cba2b46-2094-4047-868e-12c238187a06"
      unitRef="usd">9000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNi01LTEtMS0xOTQ5Mjk_c7327dd1-7150-4b8e-b663-f1a966e5952e"
      unitRef="usd">137000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNi03LTEtMS0xOTQ5Mjk_7f56f196-180b-40a5-b461-2e05fd85609a"
      unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNy01LTEtMS0xOTQ5Mjk_c2ab5fb5-4ee9-470e-8df6-2a8e0896ab57"
      unitRef="usd">1647000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjdiOWYzODEyOTNjZTRlNTZiYjcwMTczYmFmNjViZTQ0L3RhYmxlcmFuZ2U6N2I5ZjM4MTI5M2NlNGU1NmJiNzAxNzNiYWY2NWJlNDRfNy03LTEtMS0xOTQ5Mjk_557964d1-fbd7-499f-82e0-adb879473ca8"
      unitRef="usd">1319000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMi0xLTEtMS0xOTQ5Mjk_0655c80d-6f27-4ae1-bac1-2deb7b581c88"
      unitRef="usd">1100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMi0zLTEtMS0xOTQ5Mjk_30cc6fe2-2ef6-4d42-8053-ba6c6dc32371"
      unitRef="usd">1254000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMy0xLTEtMS0xOTQ5Mjk_abb2d710-c8b4-4964-9cec-f3c73938c0e2"
      unitRef="usd">90000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfMy0zLTEtMS0xOTQ5Mjk_9e3b0b0c-aa46-4b37-acf1-38f31e0618cf"
      unitRef="usd">1000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNC0xLTEtMS0xOTQ5Mjk_a6908e4f-a29e-45fa-b18f-6408ccb71326"
      unitRef="usd">37000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNC0zLTEtMS0xOTQ5Mjk_52d6203e-950f-4268-8dfd-4e0679284f7e"
      unitRef="usd">13000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNy0xLTEtMS0xOTQ5Mjk_5b962972-080f-4aa2-a610-37655d88b3c4"
      unitRef="usd">225000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfNy0zLTEtMS0xOTQ5Mjk_d4abccae-5d96-4c98-98ef-ef35bd640d58"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfOC0xLTEtMS0xOTQ5Mjk_7ff4ab7b-252a-4691-befa-2e72d835c821"
      unitRef="usd">9141000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjhmMWVmZTE5ZTNjNDQyMjNhOTE4OWY1Y2M2ZmQ5ODY5L3RhYmxlcmFuZ2U6OGYxZWZlMTllM2M0NDIyM2E5MTg5ZjVjYzZmZDk4NjlfOC0zLTEtMS0xOTQ5Mjk_bd28ca92-c4da-411f-b64f-4a9554711536"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <bvs:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ2MTM_5fb05a03-1d55-4f18-ace5-8b2f68c73390">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet and other information related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities- current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities- noncurrent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,455&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,355&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,309&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,907&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_51b6acfa-c87a-4fb7-b53a-a8714b9ae387"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0wLTEtMS0xOTQ5Mjk_b60a87e4-ce15-4577-863f-a8d1a7abd524"&gt;Property, plant and equipment - net (finance leases)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities - noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years) for leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate for leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Operating lease assets totaling $618 attributable to CartiHeal was reclassified to long-term assets attributable to discontinued operations within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Operating lease liabilities-current totaling $176 and operating lease liabilities-noncurrent of $442 were reclassified into current liabilities attributable to discontinued operations and long-term liabilities attributable to discontinued operations, respectively, within the December 31, 2022 consolidated balance sheets. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14. Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details regarding the deconsolidation of CartiHeal.&lt;/span&gt;</bvs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMS0xLTEtMS0xOTQ5Mjk_931502d0-74c1-4322-8b22-970c872b689a"
      unitRef="usd">16063000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMS0zLTEtMS0xOTQ5Mjk_22a5d79e-4bd7-421f-b1df-52e95e986ce3"
      unitRef="usd">16690000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMy0xLTEtMS0xOTQ5Mjk_db7b10a4-6c8c-43fe-a8b5-54c8b88789c8"
      unitRef="usd">3854000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMy0zLTEtMS0xOTQ5Mjk_ea045424-2453-4e2d-b59b-747a2404c43d"
      unitRef="usd">3552000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNC0xLTEtMS0xOTQ5Mjk_4a3fca90-5b63-4994-8bf2-51d563254ad4"
      unitRef="usd">13455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNC0zLTEtMS0xOTQ5Mjk_6041d043-dd41-4768-863d-cf4abb2db739"
      unitRef="usd">14355000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNS0xLTEtMS0xOTQ5Mjk_0779a34f-76bf-4841-84dc-0eeff5b4cf14"
      unitRef="usd">17309000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfNS0zLTEtMS0xOTQ5Mjk_92e33127-a367-4c73-b6b8-62962807cf5d"
      unitRef="usd">17907000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0xLTEtMS0xOTQ5Mjk_699c3417-58f6-40d8-804b-06d03a63e380"
      unitRef="usd">9034000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfOC0zLTEtMS0xOTQ5Mjk_3bc39c0d-26e2-45b8-8b0a-ced5498dafe3"
      unitRef="usd">128000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTAtMS0xLTEtMTk0OTI5_f51d8707-74aa-49d4-99b3-275fd2ce8db1"
      unitRef="usd">419000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTAtMy0xLTEtMTk0OTI5_f52803e0-702f-454f-8455-ee575113138b"
      unitRef="usd">55000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTEtMS0xLTEtMTk0OTI5_9a10eb5a-086e-47f4-9bb7-87ee284c7e86"
      unitRef="usd">6602000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTEtMy0xLTEtMTk0OTI5_b7c4912c-2635-4726-989e-cf7846add64f"
      unitRef="usd">76000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTItMS0xLTEtMTk0OTI5_bb173895-20da-4cb1-9852-2b8c193477f1"
      unitRef="usd">7021000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTItMy0xLTEtMTk0OTI5_a1890181-895d-4ae6-b799-3db2f31d2a43"
      unitRef="usd">131000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTUtMS0xLTEtMTk0OTI5_98db71bb-aca9-4f51-bd4d-5fc0e76523a2">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTUtMy0xLTEtMTk0OTI5_5e498186-c6bb-4d31-861b-469066a5a35f">P4Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTYtMS0xLTEtMTk0OTI5_59fb114d-fa1c-4a3e-93ad-37e0c1aa945d">P10Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTYtMy0xLTEtMTk0OTI5_4883e639-c92f-4c34-a2fb-4d989b87b4ae">P2Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTgtMS0xLTEtMTk0OTI5_6c8eacff-41a4-4ee9-9942-5614fd6f1e8e"
      unitRef="number">0.046</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTgtMy0xLTEtMTk0OTI5_4589d190-4fde-4fea-934d-8694cae6fdde"
      unitRef="number">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="if08a873c6cd84f99985971869a2e69d5_I20230401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTktMS0xLTEtMTk0OTI5_a6c718aa-f6f3-4d2f-ab3e-39f0882b2eea"
      unitRef="number">0.080</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i98f850194f2743b69d130043cb5b83f5_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RhYmxlOjFjY2FiMDFiMTkwMzQxMThiNTZiNmVkNmZjMmU1Mjg4L3RhYmxlcmFuZ2U6MWNjYWIwMWIxOTAzNDExOGI1NmI2ZWQ2ZmMyZTUyODhfMTktMy0xLTEtMTk0OTI5_c247e01c-47d6-4ee3-a7c0-c5b068fbddb4"
      unitRef="number">0.033</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i688306a9d855467ca189676c7d19b6cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1ODY2OA_e3721815-da24-43ab-93ea-2b5c1992d624"
      unitRef="usd">618000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i75a9b09aeea047d997e35f25ccf68400_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1OTE2NA_9533f58c-f1d7-4da7-844d-2858f4ef866e"
      unitRef="usd">176000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i75a9b09aeea047d997e35f25ccf68400_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1OTQzNQ_83e42eed-0b40-4495-9611-2a18268fded7"
      unitRef="usd">442000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i0195281e11e649b9b130d85d5763b801_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU1NTA3MA_8172215a-c91c-4e08-bf90-09a229e1248c"
      unitRef="usd">3000000</us-gaap:LossContingencyDamagesSoughtValue>
    <bvs:LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid
      contextRef="i269ccd94849d4d2ba444fb9e4e51782b_I20210819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDEyMg_89782c57-a78c-48c4-bd75-f4ba90e91405"
      unitRef="number">0.50</bvs:LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid>
    <bvs:LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold
      contextRef="i269ccd94849d4d2ba444fb9e4e51782b_I20210819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDEyOA_fa47342f-5865-43e1-93ae-f582c79adbdd"
      unitRef="number">0.50</bvs:LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i2e70fc04918244f2994b165f1a124430_D20210819-20210819"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDEzOA_69b4745f-cc91-4153-898e-6219799b68fc"
      unitRef="usd">1300000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bvs:LitigationSettlementExpenseOfClaimant
      contextRef="id46b7f3929c94e30aa38e125d5c1fb3a_D20221101-20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE0NA_7d8fadac-41a3-4c89-a138-c0b66600d61d"
      unitRef="usd">50000</bvs:LitigationSettlementExpenseOfClaimant>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i270d95a5216e45eca0d7972f80ac3edb_D20221223-20221223"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE2Mg_e102b6ff-4c58-452b-8b81-6a11e6b2f041"
      unitRef="usd">2500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i270d95a5216e45eca0d7972f80ac3edb_D20221223-20221223"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE3MQ_d9bef4e2-d842-4efe-a166-076258879d5d"
      unitRef="usd">1300000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i095df0e9d3b640bdad1576e09c931392_D20221228-20221228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE1Mw_9b322c0f-bf1a-4d6f-9f9b-8508aeca821d"
      unitRef="usd">1200000</us-gaap:LossContingencyAccrualPayments>
    <bvs:LitigationSettlementAmountRecoveredFromEscrow
      contextRef="if8a13de58ac44d4ca44be08ddc84b03b_D20221228-20221228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTY0OTI2NzU0NDE4MA_79ba340d-94a5-4334-aa41-e2823557d571"
      unitRef="usd">1300000</bvs:LitigationSettlementAmountRecoveredFromEscrow>
    <bvs:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTA3MzY_48d41a82-1380-4c3b-81a7-9b2be052632c"
      unitRef="usd">853000</bvs:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <bvs:CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData
      contextRef="i76920cf66e21420bb4f0e4336311f5de_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTA3NjU_81aea977-6739-4358-a19a-be0a445d1b0d"
      unitRef="usd">853000</bvs:CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData>
    <bvs:CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification
      contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTA5Mjg_f6f8246c-6622-4289-861c-8fac18619cf5"
      unitRef="usd">1707000</bvs:CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification>
    <bvs:CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne
      contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEwMzM_e424bfa3-901d-40b8-9b50-1790691985a7"
      unitRef="number">0.050</bvs:CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne>
    <bvs:CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold
      contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEwNDk_e122375a-7248-45a3-b724-cf5a98a53b81"
      unitRef="usd">569000</bvs:CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold>
    <bvs:CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo
      contextRef="i60fb58e6fde74b6fbaa868cd895760dc_D20211110-20211110"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEwNjU_5f61d367-aa2c-4607-967d-ed5b2328a9c8"
      unitRef="number">0.025</bvs:CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo>
    <bvs:CollaborativeArrangementRoyaltyPercentage
      contextRef="if6c32e79d61845d9a2b670c38ccad90a_D20190823-20190823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTEyMTc_2749f3fe-cd79-4c12-b9e0-0a6159f02b05"
      unitRef="number">0.03</bvs:CollaborativeArrangementRoyaltyPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="ia7b5a733f4024b57989f06cbdb94c545_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI1MDM_d5b72a07-1818-45ee-9941-f34a42109100"
      unitRef="usd">2321000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i3cc6602c201f442ea229c5c1441c0506_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI1MTA_f3277917-8c8d-462f-b0a2-aee437997aae"
      unitRef="usd">3332000</us-gaap:RoyaltyExpense>
    <bvs:SupplyCommitmentTerm
      contextRef="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI4MTI_e7fac437-df49-4c86-98dc-77204cd9afc2">P10Y</bvs:SupplyCommitmentTerm>
    <bvs:SupplyCommitmentTerm
      contextRef="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI4MzQ_e7fac437-df49-4c86-98dc-77204cd9afc2">P10Y</bvs:SupplyCommitmentTerm>
    <bvs:SupplyCommitmentRenewalTerm
      contextRef="ic97a9441996940219fb13a41e33c6afb_D20160209-20160209"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTI4OTU_12d54ec6-122c-4033-8b44-7dc2d1437dd5">P5Y</bvs:SupplyCommitmentRenewalTerm>
    <bvs:SupplyCommitmentTerm
      contextRef="if1c5e680b22440109145605beffbd285_D20201222-20201222"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTMxNzI_fd66c5e3-32e3-486b-a3de-b72775eaf137">P8Y</bvs:SupplyCommitmentTerm>
    <bvs:StopLossInsuranceThresholdPerMemberPerYear
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83My9mcmFnOjE1ZTZiNmVlMmJmOTQyYWQ4NjUxZGQyZDE2MTE1MWQ4L3RleHRyZWdpb246MTVlNmI2ZWUyYmY5NDJhZDg2NTFkZDJkMTYxMTUxZDhfMTQ1OTE_7ae92c31-95a1-49c4-821c-f5a306fc6d5f"
      unitRef="usd">200000</bvs:StopLossInsuranceThresholdPerMemberPerYear>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RleHRyZWdpb246NTY1MWNjNDA0NzFjNDhiZGE0ZTM5M2U0NWIzZjc4OGFfNDMx_26708eaa-700d-4888-a250-f9d98bde074d">Revenue recognition&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our policies for recognizing sales have not changed from those described in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. The following table presents the Company&#x2019;s net sales disaggregated by major products (Vertical) within each segment as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pain Treatments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restorative Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pain Treatments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restorative Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total International net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RleHRyZWdpb246NTY1MWNjNDA0NzFjNDhiZGE0ZTM5M2U0NWIzZjc4OGFfNDMy_4cd1855a-0bc0-410b-83c9-706ac2053741">The following table presents the Company&#x2019;s net sales disaggregated by major products (Vertical) within each segment as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pain Treatments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restorative Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pain Treatments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restorative Therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total International net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85686a2c0fc64b148872e20370023dd3_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMy01LTEtMS0xOTQ5Mjk_7ee96e39-1a7b-44fb-98c8-dfc0adc3c3f5"
      unitRef="usd">40995000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c67e34f91494006b4a5bd61a96084e8_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMy03LTEtMS0xOTQ5Mjk_c92d7bda-af01-4110-8cb0-5d79c50945ae"
      unitRef="usd">47874000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6a1353106cf447ca65be040ed56b6d0_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNC01LTEtMS0xOTQ5Mjk_d153af86-1e4e-4a35-9e7c-49ce10fcc0ca"
      unitRef="usd">32488000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6030c2e18bb140f29cddb91bd8f88824_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNC03LTEtMS0xOTQ5Mjk_7b156323-c76e-4116-9dc0-a33d8c7adfd7"
      unitRef="usd">28946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if757a0e5be5f42b2b08f3b701abff4af_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNS01LTEtMS0xOTQ5Mjk_4dce002e-3dad-440a-9e4d-ff72e68a549f"
      unitRef="usd">30495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i671287cbd69c46ef9a385740e8dbd49c_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNS03LTEtMS0xOTQ5Mjk_5b515961-49ea-4ff2-a082-4ad7c7796376"
      unitRef="usd">27261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b7e30af75d7460f92fef399bf827f6b_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNi01LTEtMS0xOTQ5Mjk_168c65d9-3f75-4c88-8daf-5e1233131768"
      unitRef="usd">103978000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5376f01c85d24e8cb1ee7b9a3e0894e7_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfNi03LTEtMS0xOTQ5Mjk_5fecdfeb-8292-46ee-8bd2-95b0d1aff8f0"
      unitRef="usd">104081000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9051c125b094e389ac08453ae46745f_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfOS01LTEtMS0xOTQ5Mjk_8795876d-4813-485e-9ea3-55b5c0912703"
      unitRef="usd">5331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1101072b1f7f4d799ac5ea6ab0705a18_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfOS03LTEtMS0xOTQ5Mjk_f8623613-6fae-4026-8171-c1f23995dfdd"
      unitRef="usd">4179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc532b467295442c823324184b9ebe64_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTAtNS0xLTEtMTk0OTI5_de921b86-55ba-42be-a6ab-441c45ae42ac"
      unitRef="usd">5614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i260d2a092ee24cd08e4a8a8282a56d28_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTAtNy0xLTEtMTk0OTI5_c12407c1-6921-45a4-a049-7f41dfcda11f"
      unitRef="usd">5414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib522fb2bab9949e69f42dd7e1b248159_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTEtNS0xLTEtMTk0OTI5_48ea4a4f-ad6c-4471-a0db-fcc0c5a755dc"
      unitRef="usd">4136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4f3a6d840244f7f92937f02e11c783d_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTEtNy0xLTEtMTk0OTI5_e24b004d-a96f-4e43-9feb-869a09e90724"
      unitRef="usd">3616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i915d046eaaee44c7881495d91a8a7d49_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTItNS0xLTEtMTk0OTI5_af2ef77f-0000-4050-885a-503d5ca6cb51"
      unitRef="usd">15081000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id797d5aea258432e9c7d0ca865cdaee7_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTItNy0xLTEtMTk0OTI5_ad779bee-270b-4abc-8246-1ee6cd81ede7"
      unitRef="usd">13209000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTQtNS0xLTEtMTk0OTI5_26fa2eb8-4e79-48ff-bec0-ef0141b43ad4"
      unitRef="usd">119059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV83OS9mcmFnOjU2NTFjYzQwNDcxYzQ4YmRhNGUzOTNlNDViM2Y3ODhhL3RhYmxlOmVlMThjNWRiMDE4ODQzNGM4NGFjY2VhODg5ZDI0YTgxL3RhYmxlcmFuZ2U6ZWUxOGM1ZGIwMTg4NDM0Yzg0YWNjZWE4ODlkMjRhODFfMTQtNy0xLTEtMTk0OTI5_1c2e0624-fb6e-4bf5-b162-1f21b6643cc3"
      unitRef="usd">117290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RleHRyZWdpb246NmFlNTE4M2JlMTFiNDgzMmE2ZGU1N2VkYTM5YzQ2NzlfNzg4_1bc520a5-ef55-44f1-a049-68236a12ac2e">SegmentsThe Company&#x2019;s two reportable segments are U.S. and International. The Company&#x2019;s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#x2019;s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment adjusted EBITDA reconciled to loss before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and succession charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CartiHeal divestiture and debt restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RleHRyZWdpb246NmFlNTE4M2JlMTFiNDgzMmE2ZGU1N2VkYTM5YzQ2NzlfMzI_b33a6a72-3863-46fb-9654-0025beb7d500"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RleHRyZWdpb246NmFlNTE4M2JlMTFiNDgzMmE2ZGU1N2VkYTM5YzQ2NzlfNzg5_55392dc4-dbfa-4c15-9879-d8aabbe4693e">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment adjusted EBITDA reconciled to loss before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring and succession charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CartiHeal divestiture and debt restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="ibc30004a37a84a44919da8653b8b5a85_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMy01LTEtMS0xOTQ5Mjk_7f90831a-7333-460a-a948-5e04b3574ebc"
      unitRef="usd">14712000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="ic681d0153e8d44509633594dee0fc4c2_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMy03LTEtMS0xOTQ5Mjk_49ec7914-9fe4-41a4-bed1-108ced176b98"
      unitRef="usd">4839000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="id7f9608964984704ad0bc120b4fb197e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNC01LTEtMS0xOTQ5Mjk_e49f8b8e-838a-4e17-9db7-f77e0dbee726"
      unitRef="usd">2239000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="i10818604d3f84a4b9f8471323205d604_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNC03LTEtMS0xOTQ5Mjk_e1dd62ec-acd5-4cb7-bab1-0e3d2b215115"
      unitRef="usd">2333000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNS01LTEtMS0xOTQ5Mjk_5c0828fa-d56a-4f07-ae28-792ba1d2dd93"
      unitRef="usd">-9694000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNS03LTEtMS0xOTQ5Mjk_dca77934-c84b-4323-a268-d8805e414a20"
      unitRef="usd">1550000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNi01LTEtMS0xOTQ5Mjk_52f4af59-4a23-469e-8ff5-2efba1372273"
      unitRef="usd">16473000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNi03LTEtMS0xOTQ5Mjk_97257d9b-4702-4daa-9d9e-c15f280dc5d0"
      unitRef="usd">12479000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNy01LTEtMS0xOTQ5Mjk_ada21dbe-47f8-4ecf-a38b-9262d3a8c936"
      unitRef="usd">1175000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfNy03LTEtMS0xOTQ5Mjk_d277fd23-e39f-474f-9830-fed9709949cc"
      unitRef="usd">7978000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RestructuringCharges
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfOS01LTEtMS0xOTQ5Mjk_87ea89a2-380c-44ae-99bb-df6a3964d33f"
      unitRef="usd">317000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfOS03LTEtMS0xOTQ5Mjk_4378371d-0414-4eda-8723-cf28c332d31c"
      unitRef="usd">577000</us-gaap:RestructuringCharges>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTAtNS0xLTEtMTk0OTI5_408aab64-9e8b-45fb-8e88-40b71902e53f"
      unitRef="usd">1846000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTAtNy0xLTEtMTk0OTI5_aaab57b2-5dd7-4d39-8dd0-50878a35d759"
      unitRef="usd">4889000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTEtNS0xLTEtMTk0OTI5_ef84a535-107e-429b-b6bc-3692baf05eb0"
      unitRef="usd">5330000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTEtNy0xLTEtMTk0OTI5_cc9fc7f3-b2fc-4121-90b1-e2d49b1ab38b"
      unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTMtNS0xLTEtMTk0OTI5_8dae1993-045d-43d9-a76c-de6c7225a6f2"
      unitRef="usd">78615000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTMtNy0xLTEtMTk0OTI5_96b67cf4-59a9-4ee1-b87f-0c5c810cbb09"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNonrecurringExpense
      contextRef="ic22822650b8d43f68f2a6087dad1073e_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTUtNS0xLTEtMTk0OTI5_2cff44c8-c26e-4bc2-8e58-001f6b24bcf7"
      unitRef="usd">3665000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="i66422f3826d94025bc779a64a4417e3b_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTUtNy0xLTEtMTk0OTI5_b0f8238f-2d13-4396-8a20-1a77541b2ded"
      unitRef="usd">2336000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTYtNS0xLTEtMTk0OTI5_3b69d5cc-7038-4fd9-8a91-b05e40fcb029"
      unitRef="usd">-100164000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4e843a081c9c40ceb92d19a6451837b5_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84Mi9mcmFnOjZhZTUxODNiZTExYjQ4MzJhNmRlNTdlZGEzOWM0Njc5L3RhYmxlOjYyOGQwYTlmZTJiMDQxYWFhODk3ODY0MGU5NDI0NzYyL3RhYmxlcmFuZ2U6NjI4ZDBhOWZlMmIwNDFhYWE4OTc4NjQwZTk0MjQ3NjJfMTYtNy0xLTEtMTk0OTI5_26a92ef9-6cdf-40df-96e1-629ac87383b7"
      unitRef="usd">-19537000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1XzM4NDgyOTA2OTczNTc_57b95bf2-018e-4084-ae2a-bfcb1f9b6a9b">Discontinued operations&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of 100% of Company&#x2019;s shares in CartiHeal to a Trustee. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3. Acquisitions and divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details concerning the CartiHeal Settlement Agreement and its deconsolidation from the Company&#x2019;s financial statements. CartiHeal had no sales for the three months ended April&#160;1, 2023 and year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes CartiHeal&#x2019;s major classes of assets and liabilities as reported on the consolidated condensed balance sheets as of December 31, 2022 as the balances were fully deconsolidated as of April&#160;1, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amounts of major classes of assets included as part of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amounts of major liabilities included as part of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April&#160;1, 2023 and April&#160;2, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;April 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bioventus Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt"&gt;Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee
      contextRef="i3f75d22eb20045e4a96e961e0a09ca92_D20230227-20230227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1XzE2NDkyNjc0NDM1NTY_147e4a87-ad0e-4628-8111-3b1defa1a31b"
      unitRef="number">1</bvs:BusinessAcquisitionPercentageOfSharesTransferredToTrustee>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCash
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMtMy0xLTEtMjEyODE2_61564cfc-de35-4e48-91f4-1b848a53bfe2"
      unitRef="usd">1628000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCash>
    <bvs:DisposalGroupIncludingDiscontinuedOperationRestrictedCash
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzQtMy0xLTEtMjEyODE2_581cd3ec-a486-4e5b-9b6d-8a813e8853c1"
      unitRef="usd">23000</bvs:DisposalGroupIncludingDiscontinuedOperationRestrictedCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzUtMy0xLTEtMjEyODE2_a4738100-684b-4083-b935-666f722a38f2"
      unitRef="usd">350000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <bvs:DisposalGroupIncludingDiscontinuedOperationInventory
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzYtMy0xLTEtMjEyODE2_cbe78c16-eeea-4f0f-b2e1-d4746ca97301"
      unitRef="usd">642000</bvs:DisposalGroupIncludingDiscontinuedOperationInventory>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzctMy0xLTEtMjEyODE2_b606d263-07fa-4078-80f5-6b8b878b9f8c"
      unitRef="usd">134000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzExLTMtMS0xLTIxMjgxNg_f3274301-72c3-4cb0-b9db-2e89f220c9dc"
      unitRef="usd">191000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzEyLTMtMS0xLTIxMjgxNg_abd9343c-5120-4b9d-b1a7-75cd6b06388e"
      unitRef="usd">6297000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzEzLTMtMS0xLTIxMjgxNg_26d10a8e-110a-4e97-85e6-8a39ff257558"
      unitRef="usd">398873000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <bvs:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzE0LTMtMS0xLTIxMjgxNg_37d6ad31-4e7a-4557-8ac8-f278350b3056"
      unitRef="usd">618000</bvs:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzE2LTMtMS0xLTIxMjgxNg_5b8bbadc-54e4-44a1-980c-7112285a5034"
      unitRef="usd">15000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzEzLTEtMS0xLTIxNjE1MA_60a3a62a-3c96-4425-872c-36df2d1a56ee"
      unitRef="usd">408771000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzIxLTMtMS0xLTIxMjgxNg_823028f3-e306-4850-9bee-d7aac8e7f511"
      unitRef="usd">852000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzIyLTMtMS0xLTIxMjgxNg_3bd041c1-5cf9-4d24-a4d9-391cc2f35a87"
      unitRef="usd">384000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <bvs:DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzI1LTMtMS0xLTIxMjgxNg_fbb54b09-02c2-42fa-aeaa-0eb0204a370e"
      unitRef="usd">117615000</bvs:DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzI2LTMtMS0xLTIxMjgxNg_f0ee8a56-4c38-48a1-ab24-4816a75598e4"
      unitRef="usd">236000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMwLTMtMS0xLTIxMjgxNg_48eb11c5-2c22-4ec6-a72c-e346f52ff34d"
      unitRef="usd">79863000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <bvs:DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMxLTMtMS0xLTIxMjgxNg_65712ebd-3f99-4c85-827d-bf2b81839a24"
      unitRef="usd">79269000</bvs:DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent>
    <bvs:DisposalGroupIncludingDiscontinuedOperationContingentConsideration
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMyLTMtMS0xLTIxMjgxNg_1ad3971d-6b80-4ad0-9ad0-88da0295ff53"
      unitRef="usd">67251000</bvs:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzMzLTMtMS0xLTIxMjgxNg_18998d9f-dbd7-4f1c-80a6-77938235823a"
      unitRef="usd">2528000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i221faa30c740451eb553a94e1f7b7017_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTpmOGZjNGIyNmYxZmU0ZmZmODQwYjg3ZDExYjYyZWU1My90YWJsZXJhbmdlOmY4ZmM0YjI2ZjFmZTRmZmY4NDBiODdkMTFiNjJlZTUzXzI1LTEtMS0xLTIxNjE1NQ_58c93b36-67fb-475a-bf8a-0504913cadbe"
      unitRef="usd">347998000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzUtNS0xLTEtMjEyODM1_15542a28-58e5-40f5-ad11-ca43514d6db4"
      unitRef="usd">1728000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzUtNy0xLTEtMjEyODM1_60fca1ce-5aa4-44d9-997b-abc34a45cac2"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <bvs:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzYtNS0xLTEtMjEyODM1_161f4a1e-2de8-4aa4-a2d3-4fd3b3fd880b"
      unitRef="usd">396000</bvs:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <bvs:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzYtNy0xLTEtMjEyODM1_37a38f7e-67c2-44b6-b5b5-723af93dc481"
      unitRef="usd">0</bvs:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <bvs:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzgtNS0xLTEtMjEyODM1_6f4191d4-cb97-4ddf-b0f3-1bc9c5a9912f"
      unitRef="usd">1710000</bvs:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration>
    <bvs:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzgtNy0xLTEtMjEyODM1_ef8527c5-4870-4ad8-b33d-d35a3105c54a"
      unitRef="usd">0</bvs:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNS0xLTEtMjEyODM1_d4647b5a-d5ec-48b1-b631-81e93c32e583"
      unitRef="usd">4264000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNy0xLTEtMjEyODM1_cebc1032-82f8-4c75-8397-0928bb6fa6b2"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNS0xLTEtMjE2MTg2_29d82650-5b91-4085-b107-f3b6307a273a"
      unitRef="usd">-8098000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzktNy0xLTEtMjE2MTkw_d9ddc6ed-47d2-4602-8fb3-4d74b1ef8c62"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEzLTUtMS0xLTIxMjgzNQ_ce67099c-4b21-443f-ad78-8371c487a788"
      unitRef="usd">4889000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEzLTctMS0xLTIxMjgzNQ_142eb39e-9ccf-4ce7-b0d8-1eda76d170b4"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE0LTUtMS0xLTIxMjgzNQ_13d4e431-dc0e-4f30-bb79-451aa43a1880"
      unitRef="usd">61442000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE0LTctMS0xLTIxMjgzNQ_b7ab4c7f-c531-410e-87b4-018bb10d22eb"
      unitRef="usd">401000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <bvs:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEyLTUtMS0xLTIxNjE4Mw_2089a7c3-4571-461d-84f3-c3827b7139d8"
      unitRef="usd">-66331000</bvs:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <bvs:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzEyLTctMS0xLTIxNjE5MA_86bcf8b5-b606-466b-b9f8-be3d5835333e"
      unitRef="usd">-401000</bvs:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE1LTUtMS0xLTIxNjE3OA_53107f40-7111-4f83-b4e6-1bbeed2258c5"
      unitRef="usd">-74429000</bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss>
    <bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE1LTctMS0xLTIxNjE5MA_f918bb0d-e290-4924-b7b0-19308bb80a55"
      unitRef="usd">-401000</bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss>
    <bvs:DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzIxLTUtMS0xLTIxMjgzNQ_a381f496-1b68-440d-811b-e7e5529cf5a6"
      unitRef="usd">14937000</bvs:DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest>
    <bvs:DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzIxLTctMS0xLTIxMjgzNQ_3f81dbd9-42e5-44a6-a395-a9fa2eb521a4"
      unitRef="usd">0</bvs:DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest>
    <bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent
      contextRef="i9c68f499443244fc9c79dffeed2774b9_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE3LTUtMS0xLTIxNjE3OA_35d3b498-7297-4c2a-8190-5adf48447abb"
      unitRef="usd">-59492000</bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent>
    <bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent
      contextRef="i6c2f1e79a5e442a3807cbc3181475d64_D20220101-20220402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90YWJsZTo2OWZlMDE0Y2QwMWE0ZTYwYjg4YmQ1YzQxOWIxYTJhMi90YWJsZXJhbmdlOjY5ZmUwMTRjZDAxYTRlNjBiODhiZDVjNDE5YjFhMmEyXzE3LTctMS0xLTIxNjE5MA_4252c891-b091-4535-a2e7-fc2c150576e1"
      unitRef="usd">-401000</bvs:DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1Xzg3OTYwOTMwMzA0NTM_88a1112b-e243-4c7e-80bb-00a93c6bfade"
      unitRef="usd">-60639000</us-gaap:DeconsolidationGainOrLossAmount>
    <bvs:NonRefundablePayments
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV81NDQvZnJhZzpmNWEyMGM1MjRhMmU0YmM2OWE1MDU1MmY3NDk3MTcyNS90ZXh0cmVnaW9uOmY1YTIwYzUyNGEyZTRiYzY5YTUwNTUyZjc0OTcxNzI1Xzg3OTYwOTMwMzA0ODM_4f98985e-12a4-454f-ae83-a3511fbcecc9"
      unitRef="usd">10150000</bvs:NonRefundablePayments>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i52374b540ac247b597e34da4fa742209_D20230101-20230401"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfMTYz_ae24e191-dbe2-4d50-b059-e4a15798fe69">Subsequent events&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 4, 2023, Mr. Reali resigned as a director and officer of the Company, and Mr. Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023. Mr. Bihl succeeds Mr. Reali as the Company&#x2019;s principal executive officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2023, the Company repaid $15,000 on its revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2023 the Company entered into a definitive agreement to sell its Wound Business, including TheraSkin and TheraGenesis, for total potential cash consideration of $85,000, including $35,000 at closing, $5,000 deferred for 18 months and $45,000 in potential earn-out payments. The Company expects to net approximately $30,000 at closing after fees and expenses that will be used to repay existing debt. The sale of the Wound Business is expected to close approximately one week before the end of May 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RepaymentsOfDebt
      contextRef="i72a1c8e6882a4bff9613fb79fbc5344d_D20230406-20230406"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfMTY0OTI2NzQ0MjI2Nw_0b077c5c-a3ff-4ef4-8489-791b771157e7"
      unitRef="usd">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzIxOA_164472bd-e372-402b-b2e4-383e38ad752b"
      unitRef="usd">85000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <bvs:DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount
      contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzIzNQ_e5bfa610-0417-44a8-b094-8a8a581d3b6b"
      unitRef="usd">35000000</bvs:DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount>
    <bvs:BusinessCombinationConsiderationTransferredDeferredAmount
      contextRef="i6bbfa06653064902b83b28df8ecfa4bc_D20230510-20230510"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzI1Nw_46089c8d-8d4c-4a25-8cca-e1b922a6d31b"
      unitRef="usd">5000000</bvs:BusinessCombinationConsiderationTransferredDeferredAmount>
    <bvs:BusinessCombinationConsiderationTransferredDeferralPeriod
      contextRef="i6bbfa06653064902b83b28df8ecfa4bc_D20230510-20230510"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfMjE5OTAyMzI1ODYzMA_71999852-cfa8-4a8f-a057-ff5ee8de1c97">P18M</bvs:BusinessCombinationConsiderationTransferredDeferralPeriod>
    <bvs:DisposalGroupIncludingDiscontinuedOperationEarnOutPayments
      contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzMwMg_72d303be-8462-47c2-874b-a9999ed47bad"
      unitRef="usd">45000000</bvs:DisposalGroupIncludingDiscontinuedOperationEarnOutPayments>
    <bvs:DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses
      contextRef="i852f13a0b8994a0b9c4197a33edb508f_I20230510"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyNDFhYmExYzBjNTQ3Zjg4NzhiZWY0MDk5YjU3OWU5L3NlYzo5MjQxYWJhMWMwYzU0N2Y4ODc4YmVmNDA5OWI1NzllOV84NS9mcmFnOmUwNDNmNDdhMjlkNDQyZTFhNjViZGNiZWIxNGE0NTRkL3RleHRyZWdpb246ZTA0M2Y0N2EyOWQ0NDJlMWE2NWJkY2JlYjE0YTQ1NGRfODc5NjA5MzAyMzM4MA_3daeb2c1-d06b-47ec-bde3-acb65361b30e"
      unitRef="usd">30000000</bvs:DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M8S2,IB .I$;]K'9;&P%-OZ_WACZ W]^<D5J@;;93> @EB9-P#-B5FM-H$N]
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MLFHNMR+-A;("\/M&2O-\8U_0_]^%]9]02P,$%     @ E8FP5J[I!L*  @
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MGTG =8":7S(F7SOZ(%Y^>/E_ 5!+ P04    " "5B;!651E!M_T'   L00
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MG[:LMELQY)9%RAAZK<A?3<A_H\CW+\IONPA]MS'!OX6I6A;J8:^S+&^FH[1
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MY%01O5,UR4,E0]<$>Y9L\.LK3GX< -23 J4%H+10U;NV*?_Y%&C-&)26*([
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MF K5O+W3?#%RYUZ N9?&R*W[N!%9(90U@-_74IJ7+_8&W3M4J_\!4$L#!!0
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M=(L:D+9;V.O NQT L5(=:RD@9DIB\LG^<@5.:CD0>J,Q\I7@RR17*TBT&I=
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M21\3*4L+\'YE8,_P@PYH/ME^\Q]02P,$%     @ E8FP5K= VU/&#   OB@
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MI[!*4@6'\M?8U4#E$*WG@Z^UZ*R_X\]*]\NAY_ _XGDIM@HZ[OF>L%<$M3*
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M]\S_)VVWW/^S[P<$#XFM2['"J]-).COSH[7^AU6-^X?:4EFK*G>Y$1SU#BW
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M/MBOX^6SXJBKU&S(!Q>8,Z8,(9=+3>R=[">[2K7R-SWONCQ%ECK5UA3LZ]!
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M$?HQ[V6:B87F5=7-HA0]'D?9VJ-!YM%V"-[9H=;),[,$)MVXB\)J^U@34\)
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M6<WIOR,[^X3_=DOQUVQ\K7NQ1D+3T>3\+";*$1?^;1B& JD-98Y7!ND\N'O
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M) J3*3*;[.SV#QRI9VKVVW!NOP=QM_'1P!7PSX8Z6@3?!D.$&0H+/WME\-U
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MY'@#OD^M#>L7-M#>KF_^ 5!+ P04    " "5B;!6GD7 Y1(;  #Q40  &0
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M6=]T 2+0364GIGBCZP^F&7;U>0_I>JP"@S9R ;YL$T<1 Y,?U+W@H^];*;_
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M#D#WSTZ_L:KUHWZC+-UZOZSII4;M#$B_5<H^;UR P]N_^@Y02P,$%     @
ME8FP5GZH6&EZ!   L@D  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
MC5;;;N,V$/V5@;98Q(!@6_(]%P.Y%1M@@PV2W?:AZ ,MC2,V$JDEJ3CNU_>0
MDIT$3=*^V+S,')XSG!GJ>*/-@RV8'3U5I;(G4>%<?3@8V*S@2MB^KEEA9ZU-
M)1RFYGY@:\,B#TY5.4B'P^F@$E)%R^.P=F.6Q[IQI51\8\@V527,]HQ+O3F)
MDFBW<"OO"^<7!LOC6MSS';L?]8W!;+!'R67%RDJMR/#Z)#I-#L_&WCX8_"9Y
M8U^,R2M9:?W@)U?Y233TA+CDS'D$@;]'/N>R]$"@\;/#C/9'>L>7XQWZKT$[
MM*R$Y7-=_BYS5YQ$\XAR7HNF=+=Z\X4[/1./E^G2AE_:M+;I(J*LL4Y7G3,8
M5%*U_^*IB\,+A_GP'8>T<T@#[_:@P/)".+$\-GI#QEL#S0^"U. -<E+Y2[ES
M!KL2?FYYQ_<(L;/' P<TOS;(.L^SUC-]QW-$UUJYPM*ERCE_[3\ BSV5=$?E
M+/T0\+0V?1HF,:7#=/0!WF@O;13P1A]+HUNNM7%2W=,?IROK#!+AS[?DMFCC
MM]%\<1S:6F1\$B'[+9M'CI:?/R73X=$'7,=[KN./T#^\AO_G^;U@.M=5+=3V
M\Z=YFLR.++F-1N%X]6)5,MG.E(1A^M&_ZY-0.5TIQT8)7R.B[--;.+71>9-U
MCK61*%]9;LGJ,B>G"?@%ND0NK;,Q58W-FE+;!U2>$V4XPWH.EBK89.!/=;&U
M& D%^UKG4CC3.BMNC+:-N6>M;'#=@V= \;Z[W9B$I0W*V?^#A2M8&JHAQ&M\
M)81RS9:4=@2.&;CM8T%2M8W-=XC5%E 6C= #>N]"\IJ^U6Q$2)\+SF1H1M?B
M@<TSJ.%'WWZTH0;(TGDVHBQU)AQCT^K&9##%OM_ ";;%UWMD&*&+M(+74@F%
MV)2$[4!.9=RG73:+_"]T!<[I\NSJ^\4IR19KIP=7M9:X;EE*MT7 $=BLRP'.
MNS#]ZW[_0RA(4-V8&G&#BC6:7KL-OBOT^9U6[X#=9\%.QT%1*]D#OU $TYA8
M9,4;&=I>WEH#=^/=VLU0=CY][3NA,)QI1*YLA>*:+:T8Y^%.5*8K!LX3VT.
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M3\ZCXJ"[7T.Y$>,DP$GT_E%:[,RTT>3I0'Q8H"=YM4R@D7 -GTB7]\++!Y2
ML>V "QD8<HM0'N+ !2@+T#G)+1\+J4IVS!3L$@<M"'\V$-=BCG,(B+B #G#T
M6(I@$,J<:Q"'A05;@NMV$Z?@&ELOS+R,6:+X.U[EUL- W-."!XWXW< >X';M
M0VFTC)"T@<I 25@86Y$KAP8?3[=&#YSKP4HW>OG,DZUPWLQ]%\P@2K7+9#SE
ML'%UL"ZPPQJ5Z1A9LU/$(1QQS%REC)@6J 4 ^[Q+A9 NZEPA47:QDE:9@'5Y
MLH@<._ 6?-SXBJ1#E3?53]_JTD2[SOH<J)Q740RFKHWU06,.^MX&Y,0A&Z
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M>(E]L.F%ESZ\J>.K:FX\WFCQ9X%',5E>@/F%08TU'QR@?6;/_@-02P,$%
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M\%W;\L6JN?ML-%(6I<X-IX(W0M,"_#]6T*I_(0:K[XBG_P902P,$%     @
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M2//3GMT.$IH@W2(2J:$P[3 X;DN2/4XNDNAWXO]SS]]VV3)O3,U?<WCZ);B
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M=XG*;&=)GCPY[N5ZXX,CFT\;L<8']%^;.TN[;,]2R1JUDT:#Q=4L6>23RT'
M1\ WB5MW8$.H9&G,C[#Y6,T2%@2APM('!D'+(UZA4H&(9/R[XTSV*4/@H?W$
M?A-KIUJ6PN&54=]EY3>S9)Q A2O1*G]OMA]P5\\P\)5&N?@+VPY;7"10MLZ;
M>A=,"FJINU7\W)W#0<"8O1+ =P$\ZNX21977PHOYU)HMV( FMF#$4F,TB9,Z
M7,J#M_154IR?WT@M="F% JF=MRV=MW?0^R*6"EU_FGG*$9!9N>.[[/CX*WP%
M?#+:;QR\UQ56+^,STK87R)\$7O*3A(O&G@'+4^",%R?XBGW!1>0K7N&[QJ6'
M:^E*95QK$?Y>+*EN>AS_'"NVXQH<YPH-,W&-*'&64$<XM(^8S-^^R4?LW0FE
M@[W2P2GV^0,U8-4J!+."6Z/7?WFT-43]'Y_OZICJD[S'53\GJ$*"TE#;.8]5
M2.XW""NCJ'^E7H-PY)L W8M4L+L74E5BO40+1>?AL"!U] +@2^"\-4)#U2)\
M+KT),(*,H'=QEE_\"<*_).O#'S#@+#W/^8%UCX]&/5+H;S3#0,/'QVCX1<H8
M@[=OQCSG[^ 6G9O 56LMG1LTQL:Q0/6IE[7W!GE:<-:'7E&D;#CJPU<MZ@#_
MG^J)$.E<2VV#=$Z. O*4#_-^6(MB_!N<7III*5^/I^/S40=BXU@C&Z1\-"2K
M& ]3EC,X]FBR@]ZNT:[C!',02;LVWWOW0W+1S89G>#=A/PF[IBX'A2L*96?G
MPP1L-[6ZC3=-G!1+XVGN1'-#@QYM -#WE3'^:1,2[/\ZYK\ 4$L#!!0    (
M )6)L%:TSB;'3@0  #P*   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;)U6;6_;. S^*X3W@@W(DMAY:=8E 9+VA@UH#T7;[3X<[H-LTXDPV4HE.5GO
MUQ\IO]3=I3G@OEC4"Q\^I$A:\X,V/^P6T<'/7!5V$6R=VYT/!C;98BYL7^^P
MH)U,FUPXFIK-P.X,BM0KY6H0#8?302YD$2SG?NW&+.>Z=$H6>&/ EGDNS.,:
ME3XL@C!H%F[E9NMX8;"<[\0&[]!]V]T8F@U:E%3F6%BI"S"8+8)5>+Z>\'E_
MX+O$@^W(P)[$6O_@R==T$0R9$"I,'",(&O9X@4HQ$-%XJ#&#UB0K=N4&_;/W
MG7R)A<4+K?Z0J=LN@ED *6:B5.Y6'[Y@[8\GF&AE_1<.U=FS20!):9W.:V5B
MD,NB&L7/.@X=A=GP!86H5H@\[\J09WDIG%C.C3Z X=.$QH)WU6L3.5GPI=PY
M0[N2]-SRLY &]D*5"#D*6QJDB#L+[^Y%K-"^GP\<6>&S@Z1&7%>(T0N(([C6
MA=M:^*U(,7VN/R!V+<6HH;B.3@*N=J8/P[ 'T3 :G< ;M2Z//-[HE,O?O<N7
MTB9*L]<6_ES%UAG*DK^.^5Q!CH]#<N6<VYU(<!%0:5@T>PR6;U^%T^&G$X3'
M+>'Q*?3E'55B6BH$G<$3^1ZLK$6Z*E&D<"5%+)5TDARYKNXQ!4KZ6TQ*8V2Q
M@;6PTA[S[+3M^RU"IA75+H,X3@K8&;V7*5F21=45N+Q( O%$2'4(Y0TAX2![
MRC>N2:KKAF#,!*&T+%_A'A5$E6M>'I&Q7>GL.5 Z2 5U.L E)IC':&!4K41P
MKYU0K=;S62=,YZ2:H6%:JUR7A8,/<$%4*/OAG7@/K^'MJUD41I^>26%XUIN&
MDX[T;Y0K31[<H\D]3J/;C&<?>]'T8S-<"./D%R2*"14-N<[F2;047^,#^P'N
MA.);E?1UNL"CJ-.S7C0)FV%->FCMBYA W,_"66<8C\)FJ"*FNI%ZW9SL"-$L
M[$VFTX[$O#A=?HT(7^*+3(1S1L9EE5A.=P*R%7N$&)%[?Z(HM60F"93.I%2U
M'J_D)-_54)8ZI]O* ISG\&M:Q$*)(D'PK;+?L7,0%K)2J4=JYLQ-*YD*1\AI
MZ?.2X3)IK(.'DI0(D\J0<Z]/U46>,J/?M4.@A57R4$HK*SKL=TJ_'.ND\QV&
M%_S)<-SWK>>8$UQ'66G(JB%"3DAE*0 ;8=*&3)<FAY#HM-[T3[2;2=MN)O^C
MW31MA7\/\-77HG>(-RL>]YAL"_E0XM$V<]KFJGD5L-&RT#'W4)\3S\L?2D=9
M^3>%C./$T1"QICSIMAMA:-7678NR]PA#^-8U44/?"DK0_ZX=?W&4U\0A$78+
M&5F!&_'H Y/6FT"'$:;]\1MJ"-/^[$U[@FY:ZI03:$Q;-$R.7=F@\T?/T6S\
MNX5)$7;U<V]7VZ?1JGH1/!VOWE77PFPD)9;"C%2'?7Z)F.JM4DV<WOGW0:P=
MO3:\N*7G'1H^0/N9IIRM)VR@?3 N_P%02P,$%     @ E8FP5D+Y"&U:!
MU@H  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULC59M<]HX$/XK.^Y=
M)YDA8)M@("',D#;W\J%M!B[IAYO[(.P%-)$E5Y(A_/M;R<:%!IA\ 4O:??;M
MV9T=;91^,2M$"Z^YD.8N6%E;W'0Z)EUASDQ;%2CI9:%TSBP=];)C"HTL\TJY
MZ,1AF'1RQF4P'OF[1ST>J=(*+O%1@RGSG.GM/0JUN0NB8'<QY<N5=1>=\:A@
M2YRA?2H>-9TZ#4K&<Y2&*PD:%W?!)+JY3YR\%WCFN#%[W^ BF2OUX@Y_9W=!
MZ!Q"@:EU"(S^UO@)A7! Y,:/&C-H3#K%_>\=^A\^=HIES@Q^4N([S^SJ+A@$
MD.&"E<).U>8OK./I.;Q4">-_85/)]I, TM)8E=?*Y$'.9?7/7NL\["D,PA,*
M<:T0>[\K0][+S\RR\4BK#6@G36CNPX?JM<DY+EU19E;3*R<].W[X47*[O7*!
M99"JG(IMF,_7Q3]L+M!<CCJ6[#CI3EICWE>8\0G,+GQ1TJX,/,@,LT/]#OG7
M.!GOG+R/SP)."MV&,&I!',;=,WC=)NBNQ^N>P/NT'^=$9O"0%T)M$>$>)2ZX
MA4?!I(%_)W-C-1'GOV-)J&Q<'[?AFNG&%"S%NX"ZQ:!>8S#^^"%*PMLS$5PW
M$5R?0Q_/J#FS4B"H!7Q5<HW&4OVF]*=YZCYG5J4O\"2Y-3!QS*<J'POBK)GC
M04QV'>R,VQ7"=/8$;,-T5O4860*:%O[)KC1E-:_H@(X.0,7D NIB C? #(D+
MF@X&+F29SU$[X-*[SB5!J-(PF9G+&_CZR_-WWW287;$U:IHAL-1,VJN,680%
MXQK63)0(!>DX!<I'G2EFX3.FZ-&ZE2\Q^10-AO ;1%%[F,"?#HI$NT.(V_T!
M/%>:%W'<O82(KOI <V&!W-U2N"F3*0T;DHC"T$LDR8'!P\"'8:\R%0_A#"%Z
M#2%Z[R;$;,4TUBW]R+8T0LFXJT^KIL6WPC'?M."9TE-W@:&B5M?':'+>^!M&
MN 9C<OOQPR".^K>NQ TZE,XMJFN&%C5--"Z77F>O7C6*\<ZJ6F]9UR,K]4[E
M/>PR*[61%8^PYIE7=\.M#5-N7JX6#H43.%'<@G;DZ;:'O\/#:X&^F3(B=4;X
ML.4H,O!AQ;>P)U&Y2K93A+42E%/AVJ#;:\=[4H(O?'"'@5ULD6ES"4D[[IUA
M0M(P(7D_$_;+#5.*WG'64>%8D<_BOF,6[(?U<Q0<=OB[!\/>*-@EZN0PV F\
M&0?XBCKE!NO*[-YA]Z[1[2V.#REYXB9]R00X7L)DN=2X=%P@9A#C#$]K=GXK
MK;'D@U,[.D<&K6$45LV=])HY0@\T$J)30R/I)M70B'XU<)B702NFX430O03Z
M[>MK\.PA:SM6/E0Q.WX#@<"I =1KA7'BO S;@SZ1K_\6ZA@;.WN[1HYZZ3<J
M0_DKI:W6CN:V6=HFU:[R4[S:^+XPO:3$@L %J8;M/DT976U1U<&JPF\N<V5I
M#_*?*UH\43L!>E\H97<'9Z!99<?_ U!+ P04    " "5B;!6$BUTQ\T"   B
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q]55%/VS 0_BNGH"&0
MJB9-:%.@K=06IB'!0,#8P[0'-[DV%HX=;(?"?OW.21K*!GU)?.?OOOLN]EU&
M:Z4?389HX247THR]S-KBQ/=-DF'.3%<5*&EGJ73.+)EZY9M"(TNKH%SX81 ,
M_)QQZ4U&E>]&3T:JM()+O-%@RCQG^G6&0JW'7L_;.&[Y*K/.X4]&!5OA'=H?
MQ8TFRV]94IZC-%Q)T+@<>]/>R>S(X2O  \>UV5J#JV2AU*,S+M*Q%SA!*#"Q
MCH'1ZQGG*(0C(AE/#:?7IG2!V^L-^]>J=JIEP0S.E?C)4YN-O:$'*2Y9*>RM
M6G_#IIZ^XTN4,-43UC4V(G!2&JOR)I@4Y%S6;_;2?(>M@&'P24#8!(25[CI1
MI?*,6389:;4&[=#$YA95J54TB>/2'<J=U;3+*<Y.[JQ*'C,E4M1F?V\8]N)3
MP*>2VU<XN&<+@>9PY%M*Y.!^TI#.:M+P$]((KI2TF8%SF6+Z/MXG@:W*<*-R
M%NXDG!:Z"T&O V$01COXHK;JJ.*+/N$[KRO\-5T8J^EB_/ZHQIKBZ&,*URPG
MIF )CCWJ!H/Z&;W)_EYO$)SN$'C4"CS:Q3ZYH^9+2X&@EG!M,]1PO99T1!DO
MX$):I(S6?"1Z-^U]AK!4@CJ1RQ58=[Y-._(_:( 2@6KS\"8/+6#V )>7<V#&
M":+3X *:TP F4SC#!/,%J8QJ;P@'LJP<!"\EM\:1V$R5AN#F\.0?CO_C7;:V
MT*WBO^S8^=ZF?(]Q):4PX^H9I2T-[21=&(2=?C"$^+@[I%"R@D'DK)BL.=U>
M+DOWC1Q3E0-Z_4X\C$E=-R3(FQ61=:\L$Q /.^%Q'WI!T W(&<>=83_8F!]=
M"G^K;W/4JVHZ&4A4*6W=PJVW'8#3NN_?X/7TO&)ZQ:4!@4L*#;IQWP-=3Z3:
ML*JHIL!"69HIU3*C(8[: 6A_J93=&"Y!^UN8_ 502P,$%     @ E8FP5M,3
MK5>Y!   2PP  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK5=A;]LV
M$/TKA#L4,:#:LBQ9=IH82-(.*]!V09VN'X9]H*6S150B-9**DW^_1TIQ[-5V
M6VQ?8E*Z>_?N^'BZ7&R4_FH*(LL>JE*:RUYA;7T^')JLH(J;@:I)XLU*Z8I;
M;/5Z:&I-//=.53F,PG RK+B0O?F%?W:KYQ>JL:60=*N9::J*Z\=K*M7FLC?J
M/3WX)-:%=0^&\XN:KVE!]G-]J[$;;E%R49$T0DFF:779NQJ=7R?.WAO\(6AC
M=M;,9;)4ZJO;O,LO>Z$C1"5EUB%P_-S3#96E P*-OSO,WC:D<]Q=/Z'_ZG-'
M+DMNZ$:57T1NB\O>M,=R6O&FM)_4YC?J\O$$,U4:_Y=M6MOQI,>RQEA5=<Y@
M4 G9_O*'K@X[#M/PB$/4.42>=QO(LWS#+9]?:+5AVED#S2U\JMX;Y(1TA[*P
M&F\%_.S\+==2R+5A->&H"JZ)G=WQ94FF?S&T".#,AED'=MV"14? QNR#DK8P
M[*W,*=_W'X+8EEWTQ.XZ.@EX5>L!"T<!B\)H? )OO,UV[/'&W\OV%MDN?+9_
M7BV-U1#'7X?R;>'BPW#NPIR;FF=TV<.-,*3OJ3=_^6(T"5^?(!MOR<:GT.<+
M7,"\*8FI%?N6^"&VI_'N"F(K5>(: HE9=\C,D#5XJ&W!+%YGJJH;R_U]053(
M762,RYSEHFPLY:Q49E<JL+DI.1Y=.=<*7A!L]M4A>CQ8"I7#PU5'.H S7JE&
M(JB0L%"- ;H)&#UD5-L.U05\CI%#UOUS=E=HHCU],:A#E*Q31[>+_"YB'YN*
M-+=*G[./:&UGCG@?04$35="J F%IA6Q<+=#BM$\:3"2LD9;E#^P7=C8*PR <
M3?M^'0=QF/0]GJ\#MU:+9=-6TBHFE72@&C5VJ ()(V_D^O+%-!I%KP^'!-]@
M/ G9.$BBV7'P:Z'N4<+&L'<R&QPL>Z'*G/1S.'!.9\$DZ>B'P32=]'^@,KDP
M'5,4^7AM4M0CFGGL.!S]E[H<"<A0\=DXW9K]S[5)9D$\BY[YOR&IT&';TGSQ
M[9SR5_P>=-;4BM$<53R^=\9"N"[!5P<NSB0*1E$<I$G$)F$03Y'99.>T?^!*
MG=#LM^'<>0^B]N##@1/PSX8Z*H)O@R'"#,+"SYX,OAOH"/%H$,5/Q&?]$XTT
MV3;2Y(<;Z152\K$P"[ %98T65I YU$U/@^YW4]E42Z2+ )M_"Z=6%MH4O"P?
MV39RIR;N!;7?QUPU]GO9!M?%=<BR<5W/GXYOUKS,FG+;K(^TZ"5EO#'D/6BU
MPC#DC''=@>:8FR8K3G+<J*;,68%T@$68HW8KV-0(#IT@5S>F_72;?O_^!G?V
MJ1\4A$C+1W;S+'-G\/M&(ITSWF>C)$BGDR!%4]A9+MH;6+=-8QHDHS0(XP2K
M-$F#-)RP3XO/Z"9!F(;!*$Q8C-L8AS&[4Y:#2Q*,TW$PG:9NB6$VF,:I#_<D
MVD5;B>X3G_O/VZJQ#<HKC&FXS+I*:,JIJML3T>[("B[77G?[B2)'=QZ'\AP<
M$OQP9\!#]U[[,=:@\/B4MK/>]NEV4KYJ!\1G\W;,_L#U6J!,):W@&@Y2R%RW
MHVN[L:KVX^)260R??EE@VB?M#/!^I2"6;N,";/]_F/\#4$L#!!0    ( )6)
ML%8,#L5"[P(  %$&   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;(U5
MWV_:,!#^5T[95+42:A('Z"] @K;3]E"MHMWV,.W!20YBU;%3VRGEO]\Y@0PD
MBO:"[?/=]]WGW!VCE38OMD!T\%Y*9<=!X5QU'88V*[#D]EQ7J.AFH4W)'1W-
M,K2509XW0:4,610-PY(+%4Q&C>W13$:Z=E(H?#1@Z[+D9CU#J5?C( ZVAKE8
M%LX;PLFHXDM\0O>C>C1T"CN47)2HK- *#"[&P32^GO6]?^/P4^#*[NS!*TFU
M?O&';_DXB'Q"*#%S'H'3\H:W**4'HC1>-YA!1^D#=_=;]"^-=M*2<HNW6OX2
MN2O&P64 .2YX+=U<K[[B1L_ XV5:VN875JWO( H@JZW3Y2:8,BB%:E?^OGF'
MG8#+CP+8)H U>;=$399WW/')R.@5&.]-:'[32&VB*3FA_$=Y<H9N!<6YR1RM
M,W7F:B/4$C)MG8739YY*M&>CT!&#]PNS#=JL16,?H"7PH)4K+-RK'//]^) R
MZ])CV_1F["C@M#+G$,4]8!%+CN EG=RDP4O^2RY7.<Q1<H<Y3'UY""?0PN]I
M2EY4+W\.O4!+T#],X'OHVE8\PW% 36+1O&$P.?D4#Z.;(^GWN_3[Q] G3]23
M>2T1] +VI<Q;+DC7\+RN&H=;^IB'!!RE."S@N4""*RNNUB>?+EE\<6.I(_<J
MI^!F26_GG[3B:VI;*B2:&5!)KKQS^\I.0UI;HK06O34C/[FFWGRMA:'[C$B,
ML+0C 8Y8%UK2W""&:[@O*ZG7B&#Q#0U7&39L#LM*&QHH('E*A&T-?Z=@TV7U
MK!V7,..RC7)P1\QE2AY)6UL,/D/2NQA&M#8*V4UGN7^G">C3%2JKC<\R9@.(
MKQ@%7\#C5FS)<X33N#<<)&>T7C'_V[OL#\YVB:F@A81-01,%Z[&$[9&VED/%
M$NZT>8DDS \S2X)KY=J.[ZS=O)RV8^*?>SML'^A=!'T7B0L*C<XO!@&8=H"U
M!Z>K9FBDVM$(:K8%S7PTWH'N%UJ[[<$3=/\BD[]02P,$%     @ E8FP5D,O
ML'QV!0  )0\  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULW5=;;]LV
M%/XKA)L6*>#8NOB:)@:<=$4+M%O09.O#L =:.K:(4:)*4G&S7[^/E&++CN-V
MV]L>;$G4.=^Y?>=0O%@K_:?)B"S[ELO"7'8R:\OS?M\D&>7<]%1)!=XLE<ZY
MQ:->]4VIB:=>*9?]* A&_9R+HC.[\&LW>G:A*BM%03>:F2K/N7ZX(JG6EYVP
M\[CP6:PRZQ;ZLXN2K^B6[*_EC<93?X.2BIP*(U3!-"TO._/P_&KHY+W ;X+6
MIG7/7"0+I?YT#Q_2RT[@'"))B74(')=[NB8I'1#<^-I@=C8FG6+[_A']G8\=
ML2RXH6LEOXC49I>=28>EM.25M)_5^CTU\7@'$R6-_V?K6G88=5A2&:OR1AD>
MY**HK_Q;DX>6PB1X1B%J%"+O=VW(>_F66SZ[T&K-M),&FKOQH7IM."<*5Y1;
MJ_%60,_.KE6>"XLL6\-XD;)$%584*RH208:=WO&%)//ZHF]ARVGTDP;WJL:-
MGL&-V2<@98;]5*24[NKWX>/&T>C1T:OH*."\U#T6A%T6!5%\!"_>!!Y[O/@'
M [_>"?RM,(E4IM+$?I\OC-5@SQ^'LE ;&1PVXCKJW)0\H<L.6L:0OJ?.[-6+
M<!2\.1+"8!/"X!CZ[!8=FE:2F%JRCP1J=A&%L8?</ ITV,V[C,"&O%2%SQ%L
M2&<#:\:R-2$SW+"EDFAK<\[N,DVT4W.&B@G)FHHU3Y%_BM@O)6GN\MT&/8%P
M,)KZ:QB-V&VFM#VSI/.VU"E_#8P1"R<Q>R<*CH+MP)RS>0X]\1?W;0^_EUZ*
M&AEN#"&>*!ZR*?M0 )Z "LGZM11\(:2PC@5A/&8ANU.6RWT_1X.QO\;AU'OT
MH4ADE4+GGFOAFJ:MX/AEJD6](@ID%:5:9R+)&$<>!>8AW!!<]MAM59:2'"UA
M,^$F8TLD&$KU_/6##&B%*L[\6S_5A'W @)0 29E53.TFU_SG:ET[2R47*1 T
MX[FJ'"-$'7**&Y;#$)K%^;UE2BN5YZV*;Z*"0UKE3]WU]0\"?XV&@R.JR]WZ
M.]6IUVLQX[ .;35B7\F8^0WI3"W/JBU+U,)B8ZMCI&])QC$A?!+J"-5"BI6O
MRDZ$3U["0!0-\?_JQ20*HS=/B+LK.^V&@[ E?616##>S8OC#LV)>Q^9X]'%;
MHBYF"%[0H?'Q'>PV9Q=<^O36GQ3.AK(9Z1T&_R.N[A+S+264+X 7A\^,DJ9R
MKBE1UA$F2ES?C$"-?>$61<^PW6KM"'RZ<*IQ=P+NN>MP^-3*CB*ZL:T;QMW!
M<,C"03?&I1X?ZGE]Y]VX&P?3^F8:C-F-=O+VH<M*9+-.(WVM1.D;# :1VM-=
M(K_VO EBYW(831J&T0%SVT!/V"!T5N'E,?%6>,AB$+'QJ(EJK__VHAIW@RCT
MO16R+_[S"#7G]T@$F@C# IVU5?5C_O2!N$8HFPXS^XDW;- ;X;<7(&9UT M8
MU!L\M91B+W<3BP&'O@O]TH._W(>? /TEBWLQ_AVUGF&==6EQJR>C<,*XM5HL
M*NOW Y#]FF-?>D](W!H,UY1(J(FEJ%M!JF)5[W8-V+ZZ#\1]I510: CE!L9:
MV SS"6UVH#V@8904J6^XG>8T/?:9EI %],\*J8E[;)Z 94;4N(YU*;Z9C146
MP[U>\)+AH.<_D0YYXQ*\K+1O^I0P/J4+=<5UZO+BG$QIZU2S16\RT_,==*S;
M'JFX374(/OI!<T2KQ6&8.QD,HGK2[!1!%$C%HUB;RS]:">?%MHS_ J$+ATQ)
M_J@BT?[_J](>VL;ZK:-+3GKE#VB&^8:M3S&;U<T9<%X??;;B]0'R$]<K 2\E
M+:$:],;8M71]**L?K"K]06BA+(Y5_C;#.9:T$\#[I4("F@=G8',RGOT-4$L#
M!!0    ( )6)L%;4WBG6*@,  -,&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;(5576_;.@S]*X0W#!M@Q)])["X)T&8;MH<!19-M#\,>%)NQ?2=+
MOI+<K/_^4K*;IA=I]F*)$GEX2)'TXB#5;UTC&OC3<J&77FU,=Q4$NJBQ97HB
M.Q1TLY>J989$506Z4\A*9]3R( [#6="R1GBKA3N[5:N%[ UO!-XJT'W;,O5P
M@UP>EE[D/1[<-55M[$&P6G2LP@V:;]VM(BDXHI1-BT(W4H#"_=*[CJYN4JOO
M%+XW>- G>["1[*3\;84OY=(++2'D6!B+P&BYQS5R;H&(QK\CIG=T:0U/]X_H
MGUSL%,N.:5Q+_J,I3;WT,@]*W+.>FSMY^(QC/%.+5TBNW1<.@VXZ]Z#HM9'M
M:$P,VD8,*_LSYN'$( M?,(A'@]CQ'APYEA^88:N%D@=05IO0[,:%ZJR)7"/L
MHVR,HMN&[,SJ#N]1]$CY+60E&I>IMUNVXZC?+0)#'JQ>4(QH-P-:_ ): E^E
M,+6&CZ+$\KE]0,R.].)'>C?Q1<#K3DT@C'R(PSBY@)<<PTT<7O*7</=*MK F
MKHK*@E)N:EB[9*."G]<[[<Y_G4O @)^>Q[<M=*4[5N#2HQ[1J.[16[UY%<W"
M]Q?8IT?VZ27TU89:LNPY@MS#AT:SJE)8,?=F=#+&=H[T1=CSI+<U94ER:MI&
M5&!L18"[%4:#H<NU;#LF'MZ\RN)H_EZ#H FB&=4-E$_4L(3= ]7K/U*1M2S[
M@JS??D=EFH+Q=R[SC0!D10T:*^IV TR/CO45;&N%^*RH@$JBX3"6Q"C%3HKA
MVV0S@5L:1;"E"65:1_8UI*&?YU.[F?O9/*5,T5,K9N<!>4#%NH9H)[&?9AG$
MF9^G,]CTJK(<82-Y;U-,"J&?$DP\]^-9!%MIZ-9Y? H]"A,_GV>TIGZ81?!%
M&%3"/1$I_Y_9U$^2"%(_FN<O<)KZLRBE;TK?,XS(-)E!0DJSD<]SAR?$IHY/
ME/AQF(^Z3[>O(8IR/YSF;D?QY2&<J]?@9-!0JU1NG&HH9"_,,'..I\>)?3T,
MJB?U8=Q_910-A<!Q3Z;A9#[U0 TC=!",[-S8VDE#?>FV-?UU4%D%NM]+:1X%
MZ^#X'UO]!U!+ P04    " "5B;!6;0NS1WP#   P!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6R-56UOVS80_BL'=2AL0+#>;,E.;0-VDJ$!6C2(
MT^W#L ^T=+:X2J1*4G6Z7[\C):O)EAK[(AV/=P^?YT@>ER>ION@2T<!370F]
M\DICFJL@T'F)-=,3V:"@F8-4-3,T5,= -PI9X9+J*HC#, UJQH6W7CK?O5HO
M96LJ+O!>@6[KFJGO6ZSD:>5%WMGQP(^EL8Y@O6S8$7=H/C?WBD;!@%+P&H7F
M4H#"P\K;1%?;J8UW ;]Q/.EG-E@E>RF_V,%=L?)"2P@KS(U%8/3[AM=851:(
M:'SM,;UA29OXW#ZC_^JTDY8]TW@MJ]]Y8<J5-_>@P -K*_,@3^^QUS.S>+FL
MM/O"J8\-/<A;;63=)Q.#FHONSY[Z.OR?A+A/B!WO;B''\H89MEXJ>0)EHPG-
M&DZJRR9R7-A-V1E%LYSRS'J'1RJQT3!Z9/L*]7@9&(*UDT'>0VP[B/@G$ E\
ME,*4&FY%@<7+_(#H#)SB,Z=M?!%PTZ@)A)$/<1@G%_"206/B\)++&N$!&ZD,
M%T?X8[/71M&)^/,UN1W:]'4T>TNN=,-R7'ET#32J;^BMW[Z)TO#=!:[3@>OT
M$OIZ1[>N:"L$>2"^N10YKSAS!Y@\GQI4S"FX5_+ #8P^2*W'<%"RAF$KC81K
M*;2L>,',OW>DDWB9Q&.)<) 575B[E+$' YQ6BZ[[:K+B+SJ>6,#M]N[Q9D,W
MM&-+'B)0$2_8(W4-!"YR62/A/*&^@L=2(;XX,D ;SBOH-[P?Q6X4GU7]9[G/
MD]T$?H%HZF=13,;4GR<+N!,&E7#U8A8C)E_L)TG2S:"FDN$3=32-XYZ7#X)Z
MWVCAIXOIF$C,9B'<(,G-^[HS40"K[<GYNW.,HM2?9LF8C)B,Q1@V^=>6:SZ$
M*ZQLY2&7VEZMR(^R&85G_B*;CVE?Z?"UN6F5+:^-UVV>HW:-+B^9.B(E)5%&
M*;.,OK>$;KX36FV9GTGX\VE*$21\3A2N&1%\CZ2ZH#:G#2=X=. %[@VH%VN.
M9E23< QOW\SC*'X'=W7#N')UIE/&M$9+.YO[:33[$?7)E*B &ZPM/3]-K29;
M7:+QX2?[33LSBL+0CU(JKK47_BS)QJ_=E.!9%ZN1BF![M2;5K3!=0QN\PW.P
MZ;K@C_#N+?E(->1"0X4'2@TGV<P#U?7G;F!DXWKB7AKJL,XLZ4E#90-H_B"E
M.0_L L,CN?X'4$L#!!0    ( )6)L%:5QC'@YP4  -T.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;)57;6_;-A#^*X0;%#&@QGJS+*6)@23=V@+K
M&C3=^F'8!UHZVUPI426I..FOWQTE*W)F>^V7Q#K>/??"YX[DQ4;IKV8-8-E#
M*2MS.5I;6Y]/)B9?0\G-F:JAPI6ETB6W^*E7$U-KX(4S*N4D]/UD4G)1C>87
M3G:KYQ>JL5)4<*N9:<J2Z\=KD&IS.0I&6\$GL5I;$DSF%S5?P1W8/^I;C5^3
M'J40)51&J(II6%Z.KH+SZYCTG<*? C9F\)M1)@NEOM+'^^)RY%- ("&WA,#Q
MWSW<@)0$A&%\ZS!'O4LR'/[>HO_J<L=<%MS C9)?1&'7EZ-TQ I8\D;:3VKS
M#KI\IH27*VG<7[9I=:?3$<L;8U79&6,$I:C:__RAJ\/ (/4/&(2=0>CB;AVY
M*-]PR^<76FV8)FU$HQ\N56>-P8F*-N7.:EP5:&?G;X3)565%U4#!<*LUIV(9
M=OJ9+R28\<7$HA?2G>0=XG6+&!Y C-@'!%P;]DM50+%K/\'H^A##;8C7X5'
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MG+:B5MK2$*H<7;!%C9*BX"3#CP(/ ORUZ*CN)IXS1-0WN(WE C05F(@1DIQ
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M971S+W-H965T-# N>&ULM93;CM,P$(9?Q0H2VI6@.;1=5B6)U'9!K+0+55?
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M(]P6Y4E+\Y68.)TO,,6\ .3_ ,)]F>U]O45+P1K!@6N%1(7F12'VUEY# >2
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MXLO] KU]\PZ],4CT>2TVBO!"37UME%E^/V]57#4JPA=4O*_D!0KP&0J#,'+
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M")3?+NTI%90SL/_/I1W\\L&=@ZIS[_A?4$L#!!0    ( )6)L%;A9(R]0PX
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M"Y?Y WNOOKSXW<,-%>LHE2AF*PCUSX=P(T7Q4X+B0/%M_G#]GBO%D_SMAE$
MK"^ SU><J\<#G:#Z0<?L?U!+ P04    " "5B;!6VS]IA-D$   N&@  &0
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M'[P&,H4%MK?9IJ61\Y59:E>*V^]_K>T/$-RI!'<:4WRC(<VQ55BZ]5Z;P5%
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M^D10W6[TH0V$"=#O4\[52\,<"YICX.)?4$L#!!0    ( )6)L%;EE#_QC D
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M&1P.\7)5/7'7&R-+-[0NI,$1V"US?$L!90/P^5)*<[>Q!=KWGN074$L#!!0
M   ( )6)L%9>N0@=  <  &@W   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;,6;76_;-A2&_PKA%4,+)+%%R5^98R"Q.JS 4@3-TEX,NZ MVA8JB2Y)
M.\FP'S_J(Z(IR;1=',,7;2R9YR7Y2H?F(Y&C9\:_BR6E$KW$42)N6DLI5]?M
MMI@M:4S$%5O11'TS9SPF4AWR15NL."5!%A1';=SI]-HQ"9/6>)2=>^#C$5O+
M*$SH T=B'<>$O][1B#W?M)S6VXDOX6(ITQ/M\6A%%O21RJ?5 U='[5(E"&.:
MB) EB-/Y3>O6N?8]G 9D);Z&]%EL?49I5Z:,?4\//@4WK4[:(AK1F4PEB/JS
MH1,:1:F2:L>/0K15UID&;G]^4_\]Z[SJS)0(.F'1MS"0RYO6H(4".B?K2'YA
MSW_0HD/=5&_&(I']CYZ+LIT6FJV%9'$1K%H0ATG^E[P41FP%X.Z. %P$X$J
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MB>=]F(3Q.FYT#!1\0-5\*#73/ T^&)]Y(,6@4 2JYD.IF>9K>,)V>/I*A<Q
M,\O]1O/L DZ6ZXT^@;(1E)KIDV8C;'\3\I;AY&5GAH.R#:B:#Z5FFJ?9!G?/
MG>&0*#,!5?.AU$SS-1AA.Q@=D.%V 2__-6\T"I2!H-1,HS0#83L#/69/WBQO
M]NSQ1]]DH# $I69ZIV$(GQN&,"@,@:KY4&JF^1J&L!V&3C"_MU?H%O/[83&_
M1TX'!>2U>8@ )2DH-7,5BB8IUPXV'U]6(<]]WCV<[M%07NT<3^VA1Z\<.044
MN1J*7#L4?<O6GM'@DFPH)PN*YB3D:$.B-<T>TVT/MVBAA@E9/)T[[$U'4;OY
M-J'R"G9B;^+1AIX"E%P-2J[]#9'Q V7'3;O2T>N90(D'2LUT<6LIV=G7DL$N
M)H-=378*C'(U1KEVC-H_&=TC@"V#)R@R0:F91FED<NVO@VJYOAL\[4I'WVZ@
M[ .E9KJHV<?MG3O70=>X@:KY4&JF^9JG7#M/'9#K=@$+>-HCCS;J%/#D:GAR
M]RQ,BU<1>Z4494G?:!0H_("J^5!JIGD:?MSAN5,<DF FH&H^E)JY.ESSD&=G
M&:B7[D4UYIJ%@3.HK4"TM^=8]Z#43/<T('EV0#IP06JALOW&TL'5!:E-A;J#
MZIKZ4_"+I_G%L_-+[6X)A5@?<'/@^HH,C#O]VKZ">CEO,!RZ51- \:.]M04I
MIGR1;>42ZIJN$YGOUBG/EMO%;K--4I7S=\[U)-_TI67R/6CWA"]"-0F,Z%Q)
M=J[ZJH<\W]:5'TBVRC8Z39F4+,X^+BD)*$\+J._GC,FW@[2"<G/=^']02P,$
M%     @ E8FP5HA2+)Q1 P  Z0H  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3DN>&ULM9;;CM,P$(9?Q0H(@42;4X]+&VG+^0*TVK)P[4VFC;6.'6RG!8F'
M9^RT::%IM%3BIK$3S^]OQI[IS+92/>@<P) ?!1=Z[N7&E%>^K],<"JK[L@2!
M7U92%=3@5*U]72J@F3,JN!\%P<@O*!->,G/O;E0RDY7A3,"-(KHJ"JI^+H#+
M[=P+O?V+6[;.C7WA)[.2KF$)YJZ\43CS&Y6,%2 TDX(H6,V]Z_!J$0ZL@5OQ
ME<%6'XV)=>5>R@<[^9C-O< 2 8?46 F*CPV\!LZM$G)\WXEZS9[6\'B\5W_G
MG$=G[JF&UY)_8YG)Y][$(QFL:,7-K=Q^@)U#0ZN72J[=+]GNU@8>22MM9+$S
M1H*"B?I)?^P"<6001V<,HIU!Y+CKC1SE&VIH,E-R2Y1=C6IVX%QUU@C'A#V5
MI5'XE:&=2=Y^KYCYV;..9225!9ZVIBY>/;+$*Y!5'(A<D<]2;$ ;7'2+#\52
M.UP:F3Z0.\&,)M<VO"A%GK\!0QG7+U#A=GFGB<ZI DV8(%]R66DJ,CWS#;);
M C_=<2YJSN@,9TP^26%R3=Z*#+(_[7WTN7$\VCN^B#H%KTO5)T'XDD1!%).G
MQ-]SUH^.'>(FM+';(3ZSP^>JN =E@U?9"+7Y7 L,V@5L0E[IDJ8P]S#C-*@-
M>,FS)^$H>-6!-VCP!EWJR0+63 @FUGBK.14ID.=X1+7W+\BOUCC4U+7NT.G:
MK-\D83B9SOQ-"\VPH1EVTKQ75-@K]5B&X0E#?(9@U!",.@F^UM?[L0"C$X!>
M%,7M".,&8=R)@'5F!0PI_-0>"/\'G/$I3A@$[3B3!F?2B8.I=LGUF)R@3(-A
M.\FT(9EVIM(W5UPAZ]$-*/RS(&M[77H9-4!6E"FRH;P"4F*ZV5QKHYK^AU0+
M@T.5#2Y(MDQR3I5VW"Z>-K"'4M1:)>M]QG\D7W\Z:H]O>/0W$#XZ_R[!JM4G
M1UA1?SPY0Q4=J*+'YN0E4-$)5(A4XS-4A[H>=M;E<VEZ"6'<1C@Z=YJ'TAYV
MU_:6S+V$;M!VUZ*_ZZQ_U'T4H-:NQ]+83%3"U(U(\[;IXZ[K[N6PO&X"/U&%
M>:()AQ6:!OTQ5A%5]U7UQ,C2]3+WTF!GY(8Y]J*@[ +\OI+2["=V@Z:[37X#
M4$L#!!0    ( )6)L%:X\3S@Z0(  $\(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;,56VXK;,!#]%>%"V87=^+:Y;1-#]E*ZT*5A0[</I0^*/8Y%
M),N5Y%S^OI+LN"XX9BF4OL2ZS#ES9B3-9+;G8BLS (4.C.9R[F1*%;>N*^,,
M&)8#7D"N=U(N&%9Z*C:N+ 3@Q((8=0//&[D,D]R)9G9M*:(9+Q4E.2P%DB5C
M6!SO@/+]W/&=T\(+V63*++C1K, ;6('Z6BR%GKD-2T(8Y)+P' E(Y\["O[V;
M&GMK\$I@+UMC9")9<[XUDZ=D[GA&$%"(E6' ^K.#>Z#4$&D9/VM.IW%I@.WQ
MB?VCC5W'LL82[CG]1A*5S9V)@Q)(<4G5"]]_@CJ>H>&+.97V%^UK6\]!<2D5
M9S58*V DK[[X4.>A!?#'9P!!#0BL[LJ15?F %8YF@N^1,-::S0QLJ!:MQ9'<
M',I*";U+-$Y%CS]+HH[7)K $Q9SIPY;8YNL:K?0-2$H*B*=HE6$!M=D2'_6Q
M*+388Y%<H97B\19]*0Q*7J%73,N*82'U45?+Z.(!%"947AI>"^#5SLQ5.@PC
MQHUKR7>5Y.",Y! ]\UQE$CWF"21_XET=?I.#X)2#NZ"7<%&( ?+\*Q1X0=C#
M%S8Y#2U?>(:OG:O[=DH70N!\ S9YZ^/YG*+OGS4E>E+ Y(^N!%7^;[K]FW=\
M*PL<P]S1#U6"V($3O7_GC[P//='=--'=]+%'+T1NKU,!@$BN0/,K)+""+ID5
MD>]9)E,>=I$W\,+IS-UU"!@V H:] AX/A7[2.F<)V9$$\@0="="D2T!%Y/MM
M =W.1XWST=N<2WN)"T%B0#M.]0%3_9"Z1(RZLA .@VXAXT;(N%?(,SX05K(N
MA[W O[P=DT;6Y#_?_<D_B&[:1#=]V^E3DMJR*-NE#%T< 0MYV:6ZGW>$+!*%
MB-G2UB75;15Y!F)C6YG4-;O,557OF]6F6RZJ)O';O&JUSUALB-9+(=50;S#6
M[T14[:N:*%[8EK'F2C<@.\QTQP=A#/1^RKDZ38R#YC]$] M02P,$%     @
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M71C3_R'7B-?47^^,;(MU@:5"0JXK11E $\FF&G46S,K.I!5.0@;!N#N>I'5
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MO.JOJXEDA6E1[YA4#:\9INJ;!+@.4/=7C,G'B7Y \Y43_0902P,$%     @
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M;9<1P/6%$/KYQ-R@VG::_PM02P,$%     @ E8FP5G'F+91/ P  @0X  !D
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M:]4C M<!ZOV2,?DXT O47>?D'U!+ P04    " "5B;!6#6EF!H(&   +.@
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M1^I(N<NK*D\W-Y<BFHNB>4#]^_L\KYY_: 9XS(OOF\6^^0]02P,$%     @
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MGF27*THB*K0!O%]PKG8W^B2O/+F=_@=02P,$%     @ E8FP5LK*& 6!!
MS1H  !D   !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULM5E;CZ,V&/TK%EU5
MNU(;L"%<IDFDF4RKCK0KC28[[4/5!T_B)&@!I[9)ME)__)I+(!#')5KG)0'S
M?8?O<C '>W*@[ O?$B+ US3)^-3:"K&[LVV^W)(4\Q'=D4Q>65.68B%/V<;F
M.T;PJG1*$QLYCF^G.,ZLV:0<>V:S"<U%$F?DF0&>IREF_SZ0A!ZF%K2. R_Q
M9BN* 7LVV>$-61#QNGMF\LQN4%9Q2C(>TPPPLIY:]_!NCL+"H;3X(R8'?G(,
MBE3>*/U2G#RMII931$02LA0%!)9_>S(G25(@R3C^J4&MYIZ%X^GQ$?VW,GF9
MS!OF9$Z3/^.5V$ZMT (KLL9Y(E[HX7=2)S0N\)8TX>4O.-2VC@66.1<TK9UE
M!&F<5?_X:UV($P>)HW9 M0/J.W@7'-S:P2T3K2(KTWK$ L\FC!X *ZPE6G%0
MUJ;TEMG$6='&A6#R:BS]Q.R%[$F6$]F1)=UD<5G:G\%"LF65)P30-7B,.=YL
M&-G@\J(<.?J\?R0"QPG_(#U>%X_@_;L/X!V(,_!Y2W..LQ6?V$+&6-S)7M;Q
M/%3QH OQN. 3S<26@U^S%5EU_6V96Y,@.B;X@+2 ]SLV @[\"2 'N8IXYD/<
M4>F.-.&X3;W=$L^]@'>YFG]]E*;@29"4_ZVJ6X7KJ7&+I_V.[_"23"WY.'/"
M]L2:_?@#])U?5$D; NN4P&M*X.G09Y^IP G(Y!3%<4*4'*D _!*@F(CV,P@C
M9QQ-[/UI%BJS $5.8]:);]S$-];&]SI:C%1!:;VN;8 AL$Z"?I.@?R,.^B9+
M8 BL4X*@*4'PO1RL ,:GY'+<* A['%29>4X(U1P,F_C"_^4@^ \\XV(VE:]G
M(=^<0AFF%N?:EA@"ZZ0<-2E'-V)E9+($AL Z)8!.^S9VOI>7-<(IXSPGBL8]
M7JK,@C#PU+R$)WH!#F'F"Y'2A.%"@\G7/6%X%U\(5PMW;7=,H7631VWRZ$8<
MK8%-E<$06K<,K8:!6GTPB*7N&?U<Y(7]V5-AAL+(\R^PM)484*\Q:I8N<K:)
MES+6!4WRHF7J6+585_?&$%HW\U:\P/&M*&I4X)A"ZY:AE3A0*Q\&4=0_IZCC
MG4^DYV8H0/Z%%SQL%0C42Y"G3!"6E5W"B3(^K?_5_3"$ULVVU3,PO!4MC2H<
M4VC=,K0:!VKUPR!:1N>*<GPJ*.M$%&8N<B(U+5&K0)!>@71H.4R"ZA&O[9 I
MM&[^K;Y!\$9$14:5CBFT;AE:I8.T$F((46N$4P:.7;?/4X65!X-+-&TE"-)+
MD#Y-!^M1/>[57;K%0@IJ90[R;D56HYK'%%JW#*WF0?H5FR%D'9^3U8=>GZP*
M*P]>^&9"K1A!>C'2)^LP6:H'O;I%MUAN0:W:0<&MF&I4!IE"ZY:AE4%(OZXS
MA*GAV:JF!UV_S]1S*]>'_>\F^V1C("5L4^Z7<+"D>2:J)?1FM-F3N2]W(GKC
M#_!N7NVLM##51L\G++F<<9"0M81T1H%\>%BU=U*="+HKMQ_>J! T+0^W!*\(
M*PSD]36EXGA2W*#9P9I] U!+ P04    " "5B;!6-S <K-L$   1%@  &0
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M:W-H965T<R]S:&5E=#<S+GAM;(U7VV[C-A#]%4)=%+M $HFTK4MJ&TAL=#=
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MDVS<DHV=$WO+5'Y$U0$4["&SUT<?V_C9^@QZ%LCI:$^,TQ;CU(EQB:B![C'
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ML*<DBI+$CP#F=Q!%& )/(XY@#L #AD11\Q[<>Q^%Z_=4N/D?WN014$L#!!0
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MAAT2J2<G5@_&].?T JFG(%;/T#* -PWYF$@]!;5Z?JT$#(R: MFF(+;-L:6
MMU%Z@6Q3$-L&8@:CID"V*:A7? [WCPPW.#)-T9EFW-UL+B\JOA225U]<\<:=
M+UE=WNNH_=/O4$RS=G_1<EO75^[<5_FW8M7^]P+[WSI<_@=02P,$%     @
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MA2)KA2)KA2)KA2)KA2)K]96RWCFW_\_QT[/L;3N\Y+/IG[7K/U!+ 0(4 Q0
M   ( )6)L%8'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ E8FP5F+;)BGN    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( )6)L%:NZ0;"@ (  .,%   8
M  " @3T6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "5
MB;!6N_\H<5P'  "I(P  &               @('S&   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ E8FP5GQ"*DXT P  A T  !@
M         ("!A2   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( )6)L%95&4&W_0<  "Q!   8              " @>\C  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "5B;!6M60?WC$(  !/)0
M&               @($B+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ E8FP5D2)*=J7$   OBT  !@              ("!B30  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )6)L%:W0-M3Q@P
M +XH   8              " @59%  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "5B;!6/[M\J+81  "@,P  &0              @(%2
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )6)L%8!
MG504X0D  $(:   9              " @3]D  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ E8FP5D01L\3I!P  2!8  !D
M     ("!5VX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )6)L%9?P,S>.08  &D/   9              "
M@;N2  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ E8FP
M5IY%P.42&P  \5$  !D              ("!*YD  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "5B;!6D:JR6K #   '"   &0
M        @(%TM   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( )6)L%9^J%AI>@0  +()   9              " @5NX  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ E8FP5C$\9O80!@  G@X
M !D              ("!#+T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "5B;!6$Z&40;0#   N"   &0              @(%3PP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )6)L%;@403\
M6P8  '(/   9              " @3['  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ E8FP5N_YF/!D!0  80T  !D
M ("!T,T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "5
MB;!6<I%>=@X(  !3'   &0              @(%KTP  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )6)L%9T[[9[\P@  /,8   9
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M970S,"YX;6Q02P$"% ,4    " "5B;!6TQ.M5[D$  !+#   &0
M    @($9]   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M )6)L%8,#L5"[P(  %$&   9              " @0GY  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ E8FP5D,OL'QV!0  )0\  !D
M             ("!+_P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "5B;!6U-XIUBH#  #3!@  &0              @('< 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( )6)L%9M"[-'? ,
M # '   9              " @3T% 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ E8FP5I7&,>#G!0  W0X  !D              ("!
M\ @! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "5B;!6
M[7]"(@\"  "D!   &0              @($.#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( )6)L%;#SI>QRP8  !LV   9
M      " @501 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ E8FP5C-59>%; P  60T  !D              ("!5A@! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "5B;!6P(A1,5@"  "/!0
M&0              @('H&P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( )6)L%;;XE7A' ,  !D)   9              " @7<> 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ E8FP5JCE4S=G
M P  )0T  !D              ("!RB$! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "5B;!6 #5X^_D"  "I"0  &0
M@(%H)0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( )6)
ML%:YPBL2UP4  !PC   9              " @9@H 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ E8FP5ML^H&2$ @  E08  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "5B;!6W'W
MMF4$  "W%P  &0              @(&C1P$ >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( )6)L%:V@#@,1P4  -PA   9
M  " @3], 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
ME8FP5ML_:839!   +AH  !D              ("!O5$! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "5B;!6+?R&*>T"  !I"0  &0
M            @('-5@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( )6)L%;,>5'0D0,  !(.   9              " @?%9 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ E8FP5N64/_&,"0
MJ',  !D              ("!N5T! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "5B;!63DE-:6X%   B+   &0              @(%\
M9P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( )6)L%:R
M6#CQC0(  "('   9              " @2%M 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ E8FP5JHX$E=+ P   PT  !D
M     ("!Y6\! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )6)L%;!+0L\ P8  *4I   9              "
M@62% 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ E8FP
M5D")RLM4 P  \0P  !D              ("!GHL! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " "5B;!6DM[O<'8$  ""$@  &0
M        @($ICP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( )6)L%9QYBV43P,  ($.   9              " @=:3 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ E8FP5@UI9@:"!@  "SH
M !D              ("!7)<! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " "5B;!6KW\[*9 "  "\!P  &0              @($5G@$
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( )6)L%:>!W/P
M<0L  *>?   9              " @=R@ 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ E8FP5M0+NMF- P  X L  !D
M ("!A*P! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "5
MB;!6GP%5P? $  #%%0  &0              @(%(L $ >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( )6)L%;*RA@%@00  ,T:   9
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M970W-2YX;6Q02P$"% ,4    " "5B;!6?EW;'S<#  #0$P  #0
M    @ $AS $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )6)L%:7BKL<P
M !,"   +              "  8// 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M )6)L%9,Z?1A.@4  &\Q   /              "  6S0 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "5B;!69_Q20DP"  !H+   &@
M@ '3U0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "5
MB;!6AJ9C2 P"  !A*P  $P              @ %7V $ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     4P!3 +P6  "4V@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>259</ContextCount>
  <ElementCount>421</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets</Role>
      <ShortName>Consolidated Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Condensed Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Condensed Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated condensed statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows</Role>
      <ShortName>Consolidated condensed statements of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Balance sheet information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Balancesheetinformation</Role>
      <ShortName>Balance sheet information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions and divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Acquisitionsanddivestitures</Role>
      <ShortName>Acquisitions and divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Financialinstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Equity-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Equitybasedcompensation</Role>
      <ShortName>Equity-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stockholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Restructuring costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Restructuringcosts</Role>
      <ShortName>Restructuring costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Discontinued operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Discontinuedoperations</Role>
      <ShortName>Discontinued operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Organization (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/OrganizationPolicies</Role>
      <ShortName>Organization (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/OrganizationTables</Role>
      <ShortName>Organization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Organization</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Balance sheet information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationTables</Role>
      <ShortName>Balance sheet information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Balancesheetinformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Acquisitions and divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/AcquisitionsanddivestituresTables</Role>
      <ShortName>Acquisitions and divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Acquisitionsanddivestitures</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FinancialinstrumentsTables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Financialinstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Fairvaluemeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Equity-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EquitybasedcompensationTables</Role>
      <ShortName>Equity-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Equitybasedcompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Stockholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Stockholdersequity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Earningspershare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Restructuring costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/RestructuringcostsTables</Role>
      <ShortName>Restructuring costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Restructuringcosts</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/CommitmentsandcontingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Commitmentsandcontingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/RevenuerecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Revenuerecognition</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Segments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Discontinued operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/DiscontinuedoperationsTables</Role>
      <ShortName>Discontinued operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Discontinuedoperations</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Organization - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Organization - Error Corrections (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails</Role>
      <ShortName>Organization - Error Corrections (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Balance sheet information - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails</Role>
      <ShortName>Balance sheet information - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Balance sheet information - Components of Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails</Role>
      <ShortName>Balance sheet information - Components of Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Balance sheet information - Schedule of Accounts Receivable, Allowance for Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails</Role>
      <ShortName>Balance sheet information - Schedule of Accounts Receivable, Allowance for Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Balance sheet information - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails</Role>
      <ShortName>Balance sheet information - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Balance sheet information - Schedule of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance sheet information - Schedule of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Balance sheet information - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails</Role>
      <ShortName>Balance sheet information - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Balance sheet information - Intangibles (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails</Role>
      <ShortName>Balance sheet information - Intangibles (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Balance sheet information - Goodwill Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails</Role>
      <ShortName>Balance sheet information - Goodwill Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Balance sheet information - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Balance sheet information - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Acquisitions and divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Acquisitions and divestitures - Held for Sale Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails</Role>
      <ShortName>Acquisitions and divestitures - Held for Sale Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails</Role>
      <ShortName>Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Acquisitions and divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions and divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Acquisitions and divestitures - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails</Role>
      <ShortName>Acquisitions and divestitures - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Financial instruments - Schedule Of Long-Term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails</Role>
      <ShortName>Financial instruments - Schedule Of Long-Term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Financial instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails</Role>
      <ShortName>Financial instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails</Role>
      <ShortName>Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Fair value measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Equity-based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails</Role>
      <ShortName>Equity-based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Equity-based compensation - Schedule of Stock Options Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails</Role>
      <ShortName>Equity-based compensation - Schedule of Stock Options Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stockholders??? equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/StockholdersequityNarrativeDetails</Role>
      <ShortName>Stockholders??? equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Stockholders??? equity - Schedule of Other Ownership Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails</Role>
      <ShortName>Stockholders??? equity - Schedule of Other Ownership Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Earnings per share - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails</Role>
      <ShortName>Earnings per share - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Earnings per share - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Earnings per share - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Restructuring costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/RestructuringcostsDetails</Role>
      <ShortName>Restructuring costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/RestructuringcostsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Incometaxes</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Commitments and contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails</Role>
      <ShortName>Commitments and contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Commitments and contingencies - Schedule of Lease, Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails</Role>
      <ShortName>Commitments and contingencies - Schedule of Lease, Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails</Role>
      <ShortName>Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue recognition - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/SegmentsDetails</Role>
      <ShortName>Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/SegmentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Discontinued operations - Schedule of Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails</Role>
      <ShortName>Discontinued operations - Schedule of Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Discontinued operations - Schedule of Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails</Role>
      <ShortName>Discontinued operations - Schedule of Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bvs-20230401.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioventus.com/role/SubsequenteventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioventus.com/role/Subsequentevents</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bvs-20230401.htm">bvs-20230401.htm</File>
    <File>bvs-20230401.xsd</File>
    <File>bvs-20230401_cal.xml</File>
    <File>bvs-20230401_def.xml</File>
    <File>bvs-20230401_lab.xml</File>
    <File>bvs-20230401_pre.xml</File>
    <File>exhibit101pavesioconsultin.htm</File>
    <File>exhibit103cartihealsettlem.htm</File>
    <File>exhibit311-q12023.htm</File>
    <File>exhibit312-q12023.htm</File>
    <File>exhibit32-q12023.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="846">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bvs-20230401.htm": {
   "axisCustom": 0,
   "axisStandard": 40,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 846,
    "http://xbrl.sec.gov/dei/2022": 33
   },
   "contextCount": 259,
   "dts": {
    "calculationLink": {
     "local": [
      "bvs-20230401_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bvs-20230401_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bvs-20230401.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bvs-20230401_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bvs-20230401_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bvs-20230401.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 671,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 64,
   "keyStandard": 357,
   "memberCustom": 42,
   "memberStandard": 44,
   "nsprefix": "bvs",
   "nsuri": "http://www.bioventus.com/20230401",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.bioventus.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:AcquisitionsAndInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisitions and divestitures",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.bioventus.com/role/Acquisitionsanddivestitures",
     "shortName": "Acquisitions and divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:AcquisitionsAndInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Financial instruments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.bioventus.com/role/Financialinstruments",
     "shortName": "Financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair value measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.bioventus.com/role/Fairvaluemeasurements",
     "shortName": "Fair value measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Equity-based compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.bioventus.com/role/Equitybasedcompensation",
     "shortName": "Equity-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stockholders\u2019 equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.bioventus.com/role/Stockholdersequity",
     "shortName": "Stockholders\u2019 equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.bioventus.com/role/Earningspershare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Restructuring costs",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.bioventus.com/role/Restructuringcosts",
     "shortName": "Restructuring costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.bioventus.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.bioventus.com/role/Commitmentsandcontingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Revenue recognition",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.bioventus.com/role/Revenuerecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Segments",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.bioventus.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Discontinued operations",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.bioventus.com/role/Discontinuedoperations",
     "shortName": "Discontinued operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Subsequent events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.bioventus.com/role/Subsequentevents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Organization (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.bioventus.com/role/OrganizationPolicies",
     "shortName": "Organization (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.bioventus.com/role/OrganizationTables",
     "shortName": "Organization (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Balance sheet information (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.bioventus.com/role/BalancesheetinformationTables",
     "shortName": "Balance sheet information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Acquisitions and divestitures (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresTables",
     "shortName": "Acquisitions and divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Financial instruments (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.bioventus.com/role/FinancialinstrumentsTables",
     "shortName": "Financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair value measurements (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.bioventus.com/role/FairvaluemeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Equity-based compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.bioventus.com/role/EquitybasedcompensationTables",
     "shortName": "Equity-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical",
     "shortName": "Consolidated Condensed Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Stockholders\u2019 equity (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.bioventus.com/role/StockholdersequityTables",
     "shortName": "Stockholders\u2019 equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.bioventus.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Restructuring costs (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.bioventus.com/role/RestructuringcostsTables",
     "shortName": "Restructuring costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and contingencies (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesTables",
     "shortName": "Commitments and contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Revenue recognition (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.bioventus.com/role/RevenuerecognitionTables",
     "shortName": "Revenue recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Segments (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.bioventus.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Discontinued operations (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.bioventus.com/role/DiscontinuedoperationsTables",
     "shortName": "Discontinued operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ia9c0fbba09b6496a91ab1685ca96483a_I20230401",
      "decimals": "-1",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Organization - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.bioventus.com/role/OrganizationNarrativeDetails",
     "shortName": "Organization - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ia9c0fbba09b6496a91ab1685ca96483a_I20230401",
      "decimals": "-1",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Organization - Error Corrections (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails",
     "shortName": "Organization - Error Corrections (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i5f04a78cee4c46279f51766a4be3f9e9_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Balance sheet information - Schedule of Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
     "shortName": "Balance sheet information - Schedule of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
     "shortName": "Consolidated Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i7ebfe75a99584627ab0c086aca856452_D20230101-20230401",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Balance sheet information - Components of Accounts Receivable (Narrative) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails",
     "shortName": "Balance sheet information - Components of Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i7ebfe75a99584627ab0c086aca856452_D20230101-20230401",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i98f850194f2743b69d130043cb5b83f5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Balance sheet information - Schedule of Accounts Receivable, Allowance for Credit Loss (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails",
     "shortName": "Balance sheet information - Schedule of Accounts Receivable, Allowance for Credit Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Balance sheet information - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
     "shortName": "Balance sheet information - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Balance sheet information - Schedule of Prepaid and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
     "shortName": "Balance sheet information - Schedule of Prepaid and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Balance sheet information - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
     "shortName": "Balance sheet information - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Balance sheet information - Intangibles (Narrative) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails",
     "shortName": "Balance sheet information - Intangibles (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Balance sheet information - Goodwill Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
     "shortName": "Balance sheet information - Goodwill Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bvs:GrossToNetDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Balance sheet information - Schedule of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
     "shortName": "Balance sheet information - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bvs:GrossToNetDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Acquisitions and divestitures - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
     "shortName": "Acquisitions and divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ib6a06c7e9385495f98dce248522deff1_D20230227-20230227",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Acquisitions and divestitures - Held for Sale Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
     "shortName": "Acquisitions and divestitures - Held for Sale Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i8c00fe1120844212b2fb0039b542d999_I20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
     "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i38e424db57644fffa0b3eb6330265e74_D20220712-20220712",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
     "shortName": "Acquisitions and divestitures - Schedule of Business Acquisitions, by Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i4dafe4682a984e7cb23b5b32626f258b_D20220703-20221001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Acquisitions and divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions and divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i31e1cf80d63a46cf9190fbadb93ff5dc_I20220712",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Acquisitions and divestitures - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
     "shortName": "Acquisitions and divestitures - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i61effdba045e47f7bcb546d32bcd31c3_D20220712-20220712",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Financial instruments - Schedule Of Long-Term Debt Instruments (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails",
     "shortName": "Financial instruments - Schedule Of Long-Term Debt Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "iad26eeedf4bb4bbda6790671a5bdff05_I20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Financial instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
     "shortName": "Financial instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i031d0465b2ad444390d6fdd9eb9e80b5_I20230401",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivative",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair value measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i7804b256d26143329ce8b1c8bfdeb7ee_I20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i323f1175cc564a45a27343e1faec2e7a_I20230401",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
     "shortName": "Fair value measurements - Schedule of Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i323f1175cc564a45a27343e1faec2e7a_I20230401",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Fair value measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
     "shortName": "Fair value measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i7dd7797604384c719b067b4dc6cf3c42_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Equity-based compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
     "shortName": "Equity-based compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ib4fed2036ec84bff9a6d9d643492a512_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails",
     "shortName": "Equity-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ib4fed2036ec84bff9a6d9d643492a512_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i1cc622914d7b4479b2f4c07410226853_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Condensed Statements of Changes in Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
     "shortName": "Consolidated Condensed Statements of Changes in Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i1cc622914d7b4479b2f4c07410226853_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "shortName": "Equity-based compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i3474f9f5f9ed419a856ea1d414b64a1c_D20230101-20230401",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i98f850194f2743b69d130043cb5b83f5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Equity-based compensation - Schedule of Stock Options Roll Forward (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails",
     "shortName": "Equity-based compensation - Schedule of Stock Options Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i98f850194f2743b69d130043cb5b83f5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ibd867d34482345439425ee5ab5255266_I20210216",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stockholders\u2019 equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.bioventus.com/role/StockholdersequityNarrativeDetails",
     "shortName": "Stockholders\u2019 equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "ibd867d34482345439425ee5ab5255266_I20210216",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i4f28a6c8e2a44fe9b2c8149437d14601_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Stockholders\u2019 equity - Schedule of Other Ownership Interests (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails",
     "shortName": "Stockholders\u2019 equity - Schedule of Other Ownership Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i4f28a6c8e2a44fe9b2c8149437d14601_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Earnings per share - Schedule of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails",
     "shortName": "Earnings per share - Schedule of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Earnings per share - Schedule of Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "Earnings per share - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i98f850194f2743b69d130043cb5b83f5_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Restructuring costs (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.bioventus.com/role/RestructuringcostsDetails",
     "shortName": "Restructuring costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income taxes (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.bioventus.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i0195281e11e649b9b130d85d5763b801_D20210201-20210228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Commitments and contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
     "shortName": "Commitments and contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i0195281e11e649b9b130d85d5763b801_D20210201-20210228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Commitments and contingencies - Schedule of Lease, Cost (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails",
     "shortName": "Commitments and contingencies - Schedule of Lease, Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated condensed statements of cash flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows",
     "shortName": "Consolidated condensed statements of cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
     "shortName": "Commitments and contingencies - Schedule of Assets and Liabilities, Lessee (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bvs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "if08a873c6cd84f99985971869a2e69d5_I20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails",
     "shortName": "Revenue recognition - Schedule of Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i8b7e30af75d7460f92fef399bf827f6b_D20230101-20230401",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Segments (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.bioventus.com/role/SegmentsDetails",
     "shortName": "Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i221faa30c740451eb553a94e1f7b7017_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Discontinued operations - Schedule of Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
     "shortName": "Discontinued operations - Schedule of Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i221faa30c740451eb553a94e1f7b7017_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Discontinued operations - Schedule of Statement of Operations (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails",
     "shortName": "Discontinued operations - Schedule of Statement of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i852f13a0b8994a0b9c4197a33edb508f_I20230510",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Subsequent events (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.bioventus.com/role/SubsequenteventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i852f13a0b8994a0b9c4197a33edb508f_I20230510",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.bioventus.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Balance sheet information",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.bioventus.com/role/Balancesheetinformation",
     "shortName": "Balance sheet information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bvs-20230401.htm",
      "contextRef": "i52374b540ac247b597e34da4fa742209_D20230101-20230401",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 100,
   "tag": {
    "bvs_A2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Plan",
        "label": "2021 Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "A2021PlanMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Reclassification To Held For Sale",
        "label": "Accounts Receivable, Allowance for Credit Loss, Reclassification To Held For Sale",
        "terseLabel": "Reclassification to held for sale"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossReclassificationToHeldForSale",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AccruedSalariesAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Salaries And Employee Benefits, Current",
        "label": "Accrued Salaries And Employee Benefits, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "AccruedSalariesAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AcquisitionRestructuringPlanOf2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Restructuring Plan Of 2022",
        "label": "Acquisition Restructuring Plan Of 2022 [Member]",
        "terseLabel": "Acquisition Restructuring Plan Of 2022"
       }
      }
     },
     "localname": "AcquisitionRestructuringPlanOf2022Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_AcquisitionsAndInvestmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions And Investments Disclosure",
        "label": "Acquisitions And Investments Disclosure [Text Block]",
        "terseLabel": "Acquisitions and divestitures"
       }
      }
     },
     "localname": "AcquisitionsAndInvestmentsDisclosureTextBlock",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/Acquisitionsanddivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items",
        "terseLabel": "Segment adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AssetImpairmentChargesAfterTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges, After Tax",
        "label": "Asset Impairment Charges, After Tax",
        "terseLabel": "Impairment charges, after tax"
       }
      }
     },
     "localname": "AssetImpairmentChargesAfterTax",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_BVLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BV LLC",
        "label": "BV LLC [Member]",
        "terseLabel": "BV LLC"
       }
      }
     },
     "localname": "BVLLCMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BionessIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioness, Inc",
        "label": "Bioness, Inc [Member]",
        "terseLabel": "Bioness, Inc",
        "verboseLabel": "Bioness contingent consideration"
       }
      }
     },
     "localname": "BionessIncMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BioventusAndContinuingLLCOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioventus And Continuing LLC Owner",
        "label": "Bioventus And Continuing LLC Owner [Member]",
        "terseLabel": "Bioventus and Continuing LLC Owner"
       }
      }
     },
     "localname": "BioventusAndContinuingLLCOwnerMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BoardOfDirectorLengthOfTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Of Director, Length Of Term",
        "label": "Board Of Director, Length Of Term",
        "terseLabel": "Length of board of directors term"
       }
      }
     },
     "localname": "BoardOfDirectorLengthOfTerm",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_BusinessAcquisitionPercentageOfSharesTransferredToTrustee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Percentage Of Shares Transferred To Trustee",
        "label": "Business Acquisition, Percentage Of Shares Transferred To Trustee",
        "terseLabel": "Business acquisition, percentage of shares transferred to trustee"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfSharesTransferredToTrustee",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_BusinessCombinationConsiderationTransferredDeferralPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Deferral Period",
        "label": "Business Combination, Consideration Transferred, Deferral Period",
        "terseLabel": "Deferral period"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredDeferralPeriod",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_BusinessCombinationConsiderationTransferredDeferredAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Deferred Amount",
        "label": "Business Combination, Consideration Transferred, Deferred Amount",
        "terseLabel": "Deferred amount"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredDeferredAmount",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Gross, Including Transaction Costs",
        "label": "Business Combination, Consideration Transferred, Gross, Including Transaction Costs",
        "totalLabel": "Subtotal of cash at closing"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Percentage Of Members Owning Diluted Shares",
        "label": "Business Combination, Consideration Transferred, Percentage Of Members Owning Diluted Shares",
        "terseLabel": "Contingent consideration transferred percentage"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredPercentageOfMembersOwningDilutedShares",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_BusinessCombinationConsiderationTransferredTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Transaction Costs",
        "label": "Business Combination, Consideration Transferred, Transaction Costs",
        "terseLabel": "Transaction related costs"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredTransactionCosts",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationContingentConsiderationLiabilityInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Interest Rate",
        "label": "Business Combination, Contingent Consideration, Liability, Interest Rate",
        "terseLabel": "Deferred amount interest rate (in percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityInterestRate",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_BusinessCombinationContingentConsiderationLiabilityNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Number Of Tranches",
        "label": "Business Combination, Contingent Consideration, Liability, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNumberOfTranches",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "negatedTerseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investment And Other Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investment And Other Assets",
        "terseLabel": "Investment and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentAndOtherAssets",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CancellationRatioRequiredStockToLLCInterestRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation Ratio, Required Stock To LLC Interest Ratio",
        "label": "Cancellation Ratio, Required Stock To LLC Interest Ratio",
        "terseLabel": "Cancellation ratio, required stock to LLC interest ratio"
       }
      }
     },
     "localname": "CancellationRatioRequiredStockToLLCInterestRatio",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bvs_CartiHealLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CartiHeal Ltd",
        "label": "CartiHeal Ltd [Member]",
        "terseLabel": "CartiHeal Ltd"
       }
      }
     },
     "localname": "CartiHealLtdMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_CartiHealMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carti Heal",
        "label": "Carti Heal [Member]",
        "terseLabel": "Carti Heal"
       }
      }
     },
     "localname": "CartiHealMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification",
        "label": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Obtaining Product Certification",
        "terseLabel": "Collaborative arrangement, amount payable upon obtaining product certification"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAmountPayableUponObtainingProductCertification",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data",
        "label": "Collaborative Arrangement, Rights And Obligations, Amount Payable Upon Transfer Of Data",
        "terseLabel": "Collaborative arrangement, amount payable upon transfer of customer data"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAmountPayableUponTransferOfData",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold",
        "label": "Collaborative Arrangement, Rights And Obligations, Royalties, Sales Threshold",
        "terseLabel": "Collaborative arrangement, sales threshold for royalties"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesSalesThreshold",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One",
        "label": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold One",
        "terseLabel": "Collaborative arrangement, royalty percentage, threshold one"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdOne",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two",
        "label": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage, Threshold Two",
        "terseLabel": "Collaborative arrangement, royalty percentage, threshold two"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltyPercentageThresholdTwo",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Collaborative arrangement, upfront payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CollaborativeArrangementRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalty Percentage",
        "label": "Collaborative Arrangement, Royalty Percentage",
        "terseLabel": "Collaborative agreement, royalty percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyPercentage",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_CommonStockNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Number Of Votes",
        "label": "Common Stock, Number Of Votes",
        "terseLabel": "Number of votes per common share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotes",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bvs_CompensationAndEmployeeBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation And Employee Benefit Plans",
        "label": "Compensation And Employee Benefit Plans [Abstract]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansAbstract",
     "nsuri": "http://www.bioventus.com/20230401",
     "xbrltype": "stringItemType"
    },
    "bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations",
        "label": "Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interest - continuing operations"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossAttributableToNoncontrollingInterestContinuingOperations",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations",
        "label": "Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Discontinuing Operations",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interest - discontinued operations"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossAttributableToNoncontrollingInterestDiscontinuingOperations",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ContingentConsiderationLiabilityWrittenOffForDeconsolidation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Liability Written Off For Deconsolidation",
        "label": "Contingent Consideration Liability Written Off For Deconsolidation",
        "terseLabel": "Contingent consideration liability written off for deconsolidation"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityWrittenOffForDeconsolidation",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ContinuingLLCOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing LLC Owner",
        "label": "Continuing LLC Owner [Member]",
        "terseLabel": "Continuing LLC Owner"
       }
      }
     },
     "localname": "ContinuingLLCOwnerMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DebtInstrumentCovenantLiquidityMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Liquidity, Minimum",
        "label": "Debt Instrument, Covenant, Liquidity, Minimum",
        "terseLabel": "Debt instrument, covenant, liquidity, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLiquidityMinimum",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DeferredAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Amount",
        "label": "Deferred Amount [Member]",
        "terseLabel": "Deferred Amount"
       }
      }
     },
     "localname": "DeferredAmountMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredAmountPayableByJanuary12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Amount Payable By January 1 2025",
        "label": "Deferred Amount Payable By January 1 2025 [Member]",
        "terseLabel": "Deferred Amount Payable by January 1 2025"
       }
      }
     },
     "localname": "DeferredAmountPayableByJanuary12025Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredAmountPayableByJanuary12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Amount Payable By January 1 2026",
        "label": "Deferred Amount Payable By January 1 2026 [Member]",
        "terseLabel": "Deferred Amount Payable by January 1 2026"
       }
      }
     },
     "localname": "DeferredAmountPayableByJanuary12026Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredAmountPayableByJanuary12027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Amount Payable By January 1 2027",
        "label": "Deferred Amount Payable By January 1 2027 [Member]",
        "terseLabel": "Deferred Amount Payable by January 1 2027"
       }
      }
     },
     "localname": "DeferredAmountPayableByJanuary12027Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredAmountPayableByJuly12023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Amount Payable By July 1 2023",
        "label": "Deferred Amount Payable By July 1 2023 [Member]",
        "terseLabel": "Deferred Amount Payable by July 1 2023"
       }
      }
     },
     "localname": "DeferredAmountPayableByJuly12023Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredAmountPayableBySeptember12023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Amount Payable By September 1 2023",
        "label": "Deferred Amount Payable By September 1 2023 [Member]",
        "terseLabel": "Deferred Amount Payable by September 1 2023"
       }
      }
     },
     "localname": "DeferredAmountPayableBySeptember12023Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Consideration",
        "label": "Deferred Consideration [Member]",
        "terseLabel": "Deferred Consideration"
       }
      }
     },
     "localname": "DeferredConsiderationMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredTaxImpactFor2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Impact For 2022",
        "label": "Deferred Tax Impact For 2022 [Member]",
        "terseLabel": "Deferred Tax Impact For 2022"
       }
      }
     },
     "localname": "DeferredTaxImpactFor2022Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredTaxesOnEquityRebalancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Taxes on Equity Rebalancing",
        "label": "Deferred Taxes on Equity Rebalancing",
        "negatedTerseLabel": "Deferred taxes on equity rebalancing"
       }
      }
     },
     "localname": "DeferredTaxesOnEquityRebalancing",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount",
        "label": "Disposal Group, Including Discontinued Operation, Consideration Including Closing Amount",
        "terseLabel": "Closing amount"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationIncludingClosingAmount",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Current Portion of Deferred Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Current Portion of Deferred Consideration",
        "terseLabel": "Current portion of deferred consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfDeferredConsideration",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Deferred Consideration, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Consideration, Noncurrent",
        "terseLabel": "Deferred consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredConsiderationNoncurrent",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationEarnOutPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Earn-Out Payments",
        "label": "Disposal Group, Including Discontinued Operation, Earn-Out Payments",
        "terseLabel": "Earn-out payments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationEarnOutPayments",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Fees and Expenses",
        "label": "Disposal Group, Including Discontinued Operation, Fees and Expenses",
        "terseLabel": "Fees and expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationFeesAndExpenses",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 2.0,
       "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest",
        "label": "Disposal Group, Including Discontinued Operation, Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Inventory",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 1.0,
       "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Net Income (Loss)",
        "label": "Disposal Group, Including Discontinued Operation, Net Income (Loss)",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent",
        "label": "Disposal Group, Including Discontinued Operation, Net Income (Loss) to Parent",
        "totalLabel": "Net loss attributable to Bioventus Inc."
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetIncomeLossToParent",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Assets",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssets",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 1.0,
       "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)",
        "negatedTotalLabel": "Other expense (income)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupIncludingDiscontinuedOperationRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCash",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ElronMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elron",
        "label": "Elron [Member]",
        "terseLabel": "Elron"
       }
      }
     },
     "localname": "ElronMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_EquityRebalancingForIssuanceOfStockThroughEquityPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Rebalancing For Issuance Of Stock Through Equity Plans",
        "label": "Equity Rebalancing For Issuance Of Stock Through Equity Plans [Member]",
        "terseLabel": "Equity Rebalancing for Issuance of Stock Through Equity Plans"
       }
      }
     },
     "localname": "EquityRebalancingForIssuanceOfStockThroughEquityPlansMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_EquityRebalancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Rebalancing",
        "label": "Equity Rebalancing [Member]",
        "terseLabel": "Equity Rebalancing"
       }
      }
     },
     "localname": "EquityRebalancingMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ErrorCorrectionInCalculationOfDeferredTaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Correction In Calculation Of Deferred Tax Assets",
        "label": "Error Correction In Calculation Of Deferred Tax Assets [Member]",
        "terseLabel": "Error Correction in Calculation of Deferred Tax Assets"
       }
      }
     },
     "localname": "ErrorCorrectionInCalculationOfDeferredTaxAssetsMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)",
        "label": "Finite-Lived Intangible Assets, Accumulated Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedForeignCurrencyTranslationGainLoss",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)",
        "label": "Finite-Lived Intangible Assets, Net, Before Foreign Currency Translation Gain (Loss)",
        "totalLabel": "Intangible assets, net before currency translation"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_GrossToNetDeductionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross-To-Net Deductions, Current",
        "label": "Gross-To-Net Deductions, Current",
        "terseLabel": "Gross-to-net deductions"
       }
      }
     },
     "localname": "GrossToNetDeductionsCurrent",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_HAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HA Product",
        "label": "HA Product [Member]",
        "terseLabel": "HA Product"
       }
      }
     },
     "localname": "HAProductMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_HarborMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harbor",
        "label": "Harbor [Member]",
        "terseLabel": "Harbor"
       }
      }
     },
     "localname": "HarborMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Stockholders' Equity And Members' Equity",
        "label": "Increase (Decrease) In Stockholders' Equity And Members' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International",
        "label": "International [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_InternationalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Segment",
        "label": "International Segment [Member]",
        "terseLabel": "International",
        "verboseLabel": "International Segment"
       }
      }
     },
     "localname": "InternationalSegmentMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities Held-for-sale, Not Part of Disposal Group, Current",
        "label": "Liabilities Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_LimitedLiabilityCompanyInterestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited Liability Company Interests",
        "label": "Limited Liability Company Interests [Member]",
        "terseLabel": "LLC Interests"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyInterestsMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Number Of Interests Held",
        "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Number Of Interests Held",
        "terseLabel": "Number of LLC interest held (in shares)"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerNumberOfInterestsHeld",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_LitigationSettlementAmountRecoveredFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Amount Recovered From Escrow",
        "label": "Litigation Settlement, Amount Recovered From Escrow",
        "terseLabel": "Amount recovered from escrow"
       }
      }
     },
     "localname": "LitigationSettlementAmountRecoveredFromEscrow",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_LitigationSettlementExpenseOfClaimant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Expense Of Claimant",
        "label": "Litigation Settlement, Expense Of Claimant",
        "terseLabel": "Expense of claimant"
       }
      }
     },
     "localname": "LitigationSettlementExpenseOfClaimant",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Damages Sought, Amount Under Dispute, Percentage Threshold",
        "label": "Loss Contingency, Damages Sought, Amount Under Dispute, Percentage Threshold",
        "terseLabel": "Loss contingency, damages sought, percentage under dispute"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtAmountUnderDisputePercentageThreshold",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Damages Sought, Percentage Of Demanded Amount To Be Paid",
        "label": "Loss Contingency, Damages Sought, Percentage Of Demanded Amount To Be Paid",
        "terseLabel": "Loss contingency, damages sought, percentage of demanded amount to be paid"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtPercentageOfDemandedAmountToBePaid",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_NonRefundablePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Payments",
        "label": "Non Refundable Payments",
        "terseLabel": "Non-refundable payments"
       }
      }
     },
     "localname": "NonRefundablePayments",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_PainTreatmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pain Treatments",
        "label": "Pain Treatments [Member]",
        "terseLabel": "Pain Treatments"
       }
      }
     },
     "localname": "PainTreatmentsMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PaymentOfDebtRefinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Debt Refinancing Costs",
        "label": "Payment Of Debt Refinancing Costs",
        "negatedTerseLabel": "Debt refinancing costs"
       }
      }
     },
     "localname": "PaymentOfDebtRefinancingCosts",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments",
        "label": "Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments",
        "terseLabel": "Investments and acquisition of distribution rights"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForAcquisitionOfIntangibleAssetsAndInvestments",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RestorativeTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restorative Therapies",
        "label": "Restorative Therapies [Member]",
        "terseLabel": "Restorative Therapies"
       }
      }
     },
     "localname": "RestorativeTherapiesMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RestructuringPlanOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan of 2021",
        "label": "Restructuring Plan of 2021 [Member]",
        "terseLabel": "Restructuring Plan of 2021"
       }
      }
     },
     "localname": "RestructuringPlanOf2021Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RestructuringPlanOf2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan Of 2022",
        "label": "Restructuring Plan Of 2022 [Member]",
        "terseLabel": "Restructuring Plan of 2022"
       }
      }
     },
     "localname": "RestructuringPlanOf2022Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SharesIssuedOrIssuableRedemptionOfLLCInterestRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued Or Issuable, Redemption Of LLC Interest Ratio",
        "label": "Shares Issued Or Issuable, Redemption Of LLC Interest Ratio",
        "terseLabel": "Shares issued or issuable, redemption of LLC interest ratio"
       }
      }
     },
     "localname": "SharesIssuedOrIssuableRedemptionOfLLCInterestRatio",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued Or Issuable, Required Stock To LLC Interest Ratio",
        "label": "Shares Issued Or Issuable, Required Stock To LLC Interest Ratio",
        "terseLabel": "Shares issued or issuable, required stock to LLC interest ratio"
       }
      }
     },
     "localname": "SharesIssuedOrIssuableRequiredStockToLLCInterestRatio",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bvs_StopLossInsuranceThresholdPerMemberPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stop Loss Insurance, Threshold Per Member Per Year",
        "label": "Stop Loss Insurance, Threshold Per Member Per Year",
        "terseLabel": "Stop loss insurance, threshold per member per year"
       }
      }
     },
     "localname": "StopLossInsuranceThresholdPerMemberPerYear",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_SupplierOfSingleInjectionOAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Of Single Injection OA Product",
        "label": "Supplier Of Single Injection OA Product [Member]",
        "terseLabel": "Supplier of Single Injection OA Product"
       }
      }
     },
     "localname": "SupplierOfSingleInjectionOAProductMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SupplyCommitmentRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Renewal Term",
        "label": "Supply Commitment, Renewal Term",
        "terseLabel": "Supply commitment, renewal term"
       }
      }
     },
     "localname": "SupplyCommitmentRenewalTerm",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_SupplyCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Term",
        "label": "Supply Commitment, Term",
        "terseLabel": "Supply commitment, term"
       }
      }
     },
     "localname": "SupplyCommitmentTerm",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_SurgicalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Solutions",
        "label": "Surgical Solutions [Member]",
        "terseLabel": "Surgical Solutions"
       }
      }
     },
     "localname": "SurgicalSolutionsMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TaxReceivableAgreementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent",
        "label": "Tax Receivable Agreement, Percent",
        "terseLabel": "Tax receivable agreement, percent"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercent",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/IncometaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_TermLoanFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facilities",
        "label": "Term Loan Facilities [Member]",
        "terseLabel": "Term Loan Facilities"
       }
      }
     },
     "localname": "TermLoanFacilitiesMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TermLoanFacilityJuly2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility, July 2022",
        "label": "Term Loan Facility, July 2022 [Member]",
        "terseLabel": "Term Loan Facility, July 2022"
       }
      }
     },
     "localname": "TermLoanFacilityJuly2022Member",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ThreeInjectionOAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Injection OA Product",
        "label": "Three Injection OA Product [Member]",
        "terseLabel": "Three Injection OA Product"
       }
      }
     },
     "localname": "ThreeInjectionOAProductMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TrailingTwelveMonthSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trailing Twelve Month Sales",
        "label": "Trailing Twelve Month Sales [Member]",
        "terseLabel": "Trailing Twelve Month Sales"
       }
      }
     },
     "localname": "TrailingTwelveMonthSalesMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_USSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Segment",
        "label": "U.S. Segment [Member]",
        "terseLabel": "U.S.",
        "verboseLabel": "US Segment"
       }
      }
     },
     "localname": "USSegmentMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_WoundBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Business",
        "label": "Wound Business [Member]",
        "terseLabel": "Wound Business"
       }
      }
     },
     "localname": "WoundBusinessMember",
     "nsuri": "http://www.bioventus.com/20230401",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/OrganizationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/OrganizationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bioventus.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r297",
      "r334",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r356",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r424",
      "r426",
      "r427",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r297",
      "r334",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r356",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r424",
      "r426",
      "r427",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r295",
      "r296",
      "r432",
      "r462",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r362",
      "r683",
      "r775",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r496",
      "r611",
      "r625",
      "r656",
      "r657",
      "r680",
      "r693",
      "r704",
      "r772",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r496",
      "r611",
      "r625",
      "r656",
      "r657",
      "r680",
      "r693",
      "r704",
      "r772",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r362",
      "r683",
      "r775",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r358",
      "r612",
      "r681",
      "r702",
      "r767",
      "r768",
      "r775",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r358",
      "r612",
      "r681",
      "r702",
      "r767",
      "r768",
      "r775",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r489",
      "r496",
      "r522",
      "r523",
      "r524",
      "r610",
      "r611",
      "r625",
      "r656",
      "r657",
      "r680",
      "r693",
      "r704",
      "r762",
      "r772",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r489",
      "r496",
      "r522",
      "r523",
      "r524",
      "r610",
      "r611",
      "r625",
      "r656",
      "r657",
      "r680",
      "r693",
      "r704",
      "r762",
      "r772",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r295",
      "r296",
      "r432",
      "r462",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r325",
      "r561",
      "r562",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r255",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r325",
      "r370",
      "r371",
      "r539",
      "r560",
      "r561",
      "r562",
      "r563",
      "r585",
      "r602",
      "r603",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r255",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r325",
      "r370",
      "r371",
      "r539",
      "r560",
      "r561",
      "r562",
      "r563",
      "r585",
      "r602",
      "r603",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r255",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r312",
      "r325",
      "r539",
      "r560",
      "r561",
      "r562",
      "r585",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r754",
      "r755",
      "r805",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "As Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r359",
      "r360",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r682",
      "r703",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r359",
      "r360",
      "r643",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r682",
      "r703",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r270",
      "r364",
      "r365",
      "r661"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonus and commission"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r272",
      "r620",
      "r631",
      "r635"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "verboseLabel": "Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r36",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r737",
      "r738",
      "r739",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Tax withholdings on equity compensation awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r164",
      "r165",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "negatedTerseLabel": "Equity compensation",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r273",
      "r366",
      "r372",
      "r373",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance",
        "terseLabel": "Accounts receivable, allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r273",
      "r366",
      "r372"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedTerseLabel": "Less: Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "negatedTerseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r68",
      "r451",
      "r583",
      "r732"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r192",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r87",
      "r126"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Impairment of assets",
        "terseLabel": "Impairment of assets",
        "verboseLabel": "Impairment of assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r221",
      "r238",
      "r265",
      "r292",
      "r342",
      "r348",
      "r354",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r553",
      "r557",
      "r574",
      "r701",
      "r770",
      "r771",
      "r815"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r259",
      "r275",
      "r292",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r553",
      "r557",
      "r574",
      "r701",
      "r770",
      "r771",
      "r815"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r124",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r127",
      "r129",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets attributable to discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r548",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r548",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of business acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "negatedTerseLabel": "Acquisition and related costs",
        "netLabel": "Transaction related fees and expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r182",
      "r183",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination, consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "auth_ref": [
      "r170",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "terseLabel": "Total consideration",
        "verboseLabel": "Fair value of consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r551",
      "r731"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows",
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r181",
      "r184",
      "r550"
     ],
     "calculation": {
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Business combination, contingent consideration, liability",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r181",
      "r185"
     ],
     "calculation": {
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of deferred consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Payment discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r181",
      "r185"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Fair Value",
        "verboseLabel": "Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Fair value of previously held equity interest"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Remeasurement gain"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CallOptionMember": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.",
        "label": "Call Option [Member]",
        "terseLabel": "Call Option"
       }
      }
     },
     "localname": "CallOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable for purchase of property, plant and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r89",
      "r261",
      "r659"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r89",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r215"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r84"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash from investing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r84"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash from operating activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r292",
      "r316",
      "r317",
      "r319",
      "r321",
      "r328",
      "r329",
      "r368",
      "r416",
      "r419",
      "r420",
      "r421",
      "r427",
      "r428",
      "r460",
      "r461",
      "r464",
      "r468",
      "r475",
      "r574",
      "r658",
      "r712",
      "r733",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/CoverPage",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r229",
      "r244"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r409",
      "r410",
      "r645",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Commitmentsandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/CoverPage",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/CoverPage",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r737",
      "r738",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Equitybasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r277",
      "r279",
      "r284",
      "r617",
      "r622"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bioventus Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r191",
      "r195",
      "r277",
      "r279",
      "r283",
      "r616",
      "r621"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r212",
      "r213",
      "r362",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r212",
      "r213",
      "r362",
      "r636",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r212",
      "r213",
      "r362",
      "r644",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r103",
      "r104",
      "r212",
      "r213",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r101",
      "r103",
      "r104",
      "r105",
      "r212",
      "r214",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r212",
      "r213",
      "r362",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r71",
      "r612"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including depreciation and amortization of $14,339, $9,218, respectively)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r102",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationComponentsofAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r290",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r445",
      "r452",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Financialinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r222",
      "r223",
      "r237",
      "r297",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r584",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r32",
      "r223",
      "r237",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r217",
      "r219",
      "r429",
      "r584",
      "r676",
      "r677"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r50",
      "r217",
      "r458",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51",
      "r297",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r584",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r148",
      "r151",
      "r152",
      "r153",
      "r216",
      "r217",
      "r219",
      "r236",
      "r297",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r584",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r216",
      "r219",
      "r773"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized discount",
        "verboseLabel": "Original issue discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "Loss on deconsolidation"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs, gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r218",
      "r773"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r531",
      "r532"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r87",
      "r128"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r87",
      "r337"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCashReceivedOnHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period on settlement of a hedge.",
        "label": "Derivative, Cash Received on Hedge",
        "terseLabel": "Received settlement"
       }
      }
     },
     "localname": "DerivativeCashReceivedOnHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r803"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Change in fair value of interest rate swap"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of interest rate swap agreements"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r486",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r5",
      "r7",
      "r11",
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "negatedTerseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r2",
      "r4",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]",
        "terseLabel": "Discontinued Operations, Held-for-sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, net of allowance of $898",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r125",
      "r129",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Long-term assets attributable to discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group.",
        "label": "Disposal Group, Including Discontinued Operation, Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r9",
      "r10",
      "r19",
      "r27"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 1.0,
       "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "terseLabel": "Interest expense (income), net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 2.0,
       "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating loss from discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r127",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails": {
       "order": 2.0,
       "parentTag": "bvs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r125",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r127",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r28",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Discontinuedoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution rights"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share of Class A common stock"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r314",
      "r316",
      "r319",
      "r320",
      "r321",
      "r325",
      "r562",
      "r563",
      "r618",
      "r623",
      "r666"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per share of class A common stock, basic (in dollars per share)",
        "totalLabel": "Net loss per share of class A common stock, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r316",
      "r319",
      "r320",
      "r321",
      "r325",
      "r562",
      "r563",
      "r618",
      "r623",
      "r666"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per share of class A common stock, diluted (in dollars per share)",
        "totalLabel": "Net loss per share of class A common stock, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Earningspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/IncometaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense net yet amortized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r802"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized compensation expense, RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r802"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized compensation expense, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee severance and temporary labor costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r147",
      "r254",
      "r280",
      "r281",
      "r282",
      "r298",
      "r299",
      "r300",
      "r302",
      "r309",
      "r312",
      "r327",
      "r369",
      "r476",
      "r528",
      "r529",
      "r530",
      "r538",
      "r539",
      "r561",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r603",
      "r626",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r227",
      "r646"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r443",
      "r573",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r564",
      "r565",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r443",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r565",
      "r607",
      "r608",
      "r609",
      "r676",
      "r677",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r207",
      "r211",
      "r443",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r564",
      "r565",
      "r567",
      "r568",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r443",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Fairvaluemeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r443",
      "r490",
      "r495",
      "r565",
      "r608",
      "r676",
      "r677",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r443",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r565",
      "r609",
      "r676",
      "r677",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r443",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r607",
      "r608",
      "r609",
      "r676",
      "r677",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r569",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r589",
      "r593",
      "r700"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r591",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from financing leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r587",
      "r601"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities - current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities - noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r590",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Property, plant and equipment - net (finance leases)"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r589",
      "r593",
      "r700"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r599",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease, weighted average discount rate (in percent)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r598",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases, weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r264",
      "r393"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Total accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization, year one"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization, remainder of fiscal year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Expected future amortization, year four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization, year three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Expected future amortization, year two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r122",
      "r614"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "bvs_FiniteLivedIntangibleAssetsNetBeforeForeignCurrencyTranslationGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r122",
      "r613"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r88",
      "r808",
      "r809"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Foreign currency fluctuations"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r87",
      "r139",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (loss) on debt retirement"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedLabel": "CartiHeal divestiture and debt restructuring"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r263",
      "r378",
      "r615",
      "r670",
      "r701",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r380",
      "r387",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r87",
      "r379",
      "r384",
      "r390",
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment of assets"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r69",
      "r292",
      "r342",
      "r347",
      "r353",
      "r356",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r574",
      "r668",
      "r770"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r732",
      "r760"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r70",
      "r88",
      "r190",
      "r303",
      "r304",
      "r306",
      "r307",
      "r318",
      "r321"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Net loss attributable to Bioventus Inc. Class A common stockholders \u2014 continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r188",
      "r191"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Loss attributable to noncontrolling interest - continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r220",
      "r232",
      "r252",
      "r342",
      "r347",
      "r353",
      "r356",
      "r619",
      "r668"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r191",
      "r292",
      "r301",
      "r342",
      "r347",
      "r353",
      "r356",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r563",
      "r574",
      "r668",
      "r770"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss from continuing operations",
        "totalLabel": "Net loss from continuing operations",
        "verboseLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r63",
      "r230",
      "r233",
      "r248",
      "r285",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r316",
      "r319",
      "r320",
      "r563",
      "r618"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Loss per share of Class A common stock from continuing operations, basic (in dollars per share)",
        "verboseLabel": "Net loss per share of Class A common stock from continuing operations, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r63",
      "r248",
      "r251",
      "r285",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r316",
      "r319",
      "r320",
      "r321",
      "r563",
      "r618",
      "r623"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Loss per share of Class A common stock from continuing operations, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share of Class A common stock from continuing operations, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r11",
      "r23",
      "r249",
      "r258",
      "r544"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) income from discontinued operations, net of tax",
        "verboseLabel": "Less: Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r11",
      "r18",
      "r23",
      "r188",
      "r191"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Loss attributable to noncontrolling interest - discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r11",
      "r18",
      "r23",
      "r191"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Net loss attributable to Bioventus Inc. Class A common stockholders \u2014 discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r66",
      "r249",
      "r251",
      "r285",
      "r317",
      "r319",
      "r320",
      "r824",
      "r825"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)",
        "verboseLabel": "Net loss per share of Class A common stock from discontinuing operations, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r196",
      "r317",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r65",
      "r87",
      "r113",
      "r231",
      "r247",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r22",
      "r24",
      "r25",
      "r26",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r535",
      "r536",
      "r537",
      "r540",
      "r542",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r294",
      "r311",
      "r312",
      "r340",
      "r533",
      "r541",
      "r543",
      "r624"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit, net",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other current and noncurrent assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r75",
      "r449",
      "r459",
      "r678",
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedLabel": "Interest expense (income), net",
        "terseLabel": "Interest (expense) income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r228",
      "r246"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r716"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r717"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r274",
      "r660",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r717"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r115",
      "r717"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedTerseLabel": "Excess and obsolete reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r600",
      "r700"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lessee, operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r292",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r554",
      "r557",
      "r558",
      "r574",
      "r667",
      "r770",
      "r815",
      "r816"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r40",
      "r226",
      "r243",
      "r701",
      "r735",
      "r753",
      "r807"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r260",
      "r292",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r554",
      "r557",
      "r558",
      "r574",
      "r701",
      "r770",
      "r815",
      "r816"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresHeldforSaleAssetsandLiabilitiesDetails",
      "http://www.bioventus.com/role/DiscontinuedoperationsScheduleofBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r127",
      "r129",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities attributable to discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r125",
      "r129",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Long-term liabilities attributable to discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "terseLabel": "Ownership %"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r154",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of ownership interest in a limited liability company (LLC), including portions attributable to both the parent and noncontrolling interests.",
        "label": "Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "LLC Interests"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r32",
      "r223",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Outstanding borrowings on line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Revolving credit facility, borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r32",
      "r223",
      "r239",
      "r442",
      "r457",
      "r676",
      "r677"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Investment and other assets"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r51",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r411",
      "r412",
      "r413",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r764"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Accrual payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r764",
      "r765",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought, value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Payment discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r56",
      "r225",
      "r242",
      "r292",
      "r368",
      "r416",
      "r419",
      "r420",
      "r421",
      "r427",
      "r428",
      "r574"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r730"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash from investing activities - continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r84",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash from operating activities - continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r67",
      "r88",
      "r234",
      "r250",
      "r258",
      "r276",
      "r278",
      "r282",
      "r292",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307",
      "r311",
      "r312",
      "r318",
      "r342",
      "r347",
      "r353",
      "r356",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r563",
      "r574",
      "r668",
      "r770"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Bioventus Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r188",
      "r476",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense (income)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of entities acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r342",
      "r347",
      "r353",
      "r356",
      "r668"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r594",
      "r700"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities- current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities- noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r592",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r599",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r598",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r143",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r94",
      "r98",
      "r106",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofAssetsandLiabilitiesLesseeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustments",
        "verboseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonrecurringExpense": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring Expense",
        "negatedTerseLabel": "Other items"
       }
      }
     },
     "localname": "OtherNonrecurringExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "verboseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r718",
      "r757"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other charges"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "terseLabel": "Payment for contingent consideration liability"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r398",
      "r729"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments made"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Tax withholdings on equity-based compensation"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r725"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r78",
      "r549"
     ],
     "calculation": {
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "bvs_BusinessCombinationConsiderationTransferredGrossIncludingTransactionCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire businesses, gross",
        "verboseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Financing arrangement"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r719"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r662",
      "r669",
      "r757"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Class A and B common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Borrowing on revolver"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows",
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r726",
      "r728"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r258",
      "r276",
      "r278",
      "r288",
      "r292",
      "r301",
      "r311",
      "r312",
      "r342",
      "r347",
      "r353",
      "r356",
      "r368",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r423",
      "r425",
      "r427",
      "r428",
      "r552",
      "r555",
      "r556",
      "r563",
      "r574",
      "r619",
      "r668",
      "r697",
      "r698",
      "r723",
      "r770"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r761",
      "r811"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r286",
      "r374"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedLabel": "Provision for losses",
        "terseLabel": "Provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableAllowanceforCreditLossDetails",
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PutOptionMember": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.",
        "label": "Put Option [Member]",
        "terseLabel": "Put Option"
       }
      }
     },
     "localname": "PutOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTypeAxis": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Axis]",
        "terseLabel": "Reclassification, Type [Axis]"
       }
      }
     },
     "localname": "ReclassificationTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTypeDomain": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Domain]",
        "terseLabel": "Reclassification, Type [Domain]"
       }
      }
     },
     "localname": "ReclassificationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r727"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayment on revolver"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "negatedTerseLabel": "Payment on revolver"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-Term Debt",
        "negatedTerseLabel": "Payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r389",
      "r390",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r389",
      "r390",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r167",
      "r253",
      "r823"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r396",
      "r398",
      "r401",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Restructuringcosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r397",
      "r400",
      "r404",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring plan, expected costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r87",
      "r402",
      "r404",
      "r763"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedTerseLabel": "Restructuring and succession charges",
        "terseLabel": "Restructuring costs",
        "verboseLabel": "Expenses incurred"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/RestructuringcostsDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r397",
      "r398",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r398",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r37",
      "r154",
      "r241",
      "r630",
      "r635",
      "r701"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r254",
      "r298",
      "r299",
      "r300",
      "r302",
      "r309",
      "r312",
      "r369",
      "r528",
      "r529",
      "r530",
      "r538",
      "r539",
      "r561",
      "r626",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r333",
      "r334",
      "r346",
      "r351",
      "r352",
      "r358",
      "r359",
      "r362",
      "r485",
      "r486",
      "r612"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total net sales",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Revenuerecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails",
      "http://www.bioventus.com/role/FinancialinstrumentsScheduleOfLongTermDebtInstrumentsDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r597",
      "r700"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Financing lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r597",
      "r700"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share in public offering (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccountsReceivableDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofBusinessAcquisitionsbyAcquisitionDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r51",
      "r148",
      "r151",
      "r152",
      "r153",
      "r216",
      "r217",
      "r219",
      "r236",
      "r676",
      "r678",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r22",
      "r24",
      "r25",
      "r26",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet and Statement of Operation",
        "verboseLabel": "Schedule of Held for Sale Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresTables",
      "http://www.bioventus.com/role/DiscontinuedoperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r308",
      "r309",
      "r311",
      "r312",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustments"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r118",
      "r121",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r118",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationGoodwillNarrativeDetails",
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r29",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other units or shares or classes of ownership in a partnership.",
        "label": "Schedule of Other Ownership Interests [Table Text Block]",
        "terseLabel": "Schedule of Other Ownership Interests"
       }
      }
     },
     "localname": "ScheduleOfOtherOwnershipInterestsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r267",
      "r268",
      "r269",
      "r328",
      "r460",
      "r461",
      "r462",
      "r464",
      "r468",
      "r473",
      "r475",
      "r680",
      "r712",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/OrganizationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityScheduleofOtherOwnershipInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FinancialinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r362",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r400",
      "r406",
      "r670",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r342",
      "r345",
      "r350",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [
      "r714",
      "r715",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G preferred stock.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G Preferred Stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant-date fair value per unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized to be awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available to be awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable and vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable and vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable and vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofNonvestedRestrictedStockUnitsActivityDetails",
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock closing price, (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of stock options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable and vested (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/EquitybasedcompensationScheduleofStockOptionsRollForwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r595",
      "r700"
     ],
     "calculation": {
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesScheduleofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r256",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r362",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r395",
      "r400",
      "r406",
      "r670",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails",
      "http://www.bioventus.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r292",
      "r316",
      "r317",
      "r319",
      "r321",
      "r328",
      "r329",
      "r368",
      "r416",
      "r419",
      "r420",
      "r421",
      "r427",
      "r428",
      "r460",
      "r461",
      "r464",
      "r468",
      "r475",
      "r574",
      "r658",
      "r712",
      "r733",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/CoverPage",
      "http://www.bioventus.com/role/EquitybasedcompensationNarrativeDetails",
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r147",
      "r254",
      "r280",
      "r281",
      "r282",
      "r298",
      "r299",
      "r300",
      "r302",
      "r309",
      "r312",
      "r327",
      "r369",
      "r476",
      "r528",
      "r529",
      "r530",
      "r538",
      "r539",
      "r561",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r603",
      "r626",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r327",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r34",
      "r35",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Number of shares issued in acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r147",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class A common stock for equity plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r147",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Class A common stock for equity plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r34",
      "r35",
      "r147",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Number of shares cancelled (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r112",
      "r701",
      "r735",
      "r753",
      "r807"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity attributable to Bioventus Inc."
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r188",
      "r189",
      "r194",
      "r254",
      "r255",
      "r281",
      "r298",
      "r299",
      "r300",
      "r302",
      "r309",
      "r369",
      "r476",
      "r528",
      "r529",
      "r530",
      "r538",
      "r539",
      "r561",
      "r576",
      "r577",
      "r581",
      "r603",
      "r627",
      "r628",
      "r735",
      "r753",
      "r807"
     ],
     "calculation": {
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofChangesinStockholdersEquity",
      "http://www.bioventus.com/role/OrganizationErrorCorrectionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r291",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r476",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r582",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r582",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r582",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r582",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails",
      "http://www.bioventus.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r604",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Subsequentevents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/StockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance sheet information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Balancesheetinformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/Consolidatedcondensedstatementsofcashflows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r33",
      "r224",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement [Domain]"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r33",
      "r224",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment [Axis]"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/CommitmentsandcontingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income and other taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/BalancesheetinformationScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r397",
      "r398",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/RestructuringcostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/FairvaluemeasurementsScheduleofFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r315",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted-average shares of Class A common stock outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r314",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares of Class A common stock outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator:",
        "verboseLabel": "Weighted-average shares of Class A common stock outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bioventus.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.bioventus.com/role/EarningspershareScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r706": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r707": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r708": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r709": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r711": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001628280-23-018472-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-018472-xbrl.zip
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M]RW5WE75KU7QY'KKOR<M/^!-SEY(KNO>5=OW8[IWG1/O'M;-50^PR3C4+_=
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MGWXO,+&HF-)@T'13(3@X2@, 8=KF?1U\@6":&_M]+SB"D X[EE,)0<0@/8
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M>^'*?O$WN-;K?EW&ZZSRR:)MLHQ)X81#,A)!6TX=X&55@[3:#R9R,QQ(O[Y
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M"RR"  ;6@S.&BV24\$J1&E'ISD3YWJ%^C4"IUA^4PZ?O=FM/0]?W'R=GN83
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M4B*^,J3&A$X$64*CP3#@T;N@^$7H/(<'(!=-(MX,^DN!^/9L;K!&2ZV"RO,
M(:=6BUI 9#%1;T:30Y28^5L ,%^(T"8Q4SJ.(EE-.!%" @AMC W4\YQP'X3C
MCO'QJE-&>7/R85ZA60Y,WCJ9PIN$-2F_RV3*C:*_LD24> =YOM=&EE/LY#P$
M$#WWS*D@QD>_HS0QW9Q\F#>QRLLV7F01@?($NVPXL^48%2I,WQG RZ*_='2S
MEY$:+BAR@_48[!FI23[06=) @JL]@.NM\CXFH6:/'$]:1L; ,X)N.-*X56#1
M"R>.V. LJP%R<TFA#XVC5XZHH,%R(X65R9H8 $,LR5B$E&9!H;7H-Q=-$)9Q
MJ1D5B5@,.C2W6C-+$V<DU6C%R8./6[UT1?G>M0;H#VV.9K1'FQ%ZQ8V]H>N]
M?M%&@+;3Q4\N/EQN45C$92+ M&009'5&KC/2Y "6D: 2_NL\78Z8/\AHZ.*(
M]+V,V:=D6'(QY2W&(D"T2(E2<<UII)Q$N932!UF%N932;Z]UB2Z!4(;EE-2@
M@V?<2\^98BHQ:?S$5)-J\(%1,K\["N?%5:W (7>*]C'4)]/9$!IMLOGL8$II
M$"0)SV74TH40M$,TX8)MY@Z^^=W7,Q\#C2-=G\H&3J,C\8YS"$G8*!P(],J!
M>,,357R9?O['1>3GDB/43 *GMX4X6:P. ^J@J1)<.N<X,6A4\(LPBBQJ\NC[
ME, '=])N$?G\J/R.9<>-MLC71!P5A92B=]4@G4[:!R^%BISY$#D-O$;C%',G
MEY=Y%,8"NCMZIRM)$-[MCJ_-FR[4<E3$>9#:ZD"%T<++Y-"?3\H1+742I ZK
MUI<R/#<F?WH!9I1*8T BM4..Y2XXQD(PUC@E5!"R3IN*YTX^']SVWT$AKOD!
M=].-6M*M,3XZ3Q*)(@K%DU/<FL"8UC)&*6!)MTMQGO$ -)?@9!342R^,3,9P
M$!9=@BHG,)/S'VS=OMW[ZF[HF@0:P3D:8B 6@URA&#?<<6&1'B2:0Q'9_&;=
MF1,HIGB^1V0* &(2WN-_T2EMB=+421]3(C70BMLR!%P&YZ?=UBD&Y]<+U41-
M0.=C?:4!2[DP0'+J$@!*@^4>XYH:J,F\83,]O8DVVL0-$>CJY/-P3$371H%4
M@3)0NDH<1BUE1,TK-M].'K(+88"XY)M3F\[\AC#\0*Z27Y( :K,$$#4%"2#.
M"*V%YAP]7C#>J7S0@  ;T;39F.9? J8$R)0D;@9\,$UI$#K2($42- @-TAON
MC10A21FU5I=KO&AS7F<>9T8,N:X-[/IRD%OZ]1P_>4%\[KSZ$](M\?I=D]M=
M+?H+\;I6UNA$K;-!",CKQ@3GWD/BR%X,^&C?"R7,+L7TCF):?[&\MI^'DB:S
M4V!&GT#)Q/,9U%X U49'KEFB(BJ(EO-QA,'GUXN=EJ3]<ES!IW3"5AYP]L[J
MX*)P7GGL,2X$M9;89(#/?\PW=[J_>";J?A8\<,N0 GP$YP5EPBJO7:*JRN7@
MO*O1B1)+$7Q8+VDFYTJ T"BFP4LBG4"R-$)(;9B*B9E$F*Z1O/[., ;I%7(,
MMX*BFVNIY4IS[:61X#!XY_,_D%;7P9IILUOQW60G\S) ""DFEPRE$H)@%#P2
M1B1YS! PK+)U.CQI*7SW*'RS9T?)) O61:JC%R92E![PP6@:J(]1DQH<:+"4
MU(>6U)F<R!"=L])+%P,D$;UQ)H"SE@IBG$M>SW_@^ML/N4]S>E0PJ[0GG@LB
MC"'&LI3E@D6N$GZ>?Z]N*0W3\[<,QF3$.XE"083@8#A0R_+LG",*N)]_;KBR
MX_+BX]]8HRO#T? UG$+K.EX7A38Z)X-^KRHQM:A_8=8:$4XC$4IZAO$["H8E
M4:48+7@+AO@:+'!9PY<]=?WB%"XM_T[1NW&D5K4R#WK]';2MNY_=R?S"<W&:
M0;QXL5L/-+B\/:GHSF<:Q,B"=%Y8T%R ]9Y[;8.+/EH>.(DCEY829IJ3#TOT
M?\C[R[-#%^_YW3V]ET5_Q?N+QJ'J6A8A"N:L \5B/H SN1"E#S6*4^84U!FX
M],JG1-%"6V8<JJLR(G+O2 I6,2[&&[7GFI[G-2W$0R8O>5G"?P;0"<.O>"A7
MBO9V<A1>X@O,KX6ZD7<N>967)TL>!'!FB)#61:>)%,FE,/\2.@W'<NZ24"[5
M93[5)5@KD=2U85$)<-1'YJV*27$25-1R_J/RI83.HX1.;Z0@\.")#Y8IJX1R
MS$E+8W26&H$")<7\2^B2T)?J\F#J8CDDK3@#Z84@&HQVZ+,S'C7W3)D:^#]S
MDK3R/H1DVDKS@"?Z3L_E<)'+&$S.]R4$,&M# / D:<8\95"#&/+W)O2ENCRH
MNEA%A=:,F+PQWS'E60A)@1+!HM-#EA[Z4D)G['(P320S I2Q7BA)? PDKU/G
M'@B82?;&>9;0):$OU>7A EK("Y+S03AY2RHJ392**64AF$# L_GW?[XIH<_Q
M&][;Z(3ZR>>\V'PCC+(J64ZH%4"C 9N04C&"D]1$5X/5$;,3D=D3^.\GK\Y#
M3"0(JGD4D5$+>0.&#E9#TD'%^?< EI1V[POLM6%)*H_NH0C"NWP(AO?64J<$
ML!ILZEA2VN\DK]H0@>9618;Q-^?,!C">!N-3!*]K-DHUUYA-SPRA1TVI8B"(
M48(Z\ +]:I6D!:> !UHKS)9*/X/5I\);F6(^=((+SH0+.1=Q7CXB*?72SK^1
MJ@MFTR-JF;Q(+!H2@A#,:,^%#HBAI,IZZ6HP/KI4^ID*$.IZHE3+$*023DC'
M-"H_T.0@,- U.-;A2N]7(O'E9I&;)?))3WF>/:]5?9!QRP7UC_/Q/SNN<SCN
M[OQUL^@4[4%[6J^9FUR-?>Y!..H4J(777^O+^Q-L(;YPO:.7K>[GFEA?HYE0
M1%3[K84(R2"SH]65.@A)>1WV"RX5<=;FZP'4Y:=(P9W=@13F11%UC%I;C;K(
MC0B:6D^4]B(&%1(/@M4H&<)T=.$G@)E]H@!!+3HS.7<*98)(9Y3-:0*H9\PD
M*F6--N#,!XHSV7'#A+9)@1.)<L%TM$X&PT.("D)>&K(HNG@QL;V(JNB2]=K1
M("DZ-@P!#$PP)9V+H#7&&O/OV;QIN<[U,RM7\Q1VOCPMTWUQGD5U<,=VVNUW
MPXTM=B^Z[7:W,SK8HR:V- JMJ4!]S><$XI]>IV1#%-8&FH*L4V*AGY>!6BHM
ML0* !L&%I4(2:RP)S@EM.(_@7)WLY^R0FXG-I!P(0;?'1 $B(58"DHDI6@.)
M6UX'__7^!Q96/[LRWI96I-<OBX#A4,6_^9C,WL[NNT54<$4#<2X0RS"H\0$-
M--5"6.:<%BZQ.E'S5,'\*>&\KP!W]F(2@U=,2*L]RW9 >,$BA> E YMS6LV_
M\S9K5;\7QXI3\#+8@-$0:JT77DNGK55$1B5I)+^K]M92QSR:Z<@(QZ#6"(\>
MLE/1QGRP-M*QI#4X.VG6&-[/<6.4BH0])=#=%49'*YP&Z5BR$>.:0&N@8S-S
MI-;;)ZWN$*#"??LDCW8LHN8J EH'"\HS)WA"6YE</GW<*&:Y,77($?_3[LQ2
M1.YFJ846R2:9+$1!K3-2@:/X47@E' TU$)$ED-6\4."6.F")8%R-49--GI/D
ME6*@F I^_L^&F;,QQBF=$*/S+(\A4DE.!;I.>86UL@DQH21 C+6-4*[I54WB
M$DLH9]H80S!<9)YZ)=%]\D9PZ0PJRX*QW2+RG-4841+OHG%!&!>]$P1)SP7+
M-6$^U6CD=PX@G,D0L) 20I"$08B"!^,(0T7#3\"35I17$%+\3S4G'^85PMV!
M[Q6Q<.4P;W>]9K/R2/Z;@<<*ME.":6[ G;FAO"9"*#\8U*J[B-"-HK\R)A&-
MTI$+81@74G KF 2,?KUD4C*E1F<N/H3D_)@IN]$#OV+*/*-6!BT(,(%AG4='
M7A%A1' >>(B+H423(MNG4*ZV6MU^KOI.3OQ2FWYD'0M008,!]%.%Y]3)O**%
M1TEC8(R'A].FAXD=GM^KNSH]'4].).6YC2S/>AGI/8D,8P;-.+H_VM=(Q[^]
M2NS]Z]<OEOK\*_I\D0E^W-);T\"/[TVJN',.>*VCUX(;J9T2 JPCG)&\/@J4
MDRB<\\L/$8JGK^'0M=:K]OR8R,T+#1A)A&-@J7=&Q)1SMT.U>Y(%QXVJE:F?
M-4_/WMA&030&K5;)F"=&K3,I*C Q4 F,>S*_RC0W#'LO6A9M<#0BU44?JHDU
M24E*,H2<<YD"U&AL:.8 S628Z,($GG;[MQ^#DF_\L/$3B2'AHG/,G! ),.X*
MA@HKN(X4(ZXYWKB>)\NV/W>@[!T5)P]I^J:X[8QZ8AA@MP0K*),V8%#"A36H
MIXHI4P.E?%@49C] 2X@0%(B(+''D4>>8#]*+?*Y,/O;!S>]RD9GIRQ3W2TMB
M,&376CD,ZH6QB&S2CB0B/ 4.-T;'ERC\_&CX-<A^9>+61<X-C3$:(WSV!+55
MWG(:(GH?ULRO??EJ<#7*$#DH.H>(687E-%:UUMR4J60392PHH9BP7F$P1Y(5
MB4:F PA; U.VL(#/WFI&P.A#>F1N#\))E V?P!-(.54*F>>S7A96*.[%0'LO
MB+&19;=6)$&=8<[%X)F5-)DD:F"@%Q;P.? %0C!$ 3ILQ*,#C;ZS<=Q$0:GE
M#@EA?GV!7T#JYP7N>=$]Q>8->JN=^,/"-S=^ 4/'7$!DW&J!G. 39U0KR=&7
M!Z"Q!G[!;P'^['T$X:/3+JG ,9R+@,&=94*I* ,+A/LYWHCQ6PC(O?@+R;E@
M##AAE!=4@6/: L%HT1)C%*^#O_!;@#][WT$XST%2+ZDD@FMG+6.*83C!\N(.
M[VM@1RX61F(-L6@-\JG.NSEC8=$OH+=^%EJ#"/%EV6V_Z+9/!OTJ6=1V6G=E
M!\'MO8%R]\B5\'QX>P67TO&Z:!=]B*\+YXL6OGFNSG6&DU.B>XMH/:R/*&["
MI"2="%S8@-XEMX8GE;P2O$X+9Q=</F:R*M<PY9C7'#1!+Y1Y[ZVF05--J+%!
M\B5__);[BB@-GN._%)(11GH4$V(( 2\U!4O<DC9F+18S80L.00H?N \!!)#@
M'5$L!:NL2TZ&)5O<$(O?*%^  :V($I)J!\)+L-$"=YPQ'_,1HG3)&/,@&C-A
M#>>%XH%+J847R01G0006G2->L9#D_(YO7@-K$/J#O*$GY^BZ=!J_N+6=3Y)C
MTQ@#_ZDD"?,RP E<&RD19$J-B$&;G/]?>L*!4@Z.+T&_&^CU2E-LC 6O-$67
M43B=/$W,26N5TE*!KU,&H*FC7TNK#BK0[.2A&G/!B372.*&LR?O/C.6Z!@.1
M<POH3,8+I1!@ M,, SQA5'*:LAB(CD)+)_0BVF):$_)4P24(,4:F'3I*RG(J
M$^<*$H<H20UR1GP#FBL[P!Y,V^X%I21SMG:J4'ORZ48:N9!1P""'!&NTJ5,R
MB7G0I-F;. /.4ZU<BOEDWZ2,=A$0/A'1=8W$++*)NV] 9V+BJ(]6<&YEROOD
MC;>!$4"-Y)X*"]&.-\Z- :5+0'\ 4'IW0.G4 (6DM79 <LY7@71K24R$R03.
M HF\#FMEYM1"SIY]K8J*Y$.FN.0B2'#2)1$%UPFO8Y11HV'#><9V-@>E(/&B
MADK!F1&2<Z<<&*NUXHXI_<7<<TV)N%[83FW=B:949E=8@1<D*$LX%RDRHW."
M?ZGF=U7:K9"^Z/;ZJYV(UZ \_5IF+CB%TG7"]TZ%^[5(98JI@J,-6F8#F:PP
M+F\M0)_(*&XM1BUU.#KWSA!M]X^@O%:Z)AAI'H5S'*V:X((QYP']&FIU]"+P
M?+QQ35V;&>O3[/V:&)CAA&F9K!2QRM#% D\V**DI\74Z)&RNM'#VR.:S2*BW
M3#@NA276^KSZDE+.:/+>L9H-T\V/Y9O>&)T+(K@(QCD3A;3!>0-@$G#O$_5U
MR+X[5SIW/U.%V/^4&<>D%D(2[HVQV)$D6<4]4N3\8E3_J7FO FH'<]%%H3VQ
MW'B0SAH5*;KOMEY=7Z\)<NQF[' 'X(C0$3UQX#(Q&4)21A R_S[Y6M$[Z?9<
MZU79'9Q4F82PPN N4_M=*1A&6S @;F,7545Z?T,KIFZ)%=0EC"+42F8H4 I*
M6(_FGI-H9)0:B<H0.LG#-AY.QD>;.<@^^V7&L[N.VF)19BX?\?.C/\J&$#'R
M%#:*R+P30B1O08"DVC _SGAFJ)TW4?_6]J)[.]?X>G8STZ1V"K++0),4B+#4
M,.Q]9JWP5&&$Z2A^YV0LNXA!<PG&-[3G*AS?T9ZK17\I7Z#R.G'+;+ ".'&.
M&Z ,:2=@F,''"_#IQ=@IG3]C/7ODT C\P,@HG4Y\R#2)5CK)J (A(3@2M=4L
M&>("A^C'R#'T*B8?ELC=@AR:(7[G,>W+HK]TO+",B8"-W"M!/'K'%(T\$%1!
M3E$5+Y S$^3NW=+7%3ES=^2FX6LDXRB/(//I(")B\"^$!V)BS&<78FQ9 ^1R
M+/.B.\A[#4^PRX;7#X=>;/@PZO?2@$H1M/ J>>>,,B$:B_I'XN@X,HK_D.;D
MPSS"]Z;LQD'H;Y>[4)X6X0I\?Z^.[]V[JX)6C)*[N2K7BOY*^AIE&<'X54$^
M7HEX+Y!$!>>*4YIDK$OVP=FC-Y.)W)Q8!,,$&Q4U0D;KF%>:!&Y"<'&\TY-:
M8BIW9?1A'M'[.G7^[4K?O>?<#Q@_H>-_)W_E9M%?F8G07CK-><K3AUYJ:VPB
M*OCHK0A2U.&T]&]#MSLXP1]"N9UVB\YA"S8ZQQ"J37</I)&S.9PS!*5(7CQ#
MDQ ,',,@$,,^(6@@DJ@:+(F:<UAGLAHJ6.TL8FBML@@9M<E3[@0%SH-RJ?)1
M*>).\EC,Z,.\P7IY=!,"F--CM(OJ:*9+:/>.2GAP/*FJQC?O,D)SL^BO&$X:
M)"A#/&,"F958*J0BTD-*/C(S8E^"H09K3C[,&YZS-YR,5$$$NXLJWBCZ*TO^
MI3+*L4!24,)388QFP C7!'D\QCJD,?BVQ_K&%9V]$EREG=_+6W.G9UT<+O$*
MNH>E.SDJ@FN-'ABR!)7#I^]V%\L.DZ T<)%L/O>!$.6%DQ[=9&<5,0)N;@R9
M5SO\^TC)3,PZ*$>YY!0=;_36=' *34!>N1ZE\BK68<OSKR/WBX*8UZ]T\P3Q
M*>P= 3Z]@(5,QJ8()X$!-1Z-#DGHUD>,U:B/)AECV,VTCO/**+^;K,R$5Y*6
MVA% ,I%),)]3AR?N-:'.IR1<J@FO?!W(W4%YF 5GMYL3Y70["V" 9D,JFC*C
M WHF-@@%R;I\9",:(!-]%#;4A%1^*T&93:I'K_-" B26F ^-3I8E2-Q:GPS3
M2=4A5>SLD9N)BDNN52(T&!E93M_A*8#VJ.A C!5P,PO+O*KX;ZASWA)) V72
MD[R,QU@72-X+Z4 H+63]K?B#QI"3\<>M;N?=0@8(>1D7T<S3I).(VJ*X2'#*
M>:*)='0YY#"WXC(3=HE!<N:129B50K!@&.=,4".\!0^J#IO,IA[LU4EH9L(Q
M3)'('+$,@(D0B0'AC#/,,"=59/7GF 47FMGX,9*QY)EWWEIA0=DD6(P:J&?"
MT%KL4YZO('/A:<:)Q)V*)J]-$>C.6&:Y3H0!I4&;<=*>.M/,(DO,3#C&4AF)
M4. <@! H)/G =1DM1?.D8RV.2ITC"&>3]4!;':4#QZ01G($-.I+@C)(A(JH+
M,%"Q\%KH \<.%8YK9X03PE(;,X#<&R^=J<.BPHME2A,8GP]Z15X^OSNJXLJ1
M/^]VQ]>F0=XOT AT6T6L=KINX*-OI/P?[X+M'$[:L8@4$)2AD5#)P<2\L=\J
MSJ45$8"D( *K 04LY6>68QKH*BIBK!+6"(U$%(D/E!$ODJ=60PWXYSZPG*;0
M5@>:=:J6H?MZ)_FM)17E_<Q&$1%YRJ;,6_Q+4\XX(S)GEZP!%2U%:3Y8*3!F
M&%.2>+1J/"F3F$.6TGF/*-%\45AI$[NG+%QK!_#M0]%"H:I*+2([*"482]PP
M%?-Z?.F#UM:I[/-2#9,]H[5GAQE!.IN$LXPFYSC)>;^%I."EY,X*H$GGE5-Z
M_K/K;'1"MPV7Q.M:.>W:[A% S@"V&F,QHMJ<7*?5[0U*Z#T?7DO)D_<(MP81
M8;X] <\E=[] 2(J_P;6F92]^,370Z.=X)3T?[M8G/Y#%B"<):X7@>:0SV*!M
M3 D@,JW1Z:B!:5A*WT-(WQR8O, 2!;1R$H1@CANB@P^<&BHT>L1U<(B7HOK@
MHCH34ZZ9H\& ,H9AY):2590GKVWR07(A)F<^"*(FK*KF551W![X'_QG@C]9/
M\8^]X<F-')XW"DQ+REYW.X?H^[77P-_RT-<8T6VG%R7$8FI/'-7VTH7J^/2;
MYYV>=ENG.9OIM4+W3[,HD.KN-*NF(+M&(LURA[$B>@7XEPV"6NUXSOXDB4GC
M_)IR_K*8S%ID'RRYY%S:F0_=02=.QEKNU?M%69=7DK_\RJ%UWB='4 (Y4<(2
MY@WWS,1D("0D[C#F:3E*W;,4^J70/ZS0W[0&\H[ID6X4O:LU>%*</<7>Z [*
M +W1UR-PL6I\+$Z?_85_C,-&)JCSZ.20((5.QFCC(8F<3UYJ"_9CCA(O?]/K
M#UNH$>VBTSR"XO"H_U3(D_Z?GXO8/WI*"?G_5JIRS_[JG;C.L[]\^01_/?H\
MJN2+JG*#FZY5'':>!LC#N%A#W_D63 KX;HD-;X9NJ^5.>O!T\N'/B$BWW!!I
MHX6H-:L?_=EVY2$VSG?[_6[[:6[;*:#;'%QK_)#J>:/;E\U^3$9-[V,']>/D
MR>/;CZM;3_KQRWO6/+;DZ[?)8WIQ[TE5=SDI,.X]?M)?J7Z';Y6[Z5\K?.7&
MBX]?!4LV8G>0.^8?V-H_3US,<OV4-&A5Q^5#GE0]<1MJH[[I=T]R;7_>UO.Y
M#9/BV*1N^30_+#\OH6PUDVL7K>'3_[.'RMIK;,'GQDZW[3K_YU'/=7K-'DIC
M&A7L%>?PE"I\2O7U\^AM-=93835^>\IRW[W;VMA;7VOL[JWNK>]>EY;OR,DL
M6KN[_N+=SL;>QOIN8W5KK;'^OR_^7MUZM=YXL;VYN;&[N[&]-<-7('=ZA0^N
M=X2BT^]V'C76'K]XW&!$"CM'S1:W-OOCC7^^VN K<J[F2,Y?;N]L-OY"*NYT
M.UN#-E82&F/&WH&4]U<QKH67@KC A/8R9V47T8GDM&",W#J$U^BX[*+DA)MK
MW3!HCSV&E?$L-G\_]&O=T]=LYW2?;P[B\?KIP2M[O'W\:;BU]O)HO[U^MG_^
M_'AK[RT_.#X46^='Q<&'?;*Y]DGN'[_CVQ_>R==\J[5_WI6;QV_/]C_\^VCS
MP^;G_?-W9(OMB^VU(/;;[]M;:ZMR^\,&W3IOM;;?F[/7[&"X_R&HK?.-S_OL
MX-/^\5%[<^\MW5H[I)L?UH>;>YO#??:.;9[C,_;6SS?/-T_CJ_<B_OWOU@%K
MG?KC+M\\?GY\T-XIME_MGVVMO2/;:^_.]O<VSC;/_WU\L+=_OK47)-9SODG-
M<'-M0WZD,6!H+G236JN;(BG6-";ZIA'.J+R4SUH,SM$#?%L9Q$L4GLU.]&V]
M)?]F\V\7_#\V7?FIL=V!?_Y01]?&"Z"/K;Z;$_!#OH5\;/@/^19?<R0FK@([
M.<O.PE6Q*#-,7W1.]^3!Y7S4\_=/CF\'Z&Q#V1KNP$FW[*\T,&9INSX^X*S_
M-!5G$)O]<E!/_GQ9^%?OU-;Q^OE!>U-L'@>L8Y]OO=H76Q_6S[9?O<W/95OG
MG_C6A[=B\WQC_)OW6$YV#O:Z;'-OJ[U_?CC<.O_WT<%Q(/A.=']O71RLY7?<
MQV<%>K!V>+[9,I]?[ZWV-W?)V>N]=;FU]FFX_?9C]-H#";0IDV1-0:5J6D :
M]E;%*&4(T:>59__]#ZN%^O.K)#R6]A\3Y!%KS$"2OZ"\2I+?OEO=V5O?>;W?
MV%E_L[VSUWCS;F?WW>K67F-ONX$NY![ZB0W*&]L[#2K_B/]L;+]L[/V]WKCB
M75YXEJLO]O)M:KFXUD=W=O9O[:K9F(*7W;+1/X+&?R9JV!B%L V,;"$^A'?T
MIGK>^BB0OJ[^$:\TV_C,H_RS9G3#YA!<V81.+>G@I]VILZWC\!$8<!T)>E,\
M&O2F)#2MT:290(H@@E$R3W6LGI1%Z[__017YDSYJY'Z_LV_UT-'HW01T>V?I
MHRQ]E-GZ*'LE-F]\DO/7G)3D6KTZ>RF;[-W9]MH&V3K?E)OM3?0@CHZP79_V
MS_>QK:OTX -Z'<<OT0OY=--+.3] CP3;R3?//PWWSS^1[5?K?/O5SO'6\<OC
MS;7WK?T];,>'EVULXVU>BN?)4Q5)TR*K-061L9F/GFLF9 #)/5@">NREB,7V
M4O9V5K=V-RI?9,9NRI@%<] ZWXY+_T(W)YY+*KOMQM7HO-'O-GXD6K_]W>?(
M)E89EGMY;J;QLD!SA[K@H7QZG][:>C67DI\V>E@MF>Y7QK,VSS]RI9,21C1M
MT+HI6/6)B*:/01EMT#TC)D]"TB;71H@?=;QF*'9W'#"]=_G:@<.BES6ZGU-.
M_WXR]OEC7F_' W5-CO\TA:>ZZ0D+3>,\MXPHS8A;>?9\8_O]^M;>N]W&QM:+
MQS42M#N.3ZZ?N=!O9!EH=%/C4BH:KM?8/8&09_1CH^@T-OJ]QHNC*G3]^ECF
M]9>L4Y @S&.J[-2C!/U8Z:__\F=K%>2Q4?<=>]SNL(WZ>S8^V[V38EYU49YT
M1RLDJL47+T99\5YTX_4!$WR#D%<O].&D[)[F>FHZ4C(>.'VUSO;W5OGFJTVV
MO1:+K5?[<OO5O_$9^V*SO3'</-X_.UC#[Z\V;X8D9'_OX&AS+6#[]L46VR 8
MMF#[]LG6\>%P_WACB*')ITW\OD]O#TE $\I<;(:4D(:9<DT;?6PBH#P(#2GD
M@=,U:+G/KH1?B$FNK198:L/WM6'/G6V,%W6-UD+5V!]]:#'?N"GF$&7*:550
MS*-K"B%"TW.JFI0;&APDQ(NN/#.T2:PA1M%O"OHBD?H?%<\V,,;<QB"S;/Q[
M4!:]6%2GUV27Y!HG5\7*0]<ISJOO_WPP_6]!^L(!N>BV64Z;?\6OVWB\\WCW
M<6.]?=+J#K%;KVMR8ZO[^(87]XV56O8;*[5^HG=_MNC/2WU]P'L89E^-L81>
M;_Q7WH= EZS^/58__\)YV;7DX'^/2&B_[[@/=K!]O#_<.G]?[.^ML\U7+S\=
M'+^EF\<;8G/OD&^Q@^/]XU7LC_WSS?9.^W_/WWZD00O'K6\Z[613&%!-+TUH
M2J.)#=22*@ 5FM&LQE B]SWO#EIPZLIXTSP\NO\1J2^%ABV%YH&%YO!C!.V8
ME:Y)=*)YU"(VO0JZ*1V7+BAEN(DKSW8'!=I49)-O#U@LR;H^9/T"/VZ7>]W/
MRSCSNUI'OJMU[76^A>^TO;:?VR?W]]Z>;;5?%MC^SP>OUN7!VJ>S@U=OQ?[Y
MX7FFZJ"!LNAUTQ!)D*JM;+ID4Y,2ZS47W@G!,$@=E$>N/3MJKCSI[?)-V3TM
M.F$Y8#%W@G3XT89 (^,<@S_-D+ZU;%H11-,Q,-Y2*8,4*\^VNF7_J/'"E5WD
M&_>0'%Z+D/&A].E-%Q6F=5"<C(;_ELKR767Y8MA#<J.D9Z3IE*X6'*BF,R(V
M.5#NDXJ.LK#RC&E-OKYZ:N%&/,;BE4<WWI3(U,6):S76SR ,<L;TQG;",!UZ
M#S>V,8==A$K7R%KWS]HO^VS\<8]TE9W"U1)<;0GJE^9PR4=/+'>:VJ: O$[
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M) =-WL.L)H0/G)\P(Y27X<SI=P$^3]<$]J5S!F]-W?/LF4S=C$4K<#G(#NA
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M_WTP.9;).5LO<X3A?!AVII=0JS]T!&6*.\&Q]90K)XR*C ?+DU6<4FS>[6>
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M\BYG:TK+D2.!(RJ5%1C 4'&[LVMH&Z^XIO:OF[J5S2@'4&,$Z<%B0 VDJF#
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M$N(Y_\D&;)"Q1-MHF#;)[>PRR9JAL0^JV/>8["S&G[::]FRCB]F(T%/A1'>
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M%?<$!<S \< QZ[ORB%#+M4XX4@E*SZAH4Z8W0ND?0+ D=[*'-PWZW6Y.">V
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M1+XZL-W]F /YDZWZK:^V,RH)*FJOIOW8'98,-U48GW$WIH[[HAXO1P-HSV
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MAYGE+AG'")X 67GBBPP9E?\^M-%21^\@@O:5B^79[FE6Q;J](;S/@MX&S:L
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MF%=G!<O@6=D6"&LM5'G=YK',P-LNA7=:,:7,W<9GI*!M9ZMR)R^5KT $OT;
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M240T*DH<,4YY#3LQJ/1L:9X@*W0LL-+:P7<RY33G G>M%SS'4/U[@J'9-#E
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MYX43_V^4U^KW5L%ZZ^W%8<#E=7^!O]D0F&FW']9&O(+' +GG:F51$K.),./
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MM-WJQN'#5/_,04W#^ <@3KAH5JT"/O-"H%_PSMG^R?;A-JB!<,^[STJ NFU
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M2:>7>]9L#>/GY034#Z_V#^ Y].WEWNGK]N'5^X\?#EHGK:N]J\.KUEGK*IS
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M/#$H>D%XSKR)4EPO'0D<00" ,=UR3G?L@ZEY7&UH/VUS:Q+^O/%Z2A+=[@Y
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M];+#25'J"(W/Z3>N &,Q@#'E\L%1"$V90"(*#8"1JQ8D'I$(8.];+FP,^BT
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MO=S#_>4D9VVS&,P2SAGA&[7MV<+UHM.56Z^FBT[N^IO;EMMFJPN;XLAVPD!
M1T4W;ZO<=7D@X1L3^<M33<='8/5GMDF^=86FND[1&<4%;VV5OE*MH*? LN@T
M#]OSHM6[:3X?1^!J9%,7T 6*P5^T"L#*FB'DKKOY&[WB0-.6=SVW5V4S[K-:
MM/X8H U$!KXS[%.? !GR5:<9H7L=0,KCHOVO;UT4,F;/SV&5BGLT<SLR@!'
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M^U7RQ$>Y8%^&,!;+V=TY*SVS%25\"+0UIRFA9R9H'1RRB65HDR;G9T8DM+,
M;IKIB-<VV9/YX!T(\M*]N-\8 -Q.>9Z( C^1^XR#0$6 %HP24P3(2.,BLPIQ
M*C48CM8CX[1 WAJ=>X4G36(^XE'3$<XOAQ,+<IJM!LOYNS %GN(F6T&,^^75
MLIQR.2N6\QC\NIIF.3IJFZ.'D9;9\94X1=I*BB33E#LK.-$:\(NR*?CZYT,M
MMR7R:[WRW?^J&<XX %0,9\$(,<5PK&-"&F)1%-$ 0@B!7.(6"9>4I(&10-7:
M)@&*,UV\[W$NGLJ1\\#]_J'=2;%9%)KJU'PN'-!Z<VZ=U\MXAJM;D9Y'0%KC
M]QFG?8EKXHU$1.I<U XK9&EBR$E&8R#,1PZD!^3J":2G<NM4I&?A&)"KH56,
M9\'P,,UX2)&?[!!3!!B/X1@Y[A/" O,80A IIH+QS"@7L?).G:4F.J.14$64
M:ZT?X+J **A^<"APO5IH7^10T^)4\0W'2"TJ.^8GQDA5Q&A^Y)L1!I7K:COM
M****>L2QY,CZZ$#[$<%EX)9ZOK9I\'2^S),.\Y^T]98\1.H-!$*][G"GQZ%@
M%>[T"O!Q.MQ),I9"T$CZR! (@D(.1X((MI8DG:3.^$C(!EU4F.C"F.&PS<]4
M">+E+H'PP&H/98F'_LZHBCQ,%WD8+R<Z4NVA2%R]*]_0$L*3,)I;*[A6P7"K
MHK TF1"X\J1*N7^A7--/M'YT&)F,V B!O#,!H,EQ9')581:U9M9Z'IQ<VZ13
MB::Y)/Q==19P5,KGX@W4<I9 %R;+B&=:4L.TMM6BO]BB[VX=2AUA-UJ+),_=
M.;0DR$4L$/-*,A.((%;>6F>AGPXZ+&.?TZW:J<2,(L\]_CAO=N*@Q\:=B>I<
M\6222"8&3HS50D9+X$?N)+?$SRLE[GXI<5/\*(^RN'C@':]$I!21+S\:EX<@
M'4$X("K!)< %%A,RA&#D52(V$6F)9MG7?5L&>BZ[-][<Z%9ETNSF#@FQ<PI:
M+-1R(Y]2LGYK ;M!?_GC=@L48[Y/F?A[V@ZQM5[6X>M>9#U4/&*DF(*]*7<U
M+!O4+2L9W%4VJ-)B*RBM_C*W&ZJTV!M;=("H)VFQL@]4T:.R=V%;>68')R4_
ML7S&[*4OC)%!V,H ]K9N^H]6]30N#P4S,-T2(^LH++XS$GY*%A2,QQXFG2EM
MICI,Q(")4L S8N+>8AT9E=0G&01GS)E[ZVGT[:/<DX"H7[MC/6$ONF4IV8$J
M&VBQ"268-=&8]AO86N&!%EM67=WC]N79H%?L""W+\K&QL'(<M]7>N'<Z5ZGV
M!MN06"V\G 7E&\2P192S>!7G<)^;W6\H9>%NYF(2V7V0VZ$\JG'W$U]_=M/M
MPBNV;#[FL_XAU=--IQL_,U\83QEZB4<45%[G#[#,._U5_@R+/'0B([J:&JOT
M(I_^W3S8!OIQW3JM;W\!#?6YV;BNPWC>_ZCOA>;!20,^;\"=WT]YD0^^_O&M
M<;T%X]Z_;.S]<=KXN,/JUZUF;IG9@'' 6+[5*>C"O8-4GPX_^AX^_LW#O_]H
M'=#6=W?2OH)WNMS]^OX*[I.]TKCQ]4,3YNSZ(!=3O ZMQO41O-,7L=_2 A@R
M5C9%BDQ(H"\I 5N,,H]4"-;@:)V7?&V3;4P[H/]Q6P?XIX=)+C58O1_4ZAOV
M0KIJQM9;BX_\J:BTR.8WLW!IL*3;_14M<6FT0$IJ_H@!7<=.N\*K!^'5K*@
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MKBVON^.!_IV=W,,+2,J?%PZ^4-O-;EG G#E=.VR)73N[9[4/T74N<NL6(@N
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M",[S)$ +$! :X;TS,I 8Y\^PS^IAA,\.?+U_PS.[5?# +#9S76>'-&*GA3?
M8;!!8/PD9*)5P'=9U"[EUNAX=K10#DZ+-QPWB\=ZCN*,Y[WLQRT<:I>YFE(G
M#B)-"J)0?*W7/HJ%Q\WF>BOC4:5G10@HK%:O'Z/6CVX;R0BK'95^_7RR.R%\
M^?8;M2GQG2&R9^W>V#>!4D104WT"=!;*P[MBS/E2%V=>G9V/H=GM=9KNHHRJ
MOLB'=F6H+KQX*, BTZINH=,*UM^!VY9G@1?G$P5<-FI_W6U$9D98G&F[R2@_
MV%29U9W!R+K=["J%O^?2F#W;#U)\6*A?Q%PZ;3%C4G"AM;6<2)[+93,7-3'W
M5DVI0OT6>R+SGC6V#C&.+CFN$9-1(>XI;%W./8I4&*%BC"S&6\+[>NTBNJ]0
MEV-UUVX+\!N<!\Y[8#T67_'7:?9V_!][>OXK**7SXWBY7H;@_I(_[4=M_%XJ
MU+P3AH$8-^$;]^R$O(F+8Q\PFTHEGK?%$%I*;\M93ANUK=O>\=Z'%/O?W9R2
M/B9HEG##/+,&\-1PS*@EG/K$HW*$$Y+(7#OI]V( K0).BEU2;:+';*)/-$<K
M!9D"HQ$EPS3B4G@$FL^AD SQA!@L%)\K1G:(]; .\?1\@.[#9(9L8>?:8B/=
M5,?%[Q4<SHT643N]R.'H.2<2=DUV4'37;U300[=-I8"6;.]\X;N?#HD5QN6^
MA1IX.^(*%)#-!)+X(**BF(3P! 4TNE/NBPB<TD[CVJN(3!]HHP&[6HW]]L#0
M@'YP[F1,Q&J\Z[W8,IF[=E-7L:S<>D/UQ]<?B/+ZM,=T?6"/C%=-;!<('D_+
M]+.<[G;>[HQ$W#4[$W?O)Y.UKE"?A-\CK8^@#8\K@3TG_@W4U6ZJP&^^&()<
M@#8YY['%!#'BP%SF4B.;3$+1BXB3%I$K,@]Q*$.3AUH33+IAR<YN[/5:I5W9
MO0"[=X19@ Z]3\HZ^2)ON\<K@G3W5Y:^"7MJ==N#S=O?^R-;^%;6D<-W*N:Q
MXIOORP]@[3(8)PWE"'89, _,%=( B8A3F0P-!NMT6V;;RS./08;<PX5Q(=9C
M)8R+$\9]LKMU2+R)3NJ C"<6<:\$TD$HY)T.6"NA"+_%<3J/,-[C9YD0L&D?
MRD-%=/H.*Z(_'LB4&^VSO+=R'>O\MH,,ZM5XUSMUY8S"(&4(_X ]C,?+%FZM
MH0_[U@25,:%9'V2]%U/7%Z+QJ@PW11DV:A\N>A>=4<_(#([>'T;WHE5\%092
M^DUR+,/PYF5,;[CP)6>WI[G:>)&<T EE3XFSV<M:?'.8J9^S8/,P;*MV;IL!
M%42IL)<*-@9#+=(ASMIC0YZC"..@7VMF7R.7YR/U_F7;,-%Y2L=:!M#GKV/H
MCV':<B6@W>P1W1W,Z'#^WW0AP\M#DR3CV#,D;&2(DV"0];FJ#^$V.4U-B&JR
M-J V!D?GO<,Y1I<(;24'FN@<UZ"A79@L9+@W7GZG\%,7Z5PYSJI,=[AK&Q5'
M:;-JZ1>R/5NN:K_<;.!,+;IED8KV!>!+Z/[SW=T5%&\_Z[[WU3?_I_]^@[B.
MHI<I(&#+GG?CN\$/OX9F][QEK]XUSPH<*[[TZSC4YHB'B6XZ!=26']\$0VS@
M,B"BWS&Z_^3^QQO%1Q,]?LK/N-R@4M_Z,=X@MWYVUVT)V9#$/.JV=W_&-*\&
MNU*#I6RNV][3[_S>[I1FZM(93>[*H*B?TPI.WU?$M]BP\S4Z?_WS,$#PV@"\
MQ^;BJ<(QTECQIJ]T[E_6;;>:869;Z;E[(XZPY&</O[MW+@L*/$8M)R*XGC(S
MU?2627A#FO*/N2>WFL)*0I=%0N\!T\<T=YXU/S##+]1=M7&7K^<IS7<7(X#/
MV8"[&N%/'^&#MU,J_F=F*U7"EGE?C9>0O'4CT8>]^\QNU"O=LIDGJJWT.E++
M>8K&4:\)-YRI0+C$MQQ43+><N:WH1\N793WZ/3EVBF+;N;9,>5*_U2N#<+,W
M8:\][ND=@.%\>6TOW,3FL>ZPLC/S21W73^%9)^%X_^M[L;_WN75P<@ _UW\<
MG'[!];TM4M][+^K7C6^3G9GKUY^N#K8_-!L4WFVO==SX"&,[A9^O/YP>['WZ
M4=_^\J.^]^VZ3C^G^A7^,=F9.7J*/94IUYH4.30H(9LX1TZ9F(3-24=F;5/2
M=8&G&^$\L#'S'6CRT,;,CP2P6['VC0'!S$-+31S6-&),O.&$"N.#((P;K520
M5.I[\CKFQH1;"P&52#'UX90/?+CI$:UV_3R[_GIJUU-MN(@6Q"X'!'J3$PZE
M0IHIJ0SG44>WMJG,QI+L^9?8//]X%/VN &=.YH$QYR3W9J")<= TECHO' ?,
M<8)Y7M8:HX2RBGF\"@PBDQ@4*(;UQ@$9*R+B-">T,2=1<"0*S'U2)!3, \OI
MOHL5\UA1()C)/!B02T^I4M+27#?1 +U(RN*$.0@#BQ,=,"=!H6(>2[OKV>2N
MI\9[!28G(I*"O4&20C:7^#(X6B =F(N4"N:AEF//OSSS6) /= 6<-K-BVA[E
MNIDQ ZN.F],$2MG F"8A!*VYR]7FE)'.,.)#$M[HRG7SBJ"T\?NTZX9)H$C&
M:V2-LD"@A$&.,X' N*-)6BL4<[F!\;K23P;3.S#EN0C4O&[R-P8$,PF43"81
M2KWDDG+CI+,:)\,3"53YR&<''E8$:@5V_93K1AAGJ(T&&1,3XMH19*1VB%"N
M%5C0$D>^MDGQ!EV./?_R!*H"G 4S#P .2X0#>\U%;@5@C4M W6,21!JL1.6Z
M>5T8-.6Z 6M="4P-4M)QQ&,"#&(8(\$2)=XJ++&NF,=K X*9S,,YCK4)-!\=
M\<2)U=3:X!TU@B2=>.6Z6=5=/^6Z@;T>I4L481Y8SN!DR'+"4%!<LFB$92P5
MS./)[MK7PCP6&6]#Q3*[;O;:/=MZ2IA-/Y+IIH%D+;0O<F)*$<TT7R3DJ@/L
M#!^/]QK+J"S&C@= 5JHMTX$38I@%TE7Y>%X3YOXUP\=#K> *,Z2-(H@KS9$3
M1B(GI?(I49L"6]M4>AWT[8(<YHO8B2MTN%8!SVT^)4HBXS%09A0';N<2HT1)
MP9C ,9)0^916%66F?$H *\EZSQ'3N:E*475<L82P5=QS8;14*M?'QQO3I?%7
M"F1>GA)6"+<DU(J[8)5-TK,$]DS4!AO*I0S"4X^9HY43ZW6!WI032SKGI7(6
MJ)64B$=+D0%)0%Y0'["STEH+U$JM:['BJ%<!SY)1JV2MUSI:KJ7C1(+H*1-S
M%4Z#M9:L<IJM+,I,.\TB6&:*&V2"H8A3[/-Q'452VNBIM%Q07%&KQ7G;_E5H
MU%D];ZI>./<6I"+Z]EXX>?0% MS;H$7RM:J!SBMIH#-O735""Y:P6*$E<V60
MZV>OR?7>=LYRD^%!?\5E*<'5^'V@$S^?[M-&L_'Q$]S[[Q/06;RQM\7WZ;ZH
M;__1K)\<M!H?W_.#KW\W)TMP-3X>G.S3'7RP?<0:7T$#;A^1^O;QR<')M\OZ
MZ<Y5 _3C_MYQZ^#K'VEW>__'(8D41TD(TBDDQ*TUR.;0,ZDX"TI;[?!4 2[O
M)(E22F--XL1[:X2W6">A+9;$R<D"7(,)OVE5<W?]JYFEK^Y]Z.9/*^4V*4"_
MV6[3;YV%[6;6$J'8C6]8J*X.<U],G2Q'1FF%>#YD!#%BR./ @TG1L> GA60U
M:S[.K"T7R^+DO>.BMIP']G[1&S8;S<6G?5$Z+I3B4FNUNR-;X]:2M[G<>;X?
M7-ELAVYN5MG-["+4?BGK,8X7F1MV@AKVAAIY1K ]FZO0+;3FYLI4GE-T@YJY
MBY7-,+,'[P!H$Y_YRB4HH[9:-=_H3ZGY]B*R\(:*LNT5A5[K[:+0Z_M<P?69
MJK(M^?(]L7K4\BWL0ZL.OESEK66=._KP*H6+*JSUHMZA@M?;'CQK#K%YV6V]
M3$6BEG^$BPRK4\LNQ+%7^R43_G_FJNCMTUBV1_(WJ9+M\U@Z@X#!G\6B0WS/
M_EA!D;_GY.G)6?)+M[;_^RFYS$ONFO_E 4?QC_*UC)_)=^&%X:=)%\Q.L67^
M ]OG ^R:F_SBW>&>>;WG\H]TY/1/S([$_M?]'_4]?[W_]3.,[?.W.OW$ZR=_
M-QNGGW!C[\-I_>2/X]WMK>O)$[/=[=;QP<G['XWKQO'!QSJ!YUX?;!]=-;[N
MT(/M3Z3^=?^J?OJ>U[<;,Y-+A">)*>]0HD$C+G1 SFN,:*Y;+P6),I3!2.N8
M3)<G^N<*UP2I$.ZU(AR/FC.+-?'&<^RC,S008R471#- O(D#?T X6B'<:T&X
MJ9@ ;U@4F!D4B4\(-!Y'VN3>A)H:HJA0V.>8 +[.\710]XL W")KD*P"XRX\
M['9DH^0NC[=T+.H6C=$)_74V*5]!(E[E/ZX <;T+QM_#Y;VK"L07!N(SPD<M
M*')A"$646XEXX@99DSR2BBE)C&(^!W91O,[DDR.[JASHY<6 EZ1V%0;\5 R8
M)G*>6V:Y0Z #6,8 BG2D!'YB/"4?G*-^;9.M"VJ6" +>FOMT)ID;;Q P,X!B
MT*6^3^_^QW7^U5^UZ7]?"_5[HH?B"3']2R<Z#_9=S/GRRZWY5L5O6RFVA2FV
MYC2YY4E1*0)'5-B(N T6:6\5D@*;Y!26)">$*K,NQ0)<L"N1^%1!7P5]R\'Z
M*^A;(/1-<7K#'9!WKY")Q"/NP*YW6"3$3=214^FD*8Z?UK62RPY]?:8_D=Y$
M1 %LSQ?GL6RD]GDB528SZY8PF&:N(2[('%QJA;;2H6#S9F2O^CW>VB'3C+ N
M$)-AYM3K">RZ!]R>[#]>NM6=GS_/>L77PY)_EH-@>V3;W/!DV&.[:<_^J/CR
MPOCR31NGJ_KV%][8]H="\(!=Q$A;J1 P9Y,+JG@DDXC":RQ8;B"I^#J?X02?
MGR\OWQ%8!5NO%;9^EG%_'VQ5R/009&)3R,1=M"Y9%%T^H2>"($L(1=8ZDZ21
MB1JRM@DZ9SE@J3J6FR?&ZA:&O(*L>(&%MEYWA,5RL,@J;/9GXOGN[]-,DWLI
MJ%,8<2LUXCP(9*SUB#/NE%?*Z^"+L%G#EJ1Y8(4'2QIQ]3-A(#5_Q("N8Z==
M(<##$&"*T06,K62)(U '&08X,#IM*1(I,,UCE(G(M<U!O,[R0,!;\VS^C(BK
MUT,$G^AG>)N!!P][^>76?:OG4AW7@I_C>4XMJV*.%ZT#ZWM;O6%7D),M7K_^
MQ@YU$"RX8%&PH/IXQ!QI$3UR07K-DY3.N;5-8=:YF6X!^6#/QG+$9E4064'D
MBKEO[X'("@4?AH)7-RC8V'[/#@EP?<X]6/\D'SMAGI!+*2!83Z]PBC+813EW
M5R!&Z^&A&<M&@A<87/)<,5HO.,2W4*YK.YZU3YMGJQJEM< (OJ6^QULZIOI:
M_!(#LC J>Q3+8KC=6RONMB]ZW9X]R^]90].%>U=0JBNG]$S26<K!8DUS/,DV
M!]*W50I?H^@DLYN*"N+=W1M1*ZJ)SV=TXXINWN]XGI'LKT@DL*82>64"L$VM
MD XR(!6\\Q@['+Q84G'IUYB?DII*8)Y38&S(IY&:H&1([ML:"3+<,^0)]B10
MYK #@9%T'<1J78EI1\T2G5Y4NF+QNN*)/HIJ\R_1YI]*(5,JA:"(18E1T!;$
M)F29="@2&[#S3DB,EU1@*G+Q\\4E:6TE\P9%%P7BEA&DJ?;(6RFML2DZH4%7
MX'6N^;J1TU'42Z0KJHS#ET[G6X$AOHF,PT$8Q!Q]>NXHZ/T&? A/YH)+M_9O
MMNKMH+_98BU=^H1:"3"B@L'TAU4QE0><NKV_B3W8^X9W]W;$(<$"<\(#PEI'
MQ#7!R$;A$%9:!FFUE$3?'<NYE"(R:B950O)4(1'2"2LM1S(9A;C$ 3DL-0I)
M29IB$%2QM4VR0:=+!RU'M>-*L56*;2[4>J)17BFV%\.LJTG%)I/S21O$54XP
MD08C[81",3#LE272,O<HQ?:R(E(IMD4*B?6&*BXXTI@6:4?P$W,$)9:8TEYB
M8_':)MZ8T99D.13;6P@C>:CA?6O)E==@>K_M*MY+;*O>'3M:*??'X_:7T8AY
MLKOW_L<A@34E0G-$.9:@X0E!5C&.HI<AP@)&21^GW)=%6"HUOTAQB4I9(XQ$
MOCB[C\DC2T'A2T<H*'G@<_GL'F^8Z?J/RU%)HM(.*V[P5=KA&;?[U<1V9\9%
ML/I .\"F1]Q%T XL2A2MH\H9CQ6)RVSZ5=KAIXJ+DHY%82F22I/<LLTBK6E$
M,MAHE>3&49FUPXS,D^70#M7IZZ@1^#KLO"=ZHOL'^.6239WAO\WLR45.S>LC
M0L]F^;RWG3.8M^[@N?WXLTIK/4!K^;&D\<;V>W&HM3!.)H5$S 'LGDMDC%6(
MX:235D$H>E< ^Q((0I_%5*+P5%$(5(9D!' 7JS$0&$61BQ*6)[DH*$Z2.;NV
M23<H?P8O]B+@=,F/=2ME6BG3)3$4*PQ=$(:.51_8P8?,,M"APB)F"<TA+@0Y
M%37BSG)J<3(\R>7R&52\ZGD$(5%AB,]$RH)&%<8@)T&9.AIYX-Q1%<LCX3FB
M]E=*F19>A'\5U4W@OZ'Y??@^1:^5IM_\'_CCX!5.;>>H>388J00D[?\ECTZ.
MJ[F3BVZOF:Y^/G[3C-]_361X_S9^9!QRB>)>WZ70/*OUCF/A:"B_DG_[O7T*
MP[XJ' KY(OA;)Z8V_)2_>&[SG#;/;:X%4^M&?]%I]IJQNU';ZM:Z%_YX'?X(
M%]E>K)W#0.)9K_#GY;M/.2H&3Y[AY)@8-L@.7).'U[ML(U]<<AI[Q^U0.[;=
M8F0NQK/!(V/8&,IBL;1C*[L  V <F_[RQS%<M.)NVCKK-8N7:WZ/?PTGY_T/
MW[H(,92!+J?G%^6<[*9)4-N#4?W6@A=>33AKQ7]_OCKX&LX=Y;+Q\>!DG^Y@
M@"/6^%J_;FP?D?KV\<G!R;?+^NG.5>/T"][?.VX=?/TC[6[O7QXZZ0W6VB'"
MB05-Y"2RWGMDK)9424H9DVNU"(A_#G/?ZUQD+]-*[M$]D./4;K7:EWD3G16I
M:UGT+R?+-9RW>R#-3=MJ7=4&8C6HX6"+';MUWFFVRG0ILE[+ EILL)$_T^+/
M%&X.^ROV);$,'<G["?#17[2&>W1T9X[L2Q>]O>@68%"+*45?=/-IGN6[%4
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M$HQ*& S;=:SP.L%/IE95=O)2 X".2N(<)*ILY"[G>)C(+*/4!4)C)!6U6G4
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M/L8R &,5GDA8\:"U ^\2&(XH5P_P-Z^TL3I:!SZ)38$9&5.A2QLB;*,,EK%
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MHH=0=ND_=0*[':_Z,S=3:/2^M9.\VN3OZ.W>U2")+!E3>"A71">I+PP50J;
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M]D)^\6U<Z9O]Y*43HF_WOG[QTO,W3?L2>WROUHZO::CR$+K+'"S&?S)7N(0
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M1=S>P&YO8%_58WB,QNG4=JL^1DW%]*J?3BZDW3D!VS095G6SIT5=YHY1+Y,
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MI!#B0I#JH<-'&X_[WNLR]Q(!OXU \2L$'EK\^V[\^[!*GVSA89NL):E(@LC
M$[%.1"(,[*CFCL=H-[;UUFI/HROBWQ=@X$[AWW6[LBUX7!M]:L'CAL%CF3QA
M-_A(,;Q?A@)]+T%LZ2GQRM%")Q>"DQO;8FNU"^,#!8],GG[+W<*WO]:+O)DM
M05KT2!2+*O]^,AIWTWGUHVX_@$ _(DQ??_?V2[1TX-?1QO<';TX>\_P",[J5
M5V]]A^3.&*]PX$__SQ429PNM!2VL"5HI690>,S6+$BPN>!P.F-(UM7V\VPFT
MO?B_+\[?O@ZGCLMB[_"?7@4_K\[?G+Q1^[M_'K_=/>+[AT\_O-W]\\/>X1N
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M9NOOM/[. _%W5CR;B^)[-1\K%OG8>O9U<Y[(A5M8KEVF/P9 E?I8[M_V*I2
M)>K5]/0H]OU\%9-;/?$O2L.S"JKZF,^,LYL,1YG=N\D(/CL">,-?/QZ<P-C.
M.R# W4% _M@[[SB0$AQ)M_]QT/N8P;CST<(')J,.0'3WI$97>S::=,?P)/S;
MT?RRG@X''BP!K&?U47@2(LI1C<WC8SON6(#\+JQVJ+X"\ C/F@YOJW,X-SSK
M_7""T#T%\O/.V7'LXP\&(QCI*",P/&L(PX6WNPSN^&J<I3W)N:$>=L&AG;&C
M01\^<-[!09T@9F]U7E>/P[\-NS">_-R94)SC.^:^"5Q\U,5W@"&!11Y/7[JX
MKF$ H\9?#]$_"_,3V,Q?[?9'XVA#-D+PRCBJ=LTB^.;QUV.'G<-?Y.6O%APF
MTPR_^>UT4'GP@ 9#"X/'W^(/-CO=U!E-_/'"5^M%.;$A;G7^RJJ0(BXUO#]^
M.HW]$:;9HC!D:XPK!8:PL8VX;5?8^4V8_@<84(8HG]>HFP4M#Q]<,U"9X?GB
M$L*ZCR;N??TR4"\8$A@H1+9)KX(Q=XXK!G^RO4W0,YQ69?Y!GA>'9VL%;U[Y
M"C@DS.\E?J<9<#V\]Y-A=P0J48DL_/CLN MK-S^T_'D,F:8$6YH?49D"6,H=
ME%98I4EOO(EL)C:T%7G$18."[_>/!K!X"^+_/__2G)6_CW!J_0!P#JN,#P.*
MT<5X/JQD_=KJX?7*#(;+6X _@8G@W@WZE5$ K>N#^1_"Z[?N >H=+@K.*4P5
MUACT==)OZ![\#'>ULH>3RFZ#U'A8PLVL,WG/:I4:H6:,8?-&>4=1>U:D<]U+
M0@32.#C-(E!C1EQ05_L598V5NL(KD(?V,J^$YRX-Z?5Q%]\W/QZ,W811-884
M*P"<?:7SL7LT& *0]VHM&TS&"/;XV@P-R)&/:G(PQ-?7VC#W<YAR'PCP: 0F
M(4_:QR&0#5C$;H5U<TQY68)1YWL180>V<CBH#/ );F#^)@#1A_[@K)^I3%;U
M@'B>C=,H;PD(RU:GMFV#TVZ_9C$@.*!%J$\KT\(YQ$_=478RY\U7QKJ\X;6Z
MG,^CUV8]<;!5U=L0[\ W\=.E#''DP9% P@][?9;W"YU)'+(-H-^C[#?4BX)8
MZNM=/+: 7W.VIOYT)Z:$,#=86+O_.YJSV77EM8JOA&XENY7$YO69=U]@:MZ.
MCCL)!G</E/M+,=?_= %/^V/@)Z-C,%S'@UY8D-D[/_F-[8-^YT\+C!RDE/'L
M=8K-%6-4:R)* MJEQG_&7^'%-O0+NL!$IJ9A (;+HRQG!QQC']G65\AA^^-L
M+@"JP%E&-[B3'?1.;<AJ_@<RV:LX(HYFKQL"0!*X1^!D^PRC^P-P2=#/ +^C
M;S<[C[MV".:NUQMT/FYUIENW"6KMMS;AXUL=]HB+C!GL]\[C?SK-'V&%!2>/
M'S\A?S[YN_/+WM;NUO[6XZV\&+]6)C,##"S!.!]G#L>(>(->S3MA,"]C;= 9
M_<7]FA>!TU_LKPV%>O+)'V<<WO'C>HGFOL/RCYAJ/@V_ 9:0HPK-Y\&6@PHB
MC89_Q:-8L]WYG4HVKU@=>D#6-]VX;K^Z@(CK.W/=AM&AV6BL/IJ&.:I<;>\4
M& ##,C6K>7F&K@GN<S?36!0-9"/]VN>!79GW$F?/&<93V+@I%YDM["C&#R C
M]L0>543*8BRNAL?8,-:M#DCLSBF8B!5Y!1>U8T]/!SB.T'EMS_OYIWT@]4_@
M)8-SX)^UQ>B\B&.0V-R<[>4Y4&4\IL908>A4H^FF5(UO\6=3@P,BG6W(0H!F
M-A< YS#)%AM,3R7(F4+-!@H;\><$!MA, ES_J78T@SP9Y VK-O2D.QK57L=E
M7IV?#]+"RN;Y\QP&+$L7J,1H1OY'M5RA_^4_=/ T<ES3O&7+#T(2>VG.Y%?/
MGK.-^-0ERYY=F8;0A(C1LVZ_<FPJK^-\ZG+U8S>;R*F_U<_6=,F[@E_<>^.3
MU?#4CJM@Y3VS.EGZ517H7# Y^!<0K*/C#$?@I($#WD4#5:_(9JU1=FHJUGI=
M4UM1*1Q2OXS$=H0PM6!*_NGB,G4MN$P6/>?.SA D%#GY7W\][OR"^LCI[_4/
M\]_8[[]6"H/@!N@Z1'<^PPDXC?4'\<E-?*/:Q-&,<\-(ZNDTVOY/-J"=/VRM
M>"]MB@!=+R>G")@U3-U((/!&SPG_YU^LE+__S !F93(F1R#Q'=W(6[-'M2BA
MM1F=5>'TC%ZU9(78/U_9X@Q8F0;@KYHM1F\]V]B/L4+*4>WZY[S:.*QAMGY!
MH]U3X-Z:_JB1[O7P/R51<\[/_//A&R_CZ;@Z2.#U?+-O4_GGHVR6EF1O_:L6
M'KR)3SX $<7G,G/Q.M;FJ5[/E07(N[$/Y"P/D!7-@Y9G?XH!9. +JT.;8Z.+
M]G#Y+0VQ18HP(PH^P\$1N,6@B 30$=]TP8+4K\1MGM/^B@$ (1@/4:::8$@?
M^>]Q]Y0T2KZT?AB7 \P8G,4%1KW\X!5QJ;W'/*4]X+C'2Q/**P6REC-SFC,N
M"WQJ/.[-!+8'# \WWQX-8_733"!!**I@+(RL80(UG,XL3F7@9]^TO5$>UD=P
M2F' 0S3<]?.G MZ,"G%W<<>ZP[DCL'EDC!]M/J!?8"59SV:.P-R@5A.IVL2I
MBQ*G>)LX=0O&\@,3I[Z:"+64.,4#E4)+&TP1)$O"*$.%D4((S8-P7TR<NKU,
M\TMRL=<%AZ+["08T\!^JT,[]8-8S\U_3:[:9@RU#Y)$QS$\8Q:M9AYD%K^(P
MWTNJ<4)O!L,/FQUO3_&)^2D1#_VVFI<VP9F(-@7^^QAS=3!2PQ]Q1OQ'0A7C
M9>>7)SDD\V;KU\XO^+J:D%=/>]PPJ(:85]9JZ9=U%*J9;(X/YT4:-5$M-\ C
M$/C+7"QK/F:U_K&8^UZS!#RQ;V(31<.[%O>C^$'[\1*<\>/+;,CCKO>#<>SU
MNBN[LKHIK-F4LBQ%YY>7:S=E[HDK.S/UKZ8O^NH>+'F&S='8U"OL8MAJ+PZ/
M8/%>3ESG6?[(_ ^>;2[OX]]-.*?S$:QY?UP=.,QV,;]QS31P>V?,E59[F;=X
MRHOY=(/[59S_5JC=BXE;HW9?V&!5E/RB#:X>MF9O^V'!15 _="DN+?&']AR0
M^"J+H16[4-KKIUV 04M+-0V<+G\K@]/W8=-4ID=?$.IJ//C\Y1%DOW'J+S7I
M9_C)I]$-J^.!J>\\G\!V]V-PU>FNGZW$U.6H79#,&9IH?8=)#.OG $W]DR\'
M^E\^>0SKWL/T+DO ;89?]WJQ?]3D3MD0_SNQ502]CMOG!+E:^,'+^G1>)1^@
MZ_5;$X:?C);CROBB!>>_VB_6J35D-Z8N:!+Z7'_GA[YL'OK5)W'9Z/(LHC\G
MK;_!&Z;G+8T'#0-]WQQPX#K\N?4WJ-Q@>&3[4U=W=BI@^[9W/NJ.E@X%1IUC
M"W"!P<#Q)IX P(LK,!EB!#MM=G[I_@I+]7[2K[S)ZL<8:L;1-&L\]46'@Y.Y
MP]C9C$^RO?@=G@:/@]7WZ/3/$"@_;';@4GVZR0Z:G.14G]_S+.$!W5\SA)W5
M&NL'(SPSZ?9];Y)?:D$?AOUX/ETI_!X>XPYGD7],E;G[FG49]CT]/QQ5V;.#
M>T+"YP,U> 93SW<F^BOS1F%[?%P?9?K8Z_SRG]A]#Q+S:^=E/F0#HV-/3G_O
M'$9_W(>9')T#?H/%^FL<ME9CXDM4:]TY[O28MLK.;2S+=3&0E9/3^H IZU$S
MK.X)Z"/(/MBJ^DPH!WO&59(<GDS.M'1US5;.$#-23$.R>,(7,D.<J1]^./9'
M56(&3OQT4J-B??2X.4O)@''E<U-<^_Q1A!<<8_-5T.W.^TDXRBBZ D.;<Y%B
MF-0TU]%.,$Z&.22^RK28C0ZC+]7)03/]3; _R7:KO+8XKG,SQGB&B@_+AZXI
M#K-\Y)6:?3$-[22 Z<EC"Q-?)[)4(=D^YH;DV-X<?RT;<5T)E*X(\&I<MADY
M?A?'MQ+"6V'_>7DPEMB\I$[7ZW[LA@E8A7")(]&YN.7*B^!Q)^LBP73=!+/2
MK9E>CB_7$EG+V6:5X(:;-@U4HD8T$@[CMO5I>TWY4I7Y-01KWQE%/XQU#D2H
MDFV:H.?J]E>/KQ/#8<O.&_6LTH4Z5>Q[,#W@4'->R736=/Z4[<O;FLT9?&<J
MU?5"P/\7%VC-4#.,S*;>1.+7+FS*9[I-=NTT;7PZP(L'-)STJA.954RU'^&I
MBQZY.U\\=*_<<V[F_//JG'S*;BOPO9A$S]KUY E64#BWL?5V5ZG,N$4SM^;T
M-%8IR:OX6@\PP0#Q0Z.98X.+A-(Y] #K%Q[C Z0"Z!_#W!N8J1+1<A(';,Y4
MG68A^E&<SUN;.^>?G>S/)?LUHV^.]P=G.=?V$EN5)1WU)^_/_:8US2G67+[8
MG9_OQO;?(%'Y:!2]DX94-U.=N^<S.\5#VNYB[,^2O^P,S:OLKYJH;&9)7TV"
M[J+8A'C2K[)_*B>LM@_53WV%&OD<:I3]#$0BT,W9:5$SG#H>M-.<8-6\ 5W]
MZK NR_TL\N"&%9& QTS]W^Q+36]J]9#@QTI[9\K[^!BY GP88,<V? 4(PV"(
M5POFDPCG*1=^<YK;@&E0V4T /G1R"B(&3P./!!"F IW<4:VZECB:.CAVM@=S
M#YM/Y)UQ)$Q*Z@W\AX4%FG_ 6@#-FKZ9CQ7!F\JI\'[ZZ6:YYNSN=!\OM7$U
MJ#2C>8Q'Z_ES^0#D61]4[;36-AP_&HZ/N(BU*U5?+<  5'8.ZPL&<T5I +S
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MVMA=B5X]5'A08)(395ZKP&74WK$82P?4+%)M9"Q;4G;'X&&5E*7H0XJ.:&Z
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M=,+R.17& SV&T\VST0AKY<GR,$J5;4^5?;J,2NUP$,1N%.F>8?NZD\0!J+(
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M<LOU(_?)2\_I.=;E:+]*U'RT8F+G9L22F%"28$-)<,F"2 +TW1JQSJW T)W
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M!)W,QC!&M(4CLRA*/\["@O]WAMT>,;!:G,+@OXZRZ-MN3X$#'#V.QF\G[\?
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M[H8)&YB&;CBFARFT/L;.0:XSGP$\C>UP /QB7R'26:E%@NR]C1AF$,);C<'
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M4^;/O[K,GZK8=S@5^SH, U^!:DS_R=GH,)3+OV8@&4UYCY$P'(L ]Z$XQJ-
M^U:M6'MF&4;PL_9[&??K2E/UMQ6FZH%.FN;IN1"Z0SZ*ZQI_0\YBB2U$*=9W
M1<[XJ.[L*PO_-=W)0'S#4+QD^5P[.@/;37]%=5/0X*@*%=35_/!'HJ9:,<L3
M!F!BQ M1/&N"YLD,*XD('W4&IEX&\QABO=9(_$HHD.DLCX8,97UKV<M+U8Z0
M1D*6-E5]J7L;Z. S+"U4-D,A-2(Z <OZR%S0CU3#N%W^Y*EI+VC6$,[BF$K8
ML#D=*J&X*C4VFXKZ<;"#PQ0H6=&$:1'8^%CLB*YLXGA8I&G"FW*T]/EQ_?E"
MJX@:*Q-YJ%\955NH)R[WZLJ%T[QJU4_P0>A.FMM3MST6+R*L4!9S4E4" RP\
M0%=Q6%7V%Y5WGF.575PLS9"P,$USB=IMS-KFZKKF4,N"U:OJP9=! 84X*L3R
MU%K8PHJ>56<53;16:4K]WD I*BEU@;62L )5"Z' (.E(0 4&(K@Y($M;76UT
MO<5%909E432#*4T$(U;/I9,"Y-Z(?BYQE(9UE8L:\H.!_X- /U7+0K0'^,1K
ML)NHE'5=6VZ$H!R."QB28P[F'A[\<Y@=O0R>;D[5)2.A1:"6C0+&0QXOV2B6
MP& T26R%V)HZ3IMJ5P$PS<:<C-Y4')2%2M)U_>BE^MNR!.DTYT/@ (39Z#,Z
M$,L15G6.]?-&RQW9)MK[:5V8_(W8OC^JS3BJ[0SR(%R6E/*W]7/U"4BEQH$M
M,\26+3^*,O^<G BS0@P/<^'?P:8@VF?3RF"4>NJRFJH/=#%D>:LFXBO@=/FZ
MEJX2)>;$&YN%B!<#^Y7U&\D8H%+L.1=OGI'GL&;1&R<B?);5V6NJ>%$9LZ/9
M&3 #$L;LM<^$.. PR?2<K+&J^BV(*ZIZ+NJ$]431.Q"+@N/+%93MU2IS2972
M^\G;3NO!@C]89!0/;HMF5&Z11>@%H!*Y==WS2SN(-"6A3Q(8!$%UFG\%G4N6
MSFO96K15L/+]ZV93R)-$&H ORW_B3JDET@6J-96+:AN1-6IZ86,.X?"^JSJ+
MUL"-?\<JR51A<7'GVJ<%/Y6[D?,Q\"'57Q3\V2913YRYN/4U8L,1]B"8:]D%
M\%E?>P_O09=?(5]2S4 4X6M-0%2GDJZIMZ^/ZI,A*M];@:Q\/\4YY=\JTUVR
MSN4#=8F!"<D"<C&]"LE>W6P2^!+8-*[\)"M9^ JYUD* U1"U:"-!.<IAF']C
M+PBDV._I.*6ZU*GH]AFQ*8M0DLIFN$388382H0Q9:8ML^9Z0-[5D0MZN44>E
MJ>4^+CID\,EFFK"^4*(VA 55(4N$.M$0:X$AW*O;VZ/F7#QNJ-]K7"FP1T%4
M(SQ!SE73>B%5=0@6E.SJ/$'AR7FNHW[A%U3BL"XA^Q7X<R*V%C<#XT]4,)$6
M3#0H)(/6T1UZP6H)6.W-6W)=_L'0?*BA; .]<FGJ]&YPL>R/!/@#*UJRAHE7
M,*<PZ)"KR?&$GJN4SD)!32\X:)>*%VH?ZR)V110*H(S*FR>:WP<5QZAW!CKO
M!2P%%=2,@B4P@=L.@;Z(3E8RE53D*P6'Q-E4Q_XM#_,9FJZF77=_SM,SK%.,
MU@^<GPR.S%GM A^S;[SEA5\\B?+0][3I:$:MOO&PH1%8;6COFFD=PG:\;Q'4
M\BJ"7O:'%[PL1Q*(U-O2#A=];!ZX#%!)\"^+\;:_@[YK-\TILS-.]D4-B.I&
MZ:V78@5,D)V-MBB6)/X5R)&/1(5DT5MF+I1%<1T'PGZ,N*QZNS %;'$#/_JX
M.%1CWB_+DU5TZ@G:H-X Q3)DHZ22&ZM'[[6D#VBF$'OJD E/(0M6BAX/<RS#
M+ O0(U3+17L%CNBC$)U\R/C+J(!^2_WA3YLS!,<B3Z6]?"5YI"')9(%+',4V
M-&PY-XEA<C&;+P87J3M#.M9$>\RV(<.K!C^H<I^EL*>H377L+T7SS'D"\Q".
M&B%+T7PVC26?S[/TVI^V5OO4Z%OU3X$8@DV%BJ?PQ!4 7?HNL+ZU-':$6TSN
MW"5A07;9XKIQC%2*M07,9M,:$+"GU&NIP8 HWR@11R##DDLGW^+ 9'M4/B_!
MKO*H %HI2<\@ W!RR5&?$%F).AJQ='SM06AW@6KY=K0XBV:R!T<3JT)B831I
MA)!-2&16O5@+Y]>P>,6'M%:R"#F6+9:QS)O)C>Q.DK]:V1A8@3R><HD,O1J@
M#T1<_A<L/3Y;B'FR)*&T%EYUOFK+E8/P5/R%$)2+YCB-QW&U@+H0\%9VMZVM
M<DIS$(;,@M.)=$:98_(/7SCXI^*S!?\NM87A$["SR^OE'OG/A@R/!!E+>3%,
MIPWVPFV";P#/(N])SFFYN);/" UV3E!?]C$CM#S;@"QM>R@2QTD65\^S48L>
MY,8&(8+8#EW-LQP,<;04I),^I[!E3\P'HT,M%UK+8&JG7K0>:GPOO5:3O"JN
M7].:)XGD[4LJGXA!/G]I3M9) >0^C%?>K1$BC7*]B&9Q]1N,S&(S%29#LR!)
MGPZ,EJ>8I)MT*%+Z@W0?-G6A5K]1E%G>D[.W80B,S M8K&68@?8*#EG:XK3]
M6/%Z83&S'1:3BR;?BE@S\L9OP)R F>;MHR8. R.)7[4.U*BY']#K&;)I-=9$
M>Q^5&7XMU2F\<>'5] ZA<&7;07L!TUV[%6VPLK)GY,J %AR#'@(6-%%('R&_
MGP$_2V=$%>AZZK>1#,BK,1P*AM[_2/1NJ!#S*7[U.W[U5G[58,[WDTNKNV@T
M89OFUZ[TRCF/LQCXJ/:YMCMOGO,)J]S-A3BQ%XS:@PT)A*'/'[0J(BD0M?4^
MVNV= ?R0$T*@6,QEFXP,Y[[V 6UJ%"^_USEU^.M7;(IG#ONUP@HC81V8U@NY
M.DFM5*;M541I-450B2)7)HH$*E&D W-Y7*T=-U2CO_;?]T_Z;[ -X"EZ,@]
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MC%UDI1=HK6)?\9%P"V$_.<';EX*7-4O*^)A8EF@YA]<EBIG(UB(P10'ULLY
MJ1<BST%-&W$\:!]$MD$5WJ-P&,G6RDO06K9@6@S5H+\K)Q.$+.4(25OW,#O#
M:;1[E]5MQY8G4.<]LRCB4RFBZCG#4&E2?R6#E3CCZD?R @=,.1M)2'VS1"DJ
M290NOHZBB>@;Q59H;#+!E: -4N+1Z5.V&IYKP;_+FU3'I[/5KQR3BS+DM;P/
M^3R3KDKRQV9Y>H:L3WQ3PA*F:-[UM6.0<AE1-4UJCUQ&.6)Q1J[0 MB_2.97
M\DT]63D)_(U0;GS%$2MJ!4C^U&F5--D<-"'6L-4G,)50?TB[>F>I'?(JI<*H
M;QWZ>?8E<+<AU#I^?_KIH_;7%(_%?BSPVN6\;CR%4EPM9</UI&#$0'U8RBR/
M=DB=9"GQ&*4N62*6OJQ+6JZM=GYNA96(JCT1VL%;8_(0"%L6SYM0FC05LF/;
M#G=YT8>?-1=)\/>4R8.,*FSLQBU1U(VQ:\#WX7_8>/KB=;M-Z,(4FP[:%_@N
MF LE%%7BM^ +XY.XA/F)\.U3HQ^TLB!:R8?8"TE>41$>"0);HD)D[<2009'F
M.@H-O)R2VLX=A6>>#MJ9L%7*VV@N.OB.DE1>Z&D2=W)^AFV@LWPQ#%9'/;++
M>UPC<'$F7F4 AQ92?,FQV]#!;<6<BK3JC4Y,(J?=YI(Z_!W?Q*+[+FA6W96E
M6H&-._QH*O+7Y:X<18?@''W79'!:/>E9G/!EQ^+U9!"NSB:KZJBV!66<@EQ'
M0IT=4_/H7-ADX@]091]Y+AK\UF,<-PVO0WX&=)F5J82K$U@Y)ECCOQ<0?"LD
MDG-IB>%9+46WV%8L'(9 _1]G!(7$PX2$6Z<.(TETBYQ^4<^["N!2!V(V*H?B
M4^%,Q5!^44%J$.L90&&QU-_XJ)A/=+N^RGOK*^FF8=SJ3OJ],]CJ(X3NT"KM
MZ_WEXFC[>W*HN2V:!U&>3ML!.[0-LPE!O*R&DI?K&F!?=.E'[G)W5P^@,9AV
M9W4(@C#O:]$XN@JI'56V'ZSP;>V4?U6E1-,SU_+!+C:0KA((C&)IIJ'_OSW1
M87=I'GN9-U&98SI)O'A]HOFXODBQQ+\B0 M_8F0 ^*,JP2%N)=VB[^PB29^H
MGK/=*)VF>LYVJ1.JZCG;F?-QMT+QA]0W5?6<[4;/V5L19E5%/AAA1Z7G]KX5
M[5KE>>_>TK-[10,)/W6LM^4NZ/#3.F)PTWJ=BJL45]U%0=RNC9!0 [NHAB>]
MKP4%)H1%^:P)-L28$A_)RH\4_1VC ^\'?;#G/>P.O+R[[?4W;>*]G1+ONS^T
MJO[_6@SB]MU'RB /U"EU=^#^MYRZ#N19DI8*W^_9P1Q8_5LVZSQ@(*;@_1V9
MRME8VA\^4STHNM_%<C^*:_ ]#<L_YTQ4#&3Q.)VD5+H:TQKE+>>#5A/[B](&
M"L8K&'\=S3R[[SQ2!CEX&/^!%YQN>8I[-4V&YF.0V>MV.NT>E]K]W30^W_V)
MW %*WT/^<#=6Z8?"'P</N$%BE_D,KX?0I4!,$C]H(;V_N,GHVX\4-BE<O1Y_
M*._X@<+J5U=47!>W<<Y$,<!6;=B#EN#["Z,,!;,5S%;\\1AA]NOK\E(.6ESO
M+Z R^_XC!50*<*]#,^O1\L<# >Z=KOA=T^T42_=0>]*#%M3[BYL&@]LF N_]
M253 >AV:R7*;CY1'M@2N:>%>QZ6VO#\^.:.ZS0<MK^4NR6PG>9_9AGV*LQG>
MCJ:,IX-*"7OF>;?U@6^#2BL/?^=.P$\_[QK*/R:.-'W%D1MR)*FC7Z@8PTM5
MSWKY9I-MJ'K6'9C+SNM9[XC]5A6)J5OU,6J.,8FH!XTL:X1U7:A%1IEI1U04
MB\?:FU_?G;X^4I5>6E^K2B^JTHNJ]+*%2B\[]1TN+_0*5$A%C[,9#!$7Z\#Q
M3A[]56;#(9574:5I#JPTS0,9.:OI<E+A("JX+,OD4KW/RY4MNWJ\K\< ]W'M
ML'/;^/1^+AMVQE^\>M7/X#\]P_0OZ:JMG=U-O>;;#&XH_CU\_G5ZCN%VC'T?
M**EIMU'RJO]=U7H8:_%D8_XS=<7<5XUWX(DK06\0[.8*ILHNVB"TT'-=8WV1
MML4->A3I/22FM))]K_H\'[[$VM\$#E#P@XVU>X<@Z*%OC]LS;6LG&_30(&MG
M)0_7RB#?ZL0&?7>=(-KE*"WB:=WNKXBX8%-,$>M[QE0UQBX?:7/0<[S=7#A5
M('']7;)@EW93;F<G2'%GTO>HZ1\G^\N.9#.4UH7Y/9*^X6.0OOL+J,R>Z=VR
M^IU"O0^U25XO\#:] :20[^:R=[%$B6BG'F&S:A3&T9#E9WP?17#T&$3P_D(K
MV_04^NWV%KG>#K?HT4#?-X!\R[F&_0'YI-A7=T/\&*3M_F(IL^<[ P5XN[U)
M3L_W=U,(\'$!WJ9/;GYU=;X]DKW\,<C>/891/=O>]/Z\PKH/O$FWN\*N\.[F
MTO>ZPA][)'23QR!T]Q=+>7YO8"H7;\=W:9>%0QX7YGU?#GFNI24?[Z.P/7L,
MPG9_P9/=&PQV4QQ9(=SUR^F!&;*I"VB/\>W]DOB*RWN+%_3W-=GUIBVYMP(T
MG=O0VU[WN1MINB)'5M/$'/0"U[P7$+$V:KQ#V\+M%P3JW$T[=3 ?Y<'T>J9G
MJ7.Y,2BYLE;68H$;>[&&$/XIIZ#C\7AN+Y6Y0BB0)G/Q43J)^:1\KIO^]DL/
M/50>^<.;K8L$-HT^4>_=)!K-8GA'5?^HI,(GXXP*GW L?*)1&07!C[(.!24V
MM3Z6)19Z& .:\@@),IKWM/BZ:P#HL'QJ.@"D _KN:="S3!_[AF#H"+\MV @F
M1M]9/=-VQ#_MGC4P\;&L+I\I[W.VBC9I5-6$8VT#XG*9_XJ,4W \1O#!F.I$
MP7N:J@?T!DP>R/D0GL0&KE@GH:_=5 /J<;-UV"6V=NP%OF9+R= IL,>9V&X1
MHZS3H\N,MG[$\8_6SXK>);Y-)^>P55D^A[7RJ3Z;HNL]0TZ'GUZDY5#\/H>_
MX#D8A>,@R%O4'*=8OSM.7W'>>GF)'> \HMXKXJET$LURW/X+GG.21""99B,1
MI8FS*8FMQ8 Y&(\3JDP'/YM%7!MR%D>@XDN4JEE^QB8P,PWFS,Y(=&G5C[E@
M+6+?6MII$=",$9MA"3SD0,5*:R9==8"5EH18.Y^MKEX@. I9A\KXL N6QX4&
MLHT4()6'U+)9KG'*B=-QJ?'B2,1RBBW6S ?I %L0]9J,FQ7],+6+81H-4?X@
MYX"L.4\+U%,)EU JYF$)^@R0'0F1A;M!BA76C%+OG!7,OFLA^3[P5L'323;1
M(U; [C=9 >+* :%[0#X /E*T!D6B@,;*,D_#F2A;"OH#I<7?:%5JO\X*F$!1
M:/&L_B8&*$_7&.!O8 TLI(**+92/*N99,^JV<^:IU$LKC F64PJ; B^N1$=1
MW5:Y!&U!YL ?9VFDP3] E402)!<S[*4.0V585QCE4QM$:\"!@FM2Q"SP/+PH
M)R0#3V98"!<63!!&:K5+Z%S * 0V:0)$KL!XA72F>0; J2QJ(#\7\\6?38",
M*/V AZ1=]^8O[?CU!QB/<#K9@A*BTVN7C\;Q^]-/'_O::R%J<<@"RPO'VG]G
M+"]1TR;2! 9*HBD-9R;$:56/"VTM2^[A<?IC",RA64!$(%4/@*+&1V ZBZ7&
M:2'+\@GTV&Y/#V^BV?3PP22+9@6-!R^ _T2P84@6VEJ:BK0^Q+96LVE;06@!
MP^\7-@L)0=CA.S K^@ ^_ \;3U^\IB\DH1<F-04#*0'LF>%"T@F\/:T9!EX(
M*VV/W]?^Y@U&?FKT PV8?H2SB1L*K^>*:#&(W"08&S$2S! ^H[=H; J3_@XL
M7G)@BZ=NWZA?",\\';3^1L]!ACR)U)V-$OA8TG<LMS/G9S-X)ZK5+(1S+GT'
MK8E<VE^:U)"=MU?M]JWZI2!"(['3Q 2UE&VX((OD[^*;6'!=07RYCO<*L7M_
M[E<:\7D*E$ZCZQVRE'-Q LKMMZ.C/[0&_AQS5J HT?3E:M[[08%K<TS^KFN9
M+R^N)U4]42.IJ3$6U.AI(8_8#%@/#F((VH<CTY5:B@@!/@:6!AZ,47Z2QX^5
M;9MR5I# AT?E<"W_&-JH/ <D <]'B"'@#7 VF/ =HBU!IV,ZRT%%7A8YL)HI
M6Q(YD\D,A7\]?CB+SWA)0J99&)S<K^),"+E1+8KFOES&'98I%RF/(;IJ"EAJ
M4=-%$"-!R0]+!G$P0\,HG.-QF@EQ"3-@HWE1TB*JWY-,%"I3%I*#G\&2Z ?"
MWYB"Q$273KU*7/AJ\I'/!W#:1/X:]@06DN-?10K\Q'*Y K'HF -!^*7E O$G
M-Q=SA:7#>_GU_EC47-FY0'CDXJIJ3DG#(;VV>AXP936URI.,*#0JVQH:P6FO
M@:DM@A(&H0T%KHTS>*;Q@Y&O=[9,V6QREK56N4C=OG9*.D>,6QM#U]5%Z+50
M,ZG0LRR++T \+WU19=GVEMPWJZ_Z]J3UO=*"[[68?,7EB=XR@?J7MI^8]HQ.
M;BJ\!'F*S"Q['30.= %J8D Z$7+\,KIAU3"]]K$&H<=&HZR%M#(XV@C^M R
M+CJHY, ->A1>!B2P1LRW.)76?!'/D9I=<-'7CUZMQ!Y]TQ5S*7U/-5W9Q5QV
MWG2E.U#EY$HP4@C,.P*%5E81-B%74+^2I0Q2(!L)Z3G,9J.81'_(:^DO8GDI
MG%4IAG*!3XI92*9D2<Z-'GY>S*AY"RK.'FF@9C[IA%2#\'H2$,$8#]DRK8@A
MBV"C8U+/9+C\U0=K E=6Z9-Z66-</LAQH5@J_3;!=Z L1ZC>#DS2[W-2PCUI
M#BT-A:LF_8MZJHY#"2]N4<),2=<)0/&*<,/\_RL6\5A#PA#-S?.47XAE 2F_
MSB;"JJ@MXGIM*W8-%4U,4A+D_[PG=5 #5\24)201L.=J0(IJ)TE@]82U0,=/
MA([O:^\:: 7@A .:F.4@MF(1!,'Y5R;_4A\?LNBK%U9 55)/AGY!'?XIS")X
MZ0>.YBEJI;= +=/0_VR#4QDJ%LJ0A:#:R+).0:^-,1)=:TTB0$Z/-=23KS]0
MHZM2QU>N;N7D]Z8/DC/H6P/_7EKV[%5_(379>^O<9*\U[%T[-QUFEZ7'18Q7
ME!OR&-I,]1 Y\6DI'$<\Q[T Q;]6,]A#ZDRDNCIMMZO3+>7%P5'H4D*WXJAK
MZ77'%O1[VAMLM:!&R^963;G7IL(Z?'7KJ]UJAEV<X99NAM.U!*_ON]T]0V0V
M_X'.H-.<LW(LG'VWOR':M1M$JX7&^C>(5BVQ*S>!KB@D9O2"8/\O9"NFVRNF
M\WJ^M_]MKQ33[1/3/1L TP4[Z>*EJDZLV5FJ?U]"H7,G[:>?MV*5K820'1<R
M'R@L1@D-%#ADTY1?W9'Y,*M9V5;/\7?8L4#5'%NK#H[?"U0MY*[ODMUS'4MM
M4K<WR;3Z][5'G5-P=W2X7N<=ZKAJ_SC+SRCMZ2,F'V)&U*WT^OYB6-OH.0?@
M3CGP7;(\K+*A=JG;NV3W+'O_G40'ODFFV;^OII>=TV[;":2N6K=I=URQG])E
M!LH+G5S*FKP%@KU#@;D.G@'#OGW_P;VH)OB(M];I&?ZF4$%M[1YL[3,XMNM'
M PYU2_=QXXS^+0_D'D*.E6&":A;5HRYM_[8!ZQICW%,JCYIAIV:XG:2G3A=I
M7WWZWF$JYX2)JV)W21OL2F*;&F.-,50ZWR-RV&+'/>4)[/@F.3W3NR\OD]JD
MK?4--MU-0WQJDQX\\M&_K\8^75)L]^RN[7H85F58H6(?F)M&CU16R(-ODJ,V
MJ>N;9!F;MJ166_30H?*^]V@\HBJYZK$F5X$9N,NVE,K"6+/!JZDVJ>.;Y%J;
MJG2U10_M3GE,EZ$>>V+50J!)95A=/@RNRL(YT)VU>Y:QJ6]?[>P^[&S/]VYY
MY>?@-G8?M\]YY!>V5)*5FJ%*LKK_7N0" 5^)>=?4%5?T!#_D$BR;$Z#C&L<,
M>H9[-RRX!A5V#!L4/S\>?O9Z5G#+V)GB9\7/7>/GGC<X=.E\Z$9=?]/:!(=D
MT_U"33A>[FL3D]7IVPL5C3N]L.N[+-5=U$0G4M$AJ<!V4DU7']%\=LY9WNY6
M0VV1XKXF.@Q0&[:*$;4+GO/GVK/T9VTIS?U__N%;IO7BZ:#=G)5'\'W!J[;0
MHC5MA).MNO05'![%;GQY&O'><I/ZQ;Z HPS>#H]@=QYL[OKQ#VW$&1ZCZ@75
M$^DXG.6%Z%$YPK:S14^T7L0&13!44G!)!381C85QEC E0;'S;#0;\Q>P3%CG
MRMR_:K5VWZU7V_2MJT>4T\)OQ)@:"(.+<OB"VB_!\##^Y2R$9G#KIL$71MT3
MMMWP/*Z^,]3I%:YY,*N=C+6G9G-JJ#<9.@M_ZE7\T^;**_>Z*TV@?LNQN^@T
MSY)4M&8]HP_$=JR8M>K^M&<]BM1DN]W]Z?9>U6#C/+]N-^I0_:):Q%#]HE2_
MJ-LO^_%T]U']HFZBD.H7M1F]5+^HAA:K^D7=8Q9/Y]9_6V_W38OOMIMTX/9<
MXY9UO_<B=TFQ\,&SL'>+>QB*A14+=V?5SZR>:1JJ1-]!904_LV];O.\.^]JY
M WW7[C\W>[<ZM^3U:JD=YETNO^>8MKIPU_5-,GQU<;7CFV1;FQ8Z4%OTP%OD
M]._K;G'G=-KCK3!%2?O;S0)4!MM=2=-MN>#9O<"\E_S1O;#XU.%0A^.:P^'V
M/.-NMV75X5"'XS /QS.SY_FW[M6QS^?BP*\C/+,VKG&SO_<15KC\;G<A0;#(
MP^:A^H/^('!ODX;JVGW7]K:??PC#>K=-B+SN.\>[AV3)O9OL>IF=JZ5<Q7.3
M;,(/]\E[RVHU7976>L^;\_ARNE2&Y<-E6"K:79O%O2\"OA-*X^"3*1]M(L3
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MDK[GW7WCI@A=M%.$EGJMBZE.#A+%G(0HT5G,5452LNWI_N&[2'[8 T<I$5U
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M'WG8H^PF-8I[!TON.;<7%81\$J>*P[O ]K.0-7/N*%XJLA NIQACIQ==Y%?
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M94QJ758C\F"^$;DSS*(9_#$N)\G/_Q]02P,$%     @ EHFP5F*?>I6O%0
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MS*$M9(S)AQD+'F_[0/M*K]N&Y;7-;]+R_:</+0J:F)1,L91!DG-@#+$J,UY
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M0C6:I%N?.JK[V^2*D%&(.%K\=I!Q.%@=.*_'93+]'"X7@Z_G^'DV\%*%A#:
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MFO.N8NW!&]G"?[K<MB;C=&EI"Y39%<,(>B$E3<Q"J%7U@7PJ)4U1DK5V>CO
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MZ1BMU)+5PG@"C:Y@<ESQU#KP_?CYUZ'R@R4ZP#36_1FXCO& AM=H;DYDK:H
M3C #*3+K@S0ZN1\X^[E=S.E8V0\PAW257_G+7Y_S[2PO^(I9ZJS(<$$4J4X/
M3N#1*2A.%)^+9*5Y:LH&&-=!@&/E.\1HS<?AK5&T)F*J&;-,T)*JO^*8J$8K
M62?2IFQ#ZZ3FQ\^_#BT?+-$AAD$^/GM^Q?'T7WASET=96E0I>. \$RIC)?B0
M.%B>0Q8^^<Q;CW3<".1*%'ZTC(<8C_BW/!U_6=R^_7Y79?*F/"H6_D>^22,9
MO2\Q2K JACK])$)0Y)1HI0DR9F0#E##L 74=C&@K^R$F)7Y#^ IG']_EF&OG
MJ3>W_\CI0QZ11UJ<9AFX262D)L+I)7DDHF2NC(HYRO8VX Y U\:*8V6^@1%'
MQPE7QLEOMW'R*=^;*#5^&:,011!+"Z\+535^J6O-KC5*)NM3>Z-@&Y;KX$$3
M26^@P" %3+Z.^%1$QN("T5+4@DSF"L1ZC!4I:+&M384++&!JY_;UE^JE%#!M
M2 04*N>D"ADUHL[88UX#"B[(@[$Z*<F35ZUODR\[(;J77O<G1/>1[ZER8;M@
M^A$3HGOIJDM2["&"/A4)K);29920>#&UVWH$)[P':VJS=>6+4/K9*K]_0G1S
MW?>1[Q!E:H]"&/=)N5*R3+:(!Z]3[3<K"5&V#.B;)8IDG)/-*U6?H+B0U.=>
MVMD1'3I M .U0'I2?N=E<MP0CRUR1P:/9. X63V2,5\\TZC<CU:8?,S9?K2,
M!RAWVE*]UP75CUJ8W$MCW8I2#Q'WZ0J3C<N>>8. O@ZRM,H3YR/M>8*7P*,(
MWK:N>+STPN0!.-!'RB<O?TJ&12ZX!"9IT8KL'/#6!$A)6N&LKB4AC2EP8>5/
M+;36JP"JC\@;M_%=J\&V+,4@90"O$&L5?@(O2@+M1#0*F>%J[?U_3H7JAVCP
M2"$-T@@]WA&+ZMI60QR8]5;3GF0S&2G*F]H\& TD6J<1V2K!6D=LGX!XUDIN
M(]H!;+:'Z\677Q^^_,<X3^DA'[^^SE_RS>*,0J<%>A^!B]IG424.F%VL>63)
M:64LQM:%0=V078L]/X >!LC\?X#VSXPS(O+B^O$IWE47\PY@AQH<U@?HF<:&
M#:#Q;:0:3%T#G#[]0!?:=='9 $PGLFRX2(37!= HC=,Y.?2M+PPN@%O[9H5=
M&K7Z:&E(2OUV^_EN/EM(0-R?OYQ<+Q^< N-X+<]- 8).M8$T-X&^55O$#D6@
MIW#.,"9L.$5NH\R16A@@8ODMD>+;F?YN//N?Y=@;H1(Y'P*L3H3-(SE/QF;@
M*BKM2A&L><KZ+CS78O$TD_D@)6X/B363V_D4XV/[OPNV@<R:7;C.8\6TT^+V
MW*8V*ABD\?\.C$$S9YDOP(.H36=$K;^IG<T\)JZ=9H*UOO X/3WV&"+G84<?
MR0_ BL=-I=__!S^O'/U 1Z>5O)9J)[*VM(3@:,-,]6Q+G@3!6]]P;T9RCIRW
M5MK:DOAVA*@'L28>GY0+KG/IA.<U)S<65@=Z!2!SR4%@17EMDE%^V*[=UV4Y
M'"7?P1NU/QJJVP778+;"9DSGLA..T]E."API\$$L@RWX(E.<V>P!4ZCC2%0=
MC$QPF6<8DA(YROBLB;#7(C@-#_K(>:#6S*L[N/_O[N9K5<JJ&>%B'E'DD ,7
MH!)J<"P*2,E&;8JW7*Z-?MEY [;Y*>?.:S]4$QONQ!J(<: KS7MDXSQ;W=L5
M1F>7#&#15TQTJ 6O+#"6O328T7::);OM\Z]/J8>);MA6ZH'9Y(W+D,E2I.W(
MD"DJG8<@K1'.R& 0>RCQZE1W@)BVWELV[JF*X^F7&F#\]"B4N1IS.BD/\<<7
MLUF>S_ VO1YC>*#AXJ^DR>V[>D4['=]^>(FS\3'C9@=$TZ2#ZZFDM=;X-=@H
MN1=HBU-*6D2IK8M.!NFYCC&-A@36Z!YA^>@7&Q_]YMNCZ1=^G]Q.OT/R^J$$
M2+-LM4P*BLZ<MKR@R>01!JS1D;%$_^Y;I\(U7<"Q-O)JQORKR:<P7@ZMKN$!
M>LZB]QW9D[15X)+92Y!?5P,_G6'*,1])5B76/<R!XX:#]LXD;AAZ;#T^[W"T
M9[S3.3E/U^WS$^EX@"#. <@?31X,SCBA!8(JN0 =JN332%5K;\F4\=Z$V+PK
MZE& ?W+T%)H>(-!P /A1YIQ'[34)*Y7:#XR3ZTUB(X.;!>.X\[EU!>X!,']2
M<CBM#E'\\4U4#W*L;:AN)E5L(YTS":/.8K>UWCEIVLTS^7=*Y\"BYQS;]WW;
MB>A'IE=#70V99'B$G):7#(H'F7ADH&,F$\(+!J%X"4QSKAW&)"_2PCYI@X++
M8>5Y]'XIS1 >Y>P]RL3Z=9K_?9=OX[(JN##FD39RL(N8B_4)T!0#42GNI<D<
MQ6#)CMMAG>M:\4Q\V9ZXW41O)\JH?0"X2NSK /&$N=IK\,Z>H=U&M1UR:%OH
MY4P42K;(4+L+2;'H-^4].>S)@F91:EF24:%UPM/9J-,] ?MLS.FCCE.E\3_L
MQ?>7" NCH&@)#@O9EX66C]PHD!AD#I:^D09+OMZ!ZS*RL(]2:)=T_6.T,4#$
MK6/5@BA.118+&9:F-CKD&0(6#APY&9Z"\Z1;EP]?=BG:Q=E!K;0W9+ECIVJ'
M+F!_%K"UU/A154:'J.OL!6PZ1BNES>"U*J DDW7 6P+&1%$B6(O-.R=? +?:
M%+"=CEI]M'3B C:7+,HZ^L4Q1YOVXOR. 8%%%55Q3ALS6%#@^16P]5)DCP*V
M/EH8TG9Z!$W>0\/D=="6@]!A,5>9%F_([U F1I&9L<:VSCW? >='(\@A6ACP
MGO!%_/?=>+:4^&+R.D=?:A]:5SL0J41;*"HEP&EF&&J!1.*![@+7H/S8YG,+
M_0QP%[,)5OURFE?IA%T #F0C[P5W'KNXB2H[T.-X/9QHG_D>*)V-&(2I$RSJ
MG6+1$;P2EH[+9%B2JEC;N@[N3$398^2>AR=]Q-\XT?H53N?C?V2\>3U/JRQB
M*>GH8PZ8JD%0E21X1DO7.C ELJ6OUQI+;4RV?OK)IS<S&HM^TDQNC:L?7M+"
M:)F_W<85%AN)K5I 4IZ./6D28$X9# \NV*2R8:Z##M<_]YHT>)3,AFC!O3F9
MZ.77AZ:4S!>N'+)E%89*-@+R[$%G8VK932JQM=.P%]2/;2&VU=D 33.V 'Q4
MZMT%X%"=_O>!.U/;_[9*[4:9(S5RNOWH<9< ([36T4!!GZI1I&C##!ZLY!PY
ML\7FUB.EST29?<,"SLR8/HIH;#^NAJ&_^%1GF]Z?I&0&!:MU :]+C=<X.DEI
M%P5OA9?6.O7DH-IH?6SZ[#,,!V@K_DE#V36V(M_C#9V=8_IC3J;1/9YH/0O"
M.C".3F8E8@+/K8)L:Y0L)6&8[*#+39]]3;H\6G9;W\OSU&,^BLLN Z=XF^H/
MEO+*\>/M^-]W^02EF#V!G+(*\Q@9K15@9L^+BHQGYYRJ?^K,T7->@K&"9]VY
M +,GIN:!I=</:<=%8M)12[ Q+(Z\ #X$A*"P!)8+%[%U?^I=>,Y0U+.NBU%*
MU4=5$83/BPLI#NAX ,T34R@066J=C=< ]D4X_8?QJD$-SU%*'.!6<?7.ORD;
MI#1[^?71ORW]6[(M"_?%@I0<:UC*01 D.6]J3P"EA2FMN]OTQ7BJNHK!>#6H
M4BZP&F)7 DC@*$0."LB07;00+. 6<VYYLI8)E+'Y+-'+S@4<EAR'I?SU4=+9
MT[&Z@/V9\M=2XT?E91VBKK-S3+O$-)T 8 /6JX04Z@ 1!UF*[)EPC,O!,IB?
M>\K?Z:C51TLG2OE;Y1(QY8T,KH"7J4X'K8GZ4D?R]2TSVNC ?6LSZSEG=/51
M9(^,KCY::&B<SZ;ST3LD+V+Q/L00C)(.H3AR#E2($1QY\Z!LB@%9YIF;+E2@
M3WU$ _JW;Q3X[H%7;=@<+MJ&I0H/(%:!O0XP^E@D733=_L7>;V,<(?QU]1TA
MN88[^1,X-K' @X=4FYZKPAUX1L"\0YNRXSIWV[7/K< M!_D ^NLAL,9Z^R=)
MZM/=IU5AG&?):]K::VM14(@24/L$(F"D0T0'W>WR<8_FOGOHZ4[5H\0^:2&S
MQJ?C/_&O1T"4DU+[VD+,U\1KP@0^BP(L*5>*0VFQT^BZ?<I[_-!GJ+R#93:
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M1I<X!%8SAKQ'"(Z$&*/3RA65=?:7>_2=9VC/N4E\$62XE**U;2XFUYD<#BN
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MS#,+#B4#%:Q?3LJQ14N50BY!MZ[+/?$2?\QWX4(I]/2-<1=K(+V?3^+_K*Q
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M;2&HDL"&9(2,R@3=.L_[9(M[1B_)"5AZ^A?J (J=(_WWX(5^7[ \2LISJ5D
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MTQBG7Q]E@BT;:(I@2^0)2JE[EJ=U>HT.HM,N%,.$L\WK_[:!N3K[KHG4AVB
M\BA%%#_1EX]20E?M=SL@'*JN>2^Z,]E_;=2Y(UVWH2Z&V$3V(V5HG$Y"T39)
M6Z=*W-:"00,L.1MY"3'SYM[BF=BRSUX\%UGZJ*!Q1N_;NW SCF]*R=.'[)N1
M0ZV5HQU3>,]!:>$A:&-IS8EI%(D%MN8R; P];OKL,]3N-I;_I*'P!K 0WWS)
MTQ<W-Y-Y=7R^JPPN-AC)D$/&2/:,I8/6":D 4_!%RIR\:=U5=2N8JZ%!6[$/
M< *L\H(?I7DNMC1MT1 $ 9*[2+!X36L@8U=%63LB<"M2ZVU_"Y1K,R%;2'R
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MN0Z;*%;'$EKS[C0KNQX3Z@*9,$"Z3B_ C[J<=8%]"ONL.^3S6&V7R*)=A_G
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M(&3M\Y^RKTUB.0O"&O(1RJ;HH=ADVZ9IVV#,M.R9L?6V[0 BM2[POX;EI_3
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MWX';7$ E[K73(K%4:AJM@=PAH&/&\>S);%!<ZQ*A1P&-'SCVM]F#%_:M-GR
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M*R=))>Z9W=MU2X57A].RZ"8I)YY/?P&2DBA+H@"*I'BF9[?;L4G@>7X@?G@
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M]]BMZD%HXYG'W0\)OJV?GI8OVFAY3$O#-E_E2OZ@RWN9/RX0TH8!,Y7?J)=
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MG/D(G,Y0CJG:<0"R]_ADIQ?'A&P?/1S]>\]S \-*;V@AA3G/D*NBMN7S7 ]
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MM#9G?Y]5M;5I[V'TYC[E6Q]+YF&<D%!"'RL"$2<1I(&FH4 1*B1#$<'"K89
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M?=3^@,S2;Y =^@U>D,=O@ &VLYZF';:1.>UB3\^1L@$.!_*UO3@_7B>#X'
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MOP&/M?#V/OZ6^'<3SCBHCG[KHP']T +T;@OHQQV@OXT$J'WTQ/# 3A1&,0S
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M<Z.7/=4 ;3OOTDH3\%2K M9:%U VRI@3>;[),RFT7O8YG88<Y&XFN^+0C7V
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MQR%GU&]O.9%Y&IC#:BUW1WDOH-83_&)G[R^@UG523IH19B;2MG5(24?=U8X
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M=IQF.>M^J;[87=JZVJO=J__S7!4XVC@3K>[L]W&^U!_LCYL9-H7*#1$0YU)
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M4KW-G CSZ<=.X\[2P%QVF)=\!W8J@+8.>WOIKGW@9&VGG4[QR"\>OI&H,H)
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MK>17F99CT_IUA.B1[_Z\V:X>]?KS4M<&EI *I40X=T^A(,F)@3Q#$AJ2)85
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M,2$,4B:8*(S,$QX4?7QQI*FMLTY0=TQ\(&I@2\'K\/KM!:* -O!RUQ.OX"W
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M6#=:@J7>EL4-W&_=S]+J"=Q[#/9]P/E.O<"3S4&FWV^E>>U)'7BE.9K/G8+
M:GA8F,']V>D)&D5=D/XO3E<P7_X%[,LY[/7U.8,*7FZ&G)!(R\T@(HZZW P)
M\O%R,^A8X6?,5<8"7_RV7CT_61$6SZJL6'DFNZ'I;+);,"\V-YD)@H4RG$"&
M%(=$91BR/$/0+C,L$PFB2GK7B1Y$PJDM-,-TQ!IN@J^[&UY]V@9>2AK]0*G@
M'=BI",ZG?+5;6[7\=QWMK5Y[COU='J\^UR,Y1UYQSH/\*H/.1X<'9IAQ1_/5
M# I;VZLS[$"]ZUM9\^,[_[/NTER[F&9"<<8$03!+7!(,(1P6KALJ5WFALBPQ
M2@6%<%X89VH+<KT9V/(_@:@DO',;O>"*5F<QS3DCJLA2J*2AT.Z_*2R8"Y#-
M4:J92*D1.*PS4@14Q^F)U,)55Z*"7VJ  S-<+H'KM]&- -C !D:-E!6QZ7</
M?GES#:D^Q<&Z<(A7%NSL*&,7!.M2]4PIL,[+PVAVL][.OND'9Z3\IE</:_[T
M8R[YHBXNCQ%+-+=<P+,\@410#$4A)4RI+EBN".?:RXW>.<K4*+8M86"Y_FXT
MNQD@&D8#?_]A\'A_^%[J=WWV]@&M3][^:_^Y=S][E(_=2[WF4_>[N*<C>;YT
M&9SG6GI]L_N4LMS69U-=->>++ZNJ./B[/[>6;.9BH3_.-]L9R46>")K#@J(<
M$J48+(0H(,$9%0I+F0H4Y#F.(=74B*16ZG);NSNP4\YMOG;J@48_\/M>0_!N
M:?>2E4T=ZB*.,N>>/N&Q9W)H)_ K3&*X\S<FZ+&\O5%D&M>]&Q/&$W]NU(?W
MK#RFJY90.QNRY5O^I+<S*K+<$&0W@((12^NNYD'.&,PRG!&#N65VKX8-GN--
MC; ;<<%\MQL,S=^ZAK ?B4;$;>CCY@:RUK;P("?D4\SNK9ZXQ*H4=F6T<8N#
M^:E^4@_,\[;>&9[5X\N2"E_X^O.ZY#)5'@E^T>NRRL(L):E,$YU E"49))G$
MD-O7":I<2X,4(A)YN=W"AIT:N^RD;@H&/?'&H^;*J:C58L'7&]=YM2JM$GCN
MY#D7?@04'^&!>6@/;EUPQ<IL7^7*-E.U@\/*715BB9J.&@!4O$15GT''3F$-
M .),<FO(W;>X$G;&5F (TH6[)_0-U$OP?CLR1.#/%1BB'LR>CO(*![,753U_
M,'OY\GXO;?GBO[%[!G60<[5>._^;&^?-R_Z2+_RE'/H/OE:?G\K2G[_9"[>;
M#\LO9:&PJMA.*@JL,Y+"!%.['J>)@0)E#&I)LBPI<$9)D.]L !FGMGB7(MJ%
MI'?ALR'FT8^X7GEV!B:]4G18R@X.DT3W"I:%C%O7U4J"4LL[4.OI2C<Y35U4
M1*5K]&). TY%).(=0L)127M B(\)?\BAPB,F75WGS=_F]C_;U;*I8<Y9)J6D
M"LI"6Z8ON$ON2@W,J<!:&21IX97A=6F J=%T*2/8">D?JG86O6Y^C8')T.1X
M"$>/EA=G<?&/P+L5GY$"Z'Q?FZ!HMR[=.X+5SMXV6JQ9E]#M4+'.Z_IF%ZGR
MQ)LOOO"Y^K!\RY_F6[ZHWSGL,E*9RB%."@X)U0+R1+CS:46-2'B>Z30L3:AC
MM*G1VEY8X*2%UD*IY0W-X.F"V,^<C ;<P-QW&;,!^EEX@1(MKZ5KK)$35#S4
M/LTT\;FI?T^*]_.-ZYY<&E7O[>\V,Y;PA!JN("Y(8KE#V?UN0204.!6)SGF&
ML%=WK\Y1IL89NXX+E:3UE@:4LH9WI3@%M9LMHD$UM/^J#TJ]^E)<1.&FQA2G
M3QV],\5%Q<ZUIKA\<>SR0#-::,-T@6"2ZA02+<HPQA2F+-.RD!E!26!GBDM#
M3>W3=Y*Z6)1-:=;^,M^E@ZBN"D#NCO^!R!W&Q1WX'\5=BM@=L&(]:9?8IQ<O
MP:7^+TZ-GZ41!_"!":3!NA2SQ+01%#A)QZCT$]F^Z!AH(C5[+ED6'G?T8YE_
MURY@1ZO[GWK-'_2G9V>J?#:_SA?/]K>GC2RD29+<G:CGU%H=!&,*628)S$A2
MI%SE&5$LA'H"QY\:']5R]C\\#\6?IDKGB>2N0XZ$1$@%[>:168-/9 A1S1.>
MAB6R##@#XR2X- I 7FFP:U=DP-L%WVS /9"M=D8';8P@4&//H-\*,>"L#+QL
M-)*#6G10R>ZFHQ*[W2G&=64L-8JWFO1$+M(2$SKZJ.M.3VB.%Z.^C^GI)I8_
MM'I>Z,]FUS'C[?-Z;7\J.\#MN\737!E%9 ISQC)(<F6WP;I0,.=)KIDP4NLP
MWZ_GP%-;DQJYW1>WDSS0I>N+N:>?=@ DA_8OG /Q#M1BU_T=@9,<E*)'/'$+
M12N6?]1WV'&=GH%@G'@R0^^_(99%7'>8BF.'Z2[+_'ZS>7ZLO*<N_5%:)OVN
MUX]HIHQ.22(Q1,*X@K\*6XN[R*#KD*U$GA@95D5L.%&G1H2-<& Q-^6'7-M_
ME>C@EQ?-U[V"78:9:$\NG<3T#<V^MX>^M*I_M!2^ [N7PND<.?YET&F)&08S
MC*#C1\,,"OC9H)AA1^S9]&:UV>Q*E,BYWGS<5;LE$N>*J0(FW!T7<*%@@0F#
MNL TX293N0FJ%G]YJ*F1OY,4'(AZ0R7B#H3]6#L.;@.S;E_(PMO=7$4C5JN;
MRP.-V^;FJL(G+6ZNW]$S%F6Q6/WATC7?K]:_KI[%UCPO[J5</2^WFZ]:ZGE9
M:O?K:K$PJ[5CKQDBB+K20] HCB&1G$"N,PXMV H3UY6;!NVK@R68&K4TPH*]
MM'=@IQ6P4H.W:ZWF6U!^4;\[5<#[2I= X@F?+3\^&G0.!J:I8> /#XSI"V&L
M8)G@\<<-H.D+STE03>\']23(DV?7063::&Y-I@0:FF%WOIA +A6!V*3*V'TX
MEB3(ZWYIH'\"N@LDL4N(>G)5!)S&IZ0A0O&N !&+6"X-,RY_7%'VA":N77];
M78FZQH7SPV^J%*4$BTQBC>V&2J4N 0%!IF0*#:.$9#AA7'N%WET=:6I\\*L6
M6S"W6]ERN95.SCOPT)E.% BM'R]$ 6Q@8BBQ^M!@];;"*G+JU54<(A>-.!WG
M5<I%7%3W4J&(RS?T3;K^J>NZ\C.4RY2F5$,M7:L/EDE+!@6%>5%D-$\ISL/(
MH/7LJ7W^+=%"RX?N\?+[PGNB,/ W[0- C^3S$U6C)9SOGSQRDOF)2J>)Y:>7
M](V6=1$^98V%\JAUEG*-&3(93#BED) \@2Q3.4PD$@()0R@.JLQR/,#4/LNW
MK1"GNZKX2FA0ZQ&"?M_H+;@,_*'6D-1E4^IV9VXQCAEN=$G_:"&K1X\?.5#U
MO'*GX:D7K@M/]GVW6*^6]?Z0(6[_3U*H>6Z_88GMCKO:=I/"2)*FN?9N:M)Z
M[M0^W5(T_\35-D+=W^@->@_\:992]4C:;>ONGZO;$X.14G2[IS\H,?>,HAWY
MN.VK1TO#/2-B._OVW)]OJ8GDCH#?6P'.MGIP=>(^F^_\SR]ZW8Y>G"5:&RPY
MMR:#ML3CPFWL=CZ%*47$&A%49HR$MV#H)<O4R*H\4]]5<KL89%UVYE,[15VL
M]6JGZMU!U/6MY>%NF6C*L)*9R:'BA>L+H3&T/V0PY04G!4&)2%6?OA"#3_4X
MH?6?FJ:+_]=,N._&<Y1)''RCVFZO6$[0^:Y)57;7KM>2G>(+UY5%3]W?K=YW
M9='!)@$F<O'!"!,0M5Y;/TE>H:;;39"=K_MVVR/['KN+[8?E9KLN#;!/]B6O
M.TUPI!*!$PESF6:04)K  M,"LE3K DO)\C0HH.G20%-;=JN#Y)V@]D.T%P?V
M\+@*KN^Y^^V0C7+L'HQ6CZ/W;BBBG;Q?&&;D@_=N94_/W:]<WX\:WCQOYDN]
MV=S+_WJ>5Y7DRQ_7NGF-:6:H2@H$I48<$ID0R)(\@9R(%#.6RR(L1_7JB%,C
MBT9@T)+X#C0R]V2-Z[C[T4=4- ?FD5N!#"84;W B,<OU\4:E&&_UC[G&_\:>
M]LA9V^>O>J',:NV*431G4D(A46C+.IHA2)26L. R@2DV&K,,T\RO*F'@N%,C
MH(O;!R<YM*)#)WN@U>(Y!9Y&3'Q@A[9IO# =(.PH$*I8-H_GJ..:0&%0G%A$
M@;>/7%?[G27,[<O>9-M\WO[0Z^\_^/)L6=>C-/#RC[_RK=ZEN\P0XP61K("D
M:K*88LA,FL.<82:R(D,*CU.-.[9F4^/;=@WO6T_7)@/RT$7 7_.E&'BMB) _
M6:'3VD1O0(D/V%J N@J+G]3_*"\!#JI64N8$*H\/-?^O7:\\NE[_'%7.AYK.
M:+71!Q/PUKHJ]]8D*?TS\Y_ZFY;/Z[*'UKL_76T]K=S1K]/TN?*#?S;O^'HY
M7SYLFMXU^VH@V!B$J$(P3Y""Q!2NBVI1V$6?9B:77#(>E"$17\2I+=SM,B-M
M'<%>R;Z56Z+-JN<R_*IS-?1Z>GV:0*-@Y6AKJ>AN:I3<-^H:J81,[,F(7FPF
MFH"O5)8F-L"7"]A$'RD\.._-/SY^?%N?LU!&<"IH!MUQNB5[M[GC:0JQUBI!
M=NO'"B]/W-%SI\;0;_X!K&S^$6IMB+J9\P;%AS[V+G7N$9[75MX_/*\G"".%
MYUUY 8+B\\YHVA&?U[YZM/B\,R*VX_/._?E6^[-='T5O78';5BO7OVF^>5YK
M]7GYU7'>VE*:M:SGFZ-"=%B9C"9(P"1G&A+%<\A3(R%E&9(H9;D(B]B+*MW4
M.*UMSNRWY'=5U_<J&*BE(VB4!-:6V:D)2CW[&J<QICS4+AUY(D<T26^;PY$L
MT8CP1S="8\CV2O9G1%@OFYXQ!^FW6M3NDN7#-_U0'IXT*2(Y25-,"E>7)H4D
M,1JR(BT@U5RGADEMLCR$]R^,,S4&WXD)&CG#F/@2G'Z<&@&D@=GQ%)\!'*-7
M8(C$4I=&&95OKJAZS!S7+N_KV%RMMZY@WD?+.&4>]TQ0D0K7?X"R)+%FG\*P
M()A#A;0DB!1&IT%YUZ=#3.W++R6$=J1'L' RE@480CU\)SCZNMIN06=PGY<#
MQDD'2O'NRG(+,?U,EY2/YO Y&6!DS\LE!4]=(!>O[/=E[^P+#[/B[\N5V.AU
M6>+EP_+I>6O_;!6T=Y4' :75,<.L$#1)$$RUL;Q@[$Y0(-==,4LYH;E!U 05
M38XMX-18I;V#\-PVW(&VHJ#4%!RJ6N\L @--H[\,?N3VFE,\,#6^TNP&4^Q0
M4Q")H*.+-RJ]#P7N\>(PV#BWI0N\73V*^;)\[+>M?FH%"C=^><NS>K/]L L<
M_JH?*[&=!?N;"W!'M$B=9P,F"@MK;28<"I444!8I*QBG"=)!R4<199O:@G(@
M('BP$O;+-H@Q;7[\_TJ3,;0KI\E@:*EU!YQBASD-NW"O2CD7T-6H=P<.)_.W
MKLGLG?$0$?;(N1$Q)'N5+(J(D%[*MX@Y1#]^_[*NR[N5U6>JYE/WSUN[0YG_
MMU8S0W.9$DO4"9*9I6SL_$)) E6*<B42E"@:E O6/=S46'@G;5,7JFZ-QW<2
M]^][=P5X/]*-!^? /+I'LBXG5?>RVPL;CQ+]0(G$<E<&&Y6X_!0_YB+/NWI$
MN\Q7KF74L_-WO-V5M?CX\>WG/Y9Z79^8\\(R3*9S6&0T@83G!!9)QF"6Z$(1
MA(H\]W) ^ XX-8K9R5RZ'/=2EQ$DI=P!X2,^@'<3RQ P#FVB[1"\OX!@GT@<
M'R@#0G0B0SI6[,Y5:"/%]03 TQ7PX_.8\2*! I0Z"!$*N:]G;:_')SY?NQ?(
M]?7;VBF?BT7MG'X_7\ZW>C'_:8T050A)9:ZAX91#DE,)N4@P5 5F6C-2"!QT
M#.PY[M0X>B^VBQ:9[P0'O)0\L/J2)_9^!N  B Y,UX=@[F6N(V_N0"4V_.CD
MCE@1*0RH6-6//$<=M])1&!0G58T";^]9D)AO?KC_[_;!/_E"EZT)-MOUW'5]
M<W^P['CXB]:5LX1KSC-#8<I<.&-A#4J1*0TIYR;5R.0)4;.G,D_HVY:OMW[T
M=9-,(9_@L63#?8U.R#L@[7^!WLM:VJ+KG2;5W_D6;']H(/3#?+DLZ].9\A>5
ML('%DF^:72;30G%9P(0X[R2E*622"IAH@GF:8YWFS>R^6ZI)SFTCUY1F5ML_
MO=J<^BUWH\W2P(M@-3GNOZ EH#LIWLU,=8F;KJ-?MN^(6(<[!K*QBG;?),NX
M%;YCP'92#CS*0WL&BKJD6I<(M=8_]')C5_)6%</56L\?EE4#</GR?<V7&R[+
M]-VE*O^UJ))YU?]YKMH2--4-9UF2,"4*#%/-<KL@2PD+S!&4AC-%N=$)#VHG
M,(R84]MXO/WADJ*=,\E4.@%9*P6V>ST WRD2&L8ZS&2GDD@FC8(*8[MM+(2"
M(A6T[!V1%IGF6,FPJL"O/]WC% S^?G96)S&I?@OTZT_4P"MW5<3C0$-P4"CX
M#M1Z@D91T-*T7-#;L[Q7MET<.&*0]: 3$BM&>Q@AQPWQ'A3HDPCQ84?KW?IS
M_:S5F]7R>:,WU?AEC#G->*$@1]) HK6&C' -<Y3E2&J2%B8-[/MY.LK45NY2
MNO)C=U7>YYO-W+=%23>8?BQ\,T0#DV@M'Z@%O*NI,F*T>2<"\1I]GAEC["Z?
ME]4\T^*SX^+^?</FE>FY<U?4'===M;[%RH6J['-.E6$H13F"RJ 4$J83*(S"
MT' BBH*FR% 9VE7,?_BID41+^IHJ6O*'=Q\+F ?/TY;!T!WZ>.4(V /1P5YV
M\/L@2;O]<(O8\2Q@\-'[H84#<ZY;6H^GA >P-)U/[Q]=:^0O_,7%4[]Y^68U
M+;VPR'F@FT1:*C-ML( BX1@2FG(H&)8P3^S_4UASE22^<2P!XTZ-TAK1024[
MJ(4OBR4VX@,$G +^P1@A\W ]O&4@= >FM$O OCD%MD>X2PC"_E$O R$]4O!+
M .)QHF!ZP-41#!/RM-%B8GJHV Z-Z7-[/[OVM]5*_3%?+"IGMQU1VG?NV>Z;
MM=K[O]UF>V9290@2J65ZG$ B-8-%FMGMK6 \PXEK>1=4.<=[Y*E1?TM0\% K
M >;[:(]%<(=[_TGPLV<'@79@WF]DO@.-U*Z!QA[I5CC-QRZ @XW88+ BV:_^
MXXYJN@;#<6RUAC^@'W.UT@;K+?Z]V&S77&YGDF6"Z:R DC+7EC-%4&A<0"YX
MRH4I<JJ#DCDN#S4U;JK% XN]Q/\6QD4=L/J13QRP!F:;EI"[0SGP>R-HQ"WR
M=30BT4G'0*/RQW6%CPG#XX[P+:T+&UBYVC(_]?<?>LV?RNSBRJ[GC"1IAB!E
MS.Y@-:*P4(;!%&<,:VHRE7AUF^@>9FK,T)(4[$3UWSAUX'E])QH'I8$IX2Q
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M'=2['V&J^2#+\O]$6TFJ35N^EF*^B1:KTGG%[*87NVG#/\WC3  MQF@'\N:
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M/2H*B% 44((*CG <*^:4-]$SUM1L6PVUSG:X:<Z$([J%._RDN(]O.]/FB<7
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M]A,]?X&[G]CI^&J:IKU;K<WYR<>5_J#7FWNU5]*_S7;&648IR0C L4P PI(
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M'I?S?TKQ7NCQYFI.MUM!50*6R=Q>BDX_)OT[_26))J.S\XLJ>G.6Q0I!5""
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M5*,[S"C#IH"#"M_MQFRU(BWOGS?E1CM83=%8/HNIBI.,,)"QQ/2B3B2@1*9
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MI%$M@H7(AY;!YA;W"DC&R']8T>4[:HYN3=6]ZF5.(14DR1C(52&U84 0$%%
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MM^^0_S_6OOU()>.W<#^&,+R%T)\&W+O5^K?5,]NHY\4MKWI=EY\EE_/O57P
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M788>-X5Z "E'"=1#GC&PNE.GG.F]JC.WM86]6Y6;<L;B1-+<E#Z40J]S2<8
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M[6P0?CT98K_81K7406@]-.5A!AD8HMY6U7F_?'K>E!_D=[F ;94+Q5"<)@7
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MV+3U_#6:5V)$1LN1.!VN4?5V-H[IAOYPS4!T4!#E.,GRE&K=5'W)& 8DSA)
M<9QDG'.4<C'[+M=L]=HJZH((&($FR_+_U([F!+1CMP((Q7C@&;2&'?WRH?HD
M*K;/!LI\K-G6 G3C:CZ9^C-FUVFS6<_9\Z9:&&Q6T4=M4O5CM! +<YG)D-3
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M]6.?^>[PN5(P7[EX0QBSB$*4XAAFL:!J:4&!5Q:O,@H$=X1S;LM)(R9HR;D
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MUL#)'_ /59SR*5^K\YPTHY<M^I(A+_,I\2%FC$!$"8=9+'^B2/@DC7P1B6!
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M\U/H9<239QT1,!0:!ZU=FFENIJ#:4[>0@G\IK* $:[@MN$ZOWL[ "FF.+<1
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M'_80O-"44ZQ:D'S<W%'YBRWG_\/7K/3-/.2MX?QE$$:4>3B%PDL)1"3$$),
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M@TDS0M0OJF#$1BAW7K<5SG%T7RS U_.R6'[>R/0#AEF>N."B"IZ#,5*!4LJ
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M7A?X/FSN"@8FO+ L-UVY--9Y)SJ#%\F!C:%XVM6BYK=R]7?N[PY UDCMT8;
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M6\^/21ZL3JI+5ABG* "\?9N[P5'=U?O'+5IOCY.C9=L!+MXM\Q><IO,NL61
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MQ"1BD6DT.BLTOG4AU2'TC5.GW2U$!U-M/_OXIC9WA_PNZC(N2S4F3-(R-$6
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M= "OUQ?D="G]7]9^%*+D\XN+_ M^P_/YU_HTO&7*H$Q,1$%Q1'V(0R<A1&%
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M?;EX.;^X7.(U$R9F:;G4X#0B,9$2Q" 04%D7F39:YM9C:>XE9-K,8E0<M5/
MQ)YFR\ 'BD87L[6<?OWR]7S^'?$E7F"9K:Z9"B0-.OX9L* 8"0<C,14C!"EX
MD4::HO,.?F?G+YSV)!O="XTC^ Y\4MT]3\I:O0O?JZ2V7!!_O\\OTI8E%WD.
MGORJTW48DP[$#9<.6(Q<JI*E4:U7D^Q UK05#4?Q5ZV5TP'>/H8_<?DC/V?6
M1T13Z!BWE DK;Q,$K0T8;V1PWF#&UH]G]Y Q[3"AH^#I4.%W@)^WJ\^X^+D$
MY#HB9"Y&G1QHF\@:ZNQ_[X('P:7UG!RSL*V[81ZG:-KAT$=!54.5= "PAQDQ
M@14C.3&24EU@ILCG)J_!),XD-]KJYBV&A\'*GC2LVBBBV83[UE5]+]+_7,Z6
MZUOD9;C(>?:-#OK9JEXD-YAV-N33V]3M[<U/HT*]EY=+@MUR^6K^)<XNKHJ@
MUN/S;I%V7?-4)/?)& >)UQ6"+!5P.2-8);B-7#-N6C<"#*.P7>G=U??>UM#+
M[[?^:W.K5YQ$D119J*H5N842XJ"DK9-<$EF54JYYL]50&J>]ZAH180]7U8V@
MO X.V7NXVCR'*4YAI_" GHX*)3,'A]'6BV9+7MT)I\>RRCND]%(^-X;^Y^V5
MT2FFZF\7>/565E+,0;, R R))A42E]$!O+;6*1\5PV.@ZP>B^G!I!ZE^!SCM
MKX?^'J"%<;H49DDB-E#"'"AA#L1,R-GK8C@343T1G?7X -U8;8\_-0^180>N
MY9')S"^__R/\G_EB7?ZW-IV0D%3-,XA85RV9H"!$:<"2AW;.HG3VB(LP[I+7
M2_G8$8ZUL936-QYO&+M5))(\"L:K!%D@<U-DN3$R#I0K.^V24-8=<<W ?21V
MN_GY,*CL#LF#]=8!+.MSQ?DYIM5E.'^WF'_%Q>K[UN%+8UE=P@I&:04*90*B
M7X,O.2HKD'G7NC7V86JZ!=OA(+CG :F!1CK UJMU%=PGDF_M<YOE;2G<R^\?
MZ0/6ABDI.#$B)\@:Z^[?0KPD7=]ADTS&BRQXZQ[+)XGJI;[K",=M6P7UB[C*
MSI5E9B&<%18"!<"@>/ 0/!T%,CL*DZUT,;1^%W^2J&E]6V,0[ :Q/34R<6;Y
M(9SC\A\S^F4UO[AJYK%2JV0H+]))ABH=1\&%16#&4T*.GE+R76:AW??970)C
M7]7-&\IQ8AS\LOW*'^2R92,'JZU($5B.=85D8"23),&$S$@LW*5B=H##(U\Q
M;3XX'BI:2;43<+SX4M];MY4;+[__K\OS[[RJ><N1X=RYG#50U"9 19_!QVCK
M!G"5BE9"9CL )X]_V[0QS?B0:2CK/M'S ;^NUKS<9HO)9$6M&[.R>LQ #,:L
M.6A76!WT)G78Y>09\)73UN\='4<'2[U/,/VO<'$9%FL+T5>';\* 47@H++.Z
M#22"SZF %5%DA1G3W7*^0=[HIR^<MG#O^ [I,(EW#R.S94J;^LXD$Q17V]&L
M#^!<=."22[JXA!QW>6?9^0NGK=2;$D;[2+Q[&-FK(<@L25,84BH@:G>'E.#1
M*TB1J_JC)*)K B,[ $:C5>9-":-])-X5C*[Z8(LW64D.!F/=968$N)PTI(!U
M-E90.<?!B!D #G?JX-A#CA/CX.,BS.CGGS[^@>??\!\DI\^;>X7MRA65T"E.
M$I$A@1*Z=EM$ UK[[$(L7!NV R(>_Y:=L.%/#QL-9=O!K?#U1(CU,\W;\F$U
M3_^]OMDTY-CJV&LPO,(="?A>5B%EYJ+@!1EO7C_Y$#&]#*T_PKM#&X5T@*S;
M]&]-3GHMK0L.=*D!&2\4BS$M0$KC;-+)^>:3"WZF8N)*R#;JO?N2<)BL.T#+
M!ZQ]J'][=_7U:U:NJJN\BHR.5PB:Y*'B.@ CGZV#T;*8DE"U;H)ZA)R)'QX.
MU/1=;]-([!,B:+E8W?+0OY(KKC4!J\_S_/JB]FQ48_OYIXBU)&$S1#&&$)61
M@-(0G\$8\((9"$R2U0E-&>1. PN(D%O0HO^Z@=6A-$Y[)724\^^H:IP8K@_Q
ML35H[S(:+1+$PB2=!$@&K56DE,-ZIQ@+P>ST#O\$(!^G8AHW=UP4S$=127\E
MWEX'E)A(*(4C*$M!A@^"$A-1O#5U;X'9Y<ZHEQ+OUOIZ8HS8 .%U$$B]_5K%
M__HBXY^8/\Y?+Y>7]-D;<5U7K11G4%AG@=>=1XH+#5&I!"S7O?><.2Z:MY7O
M0->T5]9'3?.:J^D$H'?5=^&S3*JN -0I@"(NB"N)@#'Y*&JM9O/J[=THFWCW
M07-$#(3<'NKI '2OPOGYAK.K5Q_G*',A7Y^,JD/4&(/@*)F6,2)W@:<@6C>L
MW*6A;R#MH^>[]PV'"+T#T+R[7/U ODB)3G/NP0HOZTNA!B^M!JU$8MI+Z5+K
MRM<[)$Q;N'8$R!PB\@X0\\.^R.UF9.&%,A%T(G^LI"G@F'3 ,:0</$HI6D]Y
M^HF(:1]GCQHP':: WA!T]08E94DY449A=!5#<A!TKD6<S!9CA%.F=8_'/61,
M>UP=J-C'8+*'E"<$RGH&T>+[V3\_G DZ+G6I$S92H9RS> 4!R5<:J;*P5BO*
M21_!Q1+3?WR:?_O/[2=N8+']CQM$W'Q?1P#81V7S@^0W\77->B;B9OI*.+\J
MHQ3)LB(0HC4*E,H%8BV'4U[+%)F+1MVYD;[WON:>CYXVS&BEZ19RZ^!$>#._
M^$2?]N47C*OK#"]AS*YH193[!,IP1W&1)R3SI)U)3JL4&A\)]]$Q;67/42.+
M@]70(92VQA4RL<&3AR U Z4C!R<T96G,I!B8TDFWWHYR/R73GC"':_@)R.PA
M[AY 0Y;UMKRB+YY=U;AE[E6*CCQH'9RJC")>,!GP/A>4*>72?'C[SU3T!99]
M='L7+H<)N@.H;&C_+:0ZNO+[9G"$5,JP^L3"R.^J* /X4BQD@S8*P62Y6XA\
M^#W;3U1,6V1XW(;TPU30'8BV=I5#]EF*#(+7ZA66222>K$&FNDI*$BN^=;QS
M'QT35_4<J-M'H;*'H*<N7R;W6V?P7G%P58@OHT'!,Y1(N9Q*C(1CLH20T+BZ
M'D7&LDO9\KV?WA, ]M'8O*GX)BZ0>553>5R0[%;?KTL[A%+<)Q*"%+6TPYD,
MSK  .GEI>!(VB9UF[CQ1%G/?=^\&#G;2YTP3N4^,F_?X]7*1/H<EOOBTP$V=
M[1V6K@I$K'2ZL$BA5UV2(]" 2RF 8Y['P&TP=WW)7F#:F:#I*FD.U_E\; 5,
M?!S]>KZX?K8*(5BN:DT1EY0&2,?!&^8H:V3HHW9UE-H.9]"MCYQ.\R,I:WZX
MY/HKH4LR"F4H5<,L#8FA>E1/U)> .FHN<[J[F[YE"5WS&]GCJ/] .7:0LAQI
M;6Z6T@?I)!C4=%Y;QNL(%[%>V8;!4!Z@6]?C=;3>FS^/N>,=8J4#"]IW$7"T
MVFI?1Y+F4"CY\18\\KH76$L7E?*)M9ZP^==B[T:H:[38>P@$)HX8_HL.SGSE
M8ZZN>)G2,9/(ZG(?"GB$@8 YT2^^4,[M2A2[;/:^YZ-/<[7W('7.V\FV-R>X
M;N&;E5D*U_L)D,Z=[+@'X06K#]<2O/=(V9<0'*7D(;:N WJ"I-T@]CPFJ[?4
M3M]@VUJB$8(R+V*(Z\T<9@E1Q R%BV"-%I[[UGW83Q+5D4\[% *[PVL/??0!
ML'L\_=_Q/)?Y@AB]FEJJ$C)M*<W+MC8KJ"(H8U0%6#+19!^B-B.$<+N0UBW8
M]@'$SW!KKIT.0/=;F"W^%<XO\>7WZ]_^?4;L+=+G[V_P&YZO#=6QJ$OD9*/>
M46#@*#"(7EM(R3&;DS*,Z<:8VXVRW2#W/&:GCZ"KGA#X#PPUCZKIUO)G_JZF
M,D0?/98(,>G*7*!H-YE:D,@UA:@YM6^Q'$3@Q$LC1D#(0R!LKJZ>L/CZXNOE
M:KF6F+CJQ0HB*V$=2$0!RF0-CM)W,E_*OG+@PNO17.#/Y'2"L_8@> AN!VJD
M W#=DM6:F>N22>]9\2%QL*+VTIN $!4Z\!%-4CEZ%UMW[CY$RVZP>AXCP9KH
MHU-<796Z<.%8W=YCC9%UL;8'CS(3.X5ISK(-O/5I^3 UT[JL-MK> 4)[B+Y#
M$*W3G<N+U?NPNLIL4DC%U9R)*QU :<? FYPAN%"4UDPJT[KJ_6FJ^@/5/OI_
M E8'*J,#>-WCSM_0#UZO\$M=]J-JRAP@>YY 69F@&AUHF4V6C+D46U?'/T;/
M;I Z[;%@S?72 <;6R_%>?_E*$>.ZZ.)S6'S"Y9F-BLL<#1A-3EY9,L18.^&0
M4AV42J22=RI)&X"N^RGI;G'OGIJ>-Q?[Q*^,]W/PHM"G?PQ_GFF/!EEM>(V9
MK J# )=,@!)1<I&<PKC+VIS'OV7:#M+FX&@LU@Z\RSTB>H>+5+7TB7SUO^:U
M 7?=/8O+U7*[$SN?92.*D1C 1+=VS@6<3PZ<\MYA*=J$//[9M@.ET^YK&LT[
M'4%M'8#S9HKC\BP+::*P&7*RY'B-]1 84V"XC/0;D:QKW4!VZ^NG'2D^&HSV
M%7 7V*B53&_FR^5O)*_[9W\NSS1ENYY+K NJ%;EDK<%[D2 9]*A2ELZVOMW<
MB;!I1_2.B*?62AF.-+]!V@5^HK0R?VQ^4KZ:?XFSS2B)'Y=%+,+%<D,@/Z/#
M7M<1LH \&5!22<J0LP:#=5X5\U'XUN.>AM W[>C,T4_%YBKJP-_=S]M]6TO>
MS$)<=_*=.8O&V, A8QU&&^BX]S8K<-K'))1)2AT'A8^2.>U8LB.#L9W".L#D
MN_!][=$_SK<1YA7/N/S;@@Z!,VM*MH49D';=&,88N*P1BG""!!DH46I=T_,4
M3=..JAD-;4U5T0&T?EV26/_X!;_.24IGN0:@DJAUF]YFX\";H(!906$K,B5Y
MZRFM/Q P[>"(T4"SOY [0,@CB/\=5V_+J[#\?)WX^B"%H. 2F,X%E(@)0B;'
M6K@5-LK(13BB(_J)OHD[QJ?P2H?IJ /\W7.^WY+?>SROZ<>K^9(2'H'!1A<-
M,,<$**TL!!\BN&*#,=%[T[RZ:W?J)FZZ.V;\U4(_!R2DJX.O]/>(*7^_K ^K
M;TO-?=)G7)X1/UI)@Z"-S.MAAT"\9[ >&>>!FR!WZ4UN0,K$72.CO X<6T,3
MOS'MP>[5K71]]3\3PJ$*R5.0$6,5LP8GF0>4H3C-O=!WMSNT N-M,B:NMNX%
MB'MKIH/3>!MI_#9?/,7E;R2-BT1_XT5:S;Z1M,GBDK0JH$"PRM,!@(E#<)P!
MJFSKBCPA0NM2C8,(GKB><>QX\0A:[ "R;XCJ3VNN/N!J=;ZNB]JLD'[Q1R 5
MYH_SMZO/N'A7YVN<(8^,$C .O!@-*A1BKBA&Z;Q7J9@<>6Z= @\B<.+RHM$@
M.9Z6.CFZ'WA"_O"9Y+Z\=6/^<?YQ<5D7IYTE,BJG$R5J$24E:B9""#$ -\(7
M*8JF;&W H3V8@-V@=CK/%\?31@=>[]Z&P[^%V45]-7Q[<=7M^+;<^Q?7MP:U
MS,8)QJ45$JRI-^61(<E9%N 6>7 .;;*^L3ML0_ENX#V]YXX)]-K?V_!MZ]U.
MRWJWF"5\<;[^C"J1^3S_,3L___7/KY@J#>'/7S!?4A 3SW%SKIRQ''+RG)B.
MR.JT9P61(^5_H8[!2A1XI];S'9HRL!O$3^^-93HM-_/;_]]__J03DLU_K_]H
M_2?U7[W'\O_4___G^]<_?'Z<S;_1O[I<_D>:?]E\_NT:[G"1\ZQ6><Q6=6[0
MMH?\0R".:\ED_?.K\)VB]5]P%6;GRQ\Y7,Z^?#U_:LS-X=_YGS?\WI7$]JM_
M N3XO..?*[R@>/+_;7\M?9'75-PB^$5<KA8AK<ZRQ9(=LZ"%JRLBLP6')H!/
M22LR# HA6C^,#*.P_YE\FW:%&+CWA6E(EN)]E1W),.<(,LJD A<)=>O)Y$=B
MK8\"_Q'P?/R1?,.ATD?$_NBTFT1GI@@IU8>35*?_>O">$I"Z1*EXY:WG1YP/
MM'N[[UB([1)& X=8#=%IWQ#=]BUJHS0WP4+@)#&%(I.P?*"DV4NMH@FL>4Q]
MXD.L!D%@\!"K(?KH V [C4EBLNZ;- A2U0'(.B:(A7,0JK)HDS;-'Q*>R1"K
M08#8<XC5$.UT +HC#6L5,B5K*&02OK[TL20@&LD@&^-8R98+WKH!OJ-QTJ.5
M%YQ"&- APCJPNWU'UOJ(@E7OQ5SA=0,/G9B2CDT;T)G(9-2N=0KXUQ#J1JAK
M-(1Z" 0Z'$)=5*K'+9%O<QVC)BA[EI(D&)5B/KE"/F6'E[UG,X1ZD#J?&$(]
M1+8=.,'QC?3F4E[)]5QX!2+)0K&?1HB2):A91DX\.:;MR44@U^Q-VX+^5QBR
M/]8Z,,,?N'R<R1=I/4UI^?M\A4N26UWJMWR/"6??JH9^Q]693]&J2&F/C;&.
M%I249$E'CBA;%YF*.O,17LW;,?#<XY8]8?I8\')4S$P<T@Q@O/:C7] G?:]M
M)RH$1?SE>O$@9&U[8AFB*+E(<FE&[;)X8Y_O?NX)ZF%P/HI&3\O%OUO,Z;>K
M[^](555)=<+"UZJ\,R:M5LP&H#.7DIW:Z.ETB:!Y*:8^?J7FG;8MZ'[NL='1
M'7H;A)R65;PFR%Q\6I?6K(LMSDR0:X%"R2;7?3\>@O,%/$_!)^]<BJUO- \@
M=]K90L_0!@["0P?0WU"]KI3<E>6S+(J21B<H)2*Q2/&:-Q2ON2*4H)2,1]%Z
M/-8>9$X[]NA4H#ZV_CN ^!XIRKOP?7W18 3/7D8'!NM@:^4=N) <%!MR\$*+
M5%I?%NU/[;2#EDX%\$="P\GA?D'_?:ML]*QP7BRS'ISG=>-$S!3"60':I>)2
MBIJQ$:H+]B=XVLE.SQ/]AV"B P.X1?JP \Z%P%.=.>^B$\2G"Q!1\,JL)AEK
M[G7[_L?]:)UVQ-2IP/XH2-@?\?-5.&\3S9^?S_^H*OAMOOAE?AE7Y?+\ZA2[
MN6D]$ZB]1BZAU'F8*N<"(1D$H;2T4880>>M)I;M1-NWLJU-!\PA:/L6FGZLM
M#_-[MSS$VUL>1FD VN/[1V\&.E0FTS0&R:Q#2,R $>OQJ%&#YR)#LEHK&823
M9:P)[\=I#!J\D(0;U#$$1JG&>KR$,1"3=1"\+@8MKSM0&TMD*(TGU:HS!&%W
MW>VHRNL@3+Z'JW5-&_>)LV 1BD>2F;<<?&019)(H,+#(6.N=>@^0,BW4QM7_
MTWV_@Y71*:8VLQ>ORMVX*10 ,0O&9,HE>:+81V,"'7(.3B@IL?6[R9-$]>'2
M#E+]#G#:7P\3EUR\"HO5[.](N=(J;PL=.>>*B"R M1Q,&49AM."<9..92HEG
M*W89#_/S)_<'A0/4-F\FPPY<RP/3NEY^OUY'B=%&Y[@ 9FM+6>2N[H]W4#1%
M  QCU*%UD^B31$U;?G/4(ZRM@OI%W.U-E3)EX2*"R1)!I9+!&V% 2QU%]IDG
MW[H;XTFBIO5@C4&P&\3VU,C4E83;K]S,:KE:S%WK'8728*R7H#3]XEFQX*50
MIB15I.0['&SW?7:7P-A7=?.&<IP8!W6"R_(?,_IE-;^X;B/-&$4IIHX/<N2(
MLZ'@SVK021?'?2PYFQUP<-]G3WLDC8>#@^4X(0Z6B]6MP_K^I58__Q2Q]A&M
MO2J3@:F2:FMS[?Q)P=:R# \4Q FN&<]JMXH%(N36*43_=7,"'4KCM'681PF%
MCJK&B>'Z$!]75LQ42(9[<(&1X4DCP ENH&".*BF;A=YI'\$3@'R<BFF.O..B
M8#Z*2OI+^06*S(VO6Y$=G>@V&0A:9D#KDR_:<R_8#B=B+RE_:WT]GNL/$5X'
MF==O8;;X5SB_Q)<DG5!?7#</L\O9INVZ!)2R3N"2(?C:",C .9/ *6<PVYI9
MM"[4>(*D:0NLCYKGMU1.3UB[>=ZO3_6;;&)Y-3E&4-X0ZB)'%52=5A2)G:A!
ME,05VNQC:%TYL0M=TZ9T38'P$,A:::4#I+V;+]:J65TS=P^76X>=E+/.(P<T
M+H JM?:H2%7';K/L,4BRU,: &T!>)[AKAHV[*R)&4E0'&/QUN9I]"2LZ*7;@
M+2L,2B4!&&.NRRXH:I!T5 B5=$ 1A!*E,0B'T#<M"D<#R4\+%$?26 =H?'2,
M=B)6?*KK0V6DF#75V3J2B[I!.7.A _.N=1/&8_1,VU<T=3'"?FKI &)/+JWE
MC CWC &**BB'"+&N)/58HN/!D,6V7F#=9'_P--L2!VE_Z/[@(:K8&UK?<!'G
MHZVENW<1_/JW(6W^2ET&J55F/$L'6FLZ#[RW$$Q]>F>Z2A&C2'?>#0>LI-N)
MA&D? 9I#[)@*Z62GT@YLKJWJNC3])Z:SXEID8<'(FI\YH2E8* ID8CX4JU#F
MQBA\G*!I'PBFQF1#9770D;+':L@S[F3BR2/E:(Y2MB R1<FQCK S/%O%G#!C
M[:090.:T-WVC'<YC*VS2\_H1)C^L\.LM86ZNY*^VE+Z^+K^[3KGX64DE!Z,$
M9*Q/RK$P<$86*"0.G]%Z*5MGQ2WHGC9_.29NQU5I!SG-@%/E^D!Y2 IU@OF[
MQ6R^^#B_]7'\+-F0A,@,K-=U=92IW;^V@#1:LJ0M)9='Z,UIS=:TLQ*.[+RG
M T2?-K*C7WB/7VY>,^IVP3-F-%HD]Z"#XZ!RU!!%-* +XTD)5XP^@BWL2_ZT
M$Q(Z=/R'*?ATTK_;RUTW]\/+MW]<K)N4SR]7F#<+7\^,*"$8'P!SL:"D)L/F
MI YI?4AU XOSNY2<-B=LVA$'4Z>#(RBO Z]\?S$4,4;?\'GV]8;I,RZ$QY@U
M2%<[-T4,$%@(D%TD 6=%UMIZV.3.Q$T[KF TCSJ.<DY[Q,![3/-/%[/_2X%3
MIG\_*S/<=!LOMZ=)_G'M)OW9Y1?,(P\>.)"J(XXC:"F_:884!!]<BDF#DX'7
MA4X4&Y2$(+F2K!B!3K5^'^I\2$'AT1GE*5L6FB22G("@+(/(#7'BO&*I]1S(
M9SVD8 C"#AY2,$1Y'00,#S5'EQA4$))"])"(#>$0O)*A_H[;7%0)?*R=PJ<]
MI&"0_G<<4C!$&9UBZL<N:R,E+UQJ\#(X4-9D"+Q($#DD;R7#8(^!KA,84C!(
M]8.'% S10X<="T*9(!2"<9EB<46FYEGM9M/>I61(--8^$0WVU+$PDMJ>:%P8
M(,,^7<M-;J:-H71<!W"^U-6@](O/L8#FP=//N<CQ"%[EFIX3&TW0^.#:3RT=
M06S,N_YL"Q91S=;7O<P<ZR!,3'4G7:W<U\PWGW_=R^//-&5U@S XP>//$$#T
M^M+_\U5$N%[?<'49\>*^RXC?*6V[RM5T3%A,]F!,LK6LED3B1(+L>:136R41
M6D_\&(F5CBL &UO#T17?YRFQMQA>A>7G[9J?;^&\5O">Z:RC8=% EK[Z X'@
MM-) CB!J'H,W8:?N[HG,X&>.^C@;)@7MB(9T((*>F3W=;)'+B6$NE!DY%1@Y
MNEP'ZPL%41HG-$6WMOE [E$8Z>,L>:[6LQ]>GIG1O+I<5"QL_N:[!7X-L_SK
MGU_Q8HGT]]^N/N-BNXD+F?8^%PXR2P,J)A*2#P@D'F.4Y%;G(]1GCL]H'^7R
MS]7HQL';,S/*AS=!2B92X3%#R3& "@;!:R/!9*%20BX4MEXC=!3&^JC^?ZY&
MUP9/S\S(;E9-+L^2XBY)XP$U"E!>4(YL70)'FM(BN!B:K^ =B94^VA&>JR'M
MBYD>NVH/BILW-6QW3FP72Y36,C LDT1XMA"S\Q#)Q6")(D1S9WS4KA6OS6GM
MHV&A!S/I$AW/[*C9!KVW_^#.+DQ?3*CCX4$5[NI8'0=!.P329U0Y92:;E^4>
ME<$^FB5ZL+?^\37<^/S&^"[P4UAA_CA60T9;^=S=QAD9*]J6]0&^GE5@P'%+
M_LE&9HOE4ONGBHRGH+N/=HX>+*M[U$QO6,=Q/NM3_TSJ8@-SM=NK2H;7,87&
M!C!*>2Z*$YJW'B9Z!+;ZZ%'IP=QZQ=+SM+*K;0P?PY\_K)!V+GC4#$@ZN<XR
MYA"]L_68QUH;&(T\PFR/QESM]FC,_C*RR:!TJ(UU9UZ_SR_2 [Z'RY)B8AQL
M3EA7GECPWA5@LM0%.TYP=82BO1$XV\W,_BK.F!92S_,X(X6=.8DQJ*0ANEK.
M7E@!5ZP S40L0BN>W1$Z  ]A83<+^JM XT@@Z6 ^V]_F\_S'[/S\S >518D(
M7.@$*EO*"Z7CX+Q+.=LL?/"-P7WUW;NA\M^J@F$OM9QVA_UOLXO9"M_0G]56
M\-<7&<O-3V[>L>XTC2_?A<7J9MO]+1V.W'H_%KE'[,D_BL2G:=9G:$T,GH%=
MC[] +2!P'R$7YC *J9,Y0NU73\WZJ$11F0G $ NH4"1YHQ1 "!^+6Z_Y_:M9
M?R2$'=RL/T1Y'3U%WFT2ML;9HBL'6BI0SC ZS$AFE*IS@Y*+(EO'&,^C67^0
M_G=LUA^BC$XQ]6.W<>8\QR M&%9#)5EC<%57HD<N/0^^>"..@*X3:-8?I/K!
MS?I#]-!?L[ZS2:)F#(*O0UA4"1!9L) =#]RFZ+C;90K>Z37K#U+;X\WZ0V38
M@6OY[>&H]^7W?X3_,U^\.@_+S2XS58SDR,G_ZHQD.D5#B*+N\@E&$5N4V[4>
M 3J O!-KY3_D6!M+:7WC\8:Q6_M!I4E*%T?L&>')IX<$T<4 /DEMA0P)=>M>
MY($D3KPG;BRH[ [)@_76 2SKE(#S<TRKRW!^5:"_=?BE"&T]U^"YK]-'E818
MK(/,0]',:NM2:Z_X,#7=@NUP$,Q'T4@'V/I "MIL#=V>'!_PTWI'U-8H?>(V
M4JZMF 9ED7)MBD<@\;K#K$X<-=@87H\2=&(;[ \Y9MLII@>4;6C?6EY012N'
M&HS)M5]/% @*)4B,S$E9+]Q;WT;\0,#$=Q#M%'L7,GM+>>)L\)\?MJ1O?:@B
M9J6E-(;S.GXD> ^1,P^%*Y4X,R[G.[5*]Z:"=SYV8K7OKYQY&TE-WEJTGG:T
MN> -YS_RD81*5BH&;-/R$4@>V@BP%A&C9#8:N8/&'_Z&B1.T)LIO)+^NQD/=
M.WXHUHX#SCUH5C>=1$%.,&H!3!5$$;/7L?63R<%S^D9K.9[ZSGH_M700=%P]
MG#Z2&/P7SCY]7F%^0= .G_"?2RR7YV]FA83(0C2F6"@FU6K]Y.JE'(-H0[*&
M3F37_$[[$'J[N^/<$S7SB538E4]LW7\<0Q8NB0A!1 H2LA?@/7?@;<R!\1"S
M.<+VI*/UK$\S,N\0F/>@^&YKF,CVPT6:!?JWR]7B<ITJW9R);^87GS[BXLLO
M&%>O;_["_C5(!WU=FQJB=APWJ@&J7_7+;)G.YW5IUW4E1F%&>^$,Q% K,8(K
M$-%0UDI>UC*=&%>M6TKNI^10Q_NC*#=15,PRV3KM.#A7-U+63CU6QWT5+:.T
MW'+7NIC_'C*F/=<;Z/VNJSM4U!W$E=4 5UL#_$C_9GUO(U$:N9ZXKE)]WE]O
M? J4XI40 F?UX;_U/,[[Z)@>+P<I=]Y8TAVB97L'$.O![!R'0A03%Y97:TK
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M88?9)H?HI5.H+:\M=ML HA-CN6@)+A1;M^H8"-PHD"%*C)9^D$<;;?((79V
MK148=AFD<XAF>D+;X_.'1'$JL51C%U,OH3A"#(4##UQF)3C/NO7C5,-Y8:,]
M1G1WWK;284_(W&EBD4[)2FD1O*X[ZB23M44@ V.B*!&M#<T?/)[?E+%!"#EH
MRM@0=?6$Q7MF6KEL@ZR5=(XYLMRUZT\Q $LJJ>*<-F:T/.2TIXP- L& *6-#
M--(IN.26E9"]CMIR$#JNEU"3L R%RLJD)) 9:VSK0NM'R.GDL)T$7/MHI -P
MO;Q<UHZGY8OT/Y>SY6RMJ^KJ&0^^U-<!5Z>QJTRN/B@EP&EF6- BI.:;*Q\@
M9=J^LSXBN!9:ZA1L];<+O)I_0,XX1&%JA82JV9%.X)6PY)^S85FJ8FWK*65/
M$C7MD=E$]3O :7\]3-SX^"HL5K._8SA_L\I7XR^D)$?+'#!5;XQ4EN IZ0:M
M(U,"+?W^SN/OO4V./W]R?U X0&WS9C*<& $O21 DEM<7Z8IVF\@RM("L/+E:
M:3($S B&1Q=M5FB8VT'_=S]WVO!F/.T?)+\.CI4ZR9'.VG53[L5R1FI8*^7E
M]^NU,LP7KEQ@FY%'*ML$@:,'C<;4^5BYI-9A\I-$3=L<W4=<TU9S_4+Q]HQ1
M([36R4 )/M=S6Y%M10]6<AXXL\5BZ[;&)XF:>,]<6Q#L!K$]-3+YD(?-5VXF
M[FR]-1W3T6I=*),M-9-UY*W)YL!;X:6U3OWDW!X8Z?#S9W<)C'U5-V\HQXEQ
M\"&<DY>>T2\K.KJW]"?K6136@7$108F4P7.K &V]>\A9&"9WP,%]GSUMY#,>
M#@Z68P='3HN3_,UU5:AF:+7,"HI&3I*LA4E,&+!F_7!)_]UEE=<U ],."^DC
MJIH.$1V8PU6:]&K^)<XNUII_P']<">7[*^(;:YNH8<HQRGBL*:D.WW3@N.&@
MO3.9&Q9\$(VQOS^UG3SD'!]B#]QEC:SOTT0VR3QMF8W..*%% %60HAN!$9Q4
MM;$C8/#>Q-1\I-Q!!'?REG2*^-Y3ZZ<)\3/DG"?M-0FW%E GQ2$F$C/EBBP:
MQYW'UI4=>Y!Y^J]8D\%YD(8[ /$MT=Y3^7^F$4EX&<'9VG>5-9TZ6*\U-$:6
M/"4L[8?(/$K1Z5]$MH%F0[WMC\+Y*IQWT-IVJX1B4^,0+G+]@TWBC>GSQ>Q_
M+O$(76T#"3EN0]LA4CI*+YL.)9A2+S%$J>O*(WA=Y]Y()S!;SGSS&9YC]K)=
M:>!MN><M;/GR^ZW_VB31/)?"?;$@)0_U#=-!%-'6T6/"&:4%Q?V-^1]*8R=I
MW*'H^6E/]IBJZN",W[%@-O(@*.968&Q<[R2L UUK2SW/UC(19)*C51T?7A8_
M&NS&1<=^U>]#5-43 '<K=G29:1DR4.A2RP/(E -+#E *]$PXQN5H!\&SJ7X?
MA)##JM\'J*LG+-Y3#LN4-S*Z EYF"LA9;7>2.@&2R(PV.G+?^@@^M$"YE^KW
M(2 84* \1",3@FNY6)V]#Q>?-A4 *4:CI M0G":B8TK@>/"@;$XQ,.2XVT8?
M^M1;$*+_NH'/#U\X[>WC4<['_07< RJNWVHSBSQZR'7SLRK<@6?$@'?!9G1<
MXV[N91=<3.E"#E#6777O(;F)%;[=K''50.M9]IH<5EUA"2H$"4'[#"*&1*Y1
M1[U; =43*O_A2R=6^CXJF[>0W]2*WRQ\VA*NG)3:UY<Z7SMKB ?P2)DIR\J5
MXH*T8:<=7$\I_O:73G,.-%/\WO+K(*K\^2)M$X47J74.#+S/2%PHA! 2Q3"Z
MR"@2TTFVWL1V/R73ON@<-85NH(HN 74U\X$HY\$R,%*3:"(=K($<(53VF L^
MB=BZ[N,A6J9-4%KH^4GH["'T/L&SG2Z/N<[1_.U\_L?6STIE4D8Z6T6RI7(F
M(3HK@ FO2Y(&DV_=P[8[=;T!;!\T/ VQ%JKI '1WWY>N"^(-'=7<9P&&UX#
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M@=0V"SE$J_?P<>Y]Y/"4?X*B9J=+K4=E9QR/WN-UF+R;+NNCROI2D_$B=?7
MH@0EG2:J2P M%08I'?+P4B'N M-_7,^^_R=]]-I4T!=W%F+'@CW7%S0^7DZ5
M:,]@6%.]V0@E,)-804@4[ZUK9&,J'')DUL4LT+B7LG=?1\+]U?JQ"B>K:]9
M=@.R]@:]1,P1/%M-HHP!(J.H'T4*.F6;#'LM[V 0UOXT?3QCU \1S@!<P_M7
MS.]O>WT')"EXF\&'0$Q849G0$F+] 3=>&]9Z(N9.0OI)FN\ZJCA=Y@, SOW0
M?=4/:#-*:_';8G&#^;?IO5!^1%O?2ADL9)'JD"S'P:?@P9;D.5/9)=^\Q.,
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M[#J%&*/2Z)2"[)'<-A8#.*W)5!GEBTO9L.:ICEVE$-_5;^V6[[L_:VH@YG6
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MP%&?[#8<+#9;12=CD\$"10CRD"K6 [E,X*(QM''01&[;(>0I ?U%FJ?K]"E
M3A1PW]'E(^<V:8N89(",B801L@/G7(#B7'9%HS-QGRY=_S@B;NA2XZ<J:=9&
M8@.H?UF%.3_NGO176T"$K(-1$8I=#=0F,43N/.A:'Q1Y-B&UGKFZBXY^9Z W
M/#^:"7N(@)G/ZPM0_7*S USRCFD6B(.:3ZV5!"]-M:=.!.LY*M$Z-_15HGIN
M5'RRWE\#TDE*Z#L%E$#P_/6*SX%I3F*2+*K:Z2="3)'$)+FD':B4D:^E\[VZ
MR,#0<9HR9UU(=A"&)R[PGS<DE7<U>[+VAEH'\LS%D'FN0_R(C<(R!*<EQ(+1
M%1;H.-[+?3W(W.PD92\8F8LZKTX7^3"1LW'ZC%?!:C3DW'-&(I%UD$I"T$;:
MZ+.PTK=N]_@L,7T;H0:J?AT^1\A]> #:YJD(B=)X!(>V/DLK.L +[3%O4RK6
M))]]ZRKQG80,#CC'*/EEZ!PA\0' YHE%?G_;@:'$8"+6.V>KR?FSBD$=U@<^
M<XY9"J&:-PA]GIJ] &0OZ-QJ)/@A0 @7"\1-:=?T^CV&!7[$NKVV?_N,\Z^C
MF+CB22=PBN1$?J^#Z#*#VO8.DPO6N=:F:#_*!I:%?B0.'L.KO5*& +4'POKQ
M:_@:KG'Q:79S_67YWV%R@Z-4DM/H&%@6$RAAJOEE&C")8APS7I36W==?)6I@
M&8^- -94%7T/%W^!F4U-(GWCJOQ*.ZA6LJW'#'Z>_8(?PCB/L@C9YY*!)XF@
MC"D0D3@-/I,(N$HB/S)MNX>.GT3%P!(73D/9F94R8/BMN?J#&)S_.EY\NUGB
M'>_U[F3Q93;)HY1C*D4+$):\5^7(]70Z%" WQ#$1,]=NGS>0DPD9V'-JMR!L
MKYHA'+'CY?AZI;%/N%Q.5E=\:T;?U$XDF#_/5LW)/]0<ME&0C!DCZC280/X#
MU[F.B=&@<T*?)?D0&%L?MX<0.+#GF49';V<JZML.[F"L=H:<+LC,OYV$,1GZ
M9:V]842S@,)KM6XVM0T.L[5%I$E,:QOM/DE!>RTVL.O2!O:LN8B'8+,>&NDW
M*<UOPF3;/&N4 @E)> %<!K+ & 1X8PN%.Q*SMSS;YD_%+U,TL,N,3@*"4Y0P
M0#.TMJ\?,<V^XWP]B/S=@J3^KY&3T7A9#,4UVM#Y+FR=Z.+ Q$QTH:9_[5/;
M<M"B>P'(70B NA5YSUAZ.YO0=V;K[BCW7DT_CLF!K"D^5W&RX7SQQS>2]72Y
MV3(C27ZC$X8!B4[1P1U(EC8DR%@$A=;9U98JKP/K> KV0IF_()2=21D7!+GU
M'B,FZWWV']]FT\_TZXM22TI^#<LP"L(H9CSY )R+VAG%@H\B@;/D$SCM>&:B
M,09?(6F_VUKVDZ*RI;XN&:97<;F^RMZDB[S%^7)<QFGUZR,F=8IU#"U&E4#%
M6EFE:@3$?%"6Y),\[QJU+U*X'X@OY<UA0-J\($Q_G/T(D^6/'5=&5U,<<94<
M5]K63"H/JM0BH)0*,/3H ML1LYP,X1<)V@^QE_*(T9^N+@Z@).M/88*+NPM-
M="EKS %B<J*^>BN(43(2N&1&<)Z29YU \PDI^X'RDMX\SJV?BX/CKCWX^5^S
M49V$)8MRH$2DC2B$AB"XA^QUT$F%$L0^70::$;0?-"_I):0?70T5H(\9'!F&
M+&=%OHFL7HH52 &B16"I]JPUW%MY4J3T>,'] '8I3QO=R7H U],;!C;7[".K
M74#)#7!7RWZ%JDVOZZN,IA](JU*)S0>0/:!@/^A<RJM& RD/H77*O>**56:6
MBCQ%R>D4#_443ZIF+A@/AA51AWX$:]T>]F379^^G_TMY?V@BP8$AX"-.\5]A
MLF(#11TZ95.=$11 >8HS/#<2D)&C%W7B7.[=+V?W$OOAX9*>$UK)LV]8+&??
MJG1^FRYNZ#A,=VX4'8;K?'/ZXO]@F(^"\#*AUL"8):ZT,1"XC"!KFIW(A 2^
M%TKV7G$_T%S2ZT!'TK[$^03;0;2SLDH5KC,:.YE4\,(ZG<\LV)?'7J87>,Z"
M4I).K, 1%'DRX%A.X+4SF:=L@FV=QGS6Z04/$].K[$?6(1:5#<A<2R@L2W7>
MJP9?4 7I/4N\-<M/J;BDJ06'8.2QLWRB_ <05'WZ,INO_+P[#GRT0@5C09+G
M!TK96(FGX]VY'(3-S(3F+2&>4-%OLO_Y$'2B_ > H+^-I_647Y?&U$NLJ_+'
M M\L%EA33^;+\?^NWY],UEIE'\$RMNH83E+BC-A2QN8L6(C-8;4G:?VF_)\/
M:UUH:F  _*WV!<7%-A=SY%,@8UPRH([$"OH @9%Q9I85ZWC2)+ .0?>(G'[3
M^OL!VBD:&0"X[AWL05JGC <11*%@A85U:W))H8I40D:!K2=A'78:=G9)?3[@
M'"?MXV$R6X9)$Y@\= 1OLW6S=%9+,J):KIN-<PIP:^=1E7,R4I SV/J.>C<E
M_2;@]^60'Z6' 1B=7?9SP\L5A>XACB?CY8^1<$$Y-!&RJ\F4UM16]DR"+'1.
M"Z&Y,:UGS^]'6;^)^?V><R?J:6#H^S ?D^"^W2M *$4QIK4 )VLO,Q\$Q! Y
M))&EE2XF[EJW?'N1H'YS^/O!VFE:&0#$'D4?Z\1%S+]-W_V9OM0'Z[_-Y@]-
M^=UNDDX&K1.YC9;< Y52!.>T Z=UU&3HHTFM1W.>0&Z_R?_G@^>Y-'HAX+V_
M6^\8=;&$H"GV,98[4-'0?JUW@XC%2)DSBZEYRL*QQ/9<(# LY)ZNSLM^OEI)
MIOY\RWQ]*5RUQNGX/>OUA<_XP'6@%'IY\6+:I>"5 ^WKJ*-D+.T)QR!):03Z
MPO!Q_MR%O7C5BOQ[*ZX[B*'-V3E;:.OY DJ*7/O/!> .O6%<!Y5;]T_82<@E
MO7L=@I0G8?;)6AC .5Z;C<P68?+W^>SFV]M)6"QNBV76LP@]$X4Q"SG$6AY;
M''A&?P2-S&512\-:;Z572.H77@V4/NM. \,&U';R +.BI"JLJ"SM.:RCQ!)"
MUL1G%EZ'T#IX?I6H?D'5% +[P^L(?0P#8&O7Y ;S)IB:31?_P$DNLSDQNAW.
M'+U$(W@ ;8RI?4<".*,\:"+*>^-4":V?*O8D;;!@.P803^'67#L# -UO4_*2
M\1-I:55&\$N8U%#HTQ?$)7D9;W(>5S[#Y,[%6/SRXX&DZXBMR4TF9V2WB%8;
MW14L.:L")K!$DG<%**"JSX2)\V)U*K$U9L_#6;^9+.T/[0'B80"[Y" &[\TL
M=5K;0(<9Z"A-[7@L(%CB.C.R$-P:8UWK-YPC2>W7= \1=2^Y&QU!H.\ZOC!?
MCO^!8?)^F3>G6<ZFA"(EV*A+';J;(93(@4M>DK0F<?,H]-Y=L/?DDP?D*G2E
MS%DSR0[  CX^:=[?5A+(PF1RK';YJ3-M?/;D5&5!7@]GTF:N6&EMXYXEIM]<
MO_:G<1NI#P$^#WNL/[R4'RG!K!)6 1..F'%DEWV0&G)].>(N82ZMARB\2-"P
M;F*.5/J+N3.G:&!P<+I]LWE[,Z\"'ND<#*^CXH60'%30#!SS")B-M@:EY[;U
M1<S+% TK2N@"4"?I8+B(^GTV31N&@G=<6N1@LHBU8PB'6N$&V:GL2N)2\C.!
MZHZH89UWG>+J2$T,%UHC&XHI,1'=*M;ZR!P@\-KK0R-RF[$XUVTMUV'9 )UE
MKI\51@=)?0"IQR]4=8PRN8[6Y C9(C%@2JXMM21YEI$4KX0T*34&T OD])O%
MW@V(6DE_ %9H9Y++]K!&+I+W=>Z'J>Z?B+)>C#/0EB>5D[76=%F]=92[U%D^
M>_=0.DG^0\72O0-:H AU," X1&*')3J@2^#@E30Y:R."Z+(NZUA'J;.<]3,B
MZD@M#!54H\(PJ"@01,ZVICYK\ 8CE)2M5=Z2K6W]<'1\PF1GB>AG!-!!$A^
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MP,J.S,0VVNCQV%[,EZ-;(_YWG%W/P[<OXQ0FJ[S-DH-0WB$$%Q0H$6I7*6F
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M>AH !KL_5];=UIB17,0 )=76BHY$XW).@$E+G4KF*;9.KST/9_UFJ%V"5S!
MA U@WQW$X._A*V[LF'>)!<\1$#$#Z6!5460 (].Q7G=B\SSU(TG]V?WEPU'W
MDC_3$01ZSE=^&^;+\3\P3#:'8Z[32T)A((LC.V*\J(7U=#A**7563@3]J'!G
M9ZKQHX\=D._1E1IG;60Z ,/7_<:\NW[/488H?0)GD43#-.W.DC0D8;21PAC=
M?%#A&=GK-P/YWZ['\5@;P#9\P.7+3+X-BR\C$:(0-B/D*GRE:S?+8!&B$74
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M$\8X';/QN=,*M\MKAW@0! YNAWB(/H8!L!VOO?_ 22ZS^>*NPQXO2;!H)?A
M.Y'"5 =>&X1<<LPV8DRY@WD/^Y V6+ = XB]FB">IIT!@.Y,?<+0,9:MK0='
M;?84G <7G0:376*%.XX2&V-V0/T/.RN(;'YF#Q . ]@D!S%XK\49)FX8TXH\
M[UK,')D@>Q,S<<TS<HZ.^T[GDO^[6>'QJ&O4K/ 0"/2<,/T_LYMI_N5F,9[B
M8K$YS30:9U3FX K)3<E MD1Z#]IHK;@I63S.H-F9J+?CHP?D*W2ESED[V0[
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M;VG \'0<P?3TXU$41/';EP?TOS-\LC>64S]8O/W[P)^J1%RKN>A%4QG^O9;
M(N\E*O;'_&+B_Y]ZVVA"Y_3GG ?T!MH)_%"9 ?*0VE\F_M!/1>.@WOAI']]W
MIO4'#^FD-**CRA&]>MEH'IWQ?XLC6EYN&=_!B@^C-(VF\#FT[RSK"'99Q1M:
MUW>=[B_MZ\%M7UQ>GB\M; 41;'2TY]WK_NWEH'/]0;0^]-KM*QCZ5P\:SE#\
M\\JOUN_5;UF2^N/%=Y_^2I)[?7"V_-_!Q$^$F=&V[<LF%DKLI+@DKUZ>-)L'
M9YL;"9..IT91+%&ZO,U"3\7XUHN?6W>Q4LSA-[=0M$*-LUT!JS65GA)#E<Z5
M"L4[/[J'L64)\@5<3K7=JWD>36<R7&S#6F[R(/Y)7*!Z 63H_67GW@I4 M][
ML10W\EXE?O2778J=+6<489(%J=P.OON7)1(U'JM1ZM\K(1,1C<5_RS"3\4(T
M:FP1;;_$:=L97("=MPW$5!>"-$&K68A$I8D81W$Z$;B>H -/$P%<2HRBT"-[
M-Q'#A9A/_!&_H<6HF/M!(%1X)^_P-W-B1!J)F8JAP:D8J3B5?@A=Q/?^2%$W
MA29@7\<9]*QB ;;O*/:'8 P/51#-ZS!,YST8CM/%5"[@+1&KL8IC^ *ZA"84
M].3#D.]]+Y-!0*W+[::/&QFGVZ"/"-R7Z$[13L@M5XIQT7R5;'+9ZGK=OLU"
MY)^ 9.$8OCU\/?O^?I/JV33J&]SHF?0\/[S;"]0X?=M\8Q:J>NO[AI$@0[B1
MBTV;1O7'$D#S80)XT_P: CB'AH:Q_ZT;W]B:G3^HGS0?M_D;W7!QD<7HJS6B
M$O62M"!0:ZZD2B8@B<0LCD HJ5P.@L J2%*2K?PN2-W$3U)L5Z+JX".O U$7
MD*-8?SB+U4SR"M%1F$4I].S+0"0R4,C-(V+E*?JL04CR*&V'R+T:;\X2<=4=
M_-K_+NOY:/_HFZ,-BAE0<&%OO&R4TC*:598)*46PV!(W-X8%1D%-.DGB;*,?
MCH+,4S50A=))E*4B\*=^2MM2PT9@'PVMY$J3UK/&40!J#CQ^]?+XY$SLR%TQ
M]D,XU?_'VXK[#^0 &PVJ62)"I3S>_R2;X4^5^PEJ<9.:"4=(##(#!0Z'*?[9
M()6Y)G:&NTO4@XH>+@%V&8HV_ +_NIE(F&I3&$NM'=TTK2=HJA3-S,[F_44+
ME<1_-O?^>6AZ&NU"R]-9H-SY.#0=JA':PZ#0H\I(8U+4F%[^(LVZ1^ J2A>L
M3!IR-X1>TWN"@\LW@(;IR52*.(JFJ/&*;%8#E?,>5,T9:<%^" 9Y"BT!X_[,
MDYM"=S$L8U+C,X9JQ\B?27I(NJ;YA%<#WMOQ=H6/W-P?^R.[C_GI-)^0 'OU
M\NC-&<X!!I^J.W]$780*GJ)J3903Z4^P/UP,WI5#I-J[6$YY9#MJ%Z@". @?
M>DN>.&WX+F='EDY@I26.3'T!53WUH4EL9Q[%G_DG7X4CLKJ8)Y&N+9,HE,,
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M@4:S-X2-_[PGQ[#4;V4PEXODQ=<"@5>NTC.3+D=/1;KTLR$:O#$J N'=YIT
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MKRHRL<2!9]]Y(/R(]9Y\"P@@[YF+J /Z/(7EB0>@5D%0+5X*$?3!XKJQ H2
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MNW9I!#:I_*,K2/]AN3HJHYM4%TP67=> IKAXNT86+-M1S%OB[DC(1)8&>"7
MQMZ=O$<VX9V(P#&[\^"2IOZ,*Z_E^-$-7^$T/<!8W:"M6H=I][9JR5;E+N#5
M3#G+8'/(0XI*J8ZT.81JV%R]'U\9$B./^C:9LNE(M--<]JC9#.LU:B8+M@F$
MU1PUV.OCA^OC%4#XR6^1S]B?QPD#:Q(YV JH 0E[&%(3TO)Y(Q[;!T9.2*4_
MN-3@1E,AL2;.Y#WX:[9Q*V!]MNQ#-M#%=< -O$SL5%3F,SXM43I),W9AFBQ
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M=7F(95:>@[C.!&L])V(O9^Q!2C11>Q.8(T>/'L[#GRU\T8GP).1#L.9<[DQ
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MZ>T^(O$"(Q+M#40DAMVG=H/+123,DF$U%([S04;@V/<)'_$0#(T@7D@<=58
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MD2"R)J2HZGT61K[+UNEXU+".DVAY?(\/1,&[\(6W^ =C-;6_1B8P!.!E+9X
MD!H'&TYH",]P'.]>S X^N4#6Y%-R!?]ZMKA4G((<FNN%.#R@@QLH&(>'_Q0M
MF+_$@$#S8<X#<=JN&FB&6N5QDVL&AE$ GXI-2&1*%QJ!"<-/>$, !+'"+#4T
M0@-"Y9F^P,!RLFIX<C&DV1(3X<R; E+!,U,*B&_E[ZF>_8A9WI01V_.!W4+U
MX%9) NI(Q\YW7M60KS.X;>3SQ\N5"  M)<$#]H0]?2?9R<BS%_!C$DZ=]_\/
M4$L#!!0    ( ):)L%8_)P)2] <  #DF   5    97AH:6)I=#,Q,2UQ,3(P
M,C,N:'1MW5IK<]NV$OW>7X'*<U-[1N^'9<N.9US;G:N9-DE==3+]= <B0!$U
M2;  *%GWU_<L2#UL68Z<.E/;R401B06PCX.SNQ1/O[_\>#'ZX],5BUP2LT^_
M__CS\()5:HW&Y\Y%HW$YNF3_'?WR,^O6FRTV,CRURBF=\KC1N/I0897(N6S0
M:,QFL_JL4]=FTAA=-VBI;B/6VLJZ<*)R=DIW\"FY./ON]/M:C5WJ($]DZEA@
M)'=2L-RJ=,(^"VEO6*U62EWH;&[4)'*LW6QWV&=M;M24%^-.N5B>+=8Y;137
MIPV_R>E8B_G9J5!3IL3[BCHZ%KS/99_SHZ![W!^/^UQT1.]8])K]INRT_M>"
MD@V(%W.LF\?R?251:2V2M/^@W\[<R4P)%PU:S>9_*G?DG+QU-1ZK23KPVF(T
MU*F#%@:K%E\W%G_.28OA0,?:#/::_L\)C=1"GJAX/OAAI!)IV0<Y8]<ZX>D/
M58M8UJPT*BP$K?J_A&TPTU_.2KNQ3JQ2N?!#JTW&7]U&:JP<Z[3JK;NZ/J9Q
M@#A)\^PJMW=2^>+J>C3\:7AQ/AI^_/#;5@<GW$P0];%V3B>#0RQ=WG$Z&[2.
M<+UFT)^Y=2J</VQ1NT=_GR4(W0<M&E;9>>HBG<[9ISK[444Q&PYQ,Y"&M&(N
MXN[=7N_H9$=C._5[YA8W,BX$CF8MEJ%[81YHU=F017PJF9%3)6>@$1<IRW[-
MN0'2XCF[EIDVCNF4_:1-PEK-VJ],AW"6G@*,N67#-*C#2<=OUTEM8(-;N 9.
M2.;L)M6S6(J)K!:^,H6'A,:.J08?8T&N4L8!JSQU)I=0& SMR1JNXRS!E5$\
M9B$/<,LPG8 *G"[D-@12&4AKN9F32,)O)/9=6]/BGH RV#+V3(\]2"!0!LP.
ML133H8F0ALTB%43,YO2QFC^31I:+D &)LC%2 &63F7(1#+29#+R"M&X&U;2
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M"P7]_"+[P!3HR!+=X7\JM18'0?Z5*ZCO09^G@6_(#MY^17R.OI6*"86 4R]
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MW>:4K>\>W?DL7JKRKW>=_0U02P,$%     @ EHFP5MW:Z5KW!P  LB8  !4
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M**XX380=P4%3\,0;Z/06,$TQN#G&-$;BZ7(8GC<2.E]! B>IR!%KE[9%;&N
M <0QK)?&19YB,U'75N![(DL&G<C?4B!KR+UP&[! ^!UR'**D7$"CRHJYL330
MQWR_4G,2I80 \*"0-+^<\?8DU(Q(*M7$S,"B^5 8BV;'$NIN!KMA96TIYV9F
MS(JUSSOMW0897(O1B^W]=O3RT%2)K>J%VS J304N??3."=7<YPEQ%['D+IZ$
M QRQ%&;DQ)U8!K)PA.&NF3")5*;$/$<C6LF0L$*KA#/<-F0'^6$<"0]).+M*
M1C0?<O(:._2BE)"(.K0>]7;XKI\:]5BX"I?"]0]Y (K33]PV7L)/R*>S9>.%
MTFL+I5C(^7D359!PA>:AZVFO^YB0LD-WR2DW, 1!\S3[[8S67 5(:&DVG^*H
M..;(3K52('=5:BC 5AT+XPD 4CSW>EPGLZ".9?K17%*?[HK=%RFK5=3D!@5H
M!+88)07S9Q=3QD8P0;5P#HA0@SPAYDX3^@+4!;\[C"\BGBYP.()!.+7X205:
M#)&4DCJ6@UO>B$5]P8Q0K9:+++[%W F"B#"?LX<FGD<&I_@FG#;>OBNHVGSC
M;PPN '(LF,,,-3@@.X:C!GAS'8<#$M5LEE3 3-!82&&GKN3<MJR#N,^_3VU
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M\-NO?GA+,N9K?P]5>=Y:3*$QJ*JTJU/6_N+GVF?X-9?_7=GQ/U!+ P04
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MR __ 5!+ 0(4 Q0    ( ):)L%8<AZ&M7'L" *FL&@ 0              "
M 0    !B=G,M,C R,S T,#$N:'1M4$L! A0#%     @ EHFP5F*?>I6O%0
M2/X  !               ( !BGL" &)V<RTR,#(S,#0P,2YX<V102P$"% ,4
M    " "6B;!603F&6*PL  #XX $ %               @ %GD0( 8G9S+3(P
M,C,P-# Q7V-A;"YX;6Q02P$"% ,4    " "6B;!6M26?T?:L   (U@< %
M            @ %%O@( 8G9S+3(P,C,P-# Q7V1E9BYX;6Q02P$"% ,4
M" "6B;!6@5_=_*@Y 0!O70T %               @ %M:P, 8G9S+3(P,C,P
M-# Q7VQA8BYX;6Q02P$"% ,4    " "6B;!6@I"T8:?8  !K&@H %
M        @ %'I00 8G9S+3(P,C,P-# Q7W!R92YX;6Q02P$"% ,4    " "6
MB;!6H\9!_W,E   KW   '@              @ $@?@4 97AH:6)I=#$P,7!A
M=F5S:6]C;VYS=6QT:6XN:'1M4$L! A0#%     @ EHFP5NTU]?B>)0  )54!
M !X              ( !SZ,% &5X:&EB:70Q,#-C87)T:6AE86QS971T;&5M
M+FAT;5!+ 0(4 Q0    ( ):)L%8_)P)2] <  #DF   5              "
M :G)!0!E>&AI8FET,S$Q+7$Q,C R,RYH=&U02P$"% ,4    " "6B;!6W=KI
M6O<'  "R)@  %0              @ '0T04 97AH:6)I=#,Q,BUQ,3(P,C,N
M:'1M4$L! A0#%     @ EHFP5O?TXLMZ!0  ?1\  !0              ( !
M^MD% &5X:&EB:70S,BUQ,3(P,C,N:'1M4$L%!@     +  L Y (  *;?!0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
